false	Population pharmacokinetic analyses revealed that MTX,  <e1> NSAIDs </e1> , corticosteroids, and TNF blocking agents did not influence  <e2> abatacept </e2>  clearance.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine,  <e1> chloroquine </e1> ,  <e2> gold </e2> , hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents,  <e1> azathioprine </e1> , chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and  <e2> anakinra </e2> .
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with  <e1> ORENCIA </e1> :  <e2> MTX </e2> , NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA:  <e1> MTX </e1> , NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine,  <e2> gold </e2> , hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents,  <e1> azathioprine </e1> , chloroquine,  <e2> gold </e2> , hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine,  <e1> chloroquine </e1> , gold, hydroxychloroquine,  <e2> leflunomide </e2> , sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids,  <e1> TNF blocking agents </e1> ,  <e2> azathioprine </e2> , chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA:  <e1> MTX </e1> , NSAIDs, corticosteroids, TNF blocking agents, azathioprine,  <e2> chloroquine </e2> , gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	Population pharmacokinetic analyses revealed that  <e1> MTX </e1> , NSAIDs, corticosteroids, and TNF blocking agents did not influence  <e2> abatacept </e2>  clearance.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents,  <e1> azathioprine </e1> , chloroquine, gold, hydroxychloroquine,  <e2> leflunomide </e2> , sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with  <e1> ORENCIA </e1> : MTX, NSAIDs, corticosteroids, TNF blocking agents,  <e2> azathioprine </e2> , chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX,  <e1> NSAIDs </e1> , corticosteroids, TNF blocking agents,  <e2> azathioprine </e2> , chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA:  <e1> MTX </e1> , NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide,  <e2> sulfasalazine </e2> , and anakinra.
false	Population pharmacokinetic analyses revealed that MTX,  <e1> NSAIDs </e1> , corticosteroids, and  <e2> TNF blocking agents </e2>  did not influence abatacept clearance.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX,  <e1> NSAIDs </e1> , corticosteroids,  <e2> TNF blocking agents </e2> , azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	These medications have included heparin,  <e1> warfarin </e1> ,  <e2> beta-adrenergic receptor blockers </e2> , calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
false	These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists,  <e1> angiotensin converting enzyme inhibitors </e1> , intravenous and oral  <e2> nitrates </e2> , ticlopidine, and aspirin.
false	 <e1> Heparin </e1> , other  <e2> anticoagulants </e2> , thrombolytics, and anti platelet agents are associated with an increase in bleeding.
false	These medications have included  <e1> heparin </e1> , warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and  <e2> aspirin </e2> .
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX,  <e1> NSAIDs </e1> , corticosteroids, TNF blocking agents, azathioprine, chloroquine,  <e2> gold </e2> , hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
false	These medications have included heparin,  <e1> warfarin </e1> , beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and  <e2> aspirin </e2> .
false	These medications have included  <e1> heparin </e1> , warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral  <e2> nitrates </e2> , ticlopidine, and aspirin.
false	These medications have included heparin,  <e1> warfarin </e1> , beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates,  <e2> ticlopidine </e2> , and aspirin.
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX,  <e1> NSAIDs </e1> , corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and  <e2> anakinra </e2> .
false	These medications have included heparin,  <e1> warfarin </e1> , beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral  <e2> nitrates </e2> , ticlopidine, and aspirin.
false	Concurrent administration of a TNF antagonist with  <e1> ORENCIA </e1>  has been associated with an increased risk of serious infections and no significant additional efficacy over use of the  <e2> TNF antagonists </e2>  alone.
false	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with  <e1> anxiolytics </e1> , hypnotics and sedatives (including benzodiazepines), or  <e2> non-opioid analgesics </e2>  was similar to that of subjects taking placebo with these concomitant medications.
false	The concomitant intake of  <e1> alcohol </e1>  and Acamprosate does not affect the pharmacokinetics of either alcohol or  <e2> acamprosate </e2> .
false	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and  <e1> sedatives </e1>  (including benzodiazepines), or  <e2> non-opioid analgesics </e2>  was similar to that of subjects taking placebo with these concomitant medications.
false	Pharmacokinetic studies indicate that administration of  <e1> disulfiram </e1>  or diazepam does not affect the pharmacokinetics of  <e2> acamprosate </e2> .
false	The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs,  <e1> corticosteroids </e1> , TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and  <e2> anakinra </e2> .
false	The concomitant intake of  <e1> alcohol </e1>  and Acamprosate does not affect the pharmacokinetics of either  <e2> alcohol </e2>  or acamprosate.
false	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including  <e1> benzodiazepines </e1> ), or  <e2> non-opioid analgesics </e2>  was similar to that of subjects taking placebo with these concomitant medications.
false	When such drugs are withdrawn from patients receiving  <e1> Acarbose </e1>  in combination with  <e2> sulfonylureas </e2>  or insulin, patients should be observed closely for any evidence of hypoglycemia.
false	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with  <e1> anxiolytics </e1> ,  <e2> hypnotics </e2>  and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e1> estrogens </e1> , oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	 <e1> Acarbose </e1>  did not interfere with the absorption or disposition of the sulfonylurea  <e2> glyburide </e2>  in diabetic patients.
false	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics,  <e1> hypnotics </e1>  and sedatives (including benzodiazepines), or  <e2> non-opioid analgesics </e2>  was similar to that of subjects taking placebo with these concomitant medications.
false	Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine,  <e1> propranolol </e1> , or  <e2> ranitidine </e2> .
false	 <e1> Acarbose </e1>  may affect  <e2> digoxin </e2>  bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
false	These drugs include the thiazides and other  <e1> diuretics </e1> ,  <e2> corticosteroids </e2> , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines,  <e1> thyroid products </e1> , estrogens, oral contraceptives, phenytoin,  <e2> nicotinic acid </e2> , sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid,  <e1> sympathomimetics </e1> ,  <e2> calcium channel-blocking drugs </e2> , and isoniazid.
false	Intestinal adsorbents (e. g., charcoal) and  <e1> digestive enzyme preparations </e1>  containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of  <e2> Acarbose </e2>  and should not be taken concomitantly.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g.,  <e1> amylase </e1> ,  <e2> pancreatin </e2> ) may reduce the effect of Acarbose and should not be taken concomitantly.
false	Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin,  <e1> nifedipine </e1> , propranolol, or  <e2> ranitidine </e2> .
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and  <e2> isoniazid </e2> .
false	Acarbose may affect  <e1> digoxin </e1>  bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of  <e2> digoxin </e2>  by 9% (90% confidence limit: 19% decrease to 2% increase).
false	When such drugs are withdrawn from patients receiving  <e1> Acarbose </e1>  in combination with sulfonylureas or  <e2> insulin </e2> , patients should be observed closely for any evidence of hypoglycemia.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids,  <e2> phenothiazines </e2> , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	There is little if any clinically significant interaction between  <e1> Acarbose </e1>  and  <e2> metformin </e2> .
mechanism	Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g.,  <e1> amylase </e1> , pancreatin) may reduce the effect of  <e2> Acarbose </e2>  and should not be taken concomitantly.
false	Acarbose may affect digoxin bioavailabillty and may require dose adjustment of  <e1> digoxin </e1>  by 16% (90% confidence interval: 8-23%), decrease mean C max  <e2> digoxin </e2>  by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
false	Intestinal adsorbents (e. g.,  <e1> charcoal </e1> ) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase,  <e2> pancreatin </e2> ) may reduce the effect of Acarbose and should not be taken concomitantly.
false	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with  <e1> Acamprosate </e1>  concomitantly with anxiolytics, hypnotics and sedatives (including  <e2> benzodiazepines </e2> ), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel-blocking drugs </e2> , and isoniazid.
effect	 <e1> Catecholamine-depleting drugs </e1> , such as reserpine, may have an additive effect when given with  <e2> beta-blocking agents </e2> .
false	No significant interactions with  <e1> digoxin </e1> ,  <e2> hydrochlorothiazide </e2> , hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.
false	No significant interactions with  <e1> digoxin </e1> , hydrochlorothiazide, hydralazine,  <e2> sulfinpyrazone </e2> , oral contraceptives, tolbutamide, or warfarin have been observed.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel-blocking drugs </e2> , and isoniazid.
false	No significant interactions with digoxin, hydrochlorothiazide, hydralazine,  <e1> sulfinpyrazone </e1> , oral contraceptives,  <e2> tolbutamide </e2> , or warfarin have been observed.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and  <e2> isoniazid </e2> .
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines,  <e2> thyroid products </e2> , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
false	No significant interactions with digoxin,  <e1> hydrochlorothiazide </e1> , hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or  <e2> warfarin </e2>  have been observed.
false	No significant interactions with  <e1> digoxin </e1> , hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or  <e2> warfarin </e2>  have been observed.
effect	 <e1> Acetazolamide </e1>  may prevent the urinary antiseptic effect of  <e2> methenamine </e2> .
mechanism	 <e1> Acetazolamide </e1>  may elevate  <e2> cyclosporine </e2>  levels.
false	Acetazolamide increases  <e1> lithium </e1>  excretion and the  <e2> lithium </e2>  may be decreased.
false	 <e1> Acetazolamide </e1>  increases lithium excretion and the  <e2> lithium </e2>  may be decreased.
false	By decreasing the gastrointestinal absorption of  <e1> primidone </e1> ,  <e2> DIAMOX </e2>  may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.
mechanism	 <e1> Acetazolamide </e1>  increases  <e2> lithium </e2>  excretion and the lithium may be decreased.
false	Concomitant use with  <e1> iron supplement </e1> s may result in the reduced absorption of  <e2> iron </e2> .
advise	Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral  <e1> retinoids </e1>  with  <e2> acitretin </e2>  must be avoided because of the risk of hypervitaminosis A.
false	Ethanol:Clinical evidence has shown that  <e1> etretinate </e1>  can be formed with concurrent ingestion of acitretin and  <e2> ethanol </e2> .
false	 <e1> Methotrexate </e1> : An increased risk of hepatitis has been reported to result from combined use of methotrexate and  <e2> etretinate </e2> .
false	Ethanol:Clinical evidence has shown that  <e1> etretinate </e1>  can be formed with concurrent ingestion of  <e2> acitretin </e2>  and ethanol.
false	 <e1> Vitamin A </e1>  and oral retinoids: Concomitant administration of  <e2> vitamin A </e2>  and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
false	Glibenclamide: In a study of 7 healthy male volunteers,  <e1> acitretin </e1>  treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to  <e2> chlorpropamide </e2> ) in 3 of the 7 subjects.
effect	Tetracyclines: Since both  <e1> acitretin </e1>  and  <e2> tetracyclines </e2>  can cause increased intracranial pressure, their combined use is contraindicated.
false	Other: There appears to be no pharmacokinetic interaction between acitretin and  <e1> cimetidine </e1> , digoxin, or  <e2> glyburide </e2> .
false	Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of  <e1> glibenclamide </e1>  (a  <e2> sulfonylurea </e2>  similar to chlorpropamide) in 3 of the 7 subjects.
false	Phenytoin: If  <e1> acitretin </e1>  is given concurrently with phenytoin, the protein binding of  <e2> phenytoin </e2>  may be reduced.
false	Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a  <e1> sulfonylurea </e1>  similar to  <e2> chlorpropamide </e2> ) in 3 of the 7 subjects.
false	Therefore the, combination of anakinra with other  <e1> TNF-blocking agents </e1> , including  <e2> HUMIRA </e2> , may also result i n similar toxicities.
false	The data do not suggest the need for dose adjustment of either  <e1> HUMIRA </e1>  or  <e2> MTX </e2> .
false	The safety and efficacy of  <e1> anakinra </e1>  used in combination with  <e2> HUMIRA </e2>  has not been studied.
false	Other: There appears to be no pharmacokinetic interaction between  <e1> acitretin </e1>  and  <e2> cimetidine </e2> , digoxin, or glyburide.
effect	Methotrexate: An increased risk of hepatitis has been reported to result from combined use of  <e1> methotrexate </e1>  and  <e2> etretinate </e2> .
false	Particular caution should be exercised in using preparations containing  <e1> sulfur </e1> ,  <e2> resorcinol </e2> , or salicylic acid in combination with DIFFERIN Gel.
false	Particular caution should be exercised in using preparations containing sulfur, resorcinol, or  <e1> salicylic acid </e1>  in combination with  <e2> DIFFERIN </e2>  Gel.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine,  <e1> non-steroidal anti-inflammatory </e1>  drugs (e.g.,  <e2> ibuprofen </e2> ), tacrolimus, vancomycin.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin,  <e1> amikacin </e1> ), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g.,  <e2> ibuprofen </e2> ), tacrolimus, vancomycin.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g.,  <e1> gentamicin </e1> , amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen),  <e2> tacrolimus </e2> , vancomycin.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g.,  <e1> gentamicin </e1> , amikacin), amphotericin B,  <e2> cyclosporine </e2> , non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g.,  <e1> ibuprofen </e1> ), tacrolimus,  <e2> vancomycin </e2> .
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of:  <e1> aminoglycosides </e1>  (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen),  <e2> tacrolimus </e2> , vancomycin.
false	Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine,  <e1> non-steroidal anti-inflammatory </e1>  drugs (e.g., ibuprofen),  <e2> tacrolimus </e2> , vancomycin.
false	 <e1> Anakinra </e1> : Concurrent administration of anakinra (an interleukin-1 antagonist) and another  <e2> TNF-blocking agent </e2>  has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
false	Intravenous Adenocard ( <e1> adenosine </e1> ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine,  <e2> beta-adrenergic blocking agents </e2> , calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
false	Intravenous Adenocard ( <e1> adenosine </e1> ) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and  <e2> angiotensin converting enzyme inhibitors </e2> , without any change in the adverse reaction profile.
effect	 <e1> Digoxin </e1>  and verapamil use may be rarely associated with ventricular fibrillation when combined with  <e2> Adenocard </e2> .
false	Intravenous  <e1> Adenocard </e1>  (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents,  <e2> calcium channel blocking agents </e2> , and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
false	Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as  <e1> quinidine </e1> , beta-adrenergic blocking agents, calcium channel blocking agents, and  <e2> angiotensin converting enzyme inhibitors </e2> , without any change in the adverse reaction profile.
effect	The use of  <e1> Adenocard </e1>  in patients receiving  <e2> digitalis </e2>  may be rarely associated with ventricular fibrillation.
false	The effects of adenosine are antagonized by  <e1> methylxanthines </e1>  such as caffeine and  <e2> theophylline </e2> .
false	Fluoxetine,  <e1> OCs </e1> , sertraline, diltiazem,  <e2> macrolide antibiotics </e2>  (exercise caution).
false	 <e1> Nafazodone </e1> , fluvoxamine,  <e2> cimetidine </e2>  (consider Xanax dose reduction).
false	The effects of adenosine are antagonized by  <e1> methylxanthines </e1>  such as  <e2> caffeine </e2>  and theophylline.
advise	Nafazodone, fluvoxamine,  <e1> cimetidine </e1>  (consider  <e2> Xanax </e2>  dose reduction).
false	 <e1> Fluoxetine </e1> ,  <e2> OCs </e2> , sertraline, diltiazem, macrolide antibiotics (exercise caution).
false	 <e1> Nafazodone </e1> ,  <e2> fluvoxamine </e2> , cimetidine (consider Xanax dose reduction).
false	 <e1> Praziquantel </e1> : In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of  <e2> albendazole sulfoxide </e2>  by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
false	Theophylline: The pharmacokinetics of theophylline ( <e1> aminophylline </e1>  5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of  <e2> albendazole </e2>  (400 mg) in 6 healthy subjects.
false	 <e1> Digoxin </e1>  and  <e2> verapamil </e2>  use may be rarely associated with ventricular fibrillation when combined with Adenocard.
mechanism	Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg  <e1> dexamethasone </e1>  was coadministered with each dose of  <e2> albendazole </e2>  (15 mg/kg/day) in eight neurocysticercosis patients.
false	 <e1> Theophylline </e1> : The pharmacokinetics of  <e2> theophylline </e2>  (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.
false	 <e1> Dexamethasone </e1> : Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg  <e2> dexamethasone </e2>  was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
false	Dexamethasone: Steady-state trough concentrations of  <e1> albendazole sulfoxide </e1>  were about 56% higher when 8 mg dexamethasone was coadministered with each dose of  <e2> albendazole </e2>  (15 mg/kg/day) in eight neurocysticercosis patients.
false	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and  <e1> antineoplastic agents </e1> , specifically,  <e2> dacarbazine </e2> , cis-platinum, tamoxifen and interferon-alfa.
false	Delayed Adverse Reactions to  <e1> Iodinated Contrast Media </e1> : A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered  <e2> radiographic iodinated contrast media </e2>  experienced acute, atypical adverse reactions.
false	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics,  <e1> analgesics </e1> , antiemetics,  <e2> sedatives </e2> , tranquilizers).
effect	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate,  <e1> asparaginase </e1> ) effects with  <e2> PROLEUKIN </e2>  may increase toxicity in these organ systems.
false	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g.,  <e1> narcotics </e1> , analgesics, antiemetics,  <e2> sedatives </e2> , tranquilizers).
false	Although  <e1> glucocorticoids </e1>  have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other  <e2> antihypertensives </e2>  may potentiate the hypotension seen with PROLEUKIN.
false	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides,  <e1> indomethacin </e1> ), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g.,  <e2> methotrexate </e2> , asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
false	Concurrent administration of drugs possessing nephrotoxic (e.g.,  <e1> aminoglycosides </e1> ,  <e2> indomethacin </e2> ), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
false	Although  <e1> glucocorticoids </e1>  have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12  <e2> Beta-blockers </e2>  and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
false	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g.,  <e1> doxorubicin </e1> ) or hepatotoxic (e.g.,  <e2> methotrexate </e2> , asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
effect	Concurrent administration of drugs possessing nephrotoxic (e.g.,  <e1> aminoglycosides </e1> , indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with  <e2> PROLEUKIN </e2>  may increase toxicity in these organ systems.
effect	Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving  <e1> PROLEUKIN </e1>  and  <e2> interferon-alfa </e2>  concurrently.
false	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically,  <e1> dacarbazine </e1> , cis-platinum,  <e2> tamoxifen </e2>  and interferon-alfa.
false	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics,  <e1> analgesics </e1> ,  <e2> antiemetics </e2> , sedatives, tranquilizers).
false	 <e1> Praziquantel </e1> : In the fed state,  <e2> praziquantel </e2>  (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
effect	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g.,  <e1> cytotoxic </e1>  chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with  <e2> PROLEUKIN </e2>  may increase toxicity in these organ systems.
false	Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics,  <e1> antiemetics </e1> , sedatives,  <e2> tranquilizers </e2> ).
false	Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum,  <e1> tamoxifen </e1>  and  <e2> interferon-alfa </e2> .
false	Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides,  <e1> indomethacin </e1> ), myelotoxic (e.g.,  <e2> cytotoxic </e2>  chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
false	Delayed Adverse Reactions to  <e1> Iodinated Contrast Media </e1> : A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various  <e2> interleukin-2 </e2>  containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
mechanism	Products containing calcium and other  <e1> multivalent cations </e1>  likely will interfere with absorption of  <e2> alendronate </e2> .
false	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with  <e1> ALFENTA </e1>  can significantly inhibit  <e2> ALFENTA </e2>  clearance and may increase the risk of prolonged or delayed respiratory depression.
false	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other  <e1> CNS depressants </e1>  such as barbiturates, tranquilizers, opioids, or inhalation general  <e2> anesthetics </e2> .
false	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as  <e1> barbiturates </e1> , tranquilizers, opioids, or inhalation general  <e2> anesthetics </e2> .
effect	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when  <e1> ALFENTA </e1>  is administered in combination with other CNS depressants such as barbiturates, tranquilizers,  <e2> opioids </e2> , or inhalation general anesthetics.
false	Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers,  <e1> opioids </e1> , or inhalation general  <e2> anesthetics </e2> .
mechanism	Limited clinical experience indicates that requirements for  <e1> volatile inhalation anesthetics </e1>  are reduced by 30 to 50% for the first sixty (60) minutes following  <e2> ALFENTA </e2>  induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
false	Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between  <e1> UROXATRAL </e1>  and other  <e2> alpha-blockers </e2>  have not been determined.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib,  <e1> hydrochlorothiazide </e1> , ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in  <e2> aliskiren </e2>  exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine,  <e1> metformin </e1> , celecoxib, atenolol,  <e2> atorvastatin </e2> , ramipril or hydrochlorothiazide.
false	Co-administration of lovastatin,  <e1> atenolol </e1> ,  <e2> warfarin </e2> , furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	 <e1> Ketoconazole </e1> : Co-administration of 200 mg twice-daily  <e2> ketoconazole </e2>  with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
false	Co-administration of lovastatin,  <e1> atenolol </e1> , warfarin, furosemide,  <e2> digoxin </e2> , celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin,  <e1> valsartan </e1> , amlodipine, metformin,  <e2> celecoxib </e2> , atenolol, atorvastatin, ramipril or hydrochlorothiazide.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide,  <e1> digoxin </e1> , celecoxib, hydrochlorothiazide, ramipril, valsartan,  <e2> metformin </e2>  and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin,  <e1> valsartan </e1> , amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or  <e2> hydrochlorothiazide </e2> .
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan,  <e1> amlodipine </e1> , metformin, celecoxib, atenolol, atorvastatin, ramipril or  <e2> hydrochlorothiazide </e2> .
false	Co-administration of lovastatin, atenolol,  <e1> warfarin </e1> , furosemide, digoxin, celecoxib, hydrochlorothiazide,  <e2> ramipril </e2> , valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin,  <e1> celecoxib </e1> , hydrochlorothiazide, ramipril,  <e2> valsartan </e2> , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of  <e1> lovastatin </e1> , digoxin, valsartan, amlodipine, metformin, celecoxib,  <e2> atenolol </e2> , atorvastatin, ramipril or hydrochlorothiazide.
false	Co-administration of  <e1> lovastatin </e1> , atenolol, warfarin, furosemide, digoxin,  <e2> celecoxib </e2> , hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin,  <e1> digoxin </e1> ,  <e2> valsartan </e2> , amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
false	 <e1> Warfarin </e1> : The effects of aliskiren on  <e2> warfarin </e2>  pharmacokinetics have not been evaluated in a well-controlled clinical trial.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol,  <e1> atorvastatin </e1> ,  <e2> ramipril </e2>  or hydrochlorothiazide.
mechanism	Furosemide: When  <e1> aliskiren </e1>  was co-administered with  <e2> furosemide </e2> , the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
false	Co-administration of lovastatin, atenolol, warfarin,  <e1> furosemide </e1> , digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in  <e2> aliskiren </e2>  exposure.
false	Co-administration of  <e1> aliskiren </e1>  did not significantly affect the pharmacokinetics of lovastatin, digoxin,  <e2> valsartan </e2> , amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan,  <e1> amlodipine </e1> , metformin, celecoxib, atenolol, atorvastatin,  <e2> ramipril </e2>  or hydrochlorothiazide.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine,  <e1> metformin </e1> , celecoxib,  <e2> atenolol </e2> , atorvastatin, ramipril or hydrochlorothiazide.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib,  <e1> hydrochlorothiazide </e1> ,  <e2> ramipril </e2> , valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	 <e1> Furosemide </e1> : When  <e2> aliskiren </e2>  was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
false	Co-administration of lovastatin, atenolol, warfarin,  <e1> furosemide </e1> , digoxin, celecoxib, hydrochlorothiazide, ramipril,  <e2> valsartan </e2> , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of  <e1> lovastatin </e1> , digoxin,  <e2> valsartan </e2> , amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
false	Co-administration of  <e1> lovastatin </e1> , atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril,  <e2> valsartan </e2> , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of  <e1> lovastatin </e1> , atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide,  <e2> ramipril </e2> , valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin,  <e1> valsartan </e1> , amlodipine, metformin, celecoxib, atenolol,  <e2> atorvastatin </e2> , ramipril or hydrochlorothiazide.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril,  <e1> valsartan </e1> ,  <e2> metformin </e2>  and amlodipine did not result in clinically significant increases in aliskiren exposure.
false	Co-administration of aliskiren did not significantly affect the pharmacokinetics of  <e1> lovastatin </e1> , digoxin, valsartan, amlodipine,  <e2> metformin </e2> , celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
false	Co-administration of lovastatin, atenolol, warfarin,  <e1> furosemide </e1> , digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and  <e2> amlodipine </e2>  did not result in clinically significant increases in aliskiren exposure.
false	Ketoconazole: Co-administration of 200 mg twice-daily  <e1> ketoconazole </e1>  with aliskiren resulted in an approximate 80% increase in plasma levels of  <e2> aliskiren </e2> .
false	Furosemide: When aliskiren was co-administered with  <e1> furosemide </e1> , the AUC and Cmax of  <e2> furosemide </e2>  were reduced by about 30% and 50%, respectively.
false	Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  <e1> antiretroviral agents </e1> , including protease inhibitors,  <e2> macrolide antibiotics </e2> , and azole antifungals, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.
false	Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors,  <e1> macrolide antibiotics </e1> , and azole antifungals, the effect of  <e2> Panretin </e2>  gel on the steady-state concentrations of these drugs is not known.
false	Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  <e1> antiretroviral agents </e1> , including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of  <e2> Panretin </e2>  gel on the steady-state concentrations of these drugs is not known.
false	Chlorpropamide:  <e1> Chlorpropamide </e1> s plasma half-life may be prolonged by allopurinol, since  <e2> allopurinol </e2>  and chlorpropamide may compete for excretion in the renal tubule.
false	 <e1> Dicumarol </e1> : It has been reported that allopurinol prolongs the half-life of the anticoagulant,  <e2> dicumarol </e2> .
false	 <e1> Dicumarol </e1> : It has been reported that allopurinol prolongs the half-life of the  <e2> anticoagulant </e2> , dicumarol.
effect	Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving  <e1> ampicillin </e1>  or amoxicillin concurrently with  <e2> allopurinol </e2>  compared to patients who are not receiving both drugs.
false	Subsequent adjustment of doses of  <e1> mercaptopurine </e1>  or  <e2> azathioprine </e2>  should be made on the basis of therapeutic response and the appearance of toxic effects.
false	 <e1> Mercaptopurine </e1> /Azathioprine:  <e2> Allopurinol </e2>  inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
false	Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of  <e1> mercaptopurine </e1>  and azathioprine to  <e2> 6-thiouric acid </e2> .
false	 <e1> Chlorpropamide </e1> : Chlorpropamides plasma half-life may be prolonged by allopurinol, since  <e2> allopurinol </e2>  and chlorpropamide may compete for excretion in the renal tubule.
false	 <e1> Mercaptopurine </e1> /Azathioprine: Allopurinol inhibits the enzymatic oxidation of  <e2> mercaptopurine </e2>  and azathioprine to 6-thiouric acid.
false	In patients receiving mercaptopurine (Purinethol) or azathioprine ( <e1> Imuran </e1> ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of  <e2> mercaptopurine </e2>  or azathioprine.
false	Ampicillin/ <e1> Amoxicillin </e1> : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or  <e2> amoxicillin </e2>  concurrently with allopurinol compared to patients who are not receiving both drugs.
false	 <e1> Thiazide Diuretics </e1> : The reports that the concomitant use of allopurinol and  <e2> thiazide diuretics </e2>  may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
false	 <e1> Mercaptopurine </e1> /Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to  <e2> 6-thiouric acid </e2> .
false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril,  <e1> valsartan </e1> , metformin and amlodipine did not result in clinically significant increases in  <e2> aliskiren </e2>  exposure.
mechanism	Chlorpropamide:  <e1> Chlorpropamide </e1> s plasma half-life may be prolonged by  <e2> allopurinol </e2> , since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
false	Thiazide Diuretics: The reports that the concomitant use of allopurinol and  <e1> thiazide diuretics </e1>  may contribute to the enhancement of  <e2> allopurinol </e2>  toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
false	 <e1> Uricosuric Agents </e1> : Since the excretion of oxipurinol is similar to that of urate,  <e2> uricosuric agents </e2> , which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
advise	In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of  <e1> allopurinol </e1>  per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or  <e2> azathioprine </e2> .
false	Mercaptopurine/ <e1> Azathioprine </e1> :  <e2> Allopurinol </e2>  inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
false	 <e1> Chlorpropamide </e1> : Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and  <e2> chlorpropamide </e2>  may compete for excretion in the renal tubule.
false	However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide,  <e1> doxorubicin </e1> , bleomycin, procarbazine and/or  <e2> mechlorethamine </e2> .
false	 <e1> Chlorpropamide </e1> : Chlorpropamides plasma half-life may be prolonged by  <e2> allopurinol </e2> , since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
false	In patients receiving  <e1> mercaptopurine </e1>  (Purinethol) or azathioprine ( <e2> Imuran </e2> ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
mechanism	The concomitant administration of  <e1> uricosuric agents </e1>  and  <e2> allopurinol </e2>  has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
false	In patients receiving mercaptopurine ( <e1> Purinethol </e1> ) or azathioprine ( <e2> Imuran </e2> ), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
false	In patients receiving mercaptopurine ( <e1> Purinethol </e1> ) or azathioprine (Imuran), the concomitant administration of 300-600 mg of  <e2> allopurinol </e2>  per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
false	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or  <e1> ergot-type medications </e1>  (like dihydroergotamine or  <e2> methysergide </e2> ) and AXERT within 24 hours of each other should be avoided.
false	However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with  <e1> cyclophosphamide </e1> , doxorubicin,  <e2> bleomycin </e2> , procarbazine and/or mechlorethamine.
false	Because there is a theoretical basis that these effects may be additive, use of  <e1> ergotamine </e1> -containing or ergot-type medications (like  <e2> dihydroergotamine </e2>  or methysergide) and AXERT within 24 hours of each other should be avoided.
advise	Other 5-HT1B/1D Agonists Concomitant use of other  <e1> 5-HT1B/1D agonists </e1>  within 24 hours of treatment with  <e2> AXERT </e2>  is contraindicated.
effect	Thiazide Diuretics: The reports that the concomitant use of  <e1> allopurinol </e1>  and  <e2> thiazide diuretics </e2>  may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
false	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to  <e1> almotriptan </e1>  may be expected when  <e2> almotriptan </e2>  is used concomitantly with these medications.
false	Verapamil: Coadministration of almotriptan and  <e1> verapamil </e1>  resulted in a 24% increase in plasma concentrations of  <e2> almotriptan </e2> .
false	Although the interaction between  <e1> almotriptan </e1>  and other potent CYP3A4 inhibitors (e.g., itraconazole,  <e2> ritonavir </e2> , and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
false	Coadministration of almotriptan and the potent CYP3A4 inhibitor  <e1> ketoconazole </e1>  (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of  <e2> almotriptan </e2> .
false	Because there is a theoretical basis that these effects may be additive, use of  <e1> ergotamine </e1> -containing or  <e2> ergot-type medications </e2>  (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
false	However, in a well-controlled study of patients with lymphoma on combination therapy,  <e1> allopurinol </e1>  did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or  <e2> mechlorethamine </e2> .
advise	In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of  <e1> allopurinol </e1>  per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of  <e2> mercaptopurine </e2>  or azathioprine.
false	 <e1> Ampicillin </e1> /Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with  <e2> allopurinol </e2>  compared to patients who are not receiving both drugs.
mechanism	Verapamil: Coadministration of  <e1> almotriptan </e1>  and  <e2> verapamil </e2>  resulted in a 24% increase in plasma concentrations of almotriptan.
false	 <e1> Verapamil </e1> : Coadministration of  <e2> almotriptan </e2>  and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
false	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g.,  <e1> itraconazole </e1> , ritonavir, and  <e2> erythromycin </e2> ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
false	Co-administration of lovastatin, atenolol, warfarin, furosemide,  <e1> digoxin </e1> , celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and  <e2> amlodipine </e2>  did not result in clinically significant increases in aliskiren exposure.
false	Coadministration of alosetron and strong CYP3A4 inhibitors, such as  <e1> clarithromycin </e1> ,  <e2> telithromycin </e2> , protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
advise	Concomitant administration of  <e1> alosetron </e1>  and moderate CYP1A2 inhibitors, including quinolone antibiotics and  <e2> cimetidine </e2> , has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
false	Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral  <e1> contraceptive agents </e1>   <e2> ethinyl estradiol </e2>  and levonorgestrel (CYP3A4 substrates).
advise	Coadministration of  <e1> alosetron </e1>  and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors,  <e2> voriconazole </e2> , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
mechanism	Monoamine Oxidase Inhibitors: Coadministration of  <e1> moclobemide </e1>  resulted in a 27% decrease in  <e2> almotriptan </e2>  clearance and an increase in Cmax of approximately 6%.
false	Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including  <e1> quinolone antibiotics </e1>  and  <e2> cimetidine </e2> , has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
false	Although the interaction between  <e1> almotriptan </e1>  and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and  <e2> erythromycin </e2> ) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
false	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin,  <e1> telithromycin </e1> , protease inhibitors, voriconazole, and  <e2> itraconazole </e2>  has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
false	Coadministration of alosetron and strong CYP3A4 inhibitors, such as  <e1> clarithromycin </e1> , telithromycin,  <e2> protease inhibitors </e2> , voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
false	Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents  <e1> ethinyl estradiol </e1>  and  <e2> levonorgestrel </e2>  (CYP3A4 substrates).
effect	Although not studied with  <e1> alosetron </e1> , inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and  <e2> hydralazine </e2> .
false	Coadministration of alosetron and strong CYP3A4 inhibitors, such as  <e1> clarithromycin </e1> , telithromycin, protease inhibitors, voriconazole, and  <e2> itraconazole </e2>  has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
false	Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g.,  <e1> itraconazole </e1> , ritonavir, and erythromycin) has not been studied, increased exposures to  <e2> almotriptan </e2>  may be expected when almotriptan is used concomitantly with these medications.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with  <e1> alprazolam </e1> ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with  <e2> alprazolam </e2>  for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications,  <e1> anticonvulsants </e1> , antihistaminics,  <e2> ethanol </e2> , and other drugs which themselves produce CNS depression.
effect	The  <e1> benzodiazepines </e1> , including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants,  <e2> antihistaminics </e2> , ethanol, and other drugs which themselves produce CNS depression.
false	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin,  <e1> telithromycin </e1> ,  <e2> protease inhibitors </e2> , voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following:  <e1> diltiazem </e1> ,  <e2> isoniazid </e2> , macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than  <e1> alprazolam </e1>  suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid,  <e2> macrolide antibiotics </e2>  such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  <e1> benzodiazepines </e1>  metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem,  <e2> isoniazid </e2> , macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Uricosuric Agents: Since the excretion of  <e1> oxipurinol </e1>  is similar to that of urate,  <e2> uricosuric agents </e2> , which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
false	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin,  <e1> protease inhibitors </e1> ,  <e2> voriconazole </e2> , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
int	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with  <e1> alprazolam </e1>  for the following: diltiazem, isoniazid, macrolide antibiotics such as  <e2> erythromycin </e2>  and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  <e1> benzodiazepines </e1>  metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following:  <e2> diltiazem </e2> , isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
effect	The benzodiazepines, including  <e1> alprazolam </e1> , produce additive CNS depressant effects when co-administered with other psychotropic medications,  <e2> anticonvulsants </e2> , antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with  <e1> alprazolam </e1> ): Available data from clinical studies of benzodiazepines other than  <e2> alprazolam </e2>  suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to  <e1> alprazolam </e1>  or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than  <e2> alprazolam </e2>  suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
int	Data from in vitro studies of  <e1> benzodiazepines </e1>  other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone,  <e2> nicardipine </e2> , and nifedipine.
false	Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with  <e1> alprazolam </e1>  increased the maximum plasma concentration of  <e2> alprazolam </e2>  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to  <e1> alprazolam </e1>  or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following:  <e2> diltiazem </e2> , isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	In a pharmacokinetic study, 40 healthy female subjects received  <e1> fluvoxamine </e1>  in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of  <e2> alosetron </e2>  1 mg on the last day.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to  <e1> alprazolam </e1>  or on the basis of in vitro studies with alprazolam or other  <e2> benzodiazepines </e2>  (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of  <e1> benzodiazepines </e1>  other than  <e2> alprazolam </e2>  suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  <e1> benzodiazepines </e1>  metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of  <e2> benzodiazepines </e2>  other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
int	Data from in vitro studies of alprazolam suggest a possible drug interaction with  <e1> alprazolam </e1>  for the following: sertraline and  <e2> paroxetine </e2> .
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following:  <e1> diltiazem </e1> , isoniazid, macrolide antibiotics such as erythromycin and  <e2> clarithromycin </e2> , and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem,  <e1> isoniazid </e1> , macrolide antibiotics such as erythromycin and  <e2> clarithromycin </e2> , and grapefruit juice.
mechanism	The steady state plasma concentrations of  <e1> imipramine </e1>  and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of  <e2> alprazolam </e2>  tablets in doses up to 4 mg/day.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid,  <e1> macrolide antibiotics </e1>  such as  <e2> erythromycin </e2>  and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other  <e1> benzodiazepines </e1>  (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as  <e2> erythromycin </e2>  and clarithromycin, and grapefruit juice.
false	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine,  <e1> cyclosporine </e1> , amiodarone, nicardipine, and  <e2> nifedipine </e2> .
false	Drugs That Inhibit  <e1> Alprazolam </e1>  Metabolism Via Cytochrome P450 3A: The initial step in  <e2> alprazolam </e2>  metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).
false	Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following:  <e1> ergotamine </e1> , cyclosporine, amiodarone, nicardipine, and  <e2> nifedipine </e2> .
int	Data from in vitro studies of  <e1> benzodiazepines </e1>  other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and  <e2> nifedipine </e2> .
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with  <e1> alprazolam </e1>  or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid,  <e2> macrolide antibiotics </e2>  such as erythromycin and clarithromycin, and grapefruit juice.
false	and  <e1> diuretics </e1> , such as  <e2> furosemide </e2> .
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other  <e1> benzodiazepines </e1>  (caution is recommended during coadministration with  <e2> alprazolam </e2> ): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
false	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to  <e1> alprazolam </e1>  or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as  <e2> erythromycin </e2>  and clarithromycin, and grapefruit juice.
false	Use of Antithrombotics Aspirin and  <e1> heparin </e1>  have been administered concomitantly with and following infusions of  <e2> Activase </e2>  in the management of acute myocardial infarction or pulmonary embolism.
false	Because  <e1> heparin </e1> ,  <e2> aspirin </e2> , or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.
false	In addition to bleeding associated with heparin and  <e1> vitamin K antagonists </e1> , drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and  <e2> Abciximab </e2> ) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
false	Because  <e1> heparin </e1> , aspirin, or  <e2> Activase </e2>  may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.
effect	In addition to bleeding associated with  <e1> heparin </e1>  and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after  <e2> Activase </e2>  therapy.
false	Use of  <e1> Antithrombotics </e1>  Aspirin and heparin have been administered concomitantly with and following infusions of  <e2> Activase </e2>  in the management of acute myocardial infarction or pulmonary embolism.
false	Data from a randomized trial of  <e1> HEXALEN </e1>  and cisplatin plus or minus pyridoxine in ovarian cancer indicated that  <e2> pyridoxine </e2>  significantly reduced neurotoxicity;
false	Data from a randomized trial of HEXALEN and  <e1> cisplatin </e1>  plus or minus pyridoxine in ovarian cancer indicated that  <e2> pyridoxine </e2>  significantly reduced neurotoxicity;
false	Concurrent administration of HEXALEN and  <e1> antidepressants of the MAO inhibitor class </e1>  may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased  <e2> altretamine </e2> s half-life and toxicity in a rat model.
effect	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid,  <e1> dipyridamole </e1>  and Abciximab) may increase the risk of bleeding if administered prior to, during, or after  <e2> Activase </e2>  therapy.
false	Data from a randomized trial of HEXALEN and cisplatin plus or minus  <e1> pyridoxine </e1>  in ovarian cancer indicated that  <e2> pyridoxine </e2>  significantly reduced neurotoxicity;
effect	When  <e1> amiloride </e1>  HCl is administered concomitantly with an  <e2> angiotensin-converting enzyme inhibitor </e2> , the risk of hyperkalemia may be increased.
false	In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide  <e1> d <e2> iuretics </e1>  </e2> .
advise	 <e1> Lithium </e1>  generally should not be given with  <e2> diuretics </e2>  because they reduce its renal clearance and add a high risk of lithium toxicity.
effect	Renal clearance measurements of  <e1> PAH </e1>  cannot be made with any significant accuracy in patients receiving sulfonamides,  <e2> procaine </e2> , or thiazolesulfone.
false	Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving  <e1> sulfonamides </e1> ,  <e2> procaine </e2> , or thiazolesulfone.
false	It is, however, possible that concomitant use of other known  <e1> photosensitizing agents </e1>  such as  <e2> griseofulvin </e2> , thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
false	It is, however, possible that concomitant use of other known photosensitizing agents such as  <e1> griseofulvin </e1> , thiazide diuretics, sulfonylureas, phenothiazines,  <e2> sulfonamides </e2>  and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
effect	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines,  <e1> sulfonamides </e1>  and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the  <e2> LEVULAN KERASTICK </e2>  for Topical Solution.
false	It is, however, possible that concomitant use of other known photosensitizing agents such as  <e1> griseofulvin </e1> , thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and  <e2> tetracyclines </e2>  might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
effect	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics,  <e1> sulfonylureas </e1> , phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the  <e2> LEVULAN KERASTICK </e2>  for Topical Solution.
false	It is, however, possible that concomitant use of other known  <e1> photosensitizing agents </e1>  such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines,  <e2> sulfonamides </e2>  and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
mechanism	 <e1> Aminosalicylic acid </e1>  may decrease the amount of digoxin ( <e2> Lanoxin </e2> , Lanoxicaps) that gets absorbed into your body.
false	 <e1> Aminosalicylic acid </e1>  may decrease the amount of digoxin (Lanoxin,  <e2> Lanoxicaps </e2> ) that gets absorbed into your body.
false	In the case that you are taking  <e1> digoxin </e1>  while taking aminosalicylic acid, higher doses of  <e2> digoxin </e2>  may be needed.
false	 <e1> Antihypertensives </e1> : Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or  <e2> calcium channel </e2>  antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	 <e1> Histamine H2 antagonists </e1> : Cimetidine inhibits CYP3A4 and can increase serum  <e2> amiodarone </e2>  levels.
false	Sinus bradycardia has been reported with oral amiodarone in combination with  <e1> lidocaine </e1>  ( <e2> CYP3A4 </e2>  substrate) given for local anesthesia.
false	Since the concomitant administration of  <e1> warfarin </e1>  with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the  <e2> anticoagulant </e2>  should be reduced by one-third to one-half, and prothrombin times should be monitored closely.
false	Combination of  <e1> amiodarone </e1>  with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to  <e2> amiodarone </e2> .
false	Monitoring for  <e1> amiodarone </e1>  toxicity and serial measurement of amiodarone serum concentration during concomitant  <e2> protease inhibitor </e2>  therapy should be considered.
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  - <e1> receptor </e1>  blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and  <e2> diltiazem </e2> , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	Cardiovasculars:  <e1> Cardiac glycosides </e1> : In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum  <e2> digoxin </e2>  concentration that may reach toxic levels with resultant clinical toxicity.
false	Other reported interactions with  <e1> amiodarone </e1> :  <e2> Fentanyl </e2>  (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.
false	Anticoagulants: Potentiation of warfarin-type ( <e1> CYP2C9 </e1>  and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving  <e2> amiodarone </e2>  and can result in serious or fatal bleeding.
false	Antiarrhythmics: Other  <e1> antiarrhythmic </e1>  drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with  <e2> amiodarone </e2> .
false	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2,  <e1> CYP2C9 </e1> ,  <e2> CYP2D6 </e2> , and CYP3A4.
false	Amiodarone may suppress certain CYP450 enzymes, including  <e1> CYP1A2 </e1> , CYP2C9,  <e2> CYP2D6 </e2> , and CYP3A4.
false	There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when  <e1> fluoroquinolones </e1> ,  <e2> macrolide antibiotics </e2> , or azoles were administered concomitantly.
false	There have been reports of QTc prolongation, with or without TdP, in patients taking  <e1> amiodarone </e1>  when  <e2> fluoroquinolones </e2> , macrolide antibiotics, or azoles were administered concomitantly.
false	Administration of  <e1> rifampin </e1>  concomitantly with oral  <e2> amiodarone </e2>  has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.
false	Anticoagulants: Potentiation of warfarin-type ( <e1> CYP2C9 </e1>  and CYP3A4 substrate)  <e2> anticoagulant </e2>  response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
false	Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine ( <e1> CYP3A4 </e1>  substrate) administered in combination with oral  <e2> amiodarone </e2>  has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and  <e1> diltiazem </e1> , a  <e2> CYP3A4 </e2>  inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	 <e1> Amiodarone </e1>  taken concomitantly with quinidine increases  <e2> quinidine </e2>  serum concentration by 33% after two days.
false	Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving  <e1> amiodarone </e1>  could result in reduced  <e2> amiodarone </e2>  levels.
advise	On administration of oral  <e1> amiodarone </e1> , the need for  <e2> digitalis </e2>  therapy should be reviewed and the dose reduced by approximately 50% or discontinued.
false	Antihypertensives:  <e1> Amiodarone </e1>  should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a  <e2> CYP3A4 </e2>  substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	 <e1> Amiodarone </e1>  is metabolized to  <e2> desethylamiodarone </e2>  by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.
false	Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of  <e1> amiodarone </e1>  and  <e2> desethylamiodarone </e2> .
false	Sinus bradycardia has been reported with oral  <e1> amiodarone </e1>  in combination with lidocaine (CYP3A4 substrate) given for local  <e2> anesthesia </e2> .
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a  <e1> CYP3A4 </e1>  inhibitor) or  <e2> calcium channel </e2>  antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	 <e1> Amiodarone </e1>  taken concomitantly with digoxin increases the serum  <e2> digoxin </e2>  concentration by 70% after one day.
false	Antiarrhythmics: Other  <e1> antiarrhythmic </e1>  drugs, such as quinidine, procainamide, disopyramide, and  <e2> phenytoin </e2> , have been used concurrently with amiodarone.
false	Some drugs/substances are known to accelerate the metabolism of  <e1> amiodarone </e1>  by stimulating the synthesis of  <e2> CYP3A4 </e2>  (enzyme induction).
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g.,  <e1> propranolol </e1> , a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a  <e2> CYP3A4 </e2>  inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	Reported examples include the following:  <e1> Protease Inhibitors </e1> :  <e2> Protease inhibitors </e2>  are known to inhibit CYP3A4 to varying degrees.
false	Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide,  <e1> disopyramide </e1> , and  <e2> phenytoin </e2> , have been used concurrently with amiodarone.
false	 <e1> Cholestyramine </e1>  increases enterohepatic elimination of amiodarone and may reduce its serum levels and  <e2> t1 </e2> /2.
false	Antihypertensives:  <e1> Amiodarone </e1>  should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g.,  <e2> verapamil </e2> , a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	Antiarrhythmics: Other  <e1> antiarrhythmic </e1>  drugs, such as quinidine, procainamide,  <e2> disopyramide </e2> , and phenytoin, have been used concurrently with amiodarone.
false	 <e1> Amiodarone </e1>  taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl  <e2> procainamide </e2>  by 55% and 33%, respectively.
false	Antihypertensives:  <e1> Amiodarone </e1>  should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and  <e2> diltiazem </e2> , a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g.,  <e1> propranolol </e1> , a  <e2> CYP3A4 </e2>  inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	 <e1> Antihypertensives </e1> : Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a  <e2> CYP3A4 </e2>  inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	Cardiovasculars: Cardiac glycosides: In patients receiving  <e1> digoxin </e1>  therapy, administration of oral amiodarone regularly results in an increase in serum  <e2> digoxin </e2>  concentration that may reach toxic levels with resultant clinical toxicity.
false	Antiarrhythmics: Other  <e1> antiarrhythmic </e1>  drugs, such as  <e2> quinidine </e2> , procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.
false	 <e1> HMG-CoA Reductase Inhibitors </e1> : Simvastatin (CYP3A4 substrate) in combination with  <e2> amiodarone </e2>  has been associated with reports of myopathy/rhabdomyolysis.
false	Antiarrhythmics: Other  <e1> antiarrhythmic </e1>  drugs, such as quinidine,  <e2> procainamide </e2> , disopyramide, and phenytoin, have been used concurrently with amiodarone.
false	and disulfiram When amitriptyline HCl is given with anticholinergic agents or  <e1> sympathomimetic </e1>  drugs, including epinephrine combined with local  <e2> anesthetics </e2> , close supervision and careful adjustment of dosages are required.
false	Combination of  <e1> amiodarone </e1>  with other  <e2> antiarrhythmic </e2>  therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.
false	Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine,  <e1> procainamide </e1> , disopyramide, and phenytoin, have been used concurrently with  <e2> amiodarone </e2> .
false	and  <e1> disulfiram </e1>  When  <e2> amitriptyline HCl </e2>  is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
false	While all the selective  <e1> serotonin reuptake inhibitors </e1>  (SSRIs), e.g., fluoxetine, sertraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	Discontinuation of cimetidine in well-controlled patients receiving  <e1> tricyclic antidepressants </e1>  and cimetidine may decrease the plasma levels and efficacy of the  <e2> antidepressants </e2> .
false	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics  <e1> propafenone </e1>  and  <e2> flecainide </e2> ).
false	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the  <e1> Type 1C antiarrhythmics </e1>   <e2> propafenone </e2>  and flecainide).
mechanism	 <e1> Cimetidine </e1>  is reported to reduce hepatic metabolism of certain  <e2> tricyclic antidepressants </e2> , thereby delaying elimination and increasing steady-state concentrations of these drugs.
false	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the  <e1> Type 1C antiarrhythmics </e1>  propafenone and  <e2> flecainide </e2> ).
false	Since  <e1> amiodarone </e1>  is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced  <e2> amiodarone </e2>  levels.
false	cimetidine) and many that are substrates for P450 2D6 (many other  <e1> antidepressants </e1> , phenothiazines, and the Type 1C antiarrhythmics  <e2> propafenone </e2>  and flecainide).
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  - <e1> receptor </e1>  blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a  <e2> CYP3A4 </e2>  substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	Poor metabolizers have higher than expected plasma concentrations of  <e1> tricyclic antidepressants </e1>  ( <e2> TCAs </e2> ) when given usual doses.
false	cimetidine) and many that are substrates for P450 2D6 (many other  <e1> antidepressants </e1> , phenothiazines, and the Type 1C antiarrhythmics propafenone and  <e2> flecainide </e2> ).
false	There have been case reports of increased steady-state levels of quinidine, procainamide, and  <e1> phenytoin </e1>  during concomitant therapy with  <e2> amiodarone </e2> .
false	 <e1> cimetidine </e1> ) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the  <e2> Type 1C antiarrhythmics </e2>  propafenone and flecainide).
false	In addition to the interactions noted above, chronic (  2 weeks) oral  <e1> Cordarone </e1>  administration impairs metabolism of phenytoin,  <e2> dextromethorphan </e2> , and methotrexate.
false	There have been case reports of increased steady-state levels of  <e1> quinidine </e1> , procainamide, and phenytoin during concomitant therapy with  <e2> amiodarone </e2> .
false	Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly  <e1> anticholinergic </e1> , have been reported when cimetidine was added to the  <e2> drug </e2>  regimen.
false	Antihypertensives: Amiodarone should be used with caution in patients receiving  - <e1> receptor </e1>  blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or  <e2> calcium channel </e2>  antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
false	The continued need for the other  <e1> antiarrhythmic </e1>  agent should be reviewed after the effects of  <e2> amiodarone </e2>  have been established, and discontinuation ordinarily should be attempted.
effect	Transient delirium has been reported in patients who were treated with one gram of  <e1> ethchlorvynol </e1>  and 75 - 150 mg of  <e2> amitriptyline HCl </e2> .
effect	Digitalis glycosides:  <e1> amphotericin B </e1> -induced hypokalemia may potentiate  <e2> digitalis </e2>  toxicity.
false	Imidazoles (e. g.,  <e1> ketoconazole </e1> , miconazole, clotrimazole,  <e2> fluconazole </e2> , etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
false	 <e1> Imidazoles </e1>  (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and  <e2> imidazoles </e2>  suggest that imidazoles may induce fungal resistance to amphotericin B.
false	Imidazoles (e. g., ketoconazole, miconazole,  <e1> clotrimazole </e1> , fluconazole, etc.): in vitro and animal studies with the combination of  <e2> amphotericin B </e2>  and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
false	Seizure, associated with increased  <e1> lidocaine </e1>  concentrations, has been reported with concomitant administration of intravenous  <e2> amiodarone </e2> .
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g.,  <e1> fluoxetine </e1> ,  <e2> sertraline </e2> , and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and  <e1> imidazoles </e1>  suggest that imidazoles may induce fungal resistance to  <e2> amphotericin B </e2> .
false	Antiarrhythmics: Other antiarrhythmic drugs, such as  <e1> quinidine </e1> , procainamide, disopyramide, and phenytoin, have been used concurrently with  <e2> amiodarone </e2> .
false	Imidazoles (e. g.,  <e1> ketoconazole </e1> , miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to  <e2> amphotericin B </e2> .
false	 <e1> Imidazoles </e1>  (e. g.,  <e2> ketoconazole </e2> , miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
false	Cimetidine is reported to reduce hepatic metabolism of certain  <e1> tricyclic antidepressants </e1> , thereby delaying elimination and increasing steady-state concentrations of these  <e2> drugs </e2> .
false	Imidazoles (e. g.,  <e1> ketoconazole </e1> , miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that  <e2> imidazoles </e2>  may induce fungal resistance to amphotericin B.
false	Administration of rifampin concomitantly with oral  <e1> amiodarone </e1>  has been shown to result in decreases in serum concentrations of amiodarone and  <e2> desethylamiodarone </e2> .
false	Imidazoles (e. g., ketoconazole, miconazole,  <e1> clotrimazole </e1> , fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that  <e2> imidazoles </e2>  may induce fungal resistance to amphotericin B.
false	 <e1> Imidazoles </e1>  (e. g., ketoconazole,  <e2> miconazole </e2> , clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
effect	Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous  <e1> amphotericin B </e1>  and  <e2> leukocyte transfusions </e2> .
false	Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of  <e1> skeletal muscle relaxants </e1>  (e.g.,  <e2> tubocurarine </e2> ).
false	 <e1> Skeletal muscle relaxants </e1> :  <e2> amphotericin B </e2> -induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
false	Imidazoles (e. g., ketoconazole,  <e1> miconazole </e1> ,  <e2> clotrimazole </e2> , fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
false	Bacteriostatic Antibiotics: Chloramphenicol,  <e1> erythromycins </e1> ,  <e2> sulfonamides </e2> , or tetracyclines may interfere with the bactericidal effect of penicillins.
effect	Bacteriostatic Antibiotics:  <e1> Chloramphenicol </e1> , erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of  <e2> penicillins </e2> .
false	Other nephrotoxic medications: agents such as  <e1> aminoglycosides </e1> ,  <e2> cyclosporine </e2> , and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
false	Bacteriostatic Antibiotics:  <e1> Chloramphenicol </e1> , erythromycins,  <e2> sulfonamides </e2> , or tetracyclines may interfere with the bactericidal effect of penicillins.
false	 <e1> Bacteriostatic Antibiotics </e1> : Chloramphenicol, erythromycins,  <e2> sulfonamides </e2> , or tetracyclines may interfere with the bactericidal effect of penicillins.
false	 <e1> HIV Protease Inhibitors </e1> : The effect of amprenavir on total drug concentrations of other  <e2> HIV protease inhibitors </e2>  in subjects receiving both agents was evaluated using comparisons to historical data.
false	 <e1> HIV Protease Inhibitors </e1> : The effect of  <e2> amprenavir </e2>  on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data.
effect	Skeletal muscle relaxants:  <e1> amphotericin B </e1> -induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g.,  <e2> tubocurarine </e2> ).
false	HIV Protease Inhibitors: The effect of  <e1> amprenavir </e1>  on total drug concentrations of other  <e2> HIV protease inhibitors </e2>  in subjects receiving both agents was evaluated using comparisons to historical data.
mechanism	 <e1> Indinavir </e1>  steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant  <e2> amprenavir </e2> .
false	Bacteriostatic Antibiotics: Chloramphenicol, erythromycins,  <e1> sulfonamides </e1> , or  <e2> tetracyclines </e2>  may interfere with the bactericidal effect of penicillins.
false	 <e1> Bacteriostatic Antibiotics </e1> : Chloramphenicol, erythromycins, sulfonamides, or  <e2> tetracyclines </e2>  may interfere with the bactericidal effect of penicillins.
false	In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of  <e1> anagrelide </e1> , nor does anagrelide affect the PK properties of  <e2> digoxin </e2>  or warfarin.
mechanism	There is a single case report, which suggests that  <e1> sucralfate </e1>  may interfere with  <e2> anagrelide </e2>  absorption.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were  <e1> aspirin </e1> , acetaminophen, furosemide, iron,  <e2> ranitidine </e2> , hydroxyurea, and allopurinol.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron,  <e1> ranitidine </e1> , hydroxyurea, and  <e2> allopurinol </e2> .
false	In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of  <e1> digoxin </e1>  or  <e2> warfarin </e2> .
false	In vivo interaction studies in humans have demonstrated that  <e1> digoxin </e1>  and  <e2> warfarin </e2>  do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin.
effect	The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and  <e1> cilostazol </e1>  may be exacerbated by  <e2> anagrelide </e2> .
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were  <e1> aspirin </e1> ,  <e2> acetaminophen </e2> , furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
false	In vivo interaction studies in humans have demonstrated that  <e1> digoxin </e1>  and warfarin do not affect the PK properties of anagrelide, nor does  <e2> anagrelide </e2>  affect the PK properties of digoxin or warfarin.
false	The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone,  <e1> olprinone </e1>  and  <e2> cilostazol </e2>  may be exacerbated by anagrelide.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were  <e1> aspirin </e1> , acetaminophen, furosemide,  <e2> iron </e2> , ranitidine, hydroxyurea, and allopurinol.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin,  <e1> acetaminophen </e1> , furosemide, iron, ranitidine, hydroxyurea, and  <e2> allopurinol </e2> .
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine,  <e1> hydroxyurea </e1> , and  <e2> allopurinol </e2> .
false	In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and  <e1> etanercept </e1>  therapy, a 7% rate of serious infections was observed, which was higher than that observed with  <e2> etanercept </e2>  alone (0%).
false	The effects of medicinal products with similar properties such as inotropes milrinone,  <e1> enoximone </e1> , amrinone, olprinone and  <e2> cilostazol </e2>  may be exacerbated by anagrelide.
effect	In a study in which patients with active RA were treated for up to 24 weeks with concurrent  <e1> Kineret </e1>  and  <e2> etanercept </e2>  therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).
false	In vivo interaction studies in humans have demonstrated that  <e1> digoxin </e1>  and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of  <e2> digoxin </e2>  or warfarin.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were aspirin,  <e2> acetaminophen </e2> , furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and  <e2> allopurinol </e2> .
false	Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with  <e1> anagrelide </e1>  in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine,  <e2> hydroxyurea </e2> , and allopurinol.
false	At a median follow-up of 33 months, the combination of  <e1> ARIMIDEX </e1>  and tamoxifen did not demonstrate any efficacy benefit when compared with  <e2> tamoxifen </e2>  in all patients as well as in the hormone receptor-positive subpopulation.
advise	Caution should be observed when  <e1> anileridine </e1>  is coadministered with other  <e2> opioids </e2> , sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
false	Caution should be observed when anileridine is coadministered with other  <e1> opioids </e1> , sedatives, phenothiazines, or  <e2> anesthetics </e2> , as these agents may increase respiratory and circulatory depression.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ; <e2> antibiotics </e2> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates; <e1> carbamazepine </e1> ;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*; <e2> ethchlorvynol </e2> ;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ; <e2> disulfiram </e2> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e2> mefenamic acid </e2> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e2> disulfiram </e2> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen; <e2> indomethacin </e2> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone; <e2> anabolic steroids </e2> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e1> pentoxifylline </e1> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids; <e1> antihistamines </e1> ;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid; <e2> amiodarone </e2> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate,  <e1> dextran </e1> ) may increase the bleeding tendency produced by  <e2> anticoagulants </e2>  without altering prothrombin time determinations.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e2> ibuprofen </e2> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e1> griseofulvin </e1> ;haloperidol;meprobamate;oral contraceptives;paraldehyde; <e2> primidone </e2> ;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde; <e1> primidone </e1> ;ranitidine*; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine; <e2> cinchophen </e2> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e1> griseofulvin </e1> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e1> prolonged narcotics </e1> ;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e1> sulfinpyrazone </e1> ;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e1> salicylates </e1> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e1> naproxen </e1> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains; <e2> chloral hydrate </e2> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e2> clofibrate </e2> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e2> glucagon </e2> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics; <e2> bromelains </e2> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e2> dextran </e2> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e1> sulfonamides </e1> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e1> meprobamate </e1> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral  <e2> contraceptives </e2> ;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e1> meprobamate </e1> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations; <e2> vitamin C </e2> ;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine; <e2> diazoxide </e2> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ; <e2> cinchophen </e2> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*; <e1> antacids </e1> ; <e2> antihistamines </e2> ;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e2> disulfiram </e2> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*; <e1> ethchlorvynol </e1> ;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations; <e2> vitamin C </e2> ;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide; <e2> chymotrypsin </e2> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e1> naproxen </e1> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as  <e1> antineoplastic agents </e1> ) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs,  <e2> dipyridamole </e2> , hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e2> diazoxide </e2> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e1> oxolinic acid </e1> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e2> cinchophen </e2> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e1> sulfonamides </e1> , long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ; <e2> bromelains </e2> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e1> miconazole </e1> ;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde; <e2> primidone </e2> ;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in  <e1> vitamin K </e1> ;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e2> indomethacin </e2> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e1> phenyramidol </e1> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates; <e1> carbamazepine </e1> ;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol; <e2> glutethimide </e2> ;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e1> diuretics </e1> *;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in vitamin K; <e2> diuretics </e2> *;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e2> influenza virus vaccine </e2> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include: <e2> alcohol </e2> *;
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e1> diuretics </e1> *;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone; <e2> ranitidine </e2> *;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e1> phenyramidol </e1> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e2> dextran </e2> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e1> sulfinpyrazone </e1> ;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates; <e1> carbamazepine </e1> ;chloral hydrate*; <e2> chlordiazepoxide </e2> ;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde; <e1> primidone </e1> ;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e2> chymotrypsin </e2> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e2> glucagon </e2> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*; <e2> chlorpropamide </e2> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e2> disulfiram </e2> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e2> diazoxide </e2> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives; <e1> paraldehyde </e1> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations; <e2> vitamin C </e2> ;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ; <e2> influenza virus vaccine </e2> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide; <e1> cholestyramine </e1> ;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone; <e2> ranitidine </e2> *;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e1> thyroid drugs </e1> ;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine; <e1> chloral hydrate </e1> *;chlordiazepoxide; <e2> cholestyramine </e2> ;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*; <e1> antacids </e1> ;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations; <e2> vitamin C </e2> ;warfarin sodium under-dosage.
mechanism	For example, since  <e1> cholestyramine </e1>  may reduce the gastrointestinal absorption of both the oral  <e2> anticoagulants </e2>  and vitamin K, the net effects are unpredictable.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ; <e2> aminosalicylic acid </e2> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e2> diflunisal </e2> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other  <e1> non-steroidal anti-inflammatory drugs </e1> , dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by  <e2> anticoagulants </e2>  without altering prothrombin time determinations.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e2> glucagon </e2> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other  <e1> non-steroidal anti-inflammatory drugs </e1> ,  <e2> dipyridamole </e2> , hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e1> diuretics </e1> *;ethchlorvynol; <e2> glutethimide </e2> ;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*; <e1> ethchlorvynol </e1> ; <e2> glutethimide </e2> ;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e1> diuretics </e1> *;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde; <e2> primidone </e2> ;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e2> disulfiram </e2> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e2> influenza virus vaccine </e2> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e1> meprobamate </e1> ;oral  <e2> contraceptives </e2> ;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines; <e1> barbiturates </e1> ;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol; <e2> glutethimide </e2> ;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e2> cinchophen </e2> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e1> ranitidine </e1> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen; <e2> clofibrate </e2> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e1> pyrazolones </e1> ;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e2> chloral hydrate </e2> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e1> prolonged narcotics </e1> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol; <e1> glutethimide </e1> ;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e1> prolonged narcotics </e1> ;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e1> ranitidine </e1> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs; <e2> ibuprofen </e2> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; <e1> alcohol </e1> *;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*; <e2> chlordiazepoxide </e2> ;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e2> indomethacin </e2> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin; <e2> cimetidine </e2> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e1> oxolinic acid </e1> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates; <e1> carbamazepine </e1> ;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in  <e2> vitamin K </e2> ;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e1> phenytoin </e1> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen; <e2> clofibrate </e2> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e1> pyrazolones </e1> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives; <e2> paraldehyde </e2> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e1> miconazole </e1> ;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e2> ibuprofen </e2> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates; <e1> carbamazepine </e1> ;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone; <e2> ranitidine </e2> *;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e2> indomethacin </e2> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*; <e1> chlordiazepoxide </e1> ;cholestyramine;diet high in  <e2> vitamin K </e2> ;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e1> miconazole </e1> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e2> mefenamic acid </e2> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e2> diflunisal </e2> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e2> influenza virus vaccine </e2> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in  <e1> vitamin K </e1> ;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*; <e1> ethchlorvynol </e1> ;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde; <e2> primidone </e2> ;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran; <e2> dextrothyroxine </e2> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate; <e2> dextran </e2> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e2> ibuprofen </e2> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e1> griseofulvin </e1> ; <e2> haloperidol </e2> ;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs,  <e1> dipyridamole </e1> ,  <e2> hydrochloroquine </e2> , clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e1> quinine </e1> ;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e1> quinidine </e1> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that have been reported to diminish oral  <e1> anticoagulant </e1>  response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines; <e2> barbiturates </e2> ;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ; <e2> anabolic steroids </e2> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e2> clofibrate </e2> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e2> indomethacin </e2> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e1> griseofulvin </e1> ;haloperidol;meprobamate;oral contraceptives; <e2> paraldehyde </e2> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains; <e2> chloral hydrate </e2> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e1> chloral hydrate </e1> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e1> miconazole </e1> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e2> diazoxide </e2> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e1> phenytoin </e1> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e1> prolonged narcotics </e1> ;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e2> dextrothyroxine </e2> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
mechanism	For example, since  <e1> cholestyramine </e1>  may reduce the gastrointestinal absorption of both the oral anticoagulants and  <e2> vitamin K </e2> , the net effects are unpredictable.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids; <e1> antihistamines </e1> ;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde; <e2> primidone </e2> ;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids; <e2> antihistamines </e2> ;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e1> sulindac </e1> ;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e2> chymotrypsin </e2> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e2> bromelains </e2> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e1> sulfonamides </e1> , long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e1> salicylates </e1> ;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e2> fenoprofen </e2> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine; <e1> chloral hydrate </e1> *;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde; <e2> primidone </e2> ;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e1> meprobamate </e1> ;oral contraceptives; <e2> paraldehyde </e2> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ; <e2> cimetidine </e2> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e1> phenyramidol </e1> ; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran; <e1> dextrothyroxine </e1> ;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e2> glucagon </e2> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e2> influenza virus vaccine </e2> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e2> antibiotics </e2> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e1> pentoxifylline </e1> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e1> phenytoin </e1> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*; <e1> rifampin </e1> ;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e1> monoamine oxidase inhibitors </e1> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin; <e2> influenza virus vaccine </e2> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs; <e1> ibuprofen </e1> ;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e1> ranitidine </e1> *; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e2> diflunisal </e2> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg,  <e1> aspirin </e1>  and other  <e2> non-steroidal anti-inflammatory drugs </e2> , dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e1> phenyramidol </e1> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral  <e1> contraceptives </e1> ;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations; <e2> vitamin C </e2> ;warfarin sodium under-dosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the  <e1> 5HT3 antagonist class </e1>  (including, for example,  <e2> ondansetron </e2> , granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine; <e2> cinchophen </e2> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> Antihypertensive Medication </e1> s and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or  <e2> vasodilators </e2>  (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e2> metronidazole </e2> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron,  <e1> dolasetron </e1> ,  <e2> palonosetron </e2> , and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e1> miconazole </e1> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol; <e1> glutethimide </e1> ;griseofulvin;haloperidol;meprobamate;oral contraceptives; <e2> paraldehyde </e2> ;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids; <e1> antihistamines </e1> ;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	 <e1> 5HT3 Antagonists </e1> : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron,  <e2> palonosetron </e2> , and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine; <e1> cinchophen </e1> ;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e1> phenyramidol </e1> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> 5HT3 Antagonists </e1> : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and  <e2> alosetron </e2> ) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen; <e1> indomethacin </e1> ;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e1> methylphenidate </e1> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e1> naproxen </e1> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*; <e1> chlordiazepoxide </e1> ;cholestyramine;diet high in vitamin K;diuretics*; <e2> ethchlorvynol </e2> ;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole; <e2> miconazole </e2> ;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when  <e1> apomorphine </e1>  was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and  <e2> alosetron </e2> ) is contraindicated .
effect	Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant  <e1> antihypertensive medications </e1>  or  <e2> vasodilators </e2>  (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that  <e1> dopamine antagonists </e1> , such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa; <e2> methylphenidate </e2> ;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e1> naproxen </e1> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e2> chymotrypsin </e2> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e1> diuretics </e1> *;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids; <e1> antibiotics </e1> ;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e2> cimetidine </e2> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with  <e1> ondansetron </e1> , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron,  <e2> granisetron </e2> , dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e1> diflunisal </e1> ;disulfiram;drugs affecting blood elements; <e2> ethacrynic acid </e2> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e2> chlorpropamide </e2> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen; <e1> clofibrate </e1> ;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline; <e2> phenylbutazone </e2> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the  <e1> neuroleptics </e1>  (phenothiazines,  <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*; <e1> allopurinol </e1> ;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e2> chloral hydrate </e2> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin; <e1> haloperidol </e1> ;meprobamate;oral contraceptives;paraldehyde;primidone; <e2> ranitidine </e2> *;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin; <e1> influenza virus vaccine </e1> ;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e2> pentoxifylline </e2> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine; <e1> chloral hydrate </e1> *;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol; <e2> meprobamate </e2> ;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e1> prolonged narcotics </e1> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> Antihypertensive Medication </e1> s and  <e2> Vasodilators </e2> : The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K; <e1> diuretics </e1> *;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
advise	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of  <e1> apomorphine </e1>  with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and  <e2> alosetron </e2> ) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e1> pentoxifylline </e1> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e2> prolonged narcotics </e2> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol; <e2> phenytoin </e2> ;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid; <e1> fenoprofen </e1> ;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*; <e2> salicylates </e2> ;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal; <e2> disulfiram </e2> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine; <e1> diazoxide </e1> ;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e2> anesthetics </e2> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that  <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of  <e2> APOKYN </e2> .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e1> nalidixic acid </e1> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains; <e2> chloral hydrate </e2> *;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e2> mefenamic acid </e2> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones,  <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline; <e1> phenylbutazone </e1> ;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e2> chlorpropamide </e2> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that  <e1> dopamine antagonists </e1> , such as the  <e2> neuroleptics </e2>  (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines,  <e1> butyrophenones </e1> , thioxanthenes) or  <e2> metoclopramide </e2> , may diminish the effectiveness of APOKYN.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin; <e1> cimetidine </e1> ;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e2> disulfiram </e2> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg,  <e1> aspirin </e1>  and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine,  <e2> clofibrate </e2> , dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e2> sulindac </e2> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone; <e1> anabolic steroids </e1> ;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid; <e2> naproxen </e2> ;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include: <e1> alcohol </e1> *;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone; <e2> phenyramidol </e2> ;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine; <e2> ranitidine </e2> *;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate; <e1> metronidazole </e1> ;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin; <e1> haloperidol </e1> ;meprobamate;oral contraceptives;paraldehyde; <e2> primidone </e2> ;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac; <e2> thyroid drugs </e2> ;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones; <e2> quinidine </e2> ;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
advise	5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of  <e1> apomorphine </e1>  with drugs of the 5HT3 antagonist class (including, for example,  <e2> ondansetron </e2> , granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol; <e1> aminosalicylic acid </e1> ;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Dopamine Antagonists: Since  <e1> apomorphine </e1>  is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of  <e2> APOKYN </e2> .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone; <e2> sulfonamides </e2> , long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> Dopamine Antagonists </e1> : Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or  <e2> metoclopramide </e2> , may diminish the effectiveness of APOKYN.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines; <e1> barbiturates </e1> ;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral  <e2> contraceptives </e2> ;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e2> pyrazolones </e2> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine; <e1> chloral hydrate </e1> *;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen; <e1> glucagon </e1> ;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone; <e1> pentoxifylline </e1> ;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations; <e2> warfarin sodium </e2>  overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal; <e1> disulfiram </e1> ;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation  <e1> anesthetics </e1> ;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium; <e2> trimethoprim </e2> /sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> 5HT3 Antagonists </e1> : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example,  <e2> ondansetron </e2> , granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics; <e1> pyrazolones </e1> ;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs; <e2> tolbutamide </e2> ;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid; <e1> methyldopa </e1> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	 <e1> Dopamine Antagonists </e1> : Since apomorphine is a  <e2> dopamine agonist </e2> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include:  <e1> adrenocortical steroids </e1> ;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide; <e2> griseofulvin </e2> ;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics; <e1> bromelains </e1> ;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen; <e2> oxolinic acid </e2> ;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with  <e1> CNS depressants </e1>  (alcohol, barbiturates, opiates,  <e2> sedatives </e2> , anesthetics) should be considered.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone; <e1> ranitidine </e1> *; <e2> rifampin </e2> ;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide; <e1> chymotrypsin </e1> ;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies; <e2> diflunisal </e2> ;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements; <e1> ethacrynic acid </e1> ;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
effect	Drugs that reportedly may increase oral  <e1> anticoagulant </e1>  response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*; <e1> chlordiazepoxide </e1> ;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C; <e2> warfarin sodium </e2>  under-dosage.
false	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with  <e1> CNS depressants </e1>  ( <e2> alcohol </e2> , barbiturates, opiates, sedatives, anesthetics) should be considered.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate; <e1> dextran </e1> ;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates; <e2> sulfinpyrazone </e2> ;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ;methyldopa;methylphenidate;metronidazole;miconazole; <e2> monoamine oxidase inhibitors </e2> ;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol,  <e1> barbiturates </e1> ,  <e2> opiates </e2> , sedatives, anesthetics) should be considered.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e1> oxyphenbutazone </e1> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine; <e2> quinine </e2> ;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid; <e1> amiodarone </e1> ;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors; <e2> nalidixic acid </e2> ;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
advise	Caution should be observed when  <e1> anileridine </e1>  is coadministered with other opioids, sedatives,  <e2> phenothiazines </e2> , or anesthetics, as these agents may increase respiratory and circulatory depression.
advise	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of  <e1> IOPIDINE </e1>  0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives,  <e2> anesthetics </e2> ) should be considered.
false	Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids; <e1> alcohol </e1> *;antacids;antihistamines; <e2> barbiturates </e2> ;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*; <e1> chlorpropamide </e1> ;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid; <e2> oxyphenbutazone </e2> ;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Dopamine Antagonists: Since  <e1> apomorphine </e1>  is a  <e2> dopamine agonist </e2> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
false	Oral  <e1> contraceptives </e1> : Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of  <e2> ethinyl estradiol </e2>  by 43%, and decreased the AUC of norethindrone by 8%;
false	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g.,  <e1> rifampin </e1> , carbamazepine, phenytoin) may result in reduced plasma concentrations of  <e2> aprepitant </e2>  that may result in decreased efficacy of Aprepitant.
false	The oral dexamethasone doses should be reduced by approximately 50% when coadministered with  <e1> Aprepitant </e1> , to achieve exposures of  <e2> dexamethasone </e2>  similar to those obtained when it is given without Aprepitant.
false	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of  <e1> aprepitant </e1>  that may result in decreased efficacy of  <e2> Aprepitant </e2> .
mechanism	Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of  <e1> tolbutamide </e1>  500 mg was admini,stered orally prior to the administration of the 3-day regimen of  <e2> Aprepitant </e2>  and on Days 4,8, and 15.
false	Drugs that reduce the number of blood platelets by causing bone marrow depression (such as  <e1> antineoplastic agents </e1> ) or drugs which inhibit platelet function (eg, aspirin and other  <e2> non-steroidal anti-inflammatory drugs </e2> , dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
false	Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of  <e1> tolbutamide </e1>  (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of  <e2> tolbutamide </e2>  500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
false	The IV  <e1> methylprednisolone </e1>  dose should be reduced by approximately 25%, and the oral  <e2> methylprednisolone </e2>  dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
mechanism	 <e1> Aprepitant </e1>  increased the AUC of  <e2> midazolam </e2>  by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather; <e1> prolonged narcotics </e1> ;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide; <e2> triclofos sodium </e2> ;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
advise	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of  <e1> IOPIDINE </e1>  0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol,  <e2> barbiturates </e2> , opiates, sedatives, anesthetics) should be considered.
false	 <e1> Midazolam </e1> : Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of  <e2> Aprepitant </e2>  125 mg on Day 1 and 80 mg/day on Days 2 through 5.
false	The potential effects of increased plasma concentrations of midazolam or other  <e1> benzodiazepines </e1>  metabolized via CYP3A4 (alprazolam,  <e2> triazolam </e2> ) should be considered when coadministering these agents with Aprepitant.
false	Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both  <e1> aprepitant </e1>  and  <e2> paroxetine </e2> .
false	 <e1> Warfarin </e1> : A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic  <e2> warfarin </e2>  therapy.
false	 <e1> Paroxetine </e1> : Coadministration of once daily doses of  <e2> aprepitant </e2> , as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.
false	Oral  <e1> contraceptives </e1> : Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of  <e2> norethindrone </e2>  by 8%;
false	Ketoconazole: When a single 125-mg dose of  <e1> Aprepitant </e1>  was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of  <e2> aprepitant </e2>  increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
advise	The IV  <e1> methylprednisolone </e1>  dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with  <e2> Aprepitant </e2>  to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
false	Oral contraceptives:  <e1> Aprepitant </e1> , when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of  <e2> norethindrone </e2>  by 8%;
false	Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with  <e1> dexamethasone </e1>  coadministered orally as 20 mg on Day 1, and  <e2> Aprepitant </e2>  when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
mechanism	therefore, coadministration of  <e1> Aprepitant </e1>  with drugs that strongly induce CYP3A4 activity (e.g.,  <e2> rifampin </e2> , carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
false	Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of  <e1> ethinyl estradiol </e1>  and 1 mg of  <e2> norethindrone </e2> , decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
false	 <e1> Aprepitant </e1> , when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when  <e2> methylprednisolone </e2>  was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
advise	Because moderate CYP3A4 inhibitors (e.g.,  <e1> diltiazem </e1> ) result in 2-fold increase in plasma concentrations of  <e2> aprepitant </e2> , concomitant administration should also be approached with caution.
false	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine,  <e1> phenytoin </e1> ) may result in reduced plasma concentrations of  <e2> aprepitant </e2>  that may result in decreased efficacy of Aprepitant.
false	The IV methylprednisolone dose should be reduced by approximately 25%, and the oral  <e1> methylprednisolone </e1>  dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without  <e2> Aprepitant </e2> .
false	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone,  <e1> troleandomycin </e1> ,  <e2> clarithromycin </e2> , ritonavir, nelfinavir) should be approached with caution.
false	Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral  <e1> contraceptive </e1>  containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of  <e2> norethindrone </e2>  by 8%;
false	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole,  <e1> itraconazole </e1> , nefazodone, troleandomycin, clarithromycin,  <e2> ritonavir </e2> , nelfinavir) should be approached with caution.
false	Although there was no effect of  <e1> Aprepitant </e1>  on the plasma AUC of R(+) or  <e2> S(-) warfarin </e2>  determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.
false	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole,  <e1> itraconazole </e1> , nefazodone,  <e2> troleandomycin </e2> , clarithromycin, ritonavir, nelfinavir) should be approached with caution.
false	Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral  <e1> contraceptive </e1>  containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of  <e2> ethinyl estradiol </e2>  by 43%, and decreased the AUC of norethindrone by 8%;
false	 <e1> Tolbutamide </e1> : Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of  <e2> tolbutamide </e2>  500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
false	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g.,  <e1> rifampin </e1> , carbamazepine,  <e2> phenytoin </e2> ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
advise	Consequently, concomitant administration of  <e1> Aprepitant </e1>  with strong CYP3A4 inhibitors (e.g.,  <e2> ketoconazole </e2> , itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
effect	An additive hypotensive effect has been reported with the combination of systemic  <e1> clonidine </e1>  and  <e2> neuroleptic </e2>  therapy.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics; <e1> mefenamic acid </e1> ; <e2> methyldopa </e2> ;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Corticosteroids:  <e1> Dexamethasone </e1> : Aprepitant, when given as a regimen of 125mg with  <e2> dexamethasone </e2>  coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
false	Aprepitant increased the AUC of  <e1> midazolam </e1>  by 25% on Day 4 and decreased the AUC of  <e2> midazolam </e2>  by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
mechanism	Oral contraceptives:  <e1> Aprepitant </e1> , when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of  <e2> ethinyl estradiol </e2>  and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
false	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin,  <e1> carbamazepine </e1> , phenytoin) may result in reduced plasma concentrations of  <e2> aprepitant </e2>  that may result in decreased efficacy of Aprepitant.
false	 <e1> Aprepitant </e1>  is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with  <e2> digoxin </e2>  in a clinical drug interaction study.
false	 <e1> Midazolam </e1> : Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of  <e2> midazolam </e2>  2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
false	 <e1> Corticosteroids </e1> : Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and  <e2> Aprepitant </e2>  when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
false	Although there was no effect of  <e1> Aprepitant </e1>  on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with  <e2> Aprepitant </e2> .
false	 <e1> Tolbutamide </e1> : Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of  <e2> Aprepitant </e2>  and on Days 4,8, and 15.
false	Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of  <e1> ketoconazole </e1> , a strong CYP3A4 inhibitor, the AUC of  <e2> aprepitant </e2>  increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
false	Although there was no effect of  <e1> Aprepitant </e1>  on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in  <e2> S(-)warfarin </e2>  (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.
false	The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with  <e1> Aprepitant </e1>  to achieve exposures of methylprednisolone similar to those obtained when it is given without  <e2> Aprepitant </e2> .
false	therefore, coadministration of  <e1> Aprepitant </e1>  with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of  <e2> aprepitant </e2> .
false	Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole,  <e1> nefazodone </e1> ,  <e2> troleandomycin </e2> , clarithromycin, ritonavir, nelfinavir) should be approached with caution.
false	The IV  <e1> methylprednisolone </e1>  dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without  <e2> Aprepitant </e2> .
advise	The IV methylprednisolone dose should be reduced by approximately 25%, and the oral  <e1> methylprednisolone </e1>  dose should be reduced by approximately 50% when coadministered with  <e2> Aprepitant </e2>  to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
false	Antidepressants (tricyclic),  <e1> atropine </e1>  or other anticholinergic agents, or  <e2> digitalis glycosides </e2> : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
false	The potential effects of increased plasma concentrations of midazolam or other  <e1> benzodiazepines </e1>  metabolized via CYP3A4 ( <e2> alprazolam </e2> , triazolam) should be considered when coadministering these agents with Aprepitant.
false	Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with  <e1> CNS depressants </e1>  (alcohol, barbiturates, opiates, sedatives,  <e2> anesthetics </e2> ) should be considered.
false	 <e1> Antidepressants </e1>  ( <e2> tricyclic </e2> ), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
mechanism	Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and  <e1> Aprepitant </e1>  when given as 80 mg/day with  <e2> dexamethasone </e2>  coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
false	 <e1> Diltiazem </e1> : In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of  <e2> diltiazem </e2>  AUC.
false	Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting; <e1> sulindac </e1> ;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/ <e2> sulfamethoxazole </e2> ;unreliable prothrombin time determinations;warfarin sodium overdosage.
false	Antidepressants (tricyclic),  <e1> atropine </e1>  or other  <e2> anticholinergic agents </e2> , or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
false	 <e1> Antidepressants </e1>  (tricyclic), atropine or other  <e2> anticholinergic agents </e2> , or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
false	 <e1> Antidepressants </e1>  (tricyclic), atropine or other anticholinergic agents, or  <e2> digitalis glycosides </e2> : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
false	Ketoconazole: When a single 125-mg dose of  <e1> Aprepitant </e1>  was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of  <e2> aprepitant </e2>  increased approximately 3-fold.
effect	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as  <e1> nonsteroidal anti-inflammatory drugs </e1>  (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with  <e2> ardeparin </e2> .
false	Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as  <e1> nonsteroidal anti-inflammatory drugs </e1>  (NSAIDs), and  <e2> aspirin </e2>  may increase the risk of bleeding when administered concomitantly with ardeparin.
false	 <e1> Tolbutamide </e1> :  <e2> Aprepitant </e2> , when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
false	Antidepressants (tricyclic), atropine or other anticholinergic agents, or  <e1> digitalis glycosides </e1> : concurrent use with  <e2> arbutamine </e2>  may produce additive inotropic and/or chronotropic effects.
false	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine,  <e1> phenytoin </e1> ) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of  <e2> Aprepitant </e2> .
effect	Concomitant treatment with methylxanthines (aminophylline, theophylline),  <e1> steroids </e1> , or diuretics may potentiate any hypokalemic effect of  <e2> adrenergic agonists </e2> .
false	Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with  <e1> paroxetine </e1>  20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both  <e2> aprepitant </e2>  and paroxetine.
false	BROVANA, as with other  <e1> beta2-agonists </e1> , should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of  <e2> adrenergic agonists </e2>  on the cardiovascular system may be potentiated by these agents.
false	In a 12-month controlled trial that included a 50 mcg once daily  <e1> BROVANA </e1>  dose, 30 of the 528  <e2> BROVANA </e2>  -treated subjects received concomitant theophylline at study entry.
effect	 <e1> Beta-adrenergic receptor antagonists </e1>  (beta-blockers) and  <e2> BROVANA </e2>  may interfere with the effect of each other when administered concurrently.
false	 <e1> Anticoagulants </e1>  including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as  <e2> nonsteroidal anti-inflammatory drugs </e2>  (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
false	Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-)  <e1> warfarin </e1>  determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with  <e2> Aprepitant </e2> .
effect	The ECG changes and/or hypokalemia that may result from the administration of  <e1> non-potassium sparing diuretics </e1>  (such as loop or thiazide diuretics) can be acutely worsened by  <e2> beta-agonists </e2> , especially when the recommended dose of the beta-agonist is exceeded.
false	Concomitant treatment with  <e1> methylxanthines </e1>  (aminophylline,  <e2> theophylline </e2> ), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
false	The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by  <e1> beta-agonists </e1> , especially when the recommended dose of the  <e2> beta-agonist </e2>  is exceeded.
false	The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline,  <e1> theophylline </e1> ) by patients receiving  <e2> BROVANA </e2>  has not been completely evaluated.
advise	If additional  <e1> adrenergic drugs </e1>  are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of  <e2> BROVANA </e2>  may be potentiated.
false	The concurrent use of intravenously or orally administered methylxanthines (e.g.,  <e1> aminophylline </e1> , theophylline) by patients receiving  <e2> BROVANA </e2>  has not been completely evaluated.
false	The concurrent use of intravenously or orally administered methylxanthines (e.g.,  <e1> aminophylline </e1> ,  <e2> theophylline </e2> ) by patients receiving BROVANA has not been completely evaluated.
false	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between  <e1> Argatroban </e1>  and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of  <e2> Argatroban </e2>  1.5  g/kg/min. over 18 hours).
false	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or  <e1> acetaminophen </e1>  (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of  <e2> Argatroban </e2>  1.5  g/kg/min. over 18 hours).
false	 <e1> Heparin </e1> : Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of  <e2> Argatroban </e2>  and heparin is unlikely for this indication.
false	Heparin: Since  <e1> heparin </e1>  is contraindicated in patients with  <e2> heparin </e2> -induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.
false	The concurrent use of intravenously or orally administered  <e1> methylxanthines </e1>  (e.g., aminophylline,  <e2> theophylline </e2> ) by patients receiving BROVANA has not been completely evaluated.
false	Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between  <e1> Argatroban </e1>  and  <e2> warfarin </e2>  (7.5 mg single oral dose) have not been demonstrated.
effect	Co-administration: Concomitant use of  <e1> Argatroban </e1>  with antiplatelet agents, thrombolytics, and other  <e2> anticoagulants </e2>  may increase the risk of bleeding.
false	 <e1> Aspirin </e1> /Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered  <e2> aspirin </e2>  (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
false	Aspirin/ <e1> Acetaminophen </e1> : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between  <e2> Argatroban </e2>  and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
false	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of  <e1> Argatroban </e1>  1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of  <e2> Argatroban </e2>  1.5  g/kg/min. over 18 hours).
false	 <e1> Carbamazepine </e1> : Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite,  <e2> dehydro-aripiprazole </e2> .
false	When concomitant administration of ketoconazole with  <e1> aripiprazole </e1>  occurs,  <e2> aripiprazole </e2>  dose should be reduced to one-half of its normal dose.
false	Drug-Drug Interactions Given the primary CNS effects of  <e1> aripiprazole </e1> , caution should be used when  <e2> ABILIFY </e2>  is taken in combination with other centrally acting drugs and alcohol.
advise	When  <e1> carbamazepine </e1>  is added to  <e2> aripiprazole </e2>  therapy, aripiprazole dose should be doubled.
false	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered  <e1> aspirin </e1>  (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or  <e2> acetaminophen </e2>  (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
mechanism	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine,  <e1> fluoxetine </e1> , or paroxetine) can inhibit  <e2> aripiprazole </e2>  elimination and cause increased blood levels.
false	Carbamazepine: Coadministration of  <e1> carbamazepine </e1>  (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite,  <e2> dehydro-aripiprazole </e2> .
false	Quinidine: Coadministration of a 10-mg single dose of aripiprazole with  <e1> quinidine </e1>  (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite,  <e2> dehydroaripiprazole </e2> , by 35%.
false	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between  <e1> Argatroban </e1>  and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of  <e2> Argatroban </e2>  1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
false	In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( <e1> dextromethorphan </e1> ), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 ( <e2> dextromethorphan </e2> ) substrates.
false	No clinically significant effect of  <e1> famotidine </e1> , valproate, or  <e2> lithium </e2>  was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).
false	In in vivo studies, 10- to 30-mg/day doses of  <e1> aripiprazole </e1>  had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 ( <e2> warfarin </e2> ), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.
false	Potential for  <e1> ABILIFY </e1>  to Affect Other Drugs  <e2> Aripiprazole </e2>  is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.
mechanism	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg,  <e1> quinidine </e1> , fluoxetine, or paroxetine) can inhibit  <e2> aripiprazole </e2>  elimination and cause increased blood levels.
effect	1- adrenergic receptor antagonism,  <e1> aripiprazole </e1>  has the potential to enhance the effect of certain  <e2> antihypertensive agents </e2> .
false	Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of  <e1> Argatroban </e1>  1  g/kg/min. over 4 hours) or  <e2> acetaminophen </e2>  (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
false	When  <e1> carbamazepine </e1>  is added to aripiprazole therapy,  <e2> aripiprazole </e2>  dose should be doubled.
false	 <e1> Quinidine </e1> : Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite,  <e2> dehydroaripiprazole </e2> , by 35%.
false	In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole,  <e1> warfarin </e1> ), and CYP3A4 ( <e2> dextromethorphan </e2> ) substrates.
false	Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other  <e1> centrally acting drugs </e1>  and  <e2> alcohol </e2> .
false	Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with  <e1> aripiprazole </e1>  (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite,  <e2> dehydro-aripiprazole </e2> .
false	Other significant inhibitors of CYP2D6, such as  <e1> fluoxetine </e1>  or  <e2> paroxetine </e2> , would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions.
false	 <e1> Alcohol </e1> : There was no significant difference between aripiprazole coadministered with  <e2> ethanol </e2>  and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.
advise	Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when  <e1> ABILIFY </e1>  is taken in combination with other  <e2> centrally acting drugs </e2>  and alcohol.
false	In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 ( <e1> dextromethorphan </e1> ), CYP2C9 (warfarin), CYP2C19 ( <e2> omeprazole </e2> , warfarin), and CYP3A4 (dextromethorphan) substrates.
false	In a 12-month controlled trial that included a 50 mcg once daily  <e1> BROVANA </e1>  dose, 30 of the 528 BROVANA -treated subjects received concomitant  <e2> theophylline </e2>  at study entry.
false	Tissue culture and animal studies indicate that  <e1> ELSPAR </e1>  can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on  <e2> methotrexate </e2>  activity persists as long as plasma asparagine levels are suppressed.
false	 <e1> Uricosuric Agents </e1> :  <e2> Aspirin </e2>  may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
effect	Pyrazolone Derivatives ( <e1> phenylbutazone </e1> , oxyphenbutazone, and possibly dipyrone): Concomitant administration with  <e2> aspirin </e2>  may increase the risk of gastrointestinal ulceration.
advise	Nonsteroidal Antiinflammatory Agents:  <e1> Aspirin </e1>  is contraindicated in patients who are hypersensitive to  <e2> nonsteroidal anti-inflammatory </e2>  agents.
false	 <e1> Pyrazolone Derivatives </e1>  (phenylbutazone, oxyphenbutazone, and possibly  <e2> dipyrone </e2> ): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
false	Pyrazolone Derivatives ( <e1> phenylbutazone </e1> , oxyphenbutazone, and possibly  <e2> dipyrone </e2> ): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
effect	Pyrazolone Derivatives (phenylbutazone,  <e1> oxyphenbutazone </e1> , and possibly dipyrone): Concomitant administration with  <e2> aspirin </e2>  may increase the risk of gastrointestinal ulceration.
false	Uricosuric Agents: Aspirin may decrease the effects of probenecid,  <e1> sulfinpyrazone </e1> , and  <e2> phenylbutazone </e2> .
false	Ketoconazole/Itraconazole,  <e1> Macrolides </e1> , Including  <e2> Erythromycin </e2> 
false	 <e1> Ketoconazole </e1> /Itraconazole, Macrolides, Including  <e2> Erythromycin </e2> 
false	Pyrazolone Derivatives (phenylbutazone,  <e1> oxyphenbutazone </e1> , and possibly  <e2> dipyrone </e2> ): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
effect	Catecholamine-depleting drugs (eg,  <e1> reserpine </e1> ) may have an additive effect when given with  <e2> beta-blocking agent </e2> s.
false	 <e1> Nonsteroidal Antiinflammatory </e1>  Agents:  <e2> Aspirin </e2>  is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
false	In EM individuals treated with  <e1> paroxetine </e1>  or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than  <e2> atomoxetine </e2>  alone.
false	Drug-Drug Interactions  <e1> Albuterol </e1>  -  <e2> STRATTERA </e2>  should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
advise	Dosage adjustment of  <e1> STRATTERA </e1>  may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and  <e2> quinidine </e2> .
false	In EM individuals treated with paroxetine or fluoxetine, the AUC of  <e1> atomoxetine </e1>  is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than  <e2> atomoxetine </e2>  alone.
false	Drug-Drug Interactions Albuterol -  <e1> STRATTERA </e1>  should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of  <e2> albuterol </e2>  on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
false	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives,  <e1> niacin </e1>  (nicotinic acid),  <e2> erythromycin </e2> , azole antifungals.
false	 <e1> Colestipol </e1> : Plasma concentrations of  <e2> atorvastatin </e2>  decreased approximately 25% when colestipol and atorvastatin were coadministered.
false	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of  <e1> cyclosporine </e1> ,  <e2> fibric acid derivatives </e2> , niacin (nicotinic acid), erythromycin, azole antifungals.
advise	These increases should be considered when selecting an oral  <e1> contraceptive </e1>  for a woman taking  <e2> atorvastatin </e2> .
false	Colestipol: Plasma concentrations of  <e1> atorvastatin </e1>  decreased approximately 25% when colestipol and  <e2> atorvastatin </e2>  were coadministered.
false	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of  <e1> cyclosporine </e1> , fibric acid derivatives, niacin (nicotinic acid), erythromycin,  <e2> azole antifungals </e2> .
false	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of  <e1> cyclosporine </e1> , fibric acid derivatives,  <e2> niacin </e2>  (nicotinic acid), erythromycin, azole antifungals.
false	 <e1> Digoxin </e1> : When multiple doses of  <e2> atorvastatin </e2>  and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
false	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine,  <e1> fibric acid derivatives </e1> , niacin (nicotinic acid), erythromycin,  <e2> azole antifungals </e2> .
false	 <e1> Antacid </e1> : When atorvastatin and  <e2> Maalox TC </e2>  suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
false	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives,  <e1> niacin </e1>  ( <e2> nicotinic acid </e2> ), erythromycin, azole antifungals.
mechanism	Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of  <e1> atorvastatin </e1>  and  <e2> erythromycin </e2> , a known inhibitor of cytochrome P450 3A4.
false	 <e1> Antipyrine </e1> : Because atorvastatin does not affect the pharmacokinetics of  <e2> antipyrine </e2> , interactions with other drugs metabolized via the same cytochrome isozymes are not expected.
mechanism	Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when  <e1> colestipol </e1>  and  <e2> atorvastatin </e2>  were coadministered.
false	Erythromycin: In healthy individuals, plasma concentrations of  <e1> atorvastatin </e1>  increased approximately 40% with coadministration of atorvastatin and  <e2> erythromycin </e2> , a known inhibitor of cytochrome P450 3A4.
false	Digoxin: When multiple doses of  <e1> atorvastatin </e1>  and digoxin were coadministered, steady-state plasma  <e2> digoxin </e2>  concentrations increased by approximately 20%.
false	 <e1> Colestipol </e1> : Plasma concentrations of atorvastatin decreased approximately 25% when  <e2> colestipol </e2>  and atorvastatin were coadministered.
false	The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of  <e1> phenytoin </e1>  affected by the presence of  <e2> atovaquone </e2> .
false	Rifabutin, another rifamycin, is structurally similar to  <e1> rifampin </e1>  and may possibly have some of the same drug interactions as  <e2> rifampin </e2> .
false	The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of  <e1> cyclosporine </e1> , fibric acid derivatives, niacin (nicotinic acid),  <e2> erythromycin </e2> , azole antifungals.
false	 <e1> Erythromycin </e1> : In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and  <e2> erythromycin </e2> , a known inhibitor of cytochrome P450 3A4.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include:  <e1> enflurane </e1> ;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium; <e2> magnesium </e2>  salts;procainamide;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane; <e1> halothane </e1> ;certain  <e2> antibiotics </e2> , especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
false	The extent of plasma protein binding of  <e1> atovaquone </e1>  in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of  <e2> phenytoin </e2>  affected by the presence of atovaquone.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins; <e1> lithium </e1> ; <e2> magnesium </e2>  salts;procainamide;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain  <e1> antibiotics </e1> , especially the aminoglycosides and  <e2> polymyxins </e2> ;lithium;magnesium salts;procainamide;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the  <e1> aminoglycosides </e1>  and  <e2> polymyxins </e2> ;lithium;magnesium salts;procainamide;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the  <e1> aminoglycosides </e1>  and polymyxins; <e2> lithium </e2> ;magnesium salts;procainamide;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane; <e1> halothane </e1> ;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts; <e2> procainamide </e2> ;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include:  <e1> enflurane </e1> ;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and  <e2> polymyxins </e2> ;lithium;magnesium salts;procainamide;and quinidine.
effect	Drugs which may enhance the neuromuscular blocking action of  <e1> TRACRIUM </e1>  include: enflurane;isoflurane;halothane;certain antibiotics, especially the  <e2> aminoglycosides </e2>  and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
effect	The prior administration of  <e1> succinylcholine </e1>  does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by  <e2> TRACRIUM </e2> .
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include:  <e1> enflurane </e1> ;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins; <e2> lithium </e2> ;magnesium salts;procainamide;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane; <e1> isoflurane </e1> ; <e2> halothane </e2> ;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and  <e1> polymyxins </e1> ;lithium;magnesium salts;procainamide;and  <e2> quinidine </e2> .
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane; <e1> halothane </e1> ;certain antibiotics, especially the aminoglycosides and polymyxins;lithium; <e2> magnesium </e2>  salts;procainamide;and quinidine.
false	When atropine and  <e1> pralidoxime </e1>  are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when  <e2> atropine </e2>  is used alone because pralidoxime may potentiate the effect of atropine.
effect	When  <e1> atropine </e1>  and  <e2> pralidoxime </e2>  are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
advise	 <e1> TRACRIUM </e1>  should not be administered until a patient has recovered from  <e2> succinylcholine </e2> -induced neuromuscular block.
false	Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane; <e1> isoflurane </e1> ;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium; <e2> magnesium </e2>  salts;procainamide;and quinidine.
false	Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including  <e1> Solganal </e1>  and  <e2> Myochrysine </e2> .
false	When  <e1> atropine </e1>  and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of  <e2> atropine </e2> .
advise	 <e1> Auranofin </e1>  should not be used together with penicillamine ( <e2> Depen </e2> , Cuprimine), another arthritis medication.
effect	Concomitant use of  <e1> antihistamines </e1>  with alcohol, tricyclic antidepressants, barbiturates, or other  <e2> central nervous system depressants </e2>  may have an additive effect.
false	The antihypertensive effects of methyldopa,  <e1> mecamylamine </e1> , reserpine, and  <e2> veratrum alkaloids </e2>  may be reduced by sympathomimetics.
effect	Concomitant use of  <e1> antihistamines </e1>  with alcohol, tricyclic antidepressants,  <e2> barbiturates </e2> , or other central nervous system depressants may have an additive effect.
false	 <e1> Antacids </e1>  increase the rate of absorption of pseudoephedrine, while  <e2> kaolin </e2>  decreases it.
false	The antihypertensive effects of methyldopa,  <e1> mecamylamine </e1> ,  <e2> reserpine </e2> , and veratrum alkaloids may be reduced by sympathomimetics.
false	Concomitant use of antihistamines with  <e1> alcohol </e1> ,  <e2> tricyclic antidepressants </e2> , barbiturates, or other central nervous system depressants may have an additive effect.
false	Concomitant use of antihistamines with alcohol,  <e1> tricyclic antidepressants </e1> , barbiturates, or other  <e2> central nervous system depressants </e2>  may have an additive effect.
effect	Use with Angiotensln Converting Enzyme Inhibitors: The use of  <e1> angiotensin converting enzyme inhibitors </e1>  to control hypertension in patients on  <e2> azathioprine </e2>  has been reported to induce severe leukopenia.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole,  <e1> indinavir </e1> , midazolam, rifabutin,  <e2> sildenafil </e2> , theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of  <e1> atorvastatin </e1> , carbamazepine, cetirizine, didanosine, efavirenz,  <e2> fluconazole </e2> , indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	Although a dose adjustment of azithromycin is not recommended when administered in combination with  <e1> nelfinavir </e1> , close monitoring for known side effects of  <e2> azithromycin </e2> , such as liver enzyme abnormalities and hearing impairment, is warranted.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine,  <e1> efavirenz </e1> , fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam,  <e2> trimethoprim </e2> /sulfamethoxazole or zidovudine.
mechanism	When used in therapeutic doses,  <e1> azithromycin </e1>  had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine,  <e2> didanosine </e2> , efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz,  <e1> fluconazole </e1> , indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/ <e2> sulfamethoxazole </e2>  or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine,  <e1> didanosine </e1> , efavirenz, fluconazole, indinavir,  <e2> midazolam </e2> , rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	Although a dose adjustment of  <e1> azithromycin </e1>  is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of  <e2> azithromycin </e2> , such as liver enzyme abnormalities and hearing impairment, is warranted.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine,  <e1> cetirizine </e1> , didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral),  <e2> triazolam </e2> , trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir,  <e1> midazolam </e1> , rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/ <e2> sulfamethoxazole </e2>  or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole,  <e1> indinavir </e1> , midazolam,  <e2> rifabutin </e2> , sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir,  <e1> midazolam </e1> , rifabutin, sildenafil, theophylline (intravenous and oral),  <e2> triazolam </e2> , trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir,  <e1> midazolam </e1> ,  <e2> rifabutin </e2> , sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine,  <e1> didanosine </e1> , efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/ <e2> sulfamethoxazole </e2>  or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin,  <e1> sildenafil </e1> , theophylline (intravenous and oral), triazolam, trimethoprim/ <e2> sulfamethoxazole </e2>  or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of  <e1> atorvastatin </e1> , carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin,  <e2> sildenafil </e2> , theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
mechanism	When used in therapeutic doses,  <e1> azithromycin </e1>  had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine,  <e2> cetirizine </e2> , didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin,  <e1> carbamazepine </e1> , cetirizine, didanosine, efavirenz, fluconazole, indinavir,  <e2> midazolam </e2> , rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin,  <e1> carbamazepine </e1> ,  <e2> cetirizine </e2> , didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine,  <e1> cetirizine </e1> , didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil,  <e2> theophylline </e2>  (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	Cyclosporine,  <e1> hexobarbital </e1>  and  <e2> phenytoin </e2>  concentrations.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of  <e1> atorvastatin </e1> , carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam,  <e2> trimethoprim </e2> /sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam,  <e1> trimethoprim </e1> / <e2> sulfamethoxazole </e2>  or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine,  <e1> cetirizine </e1> , didanosine, efavirenz, fluconazole, indinavir,  <e2> midazolam </e2> , rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir,  <e1> midazolam </e1> , rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or  <e2> zidovudine </e2> .
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil,  <e1> theophylline </e1>  (intravenous and oral), triazolam,  <e2> trimethoprim </e2> /sulfamethoxazole or zidovudine.
mechanism	When used in therapeutic doses,  <e1> azithromycin </e1>  had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole,  <e2> indinavir </e2> , midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	Azlocillin should not be administered concomitantly with  <e1> amikacin </e1> , ciprofloxacin, gentamicin,  <e2> netilmicin </e2> , or tobramycin.
mechanism	When used in therapeutic doses,  <e1> azithromycin </e1>  had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam,  <e2> trimethoprim </e2> /sulfamethoxazole or zidovudine.
false	Azlocillin should not be administered concomitantly with amikacin,  <e1> ciprofloxacin </e1> , gentamicin,  <e2> netilmicin </e2> , or tobramycin.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz,  <e1> fluconazole </e1> ,  <e2> indinavir </e2> , midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
advise	 <e1> Azlocillin </e1>  should not be administered concomitantly with amikacin,  <e2> ciprofloxacin </e2> , gentamicin, netilmicin, or tobramycin.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of  <e1> atorvastatin </e1> , carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam,  <e2> rifabutin </e2> , sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	Azlocillin should not be administered concomitantly with  <e1> amikacin </e1> , ciprofloxacin,  <e2> gentamicin </e2> , netilmicin, or tobramycin.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine,  <e1> cetirizine </e1> ,  <e2> didanosine </e2> , efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
false	When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine,  <e1> cetirizine </e1> , didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or  <e2> zidovudine </e2> .
false	Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin,  <e1> gentamicin </e1> ,  <e2> netilmicin </e2> , or tobramycin.
false	SIDE EFFECTS ( <e1> KEMSTRO </e1> ) The most common adverse reaction during treatment with  <e2> baclofen </e2>  is transient drowsiness (10-63%).
false	No drug interaction studies have been conducted for COLAZAL, however the use of orally administered  <e1> antibiotics </e1>  could, theoretically, interfere with the release of  <e2> mesalamine </e2>  in the colon.
false	No dose adjustment is necessary when  <e1> Simulect </e1>  is added to triple-immunosuppression regimens including cyclosporine,  <e2> corticosteroids </e2> , and either azathioprine or mycophenolate mofetil.
false	Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and  <e1> mycophenolate mofetil </e1> , respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and  <e2> corticosteroids </e2> .
false	No dose adjustment is necessary when  <e1> Simulect </e1>  is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either  <e2> azathioprine </e2>  or mycophenolate mofetil.
false	The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine,  <e1> corticosteroids </e1> ,  <e2> cyclosporine </e2> , mycophenolate mofetil, and muromonab-CD3.
false	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine,  <e1> corticosteroids </e1> , and either  <e2> azathioprine </e2>  or mycophenolate mofetil.
false	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including  <e1> cyclosporine </e1> ,  <e2> corticosteroids </e2> , and either azathioprine or mycophenolate mofetil.
false	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including  <e1> cyclosporine </e1> , corticosteroids, and either  <e2> azathioprine </e2>  or mycophenolate mofetil.
false	Nonetheless, the range of individual  <e1> Simulect </e1>  clearance values in the presence of  <e2> azathioprine </e2>  (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).
false	Total body clearance of Simulect was reduced by an average 22% and 51% when  <e1> azathioprine </e1>  and  <e2> mycophenolate mofetil </e2> , respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
false	 <e1> Albuterol </e1> , Antihistamines, antidiabetic drugs,  <e2> diuretics </e2> , digitalis.
false	Albuterol, Antihistamines, antidiabetic drugs,  <e1> diuretics </e1> ,  <e2> digitalis </e2> .
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide,  <e1> chlorthalidone </e1> ,  <e2> furosemide </e2> , digoxin, propranolol, atenolol, naproxen, or cimetidine.
false	 <e1> Lotensin </e1>  has been used concomitantly with  <e2> beta-adrenergic-blocking agents </e2> , calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with  <e1> hydrochlorothiazide </e1> , chlorthalidone, furosemide, digoxin, propranolol, atenolol, naproxen, or  <e2> cimetidine </e2> .
false	 <e1> Potassium </e1>  Supplements and  <e2> Potassium-Sparing Diuretics </e2>  Lotensin can attenuate potassium loss caused by thiazide diuretics.
false	Potassium-sparing diuretics ( <e1> spironolactone </e1> ,  <e2> amiloride </e2> , triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone,  <e1> furosemide </e1> , digoxin, propranolol, atenolol,  <e2> naproxen </e2> , or cimetidine.
false	Potassium-sparing diuretics (spironolactone,  <e1> amiloride </e1> ,  <e2> triamterene </e2> , and others) or potassium supplements can increase the risk of hyperkalemia.
false	The possibility of hypotensive effects with  <e1> Lotensin </e1>  can be minimized by either discontinuing the  <e2> diuretic </e2>  or increasing the salt intake prior to initiation of treatment with Lotensin.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin,  <e1> propranolol </e1> ,  <e2> atenolol </e2> , naproxen, or cimetidine.
false	 <e1> Potassium-sparing diuretics </e1>  (spironolactone, amiloride,  <e2> triamterene </e2> , and others) or potassium supplements can increase the risk of hyperkalemia.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with  <e1> hydrochlorothiazide </e1> , chlorthalidone, furosemide, digoxin, propranolol,  <e2> atenolol </e2> , naproxen, or cimetidine.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with  <e1> hydrochlorothiazide </e1> , chlorthalidone, furosemide,  <e2> digoxin </e2> , propranolol, atenolol, naproxen, or cimetidine.
false	Other No clinically important pharmacokinetic interactions occurred when  <e1> Lotensin </e1>  was administered concomitantly with  <e2> hydrochlorothiazide </e2> , chlorthalidone, furosemide, digoxin, propranolol, atenolol, naproxen, or cimetidine.
false	 <e1> Lotensin </e1>  has been used concomitantly with beta-adrenergic-blocking agents,  <e2> calcium-channel-blocking agents </e2> , diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
false	Lotensin has been used concomitantly with  <e1> beta-adrenergic-blocking agents </e1> , calcium-channel-blocking agents,  <e2> diuretics </e2> , digoxin, and hydralazine, without evidence of clinically important adverse interactions.
effect	If a  <e1> diuretic </e1>  is also used, the risk of  <e2> lithium </e2>  toxicity may be increased.
false	Lotensin has been used concomitantly with beta-adrenergic-blocking agents,  <e1> calcium-channel-blocking agents </e1> ,  <e2> diuretics </e2> , digoxin, and hydralazine, without evidence of clinically important adverse interactions.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone,  <e1> furosemide </e1> , digoxin,  <e2> propranolol </e2> , atenolol, naproxen, or cimetidine.
false	Oral  <e1> Anticoagulants </e1>  Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these  <e2> anticoagulants </e2> .
effect	May interact with the following: cholestyramine,  <e1> colestipol </e1>  (use with  <e2> thiazide diuretics </e2>  may prevent the diuretic from working properly;
false	 <e1> Lithium </e1> : Increased serum  <e2> lithium </e2>  levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
false	Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide,  <e1> chlorthalidone </e1> , furosemide, digoxin, propranolol, atenolol,  <e2> naproxen </e2> , or cimetidine.
false	Oral  <e1> Anticoagulants </e1>  Interaction studies with  <e2> warfarin </e2>  and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and  <e1> lidocaine </e1> ), para-aminobenzoic acid ( <e2> PABA </e2> )-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid ( <e1> PABA </e1> )-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines),  <e2> thiazide diuretics </e2>  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g.,  <e1> Tylenol </e1> ), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl),  <e2> sulfonamides </e2>  (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g.,  <e1> Tylenol </e1> ), chloramphenicol (e.g., Chloromycetin), local  <e2> anesthetics </e2>  (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
int	 <e1> Bentiromide </e1>  may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and  <e2> lidocaine </e2> ), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins),  <e1> procainamide </e1>  (e.g.,  <e2> Pronestyl </e2> ), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol),  <e1> chloramphenicol </e1>  (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines),  <e2> thiazide diuretics </e2>  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g.,  <e1> Pronestyl </e1> ),  <e2> sulfonamides </e2>  (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g.,  <e1> Tylenol </e1> ), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and  <e2> lidocaine </e2> ), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g.,  <e1> benzocaine </e1>  and  <e2> lidocaine </e2> ), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with  <e1> acetaminophen </e1>  (e.g., Tylenol),  <e2> chloramphenicol </e2>  (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with  <e1> acetaminophen </e1>  (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid ( <e2> PABA </e2> )-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e1> Chloromycetin </e1> ), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid ( <e2> PABA </e2> )-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some  <e1> multivitamins </e1> ), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines),  <e2> thiazide diuretics </e2>  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with  <e1> acetaminophen </e1>  (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g.,  <e2> Pronestyl </e2> ), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with  <e1> acetaminophen </e1>  (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g.,  <e2> benzocaine </e2>  and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
int	 <e1> Bentiromide </e1>  may interact with acetaminophen (e.g., Tylenol),  <e2> chloramphenicol </e2>  (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
int	 <e1> Bentiromide </e1>  may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g.,  <e2> benzocaine </e2>  and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g.,  <e1> Tylenol </e1> ), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins),  <e2> procainamide </e2>  (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e1> Chloromycetin </e1> ), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines),  <e2> thiazide diuretics </e2>  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins),  <e1> procainamide </e1>  (e.g., Pronestyl),  <e2> sulfonamides </e2>  (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine),  <e1> para-aminobenzoic acid </e1>  (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl),  <e2> sulfonamides </e2>  (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e1> Chloromycetin </e1> ), local  <e2> anesthetics </e2>  (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid ( <e1> PABA </e1> )-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g.,  <e2> Pronestyl </e2> ), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol),  <e1> chloramphenicol </e1>  (e.g., Chloromycetin), local  <e2> anesthetics </e2>  (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
int	 <e1> Bentiromide </e1>  may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines),  <e2> thiazide diuretics </e2>  (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g.,  <e1> Chloromycetin </e1> ), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins),  <e2> procainamide </e2>  (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
false	Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local  <e1> anesthetics </e1>  (e.g., benzocaine and lidocaine),  <e2> para-aminobenzoic acid </e2>  (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
effect	 <e1> Amphetamines </e1>  may enhance the effects of  <e2> tricyclic antidepressants </e2> .
int	 <e1> Benzthiazide </e1>  may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or  <e2> Ibuprofen </e2> , and high blood pressure medications.
false	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine,  <e1> NSAIDs </e1>  like  <e2> Aleve </e2>  or Ibuprofen, and high blood pressure medications.
false	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs,  <e1> lithium </e1> , norepinephrine,  <e2> NSAIDs </e2>  like Aleve or Ibuprofen, and high blood pressure medications.
false	Benzthiazide may interact with  <e1> alcohol </e1> ,  <e2> blood thinner </e2> s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
int	 <e1> Benzthiazide </e1>  may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs,  <e2> lithium </e2> , norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
false	Benzthiazide may interact with alcohol,  <e1> blood thinner </e1> s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium,  <e2> norepinephrine </e2> , NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
false	Benzthiazide may interact with  <e1> alcohol </e1> , blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium,  <e2> norepinephrine </e2> , NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
false	Benzthiazide may interact with  <e1> alcohol </e1> , blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs,  <e2> lithium </e2> , norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
false	Antipsychotic drugs such as  <e1> phenothiazines </e1>  or  <e2> haloperidol </e2> ;
false	Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine,  <e1> NSAIDs </e1>  like Aleve or  <e2> Ibuprofen </e2> , and high blood pressure medications.
false	 <e1> Nitrates </e1> : The concomitant use of Bepridil with long- and short-acting  <e2> nitrates </e2>  has been safely tolerated in patients with stable angina pectoris.
false	In general, these are drugs that have one or more pharmacologic activities similar to  <e1> bepridil hydrochloride </e1> , including  <e2> anti-arrhythmic agents </e2>  such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.
false	Beta-blocking Agents: The concomitant use of  <e1> Bepridil </e1>  and  <e2> beta-blocking agents </e2>  has been well tolerated in patients with stable angina.
effect	 <e1> Cardiac glycosides </e1>  could exaggerate the depression of AV nodal conduction observed with  <e2> bepridil hydrochloride </e2> .
false	 <e1> Digoxin </e1> : In controlled studies in healthy volunteers,  <e2> bepridil hydrochloride </e2>  either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.
false	Sublingual  <e1> nitroglycerin </e1>  may be taken if necessary for the control of acute angina attacks during  <e2> Bepridil </e2>  therapy.
false	In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and  <e1> procainamide </e1> , cardiac glycosides and  <e2> tricyclic anti-depressants </e2> .
false	 <e1> Digoxin </e1> : In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum  <e2> digoxin </e2>  concentrations.
false	In general, these are drugs that have one or more pharmacologic activities similar to  <e1> bepridil hydrochloride </e1> , including anti-arrhythmic agents such as  <e2> quinidine </e2>  and procainamide, cardiac glycosides and tricyclic anti-depressants.
false	Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g.,  <e1> nifedipine </e1> , while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or  <e2> diltiazem </e2> .
false	The following drugs have been coadministered with  <e1> Kerlone </e1>  and have not altered its pharmacokinetics: cimetidine, nifedipine,  <e2> chlorthalidone </e2> , and hydrochlorothiazide.
effect	Risk of Anaphylactic Reaction: Although it is known that patients on  <e1> beta-blockers </e1>  may be refractory to  <e2> epinephrine </e2>  in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
false	The following drugs have been coadministered with  <e1> Kerlone </e1>  and have not altered its pharmacokinetics: cimetidine, nifedipine, chlorthalidone, and  <e2> hydrochlorothiazide </e2> .
false	Concomitant administration of  <e1> Kerlone </e1>  with the oral  <e2> anticoagulant </e2>  warfarin has been shown not to potentiate the anticoagulant effect of warfarin.
false	Risk of Anaphylactic Reaction: Although it is known that patients on  <e1> beta-blockers </e1>  may be refractory to epinephrine in the treatment of anaphylactic shock,  <e2> beta-blockers </e2>  can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
advise	Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the  <e1> beta-blocker </e1>  should be discontinued slowly over several days before the gradual withdrawal of  <e2> clonidine </e2> .
false	The following drugs have been coadministered with  <e1> Kerlone </e1>  and have not altered its pharmacokinetics: cimetidine,  <e2> nifedipine </e2> , chlorthalidone, and hydrochlorothiazide.
false	Should it be decided to discontinue therapy in patients receiving beta-blockers and  <e1> clonidine </e1>  concurrently, the  <e2> beta-blocker </e2>  should be discontinued slowly over several days before the gradual withdrawal of clonidine.
false	The following drugs have been coadministered with  <e1> Kerlone </e1>  and have not altered its pharmacokinetics:  <e2> cimetidine </e2> , nifedipine, chlorthalidone, and hydrochlorothiazide.
false	In Study 1, patients with colorectal cancer were given irinotecan/5-FU/ <e1> leucovorin </e1>  (bolus-IFL) with or without  <e2> AVASTIN </e2> .
false	 <e1> Irinotecan </e1>  concentrations were similar in patients receiving bolus-IFL alone and in combination with  <e2> AVASTIN </e2> .
false	Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent  <e1> irinotecan </e1>  and  <e2> AVASTIN </e2>  is uncertain.
mechanism	Concomitant administration of  <e1> Targretin </e1>  capsules and  <e2> gemfibrozil </e2>  resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
false	Concomitant administration of Targretin capsules and  <e1> gemfibrozil </e1>  resulted in substantial increases in plasma concentrations of  <e2> bexarotene </e2> , probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
mechanism	Furthermore,  <e1> rifampin </e1> , phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma  <e2> bexarotene </e2>  concentrations.
false	Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of  <e1> bexarotene </e1> , probably at least partially related to cytochrome P450 3A4 inhibition by  <e2> gemfibrozil </e2> .
false	On the basis of the metabolism of  <e1> bexarotene </e1>  by cytochrome P450 3A4, ketoconazole, itraconazole,  <e2> erythromycin </e2> , gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
false	On the basis of the metabolism of bexarotene by cytochrome P450 3A4,  <e1> ketoconazole </e1> , itraconazole, erythromycin,  <e2> gemfibrozil </e2> , grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
false	Concomitant administration of  <e1> Targretin </e1>  capsules and gemfibrozil resulted in substantial increases in plasma concentrations of  <e2> bexarotene </e2> , probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
false	- When  <e1> Bezalip </e1>  or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of  <e2> Bezalip </e2>  or Bezalip retard is impaired
advise	-  <e1> Perhexiline hydrogen maleate </e1>  or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or  <e2> Bezalip retard </e2> .
false	When  <e1> Bezalip </e1>  or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and  <e2> Bezalip retard </e2>  may enhance the action of anticoagulants of the coumarin type.
false	- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with  <e1> Bezalip </e1>  or  <e2> Bezalip retard </e2> .
false	When  <e1> Bezalip </e1>  or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of  <e2> anticoagulants of the coumarin type </e2> .
advise	- When  <e1> Bezalip </e1>  or Bezalip retard is used concurrently with anion-exchange resins (e.g.  <e2> cholestryramine </e2> ), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
effect	- The action of  <e1> sulphonylureas </e1>  and insulin may be enhanced by Bezalip or  <e2> Bezalip retard </e2> .
false	- When  <e1> Bezalip </e1>  or  <e2> Bezalip retard </e2>  is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
false	When Bezalip or  <e1> Bezalip retard </e1>  is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of  <e2> anticoagulants of the coumarin type </e2> .
false	Under similar conditions,  <e1> bexarotene </e1>  concentrations were not affected by concomitant  <e2> atorvastatin </e2>  administration.
advise	For this reason, the dose of the  <e1> anticoagulant </e1>  should be reduced by 30 - 50% at the start of treatment with Bezalip or  <e2> Bezalip </e2>  retard and then titrated according to the blood clotting parameters
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the  <e1> phenothiazines </e1>  and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the  <e2> quinidine </e2>  salts, and antihistamines.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain  <e1> antiarrhythmics </e1>  such as the  <e2> quinidine </e2>  salts, and antihistamines.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the  <e1> phenothiazines </e1>  and other antipsychotics,  <e2> tricyclic antidepressants </e2> , certain antiarrhythmics such as the quinidine salts, and antihistamines.
effect	Drug Interactions: The central  <e1> anticholinergic </e1>  syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics,  <e2> tricyclic antidepressants </e2> , certain antiarrhythmics such as the quinidine salts, and antihistamines.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other  <e1> antipsychotics </e1> , tricyclic antidepressants, certain antiarrhythmics such as the  <e2> quinidine </e2>  salts, and antihistamines.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain  <e1> narcotic analgesics </e1>  such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and  <e2> antihistamines </e2> .
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain  <e1> antiarrhythmics </e1>  such as the quinidine salts, and  <e2> antihistamines </e2> .
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as  <e1> AKINETON </e1>  are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain  <e2> narcotic analgesics </e2>  such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
effect	Drug Interactions: The central  <e1> anticholinergic </e1>  syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as  <e2> meperidine </e2> , the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics,  <e1> tricyclic antidepressants </e1> , certain  <e2> antiarrhythmics </e2>  such as the quinidine salts, and antihistamines.
advise	 <e1> ZEBETA </e1>  should be used with care when  <e2> myocardial depressants </e2>  or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
false	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the  <e1> phenothiazines </e1>  and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and  <e2> antihistamines </e2> .
advise	 <e1> ZEBETA </e1>  should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as  <e2> disopyramide </e2> , are used concurrently.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and  <e1> benzothiazepine </e1>  [ <e2> diltiazem </e2> ] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
false	In patients receiving concurrent therapy with  <e1> clonidine </e1> , if therapy is to be discontinued, it is suggested that  <e2> ZEBETA </e2>  be discontinued for several days before the withdrawal of clonidine.
false	ZEBETA should be used with care when  <e1> myocardial depressants </e1>  or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [ <e2> diltiazem </e2> ] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [ <e1> verapamil </e1> ] and benzothiazepine [diltiazem] classes), or  <e2> antiarrhythmic agents </e2> , such as disopyramide, are used concurrently.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or  <e1> antiarrhythmic agents </e1> , such as  <e2> disopyramide </e2> , are used concurrently.
effect	Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as  <e1> AKINETON </e1>  are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain  <e2> antiarrhythmics </e2>  such as the quinidine salts, and antihistamines.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the  <e1> phenylalkylamine </e1>  [verapamil] and  <e2> benzothiazepine </e2>  [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [ <e1> diltiazem </e1> ] classes), or antiarrhythmic agents, such as  <e2> disopyramide </e2> , are used concurrently.
false	ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [ <e1> verapamil </e1> ] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as  <e2> disopyramide </e2> , are used concurrently.
advise	If you are also using a steroid inhaler, take  <e1> bitolterol </e1>  first and then wait about 15 minutes before using the  <e2> steroid </e2>  inhaler.
false	Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including  <e1> thiazide diuretics </e1> , digoxin, and  <e2> cimetidine </e2> .
false	In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin,  <e1> warfarin </e1> ,  <e2> thrombolytics </e2>  or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
effect	In clinical trials in patients undergoing PTCA/PCI, co-administration of  <e1> Angiomax </e1>  with  <e2> heparin </e2> , warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
false	Certain antibiotic,  <e1> cisplatin </e1> , cyclosporine,  <e2> diuretic </e2> , foscarnet, and vaccines.
false	Among 494 subjects who received  <e1> Angiomax </e1>  in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive  <e2> bivalirudin </e2>  antibody tests.
false	Certain  <e1> antibiotic </e1> ,  <e2> cisplatin </e2> , cyclosporine, diuretic, foscarnet, and vaccines.
false	Certain antibiotic, cisplatin,  <e1> cyclosporine </e1> ,  <e2> diuretic </e2> , foscarnet, and vaccines.
false	Digoxin, Nimodipine and Losartan:  <e1> Bosentan </e1>  has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of  <e2> bosentan </e2> .
false	Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both  <e1> S-warfarin </e1>  (a CYP2C9 substrate) and  <e2> R-warfarin </e2>  (a CYP3A4 substrate) by 29 and 38%, respectively.
false	Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or  <e1> warfarin </e1>  dose (baseline vs. end of the clinical studies), and the need to change the  <e2> warfarin </e2>  dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.
false	Clinical experience with concomitant administration of  <e1> bosentan </e1>  and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or  <e2> warfarin </e2>  dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.
false	Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or  <e1> warfarin </e1>  dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among  <e2> bosentan </e2> - and placebo-treated patients.
false	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable  <e1> Contraceptives </e1> : An interaction study demonstrated that co-administration of  <e2> bosentan </e2>  and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
false	 <e1> Simvastatin </e1>  and Other  <e2> Statins </e2> : Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.
false	Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and  <e1> ketoconazole </e1> , a potent CYP3A4 inhibitor, increased the plasma concentrations of  <e2> bosentan </e2>  by approximately 2-fold.
false	Ketoconazole: Co-administration of  <e1> bosentan </e1>  125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of  <e2> bosentan </e2>  by approximately 2-fold.
false	Clinical experience with concomitant administration of bosentan and  <e1> warfarin </e1>  in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the  <e2> warfarin </e2>  dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.
false	 <e1> Digoxin </e1> , Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of  <e2> bosentan </e2> .
false	Digoxin, Nimodipine and  <e1> Losartan </e1> : Bosentan has no significant pharmacokinetic interactions with  <e2> digoxin </e2>  and nimodipine, and losartan has no significant effect on plasma levels of bosentan.
advise	Therefore, the concomitant administration of  <e1> TRACLEER </e1>  and  <e2> glyburide </e2>  is contraindicated, and alternative hypoglycemic agents should be considered.
false	Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the  <e1> warfarin </e1>  dose during the trials due to changes in INR or due to adverse events was similar among  <e2> bosentan </e2> - and placebo-treated patients.
false	 <e1> Warfarin </e1> : Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both  <e2> S-warfarin </e2>  (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
false	Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive  <e1> Ortho-Novum </e1>  produced average decreases of norethindrone and  <e2> ethinyl estradiol </e2>  levels of 14% and 31%, respectively.
mechanism	Co-administration of  <e1> bosentan </e1>  decreased the plasma concentrations of  <e2> glyburide </e2>  by approximately 40%.
false	Specific interaction studies have demonstrated the following:  <e1> Cyclosporine A </e1> : During the first day of concomitant administration, trough concentrations of  <e2> bosentan </e2>  were increased by about 30-fold.
false	 <e1> Hormonal Contraceptives </e1> , Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of  <e2> norethindrone </e2>  and ethinyl estradiol levels of 14% and 31%, respectively.
false	Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and  <e1> losartan </e1>  has no significant effect on plasma levels of  <e2> bosentan </e2> .
mechanism	 <e1> Bosentan </e1>  is also expected to reduce plasma concentrations of other  <e2> statins </e2>  that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
mechanism	Warfarin: Co-administration of  <e1> bosentan </e1>  500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and  <e2> R-warfarin </e2>  (a CYP3A4 substrate) by 29 and 38%, respectively.
false	Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g.,  <e1> curare-like compounds </e1> ) should only be performed with caution as the effect of the  <e2> toxin </e2>  may be potentiated.
false	Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with  <e1> digoxin </e1>  and nimodipine, and losartan has no significant effect on plasma levels of  <e2> bosentan </e2> .
false	Co-administration of BOTOX and  <e1> aminoglycosides </e1>  or other agents interfering with neuromuscular transmission (e.g.,  <e2> curare-like compounds </e2> ) should only be performed with caution as the effect of the toxin may be potentiated.
advise	Patients using CYP3A4 metabolized  <e1> statins </e1>  should have cholesterol levels monitored after  <e2> TRACLEER </e2>  is initiated to see whether the statin dose needs adjustment.
false	 <e1> Digoxin </e1> , Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and  <e2> nimodipine </e2> , and losartan has no significant effect on plasma levels of bosentan.
false	Co-administration of  <e1> MYOBLOC </e1>  and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the  <e2> toxin </e2>  may be potentiated.
false	Co-administration of BOTOX and  <e1> aminoglycosides </e1>  or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the  <e2> toxin </e2>  may be potentiated.
effect	The pressor effects of  <e1> catecholamines </e1>  such as dopamine or norepinephrine are enhanced by  <e2> Bretylium Tosylate </e2> .
false	Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g.,  <e1> curare-like compounds </e1> ) should only be performed with caution as the effect of the  <e2> toxin </e2>  may be potentiated.
false	Caution in using concomitant drugs such as  <e1> beta-blockers </e1>  (ophthalmic and systemic),  <e2> anti-hypertensives </e2>  and/or cardiac glycosides is advised.
false	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants ( <e1> alcohol </e1> , barbiturates, opiates, sedatives, or  <e2> anesthetics </e2> ) should be considered.
false	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with  <e1> CNS depressants </e1>  (alcohol, barbiturates, opiates,  <e2> sedatives </e2> , or anesthetics) should be considered.
advise	Although specific drug interaction studies have not been conducted with  <e1> ALPHAGAN P </e1> , the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or  <e2> anesthetics </e2> ) should be considered.
false	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol,  <e1> barbiturates </e1> ,  <e2> opiates </e2> , sedatives, or anesthetics) should be considered.
false	Therefore, the potential for such drug interaction should be considered in patients receiving  <e1> AZOPT </e1>  ( <e2> brinzolamide </e2>  ophthalmic suspension) 1%.
false	The pressor effects of catecholamines such as  <e1> dopamine </e1>  or  <e2> norepinephrine </e2>  are enhanced by Bretylium Tosylate.
effect	Compounds in these categories result in a decreased efficacy of  <e1> bromocriptine mesylate </e1> : phenothiazines,  <e2> haloperidol </e2> , metoclopramide, pimozide.
false	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate:  <e1> phenothiazines </e1> , haloperidol,  <e2> metoclopramide </e2> , pimozide.
false	Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines,  <e1> haloperidol </e1> ,  <e2> metoclopramide </e2> , pimozide.
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with  <e1> alcohol </e1>  or other  <e2> CNS depressants </e2>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or  <e1> antihistamines </e1> ),  <e2> anticholinergics </e2>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e2> antihistamines </e2> ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
effect	 <e1> Dexbrompheniramine </e1>  can interact with  <e2> alcohol </e2>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with  <e1> alcohol </e1>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e1> antihistamines </e1> ), and monoamine oxidase (MAO) inhibitors (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or  <e2> antihistamines </e2> ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with  <e1> alcohol </e1>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or  <e2> antihistamines </e2> ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	 <e1> Dexbrompheniramine </e1>  can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e2> antihistamines </e2> ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with  <e1> alcohol </e1>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e2> antihistamines </e2> ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or  <e1> antihistamines </e1> ),  <e2> anticholinergics </e2>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole,  <e1> intraconazole </e1> ,  <e2> ritonavir </e2> , indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
false	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole,  <e1> intraconazole </e1> , ritonavir,  <e2> indinavir </e2> , saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
false	This drug may interact with  <e1> alcohol </e1>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e2> anticholinergics </e2>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
advise	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir,  <e1> indinavir </e1> , saquinavir, erythromycin, etc.) is indicated, reduction of the  <e2> budesonide </e2>  dose should be considered.
false	This drug may interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
advise	Thus,  <e1> probenecid </e1>  should not be administered concurrently with  <e2> bumetanide </e2> .
false	- Anticoagulants: Interaction studies in humans have shown  <e1> bumetanide </e1>  to have no effect on  <e2> warfarin </e2>  metabolism or on plasma prothrombin activity.
false	-  <e1> Indomethacin </e1> : Indomethacin blunts the increases in urine volume and sodium excretion seen during  <e2> bumetanide </e2>  treatment and inhibits the bumetanide-induced increase in plasma renin activity.
false	-  <e1> Indomethacin </e1> : Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the  <e2> bumetanide </e2> -induced increase in plasma renin activity.
false	-  <e1> Anticoagulants </e1> : Interaction studies in humans have shown  <e2> bumetanide </e2>  to have no effect on warfarin metabolism or on plasma prothrombin activity.
effect	- Probenecid: Pretreatment with  <e1> probenecid </e1>  reduces both the natriuresis and hyperreninemia produced by  <e2> bumetanide </e2> .
false	-  <e1> Probenecid </e1> : Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by  <e2> bumetanide </e2> .
false	-  <e1> Antihypertensives </e1> : Bumetanide may potentiate the effect of various  <e2> antihypertensive drugs </e2> , necessitating a reduction in the dosage of these drugs.
false	The administration of local  <e1> anesthetic solutions </e1>  containing epinephrine or  <e2> norepinephrine </e2>  to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
false	-  <e1> Lithium </e1> : Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of  <e2> lithium </e2>  toxicity.
effect	The administration of local anesthetic solutions containing epinephrine or  <e1> norepinephrine </e1>  to patients receiving monoamine oxidase inhibitors or  <e2> tricyclic antidepressants </e2>  may produce severe, prolonged hypertension.
false	ketoconazole), macrolide antibiotics (e.g.  <e1> erythromycin </e1> ), and HIV protease inhibitors (e.g. ritonavir,  <e2> indinavir </e2>  and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
false	Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with  <e1> SUBOXONE </e1>  or  <e2> SUBUTEX </e2> .
advise	 <e1> SUBUTEX </e1>  and SUBOXONE should be prescribed with caution to patients on  <e2> benzodiazepines </e2>  or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
false	ketoconazole),  <e1> macrolide antibiotics </e1>  (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and  <e2> saquinavir </e2> ) should have their dose of SUBUTEX or SUBOXONE adjusted.
false	 <e1> Buprenorphine </e1>  is metabolized to  <e2> norbuprenorphine </e2>  by cytochrome CYP 3A4.
false	ketoconazole),  <e1> macrolide antibiotics </e1>  (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or  <e2> SUBOXONE </e2>  adjusted.
false	ketoconazole),  <e1> macrolide antibiotics </e1>  (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of  <e2> SUBUTEX </e2>  or SUBOXONE adjusted.
false	 <e1> ketoconazole </e1> ), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir,  <e2> indinavir </e2>  and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
false	ketoconazole), macrolide antibiotics (e.g. erythromycin), and  <e1> HIV protease inhibitors </e1>  (e.g.  <e2> ritonavir </e2> , indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
false	 <e1> ketoconazole </e1> ), macrolide antibiotics (e.g.  <e2> erythromycin </e2> ), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
advise	Therefore, co-administration of  <e1> bupropion </e1>  with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine,  <e2> fluoxetine </e2> , sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g.,  <e1> haloperidol </e1> , risperidone,  <e2> thioridazine </e2> ), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Although  <e1> bupropion </e1>  is not metabolized by this isoenzyme,  <e2> bupropion </e2>  and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.
false	Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced  <e1> alcohol </e1>  tolerance in patients who were drinking  <e2> alcohol </e2>  during treatment with WELLBUTRIN.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline,  <e1> imipramine </e1> , desipramine,  <e2> paroxetine </e2> , fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g.,  <e1> haloperidol </e1> ,  <e2> risperidone </e2> , thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine,  <e1> desipramine </e1> ,  <e2> paroxetine </e2> , fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine,  <e1> desipramine </e1> , paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol,  <e2> risperidone </e2> , thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
advise	Therefore, co-administration of  <e1> bupropion </e1>  with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline),  <e2> antipsychotics </e2>  (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine,  <e1> fluoxetine </e1> , sertraline), antipsychotics (e.g.,  <e2> haloperidol </e2> , risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
advise	Therefore, co-administration of  <e1> bupropion </e1>  with drugs that are metabolized by CYP2D6 isoenzyme including certain  <e2> antidepressants </e2>  (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline,  <e1> imipramine </e1> , desipramine, paroxetine, fluoxetine, sertraline),  <e2> antipsychotics </e2>  (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline,  <e1> imipramine </e1> , desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone,  <e2> thioridazine </e2> ), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
mechanism	While not systematically studied, certain drugs may induce the metabolism of  <e1> bupropion </e1>  (e.g., carbamazepine,  <e2> phenobarbital </e2> , phenytoin).
false	Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of  <e1> cimetidine </e1> , the pharmacokinetics of bupropion and  <e2> hydroxybupropion </e2>  were unaffected.
advise	Drugs that Lower Seizure Threshold: Concurrent administration of  <e1> WELLBUTRIN </e1>  and agents (e.g.,  <e2> antipsychotics </e2> , other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
false	Although  <e1> bupropion </e1>  is not metabolized by this isoenzyme, bupropion and  <e2> hydroxybupropion </e2>  are inhibitors of the CYP2D6 isoenzyme in vitro.
false	Administration of WELLBUTRIN Tablets to patients receiving either  <e1> levodopa </e1>  or  <e2> amantadine </e2>  concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine,  <e1> paroxetine </e1> , fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine),  <e2> beta-blockers </e2>  (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine,  <e1> fluoxetine </e1> ,  <e2> sertraline </e2> ), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine,  <e1> sertraline </e1> ), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline,  <e1> imipramine </e1> , desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g.,  <e2> haloperidol </e2> , risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Although bupropion is not metabolized by this isoenzyme,  <e1> bupropion </e1>  and  <e2> hydroxybupropion </e2>  are inhibitors of the CYP2D6 isoenzyme in vitro.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g.,  <e1> metoprolol </e1> ), and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2> ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline),  <e1> antipsychotics </e1>  (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2> ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline),  <e1> antipsychotics </e1>  (e.g.,  <e2> haloperidol </e2> , risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	In many of these cases,  <e1> buprenorphine </e1>  was misused by self-injection of crushed  <e2> SUBUTEX </e2>  tablets.
false	 <e1> Alcohol </e1> : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking  <e2> alcohol </e2>  during treatment with WELLBUTRIN.
false	In vitro studies indicate that  <e1> bupropion </e1>  is primarily metabolized to  <e2> hydroxybupropion </e2>  by the CYP2B6 isoenzyme.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine,  <e1> fluoxetine </e1> , sertraline), antipsychotics (e.g., haloperidol, risperidone,  <e2> thioridazine </e2> ), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine,  <e1> sertraline </e1> ),  <e2> antipsychotics </e2>  (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of  <e1> bupropion </e1>  and  <e2> hydroxybupropion </e2>  were unaffected.
false	ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g.  <e1> ritonavir </e1> , indinavir and saquinavir) should have their dose of SUBUTEX or  <e2> SUBOXONE </e2>  adjusted.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine,  <e1> fluoxetine </e1> , sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g.,  <e2> metoprolol </e2> ), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
advise	Therefore, co-administration of  <e1> bupropion </e1>  with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g.,  <e2> nortriptyline </e2> , imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline,  <e1> imipramine </e1> , desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine),  <e2> beta-blockers </e2>  (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g.,  <e1> carbamazepine </e1> ,  <e2> phenobarbital </e2> , phenytoin).
false	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most  <e1> antidepressants </e1>  (SSRIs, many tricyclics), beta-blockers,  <e2> antiarrhythmics </e2> , and antipsychotics are metabolized by the CYP2D6 isoenzyme.
false	Levodopa and  <e1> Amantadine </e1> : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or  <e2> amantadine </e2> .
effect	MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of  <e1> bupropion </e1>  is enhanced by the MAO inhibitor  <e2> phenelzine </e2>  .
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine,  <e1> desipramine </e1> , paroxetine,  <e2> fluoxetine </e2> , sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline),  <e1> antipsychotics </e1>  (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g.,  <e2> metoprolol </e2> ), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine,  <e1> fluoxetine </e1> , sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine),  <e2> beta-blockers </e2>  (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine,  <e1> paroxetine </e1> , fluoxetine, sertraline),  <e2> antipsychotics </e2>  (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	It is recommended that  <e1> buspirone hydrochloride </e1>  not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of  <e2> buspirone HCl </e2>  with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline,  <e1> imipramine </e1> , desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	In vitro, buspirone does not displace tightly bound drugs like  <e1> phenytoin </e1> ,  <e2> propranolol </e2> , and warfarin from serum proteins.
false	The patient was also chronically receiving  <e1> phenytoin </e1> , phenobarbital, digoxin, and  <e2> levothyroxine sodium </e2> .
advise	Therefore, co-administration of  <e1> bupropion </e1>  with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine,  <e2> paroxetine </e2> , fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine,  <e1> desipramine </e1> , paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	The patient was also chronically receiving  <e1> phenytoin </e1> ,  <e2> phenobarbital </e2> , digoxin, and levothyroxine sodium.
mechanism	While not systematically studied, certain drugs may induce the metabolism of  <e1> bupropion </e1>  (e.g., carbamazepine, phenobarbital,  <e2> phenytoin </e2> ).
false	 <e1> Levodopa </e1>  and  <e2> Amantadine </e2> : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain  <e1> antidepressants </e1>  (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine,  <e2> sertraline </e2> ), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	It is recommended that buspirone hydrochloride not be used concomitantly with  <e1> MAO inhibitors </e1>  Because the effects of concomitant administration of buspirone HCl with most other  <e2> psychotropic drugs </e2>  have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g.,  <e1> haloperidol </e1> , risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2> ), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
effect	There is one report suggesting that the concomitant use of  <e1> trazodone hydrochloride </e1>  (Desyrel) and  <e2> buspirone HCl </e2>  may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline,  <e1> imipramine </e1> ,  <e2> desipramine </e2> , paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	Fluconazole, and the  <e1> 5-HT3 antiemetics </e1>  ondansetron (Zofran) and granisetron (Kytril) have all been used with  <e2> BUSULFEX </e2> .
false	Fluconazole, and the 5-HT3 antiemetics ondansetron ( <e1> Zofran </e1> ) and  <e2> granisetron </e2>  (Kytril) have all been used with BUSULFEX.
false	Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with  <e1> BUSULFEX </e1>  may result in reduced  <e2> busulfan </e2>  clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
false	Fluconazole, and the  <e1> 5-HT3 antiemetics </e1>  ondansetron ( <e2> Zofran </e2> ) and granisetron (Kytril) have all been used with BUSULFEX.
false	Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and  <e1> granisetron </e1>  (Kytril) have all been used with  <e2> BUSULFEX </e2> .
false	Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g.,  <e1> metoprolol </e1> ), and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
false	 <e1> Fluconazole </e1> , and the 5-HT3 antiemetics ondansetron ( <e2> Zofran </e2> ) and granisetron (Kytril) have all been used with BUSULFEX.
false	Fluconazole, and the 5-HT3 antiemetics ondansetron ( <e1> Zofran </e1> ) and granisetron (Kytril) have all been used with  <e2> BUSULFEX </e2> .
mechanism	 <e1> Phenytoin </e1>  increases the clearance of  <e2> busulfan </e2>  by 15% or more, possibly due to the induction of glutathione-S-transferase.
false	Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of  <e1> BUSULFEX </e1>  at the recommended dose may be lower and exposure (AUC) higher in patients not treated with  <e2> phenytoin </e2> .
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines),  <e1> central nervous system (CNS) depressants </e1>  (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing  <e2> estrogens </e2>  (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine),  <e1> anticoagulants </e1>  (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium,  <e2> valproic acid </e2>  (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners),  <e1> carbamazepine </e1> , corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects),  <e2> divalproex sodium </e2> , valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners),  <e1> carbamazepine </e1> , corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing  <e2> estrogens </e2>  (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine,  <e1> corticotropin </e1>  (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral  <e2> contraceptives </e2> , and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine),  <e1> anticoagulants </e1>  (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with  <e2> barbiturates </e2>  may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin ( <e1> barbiturates </e1>  may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium,  <e2> valproic acid </e2>  (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners),  <e1> carbamazepine </e1> , corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral  <e2> contraceptives </e2>  containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines),  <e1> central nervous system (CNS) depressants </e1>  (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( <e2> barbiturates </e2>  may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine),  <e1> anticoagulants </e1>  (blood thinners),  <e2> carbamazepine </e2> , corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners),  <e1> carbamazepine </e1> , corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with  <e2> barbiturates </e2>  may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	In vitro,  <e1> buspirone </e1>  does not displace tightly bound drugs like phenytoin,  <e2> propranolol </e2> , and warfarin from serum proteins.
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin ( <e1> barbiturates </e1>  may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with  <e2> barbiturates </e2>  may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine,  <e1> corticotropin </e1>  (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( <e2> barbiturates </e2>  may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing  <e1> estrogens </e1>  (barbiturates may decrease the effectiveness of these oral  <e2> contraceptives </e2> , and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with  <e1> barbiturates </e1>  may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( <e2> barbiturates </e2>  may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine,  <e1> corticotropin </e1>  (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects),  <e2> divalproex sodium </e2> , valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin ( <e1> barbiturates </e1>  may decrease the effects of these medicines),  <e2> central nervous system (CNS) depressants </e2>  (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Because busulfan is eliminated from the body via conjugation with glutathione, use of  <e1> acetaminophen </e1>  prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of  <e2> acetaminophen </e2>  to decrease glutathione levels in the blood and tissues.
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( <e1> blood thinner </e1> s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects),  <e2> divalproex sodium </e2> , valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners),  <e1> carbamazepine </e1> , corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( <e2> barbiturates </e2>  may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other  <e1> narcotic analgesic </e1> s, alcohol, general  <e2> anesthetics </e2> , tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine),  <e1> anticoagulants </e1>  (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing  <e2> estrogens </e2>  (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics,  <e1> alcohol </e1> , general  <e2> anesthetics </e2> , tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
effect	Butalbital, acetaminophen and  <e1> caffeine </e1>  may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other  <e2> CNS depressants </e2> , causing increased CNS depression.
effect	Butalbital, acetaminophen and  <e1> caffeine </e1>  may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide,  <e2> sedative-hypnotics </e2> , or other CNS depressants, causing increased CNS depression.
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics,  <e1> alcohol </e1> , general anesthetics, tranquilizers such as  <e2> chlordiazepoxide </e2> , sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
effect	The CNS effects of  <e1> butalbital </e1>  may be enhanced by  <e2> monoamine oxidase (MAO) inhibitors </e2> .
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants ( <e1> blood thinner </e1> s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral  <e2> contraceptives </e2> , and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine,  <e1> corticotropin </e1>  (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with  <e2> barbiturates </e2>  may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
false	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium,  <e1> valproic acid </e1>  (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens ( <e2> barbiturates </e2>  may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
effect	 <e1> Butalbital </e1> , acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other  <e2> CNS depressants </e2> , causing increased CNS depression.
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics,  <e1> alcohol </e1> , general anesthetics,  <e2> tranquilizers </e2>  such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
effect	Butalbital,  <e1> acetaminophen </e1>  and caffeine may enhance the effects of: other  <e2> narcotic analgesic </e2> s, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
false	 <e1> Butalbital </e1> ,  <e2> acetaminophen </e2>  and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
false	Butalbital, acetaminophen and caffeine may enhance the effects of: other  <e1> narcotic analgesic </e1> s, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other  <e2> CNS depressants </e2> , causing increased CNS depression.
effect	These results suggest that the analgesic effect of  <e1> STADOL NS </e1>  may be diminished when it is administered shortly after  <e2> sumatriptan </e2>  nasal spray, but by 30 minutes any such reduction in effect should be minimal.
false	However, in another study in healthy volunteers, the pharmacokinetics of  <e1> butorphanol </e1>  were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of  <e2> sumatriptan </e2>  nasal spray.
effect	Concurrent use of  <e1> butorphanol </e1>  with central nervous system depressants (e.g., alcohol, barbiturates,  <e2> tranquilizers </e2> , and antihistamines) may result in increased central nervous system depressant effects.
false	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol,  <e1> barbiturates </e1> , tranquilizers, and antihistamines) may result in increased  <e2> central nervous system depressant </e2>  effects.
false	Concurrent use of butorphanol with central nervous system depressants (e.g.,  <e1> alcohol </e1> , barbiturates, tranquilizers, and antihistamines) may result in increased  <e2> central nervous system depressant </e2>  effects.
false	Concurrent use of butorphanol with  <e1> central nervous system depressants </e1>  (e.g., alcohol, barbiturates,  <e2> tranquilizers </e2> , and antihistamines) may result in increased central nervous system depressant effects.
false	The pharmacokinetics of a 1-mg dose of  <e1> butorphanol </e1>  administered as  <e2> STADOL NS </e2>  were not affected by the coadministration of cimetidine (300 mg QID).
false	When the STADOL NS was administered 30 minutes after the  <e1> sumatriptan </e1>  nasal spray, the AUC of  <e2> butorphanol </e2>  increased 11% and Cmax decreased 18%.
false	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates,  <e1> tranquilizers </e1> , and antihistamines) may result in increased  <e2> central nervous system depressant </e2>  effects.
false	Conversely, the administration of  <e1> STADOL NS </e1>  (1 mg  <e2> butorphanol </e2>  QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.
false	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol,  <e1> barbiturates </e1> ,  <e2> tranquilizers </e2> , and antihistamines) may result in increased central nervous system depressant effects.
false	DOSTINEX should not be administered concurrently with D2-antagonists, such as  <e1> phenothiazines </e1> ,  <e2> butyrophenones </e2> , thioxanthines, or metoclopramide.
advise	 <e1> DOSTINEX </e1>  should not be administered concurrently with D2-antagonists, such as  <e2> phenothiazines </e2> , butyrophenones, thioxanthines, or metoclopramide.
false	When used concurrently with such drugs, the dose of  <e1> butorphanol </e1>  should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of  <e2> opioids </e2> .
false	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g.,  <e1> cimetidine </e1>  and ketoconazole) and higher  <e2> caffeine </e2>  doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
false	Based on adult data, lower doses of  <e1> caffeine </e1>  may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g.,  <e2> phenobarbital </e2>  and phenytoin).
advise	Based on adult data, lower doses of  <e1> caffeine </e1>  may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and  <e2> ketoconazole </e2> ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
false	DOSTINEX should not be administered concurrently with D2-antagonists, such as  <e1> phenothiazines </e1> , butyrophenones, thioxanthines, or  <e2> metoclopramide </e2> .
false	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and  <e1> ketoconazole </e1> ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and  <e2> phenytoin </e2> ).
false	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g.,  <e1> phenobarbital </e1>  and  <e2> phenytoin </e2> ).
false	Based on adult data, lower doses of  <e1> caffeine </e1>  may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher  <e2> caffeine </e2>  doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
false	Interconversion between  <e1> caffeine </e1>  and  <e2> theophylline </e2>  has been reported in preterm neonates.
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol):  <e1> Cholestyramine </e1> :  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for vitamin D analogues ( <e1> Vitamin D2 </e1> , Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine:  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease  <e1> caffeine </e1>  elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g.,  <e2> phenobarbital </e2>  and phenytoin).
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and  <e1> Calcidiol </e1> ):  <e2> Cholestyramine </e2> : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for vitamin D analogues (Vitamin D2,  <e1> Vitamin D3 </e1> ,  <e2> Calcitriol </e2> , and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and  <e1> Calcidiol </e1> ): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of  <e2> fat soluble vitamins </e2> ;
false	Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g.,  <e1> cimetidine </e1>  and  <e2> ketoconazole </e2> ) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
advise	 <e1> DOSTINEX </e1>  should not be administered concurrently with D2-antagonists, such as phenothiazines,  <e2> butyrophenones </e2> , thioxanthines, or metoclopramide.
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and  <e1> Calcidiol </e1> ): Cholestyramine:  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Phenytoin/ <e1> Phenobarbital </e1> : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of  <e2> calcitriol </e2> /ergocalcitriol by accelerating metabolism.
false	Magnesium:  <e1> Magnesium </e1> -containing preparations (eg,  <e2> antacids </e2> ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
mechanism	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine:  <e1> Cholestyramine </e1>  has been reported to reduce intestinal absorption of  <e2> fat soluble vitamins </e2> ;
false	 <e1> Ketoconazole </e1> : Ketoconazole may inhibit both synthetic and catabolic enzymes of  <e2> vitamin D </e2> .
false	Interactions for  <e1> vitamin D analogues </e1>  ( <e2> Vitamin D2 </e2> , Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	 <e1> Phenytoin </e1> /Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of  <e2> vitamin D </e2> , but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	 <e1> Ketoconazole </e1> : Ketoconazole may inhibit both synthetic and catabolic enzymes of  <e2> vitamin D </e2> .
mechanism	Phenytoin/Phenobarbital: The coadministration of  <e1> phenytoin </e1>  or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of  <e2> calcitriol </e2> /ergocalcitriol by accelerating metabolism.
false	Phenytoin/ <e1> Phenobarbital </e1> : The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of  <e2> calcitriol </e2> /ergocalcitriol by accelerating metabolism.
false	Since blood level of  <e1> calcitriol </e1> /ergocalcitriol will be reduced, higher doses of  <e2> Rocaltrol </e2>  may be necessary if these drugs are administered simultaneously.
false	 <e1> Magnesium </e1> : Magnesium-containing preparations (eg,  <e2> antacids </e2> ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
false	 <e1> Calcium </e1>  Supplements: Uncontrolled intake of additional  <e2> calcium </e2> -containing preparations should be avoided.
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3,  <e1> Calcitriol </e1> , and Calcidiol): Cholestyramine:  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
false	 <e1> Digitalis </e1> : Vitamin D dosage must be determined with care in patients undergoing treatment with  <e2> digitalis </e2> , as hypercalcemia in such patients may precipitate cardiac arrhythmias.
false	Phenytoin/Phenobarbital: The coadministration of phenytoin or  <e1> phenobarbital </e1>  will not affect plasma concentrations of  <e2> vitamin D </e2> , but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	 <e1> Ketoconazole </e1> :  <e2> Ketoconazole </e2>  may inhibit both synthetic and catabolic enzymes of vitamin D.
advise	Digitalis:  <e1> Vitamin D </e1>  dosage must be determined with care in patients undergoing treatment with  <e2> digitalis </e2> , as hypercalcemia in such patients may precipitate cardiac arrhythmias.
false	Interactions for  <e1> vitamin D analogues </e1>  (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of  <e2> fat soluble vitamins </e2> ;
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3,  <e1> Calcitriol </e1> , and Calcidiol):  <e2> Cholestyramine </e2> : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and  <e1> Calcidiol </e1> ): Cholestyramine:  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Using calcium acetate with  <e1> digitalis glycosides </e1>  (heart medicine) may cause hypercalcemia (too much  <e2> calcium </e2>  in the blood), which could increase the chance of developing an irregular heartbeat.
false	Concomitant use with other  <e1> calcium </e1> -containing medicines (including  <e2> antacids </e2> ) may cause too much calcium in the blood or urine, which may increase the chance of side effects.
false	 <e1> Corticosteroids </e1> : A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and  <e2> corticosteroids </e2> , which inhibit calcium absorption.
false	Interactions for  <e1> vitamin D analogues </e1>  (Vitamin D2,  <e2> Vitamin D3 </e2> , Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	May interact with cefamandole naftate, cephalothin sodium,  <e1> magnesium sulfate </e1> ,  <e2> prednisolone sodium succinate </e2> , and prochlorperazine edisylate.
false	Using  <e1> calcium acetate </e1>  with digitalis glycosides (heart medicine) may cause hypercalcemia (too much  <e2> calcium </e2>  in the blood), which could increase the chance of developing an irregular heartbeat.
false	May interact with  <e1> cefamandole naftate </e1> ,  <e2> cephalothin sodium </e2> , magnesium sulfate, prednisolone sodium succinate, and prochlorperazine edisylate.
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine,  <e1> digoxin </e1> , warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with  <e2> enalapril </e2>  to patients with heart failure (NYHA class II and III).
mechanism	An increase in serum lithium concentration has been reported during concomitant administration of  <e1> lithium </e1>  with  <e2> ATACAND </e2> , so careful monitoring of serum lithium levels is recommended during concomitant use.
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral  <e1> contraceptives </e1>  in healthy volunteers, or given with  <e2> enalapril </e2>  to patients with heart failure (NYHA class II and III).
false	 <e1> Phenytoin </e1> /Phenobarbital: The coadministration of phenytoin or  <e2> phenobarbital </e2>  will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
false	Lithium Reversible increases in serum  <e1> lithium </e1>  concentrations and toxicity have been reported during concomitant administration of lithium with  <e2> ACE inhibitors </e2> , and with some angiotensin II receptor antagonists.
false	 <e1> Lithium </e1>  Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of  <e2> lithium </e2>  with ACE inhibitors, and with some angiotensin II receptor antagonists.
false	An increase in serum lithium concentration has been reported during concomitant administration of  <e1> lithium </e1>  with ATACAND, so careful monitoring of serum  <e2> lithium </e2>  levels is recommended during concomitant use.
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as  <e1> glyburide </e1> , nifedipine, digoxin,  <e2> warfarin </e2> , hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin,  <e1> warfarin </e1> ,  <e2> hydrochlorothiazide </e2> , and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide,  <e1> nifedipine </e1> ,  <e2> digoxin </e2> , warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
effect	Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking  <e1> capecitabine </e1>  concomitantly with  <e2> coumarin-derivative anticoagulants </e2>  such as warfarin and phenprocoumon.
false	 <e1> Leucovorin </e1> : The concentration of  <e2> 5-fluorouracil </e2>  is increased and its toxicity may be enhanced by leucovorin.
false	there was no effect on the 3 major metabolites ( <e1> 5-DFUR </e1> , 5-FU and  <e2> FBAL </e2> ).
false	 <e1> Coumarin Anticoagulants </e1>  Altered coagulation parameters and/or bleeding have been reported in patients taking  <e2> capecitabine </e2>  concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
false	 <e1> Coumarin Anticoagulants </e1>  Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and  <e2> phenprocoumon </e2> .
false	Antacid: The effect of an aluminum hydroxide- and  <e1> magnesium hydroxide </e1> -containing  <e2> antacid </e2>  (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as  <e1> glyburide </e1> , nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with  <e2> enalapril </e2>  to patients with heart failure (NYHA class II and III).
false	There was a small increase in plasma concentrations of  <e1> capecitabine </e1>  and one metabolite ( <e2> 5-DFCR </e2> );
false	No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide,  <e1> nifedipine </e1> , digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with  <e2> enalapril </e2>  to patients with heart failure (NYHA class II and III).
false	Lithium: Increased serum lithium levels and symptoms of  <e1> lithium </e1>  toxicity have been reported in patients receiving concomitant  <e2> lithium </e2>  and ACE inhibitor therapy.
false	 <e1> Loop Diuretics </e1> : Furosemide administered concurrently with captopril does not alter the pharmacokinetics of  <e2> captopril </e2>  in renally impaired hypertensive patients.
false	Lithium: Increased serum  <e1> lithium </e1>  levels and symptoms of  <e2> lithium </e2>  toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
false	Lithium: Increased serum lithium levels and symptoms of  <e1> lithium </e1>  toxicity have been reported in patients receiving concomitant lithium and  <e2> ACE inhibitor </e2>  therapy.
false	 <e1> Allopurinol </e1> : In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when  <e2> captopril </e2>  and allopurinol were administered concomitantly for 6 days.
false	Loop Diuretics:  <e1> Furosemide </e1>  administered concurrently with  <e2> captopril </e2>  does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.
false	Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom  <e1> diuretic </e1>  therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of  <e2> captopril </e2> .
false	 <e1> Potassium-sparing diuretics </e1>  such as spironolactone,  <e2> triamterene </e2> , or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
effect	 <e1> Beta-adrenergic blocking drugs </e1>  add some further antihypertensive effect to  <e2> captopril </e2> , but the overall response is less than additive.
false	Agents Having Vasodilator Activity: Data on the effect of concomitant use of other  <e1> vasodilators </e1>  in patients receiving  <e2> captopril </e2>  for heart failure are not available;
false	 <e1> Allopurinol </e1> : In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and  <e2> allopurinol </e2>  were administered concomitantly for 6 days.
false	 <e1> Cardiac Glycosides </e1> : In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril- <e2> digoxin </e2>  interaction could be found.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following:  <e1> Acetazolamide </e1> , azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone,  <e1> methsuximide </e1> , and  <e2> theophylline </e2>  Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1),  <e2> fluoxetine </e2> , fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e1> theophylline </e1> , topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  <e1> EQUETROTM </e1>  are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on  <e2> EQUETROTM </e2> , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> ,  <e2> clonazepam </e2> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine,  <e2> diltiazem </e2> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine,  <e2> diazepam </e2> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e1> methadone </e1> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e2> quetiapine </e2> , risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e1> felbamate </e1> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e1> nortriptyline </e1> ,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol,  <e1> delavirdine </e1> , diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e2> itraconazole </e2> , ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e1> methadone </e1> , midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> ,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e2> citalopram </e2> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone,  <e2> citalopram </e2> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e1> tiagabine </e1> , tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e2> quetiapine </e2> , risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e2> felodipine </e2> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e1> warfarin </e1> (5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e1> felbamate </e1> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e2> glucocorticoids </e2> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e2> felodipine </e2> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e1> felbamate </e1> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2),  <e1> primidone </e1> , methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  <e2> EQUETROTM </e2>  may be necessary.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e1> propoxyphene </e1> , quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine,  <e1> fluvoxamine </e1> , grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2),  <e1> primidone </e1> , methsuximide, and  <e2> theophylline </e2>  Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e1> Phenytoin </e1> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e1> ketoconazole </e1> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e1> quinupristin </e1> , troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine,  <e2> glucocorticoids </e2> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e1> oxcarbazepine </e1> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e1> nortriptyline </e1> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> ,  <e2> citalopram </e2> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e1> praziquantel </e1> ,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e1> oxcarbazepine </e1> ,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> ,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following:  <e1> Acetazolamide </e1> , azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e1> quinupristin </e1> ,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion,  <e2> buspirone </e2> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  <e1> EQUETROTM </e1>  are the following: Cisplatin,  <e2> doxorubicin HCL </e2> , felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine,  <e1> diltiazem </e1> ,  <e2> erythromycin </e2> (1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine,  <e2> cyclosporin </e2> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1),  <e1> dalfopristin </e1> , danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e1> theophylline </e1> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> ,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e1> felbamate </e1> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e2> nicotinamide </e2> , protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e2> dicumarol </e2> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin,  <e1> danazol </e1> , delavirdine,  <e2> diltiazem </e2> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem,  <e1> erythromycin </e1> (1), fluoxetine, fluvoxamine, grapefruit juice,  <e2> isoniazid </e2> , itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Additionally, anti-malarial drugs, such as  <e1> chloroquine </e1>  and  <e2> mefloquine </e2> , may antagonize the activity of carbamazepine.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e1> triazolam </e1> , valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem,  <e1> erythromycin </e1> (1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone,  <e1> methsuximide </e1> , and theophylline Thus, if a patient has been titrated to a stable dosage on  <e2> EQUETROTM </e2> , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol,  <e2> doxycycline </e2> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents with Increased Levels in the Presence of  <e1> Carbamazepine </e1> : EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and  <e2> primidone </e2>  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin,  <e1> doxorubicin HCL </e1> , felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on  <e2> EQUETROTM </e2> , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e2> cyclosporin </e2> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol,  <e1> delavirdine </e1> , diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e2> itraconazole </e2> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e1> methadone </e1> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e2> felbamate </e2> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1),  <e1> dalfopristin </e1> , danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine,  <e2> fluvoxamine </e2> , grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e2> loratadine </e2> , nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e2> cyclosporin </e2> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1),  <e2> fluoxetine </e2> , fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin,  <e1> danazol </e1> , delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e2> loratadine </e2> , nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline,  <e2> ethosuximide </e2> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene,  <e2> quinine </e2> , quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol,  <e2> delavirdine </e2> , diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> ,  <e2> clozapine </e2> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam,  <e2> dicumarol </e2> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol,  <e1> delavirdine </e1> , diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
effect	Additionally,  <e1> anti-malarial drugs </e1> , such as chloroquine and mefloquine, may antagonize the activity of  <e2> carbamazepine </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e1> tramadol </e1> , triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e2> diazepam </e2> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e1> itraconazole </e1> , ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e2> felodipine </e2> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e1> felbamate </e1> , felodipine, glucocorticoids, haloperidol, itraconazole,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> ,  <e2> desipramine </e2> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e1> quetiapine </e1> , risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine,  <e2> clarithromycin </e2> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice,  <e1> isoniazid </e1> , itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e2> desipramine </e2> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e1> felbamate </e1> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e2> quetiapine </e2> , risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl,  <e1> Phenytoin </e1> (6), and  <e2> primidone </e2>  Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene,  <e1> quinine </e1> , quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1),  <e1> dalfopristin </e1> , danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice,  <e2> isoniazid </e2> , itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine,  <e2> cyclosporin </e2> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e2> doxycycline </e2> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline,  <e2> ethosuximide </e2> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin,  <e1> danazol </e1> , delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e1> praziquantel </e1> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e1> quinupristin </e1> , troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e2> glucocorticoids </e2> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> ,  <e2> buspirone </e2> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam,  <e2> clozapine </e2> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine,  <e2> fluvoxamine </e2> , grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e2> ketoconazole </e2> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e1> contraceptives </e1> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e1> tramadol </e1> , triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1),  <e1> dalfopristin </e1> , danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e1> nicotinamide </e1> , protease inhibitors, propoxyphene,  <e2> quinine </e2> , quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following:  <e1> Acetazolamide </e1> , azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e2> itraconazole </e2> , ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e1> propoxyphene </e1> , quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e1> contraceptives </e1> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e1> nefazodone </e1> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e1> risperidone </e1> ,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e1> methadone </e1> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e2> doxycycline </e2> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e2> ethosuximide </e2> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e2> felodipine </e2> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e1> felbamate </e1> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e1> felbamate </e1> , felodipine, glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of  <e1> EQUETROTM </e1>  are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2),  <e2> primidone </e2> , methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e1> itraconazole </e1> , ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e1> praziquantel </e1> , protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Pharmacological/Pharmacodynamic Interactions with  <e1> Carbamazepine </e1>  Concomitant administration of carbamazepine and  <e2> lithium </e2>  may increase the risk of neurotoxic side effects.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e1> praziquantel </e1> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Given the anticonvulsant properties of carbamazepine,  <e1> EQUETROTM </e1>  may reduce the thyroid function as has been reported with other  <e2> anticonvulsants </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e1> nicotinamide </e1> , protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1),  <e1> dalfopristin </e1> , danazol, delavirdine,  <e2> diltiazem </e2> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e1> loratadine </e1> , nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin,  <e2> valproate </e2> (1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following:  <e1> Acetazolamide </e1> , azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem,  <e2> erythromycin </e2> (1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e1> contraceptives </e1> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e1> loratadine </e1> , nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine,  <e1> fluvoxamine </e1> , grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e1> topiramate </e1> , tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem,  <e2> erythromycin </e2> (1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem,  <e1> erythromycin </e1> (1), fluoxetine,  <e2> fluvoxamine </e2> , grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e2> itraconazole </e2> , ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol,  <e2> delavirdine </e2> , diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> ,  <e2> doxycycline </e2> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem,  <e1> erythromycin </e1> (1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone,  <e1> niacinamide </e1> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice,  <e1> isoniazid </e1> , itraconazole,  <e2> ketoconazole </e2> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin,  <e1> phenobarbital </e1> , Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on  <e2> EQUETROTM </e2> , and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e2> quetiapine </e2> , risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e1> tramadol </e1> , triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Additionally,  <e1> anti-malarial drugs </e1> , such as chloroquine and  <e2> mefloquine </e2> , may antagonize the activity of carbamazepine.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam,  <e1> clonazepam </e1> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) ,  <e2> ziprasidone </e2> , and zonisamide.
false	 <e1> Potassium-sparing diuretics </e1>  such as spironolactone, triamterene, or  <e2> amiloride </e2> , or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> ,  <e2> amitriptyline </e2> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> ,  <e2> cyclosporin </e2> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e2> glucocorticoids </e2> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e2> quetiapine </e2> , risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e2> doxycycline </e2> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
advise	Because of its primary CNS effect, caution should be used when  <e1> EQUETROTM </e1>  is taken with other centrally acting drugs and  <e2> alcohol </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam,  <e2> dicumarol </e2> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> ,  <e2> diazepam </e2> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline,  <e1> bupropion </e1> , buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following:  <e1> Acetazolamide </e1> , azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e2> ketoconazole </e2> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following:  <e1> Cisplatin </e1> , doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone,  <e2> methsuximide </e2> , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine,  <e2> fluvoxamine </e2> , grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e2> ketoconazole </e2> , loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem,  <e1> erythromycin </e1> (1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine,  <e2> quinupristin </e2> , troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice,  <e1> isoniazid </e1> , itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1),  <e2> verapamil </e2> , zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine,  <e2> clarithromycin </e2> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e1> mirtazapine </e1> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e1> nefazodone </e1> , niacinamide, nicotinamide, protease inhibitors, propoxyphene,  <e2> quinine </e2> , quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
mechanism	 <e1> Geocillin </e1>  (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of  <e2> probenecid </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide,  <e1> azole antifungals </e1> , cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin,  <e2> troleandomycin </e2> , valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine,  <e1> diltiazem </e1> , erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e2> nicotinamide </e2> , protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e1> ethosuximide </e1> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e1> olanzapine </e1> , oral contraceptives(3),  <e2> oxcarbazepine </e2> , Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e1> topiramate </e1> , tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that have been found, or are expected to have decreased plasma levels in the presence of  <e1> EQUETROTM </e1>  due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline,  <e2> ethosuximide </e2> , felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam,  <e1> dicumarol </e1> , doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine,  <e2> Phenytoin </e2> (4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam,  <e2> clonazepam </e2> , clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e1> itraconazole </e1> , ketoconazole, loratadine, nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole,  <e1> ketoconazole </e1> , loratadine, nefazodone, niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e2> protease inhibitors </e2> , propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine,  <e2> nortriptyline </e2> , olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide,  <e1> protease inhibitors </e1> ,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin,  <e1> doxorubicin HCL </e1> , felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  <e2> EQUETROTM </e2>  may be necessary.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL,  <e1> felbamate </e1> ,  <e2> rifampin </e2> , phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin,  <e1> delavirdine </e1> , desipramine, diazepam, dicumarol, doxycycline, ethosuximide,  <e2> felbamate </e2> , felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel,  <e2> protease inhibitors </e2> , quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> , alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and  <e2> zonisamide </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine,  <e2> desipramine </e2> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam,  <e1> amitriptyline </e1> , bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine,  <e1> cyclosporin </e1> , delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e1> theophylline </e1> , topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e1> tiagabine </e1> , tramadol, triazolam, valproate,  <e2> warfarin </e2> (5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e2> midazolam </e2> , mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion,  <e1> buspirone </e1> , citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e2> haloperidol </e2> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram,  <e1> clobazam </e1> , clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e2> levothyroxine </e2> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate,  <e1> rifampin </e1> ,  <e2> phenobarbital </e2> , Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline,  <e2> olanzapine </e2> , oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen,  <e1> alprazolam </e1> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid,  <e2> itraconazole </e2> , ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2),  <e1> primidone </e1> ,  <e2> methsuximide </e2> , and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
mechanism	Geocillin ( <e1> carbenicillin indanyl sodium </e1> ) blood levels may be increased and prolonged by concurrent administration of  <e2> probenecid </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate,  <e1> felodipine </e1> , glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e2> quetiapine </e2> , risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following:  <e1> Acetaminophen </e1> ,  <e2> alprazolam </e2> , amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone,  <e1> citalopram </e1> , clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e2> lamotrigine </e2> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam,  <e2> methadone </e2> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine,  <e1> risperidone </e1> , theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals,  <e1> cimetidine </e1> , clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide,  <e2> nicotinamide </e2> , protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e1> contraceptives </e1> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam,  <e1> methadone </e1> , midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine,  <e2> tramadol </e2> , triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e1> praziquantel </e1> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam,  <e2> valproate </e2> , warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e1> lorazepam </e1> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone,  <e2> theophylline </e2> , topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam,  <e1> clozapine </e1> , cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone,  <e1> midazolam </e1> ,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors,  <e1> quetiapine </e1> ,  <e2> risperidone </e2> , theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine,  <e1> clarithromycin </e1> (1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors,  <e2> propoxyphene </e2> , quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine,  <e1> levothyroxine </e1> , lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole,  <e1> lamotrigine </e1> , levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol,  <e2> triazolam </e2> , valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate,  <e1> rifampin </e1> , phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for  <e2> EQUETROTM </e2>  may be necessary.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4),  <e2> praziquantel </e2> , protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Patients taking these drugs with  <e1> LODOSYN </e1>  and  <e2> levodopa </e2>  or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol,  <e1> itraconazole </e1> , lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Although  <e1> metoclopramide </e1>  may increase the bioavailability of levodopa by increasing gastric emptying,  <e2> metoclopramide </e2>  may also adversely affect disease control by its dopamine receptor antagonistic properties.
false	 <e1> Dopamine D2 receptor antagonists </e1>  (e.g.,  <e2> phenothiazines </e2> , butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
false	Caution should be exercised when the following drugs are administered concomitantly with  <e1> LODOSYN </e1>  (Carbidopa) given with levodopa or carbidopa- <e2> levodopa </e2>  combination products.
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following:  <e1> Acetazolamide </e1> , azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil,  <e2> zileuton </e2> .
false	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole,  <e1> loratadine </e1> , nefazodone,  <e2> niacinamide </e2> , nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Caution should be exercised when the following drugs are administered concomitantly with LODOSYN ( <e1> Carbidopa </e1> ) given with levodopa or carbidopa- <e2> levodopa </e2>  combination products.
false	Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with  <e1> levodopa </e1>  or  <e2> carbidopa </e2> -levodopa combination products.
mechanism	Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of  <e1> EQUETROTM </e1>  are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine,  <e2> nefazodone </e2> , niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
false	Dopamine D2 receptor antagonists (e.g.,  <e1> phenothiazines </e1> ,  <e2> butyrophenones </e2> , risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
false	Dopamine D2 receptor antagonists (e.g., phenothiazines,  <e1> butyrophenones </e1> ,  <e2> risperidone </e2> ) and isoniazid may reduce the therapeutic effects of levodopa.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine,  <e1> glucocorticoids </e1> , haloperidol, itraconazole, lamotrigine, levothyroxine,  <e2> lorazepam </e2> , methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
effect	Dopamine D2 receptor antagonists (e.g.,  <e1> phenothiazines </e1> , butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of  <e2> levodopa </e2> .
false	Patients taking these drugs with LODOSYN and  <e1> levodopa </e1>  or carbidopa- <e2> levodopa </e2>  combination products should be carefully observed for loss of therapeutic response.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol,  <e1> doxycycline </e1> , ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline,  <e2> topiramate </e2> , tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine,  <e1> desipramine </e1> , diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam,  <e2> mirtazapine </e2> , nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine,  <e1> diazepam </e1> , dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral  <e2> contraceptives </e2> (3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
false	Iodine or  <e1> iodine </e1>  excess may decrease the effect of  <e2> Carbimazole </e2> , and an iodine deficiency can increase the effect of Carbimazole.
mechanism	Serum concentration of digoxin and  <e1> digitoxin </e1>  may increase when patients take  <e2> antithyroid agents </e2> .
false	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids,  <e1> haloperidol </e1> , itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate,  <e2> tiagabine </e2> , tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
effect	Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and  <e1> isoniazid </e1>  may reduce the therapeutic effects of  <e2> levodopa </e2> .
false	 <e1> Iodine </e1>  or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of  <e2> Carbimazole </e2> .
false	Serum concentration of  <e1> digoxin </e1>  and  <e2> digitoxin </e2>  may increase when patients take antithyroid agents.
false	Antihistamines may enhance the effects of  <e1> tricyclic antidepressants </e1> , barbiturates, alcohol, and other  <e2> CNS depressants </e2> .
false	 <e1> Iodine </e1>  or  <e2> iodine </e2>  excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
false	Iodine or  <e1> iodine </e1>  excess may decrease the effect of Carbimazole, and an  <e2> iodine </e2>  deficiency can increase the effect of Carbimazole.
effect	 <e1> Antihistamines </e1>  may enhance the effects of tricyclic antidepressants, barbiturates,  <e2> alcohol </e2> , and other CNS depressants.
effect	 <e1> MAO inhibitors </e1>  prolong and intensify the anticholinergic effects of  <e2> antihistamines </e2> .
false	Antihistamines may enhance the effects of tricyclic antidepressants,  <e1> barbiturates </e1> , alcohol, and other  <e2> CNS depressants </e2> .
false	Sympathomimetic amines may reduce the antihypertensive effects of reserpine,  <e1> veratrum alkaloids </e1> ,  <e2> methyldopa </e2>  and mecamylamine.
effect	Effects of  <e1> sympathomimetics </e1>  are increased with MAO inhibitors and  <e2> beta adrenergic blockers </e2> .
advise	Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of  <e1> carvedilol </e1>  therapy and that the dose of  <e2> cyclosporine </e2>  be adjusted as appropriate.
false	 <e1> Clonidine </e1> : Concomitant administration of  <e2> clonidine </e2>  with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.
false	Therefore, in patients taking  <e1> insulin </e1>  or oral  <e2> hypoglycemics </e2> , regular monitoring of blood glucose is recommended.
mechanism	Cyclosporine: Modest increases in mean trough  <e1> cyclosporine </e1>  concentrations were observed following initiation of  <e2> carvedilol </e2>  treatment in 21 renal transplant patients suffering from chronic vascular rejection.
false	 <e1> Cyclosporine </e1> : Modest increases in mean trough  <e2> cyclosporine </e2>  concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.
false	poor metabolizers of  <e1> debrisoquin </e1> : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine,  <e2> fluoxetine </e2> , paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
false	In about 30% of patients, the dose of  <e1> cyclosporine </e1>  had to be reduced in order to maintain  <e2> cyclosporine </e2>  concentrations within the therapeutic range, while in the remainder no adjustment was needed.
effect	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine,  <e1> fluoxetine </e1> , paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of  <e2> carvedilol </e2>  .
false	poor metabolizers of  <e1> debrisoquin </e1> : Interactions of carvedilol with strong inhibitors of CYP2D6 (such as  <e2> quinidine </e2> , fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
effect	poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as  <e1> quinidine </e1> , fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of  <e2> carvedilol </e2>  .
false	 <e1> Digoxin </e1> :  <e2> Digoxin </e2>  concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.
false	Insulin or Oral  <e1> Hypoglycemics </e1> : Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral  <e2> hypoglycemics </e2> .
false	As with other agents with b-blocking properties, if  <e1> COREG </e1>  is to be administered orally with  <e2> calcium channel blockers </e2>  of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
false	As with other agents with b-blocking properties, if COREG is to be administered orally with  <e1> calcium channel blockers </e1>  of the verapamil or  <e2> diltiazem </e2>  type, it is recommended that ECG and blood pressure be monitored.
advise	Patients on  <e1> rifampin </e1>  should receive 70 mg of  <e2> CANCIDAS </e2>  daily.
false	CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of  <e1> CANCIDAS </e1>  70 mg daily, as compared to results from a control period in which  <e2> tacrolimus </e2>  was administered alone.
false	When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz,  <e1> nevirapine </e1> , phenytoin, dexamethasone, or  <e2> carbamazepine </e2> , use of a daily dose of 70 mg of CANCIDAS should be considered
false	When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or  <e1> carbamazepine </e1> , use of a daily dose of 70 mg of  <e2> CANCIDAS </e2>  should be considered
advise	When  <e1> CANCIDAS </e1>  is co-administered with inducers of drug clearance, such as efavirenz, nevirapine,  <e2> phenytoin </e2> , dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
false	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole,  <e1> amphotericin B </e1> ,  <e2> mycophenolate </e2> , nelfinavir, or tacrolimus.
false	When  <e1> CANCIDAS </e1>  is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of  <e2> CANCIDAS </e2>  should be considered
false	 <e1> CANCIDAS </e1>  did not increase the plasma levels of  <e2> cyclosporine </e2> .
false	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine,  <e1> phenytoin </e1> , dexamethasone, or  <e2> carbamazepine </e2> ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
false	For patients receiving both therapies, standard monitoring of  <e1> tacrolimus </e1>  blood concentrations and appropriate  <e2> tacrolimus </e2>  dosage adjustments are recommended.
mechanism	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz,  <e1> nevirapine </e1> , phenytoin, dexamethasone, or carbamazepine) with  <e2> CANCIDAS </e2>  may result in clinically meaningful reductions in caspofungin concentrations.
false	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( <e1> efavirenz </e1> , nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in  <e2> caspofungin </e2>  concentrations.
false	Clinical studies in healthy volunteers show that the pharmacokinetics of  <e1> CANCIDAS </e1>  are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or  <e2> tacrolimus </e2> .
false	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by  <e1> itraconazole </e1> , amphotericin B,  <e2> mycophenolate </e2> , nelfinavir, or tacrolimus.
false	Clinical studies in healthy volunteers show that the pharmacokinetics of  <e1> CANCIDAS </e1>  are not altered by itraconazole, amphotericin B, mycophenolate,  <e2> nelfinavir </e2> , or tacrolimus.
false	CANCIDAS reduced the blood AUC0-12 of  <e1> tacrolimus </e1>  by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when  <e2> tacrolimus </e2>  (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
mechanism	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or  <e1> carbamazepine </e1> ) with  <e2> CANCIDAS </e2>  may result in clinically meaningful reductions in caspofungin concentrations.
effect	There were transient increases in liver ALT and AST when  <e1> CANCIDAS </e1>  and  <e2> cyclosporine </e2>  were co-administered.
false	CANCIDAS reduced the blood AUC0-12 of  <e1> tacrolimus </e1>  by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which  <e2> tacrolimus </e2>  was administered alone.
false	When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz,  <e1> nevirapine </e1> ,  <e2> phenytoin </e2> , dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
false	CANCIDAS reduced the blood AUC0-12 of  <e1> tacrolimus </e1>  by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of  <e2> CANCIDAS </e2>  70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
false	 <e1> CANCIDAS </e1>  reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which  <e2> tacrolimus </e2>  was administered alone.
false	In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with  <e1> CANCIDAS </e1>  may result in clinically meaningful reductions in  <e2> caspofungin </e2>  concentrations.
false	Therefore,  <e1> OMNICEF </e1>  for Oral Suspension can be administered with  <e2> iron </e2> -fortified infant formula.
mechanism	Iron Supplements and Foods Fortified With Iron Concomitant administration of  <e1> cefdinir </e1>  with a therapeutic iron supplement containing 60 mg of elemental  <e2> iron </e2>  (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
false	 <e1> Probenecid </e1> : As with other b-lactam antibiotics, probenecid inhibits the renal excretion of  <e2> cefdinir </e2> , resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
false	 <e1> Antacids </e1>  (aluminum- or magnesium-containing): Concomitant administration of 300-mg  <e2> cefdinir </e2>  capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
false	The effect of foods highly fortified with elemental iron (primarily  <e1> iron </e1> -fortified breakfast cereals) on  <e2> cefdinir </e2>  absorption has not been studied.
false	Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using  <e1> nitroprusside </e1> , but not with those using  <e2> nitroferricyanide </e2> .
false	 <e1> Iron Supplements </e1>  and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic  <e2> iron supplement </e2>  containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
false	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental  <e1> iron </e1>  (as FeSO4) or vitamins supplemented with 10 mg of elemental  <e2> iron </e2>  reduced extent of absorption by 80% and 31%, respectively.
false	If antacids are required during  <e1> OMNICEF </e1>  therapy, OMNICEF should be taken at least 2 hours before or after the  <e2> antacid </e2> .
false	 <e1> Antacids </e1>  (aluminum- or  <e2> magnesium </e2> -containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
false	 <e1> Probenecid </e1> : As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak  <e2> cefdinir </e2>  plasma levels, and a 50% prolongation in the apparent elimination half-life.
false	There are no significant effects on  <e1> cefdinir </e1>  pharmacokinetics if the antacid is administered 2 hours before or 2 hours after  <e2> cefdinir </e2> .
false	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic  <e1> iron supplement </e1>  containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental  <e2> iron </e2>  reduced extent of absorption by 80% and 31%, respectively.
false	 <e1> Probenecid </e1> : As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of  <e2> cefditoren </e2> , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
false	If  <e1> antacids </e1>  are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the  <e2> antacid </e2> .
false	 <e1> H2-Receptor Antagonists </e1> : Co-administration of a single dose of intravenously administered  <e2> famotidine </e2>  (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
false	Probenecid: As with other b-lactam antibiotics, co-administration of  <e1> probenecid </e1>  with cefditoren pivoxil resulted in an increase in the plasma exposure of  <e2> cefditoren </e2> , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
false	Iron Supplements and Foods Fortified With Iron Concomitant administration of  <e1> cefdinir </e1>  with a therapeutic  <e2> iron supplement </e2>  containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
mechanism	H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered  <e1> famotidine </e1>  (20 mg) reduced the oral absorption of a single 400 mg dose of  <e2> cefditoren pivoxil </e2>  administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
false	Oral  <e1> Contraceptives </e1>  Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of  <e2> ethinyl estradiol </e2> , the estrogenic component in most oral contraceptives.
false	 <e1> H2-Receptor Antagonists </e1> : Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of  <e2> cefditoren pivoxil </e2>  administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
false	 <e1> Carbamazepine </e1> : Elevated  <e2> carbamazepine </e2>  levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.
effect	Nephrotoxicity has been reported following concomitant administration of other  <e1> cephalosporins </e1>  with potent  <e2> diuretics </e2>  such as furosemide.
effect	 <e1> Chloramphenicol </e1>  has been shown to be antagonistic to beta-lactam antibiotics, including  <e2> ceftazidime </e2> , based on in vitro studies and time kill curves with enteric gram-negative bacilli.
false	The bioavailability of the capsule formulation of  <e1> cefprozil </e1>  was not affected when administered 5 minutes following an  <e2> antacid </e2> .
false	however, 150 mg of ranitidine q12h for 3 days increased the  <e1> ceftibuten </e1>  C max by 23% and  <e2> ceftibuten </e2>  AUC by 16%.
false	Nephrotoxicity has been reported following concomitant administration of cephalosporins with  <e1> aminoglycoside antibiotics </e1>  or potent  <e2> diuretics </e2>  such as furosemide.
false	Although the occurrence has not been reported with  <e1> Cefizox </e1> , nephrotoxicity has been reported following concomitant administration of other  <e2> cephalosporins </e2>  and aminoglycosides.
false	Lithium: In a study conducted in healthy subjects, mean steady-state  <e1> lithium </e1>  plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with  <e2> CELEBREX </e2>  200 mg BID as compared to subjects receiving lithium alone.
effect	However, concomitant administration of  <e1> aspirin </e1>  with  <e2> CELEBREX </e2>  may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
false	Clinical studies with celecoxib have identified potentially significant interactions with  <e1> fluconazole </e1>  and  <e2> lithium </e2> .
false	Methotrexate: In an interaction study of rheumatoid arthritis patients taking  <e1> methotrexate </e1> ,  <e2> CELEBREX </e2>  did not have a significant effect on the pharmacokinetics of methotrexate.
mechanism	This increase is due to the inhibition of  <e1> celecoxib </e1>  metabolism via P450 2C9 by  <e2> fluconazole </e2>  (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
false	 <e1> Warfarin </e1> : The effect of celecoxib on the anti-coagulant effect of  <e2> warfarin </e2>  was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.
false	 <e1> Warfarin </e1> : The effect of  <e2> celecoxib </e2>  on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.
false	In these subjects,  <e1> celecoxib </e1>  did not alter the anticoagulant effect of  <e2> warfarin </e2>  as determined by prothrombin time.
false	 <e1> Methotrexate </e1> : In an interaction study of rheumatoid arthritis patients taking methotrexate,  <e2> CELEBREX </e2>  did not have a significant effect on the pharmacokinetics of methotrexate.
false	 <e1> Lithium </e1> : In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving  <e2> lithium </e2>  450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.
false	 <e1> Furosemide </e1> : Clinical studies, as well as post marketing observations, have shown that  <e2> NSAIDs </e2>  can reduce the natriuretic effect of furosemide and thiazides in some patients.
false	 <e1> Aspirin </e1> :  <e2> CELEBREX </e2>  can be used with low dose aspirin.
int	Experience with nonsteroidal anti-inflammatory drugs ( <e1> NSAIDs </e1> ) suggests the potential for interactions with furosemide and  <e2> ACE inhibitors </e2> .
advise	Aspirin:  <e1> CELEBREX </e1>  can be used with low dose  <e2> aspirin </e2> .
false	Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving  <e1> lithium </e1>  450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving  <e2> lithium </e2>  alone.
false	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of  <e1> glyburide </e1> , ketoconazole, methotrexate, phenytoin, tolbutamide, and  <e2> warfarin </e2>  have been studied in vivo and clinically important interactions have not been found.
false	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole,  <e1> methotrexate </e1> ,  <e2> phenytoin </e2> , tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
false	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of  <e1> glyburide </e1> , ketoconazole, methotrexate,  <e2> phenytoin </e2> , tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
false	The effects  <e1> celecoxib </e1>  on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin,  <e2> tolbutamide </e2> , and warfarin have been studied in vivo and clinically important interactions have not been found.
false	 <e1> Metformin </e1> : In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and  <e2> metformin </e2>  mean renal clearance decreased by 14%.
false	Metformin: In healthy subjects given single 500 mg doses of cephalexin and  <e1> metformin </e1> , plasma  <e2> metformin </e2>  mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
mechanism	Although not observed in this study, adverse effects could potentially arise from co-administration of  <e1> cephalexin </e1>  and  <e2> metformin </e2>  by inhibition of tubular secretion via organic cationic transporter systems.
false	Metformin: In healthy subjects given single 500 mg doses of  <e1> cephalexin </e1>  and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and  <e2> metformin </e2>  mean renal clearance decreased by 14%.
false	Metformin: In healthy subjects given single 500 mg doses of  <e1> cephalexin </e1>  and metformin, plasma  <e2> metformin </e2>  mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
false	Warfarin: The effect of celecoxib on the anti-coagulant effect of  <e1> warfarin </e1>  was studied in a group of healthy subjects receiving daily doses of 2-5 mg of  <e2> warfarin </e2> .
false	However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg  <e1> cerivastatin sodium </e1>  approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing  <e2> cerivastatin sodium </e2>  alone.
mechanism	In the first study, concomitant administration of 0.2 mg  <e1> cerivastatin sodium </e1>  and 12 g  <e2> cholestyramine </e2>  resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers,  <e1> calcium-channel blockers </e1> , diuretics, and  <e2> nonsteroidal anti-inflammatory drugs </e2>  (NSAIDs) without evidence of clinically significant adverse interactions.
false	Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid,  <e1> Erythromycin </e1> ,  <e2> Azole Antifungals </e2> : Skeletal Muscle.
false	 <e1> DIGOXIN </e1> : Plasma digoxin levels and  <e2> digoxin </e2>  clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.
false	 <e1> Immunosuppressive Drugs </e1> , Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin,  <e2> Azole Antifungals </e2> : Skeletal Muscle.
false	 <e1> Immunosuppressive Drugs </e1> , Fibric Acid Derivatives, Niacin (Nicotinic Acid,  <e2> Erythromycin </e2> , Azole Antifungals: Skeletal Muscle.
false	CHOLESTYRAMINE: The influence of the bile-acidsequestering agent  <e1> cholestyramine </e1>  on the pharmacokinetits of  <e2> cerivastatin sodium </e2>  was evaluated in 12 healthy males in 2 separate randomized crossover studies.
false	 <e1> WARFARIN </e1> : Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of  <e2> warfarin </e2>  and placebo.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers,  <e1> diuretics </e1> , and  <e2> nonsteroidal anti-inflammatory drugs </e2>  (NSAIDs) without evidence of clinically significant adverse interactions.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with  <e1> angiotensin- converting enzyme (ACE) inhibitors </e1> , betablockers,  <e2> calcium-channel blockers </e2> , diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.
false	Immunosuppressive Drugs, Fibric Acid Derivatives,  <e1> Niacin </e1>  ( <e2> Nicotinic Acid </e2> , Erythromycin, Azole Antifungals: Skeletal Muscle.
false	Immunosuppressive Drugs, Fibric Acid Derivatives,  <e1> Niacin </e1>  (Nicotinic Acid,  <e2> Erythromycin </e2> , Azole Antifungals: Skeletal Muscle.
false	ANTACID ( <e1> Magnesium-Aluminum Hydroxide </e1> ):  <e2> Cerivastatin </e2>  plasma concentrations were not affected by co-administration of antacid.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and  <e1> nonsteroidal anti-inflammatory drugs </e1>  ( <e2> NSAIDs </e2> ) without evidence of clinically significant adverse interactions.
false	Therefore, it would be expected that a dosing schedule of  <e1> cerivastatin sodium </e1>  given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of  <e2> cerivastatin sodium </e2> .
false	ANTACID (Magnesium-Aluminum Hydroxide):  <e1> Cerivastatin </e1>  plasma concentrations were not affected by co-administration of  <e2> antacid </e2> .
false	 <e1> Cerivastatin </e1>  plasma concentrations were also not affected by co-administration of  <e2> digoxin </e2> .
false	Pharmacokinetic interaction studies with cetirizine in adults were conducted with  <e1> pseudoephedrine </e1> , antipyrine,  <e2> ketoconazole </e2> , erythromycin and azithromycin.
false	Pharmacokinetic interaction studies with cetirizine in adults were conducted with  <e1> pseudoephedrine </e1> ,  <e2> antipyrine </e2> , ketoconazole, erythromycin and azithromycin.
false	Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine,  <e1> ketoconazole </e1> , or  <e2> erythromycin </e2> .
false	In a multiple dose study of  <e1> theophylline </e1>  (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of  <e2> cetirizine </e2>  was observed.
false	The disposition of  <e1> theophylline </e1>  was not altered by concomitant  <e2> cetirizine </e2>  administration.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies,  <e1> cerivastatin sodium </e1>  was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers,  <e2> diuretics </e2> , and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.
false	OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with  <e1> angiotensin- converting enzyme (ACE) inhibitors </e1> , betablockers, calcium-channel blockers, diuretics, and  <e2> nonsteroidal anti-inflammatory drugs </e2>  (NSAIDs) without evidence of clinically significant adverse interactions.
false	 <e1> DIGOXIN </e1> : Plasma  <e2> digoxin </e2>  levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.
false	Drug-Drug Interactions: No clinically significant drug interactions have been found with  <e1> theophylline </e1>  at a low dose,  <e2> azithromycin </e2> , pseudoephedrine, ketoconazole, or erythromycin.
false	There was no evidence of any pharmacokinetic interactions between  <e1> ERBITUX </e1>  and  <e2> irinotecan </e2> .
effect	Concurrent administration of  <e1> vasopressor drugs </e1>  (for the treatment of hypotension related to obstetric blocks) and  <e2> ergot-type oxytocic drugs </e2>  may cause severe, persistent hypertension or cerebrovascular accidents.
effect	The administration of local  <e1> anesthetic solutions </e1>  containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or  <e2> phenothiazines </e2>  may produce severe, prolonged hypotension or hypertension.
false	The administration of local  <e1> anesthetic solutions </e1>  containing epinephrine or  <e2> norepinephrine </e2>  to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
false	 <e1> Cimetidine </e1> : Cimetidine can inhibit the metabolism of  <e2> chloroquine </e2> , increasing its plasma level.
mechanism	Cimetidine:  <e1> Cimetidine </e1>  can inhibit the metabolism of  <e2> chloroquine </e2> , increasing its plasma level.
false	 <e1> Cyclosporin </e1> : After introduction of chloroquine (oral form), a sudden increase in serum  <e2> cyclosporin </e2>  level has been reported.
false	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving  <e1> monoamine oxidase inhibitors </e1> ,  <e2> tricyclic antidepressants </e2>  or phenothiazines may produce severe, prolonged hypotension or hypertension.
false	 <e1> Antacids </e1>  and kaolin:  <e2> Antacids </e2>  and kaolin can reduce absorption of chloroquine;
false	-  <e1> Non-steroidal Anti-inflammatory Drugs </e1> : In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide  <e2> diuretics </e2> .
false	-  <e1> Skeletal muscle relaxants </e1> , nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the  <e2> muscle relaxant </e2> 
false	- Cholestyramine and colestipol  <e1> resins </e1> : Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing  <e2> diuretic </e2>  absorption from the gastrointestinal tract
false	 <e1> Antacids </e1>  and kaolin: Antacids and kaolin can reduce absorption of  <e2> chloroquine </e2> ;
false	-  <e1> Cholestyramine </e1>  and colestipol  <e2> resins </e2> : Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
advise	Refer to the package insert for  <e1> lithium </e1>  preparations before use of such preparations with  <e2> chlorothiazide </e2> 
mechanism	 <e1> Diuretic agents </e1>  reduce the renal clearance of  <e2> lithium </e2>  and add a high risk of lithium toxicity.
false	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or  <e2> norepinephrine </e2>  to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
effect	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or norepinephrine to patients receiving monoamine oxidase inhibitors,  <e2> tricyclic antidepressants </e2>  or phenothiazines may produce severe, prolonged hypotension or hypertension.
false	-  <e1> Non-steroidal Anti-inflammatory Drugs </e1> : In some patients, the administration of a  <e2> non-steroidal anti-inflammatory agent </e2>  can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
false	- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide  <e1> d <e2> iuretics </e1>  </e2> .
false	-  <e1> Cholestyramine </e1>  and colestipol resins: Cholestytamine and  <e2> colestipol </e2>  resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
int	 <e1> Chlorotrianisene </e1>  may interact with antidepressants, aspirin, barbiturates,  <e2> bromocriptine </e2> , calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin,  <e1> cyclosporine </e1> ,  <e2> dantrolene </e2> , nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants,  <e1> aspirin </e1> , barbiturates, bromocriptine, calcium supplements, corticosteroids,  <e2> corticotropin </e2> , cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	- Cholestyramine and colestipol resins: Cholestytamine and  <e1> colestipol </e1>   <e2> resins </e2>  have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
false	Chlorotrianisene may interact with  <e1> antidepressants </e1> , aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and  <e2> warfarin </e2> .
false	Chlorotrianisene may interact with antidepressants, aspirin,  <e1> barbiturates </e1> , bromocriptine, calcium supplements,  <e2> corticosteroids </e2> , corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with  <e1> antidepressants </e1> , aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids,  <e2> corticotropin </e2> , cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin,  <e1> barbiturates </e1> , bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin,  <e2> tamoxifen </e2> , and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine,  <e1> calcium </e1>  supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin,  <e2> tamoxifen </e2> , and warfarin.
int	 <e1> Chlorotrianisene </e1>  may interact with  <e2> antidepressants </e2> , aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine,  <e1> calcium </e1>  supplements, corticosteroids, corticotropin,  <e2> cyclosporine </e2> , dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin,  <e1> barbiturates </e1> , bromocriptine, calcium supplements, corticosteroids, corticotropin,  <e2> cyclosporine </e2> , dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	- Cholestyramine and colestipol resins: Cholestytamine and colestipol  <e1> resins </e1>  have the potential of binding thiazide diuretics and reducing  <e2> diuretic </e2>  absorption from the gastrointestinal tract
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine,  <e1> calcium </e1>  supplements, corticosteroids, corticotropin, cyclosporine,  <e2> dantrolene </e2> , nicotine, somatropin, tamoxifen, and warfarin.
int	 <e1> Chlorotrianisene </e1>  may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements,  <e2> corticosteroids </e2> , corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with  <e1> antidepressants </e1> , aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin,  <e2> tamoxifen </e2> , and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin,  <e1> barbiturates </e1> , bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine,  <e2> dantrolene </e2> , nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates,  <e1> bromocriptine </e1> , calcium supplements, corticosteroids,  <e2> corticotropin </e2> , cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids,  <e1> corticotropin </e1> , cyclosporine, dantrolene,  <e2> nicotine </e2> , somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants,  <e1> aspirin </e1> , barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin,  <e2> tamoxifen </e2> , and warfarin.
false	Chlorotrianisene may interact with  <e1> antidepressants </e1> , aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine,  <e2> somatropin </e2> , tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements,  <e1> corticosteroids </e1> , corticotropin, cyclosporine, dantrolene, nicotine, somatropin,  <e2> tamoxifen </e2> , and warfarin.
false	Chlorotrianisene may interact with  <e1> antidepressants </e1> , aspirin, barbiturates, bromocriptine, calcium supplements,  <e2> corticosteroids </e2> , corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
false	Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids,  <e1> corticotropin </e1> , cyclosporine, dantrolene, nicotine, somatropin,  <e2> tamoxifen </e2> , and warfarin.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline,  <e1> erythromycin </e1> , imatinib, isoniazid, nefazodone,  <e2> nicardipine </e2> , propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone,  <e1> nicardipine </e1> , propofol, protease inhibitors,  <e2> quinidine </e2> , and verapamil.
false	Example inhibitors include  <e1> azole antifungals </e1> , ciprofloxacin, clarithromycin, diclofenac, doxycycline,  <e2> erythromycin </e2> , imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin,  <e1> clarithromycin </e1> , diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol,  <e2> protease inhibitors </e2> , quinidine, and verapamil.
false	Example inhibitors include  <e1> azole antifungals </e1> , ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin,  <e2> imatinib </e2> , isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include  <e1> azole antifungals </e1> , ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol,  <e2> protease inhibitors </e2> , quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin,  <e1> diclofenac </e1> , doxycycline, erythromycin, imatinib,  <e2> isoniazid </e2> , nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid,  <e1> nefazodone </e1> , nicardipine,  <e2> propofol </e2> , protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline,  <e1> erythromycin </e1> , imatinib, isoniazid, nefazodone, nicardipine,  <e2> propofol </e2> , protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin,  <e1> clarithromycin </e1> , diclofenac, doxycycline,  <e2> erythromycin </e2> , imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals,  <e1> ciprofloxacin </e1> , clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors,  <e2> quinidine </e2> , and verapamil.
false	Example inhibitors include azole antifungals,  <e1> ciprofloxacin </e1> , clarithromycin,  <e2> diclofenac </e2> , doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include  <e1> azole antifungals </e1> , ciprofloxacin, clarithromycin, diclofenac,  <e2> doxycycline </e2> , erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include  <e1> azole antifungals </e1> , ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and  <e2> verapamil </e2> .
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol,  <e1> protease inhibitors </e1> ,  <e2> quinidine </e2> , and verapamil.
false	Example inhibitors include azole antifungals,  <e1> ciprofloxacin </e1> , clarithromycin, diclofenac, doxycycline, erythromycin,  <e2> imatinib </e2> , isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib,  <e1> isoniazid </e1> ,  <e2> nefazodone </e2> , nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Increased toxicity (CNS depression):  <e1> CNS depressants </e1> , MAO inhibitors,  <e2> tricyclic antidepressants </e2> , phenothiazines.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin,  <e1> diclofenac </e1> , doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors,  <e2> quinidine </e2> , and verapamil.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline,  <e1> erythromycin </e1> ,  <e2> imatinib </e2> , isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol),  <e1> sparfloxacin </e1> , grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g.,  <e2> codeine </e2> ), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine,  <e1> guanadrel </e1> ,  <e2> metrizamide </e2> , cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a  <e1> tricyclic antidepressant </e1>  (eg,  <e2> amitriptyline </e2> )--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin,  <e1> grepafloxacin </e1> , guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g.,  <e2> diphenhydramine </e2> ), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g.,  <e1> propranolol </e1> ), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium,  <e2> narcotic </e2>  pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib,  <e1> isoniazid </e1> , nefazodone, nicardipine,  <e2> propofol </e2> , protease inhibitors, quinidine, and verapamil.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin,  <e1> guanethidine </e1> , guanadrel, metrizamide, cabergoline,  <e2> lithium </e2> , narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/ <e1> anti-anxiety drugs </e1> , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide,  <e2> cabergoline </e2> , lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid,  <e1> beta-blockers </e1>  (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g.,  <e2> diphenhydramine </e2> ), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin,  <e1> grepafloxacin </e1> , guanethidine, guanadrel, metrizamide, cabergoline, lithium,  <e2> narcotic </e2>  pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/ <e1> anti-anxiety drugs </e1> , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine,  <e2> guanadrel </e2> , metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine,  <e1> guanadrel </e1> , metrizamide, cabergoline,  <e2> lithium </e2> , narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid,  <e1> beta-blockers </e1>  (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine,  <e2> guanadrel </e2> , metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g.,  <e1> propranolol </e1> ), sparfloxacin, grepafloxacin, guanethidine,  <e2> guanadrel </e2> , metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin,  <e1> grepafloxacin </e1> , guanethidine,  <e2> guanadrel </e2> , metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following:  <e1> anti-depressants </e1> /anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin,  <e2> guanethidine </e2> , guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following:  <e1> anti-depressants </e1> /anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g.,  <e2> propranolol </e2> ), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin,  <e1> imatinib </e1> ,  <e2> isoniazid </e2> , nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
false	Interactions may also occur with the following: anti-depressants/ <e1> anti-anxiety drugs </e1> , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline,  <e2> lithium </e2> , narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol),  <e1> sparfloxacin </e1> , grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g.,  <e2> diphenhydramine </e2> ), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/ <e1> anti-anxiety drugs </e1> , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol),  <e2> sparfloxacin </e2> , grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid,  <e1> beta-blockers </e1>  (e.g., propranolol),  <e2> sparfloxacin </e2> , grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g.,  <e1> propranolol </e1> ),  <e2> sparfloxacin </e2> , grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol),  <e1> sparfloxacin </e1> , grepafloxacin, guanethidine, guanadrel, metrizamide,  <e2> cabergoline </e2> , lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg,  <e1> trihexyphenidyl </e1> ), and/or a  <e2> tricyclic antidepressant </e2>  (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
false	Interactions may also occur with the following: anti-depressants/ <e1> anti-anxiety drugs </e1> , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel,  <e2> metrizamide </e2> , cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin,  <e1> diclofenac </e1> , doxycycline, erythromycin, imatinib, isoniazid,  <e2> nefazodone </e2> , nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
effect	The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg,  <e1> chlorpromazine </e1> ), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a  <e2> tricyclic antidepressant </e2>  (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e1> estrogens </e1> , oral contraceptives, phenytoin,  <e2> nicotinic acid </e2> , sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol,  <e1> probenecid </e1> , coumarins,  <e2> monoamine oxidase inhibitors </e2> , and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives,  <e1> phenytoin </e1> , nicotinic acid, sympathomimetics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates,  <e1> sulfonamides </e1> ,  <e2> chloramphenicol </e2> , probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides,  <e1> chloramphenicol </e1> , probenecid, coumarins,  <e2> monoamine oxidase inhibitors </e2> , and beta adrenergic blocking agents.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides,  <e1> chloramphenicol </e1> ,  <e2> probenecid </e2> , coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin,  <e1> grepafloxacin </e1> , guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing  <e2> antihistamines </e2>  (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid,  <e1> coumarins </e1> ,  <e2> monoamine oxidase inhibitors </e2> , and beta adrenergic blocking agents.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates,  <e1> sulfonamides </e1> , chloramphenicol, probenecid,  <e2> coumarins </e2> , monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g.,  <e1> propranolol </e1> ), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing  <e2> antihistamines </e2>  (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol,  <e1> probenecid </e1> ,  <e2> coumarins </e2> , monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel,  <e1> metrizamide </e1> , cabergoline, lithium,  <e2> narcotic </e2>  pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates,  <e2> sulfonamides </e2> , chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	Interactions may also occur with the following:  <e1> anti-depressants </e1> /anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide,  <e2> cabergoline </e2> , lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid,  <e1> beta-blockers </e1>  (e.g., propranolol), sparfloxacin, grepafloxacin,  <e2> guanethidine </e2> , guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	In some patients, a  <e1> disulfiram </e1> -like reaction may be produced by the ingestion of  <e2> alcohol </e2> .
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
effect	A potential interaction between oral  <e1> miconazole </e1>  and oral  <e2> hypoglycemic agents </e2>  leading to severe hypoglycemia has been reported.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin,  <e1> grepafloxacin </e1> , guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g.,  <e2> codeine </e2> ), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
effect	The hypoglycemic action of  <e1> sulfonylurea </e1>  may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol,  <e2> probenecid </e2> , coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
effect	The hypoglycemic action of  <e1> sulfonylurea </e1>  may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates,  <e2> sulfonamides </e2> , chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e1> estrogens </e1> , oral contraceptives, phenytoin, nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel blocking drugs, and isoniazid.
effect	Consider additive sedative effects and confusional states to emerge, if  <e1> chlorprothixene </e1>  is given with  <e2> benzodiazepines </e2>  or barbituates.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin,  <e2> nicotinic acid </e2> , sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel blocking drugs, and isoniazid.
false	Interactions may also occur with the following:  <e1> anti-depressants </e1> / <e2> anti-anxiety drugs </e2> , drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides,  <e2> chloramphenicol </e2> , probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	If  <e1> chlorprothixene </e1>  is given concomitantly with opioids, the  <e2> opioid </e2>  dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
advise	Exert particular caution in combining  <e1> chlorprothixene </e1>  with other anticholinergic drugs ( <e2> tricyclic antidepressants </e2>  and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
false	Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g.,  <e1> propranolol </e1> ), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g.,  <e2> diphenhydramine </e2> ), any other drugs that may make you drowsy.
false	The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and  <e2> beta adrenergic blocking agents </e2> .
effect	 <e1> Chlorthalidone </e1>  may add to or potentiate the action of other  <e2> antihypertensive drugs </e2> .
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	Interactions for vitamin D analogues ( <e1> Vitamin D2 </e1> ,  <e2> Vitamin D3 </e2> , Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	 <e1> Calcium </e1>  Supplements: Uncontrolled intake of additional  <e2> calcium </e2> -containing preparations should be avoided.
false	 <e1> Phenytoin </e1> /Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of  <e2> vitamin D </e2> , but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
effect	Corticosteroids: A relationship of functional antagonism exists between  <e1> vitamin D </e1>  analogues, which promote calcium absorption, and  <e2> corticosteroids </e2> , which inhibit calcium absorption.
false	 <e1> Corticosteroids </e1> : A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and  <e2> corticosteroids </e2> , which inhibit calcium absorption.
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol):  <e1> Cholestyramine </e1> :  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
false	 <e1> Digitalis </e1> :  <e2> Vitamin D </e2>  dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
false	 <e1> Magnesium </e1> :  <e2> Magnesium </e2> -containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3,  <e1> Calcitriol </e1> , and Calcidiol):  <e2> Cholestyramine </e2> : Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for  <e1> vitamin D </e1>  analogues (Vitamin D2, Vitamin D3,  <e2> Calcitriol </e2> , and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	 <e1> Magnesium </e1> : Magnesium-containing preparations (eg,  <e2> antacids </e2> ) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3,  <e1> Calcitriol </e1> , and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of  <e2> fat soluble vitamins </e2> ;
false	When  <e1> cholestyramine </e1>   <e2> resin </e2>  is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin,  <e1> thiazide diuretics </e1>  (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and  <e2> digitalis </e2> .
false	 <e1> Cholestyramine </e1>  resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  <e2> resin </e2>  could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G,  <e1> phenobarbital </e1> , thyroid and  <e2> thyroxine </e2>  preparations, estrogens and progestins, and digitalis.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as  <e1> phenylbutazone </e1> , warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as  <e2> tetracycline </e2>  penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
mechanism	Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of  <e1> cholestyramine </e1>  resin could pose a hazard to health if a potentially toxic drug such as  <e2> digitalis </e2>  has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
false	SINCE  <e1> CHOLESTYRAMINE </e1>  RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER  <e2> CHOLESTYRAMINE </e2>  RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone,  <e1> warfarin </e1> , thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations,  <e2> estrogens </e2>  and progestins, and digitalis.
false	 <e1> Thiazides </e1> :  <e2> Thiazides </e2>  are known to induce hypercalcemia by the reduction of calcium excretion in urine.
false	When cholestyramine  <e1> resin </e1>  is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of  <e2> fat-soluble vitamins </e2>  should be considered.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as  <e1> phenylbutazone </e1> ,  <e2> warfarin </e2> , thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Because cholestyramine binds bile acids,  <e1> cholestyramine </e1>   <e2> resin </e2>  may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.
mechanism	 <e1> Cholestyramine </e1>  resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline  <e2> penicillin G </e2> , phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or  <e1> propranolol </e1>  (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and  <e2> thyroxine </e2>  preparations, estrogens and progestins, and digitalis.
mechanism	Ketoconazole:  <e1> Ketoconazole </e1>  may inhibit both synthetic and catabolic enzymes of  <e2> vitamin D </e2> .
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin,  <e1> thiazide diuretics </e1>  (acidic) or propranolol (basic), as well as tetracycline penicillin G,  <e2> phenobarbital </e2> , thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone,  <e1> warfarin </e1> , thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline  <e2> penicillin G </e2> , phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin,  <e1> thiazide diuretics </e1>  (acidic) or propranolol (basic), as well as tetracycline  <e2> penicillin G </e2> , phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Interactions for vitamin D analogues ( <e1> Vitamin D2 </e1> , Vitamin D3,  <e2> Calcitriol </e2> , and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and  <e1> Calcidiol </e1> ): Cholestyramine:  <e2> Cholestyramine </e2>  has been reported to reduce intestinal absorption of fat soluble vitamins;
false	Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking  <e1> cholestyramine </e1>   <e2> resin </e2> .
false	Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of  <e1> cholestyramine </e1>  resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine  <e2> resin </e2> .
false	Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol):  <e1> Cholestyramine </e1> : Cholestyramine has been reported to reduce intestinal absorption of  <e2> fat soluble vitamins </e2> ;
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone,  <e1> warfarin </e1> ,  <e2> thiazide diuretics </e2>  (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	SINCE  <e1> CHOLESTYRAMINE </e1>  RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE  <e2> RESIN </e2>  (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
false	Cholestyramine  <e1> resin </e1>  may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations,  <e2> estrogens </e2>  and progestins, and digitalis.
false	In a drug interaction study, co-administration of orally inhaled ciclesonide and oral  <e1> erythromycin </e1> , an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or  <e2> erythromycin </e2> .
false	Cholestyramine  <e1> resin </e1>  may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or  <e2> propranolol </e2>  (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
mechanism	In another drug interaction study, co-administration of orally inhaled  <e1> ciclesonide </e1>  and oral  <e2> ketoconazole </e2> , a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
false	In a drug interaction study, co-administration of orally inhaled  <e1> ciclesonide </e1>  and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or  <e2> erythromycin </e2> .
false	Cholestyramine  <e1> resin </e1>  may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine  <e2> resin </e2>  could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline  <e1> penicillin G </e1> , phenobarbital, thyroid and thyroxine preparations,  <e2> estrogens </e2>  and progestins, and digitalis.
false	SINCE CHOLESTYRAMINE  <e1> RESIN </e1>  MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER  <e2> CHOLESTYRAMINE </e2>  RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations,  <e1> estrogens </e1>  and progestins, and  <e2> digitalis </e2> .
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid,  <e1> barbiturates </e1> ,  <e2> benzodiazepines </e2> , bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate,  <e1> famotidine </e1> , furosemide, nonsteroidal anti-inflammatory agents, theophylline, and  <e2> zidovudine </e2> ).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g.,  <e1> tobramycin </e1> , gentamicin, and amikacin), amphotericin B,  <e2> foscarnet </e2> , intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide,  <e1> clofibrate </e1> , methotrexate, famotidine, furosemide,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir,  <e1> angiotensin-converting enzyme inhibitors </e1> , aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and  <e2> zidovudine </e2> ).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine,  <e1> vancomycin </e1> , and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
false	 <e1> Probenecid </e1>  : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir,  <e2> angiotensin-converting enzyme inhibitors </e2> , aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines,  <e1> bumetanide </e1> , clofibrate, methotrexate, famotidine,  <e2> furosemide </e2> , nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin,  <e1> gentamicin </e1> , and amikacin),  <e2> amphotericin B </e2> , foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous  <e1> aminoglycosides </e1>  (e.g., tobramycin, gentamicin, and  <e2> amikacin </e2> ), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
mechanism	Probenecid :  <e1> Probenecid </e1>  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents,  <e2> theophylline </e2> , and zidovudine).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin),  <e1> amphotericin B </e1> , foscarnet, intravenous pentamidine,  <e2> vancomycin </e2> , and non-steroidal anti-inflammatory agents] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen,  <e1> acyclovir </e1> , angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents,  <e2> theophylline </e2> , and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors,  <e1> aminosalicylic acid </e1> , barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents,  <e2> theophylline </e2> , and zidovudine).
false	 <e1> Zidovudine </e1>  should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of  <e2> VISTIDE </e2>  infusion.
false	In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either  <e1> des-ciclesonide </e1>  or  <e2> erythromycin </e2> .
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  <e1> acetaminophen </e1> , acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide,  <e1> clofibrate </e1> , methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents,  <e2> theophylline </e2> , and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  <e1> acetaminophen </e1> , acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid,  <e2> barbiturates </e2> , benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen,  <e1> acyclovir </e1> , angiotensin-converting enzyme inhibitors,  <e2> aminosalicylic acid </e2> , barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
advise	Nephrotoxic agents : Concomitant administration of  <e1> VISTIDE </e1>  and agents with nephrotoxic potential [e.g., intravenous  <e2> aminoglycosides </e2>  (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate,  <e1> methotrexate </e1> , famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and  <e2> zidovudine </e2> ).
false	 <e1> Probenecid </e1>  : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates,  <e2> benzodiazepines </e2> , bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines,  <e1> bumetanide </e1> ,  <e2> clofibrate </e2> , methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
mechanism	Probenecid :  <e1> Probenecid </e1>  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
false	 <e1> Probenecid </e1>  : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
advise	Nephrotoxic agents : Concomitant administration of  <e1> VISTIDE </e1>  and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine,  <e2> vancomycin </e2> , and non-steroidal anti-inflammatory agents] is contraindicated.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen,  <e1> acyclovir </e1> , angiotensin-converting enzyme inhibitors, aminosalicylic acid,  <e2> barbiturates </e2> , benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
mechanism	Probenecid :  <e1> Probenecid </e1>  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate,  <e2> famotidine </e2> , furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  <e1> acetaminophen </e1> , acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines,  <e2> bumetanide </e2> , clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or  <e1> propranolol </e1>  (basic), as well as tetracycline penicillin G,  <e2> phenobarbital </e2> , thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors,  <e1> aminosalicylic acid </e1> , barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine,  <e2> furosemide </e2> , nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates,  <e1> benzodiazepines </e1> , bumetanide, clofibrate, methotrexate, famotidine, furosemide,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors,  <e1> aminosalicylic acid </e1> , barbiturates,  <e2> benzodiazepines </e2> , bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin,  <e1> gentamicin </e1> , and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
advise	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when  <e1> PLETAL </e1>  is coadministered with inhibitors of C.P.A. such as  <e2> ketoconazole </e2>  and erythromycin or inhibitors of CYP2C19 such as omeprazole.
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g.,  <e1> tobramycin </e1> , gentamicin, and amikacin), amphotericin B, foscarnet, intravenous  <e2> pentamidine </e2> , vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and  <e1> amikacin </e1> ),  <e2> amphotericin B </e2> , foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
mechanism	Probenecid :  <e1> Probenecid </e1>  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g.,  <e2> acetaminophen </e2> , acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate,  <e1> methotrexate </e1> , famotidine, furosemide,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
false	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine,  <e1> furosemide </e1> ,  <e2> nonsteroidal anti-inflammatory </e2>  agents, theophylline, and zidovudine).
false	Since  <e1> PLETAL </e1>  is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and  <e2> erythromycin </e2>  or inhibitors of CYP2C19 such as omeprazole.
false	Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous  <e1> pentamidine </e1> , vancomycin, and  <e2> non-steroidal anti-inflammatory agents </e2> ] is contraindicated.
false	Pharmacokinetic studies have demonstrated that  <e1> omeprazole </e1>  and  <e2> erythromycin </e2>  significantly increased the systemic exposure of cilostazol and/or its major metabolites.
false	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as  <e1> ketoconazole </e1>  and  <e2> erythromycin </e2>  or inhibitors of CYP2C19 such as omeprazole.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants,  <e1> phenytoin </e1> , propranolol, nifedipine, chlordiazepoxide,  <e2> diazepam </e2> , certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol,  <e1> nifedipine </e1> , chlordiazepoxide, diazepam, certain tricyclic antidepressants,  <e2> lidocaine </e2> , theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol,  <e1> nifedipine </e1> ,  <e2> chlordiazepoxide </e2> , diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of  <e1> warfarin-type anticoagulants </e1> , phenytoin, propranolol, nifedipine, chlordiazepoxide,  <e2> diazepam </e2> , certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine,  <e1> theophylline </e1>  and  <e2> metronidazole </e2> , thereby delaying elimination and increasing blood levels of these drugs.
false	However, a crossover study in healthy subjects receiving either  <e1> Tagamet </e1>  300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state  <e2> theophylline </e2>  peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
mechanism	 <e1> Tagamet </e1> , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin,  <e2> propranolol </e2> , nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of  <e1> warfarin-type anticoagulants </e1> , phenytoin,  <e2> propranolol </e2> , nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of  <e1> warfarin-type anticoagulants </e1> , phenytoin, propranolol,  <e2> nifedipine </e2> , chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
mechanism	 <e1> Tagamet </e1> , apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol,  <e2> nifedipine </e2> , chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of  <e1> warfarin-type anticoagulants </e1> , phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and  <e2> metronidazole </e2> , thereby delaying elimination and increasing blood levels of these drugs.
false	Interaction with  <e1> phenytoin </e1> ,  <e2> lidocaine </e2>  and theophylline has also been reported to produce adverse clinical effects.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain  <e1> tricyclic antidepressants </e1> ,  <e2> lidocaine </e2> , theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin,  <e1> propranolol </e1> , nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine,  <e2> theophylline </e2>  and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
mechanism	Probenecid :  <e1> Probenecid </e1>  is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid,  <e2> barbiturates </e2> , benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
false	 <e1> Ketoconazole </e1> :  <e2> Sensipar </e2>  is metabolized in part by CYP3A4.
false	Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g.,  <e1> flecainide </e1> ,  <e2> vinblastine </e2> , thioridazine and most tricyclic antidepressants) may be required.
false	 <e1> Amitriptyline </e1> : Concurrent administration of 25 mg or 100 mg  <e2> cinacalcet </e2>  with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
mechanism	Co-administration of  <e1> ketoconazole </e1> , a strong inhibitor of CYP3A4, increased  <e2> cinacalcet </e2>  exposure following a single 90 mg dose of Sensipar by 2.3 fold.
false	Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide,  <e1> vinblastine </e1> , thioridazine and most  <e2> tricyclic antidepressants </e2> ) may be required.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine,  <e1> chlordiazepoxide </e1> , diazepam, certain tricyclic antidepressants, lidocaine,  <e2> theophylline </e2>  and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine,  <e1> chlordiazepoxide </e1> ,  <e2> diazepam </e2> , certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
false	 <e1> Amitriptyline </e1> : Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased  <e2> amitriptyline </e2>  exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
advise	Dose adjustment of  <e1> Sensipar </e1>  may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin,  <e2> itraconazole </e2> ;
false	Seizures have been reported in patients taking another quinolone class antimicrobial and the  <e1> nonsteroidal anti-inflammatory drug </e1>   <e2> fenbufen </e2>  concurrently.
effect	Seizures have been reported in patients taking another  <e1> quinolone class antimicrobial </e1>  and the nonsteroidal anti-inflammatory drug  <e2> fenbufen </e2>  concurrently.
false	Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg  <e1> amitriptyline </e1>  increased  <e2> amitriptyline </e2>  exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
mechanism	 <e1> Quinolones </e1>  have also been shown to interfere with the metabolism of  <e2> caffeine </e2> .
mechanism	Antacids or  <e1> sucralfate </e1>  substantially interfere with the absorption of some  <e2> quinolones </e2> , resulting in low urine levels.
false	Elevated  <e1> cyclosporine </e1>  serum levels have been reported with the concomitant use of  <e2> quinolones </e2>  and cyclosporine.
false	There have been reports of  <e1> theophylline </e1> -related side-effects in patients on concomitant  <e2> theophylline </e2> -quinolone therapy.
false	Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or  <e1> Videx </e1>  ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
false	Also, concomitant administration of  <e1> quinolones </e1>  with products containing iron,  <e2> multivitamins </e2>  containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
advise	Physicians are provided this information to increase awareness of the potential for serious interactions when  <e1> cinoxacin </e1>  and certain  <e2> nonsteroidal anti-inflammatory agents </e2>  are administered concomitantly.
false	Some  <e1> quinolones </e1> , including  <e2> ciprofloxacin </e2> , have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids,  <e1> sucralfate </e1> , VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or  <e2> zinc </e2>  may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
effect	Quinolones, including  <e1> cinoxacin </e1> , may enhance the effects of oral  <e2> anticoagulants </e2> , such as warfarin or its derivatives.
false	Theophylline: As with some other quinolones, concurrent administration of  <e1> ciprofloxacin </e1>  with theophylline may lead to elevated serum concentrations of  <e2> theophylline </e2>  and prolongation of its elimination half-life.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing  <e1> calcium </e1> , iron, or zinc may substantially decrease the absorption of  <e2> ciprofloxacin </e2> , resulting in serum and urine levels considerably lower than desired.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids,  <e1> sucralfate </e1> ,  <e2> VIDEX </e2>  chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum  <e1> antacids </e1> , sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium,  <e2> iron </e2> , or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	 <e1> Histamine H2-receptor antagonists </e1> : Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of  <e2> ciprofloxacin </e2> .
mechanism	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including  <e1> ciprofloxacin </e1> , with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing  <e2> calcium </e2> , iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	 <e1> Methotrexate </e1>  Renal tubular transport of  <e2> methotrexate </e2>  may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
false	 <e1> Phenytoin </e1> : Altered serum levels of  <e2> phenytoin </e2>  (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
false	 <e1> Probenecid </e1> : Probenecid interferes with renal tubular secretion of  <e2> ciprofloxacin </e2>  and produces an increase in the level of ciprofloxacin in serum.
mechanism	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including  <e1> ciprofloxacin </e1> , with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate,  <e2> VIDEX </e2>  chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as  <e1> magnesium </e1>  or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of  <e2> ciprofloxacin </e2> , resulting in serum and urine levels considerably lower than desired.
false	Glyburide: The concomitant administration of ciprofloxacin with the  <e1> sulfonylurea </e1>   <e2> glyburide </e2>  has, on rare occasions, resulted in severe hypoglycemia.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum  <e1> antacids </e1> , sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of  <e2> ciprofloxacin </e2> , resulting in serum and urine levels considerably lower than desired.
false	Some  <e1> quinolones </e1> , including  <e2> ciprofloxacin </e2> , have also been shown to interfere with the metabolism of caffeine.
false	Omeprazole: The rate and extent of absorption of  <e1> ciprofloxacin </e1>  was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after  <e2> omeprazole </e2>  at the dose that maximally suppresses gastric acid secretion.
false	Theophylline: As with some other  <e1> quinolones </e1> , concurrent administration of  <e2> ciprofloxacin </e2>  with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
mechanism	Multivalent Cation-Containing Products: Concurrent administration of a  <e1> quinolone </e1> , including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate,  <e2> VIDEX </e2>  chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	Warfarin: Quinolones have been reported to enhance the effects of the oral  <e1> anticoagulant </e1>   <e2> warfarin </e2>  or its derivatives.
mechanism	Multivalent Cation-Containing Products: Concurrent administration of a  <e1> quinolone </e1> , including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or  <e2> zinc </e2>  may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
mechanism	 <e1> Antacids </e1>  or sucralfate substantially interfere with the absorption of some  <e2> quinolones </e2> , resulting in low urine levels.
false	Warfarin:  <e1> Quinolones </e1>  have been reported to enhance the effects of the oral  <e2> anticoagulant </e2>  warfarin or its derivatives.
mechanism	Antidepressants: In vitro data indicate that  <e1> nefazodone </e1>  inhibits the metabolism of  <e2> cisapride </e2> , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
mechanism	Human pharmacokinetic data indicate that oral  <e1> ketoconazole </e1>  markedly inhibits the metabolism of  <e2> cisapride </e2> , resulting in a mean eight-fold increase in AUC of cisapride.
false	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain  <e1> antiarrhythmics </e1> , including those of Class IA (such as quinidine and procainamide) and Class III (such as  <e2> sotalol </e2> );
false	Antibiotics: In vitro and/or in vivo data show that  <e1> clarithromycin </e1> , erythromycin, and  <e2> troleandomycin </e2>  markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral  <e1> ketoconazole </e1>  markedly inhibit the metabolism of cisapride, which can result in an increase in plasma  <e2> cisapride </e2>  levels and prolongation of the QT interval on the ECG.
false	 <e1> Amitriptyline </e1> : Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg  <e2> amitriptyline </e2>  increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
false	 <e1> Protease Inhibitors </e1> : In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of  <e2> cisapride </e2>  which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as  <e1> quinidine </e1>  and  <e2> procainamide </e2> ) and Class III (such as sotalol);
false	 <e1> Non-steroidal anti-inflammatory drugs </e1>  (but not aspirin): These drugs in combination with very high doses of  <e2> quinolones </e2>  have been shown to provoke convulsions in pre-clinical studies.
advise	Therefore, patients under  <e1> methotrexate </e1>  therapy should be carefully monitored when concomitant  <e2> ciprofloxacin </e2>  therapy is indicated.
mechanism	Antifungals: In vitro and/or in vivo data indicate that  <e1> fluconazole </e1> , itraconazole, and oral ketoconazole markedly inhibit the metabolism of  <e2> cisapride </e2> , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	 <e1> Anticholinergics </e1> : Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and  <e2> dicyclomine </e2> , would be expected to compromise the beneficial effects of cisapride.
false	In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when  <e1> cisapride </e1>  was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood  <e2> cisapride </e2>  levels were noted at the time of the QT prolongation.
false	Antifungals: In vitro and/or in vivo data indicate that  <e1> fluconazole </e1> ,  <e2> itraconazole </e2> , and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	 <e1> Antidepressants </e1> : In vitro data indicate that nefazodone inhibits the metabolism of  <e2> cisapride </e2> , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on  <e1> cisapride </e1>  absorption when it is coadministered with  <e2> ranitidine </e2> .
false	Human pharmacokinetic data indicate that oral  <e1> ketoconazole </e1>  markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of  <e2> cisapride </e2> .
false	Antibiotics: In vitro and/or in vivo data show that clarithromycin,  <e1> erythromycin </e1> , and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma  <e2> cisapride </e2>  levels and prolongation of the QT interval on the ECG.
false	Protease Inhibitors: In vitro data indicate that indinavir and  <e1> ritonavir </e1>  markedly inhibit the metabolism of cisapride which can result in an increase in plasma  <e2> cisapride </e2>  levels and prolongation of the QT interval on the ECG.
effect	Anticholinergics: Concurrent administration of certain  <e1> anticholinergic compounds </e1> , such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of  <e2> cisapride </e2> .
false	Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and  <e1> troleandomycin </e1>  markedly inhibit the metabolism of cisapride, which can result in an increase in plasma  <e2> cisapride </e2>  levels and prolongation of the QT interval on the ECG.
false	 <e1> Antidepressants </e1> : In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma  <e2> cisapride </e2>  levels and prolongation of the QT interval on the ECG.
mechanism	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including  <e1> ciprofloxacin </e1> , with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of  <e2> ciprofloxacin </e2> , resulting in serum and urine levels considerably lower than desired.
false	 <e1> Antifungals </e1> : In vitro and/or in vivo data indicate that  <e2> fluconazole </e2> , itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines,  <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
effect	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as  <e2> NIMBEX </e2>  include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	 <e1> tricyclic antidepressants </e1>  (such as  <e2> amitriptyline </e2> );
false	certain  <e1> tetracyclic antidepressants </e1>  (such as  <e2> maprotiline </e2> );
effect	 <e1> Isoflurane </e1>  or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of  <e2> NIMBEX </e2> .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> NIMBEX </e1>  include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
effect	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e2> clindamycin </e2> , colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
advise	In long surgical procedures during  <e1> enflurane </e1>  or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of  <e2> NIMBEX </e2>  may be necessary.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
effect	 <e1> Isoflurane </e1>  or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of  <e2> NIMBEX </e2>  and decrease the required infusion rate of NIMBEX.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistemethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts,  <e1> lithium </e1> , local anesthetics, procainamide, and  <e2> quinidine </e2> .
effect	Isoflurane or  <e1> enflurane </e1>  administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of  <e2> NIMBEX </e2>  and decrease the required infusion rate of NIMBEX.
false	Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum  <e1> antacids </e1> , sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or  <e2> zinc </e2>  may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e1> colistin </e1> , and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> .
false	H2 Receptor Antagonists:  <e1> Cimetidine </e1>  coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with  <e2> ranitidine </e2> .
false	Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of  <e1> NIMBEX </e1>  and decrease the required infusion rate of  <e2> NIMBEX </e2> .
false	Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of  <e1> NIMBEX </e1>  and therefore, no adjustment to the initial dose should be necessary when  <e2> NIMBEX </e2>  is administered shortly after initiation of volatile agents.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate),  <e1> magnesium </e1>  salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e2> clindamycin </e2> , colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of  <e1> NIMBEX </e1>  were comparable to or slightly greater than when  <e2> succinylcholine </e2>  was not administered.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine.
false	Isoflurane or  <e1> enflurane </e1>  administered with nitrous oxide/ <e2> oxygen </e2>  to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
false	 <e1> Antifungals </e1> : In vitro and/or in vivo data indicate that fluconazole,  <e2> itraconazole </e2> , and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate),  <e1> magnesium </e1>  salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> , colistin, and  <e2> sodium colistemethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistemethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.
effect	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistemethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
mechanism	H2 Receptor Antagonists:  <e1> Cimetidine </e1>  coadministration leads to an increased peak plasma concentration and AUC of  <e2> cisapride </e2> , there is no effect on cisapride absorption when it is coadministered with ranitidine.
effect	Resistance to the neuromuscular blocking action of  <e1> nondepolarizing neuromuscular blocking agents </e1>  has been demonstrated in patients chronically administered  <e2> phenytoin </e2>  or carbamazepine.
false	Infusion requirements of NIMBEX in patients administered  <e1> succinylcholine </e1>  prior to infusions of NIMBEX were comparable to or slightly greater than when  <e2> succinylcholine </e2>  was not administered.
false	 <e1> Isoflurane </e1>  or enflurane administered with  <e2> nitrous oxide </e2> /oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
effect	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e2> colistin </e2> , and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> , lincomycin,  <e2> clindamycin </e2> , colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e1> sodium colistemethate </e1> ), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin,  <e2> colistin </e2> , and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e2> colistin </e2> , and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium,  <e1> pancuronium </e1> , or atracurium were administered following varying degrees of recovery from single doses or infusions of  <e2> NIMBEX </e2> .
effect	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
false	 <e1> Antibiotics </e1> : In vitro and/or in vivo data show that clarithromycin,  <e2> erythromycin </e2> , and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local  <e1> anesthetics </e1> ,  <e2> procainamide </e2> , and quinidine.
effect	Infusion requirements of NIMBEX in patients administered  <e1> succinylcholine </e1>  prior to infusions of  <e2> NIMBEX </e2>  were comparable to or slightly greater than when succinylcholine was not administered.
false	The use of  <e1> NIMBEX </e1>  before succinylcholine to attenuate some of the side effects of  <e2> succinylcholine </e2>  has not been studied.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
false	 <e1> Central nervous system depressant </e1>  (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics,  <e2> sedatives </e2> , sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines,  <e1> antipsychotics </e1> , blood pressure medications (reserpine,  <e2> methyldopa </e2> , beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including  <e1> alcohol </e1> , antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa,  <e2> beta-blockers </e2> ), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol,  <e1> antidepressants </e1> , antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa,  <e2> beta-blockers </e2> ), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa,  <e1> beta-blockers </e1> ), motion sickness medications, muscle relaxants,  <e2> narcotics </e2> , sedatives, sleeping pills and tranquilizers
false	 <e1> Central nervous system depressant </e1>  (CNS) drugs including alcohol, antidepressants,  <e2> antihistamines </e2> , antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants,  <e1> antihistamines </e1> , antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications,  <e2> muscle relaxants </e2> , narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol,  <e1> antidepressants </e1> , antihistamines,  <e2> antipsychotics </e2> , blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	 <e1> Central nervous system depressant </e1>  (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants,  <e2> narcotics </e2> , sedatives, sleeping pills and tranquilizers
false	 <e1> Central nervous system depressant </e1>  (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications ( <e2> reserpine </e2> , methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants,  <e1> narcotics </e1> ,  <e2> sedatives </e2> , sleeping pills and tranquilizers
false	 <e1> Central nervous system depressant </e1>  (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and  <e2> tranquilizers </e2> 
false	Central nervous system depressant (CNS) drugs including  <e1> alcohol </e1> , antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics,  <e2> sedatives </e2> , sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa,  <e1> beta-blockers </e1> ), motion sickness medications, muscle relaxants, narcotics,  <e2> sedatives </e2> , sleeping pills and tranquilizers
false	Central nervous system depressant (CNS) drugs including alcohol, antidepressants,  <e1> antihistamines </e1> ,  <e2> antipsychotics </e2> , blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	 <e1> Central nervous system depressant </e1>  (CNS) drugs including  <e2> alcohol </e2> , antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
false	In controlled clinical trials of  <e1> AUGMENTIN XR </e1> , 22 patients received concomitant  <e2> allopurinol </e2>  and AUGMENTIN XR.
false	However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant  <e1> AUGMENTIN XR </e1>  and  <e2> allopurinol </e2>  use.
effect	In common with other  <e1> broad-spectrum antibiotics </e1> , AUGMENTIN XR may reduce the efficacy of oral  <e2> contraceptives </e2> 
effect	Additive CNS depression may occur when  <e1> antihistamines </e1>  are administered concomitantly with other CNS depressants including barbiturates,  <e2> tranquilizers </e2> , and alcohol.
false	Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including  <e1> barbiturates </e1> ,  <e2> tranquilizers </e2> , and alcohol.
false	In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant  <e1> allopurinol </e1>  and  <e2> AUGMENTIN XR </e2> .
effect	 <e1> Clidinium </e1>  may decrease the effect of phenothiazines, levodopa, and  <e2> ketoconazole </e2> .
false	Clidinium may decrease the effect of phenothiazines,  <e1> levodopa </e1> , and  <e2> ketoconazole </e2> .
effect	Antagonism has been demonstrated between  <e1> clindamycin </e1>  and  <e2> erythromycin </e2>  in vitro.
false	While it is not known whether this interaction occurs with  <e1> fibrates </e1>  other than  <e2> gemfibrozil </e2> , myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.
effect	The hypoglycemic effect of  <e1> tolbutamide </e1>  has been reported to increase when  <e2> Atromid-S </e2>  is given concurrently.
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g.,  <e1> fluoxetine </e1> ,  <e2> sertraline </e2> , paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
mechanism	plasma levels of several closely related  <e1> tricyclic antidepressants </e1>  have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine,  <e2> fluoxetine </e2> ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
false	 <e1> cimetidine </e1> ) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics  <e2> propafenone </e2>  and flecainide).
false	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants,  <e1> phenothiazines </e1> , and the Type 1C antiarrhythmics propafenone and  <e2> flecainide </e2> ).
false	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of  <e1> methylphenidate </e1>  or hepatic enzyme inhibitors (e.g., cimetidine,  <e2> fluoxetine </e2> ) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
advise	Close supervision and careful adjustment of dosage are required when  <e1> Anafranil </e1>  is administered with anticholinergic or  <e2> sympathomimetic drugs </e2> .
mechanism	Because Anafranil is highly bound to serum protein, the administration of  <e1> Anafranil </e1>  to patients taking other drugs that are highly bound to protein (e.g.,  <e2> warfarin </e2> , digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
false	plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g.,  <e1> cimetidine </e1> , fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  <e2> barbiturates </e2> , phenytoin), and such an effect may be anticipated with CMI as well.
false	cimetidine) and many that are substrates for P450 2D6 (many other  <e1> antidepressants </e1> , phenothiazines, and the Type 1C antiarrhythmics propafenone and  <e2> flecainide </e2> ).
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g.,  <e1> fluoxetine </e1> , sertraline, paroxetine, and  <e2> fluvoxamine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	While all the  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs), e.g., fluoxetine, sertraline,  <e2> paroxetine </e2> , and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
mechanism	plasma levels of several closely related  <e1> tricyclic antidepressants </e1>  have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g.,  <e2> barbiturates </e2> , phenytoin), and such an effect may be anticipated with CMI as well.
false	 <e1> cimetidine </e1> ) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the  <e2> Type 1C antiarrhythmics </e2>  propafenone and flecainide).
false	While all the  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs), e.g., fluoxetine,  <e2> sertraline </e2> , paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
effect	Several  <e1> tricyclic antidepressants </e1>  have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other  <e2> tricyclic antidepressants </e2> .
false	plasma levels of several closely related  <e1> tricyclic antidepressants </e1>  have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with  <e2> CMI </e2>  as well.
false	The extent to which  <e1> SSRI </e1> -TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the  <e2> SSRI </e2>  involved.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e1> classes of antipsychotic agents </e1> ,  <e2> monoamine oxidase inhibitors </e2>  and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by  <e1> alcohol </e1> , narcotics, barbiturates,  <e2> nonbarbiturate hypnotics </e2> , antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Effect of  <e1> Clonazepam </e1>  on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of  <e2> phenytoin </e2> , carbamazepine, or phenobarbital.
false	Cytochrome P-450 inducers, such as  <e1> phenytoin </e1> , carbamazepine and  <e2> phenobarbital </e2> , induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
false	Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin,  <e1> carbamazepine </e1> , or  <e2> phenobarbital </e2> .
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates,  <e1> nonbarbiturate hypnotics </e1> , antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other  <e2> anticonvulsant drugs </e2> .
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics,  <e1> antianxiety agents </e1> , the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates,  <e1> nonbarbiturate hypnotics </e1> , antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents,  <e2> monoamine oxidase inhibitors </e2>  and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine,  <e1> sertraline </e1> , paroxetine, and  <e2> fluvoxamine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics,  <e1> barbiturates </e1> ,  <e2> nonbarbiturate hypnotics </e2> , antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates,  <e1> nonbarbiturate hypnotics </e1> , antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
mechanism	Administration of  <e1> CMI </e1>  has been reported to increase the plasma levels of  <e2> phenobarbital </e2> , if given concomitantly.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates,  <e1> nonbarbiturate hypnotics </e1> ,  <e2> antianxiety agents </e2> , the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics,  <e1> barbiturates </e1> , nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the  <e2> tricyclic antidepressants </e2> , and by other anticonvulsant drugs.
false	In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of  <e1> clonazepam </e1>  was 10% lower and the Cmax of  <e2> clonazepam </e2>  was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
effect	Pharmacodynamic Interactions: The CNS-depressant action of the  <e1> benzodiazepine class </e1>  of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other  <e2> anticonvulsant drugs </e2> .
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by  <e1> alcohol </e1> , narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates,  <e1> nonbarbiturate hypnotics </e1> , antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e1> c <e2> lasses of antipsychotic agents </e1>  </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
effect	Pharmacodynamic Interactions: The CNS-depressant action of the  <e1> benzodiazepine class </e1>  of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
mechanism	In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of  <e1> clonazepam </e1>  was 20% lower when the orally disintegrating tablet was given with  <e2> propantheline </e2>  compared to when it was given alone.
false	Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in  <e1> clonazepam </e1>  metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving  <e2> clonazepam </e2> .
false	In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an  <e1> anticholinergic agent </e1>  with multiple effects on the GI tract) to healthy volunteers, the AUC of  <e2> clonazepam </e2>  was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates,  <e1> nonbarbiturate hypnotics </e1> , antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the  <e2> tricyclic antidepressants </e2> , and by other anticonvulsant drugs.
false	Effect of  <e1> Clonazepam </e1>  on the Pharmacokinetics of Other Drugs:  <e2> Clonazepam </e2>  does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.
advise	Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving  <e1> clonidine </e1>  with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and  <e2> beta-blockers </e2> .)
effect	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection  <e1> Clonidine </e1>  may potentiate the CNS-depressive effect of alcohol, barbiturates or other  <e2> sedating drugs </e2> .
false	Cytochrome P-450 inducers, such as phenytoin, carbamazepine and  <e1> phenobarbital </e1> , induce clonazepam metabolism, causing an approximately 30% decrease in plasma  <e2> clonazepam </e2>  levels.
false	Amitriptyline in combination with  <e1> clonidine </e1>  enhances the manifestation of corneal lesions in rats Epidural Injection  <e2> Clonidine </e2>  may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
false	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol,  <e1> barbiturates </e1>  or other  <e2> sedating drugs </e2> .
false	Amitriptyline in combination with  <e1> clonidine </e1>  enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other  <e2> sedating drugs </e2> .
effect	 <e1> Tricyclic antidepressants </e1>  may antagonize the hypotensive effects of  <e2> clonidine </e2> .
false	Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol,  <e1> barbiturates </e1>  or other  <e2> sedatives </e2> .
false	Clonidine hydrochloride may enhance the CNS-depressive effects of  <e1> alcohol </e1> ,  <e2> barbiturates </e2>  or other sedatives.
false	Amitriptyline in combination with  <e1> clonidine </e1>  enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of  <e2> alcohol </e2> , barbiturates or other sedating drugs.
effect	Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection  <e1> Clonidine </e1>  may potentiate the CNS-depressive effect of alcohol,  <e2> barbiturates </e2>  or other sedating drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol,  <e1> narcotics </e1> , barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone  <e2> classes of antipsychotic agents </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Amitriptyline in combination with  <e1> clonidine </e1>  enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol,  <e2> barbiturates </e2>  or other sedating drugs.
effect	Tablet If a patient receiving  <e1> clonidine hydrochloride </e1>  is also taking  <e2> tricyclic antidepressants </e2> , the effect of clonidine may be reduced, thus necessitating an increase in dosage.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and  <e1> butyrophenone c <e2> lasses of antipsychotic agents </e1>  </e2> , monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
false	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by  <e1> alcohol </e1> , narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other  <e2> anticonvulsant drugs </e2> .
effect	Animal experience indicates that  <e1> clorazepate dipotassium </e1>  prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of  <e2> chlorpromazine </e2> , but does not exhibit monoamine oxidase inhibition.
effect	The actions of the  <e1> benzodiazepines </e1>  may be potentiated by barbiturates,  <e2> narcotics </e2> , phenothiazines, monoamine oxidase inhibitors or other antidepressants.
false	The actions of the benzodiazepines may be potentiated by barbiturates,  <e1> narcotics </e1> , phenothiazines, monoamine oxidase inhibitors or other  <e2> antidepressants </e2> .
false	Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after  <e1> ethyl alcohol </e1> , increases the inhibitory effects of  <e2> chlorpromazine </e2> , but does not exhibit monoamine oxidase inhibition.
false	Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after  <e1> hexobarbital </e1>  or after ethyl alcohol, increases the inhibitory effects of  <e2> chlorpromazine </e2> , but does not exhibit monoamine oxidase inhibition.
mechanism	Phenytoin,  <e1> nicotine </e1> , and rifampin may decrease  <e2> Clozapine </e2>  plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines,  <e1> carbamazepine </e1> , and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and  <e1> Type 1C antiarrhythmics </e1>  (e.g., propafenone, flecainide and  <e2> encainide </e2> ), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines,  <e1> carbamazepine </e1> , and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2>  and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
advise	Therefore, co-administration of  <e1> clozapine </e1>  with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and  <e2> encainide </e2> ), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2>  and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
advise	Therefore, co-administration of  <e1> clozapine </e1>  with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	The actions of the benzodiazepines may be potentiated by barbiturates,  <e1> narcotics </e1> ,  <e2> phenothiazines </e2> , monoamine oxidase inhibitors or other antidepressants.
false	After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and  <e1> clozapine N-oxide </e1> , were elevated with  <e2> fluvoxamine </e2>  by about three-fold compared to baseline concentrations.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g.,  <e1> propafenone </e1> , flecainide and encainide), or that inhibit this enzyme (e.g.,  <e2> quinidine </e2> ), should be approached with caution.
effect	 <e1> Clozapine </e1>  may potentiate the hypotensive effects of  <e2> antihypertensive drugs </e2>  and the anticholinergic effects of atropine-type drugs.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including  <e1> antidepressants </e1> , phenothiazines,  <e2> carbamazepine </e2> , and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and  <e1> encainide </e1> ), or that inhibit this enzyme (e.g.,  <e2> quinidine </e2> ), should be approached with caution.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone,  <e1> flecainide </e1>  and encainide), or that inhibit this enzyme (e.g.,  <e2> quinidine </e2> ), should be approached with caution.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including  <e1> antidepressants </e1> ,  <e2> phenothiazines </e2> , carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites,  <e1> N-desmethylclozapine </e1>  and  <e2> clozapine N-oxide </e2> , were elevated with fluvoxamine by about three-fold compared to baseline concentrations.
false	Although it has not been established that there is an interaction between Clozapine and  <e1> benzodiazepines </e1>  or other psychotropics, caution is advised when clozapine is initiated in patients taking a  <e2> benzodiazepine </e2>  or any other psychotropic drug.
mechanism	 <e1> Paroxetine </e1>  produced only minor changes in the levels of  <e2> clozapine </e2>  and its metabolites.
false	After 14 days of co-administration, mean trough concentrations of  <e1> clozapine </e1>  and its metabolites,  <e2> N-desmethylclozapine </e2>  and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.
false	Aspirin,  <e1> warfarin </e1> ,  <e2> heparin </e2> , NSAIDs
false	The actions of the benzodiazepines may be potentiated by  <e1> barbiturates </e1> ,  <e2> narcotics </e2> , phenothiazines, monoamine oxidase inhibitors or other antidepressants.
false	After 14 days of co-administration, mean trough concentrations of  <e1> clozapine </e1>  and its metabolites, N-desmethylclozapine and  <e2> clozapine N-oxide </e2> , were elevated with fluvoxamine by about three-fold compared to baseline concentrations.
false	However, other published reports describe modest elevations (less than two-fold) of  <e1> clozapine </e1>  and metabolite concentrations when  <e2> clozapine </e2>  was taken with paroxetine, fluoxetine, and sertraline.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants,  <e1> phenothiazines </e1> , carbamazepine, and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
advise	Therefore, co-administration of  <e1> clozapine </e1>  with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
false	Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other  <e1> psychotropics </e1> , caution is advised when  <e2> clozapine </e2>  is initiated in patients taking a benzodiazepine or any other psychotropic drug.
false	Cimetidine,  <e1> caffeine </e1> , and  <e2> erythromycin </e2>  may increase plasma levels of Clozapine, potentially resulting in adverse effects.
false	In addition, certain drugs that are metabolized by this isozyme, including many  <e1> antidepressants </e1>  (clozapine,  <e2> selective serotonin reuptake inhibitors </e2> , and others), may inhibit the activity of this isozyme, and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.
false	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines,  <e1> tranquilizers </e1> , sedative-hypnotics, or other CNS depressants (including  <e2> alcohol </e2> ) has additive depressant effects.
false	Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other  <e1> CNS depressants </e1>  (including  <e2> alcohol </e2> ) has additive depressant effects.
effect	 <e1> Codeine </e1>  in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other  <e2> CNS depressants </e2>  (including alcohol) has additive depressant effects.
false	Codeine in combination with other narcotic analgesics, general  <e1> anesthetics </e1> , phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including  <e2> alcohol </e2> ) has additive depressant effects.
false	Although concomitant use of  <e1> Clozapine </e1>  and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in  <e2> Clozapine </e2>  plasma levels.
false	Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and  <e2> encainide </e2> ), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
effect	 <e1> Codeine </e1>  in combination with other narcotic analgesics, general anesthetics, phenothiazines,  <e2> tranquilizers </e2> , sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
false	Codeine in combination with other  <e1> narcotic analgesics </e1> , general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other  <e2> CNS depressants </e2>  (including alcohol) has additive depressant effects.
false	WelChol  was found to have no significant effect on the bioavailability of  <e1> digoxin </e1> , lovastatin, metoprolol, quinidine, valproic acid, and  <e2> warfarin </e2> .
false	In clinical studies, coadministration of WelChol  with atorvastatin,  <e1> lovastatin </e1> , or  <e2> simvastatin </e2>  did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.
false	WelChol  was found to have no significant effect on the bioavailability of  <e1> digoxin </e1> , lovastatin,  <e2> metoprolol </e2> , quinidine, valproic acid, and warfarin.
false	WelChol  was found to have no significant effect on the bioavailability of digoxin, lovastatin,  <e1> metoprolol </e1> , quinidine,  <e2> valproic acid </e2> , and warfarin.
false	WelChol  was found to have no significant effect on the bioavailability of digoxin, lovastatin, metoprolol,  <e1> quinidine </e1> ,  <e2> valproic acid </e2> , and warfarin.
mechanism	 <e1> WelChol </e1>   decreased the Cmax and AUC of sustained-release  <e2> verapamil </e2>  (Calan SR ) by approximately 31% and 11%, respectively.
false	WelChol  was found to have no significant effect on the bioavailability of digoxin, lovastatin,  <e1> metoprolol </e1> , quinidine, valproic acid, and  <e2> warfarin </e2> .
false	In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or  <e1> simvastatin </e1>  did not interfere with the lipid-lowering activity of the  <e2> HMG-CoA reductase inhibitor </e2> .
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs:  <e1> aspirin </e1> , clindamycin,  <e2> clofibrate </e2> , methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.
false	Particular caution should be observed with  <e1> digitalis preparations </e1>  since there are conflicting results for the effect of colestipol hydrochloride on the availability of  <e2> digoxin </e2>  and digitoxin.
false	No depressant effect on blood levels in humans was noted when  <e1> colestipol hydrochloride </e1>  was administered with any of the following drugs: aspirin,  <e2> clindamycin </e2> , clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.
false	WelChol  was found to have no significant effect on the bioavailability of digoxin,  <e1> lovastatin </e1> , metoprolol, quinidine, valproic acid, and  <e2> warfarin </e2> .
false	Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the  <e1> resin </e1>  has been titrated to a maintenance level while the patient was taking  <e2> colestipol hydrochloride </e2> .
false	Repeated doses of colestipol hydrochloride given prior to a single dose of  <e1> propranolol </e1>  in human trials have been reported to decrease  <e2> propranolol </e2>  absorption.
false	WelChol  was found to have no significant effect on the bioavailability of digoxin,  <e1> lovastatin </e1> ,  <e2> metoprolol </e2> , quinidine, valproic acid, and warfarin.
false	Repeated doses of  <e1> colestipol hydrochloride </e1>  given prior to a single dose of propranolol in human trials have been reported to decrease  <e2> propranolol </e2>  absorption.
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid ( <e1> niacin </e1> ), tolbutamide, phenytoin or  <e2> warfarin </e2> .
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin),  <e1> tolbutamide </e1> , phenytoin or  <e2> warfarin </e2> .
mechanism	 <e1> Bile acid binding resins </e1>  may also interfere with the absorption of oral  <e2> phosphate </e2>  supplements and hydrocortisone.
mechanism	Studies in humans show that the absorption of  <e1> chlorothiazide </e1>  as reflected in urinary excretion is markedly decreased even when administered one hour before  <e2> colestipol hydrochloride </e2> .
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin,  <e1> clofibrate </e1> , methyldopa, nicotinic acid (niacin), tolbutamide,  <e2> phenytoin </e2>  or warfarin.
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin,  <e1> clofibrate </e1> , methyldopa, nicotinic acid ( <e2> niacin </e2> ), tolbutamide, phenytoin or warfarin.
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa,  <e1> nicotinic acid </e1>  ( <e2> niacin </e2> ), tolbutamide, phenytoin or warfarin.
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide,  <e1> phenytoin </e1>  or  <e2> warfarin </e2> .
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin,  <e1> clindamycin </e1> , clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide,  <e2> phenytoin </e2>  or warfarin.
effect	 <e1> Sodium cephalothin </e1>  may enhance the nephrotoxicity of  <e2> Coly-Mycin M </e2>  Parenteral.
false	The absorption of  <e1> tetracycline </e1> ,  <e2> furosemide </e2> , penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
false	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin,  <e1> clofibrate </e1> , methyldopa, nicotinic acid (niacin),  <e2> tolbutamide </e2> , phenytoin or warfarin.
false	 <e1> Curariform muscle relaxants </e1>  (eg, tubocurarine) and other drugs, including ether, succinylcholine,  <e2> gallamine </e2> , decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
false	Certain other  <e1> antibiotics </e1>  ( <e2> aminoglycosides </e2>  and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction.
false	The absorption of  <e1> tetracycline </e1> , furosemide, penicillin G, hydrochlorothiazide, and  <e2> gemfibrozil </e2>  was significantly decreased when given simultaneously with colestipol hydrochloride;
false	 <e1> Curariform muscle relaxants </e1>  (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine,  <e2> decamethonium </e2>  and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
false	Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of  <e1> digoxin </e1>  and  <e2> digitoxin </e2> .
false	Curariform muscle relaxants (eg,  <e1> tubocurarine </e1> ) and other drugs, including ether,  <e2> succinylcholine </e2> , gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
false	No depressant effect on blood levels in humans was noted when  <e1> colestipol hydrochloride </e1>  was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide,  <e2> phenytoin </e2>  or warfarin.
false	 <e1> Digoxin </e1> : Coadministration of  <e2> digoxin </e2> , a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
mechanism	 <e1> Bile acid binding resins </e1>  may also interfere with the absorption of oral phosphate supplements and  <e2> hydrocortisone </e2> .
false	Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating  <e1> corticosteroids </e1>  and  <e2> sex steroids </e2> , respectively.
advise	Drugs that induce hepatic enzymes such as phenobarbital,  <e1> phenytoin </e1>  and rifampin may increase the clearance of corticosteroids and may require increases in  <e2> corticosteroid </e2>  dose to achieve the desired response.
false	Drugs such as  <e1> troleandomycin </e1>  and  <e2> ketoconazole </e2>  may inhibit the metabolism of corticosteroids and thus decrease their clearance.
effect	There are reports of enhanced as well as diminished effects of  <e1> anticoagulants </e1>  when given concurrently with  <e2> corticosteroids </e2> .
mechanism	Drugs such as  <e1> troleandomycin </e1>  and ketoconazole may inhibit the metabolism of  <e2> corticosteroids </e2>  and thus decrease their clearance.
false	Persons taking most antibiotics, methotrexate and pyrimethamine invalidate  <e1> folic acid </e1>  and  <e2> vitamin B12 </e2>  diagnostic blood assays.
mechanism	Colchicine para-aminosalicylic acid and heavy  <e1> alcohol </e1>  intake for longer than 2 weeks may produce malabsorption of  <e2> vitamin B12 </e2> .
false	Persons taking most antibiotics,  <e1> methotrexate </e1>  and  <e2> pyrimethamine </e2>  invalidate folic acid and vitamin B12 diagnostic blood assays.
false	Persons taking most antibiotics, methotrexate and  <e1> pyrimethamine </e1>  invalidate  <e2> folic acid </e2>  and vitamin B12 diagnostic blood assays.
false	FLEXERIL may enhance the effects of  <e1> alcohol </e1> ,  <e2> barbiturates </e2> , and other CNS depressants.
effect	 <e1> Tricyclic antidepressants </e1>  may enhance the seizure risk in patients taking  <e2> tramadol </e2> 
effect	 <e1> Tricyclic antidepressants </e1>  may block the antihypertensive action of  <e2> guanethidine </e2>  and similarly acting compounds.
false	May interact with wthionamide ( <e1> Trecator-SC </e1> ) and  <e2> isoniazid </e2>  (Nydrazid).
effect	 <e1> Antihistamines </e1>  may have additive effects with alcohol and other CNS depressants, e.g.,  <e2> hypnotics </e2> , sedatives, tranquilizers, antianxiety agents.
false	Antihistamines may have additive effects with  <e1> alcohol </e1>  and other  <e2> CNS depressants </e2> , e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
false	Antihistamines may have additive effects with  <e1> alcohol </e1>  and other CNS depressants, e.g., hypnotics,  <e2> sedatives </e2> , tranquilizers, antianxiety agents.
false	Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics,  <e1> sedatives </e1> ,  <e2> tranquilizers </e2> , antianxiety agents.
false	Antihistamines may have additive effects with alcohol and other  <e1> CNS depressants </e1> , e.g., hypnotics,  <e2> sedatives </e2> , tranquilizers, antianxiety agents.
false	The combination of therapeutic doses of intravenous dantrolene sodium and  <e1> verapamil </e1>  in  <e2> halothane </e2>  a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.
false	However, neither phenobarbital nor  <e1> diazepam </e1>  appears to affect  <e2> Dantrium </e2>  metabolism.
false	Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine ( <e1> DHA </e1> ) was more than doubled in the presence of  <e2> TMP </e2> /SMX.
false	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/ <e1> sulfamethoxazole </e1>  ( <e2> TMP </e2> /SMX).
false	Notably, systemic exposure (AUC0-12) of  <e1> dapsone hydroxylamine </e1>  ( <e2> DHA </e2> ) was more than doubled in the presence of TMP/SMX.
false	A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole ( <e1> TMP </e1> / <e2> SMX </e2> ).
false	During co-administration, systemic levels of  <e1> TMP </e1>  and  <e2> SMX </e2>  were essentially unchanged.
false	 <e1> HMG-CoA Reductase Inhibitors </e1> :  <e2> Inhibitors of HMG-CoA reductase </e2>  may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.
false	 <e1> Warfarin </e1> : Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and  <e2> warfarin </e2>  (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.
false	Experience with co-administration of  <e1> HMG-CoA reductase inhibitors </e1>  and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving  <e2> Fentanyl </e2> .
false	A drug-drug interaction study evaluated the effect of the use of  <e1> ACZONE </e1>  Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole ( <e2> TMP </e2> /SMX).
advise	Caution should be taken when  <e1> ENABLEX </e1>  is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as  <e2> flecainide </e2> , thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
false	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole,  <e1> itraconazole </e1> , ritonavir, nelfinavir,  <e2> clarithromycin </e2>  and nefazadone) .
advise	The daily dose of  <e1> ENABLEX </e1>  should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole,  <e2> ritonavir </e2> , nelfinavir, clarithromycin and nefazadone) .
false	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole,  <e1> ritonavir </e1> , nelfinavir,  <e2> clarithromycin </e2>  and nefazadone) .
false	The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole,  <e1> ritonavir </e1> ,  <e2> nelfinavir </e2> , clarithromycin and nefazadone) .
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole,  <e1> itraconazole </e1> , erythromycin, clarithromycin, ritonavir, atazanavir,  <e2> indinavir </e2> , nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir,  <e1> nefazodone </e1> , nelfinavir, saquinavir, telithromycin) may increase exposure to  <e2> dasatinib </e2>  and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as  <e1> alfentanil </e1> , astemizole, terfenadine, cisapride, cyclosporine, fentanyl,  <e2> pimozide </e2> , quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by  <e1> H2 blockers </e1>  or proton pump inhibitors (eg, famotidine and  <e2> omeprazole </e2> ) is likely to reduce dasatinib exposure.
advise	If  <e1> antacid </e1>  therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of  <e2> SPRYCEL </e2> .
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl,  <e1> pimozide </e1> , quinidine, sirolimus, tacrolimus, or  <e2> ergot alkaloids </e2>  (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl,  <e1> pimozide </e1> ,  <e2> quinidine </e2> , sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as  <e1> alfentanil </e1> , astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus,  <e2> tacrolimus </e2> , or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine,  <e1> fentanyl </e1> , pimozide,  <e2> quinidine </e2> , sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole,  <e1> erythromycin </e1> , clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir,  <e2> saquinavir </e2> , telithromycin) may increase exposure to dasatinib and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl,  <e1> pimozide </e1> , quinidine, sirolimus, tacrolimus, or ergot alkaloids ( <e2> ergotamine </e2> , dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole,  <e1> itraconazole </e1> ,  <e2> erythromycin </e2> , clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide,  <e1> quinidine </e1> , sirolimus, tacrolimus, or ergot alkaloids ( <e2> ergotamine </e2> , dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	In patients in whom CYP3A4 inducers (eg, dexamethasone,  <e1> phenytoin </e1> , carbamazepine, rifampicin,  <e2> phenobarbital </e2> ) are indicated, alternative agents with less enzyme induction potential should be used.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir,  <e1> atazanavir </e1> , indinavir,  <e2> nefazodone </e2> , nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	In patients in whom CYP3A4 inducers (eg,  <e1> dexamethasone </e1> ,  <e2> phenytoin </e2> , carbamazepine, rifampicin, phenobarbital) are indicated, alternative agents with less enzyme induction potential should be used.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride,  <e1> cyclosporine </e1> , fentanyl, pimozide, quinidine,  <e2> sirolimus </e2> , tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride,  <e1> cyclosporine </e1> , fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine,  <e2> dihydroergotamine </e2> ) should be administered with caution in patients receiving SPRYCEL.
false	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or  <e1> proton pump inhibitors </e1>  (eg,  <e2> famotidine </e2>  and omeprazole) is likely to reduce dasatinib exposure.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine,  <e1> fentanyl </e1> , pimozide, quinidine, sirolimus, tacrolimus, or  <e2> ergot alkaloids </e2>  (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg,  <e1> ketoconazole </e1> , itraconazole, erythromycin,  <e2> clarithromycin </e2> , ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	H2 Blockers/ <e1> Proton Pump Inhibitors </e1> : Long-term suppression of gastric acid secretion by H2 blockers or  <e2> proton pump inhibitors </e2>  (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir,  <e1> saquinavir </e1> ,  <e2> telithromycin </e2> ) may increase exposure to dasatinib and should be avoided.
advise	The use of antacids should be considered in place of  <e1> H2 blockers </e1>  or proton pump inhibitors in patients receiving  <e2> SPRYCEL </e2>  therapy.
false	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg,  <e1> famotidine </e1>  and  <e2> omeprazole </e2> ) is likely to reduce dasatinib exposure.
false	Drugs that may increase  <e1> dasatinib </e1>  plasma concentrations CYP3A4 Inhibitors:  <e2> Dasatinib </e2>  is a CYP3A4 substrate.
false	In patients in whom CYP3A4 inducers (eg, dexamethasone,  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , rifampicin, phenobarbital) are indicated, alternative agents with less enzyme induction potential should be used.
advise	Simultaneous administration of  <e1> SPRYCEL </e1>  with  <e2> antacids </e2>  should be avoided.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir,  <e1> indinavir </e1> , nefazodone, nelfinavir, saquinavir,  <e2> telithromycin </e2> ) may increase exposure to dasatinib and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide,  <e1> quinidine </e1> , sirolimus, tacrolimus, or  <e2> ergot alkaloids </e2>  (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or  <e1> ergot alkaloids </e1>  ( <e2> ergotamine </e2> , dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
mechanism	Concomitant use of  <e1> SPRYCEL </e1>  and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin,  <e2> clarithromycin </e2> , ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine,  <e1> fentanyl </e1> , pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids ( <e2> ergotamine </e2> , dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
mechanism	Concomitant use of  <e1> SPRYCEL </e1>  and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir,  <e2> telithromycin </e2> ) may increase exposure to dasatinib and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide,  <e1> quinidine </e1> , sirolimus,  <e2> tacrolimus </e2> , or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	H2 Blockers/ <e1> Proton Pump Inhibitors </e1> : Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg,  <e2> famotidine </e2>  and omeprazole) is likely to reduce dasatinib exposure.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole,  <e1> itraconazole </e1> , erythromycin, clarithromycin, ritonavir, atazanavir, indinavir,  <e2> nefazodone </e2> , nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil,  <e1> astemizole </e1> , terfenadine, cisapride,  <e2> cyclosporine </e2> , fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
effect	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or  <e1> proton pump inhibitors </e1>  (eg, famotidine and omeprazole) is likely to reduce  <e2> dasatinib </e2>  exposure.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride,  <e1> cyclosporine </e1> , fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or  <e2> ergot alkaloids </e2>  (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
advise	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine,  <e1> fentanyl </e1> , pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving  <e2> SPRYCEL </e2> .
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil,  <e1> astemizole </e1> , terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus,  <e2> tacrolimus </e2> , or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	 <e1> H2 Blockers </e1> /Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg,  <e2> famotidine </e2>  and omeprazole) is likely to reduce dasatinib exposure.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin,  <e1> clarithromycin </e1> , ritonavir, atazanavir,  <e2> indinavir </e2> , nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg,  <e1> ketoconazole </e1> , itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir,  <e2> nefazodone </e2> , nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
effect	 <e1> Cyclophosphamide </e1>  used concurrently with  <e2> Cerubidine </e2>  may also result in increased cardiotoxicity.
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole,  <e1> terfenadine </e1> , cisapride, cyclosporine, fentanyl, pimozide, quinidine,  <e2> sirolimus </e2> , tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	The concomitant use of  <e1> H2 blockers </e1>  or  <e2> proton pump inhibitors </e2>  with SPRYCEL is not recommended.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg,  <e1> ketoconazole </e1> , itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone,  <e2> nelfinavir </e2> , saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
false	Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin,  <e1> clarithromycin </e1> , ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir,  <e2> telithromycin </e2> ) may increase exposure to dasatinib and should be avoided.
advise	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus,  <e1> tacrolimus </e1> , or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving  <e2> SPRYCEL </e2> .
false	 <e1> H2 Blockers </e1> / <e2> Proton Pump Inhibitors </e2> : Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
false	Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of  <e1> doxorubicin </e1>  or  <e2> Cerubidine </e2> .
false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine,  <e1> cisapride </e1> , cyclosporine, fentanyl, pimozide,  <e2> quinidine </e2> , sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like  <e1> lidocaine </e1> , procaine,  <e2> beta-blockers </e2> , metaclopramide, lithium carbonate, and terbutaline.
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like  <e1> lidocaine </e1> ,  <e2> procaine </e2> , beta-blockers, metaclopramide, lithium carbonate, and terbutaline.
false	Anticholinesterases (neostgmine,  <e1> physostigmine </e1> ), lignocaine,  <e2> quinine </e2> , procainamide can enhance toxicity and cause cardio respiratory depression.
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like  <e1> lidocaine </e1> , procaine, beta-blockers, metaclopramide, lithium carbonate, and  <e2> terbutaline </e2> .
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local  <e1> anesthetics </e1>  like lidocaine, procaine, beta-blockers, metaclopramide,  <e2> lithium carbonate </e2> , and terbutaline.
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine,  <e1> procaine </e1> ,  <e2> beta-blockers </e2> , metaclopramide, lithium carbonate, and terbutaline.
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine,  <e1> beta-blockers </e1> ,  <e2> metaclopramide </e2> , lithium carbonate, and terbutaline.
false	 <e1> Anticholinesterases </e1>  (neostgmine,  <e2> physostigmine </e2> ), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like  <e1> lidocaine </e1> , procaine, beta-blockers,  <e2> metaclopramide </e2> , lithium carbonate, and terbutaline.
false	 <e1> Anticholinesterases </e1>  (neostgmine, physostigmine), lignocaine,  <e2> quinine </e2> , procainamide can enhance toxicity and cause cardio respiratory depression.
false	In addition, neuromuscular blocking action is enhanced by general  <e1> anesthetics </e1> , local  <e2> anesthetics </e2>  like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.
false	Although deferasirox has a lower affinity for aluminum than for  <e1> iron </e1> , Exjade should not be taken with  <e2> aluminum </e2> -containing antacid preparations.
false	The effect of  <e1> digoxin </e1>  on  <e2> Exjade </e2>  pharmacokinetics has not been studied.
false	The concomitant administration of Exjade and  <e1> aluminum </e1> -containing  <e2> antacid preparations </e2>  has not been formally studied.
false	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like  <e1> lidocaine </e1> , procaine, beta-blockers, metaclopramide,  <e2> lithium carbonate </e2> , and terbutaline.
false	The concomitant administration of  <e1> Exjade </e1>  and  <e2> aluminum </e2> -containing antacid preparations has not been formally studied.
false	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir,  <e1> Ketoconazole </e1> , Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir,  <e2> Saquinavir </e2> .
false	Antiacid,  <e1> clarithromycin </e1> , Didanosine,  <e2> Fluconazole </e2> , Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Antiacid, clarithromycin, Didanosine, Fluconazole,  <e1> Fluoxetine </e1> , Indanavir, Ketoconazole, Phenytoin, Phenobarbitol,  <e2> carbamazepine </e2> , Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine,  <e1> Rifabutin </e1> , Rifampin, Ritanovir,  <e2> Saquinavir </e2> .
false	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole,  <e1> Phenytoin </e1> , Phenobarbitol, carbamazepine, Rifabutin,  <e2> Rifampin </e2> , Ritanovir, Saquinavir.
false	Antiacid,  <e1> clarithromycin </e1> , Didanosine, Fluconazole, Fluoxetine, Indanavir,  <e2> Ketoconazole </e2> , Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Antiacid, clarithromycin,  <e1> Didanosine </e1> , Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol,  <e2> carbamazepine </e2> , Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Although deferasirox has a lower affinity for aluminum than for  <e1> iron </e1> , Exjade should not be taken with aluminum-containing  <e2> antacid preparations </e2> .
false	No inhibition of  <e1> deferasirox </e1>  metabolism by  <e2> hydroxyurea </e2>  is expected based on the results of an in vitro study.
false	Antiacid, clarithromycin, Didanosine, Fluconazole,  <e1> Fluoxetine </e1> , Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine,  <e2> Rifabutin </e2> , Rifampin, Ritanovir, Saquinavir.
false	Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole,  <e1> Phenytoin </e1> , Phenobarbitol, carbamazepine,  <e2> Rifabutin </e2> , Rifampin, Ritanovir, Saquinavir.
false	Antiacid,  <e1> clarithromycin </e1> , Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol,  <e2> carbamazepine </e2> , Rifabutin, Rifampin, Ritanovir, Saquinavir.
false	Concurrent use of tetracyclines with oral  <e1> contraceptives </e1>  may render oral  <e2> contraceptives </e2>  less effective.
false	Concurrent use of  <e1> tetracyclines </e1>  with oral contraceptives may render oral  <e2> contraceptives </e2>  less effective.
false	No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia ( <e1> muscle relaxants </e1> , intravenous agents, and local  <e2> anesthetic agents </e2> ) were reported in clinical trials.
false	If desipramine hydrochloride is to be combined with other psychotropic agents such as  <e1> tranquilizers </e1>  or sedative/ <e2> hypnotics </e2> , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
mechanism	There have been greater than two-fold increases of previously stable plasma levels of  <e1> tricyclic antidepressants </e1>  when  <e2> fluoxetine </e2>  has been administered in combination with these agents.
false	If desipramine hydrochloride is to be combined with other  <e1> psychotropic agents </e1>  such as tranquilizers or  <e2> sedative </e2> /hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
effect	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  <e1> desipramine </e1>  and benzodiazepines (e.g.,  <e2> chlordiazepoxide </e2>  or diazepam) are additive.
false	If  <e1> desipramine hydrochloride </e1>  is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  <e2> desipramine </e2>  and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
false	While all the selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), e.g.,  <e2> fluoxetine </e2> , seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
effect	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  <e1> desipramine </e1>  and benzodiazepines (e.g., chlordiazepoxide or  <e2> diazepam </e2> ) are additive.
false	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or  <e1> sedative </e1> /hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of  <e2> desipramine </e2>  and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
false	Concurrent administration of  <e1> cimetidine </e1>  and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the  <e2> tricyclic antidepressants </e2> .
false	If desipramine hydrochloride is to be combined with other psychotropic agents such as  <e1> tranquilizers </e1>  or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g.,  <e2> chlordiazepoxide </e2>  or diazepam) are additive.
false	If desipramine hydrochloride is to be combined with other psychotropic agents such as  <e1> tranquilizers </e1>  or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or  <e2> diazepam </e2> ) are additive.
false	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and  <e1> benzodiazepines </e1>  (e.g., chlordiazepoxide or  <e2> diazepam </e2> ) are additive.
false	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/ <e1> hypnotics </e1> , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and  <e2> benzodiazepines </e2>  (e.g., chlordiazepoxide or diazepam) are additive.
false	 <e1> Desloratadine </e1>   <e2> 3-Hydroxydesloratadine </e2> 
false	While all the  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs), e.g., fluoxetine, seriraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or  <e1> sedative </e1> / <e2> hypnotics </e2> , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
false	If desipramine hydrochloride is to be combined with other  <e1> psychotropic agents </e1>  such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or  <e2> diazepam </e2> ) are additive.
false	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with  <e1> azithromycin </e1>  500 mg followed by 250 mg once daily for 4 days (n=18) or with  <e2> fluoxetine </e2>  20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
false	While all the selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), e.g., fluoxetine, seriraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with  <e1> azithromycin </e1>  500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with  <e2> cimetidine </e2>  600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
false	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin,  <e1> ampicillin </e1> , and  <e2> tetracyclines </e2>  (72)
false	A similar association, though less marked, has been suggested with  <e1> barbiturates </e1> , phenyl-butazone, phenytoin sodium, carbamazepine and possibly with  <e2> griseofulvin </e2> , ampicillin, and tetracyclines (72)
false	Although the pressor activity of  <e1> Desmopressin </e1>  is very low compared to its antidiuretic activity, large doses of  <e2> Desmopressin </e2>  Tablets should be used with other pressor agents only with careful patient monitoring.
false	A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone,  <e1> phenytoin sodium </e1> , carbamazepine and possibly with griseofulvin,  <e2> ampicillin </e2> , and tetracyclines (72)
false	 <e1> Phenytoin </e1> : In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with  <e2> dexamethasone </e2>  co-administration, leading to alterations in seizure control.
false	Anticoagulants, oral: Co-administration of  <e1> corticosteroids </e1>  and warfarin usually results in inhibition of response to  <e2> warfarin </e2> , although there have been some conflicting reports.
false	 <e1> Ketoconazole </e1> :  <e2> Ketoconazole </e2>  has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.
advise	Amphotericin B injection and potassium-depleting agents: When  <e1> corticosteroids </e1>  are administered concomitantly with potassium-depleting agents (e.g., amphotericin B,  <e2> diuretics </e2> ), patients should be observed closely for development of hypokalemia.
false	Drugs which inhibit CYP 3A4 (e.g., ketoconazole,  <e1> macrolide antibiotics </e1>  such as  <e2> erythromycin </e2> ) have the potential to result in increased plasma concentrations of corticosteroids.
false	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin,  <e1> carbamazepine </e1> ,  <e2> rifampin </e2> ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
mechanism	Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as  <e1> erythromycin </e1> ) have the potential to result in increased plasma concentrations of  <e2> corticosteroids </e2> .
false	Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g.,  <e1> amphotericin B </e1> ,  <e2> diuretics </e2> ), patients should be observed closely for development of hypokalemia.
false	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  <e1> barbiturates </e1> , phenytoin,  <e2> carbamazepine </e2> , rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
false	 <e1> Antidiabetics </e1> : Because  <e2> corticosteroids </e2>  may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.
mechanism	Drugs which inhibit CYP 3A4 (e.g., ketoconazole,  <e1> macrolide antibiotics </e1>  such as erythromycin) have the potential to result in increased plasma concentrations of  <e2> corticosteroids </e2> .
effect	Anticholinesterases: Concomitant use of  <e1> anticholinesterase agents </e1>  and  <e2> corticosteroids </e2>  may produce severe weakness in patients with myasthenia gravis.
false	 <e1> Nonsteroidal anti-inflammatory agents </e1>  (NSAIDS): Concomitant use of aspirin (or other  <e2> nonsteroidal antiinflammatory agents </e2> ) and corticosteroids increases the risk of gastrointestinal side effects.
false	 <e1> Cyclosporine </e1> : Increased activity of both  <e2> cyclosporine </e2>  and corticosteroids may occur when the two are used concurrently.
false	 <e1> Phenytoin </e1> : In post-marketing experience, there have been reports of both increases and decreases in  <e2> phenytoin </e2>  levels with dexamethasone co-administration, leading to alterations in seizure control.
mechanism	Ketoconazole:  <e1> Ketoconazole </e1>  has been reported to decrease the metabolism of certain  <e2> corticosteroids </e2>  by up to 60%, leading to increased risk of corticosteroid side effects.
effect	Cyclosporine: Increased activity of both  <e1> cyclosporine </e1>  and  <e2> corticosteroids </e2>  may occur when the two are used concurrently.
false	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g.,  <e1> barbiturates </e1> , phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the  <e2> corticosteroid </e2>  be increased.
false	 <e1> Ketoconazole </e1> : Ketoconazole has been reported to decrease the metabolism of certain  <e2> corticosteroids </e2>  by up to 60%, leading to increased risk of corticosteroid side effects.
false	Drugs which inhibit CYP 3A4 (e.g.,  <e1> ketoconazole </e1> , macrolide antibiotics such as  <e2> erythromycin </e2> ) have the potential to result in increased plasma concentrations of corticosteroids.
false	Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine,  <e1> rifampin </e1> ) may enhance the metabolism of corticosteroids and require that the dosage of the  <e2> corticosteroid </e2>  be increased.
false	Dexbrompheniramine can interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or  <e2> antihistamines </e2> ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
int	 <e1> Dexbrompheniramine </e1>  can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain  <e1> corticosteroids </e1>  by up to 60%, leading to increased risk of  <e2> corticosteroid </e2>  side effects.
effect	Vaccines: Patients on  <e1> corticosteroid </e1>  therapy may exhibit a diminished response to toxoids and live or  <e2> inactivated vaccines </e2>  due to inhibition of antibody response.
false	Dexbrompheniramine can interact with  <e1> alcohol </e1>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e2> antihistamines </e2> ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e2> antihistamines </e2> ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
mechanism	The clearance of  <e1> salicylates </e1>  may be increased with concurrent use of  <e2> corticosteroids </e2> .
false	Dexbrompheniramine can interact with  <e1> alcohol </e1>  or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e2> monoamine oxidase (MAO) inhibitors </e2>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	 <e1> Anticoagulants </e1> , oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to  <e2> warfarin </e2> , although there have been some conflicting reports.
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e1> monoamine oxidase (MAO) inhibitors </e1>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e1> monoamine oxidase (MAO) inhibitors </e1>  (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
advise	 <e1> Dexfenfluramine </e1>  should not be administered with other  <e2> serotoninergic agents </e2> .
false	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as  <e1> Imitrex </e1>  ( <e2> sumatriptan succinate </e2> ) and dihydroergotamine.
effect	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g.,  <e1> selegiline hydrochloride </e1> ) in combination with serotoninergic agents (e.g., fluoxetine,  <e2> fluvoxamine </e2> , paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
false	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine,  <e1> fluvoxamine </e1> , paroxetine,  <e2> sertraline </e2> , venlafaxine), there have been reports of serious, sometimes fatal, reactions.
false	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or  <e1> antihistamines </e1> ),  <e2> anticholinergics </e2>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
effect	In patients receiving nonselective  <e1> monoamine oxidase inhibitors </e1>  (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline,  <e2> venlafaxine </e2> ), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective  <e1> monoamine oxidase inhibitors </e1>  (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine,  <e2> fluvoxamine </e2> , paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
false	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with  <e1> serotoninergic agents </e1>  (e.g.,  <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
false	A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex ( <e1> sumatriptan succinate </e1> ) and  <e2> dihydroergotamine </e2> .
false	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g.,  <e1> fluoxetine </e1> ,  <e2> fluvoxamine </e2> , paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine oxidase inhibitors ( <e1> MAOIs </e1> ) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g.,  <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
false	In patients receiving nonselective  <e1> monoamine oxidase inhibitors </e1>  (MAOIs) (e.g.,  <e2> selegiline hydrochloride </e2> ) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
effect	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g.,  <e1> selegiline hydrochloride </e1> ) in combination with  <e2> serotoninergic agents </e2>  (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
false	Anesthetics/Sedatives/ <e1> Hypnotics </e1> /Opioids: Co-administration of  <e2> PRECEDEX </e2>  with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
advise	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of  <e1> PRECEDEX </e1>  on the concomitant  <e2> anesthetic </e2> , sedative, hypnotic or opioid may be required.
false	No pharmacokinetic interactions between  <e1> dexmedetomidine </e1>  and isoflurane,  <e2> propofol </e2> , alfentanil, and midazolam have been demonstrated.
false	Anesthetics/ <e1> Sedatives </e1> /Hypnotics/ <e2> Opioids </e2> : Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
false	Anesthetics/Sedatives/ <e1> Hypnotics </e1> /Opioids: Co-administration of PRECEDEX with anesthetics, sedatives,  <e2> hypnotics </e2> , and opioids is likely to lead to an enhancement of effects.
false	 <e1> Neuromuscular Blockers </e1> : In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with  <e2> rocuronium </e2>  administration.
effect	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of  <e1> PRECEDEX </e1>  with anesthetics, sedatives, hypnotics, and  <e2> opioids </e2>  is likely to lead to an enhancement of effects.
false	No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol,  <e1> alfentanil </e1> , and  <e2> midazolam </e2>  have been demonstrated.
false	Anesthetics/Sedatives/Hypnotics/ <e1> Opioids </e1> : Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and  <e2> opioids </e2>  is likely to lead to an enhancement of effects.
false	Anesthetics/Sedatives/ <e1> Hypnotics </e1> /Opioids: Co-administration of PRECEDEX with  <e2> anesthetics </e2> , sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
false	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic,  <e1> sedative </e1> ,  <e2> hypnotic </e2>  or opioid may be required.
false	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant  <e1> anesthetic </e1> , sedative, hypnotic or  <e2> opioid </e2>  may be required.
false	In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine,  <e1> fluvoxamine </e1> ,  <e2> paroxetine </e2> , sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
false	However, due to possible pharmacodynamic interactions, when co-administered with  <e1> PRECEDEX </e1> , a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative,  <e2> hypnotic </e2>  or opioid may be required.
false	 <e1> Anesthetics </e1> /Sedatives/Hypnotics/ <e2> Opioids </e2> : Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
effect	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of  <e1> PRECEDEX </e1>  with anesthetics,  <e2> sedatives </e2> , hypnotics, and opioids is likely to lead to an enhancement of effects.
false	Anesthetics/ <e1> Sedatives </e1> /Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives,  <e2> hypnotics </e2> , and opioids is likely to lead to an enhancement of effects.
false	Specific studies have confirmed these effects with  <e1> sevoflurane </e1> , isoflurane,  <e2> propofol </e2> , alfentanil, and midazolam.
false	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative,  <e1> hypnotic </e1>  or  <e2> opioid </e2>  may be required.
false	Specific studies have confirmed these effects with  <e1> sevoflurane </e1> ,  <e2> isoflurane </e2> , propofol, alfentanil, and midazolam.
false	 <e1> MAO inhibitors </e1> :  <e2> MAOI antidepressants </e2> , as well as a metabolite of furazolidone, slow amphetamine metabolism.
false	 <e1> Lithium carbonate </e1> : The stimulatory effects of  <e2> amphetamines </e2>  may be inhibited by lithium carbonate.
effect	Antihistamines:  <e1> Amphetamines </e1>  may counteract the sedative effect of  <e2> antihistamines </e2> .
false	Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by  <e1> acidifying agents </e1>  used in  <e2> methenamine </e2>  therapy.
false	 <e1> Acidifying agents </e1> :  <e2> Gastrointestinal acidifying agents </e2>  (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
false	 <e1> Veratrum alkaloids </e1> : Amphetamines inhibit the hypotensive effect of  <e2> veratrum alkaloids </e2> .
effect	Antidepressants, tricyclic:  <e1> Amphetamines </e1>  may enhance the activity of  <e2> tricyclic </e2>  or sympathomimetic agents;
false	 <e1> Meperidine </e1> :  <e2> Amphetamines </e2>  potentiate the analgesic effect of meperidine.
false	Acidifying agents:  <e1> Gastrointestinal acidifying agents </e1>  ( <e2> guanethidine </e2> , reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
mechanism	MAO inhibitors: MAOI antidepressants, as well as a metabolite of  <e1> furazolidone </e1> , slow  <e2> amphetamine </e2>  metabolism.
false	 <e1> Phenobarbital </e1> :  <e2> Amphetamines </e2>  may delay intestinal absorption of phenobarbital;
false	Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of  <e1> amphetamines </e1> , and can be used to treat  <e2> amphetamine </e2>  poisoning.
mechanism	Phenytoin:  <e1> Amphetamines </e1>  may delay intestinal absorption of  <e2> phenytoin </e2> ;
mechanism	Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl,  <e1> ascorbic acid </e1> , fruit juices, etc.) lower absorption of  <e2> amphetamines </e2> .
mechanism	 <e1> d-amphetamine </e1>  with desipramine or protriptyline and possibly other  <e2> tricyclics </e2>  cause striking and sustained increases in the concentration of d-amphetamine in the brain;
false	d-amphetamine with desipramine or  <e1> protriptyline </e1>  and possibly other  <e2> tricyclics </e2>  cause striking and sustained increases in the concentration of d-amphetamine in the brain;
false	 <e1> Antidepressants </e1> , tricyclic: Amphetamines may enhance the activity of  <e2> tricyclic </e2>  or sympathomimetic agents;
false	d-amphetamine with desipramine or  <e1> protriptyline </e1>  and possibly other tricyclics cause striking and sustained increases in the concentration of  <e2> d-amphetamine </e2>  in the brain;
false	Acidifying agents: Gastrointestinal acidifying agents ( <e1> guanethidine </e1> ,  <e2> reserpine </e2> , glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
false	 <e1> Antihypertensives </e1> :  <e2> Amphetamines </e2>  may antagonize the hypotensive effects of antihypertensives.
false	 <e1> Methenamine </e1>  therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in  <e2> methenamine </e2>  therapy.
effect	Lithium carbonate: The stimulatory effects of  <e1> amphetamines </e1>  may be inhibited by  <e2> lithium carbonate </e2> .
false	Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs,  <e1> hypnotics </e1> ,  <e2> alcohol </e2> , and other opiate analgesics.
false	Antidepressants,  <e1> tricyclic </e1> : Amphetamines may enhance the activity of tricyclic or  <e2> sympathomimetic agents </e2> ;
false	Additive depressant effect when used with general  <e1> anesthetics </e1> , sedatives, antianxiety drugs, hypnotics, alcohol, and other  <e2> opiate analgesics </e2> .
mechanism	MAO inhibitors:  <e1> MAOI antidepressants </e1> , as well as a metabolite of furazolidone, slow  <e2> amphetamine </e2>  metabolism.
false	 <e1> Phenytoin </e1> :  <e2> Amphetamines </e2>  may delay intestinal absorption of phenytoin;
false	Additive depressant effect when used with general anesthetics,  <e1> sedatives </e1> , antianxiety drugs, hypnotics, alcohol, and other  <e2> opiate analgesics </e2> .
false	Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics,  <e1> alcohol </e1> , and other  <e2> opiate analgesics </e2> .
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products,  <e1> antacids </e1> , H2-antagonists (e.g.,  <e2> famotidine </e2> , ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine),  <e1> iodine </e1> -containing products, antacids, H2-antagonists (e.g.,  <e2> famotidine </e2> , ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine),  <e1> iodine </e1> -containing products,  <e2> antacids </e2> , H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine),  <e1> iodine </e1> -containing products, antacids,  <e2> H2-antagonists </e2>  (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g.,  <e1> famotidine </e1> , ranitidine), and proton pump inhibitors (e.g., lansoprazole,  <e2> omeprazole </e2> ).
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g.,  <e1> lansoprazole </e1> ,  <e2> omeprazole </e2> ).
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids,  <e1> H2-antagonists </e1>  (e.g., famotidine,  <e2> ranitidine </e2> ), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products,  <e1> antacids </e1> , H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole,  <e2> omeprazole </e2> ).
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products,  <e1> antacids </e1> , H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g.,  <e2> lansoprazole </e2> , omeprazole).
false	May interact with thyroid medication (e.g., levothyroxine), iodine-containing products,  <e1> antacids </e1> ,  <e2> H2-antagonists </e2>  (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
false	 <e1> Anticoagulants </e1> : While studies have not shown diclofenac to interact with  <e2> anticoagulants of the warfarin type </e2> , caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine,  <e1> gold </e1> , chloroquine, D-penicillamine, prednisolone, doxycycline, or  <e2> digitoxin </e2>  did not significantly affect the peak levels and AUC values of diclofenac.
false	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin,  <e1> erythromycin </e1> , and  <e2> sulfamethoxazole </e2>  have no influence in vitro on the protein binding of diclofenac in human serum.
false	Benzylpenicillin,  <e1> ampicillin </e1> , oxacillin, chlortetracycline,  <e2> doxycycline </e2> , cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	In patients taking  <e1> diclofenac </e1>  and lithium concomitantly,  <e2> lithium </e2>  toxicity may develop.
effect	There are rare reports, however, from marketing experiences, of changes in effects of  <e1> insulin </e1>  or oral hypoglycemic agents in the presence of  <e2> diclofenac </e2>  that necessitated changes in the doses of such agents.
false	Benzylpenicillin, ampicillin,  <e1> oxacillin </e1> , chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of  <e2> diclofenac </e2>  in human serum.
advise	Aspirin: Concomitant administration of  <e1> diclofenac </e1>  and  <e2> aspirin </e2>  is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
false	Aspirin: Concomitant administration of diclofenac and  <e1> aspirin </e1>  is not recommended because  <e2> diclofenac </e2>  is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
false	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including  <e1> diclofenac </e1> , and warfarin requires close monitoring of patients to be certain that no change in their  <e2> anticoagulant </e2>  dosage is required.
mechanism	Lithium:  <e1> Diclofenac </e1>  decreases lithium renal clearance and increases  <e2> lithium </e2>  plasma levels.
effect	Diuretics:  <e1> Diclofenac </e1>  and other NSAIDs can inhibit the activity of  <e2> diuretics </e2> .
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine,  <e1> prednisolone </e1> , doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of  <e2> diclofenac </e2> .
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone,  <e1> doxycycline </e1> , or  <e2> digitoxin </e2>  did not significantly affect the peak levels and AUC values of diclofenac.
false	Ingestion of diclofenac may increase serum concentrations of digoxin and  <e1> methotrexate </e1>  and increase  <e2> cyclosporine </e2>  s nephrotoxicity.
effect	Patients who begin taking diclofenac or who increase their diclofenac dose or any other  <e1> NSAID </e1>  while taking digoxin, methotrexate, or  <e2> cyclosporine </e2>  may develop toxicity characteristics for these drugs.
false	Because prostaglandins play an important role in hemostasis, and  <e1> NSAIDs </e1>  affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and  <e2> warfarin </e2>  requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold,  <e1> chloroquine </e1> , D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of  <e2> diclofenac </e2> .
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine,  <e1> gold </e1> , chloroquine, D-penicillamine,  <e2> prednisolone </e2> , doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
false	 <e1> Aspirin </e1> : Concomitant administration of diclofenac and aspirin is not recommended because  <e2> diclofenac </e2>  is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  <e1> azathioprine </e1> , gold,  <e2> chloroquine </e2> , D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
false	Benzylpenicillin, ampicillin, oxacillin,  <e1> chlortetracycline </e1> , doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of  <e2> diclofenac </e2>  in human serum.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone,  <e1> doxycycline </e1> , or digitoxin did not significantly affect the peak levels and AUC values of  <e2> diclofenac </e2> .
false	Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding),  <e1> tolbutamide </e1> ,  <e2> prednisolone </e2>  (10% decrease in binding), or warfarin.
false	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and  <e1> warfarin </e1>  requires close monitoring of patients to be certain that no change in their  <e2> anticoagulant </e2>  dosage is required.
false	 <e1> Digoxin </e1> , Methotrexate, Cyclosporine: Diclofenac, like other  <e2> NSAIDs </e2> , may affect renal prostaglandins and increase the toxicity of certain drugs.
false	Digoxin,  <e1> Methotrexate </e1> ,  <e2> Cyclosporine </e2> : Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine,  <e1> prednisolone </e1> ,  <e2> doxycycline </e2> , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
false	Benzylpenicillin,  <e1> ampicillin </e1> , oxacillin, chlortetracycline, doxycycline, cephalothin,  <e2> erythromycin </e2> , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline,  <e1> cephalothin </e1> , erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of  <e2> diclofenac </e2>  in human serum.
mechanism	Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because  <e1> diclofenac </e1>  is displaced from its binding sites during the concomitant administration of  <e2> aspirin </e2> , resulting in lower plasma concentrations, peak plasma levels, and AUC values.
false	Benzylpenicillin, ampicillin, oxacillin,  <e1> chlortetracycline </e1> , doxycycline,  <e2> cephalothin </e2> , erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	There are rare reports, however, from marketing experiences, of changes in effects of  <e1> insulin </e1>  or oral  <e2> hypoglycemic agents </e2>  in the presence of diclofenac that necessitated changes in the doses of such agents.
false	Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all  <e1> NSAIDs </e1> , including  <e2> diclofenac </e2> , and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
false	 <e1> Benzylpenicillin </e1> , ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin,  <e2> erythromycin </e2> , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	Benzylpenicillin, ampicillin,  <e1> oxacillin </e1> , chlortetracycline, doxycycline, cephalothin,  <e2> erythromycin </e2> , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
false	Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of  <e1> azathioprine </e1> , gold, chloroquine,  <e2> D-penicillamine </e2> , prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
false	Tetracycline, a  <e1> bacteriostatic antibiotic </e1> , may antagonize the bactercidal effect of  <e2> penicillin </e2>  and concurrent use of these drugs should be avoided.
effect	Patients who begin taking  <e1> diclofenac </e1>  or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or  <e2> cyclosporine </e2>  may develop toxicity characteristics for these drugs.
false	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine),  <e1> antihistamines </e1>  antipsychotic agents (e.g. phenothiazines),  <e2> benzodiazepines </e2> .
mechanism	 <e1> Anticholinergic agents </e1>  may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of  <e2> digoxin </e2> ;
false	The following agents may increase certain actions or side effects of anticholinergic drugs.  <e1> amantadine </e1>  antiarrhythmic agents of class (e.g.  <e2> quinidine </e2> ), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
false	MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and  <e1> nitrites </e1> , sympathomimetic agents,  <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.
false	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine  <e1> antiarrhythmic agents </e1>  of class (e.g. quinidine),  <e2> antihistamines </e2>  antipsychotic agents (e.g. phenothiazines), benzodiazepines.
false	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine),  <e1> antihistamines </e1>  antipsychotic agents (e.g.  <e2> phenothiazines </e2> ), benzodiazepines.
false	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g.  <e1> phenothiazines </e1> ),  <e2> benzodiazepines </e2> .
false	Patients who begin taking diclofenac or who increase their  <e1> diclofenac </e1>  dose or any other NSAID while taking digoxin, methotrexate, or  <e2> cyclosporine </e2>  may develop toxicity characteristics for these drugs.
false	The following agents may increase certain actions or side effects of anticholinergic drugs.  <e1> amantadine </e1>  antiarrhythmic agents of class (e.g. quinidine),  <e2> antihistamines </e2>  antipsychotic agents (e.g. phenothiazines), benzodiazepines.
false	The following agents may increase certain actions or side effects of anticholinergic drugs.  <e1> amantadine </e1>  antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g.  <e2> phenothiazines </e2> ), benzodiazepines.
false	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine  <e1> antiarrhythmic agents </e1>  of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines),  <e2> benzodiazepines </e2> .
false	Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline,  <e1> cephalothin </e1> , erythromycin, and  <e2> sulfamethoxazole </e2>  have no influence in vitro on the protein binding of diclofenac in human serum.
mechanism	Allopurinol: The AUC of didanosine was increased about 4-fold when  <e1> allopurinol </e1>  at 300 mg/day was coadministered with a single 200-mg dose of  <e2> VIDEX </e2>  to two patients with renal impairment (CLcr=15 and 18 mL/min).
false	Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as  <e1> ketoconazole </e1>  and  <e2> itraconazole </e2>  should be administered at least 2 hours prior to dosing with VIDEX.
false	 <e1> Antacids </e1> : Concomitant administration of antacids containing magnesium or  <e2> aluminum </e2>  with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
false	 <e1> Ganciclovir </e1> : Administration of VIDEX 2 hours prior to or concurrent with oral  <e2> ganciclovir </e2>  was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).
advise	Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as  <e1> ketoconazole </e1>  and itraconazole should be administered at least 2 hours prior to dosing with  <e2> VIDEX </e2> .
false	Antacids: Concomitant administration of antacids containing magnesium or  <e1> aluminum </e1>  with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the  <e2> antacid </e2>  components.
false	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with  <e1> antacids </e1>  containing magnesium,  <e2> calcium </e2> , or aluminum.
false	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of  <e1> ciprofloxacin </e1>  are decreased when administered with  <e2> antacids </e2>  containing magnesium, calcium, or aluminum.
false	Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including  <e1> stavudine </e1> , and these patients may be at increased risk of neuropathy during  <e2> VIDEX </e2>  therapy (see ADVERSE REACTIONS).
mechanism	In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when  <e1> ciprofloxacin </e1>  was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of  <e2> VIDEX </e2> .
false	 <e1> Quinolone Antibiotic </e1> s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing  <e2> magnesium </e2> , calcium, or aluminum.
false	Antacids: Concomitant administration of  <e1> antacids </e1>  containing  <e2> magnesium </e2>  or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
false	Allopurinol: The AUC of  <e1> didanosine </e1>  was increased about 4-fold when  <e2> allopurinol </e2>  at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
false	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with  <e1> ciprofloxacin </e1>  because plasma concentrations of ciprofloxacin are decreased when administered with  <e2> antacids </e2>  containing magnesium, calcium, or aluminum.
effect	Antacids: Concomitant administration of antacids containing magnesium or  <e1> aluminum </e1>  with  <e2> VIDEX </e2>  Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
false	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine  <e1> antiarrhythmic agents </e1>  of class (e.g.  <e2> quinidine </e2> ), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
mechanism	In a single subject given one dose of  <e1> ciprofloxacin </e1>  2 hours after a dose of  <e2> didanosine </e2> -placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
false	The AUC of  <e1> ciprofloxacin </e1>  was decreased an average of 15-fold in 12 healthy subjects given  <e2> ciprofloxacin </e2>  and didanosine-placebo tablets concurrently.
false	In eight HIV-infected patients, the steady-state AUC of  <e1> ciprofloxacin </e1>  was decreased an average of 26% (95% CI = 14%, 37%) when  <e2> ciprofloxacin </e2>  was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.
false	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with  <e1> ciprofloxacin </e1>  because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing  <e2> magnesium </e2> , calcium, or aluminum.
false	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with  <e1> ciprofloxacin </e1>  because plasma concentrations of  <e2> ciprofloxacin </e2>  are decreased when administered with antacids containing magnesium, calcium, or aluminum.
false	A 21 (17)% decrease in the steady-state AUC of  <e1> ganciclovir </e1>  was observed when  <e2> VIDEX </e2>  was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
false	The pharmacokinetics of  <e1> nelfinavir </e1>  are not altered to a clinically significant degree when it is administered with a light meal 1 hour after  <e2> VIDEX </e2> .
false	 <e1> Quinolone Antibiotic </e1> s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or  <e2> aluminum </e2> .
false	Antacids: Concomitant administration of  <e1> antacids </e1>  containing magnesium or  <e2> aluminum </e2>  with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
mechanism	Plasma concentrations of  <e1> quinolone antibiotics </e1>  are decreased when administered with antacids containing  <e2> magnesium </e2> , calcium, or aluminum.
false	Quinolone Antibiotics:  <e1> VIDEX </e1>  should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with  <e2> antacids </e2>  containing magnesium, calcium, or aluminum.
int	conversely,  <e1> diethylpropion </e1>  may interfere with antihypertensive drugs (i.e.,  <e2> guanethidine </e2> , a-methyldopa).
false	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates,  <e1> rifampin </e1>  and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of  <e2> diethylstilbestrol </e2> ), corticosteroids (increased effect of corticosteroids).
false	May interact  <e1> anticoagulants </e1>  (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol),  <e2> corticosteroids </e2>  (increased effect of corticosteroids).
false	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol),  <e1> corticosteroids </e1>  (increased effect of  <e2> corticosteroids </e2> ).
false	 <e1> Cyclosporine </e1> : Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in  <e2> cyclosporine </e2> -induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
false	May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates,  <e1> rifampin </e1>  and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of  <e2> corticosteroids </e2> ).
effect	In some patients the combined use of  <e1> indomethacin </e1>  and  <e2> diflunisal </e2>  has been associated with fatal gastrointestinal hemorrhage.
effect	 <e1> Diflunisal </e1>  decreased the hyperuricemic effect of  <e2> furosemide </e2> .
false	Aspirin: In normal volunteers, a small decrease in  <e1> diflunisal </e1>  levels was observed when multiple doses of diflunisal and  <e2> aspirin </e2>  were administered concomitantly.
advise	Accordingly, when  <e1> diflunisal </e1>  is administered with oral  <e2> anticoagulants </e2> , the prothrombin time should be closely monitored during and for several days after concomitant drug administration.
false	Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and  <e1> hydrochlorothiazide </e1>  resulted in significantly increased plasma levels of  <e2> hydrochlorothiazide </e2> .
false	 <e1> Sulindac </e1> : The concomitant administration of  <e2> diflunisal </e2>  and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
false	 <e1> Sulindac </e1> : The concomitant administration of diflunisal and  <e2> sulindac </e2>  in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
false	 <e1> Furosemide </e1> : In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of  <e2> furosemide </e2> .
false	Naproxen: The concomitant administration of  <e1> diflunisal </e1>  and naproxen in normal volunteers had no effect on the plasma levels of  <e2> naproxen </e2> , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
false	 <e1> Naproxen </e1>  had no effect on plasma levels of  <e2> diflunisal </e2> .
false	 <e1> Naproxen </e1> : The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of  <e2> naproxen </e2> , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
false	Since  <e1> acetaminophen </e1>  in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and  <e2> acetaminophen </e2>  should be used cautiously, with careful monitoring of patients.
mechanism	Sulindac: The concomitant administration of  <e1> diflunisal </e1>  and  <e2> sulindac </e2>  in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
mechanism	Antacids: Concomitant administration of  <e1> antacids </e1>  may reduce plasma levels of  <e2> diflunisal </e2> .
false	 <e1> Aspirin </e1> : In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and  <e2> aspirin </e2>  were administered concomitantly.
false	 <e1> Naproxen </e1> : The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of  <e2> naproxen </e2>  and its glucuronide metabolite.
false	Tolbutamide: In diabetic patients receiving  <e1> diflunisal </e1>  and tolbutamide, no significant effects were seen on  <e2> tolbutamide </e2>  plasma levels or fasting blood glucose.
false	Concomitant administration of diflunisal and  <e1> acetaminophen </e1>  in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/ <e2> acetaminophen </e2> ) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
false	Quinidine, verapamil,  <e1> amiodarone </e1> ,  <e2> propafenone </e2> , indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	Tolbutamide: In diabetic patients receiving diflunisal and  <e1> tolbutamide </e1> , no significant effects were seen on  <e2> tolbutamide </e2>  plasma levels or fasting blood glucose.
false	Quinidine, verapamil, amiodarone, propafenone,  <e1> indomethacin </e1> , itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  <e2> digitalis </e2>  intoxication may result.
false	Antacids,  <e1> kaolin </e1> -pectin,  <e2> sulfasalazine </e2> , neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
false	Quinidine, verapamil, amiodarone,  <e1> propafenone </e1> , indomethacin, itraconazole,  <e2> alprazolam </e2> , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	Furthermore, caution should be exercised when combining  <e1> digoxin </e1>  with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of  <e2> digoxin </e2> .
false	Antacids, kaolin-pectin, sulfasalazine, neomycin,  <e1> cholestyramine </e1> , certain anticancer drugs, and  <e2> metoclopramide </e2>  may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
false	Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and  <e1> tetracycline </e1>  may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that  <e2> digitalis </e2>  intoxication may result.
false	 <e1> Antacids </e1> ,  <e2> kaolin </e2> -pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
false	Erythromycin and  <e1> clarithromycin </e1>  (and possibly other  <e2> macrolide antibiotics </e2> ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
false	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and  <e1> spironolactone </e1>  raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  <e2> digitalis </e2>  intoxication may result.
false	 <e1> Quinidine </e1> ,  <e2> verapamil </e2> , amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	 <e1> Antacids </e1> , kaolin-pectin, sulfasalazine, neomycin,  <e2> cholestyramine </e2> , certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
false	Quinidine,  <e1> verapamil </e1> , amiodarone, propafenone, indomethacin, itraconazole,  <e2> alprazolam </e2> , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	Furosemide: In normal volunteers, the concomitant administration of diflunisal and  <e1> furosemide </e1>  had no effect on the diuretic activity of  <e2> furosemide </e2> .
false	 <e1> Quinidine </e1> , verapamil, amiodarone, propafenone, indomethacin, itraconazole,  <e2> alprazolam </e2> , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
mechanism	Quinidine, verapamil, amiodarone, propafenone, indomethacin,  <e1> itraconazole </e1> , alprazolam, and spironolactone raise the serum  <e2> digoxin </e2>  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	 <e1> Erythromycin </e1>  and clarithromycin (and possibly other  <e2> macrolide antibiotics </e2> ) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
mechanism	Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole,  <e1> alprazolam </e1> , and spironolactone raise the serum  <e2> digoxin </e2>  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
mechanism	 <e1> Erythromycin </e1>  and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase  <e2> digoxin </e2>  absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
false	Quinidine, verapamil,  <e1> amiodarone </e1> , propafenone, indomethacin, itraconazole,  <e2> alprazolam </e2> , and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
mechanism	Quinidine, verapamil, amiodarone,  <e1> propafenone </e1> , indomethacin, itraconazole, alprazolam, and spironolactone raise the serum  <e2> digoxin </e2>  concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
mechanism	Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of  <e1> diflunisal </e1>  and  <e2> aspirin </e2>  were administered concomitantly.
effect	Although  <e1> beta-adrenergic blockers </e1>  or calcium channel blockers and  <e2> digoxin </e2>  may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
false	 <e1> Naproxen </e1> : The concomitant administration of diflunisal and  <e2> naproxen </e2>  in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
false	Erythromycin and clarithromycin (and possibly other  <e1> macrolide antibiotics </e1> ) and tetracycline may increase digoxin absorption in patients who inactivate  <e2> digoxin </e2>  by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
false	Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  ( <e1> dihydroergotamine mesylate </e1> ) Injection, USP is a member, have been shown to interact with  <e2> antibiotics </e2>  of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	 <e1> fluoxetine </e1> , fluvoxamine,  <e2> paroxetine </e2> , sertraline).
false	Oral  <e1> Contraceptives </e1> : The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45  ( <e2> dihydroergotamine mesylate </e2> ) Injection, USP has not been studied.
false	 <e1> Macrolide Antibiotics </e1>  (e. g. erythromycin and troleandomycin): Agents of the  <e2> ergot alkaloid class </e2> , of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
effect	Nicotine:  <e1> Nicotine </e1>  may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to  <e2> ergot </e2>  therapy.
false	Macrolide Antibiotics (e. g.  <e1> erythromycin </e1>  and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the  <e2> macrolide class </e2> , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of  <e1> D.H.E. 45 </e1>   (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of  <e2> ergotamine </e2>  by blocking the vasodilating property of epinephrine.
false	 <e1> Macrolide Antibiotics </e1>  (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with  <e2> antibiotics </e2>  of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
mechanism	Propantheline and  <e1> diphenoxylate </e1> , by decreasing gut motility, may increase  <e2> digoxin </e2>  absorption.
false	 <e1> Quinidine </e1> , verapamil,  <e2> amiodarone </e2> , propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
false	Macrolide Antibiotics (e. g.  <e1> erythromycin </e1>  and troleandomycin): Agents of the  <e2> ergot alkaloid class </e2> , of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	 <e1> Macrolide Antibiotics </e1>  (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the  <e2> macrolide class </e2> , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	Quinidine, verapamil, amiodarone, propafenone,  <e1> indomethacin </e1> ,  <e2> itraconazole </e2> , alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
advise	 <e1> Sumatriptan </e1>  and  <e2> D.H.E. 45 </e2>   (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
effect	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that  <e1> propranolol </e1>  may potentiate the vasoconstrictive action of  <e2> ergotamine </e2>  by blocking the vasodilating property of epinephrine.
false	 <e1> Macrolide Antibiotics </e1>  (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  ( <e2> dihydroergotamine mesylate </e2> ) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	 <e1> Quinidine </e1> , verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that  <e2> digitalis </e2>  intoxication may result.
false	 <e1> Vasoconstrictors </e1> : D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with  <e2> peripheral vasoconstrictors </e2>  because the combination may cause synergistic elevation of blood pressure.
false	Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with  <e1> D.H.E. 45 </e1>   ( <e2> dihydroergotamine mesylate </e2> ) Injection, USP.
false	There have been no reported cases from spontaneous reports of drug interaction between  <e1> SSRIs </e1>  and D.H.E. 45  ( <e2> dihydroergotamine mesylate </e2> ) Injection, USP.
false	Antacids,  <e1> kaolin </e1> -pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and  <e2> metoclopramide </e2>  may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
false	 <e1> SSRIs </e1> : Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with  <e2> SSRIs </e2>  (e. g.
effect	Vasospastic reactions have been reported with therapeutic doses of  <e1> ergotamine </e1> -containing drugs when co-administered with these  <e2> antibiotics </e2> .
effect	These pharmacokinetic effects seen during  <e1> diltiazem </e1>  coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and  <e2> triazolam </e2> .
false	These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both  <e1> midazolam </e1>  and  <e2> triazolam </e2> .
false	Diltiazem plasma levels were not significantly affected by  <e1> lovastatin </e1>  or  <e2> pravastatin </e2> .
mechanism	Administration of  <e1> diltiazem hydrochloride </e1>  concomitantly with  <e2> propranolol </e2>  in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
false	Coadministration of  <e1> rifampin </e1>  with diltiazem lowered the  <e2> diltiazem </e2>  plasma concentrations to undetectable levels.
false	 <e1> Diltiazem </e1>  plasma levels were not significantly affected by lovastatin or  <e2> pravastatin </e2> .
mechanism	In a ten-subject study, coadministration of  <e1> diltiazem </e1>  (120 mg bid) with  <e2> lovastatin </e2>  resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;
false	Macrolide Antibiotics (e. g.  <e1> erythromycin </e1>  and  <e2> troleandomycin </e2> ): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
false	In a ten-subject study, coadministration of diltiazem (120 mg bid) with  <e1> lovastatin </e1>  resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs.  <e2> lovastatin </e2>  alone;
mechanism	The effect may be mediated by  <e1> cimetidine </e1> s known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of  <e2> diltiazem </e2> .
advise	If these agents are to be administered concurrently,  <e1> cyclosporine </e1>  concentrations should be monitored, especially when  <e2> diltiazem </e2>  therapy is initiated, adjusted, or discontinued.
false	The elimination half life of  <e1> midazolam </e1>  and  <e2> triazolam </e2>  also increased (1.5-2.5 fold) during coadministration with diltiazem.
false	 <e1> Dimenhydrinate </e1>  may decrease  <e2> emetic </e2>  response to apomorphine.
false	In a ten-subject study, coadministration of  <e1> diltiazem </e1>  (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs.  <e2> lovastatin </e2>  alone;
mechanism	Studies showed that  <e1> diltiazem </e1>  increased the AUC of midazolam and  <e2> triazolam </e2>  by 3-4 fold and the Cmax by 2-fold, compared to placebo.
false	 <e1> Oxytocin </e1>  or other  <e2> oxytocics </e2>  (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
effect	 <e1> Oxytocin </e1>  or other oxytocics (concurrent use with  <e2> dinoprost </e2>  may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
effect	 <e1> Diphenhydramine hydrochloride </e1>  has additive effects with alcohol and other CNS depressants ( <e2> hypnotics </e2> , sedatives, tranquilizers, etc).
false	Diphenhydramine hydrochloride has additive effects with alcohol and other  <e1> CNS depressants </e1>  ( <e2> hypnotics </e2> , sedatives, tranquilizers, etc).
false	Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants ( <e1> hypnotics </e1> ,  <e2> sedatives </e2> , tranquilizers, etc).
false	 <e1> apomorphine </e1>  - prior ingestion of diphenidol may decrease the  <e2> emetic </e2>  response to apomorphine in the treatment of poisoning.
false	 <e1> anticholinergics </e1>  or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with  <e2> diphenidol </e2> ;
false	 <e1> Diphenoxylate HCl </e1>  and  <e2> atropine sulfate </e2>  may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
false	Diphenoxylate HCl and atropine sulfate may interact with  <e1> MAO inhibitors </e1>  In studies with male rats,  <e2> diphenoxylate hydrochloride </e2>  was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e1> antihistamines </e1> ), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
false	This drug may interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e2> anticholinergics </e2>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or  <e1> antihistamines </e1> ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other  <e1> CNS depressants </e1>  (may potentiate the CNS depressant effects of either these medications or  <e2> antihistamines </e2> ), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines),  <e1> anticholinergics </e1>  or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with  <e1> antihistamines </e1> ), and monoamine oxidase (MAO) inhibitors (concurrent use with  <e2> antihistamines </e2>  may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with  <e1> alcohol </e1>  or other  <e2> CNS depressants </e2>  (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
false	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and  <e1> monoamine oxidase (MAO) inhibitors </e1>  (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of  <e2> antihistamines </e2> ).
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including  <e1> cyclosporine </e1> , hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and  <e2> lovastatin </e2> .
false	These six volunteers received  <e1> terfenadine </e1>  alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with  <e2> dirithromycin </e2>  (500 mg once daily) for 10 days.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine,  <e1> hexobarbital </e1> ,  <e2> carbamazepine </e2> , alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
false	Antacids or  <e1> H 2 receptor antagonists </e1> : When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of  <e2> dirithromycin </e2>  is slightly enhanced.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide,  <e1> phenytoin </e1> , bromocriptine, valproate,  <e2> astemizole </e2> , and lovastatin.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including  <e1> cyclosporine </e1> ,  <e2> hexobarbital </e2> , carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
false	Digoxin: Concomitant administration of erythromycin and  <e1> digoxin </e1>  has been reported to result in elevated  <e2> digoxin </e2>  serum levels.
false	 <e1> Digoxin </e1> : Concomitant administration of erythromycin and  <e2> digoxin </e2>  has been reported to result in elevated digoxin serum levels.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including  <e1> cyclosporine </e1> , hexobarbital, carbamazepine,  <e2> alfentanil </e2> , disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine,  <e1> hexobarbital </e1> , carbamazepine, alfentanil, disopyramide, phenytoin,  <e2> bromocriptine </e2> , valproate, astemizole, and lovastatin.
mechanism	Digoxin: Concomitant administration of  <e1> erythromycin </e1>  and  <e2> digoxin </e2>  has been reported to result in elevated digoxin serum levels.
effect	Ergotamine: Concurrent use of  <e1> erythromycin </e1>  and  <e2> ergotamine </e2>  or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
false	Antacids or H 2 receptor antagonists: When  <e1> dirithromycin </e1>  is administered immediately following antacids or H 2 -receptor antagonists, the absorption of  <e2> dirithromycin </e2>  is slightly enhanced.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil,  <e1> disopyramide </e1> , phenytoin, bromocriptine, valproate, astemizole, and  <e2> lovastatin </e2> .
false	in one man, the C max of  <e1> terfenadine </e1>  was 8.1 ng/mL with  <e2> terfenadine </e2>  alone and 7.2 ng/mL with terfenadine plus dirithromycin.
false	 <e1> Theophylline </e1> : Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of  <e2> theophylline </e2>  was not significantly altered.
false	The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with  <e1> terfenadine </e1>  alone, and with  <e2> terfenadine </e2>  plus dirithromycin.
false	However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given  <e1> theophylline </e1>  plasma concentration for optimal pulmonary function or in patients with  <e2> theophylline </e2>  concentrations at the higher end of the therapeutic range.
int	Other drugs Drug interactions have been reported with concomitant administration of  <e1> erythromycin </e1>  and other medications, including  <e2> cyclosporine </e2> , hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
false	 <e1> Digoxin </e1> : Concomitant administration of erythromycin and digoxin has been reported to result in elevated  <e2> digoxin </e2>  serum levels.
int	Other drugs Drug interactions have been reported with concomitant administration of  <e1> erythromycin </e1>  and other medications, including cyclosporine,  <e2> hexobarbital </e2> , carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
false	In general, most patients treated with  <e1> dirithromycin </e1>  who are receiving concomitant theophylline therapy may not require empiric adjustment of  <e2> theophylline </e2>  dosage or monitoring of theophylline plasma concentrations.
false	 <e1> Antacids </e1>  or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or  <e2> H 2 -receptor antagonists </e2> , the absorption of dirithromycin is slightly enhanced.
false	in one man, the C max of  <e1> terfenadine </e1>  was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with  <e2> terfenadine </e2>  plus dirithromycin.
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil,  <e1> disopyramide </e1> , phenytoin, bromocriptine, valproate,  <e2> astemizole </e2> , and lovastatin.
false	 <e1> Anticoagulants </e1> : There have been reports of increased anticoagulant effects when  <e2> erythromycin </e2>  and oral anticoagulants were used concomitantly.
false	In general, most patients treated with dirithromycin who are receiving concomitant  <e1> theophylline </e1>  therapy may not require empiric adjustment of  <e2> theophylline </e2>  dosage or monitoring of theophylline plasma concentrations.
false	Until data on possible interactions between verapamil and  <e1> disopyramide phosphate </e1>  are obtained,  <e2> disopyramide </e2>  should not be administered within 48 hours before or 24 hours after verapamil administration.
false	In healthy subjects, no significant drug-drug interaction was observed when  <e1> Norpace </e1>  was coadministered with either propranolol or  <e2> diazepam </e2> .
mechanism	Concomitant administration of  <e1> Norpace </e1>  and  <e2> quinidine </e2>  resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
false	Other  <e1> antiarrhythmic drugs </e1>  (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with  <e2> Norpace </e2> .
false	Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide,  <e1> phenytoin </e1> ,  <e2> bromocriptine </e2> , valproate, astemizole, and lovastatin.
false	 <e1> Norpace </e1>  does not increase serum  <e2> digoxin </e2>  levels.
false	Other antiarrhythmic drugs (eg, quinidine,  <e1> procainamide </e1> ,  <e2> lidocaine </e2> , propranolol) have occasionally been used concurrently with Norpace.
false	Antacids or  <e1> H 2 receptor antagonists </e1> : When dirithromycin is administered immediately following antacids or  <e2> H 2 -receptor antagonists </e2> , the absorption of dirithromycin is slightly enhanced.
false	If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or  <e1> Norpace CR </e1> , lower plasma levels of  <e2> disopyramide </e2>  may occur.
false	Until data on possible interactions between verapamil and  <e1> disopyramide phosphate </e1>  are obtained, disopyramide should not be administered within 48 hours before or 24 hours after  <e2> verapamil </e2>  administration.
false	In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either  <e1> propranolol </e1>  or  <e2> diazepam </e2> .
false	Other  <e1> antiarrhythmic drugs </e1>  (eg,  <e2> quinidine </e2> , procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.
advise	It may be necessary to adjust the dosage of oral  <e1> anticoagulants </e1>  upon beginning or stopping  <e2> disulfiram </e2> . since disulfiram may prolong prothrombin time.
false	In rats, simultaneous ingestion of disulfiram and  <e1> nitrite </e1>  in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that  <e2> disulfiram </e2>  may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
effect	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING  <e1> DISULFIRAM </e1>  TO A PATIENT ON  <e2> PHENYTOIN </e2>  THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
false	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO  <e1> PHENYTOIN </e1>  INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE  <e2> PHENYTOIN </e2>  SERUM LEVEL SHOULD BE OBTAINED.
false	SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON  <e1> PHENYTOIN </e1>  THERAPY, A BASELINE  <e2> PHENYTOIN </e2>  SERUM LEVEL SHOULD BE OBTAINED.
false	Other  <e1> antiarrhythmic drugs </e1>  (eg, quinidine,  <e2> procainamide </e2> , lidocaine, propranolol) have occasionally been used concurrently with Norpace.
false	There was no evidence of drug interactions in clinical studies in which  <e1> dobutamine </e1>  was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including  <e1> digitalis preparations </e1> , furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate,  <e2> morphine </e2> , atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine,  <e1> atropine </e1> ,  <e2> heparin </e2> , protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine,  <e1> potassium chloride </e1> ,  <e2> folic acid </e2> , and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine,  <e1> glyceryl trinitrate </e1> , isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including  <e1> digitalis preparations </e1> , furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride,  <e2> folic acid </e2> , and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including  <e1> digitalis preparations </e1> , furosemide, spironolactone, lidocaine,  <e2> glyceryl trinitrate </e2> , isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide,  <e1> spironolactone </e1> , lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin,  <e2> protamine </e2> , potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine,  <e1> glyceryl trinitrate </e1> , isosorbide dinitrate, morphine, atropine,  <e2> heparin </e2> , protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone,  <e1> lidocaine </e1> , glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin,  <e2> protamine </e2> , potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate,  <e1> isosorbide dinitrate </e1> , morphine, atropine, heparin, protamine, potassium chloride,  <e2> folic acid </e2> , and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone,  <e1> lidocaine </e1> , glyceryl trinitrate,  <e2> isosorbide dinitrate </e2> , morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate,  <e1> morphine </e1> , atropine, heparin, protamine,  <e2> potassium chloride </e2> , folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone,  <e1> lidocaine </e1> , glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride,  <e2> folic acid </e2> , and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide,  <e1> spironolactone </e1> , lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine,  <e2> potassium chloride </e2> , folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which  <e1> dobutamine </e1>  was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride,  <e2> folic acid </e2> , and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide,  <e1> spironolactone </e1> , lidocaine, glyceryl trinitrate, isosorbide dinitrate,  <e2> morphine </e2> , atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine,  <e1> glyceryl trinitrate </e1> ,  <e2> isosorbide dinitrate </e2> , morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin,  <e1> protamine </e1> , potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations,  <e1> furosemide </e1> , spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and  <e2> acetaminophen </e2> .
mechanism	In vitro studies have shown that the metabolism of  <e1> docetaxel </e1>  may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole,  <e2> erythromycin </e2> , and troleandomycin.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate,  <e1> isosorbide dinitrate </e1> , morphine, atropine, heparin,  <e2> protamine </e2> , potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone,  <e1> lidocaine </e1> , glyceryl trinitrate, isosorbide dinitrate, morphine, atropine,  <e2> heparin </e2> , protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which  <e1> dobutamine </e1>  was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine,  <e2> glyceryl trinitrate </e2> , isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine,  <e1> heparin </e1> , protamine, potassium chloride,  <e2> folic acid </e2> , and acetaminophen.
false	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as  <e1> cyclosporine </e1> , terfenadine,  <e2> ketoconazole </e2> , erythromycin, and troleandomycin.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone,  <e1> cannabinoids </e1> , diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine,  <e2> zafirlukast </e2> ) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin,  <e1> glyburide </e1> ,  <e2> ranitidine </e2> , omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
advise	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice,  <e1> nefazadone </e1> , norfloxacin, quinine, zafirlukast) should be cautiously coadministered with  <e2> TIKOSYN </e2>  as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and  <e1> magnesium hydroxide </e1> s) and theophylline did not affect the pharmacokinetics of  <e2> TIKOSYN </e2> .
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine,  <e1> omeprazole </e1> , hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium  <e2> hydroxide </e2> s) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	HCTZ 50 mg QD or  <e1> HCTZ </e1> /triamterene 50/100 mg QD was co-administered with  <e2> TIKOSYN </e2>  (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin,  <e1> quinine </e1> , zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase  <e2> dofetilide </e2>  levels.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents,  <e1> protease inhibitors </e1> , serotonin reuptake inhibitors,  <e2> amiodarone </e2> , cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or  <e1> antacids </e1>  (aluminum and magnesium hydroxides) be used as alternatives to  <e2> cimetidine </e2> , as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
false	Other Drugs: In healthy volunteers,  <e1> amlodipine </e1> , phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium  <e2> hydroxide </e2> s) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Concomitant medications were grouped as ACE inhibitors, oral  <e1> anticoagulants </e1> , calcium channel blockers,  <e2> beta blockers </e2> , cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Other Drugs: In healthy volunteers,  <e1> amlodipine </e1> , phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and  <e2> theophylline </e2>  did not affect the pharmacokinetics of TIKOSYN.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents,  <e1> protease inhibitors </e1> , serotonin reuptake inhibitors, amiodarone,  <e2> cannabinoids </e2> , diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and  <e1> magnesium h <e2> ydroxide </e1>  </e2> s) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids,  <e1> diltiazem </e1> , grapefruit juice, nefazadone,  <e2> norfloxacin </e2> , quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Inhibitors of this isoenzyme (e.g.,  <e1> macrolide antibiotics </e1> , azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine,  <e2> zafirlukast </e2> ) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Hydrochlorothiazide ( <e1> HCTZ </e1> ) Alone or in Combination with Triamterene: Concomitant use of  <e2> HCTZ </e2>  alone or in combination with triamterene is contraindicated.
false	Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with  <e1> TIKOSYN </e1>  (500 mcg BID) for 7 days has been shown to increase  <e2> dofetilide </e2>  Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated  <e1> estrogens </e1>  and medroxyprogesterone), antacid (aluminum and magnesium  <e2> hydroxide </e2> s) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	 <e1> Trimethoprim </e1>  Alone or in Combination with  <e2> Sulfamethoxazole </e2> : Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.
advise	Inhibitors of this isoenzyme (e.g.,  <e1> macrolide antibiotics </e1> , azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with  <e2> TIKOSYN </e2>  as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and  <e1> medroxyprogesterone </e1> ), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of  <e2> TIKOSYN </e2> .
false	If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole,  <e1> ranitidine </e1> , or antacids (aluminum and  <e2> magnesium hydroxide </e2> s) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
false	Inhibitors of this isoenzyme (e.g.,  <e1> macrolide antibiotics </e1> , azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin,  <e2> quinine </e2> , zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated  <e1> estrogens </e1>  and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and  <e2> theophylline </e2>  did not affect the pharmacokinetics of TIKOSYN.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone,  <e1> norfloxacin </e1> , quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase  <e2> dofetilide </e2>  levels.
false	 <e1> Cimetidine </e1>  at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase  <e2> dofetilide </e2>  plasma levels by 58%.
false	Hydrochlorothiazide (HCTZ) Alone or in Combination with  <e1> Triamterene </e1> : Concomitant use of  <e2> HCTZ </e2>  alone or in combination with triamterene is contraindicated.
false	If a patient requires  <e1> TIKOSYN </e1>  and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and  <e2> magnesium hydroxide </e2> s) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
false	Other Drugs: In healthy volunteers, amlodipine,  <e1> phenytoin </e1> , glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium  <e2> hydroxide </e2> s) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone,  <e1> cannabinoids </e1> , diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase  <e2> dofetilide </e2>  levels.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors,  <e1> serotonin reuptake inhibitors </e1> , amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase  <e2> dofetilide </e2>  levels.
false	Concomitant medications were grouped as ACE inhibitors, oral  <e1> anticoagulants </e1> , calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein,  <e2> nitrates </e2> , sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide,  <e1> ranitidine </e1> , omeprazole, hormone replacement therapy (a combination of conjugated  <e2> estrogens </e2>  and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants,  <e1> calcium channel blockers </e1> , beta blockers,  <e2> cardiac glycosides </e2> , inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	 <e1> Hydrochlorothiazide </e1>  ( <e2> HCTZ </e2> ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein,  <e1> nitrates </e1> , sulphonylureas, loop diuretics,  <e2> potassium sparing diuretics </e2> , thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Other Drugs: In healthy volunteers,  <e1> amlodipine </e1> , phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated  <e2> estrogens </e2>  and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
advise	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents,  <e1> protease inhibitors </e1> , serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with  <e2> TIKOSYN </e2>  as they can potentially increase dofetilide levels.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone,  <e1> cannabinoids </e1> , diltiazem, grapefruit juice,  <e2> nefazadone </e2> , norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide,  <e1> ranitidine </e1> , omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and  <e2> magnesium hydroxide </e2> s) and theophylline did not affect the pharmacokinetics of TIKOSYN.
mechanism	In vitro studies have shown that the metabolism of  <e1> docetaxel </e1>  may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine,  <e2> ketoconazole </e2> , erythromycin, and troleandomycin.
false	Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of  <e1> trimethoprim </e1>  alone or in combination with  <e2> sulfamethoxazole </e2>  is contraindicated.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin,  <e1> glyburide </e1> , ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and  <e2> magnesium hydroxide </e2> s) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Inhibitors of this isoenzyme (e.g.,  <e1> macrolide antibiotics </e1> ,  <e2> azole antifungal agents </e2> , protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that  <e1> omeprazole </e1> , ranitidine, or antacids (aluminum and  <e2> magnesium hydroxide </e2> s) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers,  <e1> beta blockers </e1> ,  <e2> cardiac glycosides </e2> , inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers,  <e1> beta blockers </e1> , cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics,  <e2> thiazide diuretics </e2> , substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine,  <e1> zafirlukast </e1> ) should be cautiously coadministered with TIKOSYN as they can potentially increase  <e2> dofetilide </e2>  levels.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone,  <e1> cannabinoids </e1> , diltiazem, grapefruit juice, nefazadone, norfloxacin,  <e2> quinine </e2> , zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin,  <e1> glyburide </e1> , ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium  <e2> hydroxide </e2> s) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and  <e1> medroxyprogesterone </e1> ), antacid (aluminum and magnesium  <e2> hydroxide </e2> s) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Other Drugs: In healthy volunteers,  <e1> amlodipine </e1> , phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and  <e2> medroxyprogesterone </e2> ), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine,  <e1> omeprazole </e1> , hormone replacement therapy (a combination of conjugated estrogens and  <e2> medroxyprogesterone </e2> ), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin,  <e1> theophylline </e1> , or oral  <e2> contraceptives </e2> .
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics,  <e1> azole antifungal agents </e1> , protease inhibitors,  <e2> serotonin reuptake inhibitors </e2> , amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	HCTZ 50 mg QD or HCTZ/ <e1> triamterene </e1>  50/100 mg QD was co-administered with  <e2> TIKOSYN </e2>  (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).
false	Other Drug Interaction Information  <e1> Digoxin </e1> : Studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics of  <e2> digoxin </e2> .
false	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of  <e1> warfarin </e1> , or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin,  <e2> theophylline </e2> , or oral contraceptives.
false	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily),  <e1> phenytoin </e1> ,  <e2> theophylline </e2> , or oral contraceptives.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein,  <e1> nitrates </e1> , sulphonylureas, loop diuretics, potassium sparing diuretics,  <e2> thiazide diuretics </e2> , substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors,  <e1> amiodarone </e1> , cannabinoids, diltiazem, grapefruit juice, nefazadone,  <e2> norfloxacin </e2> , quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil,  <e1> glyburide </e1> ,  <e2> propranolol </e2> , and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	In patients taking furosemide, nifedipine, diltiazem,  <e1> ACE inhibitors </e1> , verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of  <e2> hydrodolasetron </e2> .
false	The potential for clinically significant drug-drug interactions posed by dolasetron and  <e1> hydrodolasetron </e1>  appears to be low for drugs commonly used in chemotherapy or surgery, because  <e2> hydrodolasetron </e2>  is eliminated by multiple routes.
false	Dolasetron mesylate did not inhibit the antitumor activity of four  <e1> chemotherapeutic agents </e1>  ( <e2> cisplatin </e2> , 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.
false	In patients taking  <e1> furosemide </e1> , nifedipine, diltiazem,  <e2> ACE inhibitors </e2> , verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	Blood levels of  <e1> hydrodolasetron </e1>  increased 24% when  <e2> dolasetron </e2>  was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
false	 <e1> Dolasetron mesylate </e1>  did not inhibit the antitumor activity of four chemotherapeutic agents ( <e2> cisplatin </e2> , 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors,  <e1> serotonin reuptake inhibitors </e1> , amiodarone,  <e2> cannabinoids </e2> , diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	If a patient requires TIKOSYN and  <e1> anti-ulcer </e1>  therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of  <e2> TIKOSYN </e2> .
advise	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin,  <e1> quinine </e1> , zafirlukast) should be cautiously coadministered with  <e2> TIKOSYN </e2>  as they can potentially increase dofetilide levels.
false	 <e1> Trimethoprim </e1>  Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with  <e2> sulfamethoxazole </e2>  is contraindicated.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants,  <e1> calcium channel blockers </e1> ,  <e2> beta blockers </e2> , cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone),  <e1> antacid </e1>  (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of  <e2> TIKOSYN </e2> .
mechanism	Clearance of hydrodolasetron decreased by about 27% when  <e1> dolasetron mesylate </e1>  was administered intravenously concomitantly with  <e2> atenolol </e2> .
false	In patients taking  <e1> furosemide </e1> , nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide,  <e2> propranolol </e2> , and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations,  <e1> furosemide </e1> , spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine,  <e2> atropine </e2> , heparin, protamine, potassium chloride, folic acid, and acetaminophen.
false	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors,  <e1> amiodarone </e1> , cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine,  <e2> zafirlukast </e2> ) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
false	In patients taking furosemide, nifedipine,  <e1> diltiazem </e1> , ACE inhibitors,  <e2> verapamil </e2> , glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	In patients taking  <e1> furosemide </e1> , nifedipine,  <e2> diltiazem </e2> , ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	Other Drug Interaction Information Digoxin: Studies in healthy volunteers have shown that  <e1> TIKOSYN </e1>  does not affect the pharmacokinetics of  <e2> digoxin </e2> .
false	Blood levels of  <e1> hydrodolasetron </e1>  increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of  <e2> rifampin </e2>  (potent inducer of cytochrome P-450) for 7 days.
false	In patients taking furosemide,  <e1> nifedipine </e1> , diltiazem, ACE inhibitors,  <e2> verapamil </e2> , glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	Dolasetron mesylate did not inhibit the antitumor activity of four  <e1> chemotherapeutic agents </e1>  (cisplatin, 5-fluorouracil, doxorubicin,  <e2> cyclophosphamide </e2> ) in four murine models.
false	Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas,  <e1> loop diuretics </e1> ,  <e2> potassium sparing diuretics </e2> , thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
false	In patients taking  <e1> furosemide </e1> , nifedipine, diltiazem, ACE inhibitors,  <e2> verapamil </e2> , glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
false	Other Drugs: In healthy volunteers, amlodipine,  <e1> phenytoin </e1> , glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone),  <e2> antacid </e2>  (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
false	Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin,  <e1> 5-fluorouracil </e1> , doxorubicin,  <e2> cyclophosphamide </e2> ) in four murine models.
effect	 <e1> Butyrophenones </e1>  (such as haloperidol) and phenothiazines can suppress the  <e2> dopamine </e2> rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.
effect	Butyrophenones (such as haloperidol) and  <e1> phenothiazines </e1>  can suppress the  <e2> dopamine </e2> rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.
false	 <e1> Butyrophenones </e1>  (such as haloperidol) and  <e2> phenothiazines </e2>  can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
false	 <e1> Butyrophenones </e1>  (such as  <e2> haloperidol </e2> ) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
effect	Cyclopropane or  <e1> halogenated hydrocarbon anesthetics </e1>  increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered  <e2> catecholamines </e2> , such as dopamine.
advise	It is suggested that in patients receiving  <e1> dopamine HCl </e1> , alternatives to  <e2> phenytoin </e2>  should be used if anticonvulsant therapy is needed.
false	Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving  <e1> cyclopropane </e1>  or  <e2> halogenated hydrocarbon anesthetics </e2> .
false	Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as  <e1> propranolol </e1>  and  <e2> metoprolol </e2> .
false	Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics,  <e1> bronchodilators </e1> , enzyme supplements, vitamins, oral or inhaled corticosteroids, and  <e2> analgesics </e2> .
false	Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements,  <e1> vitamins </e1> , oral or inhaled corticosteroids, and  <e2> analgesics </e2> .
effect	It has been reported that results of studies in animals indicate that  <e1> dopamine </e1> -induced ventricular arrhythmias during anesthesia can be reversed by  <e2> propranolol </e2> .
false	Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or  <e1> beta-a <e2> drenergic blocking agents </e1>  </e2> .
false	Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral  <e1> antibiotics </e1> , bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and  <e2> analgesics </e2> .
false	Clinical trials have indicated that  <e1> Pulmozyme </e1>  can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and  <e2> analgesics </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e1> lithium </e1> , local  <e2> anesthetics </e2> , procainamide, and quinidine.
false	Isoflurane,  <e1> enflurane </e1> , and  <e2> halothane </e2>  decrease the ED50 of NUROMAX by 30% to 45%.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins,  <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins,  <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> NUROMAX </e1>  include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
false	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving  <e1> phenytoin </e1>  or  <e2> carbamazepine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins,  <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> ,  <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin,  <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e1> lincomycin </e1> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine.
effect	As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by  <e1> NUROMAX </e1>  is lengthened and the duration of block is shortened in patients receiving phenytoin or  <e2> carbamazepine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.
false	The use of  <e1> NUROMAX </e1>  before  <e2> succinylcholine </e2>  to attenuate some of the side effects of succinylcholine has not been studied.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e1> colistin </e1> , and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> ,  <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine.
effect	As with some other  <e1> nondepolarizing neuromuscular blocking agents </e1> , the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving  <e2> phenytoin </e2>  or carbamazepine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides,  <e1> tetracyclines </e1> ,  <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> .
mechanism	Isoflurane, enflurane, and  <e1> halothane </e1>  decrease the ED50 of  <e2> NUROMAX </e2>  by 30% to 45%.
effect	As with some other  <e1> nondepolarizing neuromuscular blocking agents </e1> , the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or  <e2> carbamazepine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain  <e1> antibiotics </e1>  (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e1> lithium </e1> , local anesthetics, procainamide, and  <e2> quinidine </e2> .
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics,  <e1> procainamide </e1> , and  <e2> quinidine </e2> .
effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> NUROMAX </e1>  include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin,  <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral  <e1> carbonic anhydrase inhibitors </e1>  and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose  <e2> salicylate </e2>  therapy).
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.
false	 <e1> Doxazosin mesylate </e1>  has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics,  <e2> beta-blocking agent </e2> s, and nonsteroidal anti-inflammatory drugs.
false	Analgesic/anti-inflammatory (e.g.,  <e1> acetaminophen </e1> , aspirin,  <e2> codeine </e2>  and codeine combinations, ibuprofen, indomethacin).
false	In vitro data in human plasma indicate that  <e1> doxazosin mesylate </e1>  has no effect on protein binding of digoxin, warfarin,  <e2> phenytoin </e2>  or indomethacin.
false	Analgesic/ <e1> anti-inflammatory </e1>  (e.g., acetaminophen,  <e2> aspirin </e2> , codeine and codeine combinations, ibuprofen, indomethacin).
false	In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of  <e1> doxazosin </e1>  (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of  <e2> doxazosin </e2> .
false	Analgesic/anti-inflammatory (e.g.,  <e1> acetaminophen </e1> ,  <e2> aspirin </e2> , codeine and codeine combinations, ibuprofen, indomethacin).
false	Analgesic/anti-inflammatory (e.g.,  <e1> acetaminophen </e1> , aspirin, codeine and codeine combinations,  <e2> ibuprofen </e2> , indomethacin).
false	In vitro data in human plasma indicate that  <e1> doxazosin mesylate </e1>  has no effect on protein binding of  <e2> digoxin </e2> , warfarin, phenytoin or indomethacin.
false	Antibiotics (e.g.,  <e1> erythromycin </e1> ,  <e2> trimethoprim </e2>  and sulfamethoxazole, amoxicillin).
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> ,  <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
false	In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of  <e1> digoxin </e1> , warfarin,  <e2> phenytoin </e2>  or indomethacin.
false	 <e1> Analgesic </e1> /anti-inflammatory (e.g.,  <e2> acetaminophen </e2> , aspirin, codeine and codeine combinations, ibuprofen, indomethacin).
false	Analgesic/anti-inflammatory (e.g.,  <e1> acetaminophen </e1> , aspirin, codeine and codeine combinations, ibuprofen,  <e2> indomethacin </e2> ).
false	Analgesic/anti-inflammatory (e.g.,  <e1> acetaminophen </e1> , aspirin, codeine and  <e2> codeine </e2>  combinations, ibuprofen, indomethacin).
false	 <e1> Tolazamide </e1> : A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of  <e2> doxepin </e2>  (75 mg/day).
false	 <e1> cimetidine </e1> ) and many that are substrates for P450 2D6 (many other antidepressants,  <e2> phenothiazines </e2> , and the Type 1C antiarrhythmics propafenone and flecainide).
mechanism	Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [ <e1> SSRIs </e1> ]) may increase the plasma concentration of  <e2> doxepin </e2>  when administered concomitantly.
false	 <e1> cimetidine </e1> ) and many that are substrates for P450 2D6 (many other  <e2> antidepressants </e2> , phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
false	In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent  <e1> cimetidine </e1>  therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum  <e2> tricyclic antidepressant </e2>  levels and compromise their therapeutic effects.
false	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram,  <e1> fluoxetine </e1> , sertraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	 <e1> Cimetidine </e1> : Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various  <e2> tricyclic antidepressants </e2> .
false	 <e1> Cimetidine </e1> :  <e2> Cimetidine </e2>  has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.
false	 <e1> cimetidine </e1> ) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and  <e2> flecainide </e2> ).
false	Inhibitors or substrates of CYP2D6 (i.e., quinidine,  <e1> selective serotonin reuptake inhibitors </e1>  [ <e2> SSRIs </e2> ]) may increase the plasma concentration of doxepin when administered concomitantly.
false	It is desirable to monitor  <e1> TCA </e1>  plasma levels whenever a  <e2> TCA </e2>  is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
false	Poor metabolizers have higher than expected plasma concentrations of  <e1> tricyclic antidepressants </e1>  ( <e2> TCAs </e2> ) when given usual doses.
false	 <e1> Alcohol </e1> : It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional  <e2> SINEQUAN </e2>  overdosage.
false	Inhibitors or substrates of CYP2D6 (i.e.,  <e1> quinidine </e1> , selective serotonin reuptake inhibitors [ <e2> SSRIs </e2> ]) may increase the plasma concentration of doxepin when administered concomitantly.
false	While all the  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs), e.g., citalopram, escitalopram, fluoxetine,  <e2> sertraline </e2> , and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
false	 <e1> MAO Inhibitors </e1> : Serious side effects and even death have been reported following the concomitant use of certain drugs with  <e2> MAO inhibitors </e2> .
false	In vitro data in human plasma indicate that  <e1> doxazosin mesylate </e1>  has no effect on protein binding of digoxin,  <e2> warfarin </e2> , phenytoin or indomethacin.
false	While all the selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), e.g., citalopram, escitalopram, fluoxetine, sertraline, and  <e2> paroxetine </e2> , inhibit P450 2D6, they may vary in the extent of inhibition.
false	 <e1> Sedatives </e1>  and  <e2> tranquilizers </e2>  (e.g., diazepam).
mechanism	Absorption of  <e1> tetracyclines </e1>  is impaired by antacids containing aluminum, calcium, or magnesium, and  <e2> iron </e2> -containing preparations.
false	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or  <e1> magnesium </e1> , and  <e2> iron </e2> -containing preparations.
false	Absorption of tetracyclines is impaired by antacids containing  <e1> aluminum </e1> , calcium, or  <e2> magnesium </e2> , and iron-containing preparations.
mechanism	Alcohol: It should be borne in mind that  <e1> alcohol </e1>  ingestion may increase the danger inherent in any intentional or unintentional  <e2> SINEQUAN </e2>  overdosage.
false	 <e1> Barbiturates </e1> ,  <e2> carbamazepine </e2> , and phenytoin decrease the half-life of doxycycline.
effect	The concurrent use of  <e1> tetracycline </e1>  and Penthrane ( <e2> methoxyflurane </e2> ) has been reported to result in fatal renal toxicity.
effect	 <e1> Antihistamines </e1>  may partially counteract the anticoagulation effects of  <e2> heparin </e2>  or warfarin.
false	 <e1> Barbiturates </e1> , carbamazepine, and  <e2> phenytoin </e2>  decrease the half-life of doxycycline.
false	Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on  <e1> anticoagulant </e1>  therapy may require downward adjustment of their  <e2> anticoagulant </e2>  dosage.
false	Concurrent administration of  <e1> oxyphenbutazone </e1>  and androgens may result in elevated serum levels of  <e2> oxyphenbutazone </e2> .
false	Other CNS depressant drugs (e.g.  <e1> barbiturates </e1> , tranquilizers, opioids and general  <e2> anesthetics </e2> ) have additive or potentiating effects with INAPSINE.
effect	Other CNS depressant drugs (e.g. barbiturates, tranquilizers,  <e1> opioids </e1>  and general anesthetics) have additive or potentiating effects with  <e2> INAPSINE </e2> .
false	Other CNS depressant drugs (e.g. barbiturates,  <e1> tranquilizers </e1> ,  <e2> opioids </e2>  and general anesthetics) have additive or potentiating effects with INAPSINE.
false	Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose  <e1> heparin </e1>  ( <e2> unfractionated heparin </e2>  up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.
false	Other CNS depressant drugs (e.g. barbiturates, tranquilizers,  <e1> opioids </e1>  and general  <e2> anesthetics </e2> ) have additive or potentiating effects with INAPSINE.
false	 <e1> Duloxetine </e1>  May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and  <e2> ethanol </e2>  were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
false	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When  <e1> Duloxetine </e1>  and  <e2> ethanol </e2>  were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
false	However, co-administration of  <e1> Duloxetine </e1>  with aluminum- and magnesium-containing antacids (51 mEq) or  <e2> Duloxetine </e2>  with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as  <e1> nortriptyline </e1> , amitriptyline, and imipramine),  <e2> phenothiazines </e2>  and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain  <e1> antidepressants </e1>  (tricyclic antidepressants [TCAs], such as nortriptyline,  <e2> amitriptyline </e2> , and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [ <e1> TCAs </e1> ], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution.
false	Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and  <e1> ethanol </e1>  were administered several hours apart so that peak concentrations of each would coincide,  <e2> Duloxetine </e2>  did not increase the impairment of mental and motor skills caused by alcohol.
false	Plasma  <e1> TCA </e1>  concentrations may need to be monitored and the dose of the TCA may need to be reduced if a  <e2> TCA </e2>  is co-administered with Duloxetine.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline,  <e1> amitriptyline </e1> , and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution.
false	 <e1> Paroxetine </e1>  (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of  <e2> paroxetine </e2> .
false	Inhibitors of CYP1A2: Concomitant use of  <e1> duloxetine </e1>  with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of  <e2> duloxetine </e2> .
false	Inhibitors of CYP2D6: Because CYP2D6 is involved in  <e1> duloxetine </e1>  metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of  <e2> duloxetine </e2> .
false	Other CNS depressant drugs (e.g. barbiturates,  <e1> tranquilizers </e1> , opioids and general  <e2> anesthetics </e2> ) have additive or potentiating effects with INAPSINE.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline,  <e1> amitriptyline </e1> , and imipramine), phenothiazines and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as  <e1> nortriptyline </e1> , amitriptyline, and  <e2> imipramine </e2> ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
mechanism	When  <e1> duloxetine </e1>  was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of  <e2> desipramine </e2> , a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
false	However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with  <e1> famotidine </e1> , had no significant effect on the rate or extent of  <e2> duloxetine </e2>  absorption after administration of a 40-mg oral dose.
advise	Therefore, co-administration of  <e1> Duloxetine </e1>  with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine),  <e2> phenothiazines </e2>  and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain  <e1> antidepressants </e1>  (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and  <e2> Type 1C antiarrhythmics </e2>  (e.g., propafenone, flecainide), should be approached with caution.
advise	Therefore, co-administration of  <e1> Duloxetine </e1>  with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants ( <e2> tricyclic antidepressants </e2>  [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Similar effects would be expected with other potent CYP2D6 inhibitors (e.g.,  <e1> fluoxetine </e1> ,  <e2> quinidine </e2> ).
false	However, co-administration of Duloxetine with  <e1> aluminum </e1> - and magnesium-containing  <e2> antacids </e2>  (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain  <e1> antidepressants </e1>  (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine),  <e2> phenothiazines </e2>  and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [ <e1> TCAs </e1> ], such as  <e2> nortriptyline </e2> , amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Concurrent administration of dyphylline and  <e1> probenecid </e1> , which competes for tubular secretion, has been shown to increase the plasma half-life of  <e2> dyphylline </e2>  .
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [ <e1> TCAs </e1> ], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone,  <e2> flecainide </e2> ), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [ <e1> TCAs </e1> ], such as nortriptyline, amitriptyline, and  <e2> imipramine </e2> ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
false	Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline,  <e1> amitriptyline </e1> , and  <e2> imipramine </e2> ), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
advise	Therefore, co-administration of  <e1> Duloxetine </e1>  with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g.,  <e2> propafenone </e2> , flecainide), should be approached with caution.
effect	Synergism between  <e1> xanthine bronchodilators </e1>  (e.g., theophylline), ephedrine, and other  <e2> sympathomimetic bronchodilators </e2>  has been reported.
false	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of  <e1> thioridazine </e1> ,  <e2> Duloxetine </e2>  and thioridazine should not be co-administered.
false	Synergism between  <e1> xanthine bronchodilators </e1>  (e.g., theophylline),  <e2> ephedrine </e2> , and other sympathomimetic bronchodilators has been reported.
false	Phospholine Iodide potentiates other  <e1> cholinesterase inhibitors </e1>  such as succinylcholine or organophosphate and  <e2> carbamate insecticide </e2> s.
effect	 <e1> Phospholine Iodide </e1>  potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and  <e2> carbamate insecticide </e2> s.
false	 <e1> Steroids </e1>  enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the  <e2> zinc </e2> . 7
false	Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of  <e1> zinc insulin </e1>  preparations by chelating the  <e2> zinc </e2> . 7
advise	Acellular, live and  <e1> live-attenuated vaccines </e1>  should not be administered during  <e2> RAPTIVA </e2>  treatment.
false	Steroids enhance the renal toxicity of  <e1> edetate calcium disodium </e1>  in animals. 7 Edetate calcium disodium interferes with the action of  <e2> zinc insulin </e2>  preparations by chelating the zinc. 7
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  <e1> SUSTIVA </e1>  (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and  <e2> zidovudine </e2> .
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA ( <e1> efavirenz </e1> ) is given with the following:  <e2> aluminum/magnesium hydroxide antacids </e2> , azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin,  <e1> cetirizine </e1> , famotidine,  <e2> fluconazole </e2> , lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
false	Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with  <e1> SUSTIVA </e1>  ( <e2> efavirenz </e2> ).
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine,  <e1> fluconazole </e1> , lamivudine, lorazepam, nelfinavir, paroxetine, and  <e2> zidovudine </e2> .
false	Specific drug interaction studies have not been performed with SUSTIVA and  <e1> NRTIs </e1>  other than  <e2> lamivudine </e2>  and zidovudine.
false	Other  <e1> macrolide antibiotics </e1> , such as  <e2> erythromycin </e2> , have not been studied in combination with SUSTIVA.
false	 <e1> Anti-HIV protease inhibitors </e1> :  <e2> Saquinavir </e2> /ritonavir combination
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA ( <e1> efavirenz </e1> ) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir,  <e2> paroxetine </e2> , and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin,  <e1> cetirizine </e1> ,  <e2> famotidine </e2> , fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
false	SUSTIVA has the potential to decrease plasma concentrations of  <e1> itraconazole </e1>  and  <e2> ketoconazole </e2> .
false	 <e1> Antifungals </e1> :  <e2> Itraconazole </e2>  Ketoconazole
false	Anti-HIV protease inhibitors:  <e1> Saquinavir </e1> / <e2> ritonavir </e2>  combination
false	Anticonvulsants:  <e1> Phenytoin </e1>   <e2> Phenobarbital </e2>  Carbamazepine
false	Clinically significant interactions would not be expected since the  <e1> NRTIs </e1>  are metabolized via a different route than  <e2> efavirenz </e2>  and would be unlikely to compete for the same metabolic enzymes and elimination pathways.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA ( <e1> efavirenz </e1> ) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and  <e2> zidovudine </e2> .
false	When indinavir at an increased dose (1000 mg every 8 hours) was given with  <e1> SUSTIVA </e1>  (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when  <e2> indinavir </e2>  (800 mg every 8 hours) was given alone.
false	Because the potential interaction of  <e1> efavirenz </e1>  with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral  <e2> contraceptives </e2> .
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine,  <e1> fluconazole </e1> , lamivudine, lorazepam,  <e2> nelfinavir </e2> , paroxetine, and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine,  <e1> fluconazole </e1> , lamivudine,  <e2> lorazepam </e2> , nelfinavir, paroxetine, and zidovudine.
false	 <e1> Anticonvulsants </e1> :  <e2> Phenytoin </e2>  Phenobarbital Carbamazepine
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following:  <e1> aluminum/magnesium hydroxide antacids </e1> , azithromycin,  <e2> cetirizine </e2> , famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following:  <e1> aluminum/magnesium hydroxide antacids </e1> , azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam,  <e2> nelfinavir </e2> , paroxetine, and zidovudine.
advise	A dose increase of  <e1> lopinavir </e1> /ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with  <e2> SUSTIVA </e2> .
false	 <e1> astemizole </e1>  midazolam,  <e2> triazolam </e2>  cisapride ergot derivatives voriconazole
false	Antihistamines: Benzodiazepines GI Motility Agents  <e1> Anti-Migraine </e1>   <e2> Antifungal </e2> 
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  <e1> SUSTIVA </e1>  (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids,  <e2> azithromycin </e2> , cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
mechanism	Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin,  <e1> rifabutin </e1> ) would be expected to increase the clearance of  <e2> efavirenz </e2>  resulting in lowered plasma concentrations.
false	 <e1> Anticonvulsants </e1> : Phenytoin Phenobarbital  <e2> Carbamazepine </e2> 
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids,  <e1> azithromycin </e1> , cetirizine, famotidine, fluconazole,  <e2> lamivudine </e2> , lorazepam, nelfinavir, paroxetine, and zidovudine.
mechanism	When  <e1> indinavir </e1>  at an increased dose (1000 mg every 8 hours) was given with  <e2> SUSTIVA </e2>  (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.
false	astemizole  <e1> midazolam </e1> , triazolam cisapride ergot derivatives  <e2> voriconazole </e2> 
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA ( <e1> efavirenz </e1> ) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine,  <e2> famotidine </e2> , fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
false	The potential for drug interactions with EMTRIVA has been studied in combination with  <e1> indinavir </e1> , stavudine, famciclovir, and  <e2> tenofovir disoproxil fumarate </e2> .
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when  <e1> SUSTIVA </e1>  (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole,  <e2> lamivudine </e2> , lorazepam, nelfinavir, paroxetine, and zidovudine.
false	The potential for drug interactions with EMTRIVA has been studied in combination with  <e1> indinavir </e1> , stavudine,  <e2> famciclovir </e2> , and tenofovir disoproxil fumarate.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine,  <e1> lorazepam </e1> ,  <e2> nelfinavir </e2> , paroxetine, and zidovudine.
false	astemizole midazolam,  <e1> triazolam </e1>  cisapride ergot derivatives  <e2> voriconazole </e2> 
false	 <e1> Antifungals </e1> : Itraconazole  <e2> Ketoconazole </e2> 
false	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents,  <e1> hydralazine </e1> , prazosin and  <e2> digoxin </e2>  without evidence of clinically significant adverse interactions.
false	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates,  <e1> calcium-blocking agents </e1> , hydralazine,  <e2> prazosin </e2>  and digoxin without evidence of clinically significant adverse interactions.
false	In a clinical pharmacology study, indomethacin or  <e1> sulindac </e1>  was administered to hypertensive patients receiving  <e2> VASOTEC </e2> .
false	Potassium-sparing diuretics (e.g.,  <e1> spironolactone </e1> , triamterene, or  <e2> amiloride </e2> ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	 <e1> Lithium </e1> : Lithium toxicity has been reported in patients receiving  <e2> lithium </e2>  concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
false	 <e1> Potassium-sparing diuretics </e1>  (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or  <e2> potassium </e2> -containing salt substitutes may lead to significant increases in serum potassium.
false	Lithium:  <e1> Lithium </e1>  toxicity has been reported in patients receiving  <e2> lithium </e2>  concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
false	Potassium-sparing diuretics (e.g.,  <e1> spironolactone </e1> , triamterene, or amiloride), potassium supplements, or  <e2> potassium </e2> -containing salt substitutes may lead to significant increases in serum potassium.
false	Agents Causing Renin Release: The antihypertensive effect of  <e1> enalapril </e1>  and  <e2> enalapril </e2>  IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine,  <e1> lorazepam </e1> , nelfinavir,  <e2> paroxetine </e2> , and zidovudine.
effect	Agents Increasing Serum Potassium:  <e1> Enalapril </e1>  and enalapril IV attenuate potassium loss caused by  <e2> thiazide-type diuretics </e2> .
false	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa,  <e1> nitrates </e1> , calcium-blocking agents, hydralazine, prazosin and  <e2> digoxin </e2>  without evidence of clinically significant adverse interactions.
effect	Agents Causing Renin Release: The antihypertensive effect of  <e1> enalapril </e1>  and enalapril IV is augmented by  <e2> antihypertensive agents </e2>  that cause renin release (e.g., diuretics).
false	Other Cardiovascular Agents: Enalapril and  <e1> enalapril </e1>  IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa,  <e2> nitrates </e2> , calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
false	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with  <e1> beta adrenergic-blocking agents </e1> , methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and  <e2> digoxin </e2>  without evidence of clinically significant adverse interactions.
false	Potassium-sparing diuretics (e.g., spironolactone,  <e1> triamterene </e1> , or amiloride),  <e2> potassium </e2>  supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
effect	Agents Causing Renin Release: The antihypertensive effect of  <e1> enalapril </e1>  and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g.,  <e2> diuretics </e2> ).
false	The possibility of hypotensive effects with  <e1> enalapril </e1>  or  <e2> enalaprilat </e2>  can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
false	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin,  <e1> cetirizine </e1> , famotidine, fluconazole, lamivudine, lorazepam,  <e2> nelfinavir </e2> , paroxetine, and zidovudine.
false	The potential for drug interactions with EMTRIVA has been studied in combination with indinavir,  <e1> stavudine </e1> , famciclovir, and  <e2> tenofovir disoproxil fumarate </e2> .
false	The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with  <e1> enalapril </e1>  or  <e2> enalaprilat </e2> .
false	Drug interaction studies with  <e1> SUSTIVA </e1>  and these imidazole and  <e2> triazole antifungals </e2>  have not been conducted.
false	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or  <e1> amiloride </e1> ),  <e2> potassium </e2>  supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	Other Cardiovascular Agents:  <e1> Enalapril </e1>  and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa,  <e2> nitrates </e2> , calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
false	 <e1> Potassium-sparing diuretics </e1>  (e.g.,  <e2> spironolactone </e2> , triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents,  <e1> methyldopa </e1> , nitrates, calcium-blocking agents,  <e2> hydralazine </e2> , prazosin and digoxin without evidence of clinically significant adverse interactions.
false	 <e1> Non-steroidal anti-inflammatory agents </e1> : Seizures have been reported in patients taking  <e2> enoxacin </e2>  concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.
false	Trough plasma  <e1> enoxacin </e1>  levels were also 20% higher when caffeine and  <e2> enoxacin </e2>  were administered concomitantly.
false	 <e1> Digoxin </e1> :  <e2> Enoxacin </e2>  may raise serum digoxin levels in some individuals.
false	In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of  <e1> caffeine </e1> , thereby decreasing the clearance of  <e2> caffeine </e2>  by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
false	or with  <e1> multivitamins </e1>  containing  <e2> zinc </e2>  may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.
false	In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of  <e1> caffeine </e1>  by up to 80% and leading to a five-fold increase in the AUC and the half-life of  <e2> caffeine </e2> .
false	 <e1> Warfarin </e1> : Quinolones, including enoxacin, decrease the clearance of  <e2> R-warfarin </e2> , the less active isomer of racemic warfarin.
false	Warfarin: Quinolones, including  <e1> enoxacin </e1> , decrease the clearance of R-warfarin, the less active isomer of racemic  <e2> warfarin </e2> .
false	 <e1> Theophylline </e1> :  <e2> Enoxacin </e2>  is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
false	If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and  <e1> digoxin </e1>  are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust  <e2> digoxin </e2>  doses appropriately.
mechanism	Caffeine:  <e1> Enoxacin </e1>  is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of  <e2> methylxanthines </e2> .
mechanism	 <e1> Enoxacin </e1>  interferes with the metabolism of  <e2> theophylline </e2>  resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
false	or with  <e1> multivitamins </e1>  containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue  <e2> quinolone </e2>  concentrations.
false	Therefore, administration of quinolones with antacids containing  <e1> calcium </e1> ,  <e2> magnesium </e2> , or aluminum;
mechanism	Antacids containing aluminum hydroxide and  <e1> magnesium hydroxide </e1>  reduce the oral absorption of  <e2> enoxacin </e2>  by 75%.
false	Therefore, administration of quinolones with  <e1> antacids </e1>  containing  <e2> calcium </e2> , magnesium, or aluminum;
false	 <e1> Caffeine </e1> : Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of  <e2> methylxanthines </e2> .
false	Therefore, administration of  <e1> quinolones </e1>  with antacids containing calcium,  <e2> magnesium </e2> , or aluminum;
false	Bismuth:  <e1> Bismuth subsalicylate </e1> , given concomitantly with enoxacin or 60 minutes following  <e2> enoxacin </e2>  administration, decreased enoxacin bioavailability by approximately 25%.
effect	Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking  <e1> enoxacin </e1>  concomitantly with the nonsteroidal anti-inflammatory drug  <e2> fenbufen </e2> .
false	 <e1> Non-steroidal anti-inflammatory agents </e1> : Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug  <e2> fenbufen </e2> .
false	Warfarin:  <e1> Quinolones </e1> , including  <e2> enoxacin </e2> , decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
mechanism	Warfarin: Quinolones, including  <e1> enoxacin </e1> , decrease the clearance of  <e2> R-warfarin </e2> , the less active isomer of racemic warfarin.
false	Cyclosporine: Elevated serum levels of  <e1> cyclosporine </e1>  have been reported with concomitant use of cyclosporine with other members of the  <e2> quinolone class </e2> .
false	These agents include medications such as: anticoagulants,  <e1> platelet inhibitors </e1>  including acetylsalicylic acid, sali-cylates,  <e2> NSAIDs </e2>  (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
false	Therefore, administration of quinolones with  <e1> antacids </e1>  containing calcium,  <e2> magnesium </e2> , or aluminum;
false	These agents include medications such as:  <e1> anticoagulants </e1> , platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine),  <e2> dipyridamole </e2> , or sulfinpyrazone.
false	These agents include medications such as: anticoagulants,  <e1> platelet inhibitors </e1>  including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine),  <e2> dipyridamole </e2> , or sulfinpyrazone.
false	No interaction with the tricyclic antidepressant  <e1> imipramine </e1>  was shown in a single-dose study with entacapone without coadministered levodopa/ <e2> dopa-decarboxylase inhibitor </e2> .
false	More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with  <e1> entacapone </e1>  and  <e2> levodopa </e2> /dopa decarboxylase inhibitor.
false	These include probenecid,  <e1> cholestyramine </e1> , and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and  <e2> chloramphenicol </e2> ).
false	These agents include medications such as:  <e1> anticoagulants </e1> , platelet inhibitors including  <e2> acetylsalicylic acid </e2> , sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
false	In vitro studies have shown no binding displacement between  <e1> entacapone </e1>  and other highly bound drugs, such as  <e2> warfarin </e2> , salicylic acid, phenylbutazone, and diazepam.
false	These include  <e1> probenecid </e1> , cholestyramine, and some  <e2> antibiotics </e2>  (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).
false	In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as  <e1> warfarin </e1> ,  <e2> salicylic acid </e2> , phenylbutazone, and diazepam.
false	More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and  <e1> levodopa </e1> / <e2> dopa decarboxylase inhibitor </e2> .
false	No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with  <e1> entacapone </e1>  without coadministered levodopa/ <e2> dopa-decarboxylase inhibitor </e2> .
false	These include probenecid, cholestyramine, and some antibiotics (e.g.  <e1> erythromycin </e1> , rifamipicin, ampicillin and  <e2> chloramphenicol </e2> ).
false	No interaction with the  <e1> tricyclic antidepressant </e1>  imipramine was shown in a single-dose study with entacapone without coadministered  <e2> levodopa </e2> /dopa-decarboxylase inhibitor.
false	More than 600 Parkinsons disease patients in clinical trials have used  <e1> selegiline </e1>  in combination with entacapone and levodopa/ <e2> dopa decarboxylase inhibitor </e2> .
false	No interaction was noted with the MAO-B inhibitor  <e1> selegiline </e1>  in two multiple-dose interaction studies when  <e2> entacapone </e2>  was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29).
false	Since entecavir is primarily eliminated by the kidneys, coadministration of  <e1> BARACLUDE </e1>  with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either  <e2> entecavir </e2>  or the coadministered drug.
false	These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates,  <e1> NSAIDs </e1>  (including ketorolac tromethamine),  <e2> dipyridamole </e2> , or sulfinpyrazone.
false	No interaction with the  <e1> tricyclic antidepressant </e1>  imipramine was shown in a single-dose study with  <e2> entacapone </e2>  without coadministered levodopa/dopa-decarboxylase inhibitor.
false	Coadministration of  <e1> entecavir </e1>  with lamivudine, adefovir dipivoxil,or  <e2> tenofovir disoproxil fumarate </e2>  did not result in significant drug interactions.
false	Coadministration of entecavir with lamivudine,  <e1> adefovir dipivoxil </e1> ,or  <e2> tenofovir disoproxil fumarate </e2>  did not result in significant drug interactions.
false	Administration of epinephrine to patients receiving  <e1> cyclopropane </e1>  or  <e2> halogenated hydrocarbon general anesthetics </e2>  such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
advise	 <e1> Epinephrine </e1>  should not be administered concomitantly with other sympathomimetic drugs (such as  <e2> isoproterenol </e2> ) because of possible additive effects and increased toxicity.
false	Epinephrine also should be used cautiously with other drugs (e.g.,  <e1> digitalis </e1> ,  <e2> glycosides </e2> ) that sensitize the myocardium to the actions of sympathomimetic drugs.
effect	Administration of  <e1> epinephrine </e1>  to patients receiving cyclopropane or  <e2> halogenated hydrocarbon general anesthetics </e2>  such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
advise	Concomitant use of  <e1> ELLENCE </e1>  with other cardioactive compounds that could cause heart failure (e.g.,  <e2> calcium channel blockers </e2> ), requires close monitoring of cardiac function throughout treatment.
false	Administration of  <e1> eplerenone </e1>  with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of  <e2> eplerenone </e2>  ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
false	Administration of eplerenone with other CYP3A4 inhibitors (e.g.,  <e1> erythromycin </e1>  500 mg BID, verapamil 240 mg QD,  <e2> saquinavir </e2>  1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
false	Serum  <e1> lithium </e1>  levels should be monitored frequently if  <e2> INSPRA </e2>  is administered concomitantly with lithium.
false	ACE Inhibitors and  <e1> Angiotensin II Receptor Antagonists </e1>  (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or  <e2> angiotensin II receptor antagonists </e2>  (ACEI/ARB).
false	 <e1> ACE Inhibitors </e1>  and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received  <e2> ACE inhibitors </e2>  or angiotensin II receptor antagonists (ACEI/ARB).
false	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists ( <e1> ACEI </e1> / <e2> ARB </e2> ).
false	ACE Inhibitors and  <e1> Angiotensin II Receptor Antagonists </e1>  (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and  <e2> angiotensin II receptor antagonists </e2>  increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
false	 <e1> Nonsteroidal Anti-Inflammatory Drugs </e1>  (NSAIDs)-A drug interaction study of eplerenone with an  <e2> NSAID </e2>  has not been conducted.
false	In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the  <e1> ACE inhibitor </e1>   <e2> enalapril </e2>  10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.
mechanism	Administration of  <e1> eplerenone </e1>  with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID,  <e2> fluconazole </e2>  200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
false	ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received  <e1> ACE inhibitors </e1>  or angiotensin II receptor antagonists (ACEI/ <e2> ARB </e2> ).
false	ACE Inhibitors and  <e1> Angiotensin II Receptor Antagonists </e1>  (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving  <e2> INSPRA </e2>  25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).
false	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of  <e1> eplerenone </e1>  with an  <e2> NSAID </e2>  has not been conducted.
false	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD,  <e1> saquinavir </e1>  1200 mg TID,  <e2> fluconazole </e2>  200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
effect	In a study in diabetics with microalbuminuria  <e1> INSPRA </e1>  200 mg combined with the ACE inhibitor  <e2> enalapril </e2>  10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.
false	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID,  <e1> verapamil </e1>  240 mg QD,  <e2> saquinavir </e2>  1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
false	In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor  <e1> enalapril </e1>  10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on  <e2> enalapril </e2>  alone to 38%.
false	In clinical trials, FLOLAN was used with digoxin,  <e1> diuretics </e1> , anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or  <e2> digoxin </e2>  in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral  <e1> vasodilators </e1> , and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for  <e2> furosemide </e2>  (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with  <e1> FLOLAN </e1> , which may be clinically significant in patients prone to  <e2> digoxin </e2>  toxicity.
false	When other  <e1> antiplatelet agents </e1>  or  <e2> anticoagulants </e2>  are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
false	In clinical trials, FLOLAN was used with  <e1> digoxin </e1> , diuretics,  <e2> anticoagulants </e2> , oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin, diuretics,  <e1> anticoagulants </e1> , oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with  <e2> FLOLAN </e2>  was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
mechanism	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or  <e1> digoxin </e1>  in whom therapy with  <e2> FLOLAN </e2>  was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with  <e1> digoxin </e1> , diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or  <e2> digoxin </e2>  in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	Additional reductions in blood pressure may occur when FLOLAN is administered with  <e1> diuretics </e1> , antihypertensive agents, or other  <e2> vasodilators </e2> .
false	Additional reductions in blood pressure may occur when FLOLAN is administered with  <e1> diuretics </e1> ,  <e2> antihypertensive agents </e2> , or other vasodilators.
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with  <e1> FLOLAN </e1>  was initiated, apparent oral clearance values for furosemide (n = 23) and  <e2> digoxin </e2>  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
effect	Additional reductions in blood pressure may occur when  <e1> FLOLAN </e1>  is administered with  <e2> diuretics </e2> , antihypertensive agents, or other vasodilators.
false	In clinical trials, FLOLAN was used with digoxin,  <e1> diuretics </e1> , anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving  <e2> furosemide </e2>  or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials,  <e1> FLOLAN </e1>  was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for  <e2> furosemide </e2>  (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with  <e1> digoxin </e1> , diuretics, anticoagulants, oral  <e2> vasodilators </e2> , and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with  <e1> digoxin </e1> , diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for  <e2> furosemide </e2>  (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin,  <e1> diuretics </e1> , anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for  <e2> furosemide </e2>  (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral  <e1> vasodilators </e1> , and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and  <e2> digoxin </e2>  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	 <e1> Eprosartan </e1>  (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a  <e2> thiazide diuretic </e2>  (hydrochlorothiazide).
false	 <e1> Eprosartan </e1>  has been shown to have no effect on the pharmacokinetics of  <e2> digoxin </e2>  and the pharmacodynamics of warfarin and glyburide.
false	In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for  <e1> furosemide </e1>  (n = 23) and  <e2> digoxin </e2>  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
false	 <e1> Eprosartan </e1>  has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and  <e2> glyburide </e2> .
false	 <e1> Enoxaparin </e1>  dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of  <e2> eptifibatide </e2>  or the level of platelet aggregation in healthy adults.
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to,  <e1> atazanavir </e1> , clarithromycin,  <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
mechanism	The effects of  <e1> ERGOMAR </e1>  may be potentiated by  <e2> triacetyloleandomycin </e2>  which inhibits the metabolism of ergotamine.
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir,  <e1> clarithromycin </e1> ,  <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole,  <e1> nefazodone </e1> , nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2> , troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with  <e1> ketoconazole </e1>  and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir,  <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
advise	Caution should be used when administering or taking  <e1> TARCEVA </e1>  with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir,  <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
advise	Caution should be used when administering or taking  <e1> TARCEVA </e1>  with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,  <e2> troleandomycin </e2>  (TAO), and voriconazole .
false	Other CYP3A4 inducers include, but are not limited to,  <e1> rifabutin </e1> , rifapentine, phenytoin, carbamazepine,  <e2> phenobarbital </e2>  and St. Johns Wort.
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to,  <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2> , troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,  <e1> ritonavir </e1> , saquinavir, telithromycin,  <e2> troleandomycin </e2>  (TAO), and voriconazole .
false	Other CYP3A4 inducers include, but are not limited to,  <e1> rifabutin </e1> , rifapentine,  <e2> phenytoin </e2> , carbamazepine, phenobarbital and St. Johns Wort.
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir,  <e1> telithromycin </e1> ,  <e2> troleandomycin </e2>  (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,  <e1> troleandomycin </e1>  (TAO), and  <e2> voriconazole </e2>  .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to,  <e1> atazanavir </e1> ,  <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone,  <e1> nelfinavir </e1> , ritonavir, saquinavir, telithromycin,  <e2> troleandomycin </e2>  (TAO), and voriconazole .
advise	Caution should be used when administering or taking  <e1> TARCEVA </e1>  with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2> , troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole,  <e1> nefazodone </e1> ,  <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine,  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , phenobarbital and St. Johns Wort.
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,  <e1> troleandomycin </e1>  ( <e2> TAO </e2> ), and voriconazole .
false	Other CYP3A4 inducers include, but are not limited to, rifabutin,  <e1> rifapentine </e1> , phenytoin, carbamazepine,  <e2> phenobarbital </e2>  and St. Johns Wort.
false	Other CYP3A4 inducers include, but are not limited to, rifabutin,  <e1> rifapentine </e1> , phenytoin,  <e2> carbamazepine </e2> , phenobarbital and St. Johns Wort.
false	Caution should be used when administering or taking TARCEVA with  <e1> ketoconazole </e1>  and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with  <e1> ketoconazole </e1>  and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and  <e2> voriconazole </e2>  .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone,  <e1> nelfinavir </e1> ,  <e2> ritonavir </e2> , saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone,  <e1> nelfinavir </e1> , ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and  <e2> voriconazole </e2>  .
advise	Caution should be used when administering or taking  <e1> TARCEVA </e1>  with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone,  <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	When  <e1> ertapenem </e1>  is co-administered with probenecid (500 mg p.o. every 6 hours),  <e2> probenecid </e2>  competes for active tubular secretion and reduces the renal clearance of ertapenem.
false	When ertapenem is co-administered with  <e1> probenecid </e1>  (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of  <e2> ertapenem </e2> .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir,  <e1> clarithromycin </e1> , indinavir, itraconazole,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine,  <e1> tacrolimus </e1> , hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin,  <e2> bromocriptine </e2> , valproate, terfenadine, and astemizole.
false	 <e1> Erythromycin </e1>  has been reported to significantly alter the metabolism of nonsedating  <e2> antihistamines </e2>  terfenadine and astemizole when taken concomitantly.
false	There have been postmarketing reports of drug interactions when  <e1> erythromycin </e1>  is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by  <e2> erythromycin </e2> .
false	Concomitant administration of erythromycin and  <e1> digoxin </e1>  has been reported to result in elevated  <e2> digoxin </e2>  serum levels.
false	When ertapenem is co-administered with  <e1> probenecid </e1>  (500 mg p.o. every 6 hours),  <e2> probenecid </e2>  competes for active tubular secretion and reduces the renal clearance of ertapenem.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate,  <e1> terfenadine </e1> , and  <e2> astemizole </e2> .
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus,  <e1> hexobarbital </e1> ,  <e2> phenytoin </e2> , alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin,  <e1> alfentanil </e1> , cisapride, disopyramide, lovastatin, bromocriptine, valproate,  <e2> terfenadine </e2> , and astemizole.
int	There have been reports of interactions of  <e1> erythromycin </e1>  with carbamazepine, cyclosporine,  <e2> tacrolimus </e2> , hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
int	There have been reports of interactions of  <e1> erythromycin </e1>  with  <e2> carbamazepine </e2> , cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
mechanism	Concomitant administration of  <e1> erythromycin </e1>  and  <e2> digoxin </e2>  has been reported to result in elevated digoxin serum levels.
false	There have been postmarketing reports of drug interactions when erythromycin is coadministered with  <e1> cisapride </e1> , resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by  <e2> erythromycin </e2> .
false	There have been reports of interactions of erythromycin with carbamazepine,  <e1> cyclosporine </e1> , tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide,  <e2> lovastatin </e2> , bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus,  <e1> hexobarbital </e1> , phenytoin, alfentanil, cisapride,  <e2> disopyramide </e2> , lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus,  <e1> hexobarbital </e1> , phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine,  <e2> valproate </e2> , terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine,  <e1> cyclosporine </e1> , tacrolimus, hexobarbital, phenytoin, alfentanil,  <e2> cisapride </e2> , disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	 <e1> Erythromycin </e1>  use in patients who are receiving high doses of theophylline may be associated with an increase in serum  <e2> theophylline </e2>  levels and potential theophylline toxicity.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide,  <e1> lovastatin </e1> ,  <e2> bromocriptine </e2> , valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride,  <e1> disopyramide </e1> ,  <e2> lovastatin </e2> , bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with  <e1> carbamazepine </e1> , cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil,  <e2> cisapride </e2> , disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with  <e1> carbamazepine </e1> ,  <e2> cyclosporine </e2> , tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with  <e1> carbamazepine </e1> , cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine,  <e2> valproate </e2> , terfenadine, and astemizole.
effect	In addition, deaths have been reported rarely with concomitant administration of  <e1> terfenadine </e1>  and  <e2> erythromycin </e2> .
false	There have been reports of interactions of erythromycin with  <e1> carbamazepine </e1> , cyclosporine,  <e2> tacrolimus </e2> , hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
int	There have been reports of interactions of  <e1> erythromycin </e1>  with carbamazepine, cyclosporine, tacrolimus,  <e2> hexobarbital </e2> , phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine,  <e1> tacrolimus </e1> , hexobarbital, phenytoin, alfentanil, cisapride, disopyramide,  <e2> lovastatin </e2> , bromocriptine, valproate, terfenadine, and astemizole.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus,  <e1> hexobarbital </e1> , phenytoin, alfentanil,  <e2> cisapride </e2> , disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
advise	In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of  <e1> theophylline </e1>  should be reduced while the patient is receiving concomitant  <e2> erythromycin </e2>  therapy.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital,  <e1> phenytoin </e1> , alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and  <e2> astemizole </e2> .
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine,  <e1> valproate </e1> , terfenadine, and  <e2> astemizole </e2> .
false	 <e1> Digoxin </e1>  - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either  <e2> citalopram </e2>  or digoxin.
false	If concomitant treatment with sumatriptan and an  <e1> SSRI </e1>  (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	Because  <e1> escitalopram </e1>  is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease  <e2> escitalopram </e2>  clearance.
false	Ritonavir - Combined administration of a single dose of  <e1> ritonavir </e1>  (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and  <e2> escitalopram </e2>  (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.
false	 <e1> Pimozide </e1>  and Celexa - In a controlled study, a single dose of  <e2> pimozide </e2>  2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
false	 <e1> Digoxin </e1>  - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and  <e2> digoxin </e2>  (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.
false	 <e1> Lithium </e1>  - Coadministration of racemic citalopram (40 mg/day for 10 days) and  <e2> lithium </e2>  (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.
false	Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of  <e1> carbamazepine </e1> , the possibility that  <e2> carbamazepine </e2>  might increase the clearance of escitalopram should be considered if the two drugs are coadministered.
effect	There have been postmarketing reports of drug interactions when  <e1> erythromycin </e1>  is coadministered with  <e2> cisapride </e2> , resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
false	Drugs That Interfere With Hemostasis (NSAIDs,  <e1> Aspirin </e1> ,  <e2> Warfarin </e2> , etc.)
false	Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of  <e1> citalopram </e1>  or  <e2> lithium </e2> .
false	However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant  <e1> desipramine </e1>  (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of  <e2> desipramine </e2> .
false	Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,  <e1> ritonavir </e1> ,  <e2> saquinavir </e2> , telithromycin, troleandomycin (TAO), and voriconazole .
false	Because  <e1> lithium </e1>  may enhance the serotonergic effects of escitalopram, caution should be exercised when  <e2> LEXAPRO </e2>  and lithium are coadministered.
false	Nevertheless, plasma  <e1> lithium </e1>  levels should be monitored with appropriate adjustment to the  <e2> lithium </e2>  dose in accordance with standard clinical practice.
mechanism	Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that  <e1> carbamazepine </e1>  might increase the clearance of  <e2> escitalopram </e2>  should be considered if the two drugs are coadministered.
advise	If concomitant treatment with  <e1> sumatriptan </e1>  and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine,  <e2> sertraline </e2> , citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for  <e1> escitalopram </e1> , i.e., coadministration of escitalopram (20 mg/day for 21 days) with the  <e2> tricyclic antidepressant </e2>  desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.
false	Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and  <e1> escitalopram </e1>  (20 mg) did not affect the pharmacokinetics of either ritonavir or  <e2> escitalopram </e2> .
false	Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of  <e1> alcohol </e1>  in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking  <e2> LEXAPRO </e2>  is not recommended.
false	If concomitant treatment with sumatriptan and an  <e1> SSRI </e1>  (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline,  <e2> citalopram </e2> , escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic  <e1> citalopram </e1>  ( <e2> Celexa </e2> ), the two agents should not be coadministered.
advise	Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other  <e1> psychotropic medications </e1> , the use of alcohol by patients taking  <e2> LEXAPRO </e2>  is not recommended.
false	Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate  <e1> triazolam </e1>  (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either  <e2> citalopram </e2>  or triazolam.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride,  <e1> disopyramide </e1> , lovastatin, bromocriptine,  <e2> valproate </e2> , terfenadine, and astemizole.
false	Theophylline - Combined administration of racemic  <e1> citalopram </e1>  (40 mg/day for 21 days) and the CYP1A2 substrate  <e2> theophylline </e2>  (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
false	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine,  <e1> paroxetine </e1> ,  <e2> sertraline </e2> , citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	Alcohol - Although  <e1> LEXAPRO </e1>  did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of  <e2> alcohol </e2>  by patients taking LEXAPRO is not recommended.
false	Ketoconazole - Combined administration of racemic citalopram (40 mg) and  <e1> ketoconazole </e1>  (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of  <e2> citalopram </e2> .
false	Concomitant Administration with Racemic  <e1> Citalopram </e1>  Citalopram - Since  <e2> escitalopram </e2>  is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
false	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital,  <e1> phenytoin </e1> , alfentanil, cisapride, disopyramide, lovastatin,  <e2> bromocriptine </e2> , valproate, terfenadine, and astemizole.
false	If concomitant treatment with sumatriptan and an SSRI (e.g.,  <e1> fluoxetine </e1> ,  <e2> fluvoxamine </e2> , paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	There have been reports of interactions of erythromycin with carbamazepine,  <e1> cyclosporine </e1> ,  <e2> tacrolimus </e2> , hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
false	In addition, steady state levels of racemic  <e1> citalopram </e1>  were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of  <e2> citalopram </e2> , suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.
false	 <e1> Sumatriptan </e1>  - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and  <e2> sumatriptan </e2> .
false	However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for  <e1> escitalopram </e1> , i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant  <e2> desipramine </e2>  (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.
false	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine,  <e1> fluvoxamine </e1> , paroxetine, sertraline, citalopram,  <e2> escitalopram </e2> ) is clinically warranted, appropriate observation of the patient is advised.
false	 <e1> Theophylline </e1>  - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of  <e2> theophylline </e2> .
effect	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of  <e1> psychotropic drugs </e1>  that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or  <e2> aspirin </e2>  potentiated the risk of bleeding.
false	However, coadministration of escitalopram (20 mg) and  <e1> ritonavir </e1>  (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of  <e2> escitalopram </e2> .
false	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine,  <e1> paroxetine </e1> , sertraline,  <e2> citalopram </e2> , escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and  <e1> digoxin </e1>  (single dose of 1 mg) did not significantly affect the pharmacokinetics of either  <e2> citalopram </e2>  or digoxin.
false	Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as  <e1> dopamine </e1> ,  <e2> epinephrine </e2> , and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
false	 <e1> Metoprolol </e1>  - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker  <e2> metoprolol </e2>  (given in a single dose of 100 mg).
false	A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of  <e1> BREVIBLOC </e1>  and  <e2> warfarin </e2>  does not alter warfarin plasma levels.
effect	Catecholamine-depleting drugs, e.g.,  <e1> reserpine </e1> , may have an additive effect when given with  <e2> beta blocking agents </e2> .
mechanism	When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but  <e1> BREVIBLOC </e1>  steady-state blood levels were increased by 46% in the presence of  <e2> morphine </e2> .
false	When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on  <e1> morphine </e1>  blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of  <e2> morphine </e2> .
false	When intravenous  <e1> morphine </e1>  and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of  <e2> morphine </e2> .
advise	If concomitant treatment with  <e1> sumatriptan </e1>  and an SSRI (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate  <e1> triazolam </e1>  (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or  <e2> triazolam </e2> .
false	A study of interaction between  <e1> BREVIBLOC </e1>  and  <e2> warfarin </e2>  showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.
advise	Although the interactions observed in these studies do not appear to be of major clinical importance,  <e1> BREVIBLOC </e1>  should be titrated with caution in patients being treated concurrently with  <e2> digoxin </e2> , morphine, succinylcholine or warfarin.
false	When intravenous  <e1> morphine </e1>  and BREVIBLOC were concomitantly administered in normal subjects, no effect on  <e2> morphine </e2>  blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
false	A study of interaction between BREVIBLOC and  <e1> warfarin </e1>  showed that concomitant administration of BREVIBLOC and  <e2> warfarin </e2>  does not alter warfarin plasma levels.
false	A study of interaction between  <e1> BREVIBLOC </e1>  and warfarin showed that concomitant administration of  <e2> BREVIBLOC </e2>  and warfarin does not alter warfarin plasma levels.
false	When intravenous morphine and  <e1> BREVIBLOC </e1>  were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but  <e2> BREVIBLOC </e2>  steady-state blood levels were increased by 46% in the presence of morphine.
false	 <e1> Alcohol </e1>  - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of  <e2> alcohol </e2>  by patients taking LEXAPRO is not recommended.
false	If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine,  <e1> fluvoxamine </e1> , paroxetine,  <e2> sertraline </e2> , citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
false	When intravenous  <e1> morphine </e1>  and  <e2> BREVIBLOC </e2>  were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
false	Coadministration of oral contraceptives, diazepam, phenytoin, or  <e1> quinidine </e1>  did not seem to change the pharmacokinetic profile of  <e2> esomeprazole </e2> .
false	Drug interaction studies have shown that  <e1> esomeprazole </e1>  does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or  <e2> amoxicillin </e2> .
advise	Although the interactions observed in these studies do not appear to be of major clinical importance,  <e1> BREVIBLOC </e1>  should be titrated with caution in patients being treated concurrently with digoxin, morphine,  <e2> succinylcholine </e2>  or warfarin.
false	Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin,  <e1> warfarin </e1> , quinidine,  <e2> clarithromycin </e2>  or amoxicillin.
false	Coadministration of oral  <e1> contraceptives </e1> , diazepam,  <e2> phenytoin </e2> , or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
false	Drug interaction studies have shown that  <e1> esomeprazole </e1>  does not have any clinically significant interactions with  <e2> phenytoin </e2> , warfarin, quinidine, clarithromycin or amoxicillin.
mechanism	Therefore,  <e1> esomeprazole </e1>  may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and  <e2> digoxin </e2> ).
false	Coadministration of  <e1> esomeprazole </e1>  30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of  <e2> diazepam </e2> .
false	Coadministration of oral  <e1> contraceptives </e1> , diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of  <e2> esomeprazole </e2> .
false	When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on  <e1> morphine </e1>  blood levels was seen, but  <e2> BREVIBLOC </e2>  steady-state blood levels were increased by 46% in the presence of morphine.
false	 <e1> Theophylline </e1>  - Combined administration of racemic  <e2> citalopram </e2>  (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
mechanism	While no in vivo drug-drug interaction studies were conducted between  <e1> estazolam </e1>  and inducers of CYP3A, compounds that are potent CYP3A inducers (such as  <e2> carbamazepine </e2> , phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
false	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics,  <e1> phenothiazines </e1> ,  <e2> psychotropic medications </e2> , or other drugs that produce CNS depression.
false	The action of the benzodiazepines may be potentiated by  <e1> anticonvulsants </e1> , antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics,  <e2> phenothiazines </e2> , psychotropic medications, or other drugs that produce CNS depression.
false	While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as  <e1> carbamazepine </e1> , phenytoin, rifampin, and barbiturates) would be expected to decrease  <e2> estazolam </e2>  concentrations.
effect	The action of the  <e1> benzodiazepines </e1>  may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics,  <e2> phenothiazines </e2> , psychotropic medications, or other drugs that produce CNS depression.
false	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines,  <e1> alcohol </e1> , barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines,  <e2> psychotropic medications </e2> , or other drugs that produce CNS depression.
mechanism	Therefore,  <e1> esomeprazole </e1>  may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg,  <e2> ketoconazole </e2> , iron salts and digoxin).
false	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A:  <e1> nefazodone </e1> , fluvoxamine, cimetidine, diltiazem,  <e2> isoniazide </e2> , and some macrolide antibiotics.
false	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines,  <e1> alcohol </e1> ,  <e2> barbiturates </e2> , monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
effect	The action of the  <e1> benzodiazepines </e1>  may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors,  <e2> narcotics </e2> , phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
false	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates,  <e1> monoamine oxidase inhibitors </e1> , narcotics,  <e2> phenothiazines </e2> , psychotropic medications, or other drugs that produce CNS depression.
false	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol,  <e1> barbiturates </e1> , monoamine oxidase inhibitors, narcotics,  <e2> phenothiazines </e2> , psychotropic medications, or other drugs that produce CNS depression.
false	The action of the benzodiazepines may be potentiated by anticonvulsants,  <e1> antihistamines </e1> , alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines,  <e2> psychotropic medications </e2> , or other drugs that produce CNS depression.
false	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine,  <e1> diltiazem </e1> , isoniazide, and some  <e2> macrolide antibiotics </e2> .
false	The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol,  <e1> barbiturates </e1> , monoamine oxidase inhibitors, narcotics, phenothiazines,  <e2> psychotropic medications </e2> , or other drugs that produce CNS depression.
false	The action of the benzodiazepines may be potentiated by anticonvulsants,  <e1> antihistamines </e1> , alcohol, barbiturates, monoamine oxidase inhibitors,  <e2> narcotics </e2> , phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
false	 <e1> Estazolam </e1> : Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of  <e2> estazolam </e2>  to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.
false	The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A:  <e1> nefazodone </e1> ,  <e2> fluvoxamine </e2> , cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
false	Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg,  <e1> ketoconazole </e1> ,  <e2> iron </e2>  salts and digoxin).
false	Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating  <e1> corticosteroids </e1>  and  <e2> sex steroids </e2> , respectively.
mechanism	The following are examples of drugs known to inhibit the metabolism of other related  <e1> benzodiazepines </e1> , presumably through inhibition of CYP3A:  <e2> nefazodone </e2> , fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
false	While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine,  <e1> phenytoin </e1> , rifampin, and  <e2> barbiturates </e2> ) would be expected to decrease estazolam concentrations.
false	The action of the benzodiazepines may be potentiated by  <e1> anticonvulsants </e1> , antihistamines, alcohol, barbiturates,  <e2> monoamine oxidase inhibitors </e2> , narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
false	Warfarin:  <e1> Eszopiclone </e1>  3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or  <e2> (S)-warfarin </e2> , nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin
false	CNS-Active Drugs  <e1> Ethanol </e1>  An additive effect on psychomotor performance was seen with coadministration of  <e2> eszopiclone </e2>  and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
false	 <e1> Warfarin </e1> : Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of  <e2> warfarin </e2> 
false	Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S) <e1> -warfari </e1> n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of  <e2> warfarin </e2> 
false	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin,  <e1> ritonavir </e1> ,  <e2> nelfinavir </e2> ) would be expected to behave similarly.
false	Drugs With A Narrow Therapeutic Index Digoxin A single dose of  <e1> eszopiclone </e1>  3 mg did not affect the pharmacokinetics of  <e2> digoxin </e2>  measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.
false	 <e1> Olanzapine </e1> : Coadministration of  <e2> eszopiclone </e2>  3 mg and olanzapine 10 mg produced a decrease in DSST scores.
false	Drugs That Induce CYP3A4 ( <e1> Rifampicin </e1> ) Racemic zopiclone exposure was decreased 80% by concomitant useof  <e2> rifampicin </e2> , a potent inducer of CYP3A4.
false	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone,  <e1> troleandomycin </e1> , ritonavir,  <e2> nelfinavir </e2> ) would be expected to behave similarly.
false	Patients in a clinical study who were on established therapy with  <e1> sulfasalazine </e1> , to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either  <e2> ENBREL </e2>  CI or sulfasalazine alone.
false	Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin,  <e1> nefazodone </e1> , troleandomycin, ritonavir,  <e2> nelfinavir </e2> ) would be expected to behave similarly.
false	However, it was observed that the pharmacokinetics of  <e1> ENBREL </e1>   was unaltered by concomitant  <e2> methotrexate </e2>  in rheumatoid arthritis patients.
effect	Patients in a clinical study who were on established therapy with  <e1> sulfasalazine </e1> , to which  <e2> ENBREL </e2>  was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.
false	Lithium generally should not be given with  <e1> diuretics </e1>  because they reduce its renal clearance and add a high risk of  <e2> lithium </e2>  toxicity.
false	Paroxetine: Coadministration of single doses of  <e1> eszopiclone </e1>  3 mg and  <e2> paroxetine </e2>  20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.
effect	In some patients, the administration of a  <e1> non- steroidal antiinflammatory agent </e1>  can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and  <e2> thiazide diuretics </e2> .
false	The results of a study of coadministration of  <e1> ethambutol </e1>  (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of  <e2> ethambutol </e2>  may be reduced by these antacid products.
false	It is recommended to avoid concurrent administration of ethambutol with  <e1> aluminum hydroxide </e1>  containing antacids for at least 4 hours following  <e2> ethambutol </e2>  administration.
false	The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  <e1> ethambutol </e1>  of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these  <e2> antacid products </e2> .
false	The results of a study of coadministration of  <e1> ethambutol </e1>  (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these  <e2> antacid products </e2> .
effect	Other depressasnts such as alcohol, barbiturates, and  <e1> MAOIs </e1>  may enhance CNS depression when administered with  <e2> ethchlorvynol </e2> .
false	The results of a study of coadministration of ethambutol (50 mg/kg) with an  <e1> aluminum hydroxide </e1>  containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of  <e2> ethambutol </e2>  of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
false	The results of a study of coadministration of  <e1> ethambutol </e1>  (50 mg/kg) with an aluminum hydroxide containing  <e2> antacid </e2>  to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
false	May interact with addictive medications, especially  <e1> central nervous system (CNS) depressants </e1>  with habituating potential (prolonged concurrent use may increase the risk of habituation),  <e2> alcohol </e2>  or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate).
effect	 <e1> Ethopropazine </e1>  may interact with alcohol or other  <e2> CNS depressants </e2> , causing increased sedative effects.
false	Ethopropazine may interact with  <e1> alcohol </e1>  or other  <e2> CNS depressants </e2> , causing increased sedative effects.
false	Since  <e1> Zarontin </e1>  (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and  <e2> valproic acid </e2>  has been reported to both increase and decrease ethosuximide levels).
false	Since  <e1> Zarontin </e1>  ( <e2> ethosuximide </e2> ) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
false	Since  <e1> Zarontin </e1>  (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg,  <e2> ethosuximide </e2>  may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
false	Since Zarontin (ethosuximide) may interact with concurrently administered  <e1> antiepileptic drugs </e1> , periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease  <e2> ethosuximide </e2>  levels).
false	Presumably, phenytoin acts as a stimulator of  <e1> coumarin </e1>  metabolism and has been reported to cause decreased serum levels of the  <e2> coumarin anticoagulants </e2>  and increased prothrombin-proconvertin concentrations.
advise	Considerable caution should be exercised if  <e1> PEGANONE </e1>  is administered concurrently with Phenurone ( <e2> phenacemide </e2> ) since paranoid symptoms have been reported during therapy with this combination.
mechanism	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and  <e1> valproic acid </e1>  has been reported to both increase and decrease  <e2> ethosuximide </e2>  levels).
int	A two-way interaction between the  <e1> hydantoin antiepileptic </e1> ,  <e2> phenytoin </e2> , and the coumarin anticoagulants has been suggested.
false	Ethoxzolamide may increase the action of tricyclics, amphetamines,  <e1> procainamide </e1> , and  <e2> quinidine </e2> .
false	Coadministration of ethoxzolamide with other  <e1> diuretics </e1> , amphotericin B, and  <e2> corticosteroids </e2>  may cause hypokalemia.
effect	Coadministration of  <e1> ethoxzolamide </e1>  with other  <e2> diuretics </e2> , amphotericin B, and corticosteroids may cause hypokalemia.
false	Considerable caution should be exercised if PEGANONE is administered concurrently with  <e1> Phenurone </e1>  ( <e2> phenacemide </e2> ) since paranoid symptoms have been reported during therapy with this combination.
mechanism	Anticonvulsants (carbamazepine, felbamate,  <e1> phenobarbital </e1> , phenytoin, topiramate): Increase the metabolism of  <e2> ethinyl estradiol </e2>  and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of  <e1> ethinyl estradiol </e1>  and/or some  <e2> progestins </e2> , leading to possible decrease in contraceptive effectiveness.
false	 <e1> Morphine </e1> : Combination hormonal contraceptives may increase the clearance of  <e2> morphine </e2> .
false	 <e1> Anticoagulants </e1> : Combination hormonal contraceptives may increase or decrease the effects of  <e2> coumarin derivatives </e2> .
false	 <e1> Cyclosporine </e1> : Combination hormonal contraceptives may inhibit the metabolism of  <e2> cyclosporine </e2> , leading to increased plasma concentrations;
mechanism	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin,  <e1> topiramate </e1> ): Increase the metabolism of  <e2> ethinyl estradiol </e2>  and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	Example inducers include  <e1> aminoglutethimide </e1> , carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and  <e2> rifamycins </e2> .
mechanism	Anticonvulsants (carbamazepine, felbamate, phenobarbital,  <e1> phenytoin </e1> , topiramate): Increase the metabolism of  <e2> ethinyl estradiol </e2>  and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	 <e1> Non-nucleoside reverse transcriptase inhibitors </e1>  ( <e2> NNRTIs </e2> ): Nevirapine may decrease plasma levels of combination hormonal contraceptives;
false	Antibiotics ( <e1> ampicillin </e1> ,  <e2> tetracycline </e2> ): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.
false	ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of  <e1> caffeine </e1>  may be enhanced if  <e2> combination hormonal contraceptives </e2>  are used concurrently with caffeine.
mechanism	Atorvastatin:  <e1> Atorvastatin </e1>  increases the AUC for norethindrone and  <e2> ethinyl estradiol </e2> .
false	Example inducers include aminoglutethimide, carbamazepine,  <e1> nafcillin </e1> , nevirapine, phenobarbital,  <e2> phenytoin </e2> , and rifamycins.
false	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam,  <e1> chlordiazepoxide </e1> , diazepam) and increase the clearance of others (lorazepam, oxazepam,  <e2> temazepam </e2> ).
false	Protease inhibitors:  <e1> Amprenavir </e1> , lopinavir, nelfinavir, and  <e2> ritonavir </e2>  have been shown to decrease plasma levels of combination hormonal contraceptives;
mechanism	 <e1> Tricyclic antidepressants </e1>  (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by  <e2> combination hormonal contraceptives </e2> , increasing plasma levels of antidepressant;
false	Non-nucleoside reverse transcriptase inhibitors ( <e1> NNRTIs </e1> ): Nevirapine may decrease plasma levels of  <e2> combination hormonal contraceptives </e2> ;
mechanism	Protease inhibitors:  <e1> Amprenavir </e1> , lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of  <e2> combination hormonal contraceptives </e2> ;
false	 <e1> Rifampin </e1> : Rifampin increases the metabolism of  <e2> ethinyl estradiol </e2>  and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
mechanism	Benzodiazepines: Combination  <e1> hormonal contraceptives </e1>  may decrease the clearance of some benzodiazepines (alprazolam,  <e2> chlordiazepoxide </e2> , diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
mechanism	Benzodiazepines: Combination  <e1> hormonal contraceptives </e1>  may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide,  <e2> diazepam </e2> ) and increase the clearance of others (lorazepam, oxazepam, temazepam).
false	 <e1> Salicylic acid </e1> : Combination  <e2> hormonal contraceptives </e2>  may increase the clearance of salicylic acid.
false	 <e1> Antibiotics </e1>  (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these  <e2> antibiotics </e2>  on plasma concentrations of synthetic steroids.
false	ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of  <e1> caffeine </e1>  may be enhanced if combination hormonal contraceptives are used concurrently with  <e2> caffeine </e2> .
false	Example inducers include  <e1> aminoglutethimide </e1> , carbamazepine, nafcillin, nevirapine,  <e2> phenobarbital </e2> , phenytoin, and rifamycins.
mechanism	Cyclosporine: Combination  <e1> hormonal contraceptives </e1>  may inhibit the metabolism of  <e2> cyclosporine </e2> , leading to increased plasma concentrations;
false	 <e1> Clofibric acid </e1> : Combination hormonal contraceptives may increase the clearance of  <e2> clofibric acid </e2> .
false	Anticonvulsants ( <e1> carbamazepine </e1> , felbamate,  <e2> phenobarbital </e2> , phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	 <e1> Anticonvulsants </e1>  (carbamazepine,  <e2> felbamate </e2> , phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	Example inducers include aminoglutethimide, carbamazepine,  <e1> nafcillin </e1> , nevirapine, phenobarbital, phenytoin, and  <e2> rifamycins </e2> .
effect	Coadministration of  <e1> ethoxzolamide </e1>  with other diuretics,  <e2> amphotericin B </e2> , and corticosteroids may cause hypokalemia.
false	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others ( <e1> lorazepam </e1> ,  <e2> oxazepam </e2> , temazepam).
false	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines ( <e1> alprazolam </e1> , chlordiazepoxide, diazepam) and increase the clearance of others ( <e2> lorazepam </e2> , oxazepam, temazepam).
false	 <e1> Benzodiazepines </e1> : Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam,  <e2> temazepam </e2> ).
false	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some  <e1> benzodiazepines </e1>  (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam,  <e2> oxazepam </e2> , temazepam).
false	 <e1> Selegiline </e1> :  <e2> Combination hormonal contraceptives </e2>  may increase the serum concentration of selegiline.
false	Anticonvulsants (carbamazepine, felbamate,  <e1> phenobarbital </e1> , phenytoin,  <e2> topiramate </e2> ): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	Tricyclic antidepressants (amitriptyline,  <e1> imipramine </e1> ,  <e2> nortriptyline </e2> ): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
false	Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some  <e1> benzodiazepines </e1>  (alprazolam,  <e2> chlordiazepoxide </e2> , diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
false	 <e1> Anticonvulsants </e1>  ( <e2> carbamazepine </e2> , felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	Rifampin: Rifampin increases the metabolism of  <e1> ethinyl estradiol </e1>  and some  <e2> progestins </e2>  (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
mechanism	Combination  <e1> hormonal contraceptives </e1>  may also decrease the plasma concentration of  <e2> acetaminophen </e2> .
mechanism	Protease inhibitors: Amprenavir, lopinavir,  <e1> nelfinavir </e1> , and ritonavir have been shown to decrease plasma levels of  <e2> combination hormonal contraceptives </e2> ;
false	Example inducers include  <e1> aminoglutethimide </e1> , carbamazepine,  <e2> nafcillin </e2> , nevirapine, phenobarbital, phenytoin, and rifamycins.
false	 <e1> Tricyclic antidepressants </e1>  ( <e2> amitriptyline </e2> , imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
false	Anticonvulsants (carbamazepine, felbamate,  <e1> phenobarbital </e1> ,  <e2> phenytoin </e2> , topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
false	 <e1> Benzodiazepines </e1> : Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam,  <e2> oxazepam </e2> , temazepam).
false	Thus, when NSAIDs and  <e1> lithium </e1>  are administered concurrently, subjects should be observed carefully for signs of  <e2> lithium </e2>  toxicity.
false	Thus, when  <e1> NSAIDs </e1>  and lithium are administered concurrently, subjects should be observed carefully for signs of  <e2> lithium </e2>  toxicity.
false	Antibiotics (ampicillin,  <e1> tetracycline </e1> ): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these  <e2> antibiotics </e2>  on plasma concentrations of synthetic steroids.
false	however, as with other  <e1> NSAIDs </e1> , concomitant administration of Lodine and  <e2> aspirin </e2>  is not generally recommended because of the potential of increased adverse effects.
false	Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of  <e1> furosemide </e1>  and  <e2> thiazides </e2>  in some patients.
false	Thus, concomitant therapy with  <e1> warfarin </e1>  and  <e2> Lodine </e2>  should not require dosage adjustment of either drug.
false	Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  ( <e1> etodolac </e1>  capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free  <e2> warfarin </e2> .
mechanism	Aspirin: When  <e1> Lodine </e1>  is administered with  <e2> aspirin </e2> , its protein binding is reduced, although the clearance of free etodolac is not altered.
mechanism	Cyclosporine, Digoxin, Methotrexate Lodine, like other  <e1> NSAIDs </e1> , through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of  <e2> cyclosporine </e2> , digoxin, methotrexate, and increased toxicity.
false	Diuretics: Etodolac has no apparent pharmacokinetic interaction when administered with  <e1> furosemide </e1>  or  <e2> hydrochlorothiazide </e2> .
false	 <e1> Warfarin </e1> : The effects of warfarin and  <e2> NSAIDs </e2>  on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.
false	 <e1> Lithium </e1> : NSAIDs have produced an elevation of plasma  <e2> lithium </e2>  levels and a reduction in renal lithium clearance.
false	however, as with other  <e1> NSAIDs </e1> , concomitant administration of  <e2> Lodine </e2>  and aspirin is not generally recommended because of the potential of increased adverse effects.
mechanism	Cyclosporine, Digoxin, Methotrexate  <e1> Lodine </e1> , like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of  <e2> cyclosporine </e2> , digoxin, methotrexate, and increased toxicity.
effect	However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in  <e1> etodolac </e1> -treated patients receiving concomitant  <e2> warfarin </e2>  therapy.
advise	This interaction should be given consideration in patients taking  <e1> NSAIDs </e1>  concomitantly with  <e2> ACE-inhibitors </e2> .
false	 <e1> Aminophylline </e1>       <e2> Etomidate </e2>  antagonism
false	 <e1> Aspirin </e1> : When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free  <e2> etodolac </e2>  is not altered.
false	Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of  <e1> cyclosporine </e1> ,  <e2> digoxin </e2> , methotrexate, and increased toxicity.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals ( <e2> Gris-PEG </e2> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e1> Sandimmune </e1> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e2> Dilantin </e2> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e1> Sandimmune </e1> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e1> Sandimmune </e1> ), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e1> temazepam </e1> , theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e1> Lipitor </e1> ), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e1> Norvir </e1> , Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e2> Sandimmune </e2> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e1> Lipitor </e1> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e2> Crixivan </e2> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e1> Crixivan </e1> , Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e1> MS Contin </e1> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e1> Astramorph </e1> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax,  <e2> Felbatol </e2> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e1> clofibrate </e1>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e2> atorvastatin </e2>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline,  <e2> anticonvulsants </e2>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e1> Sandimmune </e1> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e1> Viracept </e1> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e1> phenylbutazone </e1> , prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e1> Crixivan </e1> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  ( <e2> Dilantin </e2> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e1> Lipitor </e1> ), clofibrate (Atromid-S),  <e2> cyclosporine </e2>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e1> Viracept </e1> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e2> Topamax </e2> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e1> Invirase </e1> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e1> Crixivan </e1> , Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e1> Crixivan </e1> , Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e1> Kadian </e1> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e1> morphine </e1>  ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e1> phenylbutazone </e1> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol,  <e2> Trileptal </e2> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e1> Sporanox </e1> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e2> Crixivan </e2> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e2> Nizoral </e2> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin,  <e2> Phenobarbital </e2> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e2> antifungals </e2>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e1> Sandimmune </e1> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e1> Lipitor </e1> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e2> Felbatol </e2> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e2> Crixivan </e2> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax,  <e2> Felbatol </e2> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol),  <e2> antifungals </e2>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e1> Norvir </e1> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e2> Gris-PEG </e2> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e1> Sporanox </e1> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e2> Sporanox </e2> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e1> Lipitor </e1> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e2> Sandimmune </e2> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e1> Invirase </e1> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e2> Phenobarbital </e2> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e1> Norvir </e1> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox),  <e2> atorvastatin </e2>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral,  <e2> Sporanox </e2> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e2> atorvastatin </e2>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e2> Felbatol </e2> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e2> cyclosporine </e2>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ),  <e2> cyclosporine </e2>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e1> Crixivan </e1> , Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e1> Sandimmune </e1> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e1> Viracept </e1> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e2> Fortovase </e2> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral,  <e2> Sporanox </e2> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and  <e2> tetracycline </e2> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase,  <e2> Crixivan </e2> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox),  <e2> atorvastatin </e2>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e1> Sandimmune </e1> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> ,  <e2> Felbatol </e2> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e2> Topamax </e2> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e1> Sporanox </e1> ), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e1> clofibrate </e1>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e2> Felbatol </e2> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e1> Norvir </e1> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e2> Crixivan </e2> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin ( <e2> rifampin </e2> ), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase,  <e2> Crixivan </e2> , Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ),  <e2> antibiotics </e2>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e1> Agenerase </e1> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e1> Neoral </e1> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e2> Astramorph </e2> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e1> Kaletra </e1> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e2> atorvastatin </e2>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e1> Kaletra </e1> , Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e2> Nizoral </e2> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e1> Kaletra </e1> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e1> morphine </e1>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e1> rifadin </e1>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e1> MS Contin </e1> ),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral,  <e2> Sporanox </e2> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e1> Sporanox </e1> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e1> Astramorph </e1> , Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol,  <e2> Trileptal </e2> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin ( <e2> Lipitor </e2> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e2> Felbatol </e2> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e2> Sandimmune </e2> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e2> Nizoral </e2> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort,  <e2> temazepam </e2> , theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e1> Norvir </e1> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept),  <e2> morphine </e2>  (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e2> Topamax </e2> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as  <e2> ampicillin </e2>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral,  <e2> Sandimmune </e2> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e2> Fortovase </e2> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e1> Kadian </e1> , MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e1> MS Contin </e1> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone,  <e2> prednisolone </e2>  (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e2> cyclosporine </e2>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e2> cyclosporine </e2>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine ( <e1> Astramorph </e1> , Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e2> Nizoral </e2> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol),  <e2> antifungals </e2>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e1> Agenerase </e1> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and  <e1> tetracycline </e1> , anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e2> Trileptal </e2> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e2> Atromid-S </e2> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e1> Nizoral </e1> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax,  <e1> Felbatol </e1> ), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	High-dose  <e1> cyclosporin A </e1>  resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to  <e2> etoposide </e2>  alone.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e1> clofibrate </e1>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra,  <e2> Norvir </e2> , Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e2> atorvastatin </e2>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e1> phenylbutazone </e1> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S),  <e1> cyclosporine </e1>  (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral,  <e1> Sporanox </e1> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and  <e2> vitamin C </e2> .
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e2> Kadian </e2> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral,  <e2> Sandimmune </e2> ), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e1> Viracept </e1> ), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital,  <e1> Tegretol </e1> , Trileptal, Topamax, Felbatol), antifungals (Gris-PEG,  <e2> Nizoral </e2> , Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam,  <e2> theophylline </e2>  (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline,  <e1> anticonvulsants </e1>  (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral,  <e2> Sporanox </e2> ), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	High-dose  <e1> cyclosporin A </e1>  resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of  <e2> etoposide </e2>  compared to etoposide alone.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph,  <e1> Kadian </e1> , MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e1> Agenerase </e1> , Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as  <e1> ampicillin </e1>  and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e2> atorvastatin </e2>  (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> , Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone),  <e2> rifadin </e2>  (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol),  <e1> antibiotics </e1>  such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e2> protease inhibitors </e2>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan,  <e1> Fortovase </e1> ,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
int	 <e1> Etonogestrel </e1>  may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol),  <e1> antifungals </e1>  (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol,  <e1> Trileptal </e1> , Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin ( <e2> Lipitor </e2> ), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	 <e1> Lithium </e1> : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal  <e2> lithium </e2>  clearance.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir,  <e2> Viracept </e2> ), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin),  <e2> phenylbutazone </e2> , prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as  <e1> protease inhibitors </e1>  (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline ( <e2> Theo-Dur </e2> ), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal,  <e1> Topamax </e1> , Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine ( <e2> Neoral </e2> , Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin,  <e1> Phenobarbital </e1> , Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase,  <e2> Invirase </e2> , Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen ( <e1> Tylenol </e1> ), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian,  <e2> MS Contin </e2> ), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate ( <e1> Atromid-S </e1> ), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants ( <e1> Dilantin </e1> , Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors ( <e2> Agenerase </e2> , Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e1> Gris-PEG </e1> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase,  <e2> Kaletra </e2> , Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor),  <e1> clofibrate </e1>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone ( <e2> Prelone </e2> ), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
mechanism	Co-medications that induce CYP 3A4 (e.g., rifampicin,  <e1> phenytoin </e1> , carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to  <e2> exemestane </e2> .
false	Etonogestrel may interact with the following medications:  <e1> acetaminophen </e1>  (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals ( <e2> Gris-PEG </e2> , Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox),  <e1> atorvastatin </e1>  (Lipitor),  <e2> clofibrate </e2>  (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
false	Co-medications that induce CYP 3A4 (e.g.,  <e1> rifampicin </e1> , phenytoin, carbamazepine,  <e2> phenobarbital </e2> , or St. John s wort) may significantly decrease exposure to exemestane.
false	Co-medications that induce CYP 3A4 (e.g., rifampicin,  <e1> phenytoin </e1> , carbamazepine,  <e2> phenobarbital </e2> , or St. John s wort) may significantly decrease exposure to exemestane.
false	Compounds tested in man include warfarin,  <e1> theophylline </e1> , phenytoin, diazepam,  <e2> aminopyrine </e2>  and antipyrine.
false	Compounds tested in man include warfarin, theophylline,  <e1> phenytoin </e1> , diazepam, aminopyrine and  <e2> antipyrine </e2> .
false	Compounds tested in man include warfarin,  <e1> theophylline </e1> ,  <e2> phenytoin </e2> , diazepam, aminopyrine and antipyrine.
false	In a controlled clinical trial, a 20% reduction of the  <e1> phenytoin </e1>  dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to  <e2> Felbatol </e2>   administration.
false	Steady-state plasma  <e1> felbamate </e1>  concentrations were found to be 29% lower than the mean concentrations of a group of newly diagnosed subjects with epilepsy also receiving 2400 mg of  <e2> felbamate </e2>  a day.
false	Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral  <e1> contraceptive </e1>  regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral  <e2> contraceptive </e2>  cycles.
false	Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on  <e1> Felbatol </e1>   ( <e2> felbamate </e2> ) plasma concentrations.
false	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of  <e1> Felbatol </e1>   therapy resulted in phenytoin levels comparable to those prior to  <e2> Felbatol </e2>   administration.
false	Carbamazepine:  <e1> Carbamazepine </e1>  causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of  <e2> Felbatol </e2>   as compared to the same dose of Felbatol  given as monotherapy.
false	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of  <e1> Felbatol </e1>   as compared to the same dose of  <e2> Felbatol </e2>   given as monotherapy.
false	 <e1> Valproate </e1> : Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  ( <e2> felbamate </e2> ) plasma concentrations.
false	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  ( <e1> felbamate </e1> ) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of  <e2> Felbatol </e2>   given as monotherapy.
false	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of  <e1> Felbatol </e1>   at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of  <e2> Felbatol </e2>   given as monotherapy.
mechanism	Valproate:  <e1> Felbatol </e1>   causes an increase in steady-state  <e2> valproate </e2>  concentrations.
false	 <e1> Carbamazepine </e1> :  <e2> Felbatol </e2>   causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.
false	 <e1> Carbamazepine epoxide </e1>  steady-state Cmin concentrations increased 57% from 1.0 0.3 to 1.6 0.4 micrograms/mL with the addition of  <e2> felbamate </e2> .
false	Use in Conjunction with Other  <e1> Antiepileptic Drugs </e1> : The addition of Felbatol  to  <e2> antiepileptic drugs </e2>  (AEDs) affects the steady-state plasma concentrations of AEDs.
false	Specific Effects of Felbatol  on Other Antiepileptic Drugs  <e1> Phenytoin </e1> :  <e2> Felbatol </e2>   causes an increase in steady-state phenytoin plasma concentrations.
false	Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg  <e1> ethinyl estradiol </e1>  and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral  <e2> contraceptive </e2>  cycles.
false	Use in Conjunction with Other  <e1> Antiepileptic Drugs </e1> : The addition of Felbatol  to antiepileptic drugs ( <e2> AEDs </e2> ) affects the steady-state plasma concentrations of AEDs.
mechanism	The  <e1> carbamazepine </e1>  steady-state Cmin decreased 31% to 5 1 micrograms/mL when  <e2> felbamate </e2>  (3000 mg/day, divided into three doses) was coadministered.
false	Effects of Other  <e1> Antiepileptic Drugs </e1>  on Felbatol   <e2> Phenytoin </e2> : Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
false	Compounds tested in man include warfarin, theophylline, phenytoin, diazepam,  <e1> aminopyrine </e1>  and  <e2> antipyrine </e2> .
false	The ratios of the AUCs of unbound  <e1> valproate </e1>  to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of  <e2> Felbatol </e2>  , respectively.
false	 <e1> Phenobarbital </e1> : Coadministration of felbamate with phenobarbital causes an increase in  <e2> phenobarbital </e2>  plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
false	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of  <e1> Felbatol </e1>   (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of  <e2> Felbatol </e2>   as compared to the same dose of Felbatol  given as monotherapy.
false	Effects of  <e1> Felbatol </e1>   on Low-Dose  <e2> Combination Oral Contraceptives </e2>  A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
false	Use in Conjunction with Other  <e1> Antiepileptic Drugs </e1> : The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of  <e2> AEDs </e2> .
false	In a controlled clinical trial, a 20% reduction of the  <e1> phenytoin </e1>  dose at the initiation of Felbatol  therapy resulted in  <e2> phenytoin </e2>  levels comparable to those prior to Felbatol  administration.
mechanism	Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of  <e1> carbamazepine </e1>  results in an approximate 40% decrease in the steady-state trough concentrations of  <e2> Felbatol </e2>   as compared to the same dose of Felbatol  given as monotherapy.
false	The net effect of these interactions is summarized in the following table:  <e1> AED </e1>   <e2> AED </e2>  Felbatol
false	 <e1> Phenobarbital </e1> : It appears that phenobarbital may reduce plasma  <e2> felbamate </e2>  concentrations.
false	Effects of Other Antiepileptic Drugs on  <e1> Felbatol </e1>   Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of  <e2> Felbatol </e2>   as compared to the same dose of Felbatol  given as monotherapy.
false	Effects of  <e1> Antacids </e1>  on Felbatol  The rate and extent of absorption of a 2400 mg dose of Felbatol  as monotherapy given as tablets was not affected when coadministered with  <e2> antacids </e2> .
false	In order to maintain  <e1> phenytoin </e1>  levels, limit adverse experiences, and achieve the  <e2> felbamate </e2>  dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.
false	Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral  <e1> contraceptive </e1>  regimen containing 30 mg  <e2> ethinyl estradiol </e2>  and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
false	Corresponding values for free  <e1> valproate </e1>  Cmin concentrations were 7 3, 9 4, and 11 6 micrograms/mL for 0, 1200, and 2400 mg/day  <e2> Felbatol </e2>  , respectively.
false	Use in Conjunction with Other Antiepileptic Drugs: The addition of  <e1> Felbatol </e1>   to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of  <e2> AEDs </e2> .
false	 <e1> CYP3A4 </e1>  Inhibitors Felodipine is metabolized by  <e2> CYP3A4 </e2> .
false	Co-administration of CYP3A4 inhibitors (eg,  <e1> ketoconazole </e1> , itraconazole, erythromycin, grapefruit juice, cimetidine) with  <e2> felodipine </e2>  may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
false	Erythromycin Co-administration of  <e1> felodipine </e1>  (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of  <e2> felodipine </e2> .
false	Specific Effects of Felbatol  on Other  <e1> Antiepileptic Drugs </e1>   <e2> Phenytoin </e2> : Felbatol  causes an increase in steady-state phenytoin plasma concentrations.
false	Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  ( <e1> felbamate </e1> ) at steady state and, therefore, the addition of  <e2> phenytoin </e2>  causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
false	Effects of Felbatol  on Low-Dose  <e1> Combination Oral Contraceptives </e1>  A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral  <e2> contraceptive </e2>  cycles.
false	Use in Conjunction with Other  <e1> Antiepileptic Drugs </e1> : The addition of  <e2> Felbatol </e2>   to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
false	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg,  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , or phenobarbital) than in healthy volunteers.
false	Erythromycin Co-administration of  <e1> felodipine </e1>  (PLENDIL) with  <e2> erythromycin </e2>  resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.
false	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term  <e1> anticonvulsant </e1>  therapy (eg, phenytoin,  <e2> carbamazepine </e2> , or phenobarbital) than in healthy volunteers.
false	Beta-Blocking Agents  A pharmacokinetic study of  <e1> felodipine </e1>  in conjunction with  <e2> metoprolol </e2>  demonstrated no significant effects on the pharmacokinetics of felodipine.
false	Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral  <e1> contraceptive </e1>  regimen containing 30 mg ethinyl estradiol and 75 mg  <e2> gestodene </e2>  for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
mechanism	Phenobarbital: It appears that  <e1> phenobarbital </e1>  may reduce plasma  <e2> felbamate </e2>  concentrations.
false	Specific Effects of  <e1> Felbatol </e1>   on Other Antiepileptic Drugs  <e2> Phenytoin </e2> : Felbatol  causes an increase in steady-state phenytoin plasma concentrations.
false	Co-administration of CYP3A4 inhibitors (eg,  <e1> ketoconazole </e1> , itraconazole,  <e2> erythromycin </e2> , grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
false	In controlled clinical trials, however,  <e1> beta blockers </e1>  including metoprolol were concurrently administered with  <e2> felodipine </e2>  and were well tolerated.
false	Co-administration of CYP3A4 inhibitors (eg,  <e1> ketoconazole </e1> , itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of  <e2> felodipine </e2> , either due to an increase in bioavailability or due to a decrease in metabolism.
false	Caution should be used when  <e1> CYP3A4 </e1>  inhibitors are co-administered with  <e2> felodipine </e2> .
false	In controlled clinical trials, however,  <e1> beta blockers </e1>  including  <e2> metoprolol </e2>  were concurrently administered with felodipine and were well tolerated.
false	Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine,  <e1> methyldopa </e1> ,  <e2> reserpine </e2> .
false	 <e1> Anticonvulsants </e1> : In a pharmacokinetic study, maximum plasma concentrations of  <e2> felodipine </e2>  were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
false	Fenfluramine may increase slightly the effect of  <e1> antihypertensive drugs </e1> , e.g., guanethidine,  <e2> methyldopa </e2> , reserpine.
false	When given concomitantly with  <e1> felodipine </e1> , the  <e2> tacrolimus </e2>  blood concentration should be followed and the tacrolimus dose may need to be adjusted.
effect	 <e1> Fenfluramine </e1>  may increase slightly the effect of antihypertensive drugs, e.g.,  <e2> guanethidine </e2> , methyldopa, reserpine.
false	 <e1> Resins </e1> : Since bile acid sequestrants may bind other drugs given concurrently, patients should take  <e2> TRICOR </e2>  at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.
mechanism	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of  <e1> felodipine </e1>  were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg,  <e2> phenytoin </e2> , carbamazepine, or phenobarbital) than in healthy volunteers.
false	Concomitant administration of  <e1> fenofibrate </e1>  (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in  <e2> atorvastatin </e2>  AUC values in 22 healthy males.
effect	Cyclosporine: Because  <e1> cyclosporine </e1>  can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including  <e2> TRICOR </e2> , there is a risk that an interaction will lead to deterioration.
false	Concomitant administration of  <e1> fenofibrate </e1>  (equivalent to 145 mg  <e2> TRICOR </e2> ) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
false	Resins: Since  <e1> bile acid sequestrants </e1>  may bind other drugs given concurrently, patients should take  <e2> TRICOR </e2>  at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.
false	 <e1> Cyclosporine </e1> : Because  <e2> cyclosporine </e2>  can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
advise	The benefits and risks of using  <e1> TRICOR </e1>  with  <e2> immunosuppressants </e2>  and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed
false	The  <e1> atorvastatin </e1>  Cmax values were not significantly affected by  <e2> fenofibrate </e2> .
false	There is limited experience with concomitant  <e1> antihypertensive agents </e1>  such as  <e2> alpha-blockers </e2> , calcium channel-blockers, ACE inhibitors, and diuretics (both thiazide-like and loop).
false	Drug Interactions with  <e1> Beta-Blockers </e1> : Concomitant use of  <e2> fenoldopam </e2>  with beta-blockers should be avoided.
false	Drug Interactions with  <e1> Beta-Blockers </e1> : Concomitant use of fenoldopam with  <e2> beta-blockers </e2>  should be avoided.
false	Drug Interactions, General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as  <e1> digitalis </e1>  and sublingual  <e2> nitroglycerin </e2> .
false	There is limited experience with concomitant antihypertensive agents such as  <e1> alpha-blockers </e1> , calcium channel-blockers, ACE inhibitors, and  <e2> diuretics </e2>  (both thiazide-like and loop).
mechanism	The coadministration of  <e1> aspirin </e1>  decreases the biologic half-life of  <e2> fenoprofen </e2>  because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.
false	The coadministration of  <e1> aspirin </e1>  decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of  <e2> hydroxylated fenoprofen </e2>  in the urine.
false	There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers,  <e1> ACE inhibitors </e1> , and  <e2> diuretics </e2>  (both thiazide-like and loop).
advise	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of  <e1> Nalfon </e1>  and  <e2> salicylates </e2>  is not recommended.
false	In patients receiving Nalfon and a  <e1> steroid </e1>  concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden  <e2> steroid </e2>  withdrawal.
false	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of  <e1> Nalfon </e1> , the concomitant use of  <e2> Nalfon </e2>  and salicylates is not recommended.
false	Patients receiving  <e1> hydantoins </e1> ,  <e2> sulfonamides </e2> , or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.
false	There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and  <e1> diuretics </e1>  (both  <e2> thiazide </e2> -like and loop).
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other  <e1> central nervous system depressants </e1> , including but not limited to other opioids, sedatives,  <e2> hypnotics </e2> , tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids,  <e1> sedatives </e1> , hypnotics, tranquilizers (e.g.,  <e2> benzodiazepines </e2> ), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin,  <e1> clarithromycin </e1> ,  <e2> nelfinavir </e2> , and nefazadone may result in an increase in fentanyl plasma concentrations.
mechanism	The concomitant use of other CYP3A4 inhibitors such as diltiazem and  <e1> erythromycin </e1>  with transdermal  <e2> fentanyl </e2>  may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
mechanism	The concomitant use of transdermal  <e1> fentanyl </e1>  with ritonavir or other potent 3A4 inhibitors such as  <e2> ketoconazole </e2> , itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
effect	Central Nervous System Depressants: The concomitant use of  <e1> DURAGESIC </e1>   (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids,  <e2> sedatives </e2> , hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central Nervous System Depressants: The concomitant use of DURAGESIC  ( <e1> fentanyl </e1>  transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics,  <e2> tranquilizers </e2>  (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central Nervous System Depressants: The concomitant use of DURAGESIC  ( <e1> fentanyl </e1>  transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics,  <e2> phenothiazines </e2> , skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other  <e1> opioids </e1> , sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other  <e1> central nervous system depressants </e1> , including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general  <e2> anesthetics </e2> , phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general  <e1> anesthetics </e1> ,  <e2> phenothiazines </e2> , skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other  <e1> central nervous system depressants </e1> , including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics,  <e2> phenothiazines </e2> , skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
effect	Central Nervous System Depressants: The concomitant use of  <e1> DURAGESIC </e1>   (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives,  <e1> hypnotics </e1> , tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids,  <e1> sedatives </e1> , hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	There is limited experience with concomitant  <e1> antihypertensive agents </e1>  such as alpha-blockers,  <e2> calcium channel-blockers </e2> , ACE inhibitors, and diuretics (both thiazide-like and loop).
false	 <e1> Central Nervous System Depressants </e1> : The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g.,  <e2> benzodiazepines </e2> ), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other  <e1> opioids </e1> ,  <e2> sedatives </e2> , hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole,  <e1> itraconazole </e1> , troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in  <e2> fentanyl </e2>  plasma concentrations.
advise	Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN  <e1> COUMARIN ANTICOAGULANTS </e1>  ARE GIVEN IN CONJUNCTION WITH  <e2> TRICOR </e2> .
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids,  <e1> sedatives </e1> , hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines,  <e2> skeletal muscle relaxants </e2> , and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received  <e1> MAOI </e1>  within 14 days because severe and unpredictable potentiation by  <e2> MAO inhibitors </e2>  has been reported with opioid analgesics
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other  <e1> opioids </e1> , sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines,  <e2> skeletal muscle relaxants </e2> , and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics,  <e1> tranquilizers </e1>  (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin,  <e1> clarithromycin </e1> , nelfinavir, and nefazadone may result in an increase in  <e2> fentanyl </e2>  plasma concentrations.
false	 <e1> Central Nervous System Depressants </e1> : The concomitant use of DURAGESIC  (fentanyl transdermal system) with other  <e2> central nervous system depressants </e2> , including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	MAO Inhibitors:  <e1> DURAGESIC </e1>   is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with  <e2> opioid analgesics </e2> 
false	Drug Interactions with  <e1> Antacids </e1>  Administration of 120 mg of  <e2> fexofenadine hydrochloride </e2>  (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
false	Drug Interaction with  <e1> Erythromycin </e1>  and Ketoconazole  <e2> Fexofenadine </e2>  has been shown to exhibit minimal (ca. 5%) metabolism.
false	 <e1> Fexofenadine </e1>  had no effect on the pharmacokinetics of either erythromycin or  <e2> ketoconazole </e2> .
false	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing  <e1> antacid </e1>  ( <e2> Maalox </e2>  ) decreased fexofenadine AUC by 41% and cmax by 43%.
false	Therefore, to maximize the effects of  <e1> fexofenadine </e1> , it is recommended that  <e2> ALLEGRA </e2>  should be taken with water
false	However, co  administration of fexofenadine hydrochloride with either ketoconazole or  <e1> erythromycin </e1>  led to increased plasma concentrations of  <e2> fexofenadine </e2> .
effect	Central Nervous System Depressants: The concomitant use of DURAGESIC  ( <e1> fentanyl </e1>  transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general  <e2> anesthetics </e2> , phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
mechanism	Drug Interactions with Antacids Administration of 120 mg of  <e1> fexofenadine hydrochloride </e1>  (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid ( <e2> Maalox </e2>  ) decreased fexofenadine AUC by 41% and cmax by 43%.
false	Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because  <e1> aspirin </e1>  increases the rate of excretion of Nalfon, the concomitant use of  <e2> Nalfon </e2>  and salicylates is not recommended.
false	Drug Interactions with  <e1> Antacids </e1>  Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an  <e2> aluminum </e2>  and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
false	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an  <e1> aluminum </e1>  and  <e2> magnesium </e2>  containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
false	These studies indicate that  <e1> ketoconazole </e1>  or  <e2> erythromycin </e2>  co-administration enhances fexofenadine gastrointestinal absorption.
false	In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either  <e1> erythromycin </e1>  500 mg every 8 hours or  <e2> ketoconazole </e2>  400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).
false	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing  <e1> antacid </e1>  (Maalox ) decreased  <e2> fexofenadine </e2>  AUC by 41% and cmax by 43%.
mechanism	Drug Interactions with Antacids Administration of 120 mg of  <e1> fexofenadine hydrochloride </e1>  (2 x 60 mg capsule) within 15 minutes of an  <e2> aluminum </e2>  and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
false	Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g.,  <e1> benzodiazepines </e1> ), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid ( <e1> Maalox </e1>  ) decreased  <e2> fexofenadine </e2>  AUC by 41% and cmax by 43%.
false	In 2 separate studies,  <e1> fexofenadine hydrochloride </e1>  120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or  <e2> ketoconazole </e2>  400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).
false	 <e1> Central Nervous System Depressants </e1> : The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and  <e2> alcohol </e2> , may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics,  <e1> angiotensin-converting enzyme (ACE) inhibitors </e1> , anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and  <e2> quinolone anti-infectives </e2>  without evidence of clinically significant adverse interactions.
false	Further, in clinical studies with  <e1> PROSCAR </e1>  ( <e2> finasteride </e2> , 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists,  <e1> HMG-CoA reductase inhibitors </e1> , prostaglandin synthetase inhibitors (also referred to as NSAIDs), and  <e2> quinolone anti-infectives </e2>  without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers,  <e1> analgesics </e1> , angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors,  <e2> prostaglandin synthetase inhibitors </e2>  (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers,  <e1> analgesics </e1> , angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants,  <e2> benzodiazepines </e2> , beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with  <e1> acetaminophen </e1> , acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors,  <e2> prostaglandin synthetase inhibitors </e2>  (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed,  <e1> finasteride </e1>  doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and  <e2> quinolone anti-infectives </e2>  without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed,  <e1> finasteride </e1>  doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics,  <e2> angiotensin-converting enzyme (ACE) inhibitors </e2> , anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants,  <e1> benzodiazepines </e1> ,  <e2> beta blockers </e2> , calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics,  <e1> H2 antagonists </e1> ,  <e2> HMG-CoA reductase inhibitors </e2> , prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Compounds that have been tested in man include  <e1> antipyrine </e1> , digoxin,  <e2> propranolol </e2> , theophylline, and warfarin and no clinically meaningful interactions were found.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen,  <e1> acetylsalicylic acid </e1> , a-blockers,  <e2> analgesics </e2> , angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers,  <e1> analgesics </e1> , angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines,  <e2> beta blockers </e2> , calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates,  <e1> diuretics </e1> , H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as  <e2> NSAIDs </e2> ), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates,  <e1> diuretics </e1> , H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and  <e2> quinolone anti-infectives </e2>  without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers,  <e1> analgesics </e1> , angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac  <e2> nitrates </e2> , diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen,  <e1> acetylsalicylic acid </e1> , a-blockers, analgesics,  <e2> angiotensin-converting enzyme (ACE) inhibitors </e2> , anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Compounds that have been tested in man include  <e1> antipyrine </e1> ,  <e2> digoxin </e2> , propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers,  <e1> calcium-channel blockers </e1> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as  <e2> NSAIDs </e2> ), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists,  <e1> HMG-CoA reductase inhibitors </e1> , prostaglandin synthetase inhibitors (also referred to as  <e2> NSAIDs </e2> ), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants,  <e1> benzodiazepines </e1> , beta blockers, calcium-channel blockers, cardiac nitrates,  <e2> diuretics </e2> , H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists,  <e1> HMG-CoA reductase inhibitors </e1> ,  <e2> prostaglandin synthetase inhibitors </e2>  (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines,  <e1> beta blockers </e1> , calcium-channel blockers, cardiac nitrates,  <e2> diuretics </e2> , H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen,  <e1> acetylsalicylic acid </e1> , a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and  <e2> quinolone anti-infectives </e2>  without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines,  <e1> beta blockers </e1> , calcium-channel blockers, cardiac nitrates, diuretics,  <e2> H2 antagonists </e2> , HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers,  <e1> calcium-channel blockers </e1> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and  <e2> quinolone anti-infectives </e2>  without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac  <e1> nitrates </e1> , diuretics,  <e2> H2 antagonists </e2> , HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines,  <e1> beta blockers </e1> , calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors,  <e2> prostaglandin synthetase inhibitors </e2>  (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	In a study involving healthy subjects receiving  <e1> TAMBOCOR </e1>  and propranolol concurrently, plasma flecainide levels were increased about 20% and  <e2> propranolol </e2>  levels were increased about 30% compared to control values.
false	In  <e1> TAMBOCOR </e1>  clinical trials, patients who were receiving  <e2> beta blockers </e2>  concurrently did not experience an increased incidence of side effects.
false	In a study involving healthy subjects receiving TAMBOCOR and  <e1> propranolol </e1>  concurrently, plasma  <e2> flecainide </e2>  levels were increased about 20% and propranolol levels were increased about 30% compared to control values.
mechanism	Drugs that inhibit cytochrome P450IID6, such as  <e1> quinidine </e1>  , might increase the plasma concentrations of  <e2> flecainide </e2>  in patients that are on chronic flecainide therapy;
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers,  <e1> analgesics </e1> , angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers,  <e2> calcium-channel blockers </e2> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics,  <e1> angiotensin-converting enzyme (ACE) inhibitors </e1> , anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates,  <e2> diuretics </e2> , H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	When amiodarone is added to  <e1> flecainide </e1>  therapy, plasma flecainide levels may increase two-fold or more in some patients, if  <e2> flecainide </e2>  dosage is not reduced.
false	Limited data in patients receiving known enzyme inducers (  <e1> phenytoin </e1> , phenobarbital,  <e2> carbamazepine </e2>  ) indicate only a 30% increase in the rate of flecainide elimination.
false	There has been little experience with the coadministration of  <e1> TAMBOCOR </e1>  and either  <e2> disopyramide </e2>  or verapamil.
false	Compounds that have been tested in man include antipyrine, digoxin,  <e1> propranolol </e1> ,  <e2> theophylline </e2> , and warfarin and no clinically meaningful interactions were found.
mechanism	Limited data in patients receiving known enzyme inducers (  <e1> phenytoin </e1> , phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of  <e2> flecainide </e2>  elimination.
false	In a study involving healthy subjects receiving TAMBOCOR and  <e1> propranolol </e1>  concurrently, plasma flecainide levels were increased about 20% and  <e2> propranolol </e2>  levels were increased about 30% compared to control values.
false	When  <e1> amiodarone </e1>  is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if  <e2> flecainide </e2>  dosage is not reduced.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with  <e1> acetaminophen </e1> , acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants,  <e2> benzodiazepines </e2> , beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen,  <e1> acetylsalicylic acid </e1> , a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers,  <e2> calcium-channel blockers </e2> , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
false	 <e1> Cytosine arabinoside </e1> , a  <e2> cytostatic agent </e2> , has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.
false	Observe the patient for possible diminished effect of  <e1> steroid </e1>  and increase the  <e2> steroid </e2>  dosage accordingly.
false	Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs,  <e1> ethacrynic acid </e1>  and  <e2> furosemide </e2> ) enhanced hypokalemia.
false	 <e1> Anabolic steroids </e1>  (particularly C-17 alkylated androgens such as oxymetholone,  <e2> methandrostenolone </e2> , norethandrolone, and similar compounds) enhanced tendency toward edema.
mechanism	Barbiturates,  <e1> phenytoin </e1> , or rifampin increased metabolic clearance of  <e2> fludrocortisone acetate </e2>  because of the induction of hepatic enzymes.
false	Amphotericin B or  <e1> potassium-depleting diuretics </e1>  (benzothiadiazines and related drugs, ethacrynic acid and  <e2> furosemide </e2> ) enhanced hypokalemia.
false	Anabolic steroids (particularly C-17 alkylated  <e1> androgens </e1>  such as oxymetholone,  <e2> methandrostenolone </e2> , norethandrolone, and similar compounds) enhanced tendency toward edema.
false	 <e1> Amphotericin B </e1>  or potassium-depleting diuretics ( <e2> benzothiadiazines </e2>  and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.
false	An adequate period of observation must be provided for any patient in whom either  <e1> long-acting benzodiazepines </e1>  (such as diazepam) or large doses of  <e2> short-acting benzodiazepines </e2>  (such as  10 mg of midazolam) have been used.
false	however, no deleterious interactions were seen when  <e1> ROMAZICON </e1>  was administered after  <e2> narcotics </e2> , inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.
false	An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam) or large doses of  <e1> short-acting benzodiazepines </e1>  (such as  10 mg of  <e2> midazolam </e2> ) have been used.
false	Because of the increased risk of adverse reactions in patients who have been taking  <e1> benzodiazepines </e1>  on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and  <e2> sedative </e2>  use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
effect	Particular caution is necessary when using  <e1> ROMAZICON </e1>  in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially  <e2> cyclic antidepressants </e2> ) may emerge with the reversal of the benzodiazepine effect by flumazenil.
false	An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as  <e1> diazepam </e1> ) or large doses of short-acting benzodiazepines (such as  10 mg of  <e2> midazolam </e2> ) have been used.
false	The pharmacokinetics of  <e1> benzodiazepines </e1>  are unaltered in the presence of  <e2> flumazenil </e2>  and vice versa.
false	Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine,  <e1> alcohol </e1>  and  <e2> sedative </e2>  use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
false	Because of the increased risk of adverse reactions in patients who have been taking  <e1> benzodiazepines </e1>  on a regular basis, it is particularly important that physicians query patients or their guardians carefully about  <e2> benzodiazepine </e2> , alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
false	however, no deleterious interactions were seen when ROMAZICON was administered after  <e1> narcotics </e1> , inhalational  <e2> anesthetics </e2> , muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.
false	Tell your doctor if you are taking any of the following drugs:  <e1> blood thinner </e1> s (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa  <e2> lithium </e2>  muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines  <e1> carbamazepine </e1>  (Tegretol) cimetidine (Tagamet) estrogens fluoxetine ( <e2> Prozac </e2> ) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine ( <e1> Tegretol </e1> ) cimetidine ( <e2> Tagamet </e2> ) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet)  <e1> estrogens </e1>  fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole ( <e2> Nizoral </e2> ) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol)  <e1> cimetidine </e1>  (Tagamet)  <e2> estrogens </e2>  fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine ( <e1> Tegretol </e1> ) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e2> Sporanox </e2> ) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol  <e1> antihistamines </e1>  carbamazepine (Tegretol) cimetidine (Tagamet) estrogens  <e2> fluoxetine </e2>  (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole ( <e1> Nizoral </e1> )  <e2> levodopa </e2>  lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine ( <e1> Prozac </e1> ) intraconazole ( <e2> Sporanox </e2> ) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs:  <e1> blood thinner </e1> s (Coumadin) other  <e2> antidepressants </e2>  metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other  <e1> antidepressants </e1>  metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e2> Sporanox </e2> ) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral)  <e1> levodopa </e1>  lithium  <e2> muscle relaxants </e2>  birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e1> Sporanox </e1> ) ketoconazole (Nizoral) levodopa lithium  <e2> muscle relaxants </e2>  birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants  <e1> metoprolol </e1>  antihistamines carbamazepine (Tegretol)  <e2> cimetidine </e2>  (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa  <e1> lithium </e1>   <e2> muscle relaxants </e2>  birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other  <e1> antidepressants </e1>  metoprolol antihistamines carbamazepine (Tegretol)  <e2> cimetidine </e2>  (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines  <e1> carbamazepine </e1>  (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole ( <e2> Nizoral </e2> ) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines  <e1> carbamazepine </e1>  (Tegretol) cimetidine (Tagamet)  <e2> estrogens </e2>  fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants  <e1> metoprolol </e1>   <e2> antihistamines </e2>  carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other  <e1> antidepressants </e1>  metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium  <e2> muscle relaxants </e2>  birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol)  <e1> cimetidine </e1>  (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa  <e2> lithium </e2>  muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol)  <e1> cimetidine </e1>  (Tagamet) estrogens fluoxetine ( <e2> Prozac </e2> ) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine ( <e1> Tagamet </e1> ) estrogens fluoxetine (Prozac) intraconazole (Sporanox)  <e2> ketoconazole </e2>  (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners ( <e1> Coumadin </e1> ) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa  <e2> lithium </e2>  muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol  <e1> antihistamines </e1>  carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium  <e2> muscle relaxants </e2>  birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine ( <e1> Tegretol </e1> ) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium  <e2> muscle relaxants </e2>  birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol)  <e1> cimetidine </e1>  (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox)  <e2> ketoconazole </e2>  (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines  <e1> carbamazepine </e1>  (Tegretol) cimetidine (Tagamet) estrogens  <e2> fluoxetine </e2>  (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners ( <e1> Coumadin </e1> ) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens  <e2> fluoxetine </e2>  (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet)  <e1> estrogens </e1>  fluoxetine (Prozac) intraconazole ( <e2> Sporanox </e2> ) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet)  <e1> estrogens </e1>  fluoxetine (Prozac) intraconazole (Sporanox)  <e2> ketoconazole </e2>  (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine ( <e1> Prozac </e1> ) intraconazole (Sporanox) ketoconazole ( <e2> Nizoral </e2> ) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol  <e1> antihistamines </e1>   <e2> carbamazepine </e2>  (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine ( <e1> Tagamet </e1> ) estrogens fluoxetine ( <e2> Prozac </e2> ) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet)  <e1> estrogens </e1>  fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral)  <e2> levodopa </e2>  lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Caution should be exercised when taking this medicine certain  <e1> antibiotics </e1> , such as erythromycin,  <e2> clarithromycin </e2> , or azithromycin.
false	Concurrent administration of oxyphenbutazone and  <e1> androgens </e1>  may result in elevated serum levels of  <e2> oxyphenbutazone </e2> .
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants  <e1> metoprolol </e1>  antihistamines carbamazepine ( <e2> Tegretol </e2> ) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e1> Sporanox </e1> ) ketoconazole (Nizoral) levodopa  <e2> lithium </e2>  muscle relaxants birth control pills sleeping pills thyroid medications
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet)  <e1> estrogens </e1>  fluoxetine ( <e2> Prozac </e2> ) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Drug Interactions: Flupenthixol may interact with some drugs, like  <e1> Monoamine oxidase inhibitors </e1>  (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of  <e2> Tricyclic antidepressants </e2> 
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol  <e1> antihistamines </e1>  carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole ( <e2> Sporanox </e2> ) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Drug Interactions: Flupenthixol may interact with some drugs, like  <e1> Monoamine oxidase inhibitors </e1>  (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants:  <e2> Flupenthixol </e2>  increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors ( <e1> MAOI </e1> ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of  <e2> Tricyclic antidepressants </e2> 
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors ( <e1> MAOI </e1> ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and  <e2> Ethanol </e2>  cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol:  <e1> Flupenthixol </e1>  and Ethanol cause additive CNS depression -  <e2> Tricyclic antidepressants </e2> : Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions:  <e1> Flupenthixol </e1>  may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants:  <e2> Flupenthixol </e2>  increases the effect of Tricyclic antidepressants
false	Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other  <e1> antidepressants </e1>  metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox)  <e2> ketoconazole </e2>  (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI):  <e1> MAOI </e1>  could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine -  <e2> Ethanol </e2> : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression -  <e1> Tricyclic antidepressants </e1> :  <e2> Flupenthixol </e2>  increases the effect of Tricyclic antidepressants
false	Caution should be exercised when taking this medicine certain  <e1> antibiotics </e1> , such as  <e2> erythromycin </e2> , clarithromycin, or azithromycin.
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics -  <e1> Arecoline </e1>  - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants:  <e2> Flupenthixol </e2>  increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine -  <e1> Ethanol </e1> : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants:  <e2> Flupenthixol </e2>  increases the effect of Tricyclic antidepressants
effect	Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI):  <e1> MAOI </e1>  could theoretically affect  <e2> flupenthixol </e2>  pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Drug Interactions: Flupenthixol may interact with some drugs, like  <e1> Monoamine oxidase inhibitors </e1>  ( <e2> MAOI </e2> ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
false	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving  <e1> glyburide </e1>  (n=4),  <e2> metformin </e2>  (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).
false	Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of  <e1> propranolol </e1>  but not  <e2> atenolol </e2> .
false	Oral  <e1> Hypoglycemic Agents </e1> : In one study,  <e2> flurbiprofen </e2>  was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).
false	 <e1> Cimetidine </e1> , Ranitidine: In normal volunteers (n=9), pretreatment with  <e2> cimetidine </e2>  or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
false	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving  <e1> glyburide </e1>  (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with  <e2> phenformin </e2>  (n=6).
effect	Other  <e1> nonsteroidal anti-inflammatory drugs </e1>  that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with  <e2> potassium-sparing diuretics </e2> .
false	Drug Interactions: Flupenthixol may interact with some drugs, like  <e1> Monoamine oxidase inhibitors </e1>  (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression -  <e2> Tricyclic antidepressants </e2> : Flupenthixol increases the effect of Tricyclic antidepressants
false	 <e1> Digoxin </e1> : Studies of concomitant administration of flurbiprofen and  <e2> digoxin </e2>  to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.
effect	Diuretics: Studies in normal volunteers have shown that flurbiprofen like other  <e1> nonsteroidal anti-inflammatory drugs </e1> , can interfere with the effects of  <e2> furosemide </e2> .
false	 <e1> Cimetidine </e1> , Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of  <e2> flurbiprofen </e2>  resulted with cimetidine.
false	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving  <e1> glyburide </e1>  (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or  <e2> glyburide </e2>  with phenformin (n=6).
false	 <e1> Beta-adrenergic Blocking Agents </e1> : The effect of  <e2> flurbiprofen </e2>  on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).
false	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2)  <e1> chlorpropamide </e1>  with phenformin (n= 3) or glyburide with  <e2> phenformin </e2>  (n=6).
false	Oral Hypoglycemic Agents: In one study,  <e1> flurbiprofen </e1>  was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with  <e2> phenformin </e2>  (n=6).
false	Cimetidine,  <e1> Ranitidine </e1> : In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of  <e2> flurbiprofen </e2>  resulted with cimetidine.
false	Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2)  <e1> chlorpropamide </e1>  with  <e2> phenformin </e2>  (n= 3) or glyburide with phenformin (n=6).
false	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with  <e1> cimetidine </e1>  or  <e2> ranitidine </e2>  did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
false	Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with  <e1> antacid </e1>  suspension yielded similar serum  <e2> flurbiprofen </e2>  time profiles in young subjects (n=12).
false	Antacids: Administration of  <e1> flurbiprofen </e1>  to volunteers under fasting conditions, or with  <e2> antacid </e2>  suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).
false	 <e1> Cimetidine </e1> , Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect  <e2> flurbiprofen </e2>  pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
false	Oral  <e1> Hypoglycemic Agents </e1> : In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or  <e2> glyburide </e2>  with phenformin (n=6).
advise	Patients receiving  <e1> flurbiprofen </e1>  and  <e2> furosemide </e2>  or other diuretics should be observed closely to determine if the desired effect is obtained.
false	 <e1> Aspirin </e1> : Concurrent administration of aspirin and  <e2> flurbiprofen </e2>  resulted in 50% lower serum flurbiprofen concentrations.
false	Therefore, close monitoring of prothrombin time is recommended and adjustment of the  <e1> anticoagulant </e1>  dose may be necessary when EULEXIN Capsules are administered concomitantly with  <e2> warfarin </e2> .
false	Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with  <e1> thiazide diuretics </e1>  in some studies and with  <e2> potassium-sparing diuretics </e2> .
false	 <e1> Anticoagulants </e1> : Flurbiprofen like other  <e2> nonsteroidal anti-inflammatory drugs </e2> , has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
false	Alprazolam: When fluvoxamine maleate (100 mg qd) and  <e1> alprazolam </e1>  (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of  <e2> alprazolam </e2>  were approximately twice those observed when alprazolam was administered alone;
false	Consequently, it is recommended that fluvoxamine not be used in combination with either  <e1> terbinafine </e1> ,  <e2> astemizole </e2> , or cisapride.
false	Increased plasma concentrations of terfenadine,  <e1> astemizole </e1> , and  <e2> cisapride </e2>  cause QT prolongation and have been associated with torsades de pointes-type ventricular tachycardia, sometimes fatal.
false	In patients receiving another serotonin reuptake inhibitor drug in combination with  <e1> monoamine oxidase inhibitors </e1>  ( <e2> MAOI </e2> ), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
false	Warfarin: When  <e1> fluvoxamine maleate </e1>  (50 mg tid) was administered concomitantly with warfarin for two weeks,  <e2> warfarin </e2>  plasma concentrations increased by 98% and prothrombin times were prolonged.
effect	Moreover, as noted with  <e1> alprazolam </e1> , the effect of  <e2> fluvoxamine </e2>  may even be more pronounced when it is administered at higher doses.
false	Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with  <e1> warfarin </e1>  for two weeks,  <e2> warfarin </e2>  plasma concentrations increased by 98% and prothrombin times were prolonged.
false	Therefore, close monitoring of prothrombin time is recommended and adjustment of the  <e1> anticoagulant </e1>  dose may be necessary when  <e2> EULEXIN </e2>  Capsules are administered concomitantly with warfarin.
false	The clearance of  <e1> benzodiazepines </e1>  metabolized by glucuronidation (e. g., lorazepam, oxazepam, temazepam) is unlikely to be affected by  <e2> fluvoxamine </e2> .
false	 <e1> Alprazolam </e1> : When  <e2> fluvoxamine maleate </e2>  (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
false	 <e1> Warfarin </e1> : When  <e2> fluvoxamine maleate </e2>  (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
advise	Evidence supporting the conclusion that it is inadvisable to co-administer  <e1> fluvoxamine </e1>  and  <e2> diazepam </e2>  is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.
false	The clearance of  <e1> benzodiazepines </e1>  metabolized by glucuronidation (e. g., lorazepam,  <e2> oxazepam </e2> , temazepam) is unlikely to be affected by fluvoxamine.
false	This interaction, which has not been investigated using higher doses of  <e1> fluvoxamine </e1> , may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial  <e2> alprazolam </e2>  dosage should be at least halved and titration to the lowest effective dose is recommended.
false	This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since  <e1> fluvoxamine </e1>  exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial  <e2> alprazolam </e2>  dosage should be at least halved and titration to the lowest effective dose is recommended.
false	Other Potentially Important Drug Interactions:  <e1> Benzodiazepines </e1> :  <e2> Benzodiazepines </e2>  metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
advise	Thus patients receiving oral  <e1> anticoagulants </e1>  and  <e2> Fluvoxamine </e2>  Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.
mechanism	Other Potentially Important Drug Interactions: Benzodiazepines:  <e1> Benzodiazepines </e1>  metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by  <e2> fluvoxamine </e2> .
false	 <e1> Theophylline </e1> : The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of  <e2> Theophylline </e2>  (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.
mechanism	Alprazolam: When  <e1> fluvoxamine maleate </e1>  (100 mg qd) and  <e2> alprazolam </e2>  (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
advise	This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If  <e1> alprazolam </e1>  is co-administered with  <e2> Fluvoxamine </e2>  Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
false	Thus patients receiving oral  <e1> anticoagulants </e1>  and Fluvoxamine Tablets should have their prothrombin time monitored and their  <e2> anticoagulant </e2>  dose adjusted accordingly.
false	 <e1> Cimetidine </e1> ,  <e2> Ranitidine </e2> : In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
false	Other Potentially Important Drug Interactions: Benzodiazepines:  <e1> Benzodiazepines </e1>  metabolized by hepatic oxidation (e.g., alprazolam, midazolam,  <e2> triazolam </e2>  elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
false	Medications can interfere with folate utilization, including:  <e1> anticonvulsant medications </e1>  (such as phenytoin, and  <e2> primidone </e2> ) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including:  <e1> anticonvulsant medications </e1>  (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a  <e2> diuretic </e2> ) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and  <e1> primidone </e1> ) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic)  <e2> Methotrexate </e2>  There has been concern about the interaction between vitamin B12 and folic acid.
false	Other Potentially Important Drug Interactions: Benzodiazepines:  <e1> Benzodiazepines </e1>  metabolized by hepatic oxidation (e.g., alprazolam,  <e2> midazolam </e2> , triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
false	Medications can interfere with folate utilization, including:  <e1> anticonvulsant medications </e1>  (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic)  <e2> Methotrexate </e2>  There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as  <e1> phenytoin </e1> , and  <e2> primidone </e2> ) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes)  <e1> sulfasalazine </e1>  (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between  <e2> vitamin B12 </e2>  and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and  <e1> primidone </e1> ) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis)  <e2> triamterene </e2>  (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
false	Other Potentially Important Drug Interactions:  <e1> Benzodiazepines </e1> : Benzodiazepines metabolized by hepatic oxidation (e.g.,  <e2> alprazolam </e2> , midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
false	Therefore, intake of supplemental  <e1> folic acid </e1>  should not exceed 1000 micrograms ( g, sometimes mcg) per day to prevent  <e2> folic acid </e2>  from masking symptoms of vitamin B12 deficiency.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes)  <e1> sulfasalazine </e1>  (used to control inflammation associated with Crohns disease and ulcerative colitis)  <e2> triamterene </e2>  (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as  <e1> phenytoin </e1> , and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and  <e2> folic acid </e2> .
false	Consequently, it is recommended that fluvoxamine not be used in combination with either  <e1> terbinafine </e1> , astemizole, or  <e2> cisapride </e2> .
false	Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and  <e1> primidone </e1> ) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and  <e2> folic acid </e2> .
mechanism	Reciprocal interactions may occur with concomitant use of  <e1> Antizol </e1>  and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin,  <e2> carbamazepine </e2> , cimetidine, ketoconazole), though this has not been studied
false	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g.,  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , cimetidine, ketoconazole), though this has not been studied
false	Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine,  <e1> cimetidine </e1> ,  <e2> ketoconazole </e2> ), though this has not been studied
false	In clinical studies performed with Fondaparinux, the concomitant use of oral  <e1> anticoagulants </e1>  (warfarin),  <e2> platelet inhibitors </e2>  (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	In addition, Fondaparinux neither influenced the pharmacodynamics of  <e1> warfarin </e1> , acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of  <e2> digoxin </e2>  at steady state.
false	In clinical studies performed with  <e1> Fondaparinux </e1> , the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of  <e2> fondaparinux sodium </e2> .
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin),  <e1> platelet inhibitors </e1>  ( <e2> acetylsalicylic acid </e2> ), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	In addition,  <e1> Fondaparinux </e1>  neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid,  <e2> piroxicam </e2> , and digoxin, nor the pharmacokinetics of digoxin at steady state.
false	In addition,  <e1> Fondaparinux </e1>  neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of  <e2> digoxin </e2>  at steady state.
false	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid,  <e1> piroxicam </e1> , and  <e2> digoxin </e2> , nor the pharmacokinetics of digoxin at steady state.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs ( <e1> piroxicam </e1> ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of  <e2> fondaparinux sodium </e2> .
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants ( <e1> warfarin </e1> ), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and  <e2> digoxin </e2>  did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	In clinical studies performed with  <e1> Fondaparinux </e1> , the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs ( <e2> piroxicam </e2> ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	In clinical studies performed with  <e1> Fondaparinux </e1> , the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid),  <e2> NSAIDs </e2>  (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	 <e1> Monoamine Oxidase Inhibitors </e1>  and Tricyclic Antidepressants:  <e2> FORADIL </e2>  should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
false	Other Drugs:Drugs such as  <e1> quinidine </e1> ,  <e2> disopyramide </e2> , procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
false	Other Drugs:Drugs such as quinidine,  <e1> disopyramide </e1> ,  <e2> procainamide </e2> , phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
false	Corticosteroids, Methylxanthines and  <e1> Diuretics </e1> : Concomitant treatment with xanthine derivatives, steroids, or  <e2> diuretics </e2>  may potentiate a possible hypokalemic effect of  beta2-agonists.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants ( <e1> warfarin </e1> ), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of  <e2> fondaparinux sodium </e2> .
false	 <e1> Monoamine Oxidase Inhibitors </e1>  and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of  <e2> formoterol </e2>  on the cardiovascular system may be potentiated by these agents.
false	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with  <e1> monoamine oxidase inhibitors </e1>  or  <e2> tricyclic antidepressants </e2>  because the action of formoterol on the cardiovascular system may be potentiated by these agents.
false	 <e1> Corticosteroids </e1> , Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives,  <e2> steroids </e2> , or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.
false	 <e1> Corticosteroids </e1> , Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of   <e2> beta2-agonists. </e2> 
false	Other Drugs:Drugs such as  <e1> quinidine </e1> , disopyramide, procainamide, phenothiazines, antihistamines, and  <e2> tricyclic antidepressants </e2>  may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
false	In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors ( <e1> acetylsalicylic acid </e1> ), NSAIDs ( <e2> piroxicam </e2> ), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
false	Acute symptoms should be treated with a short-acting, inhaled   <e1> beta2-agonist </e1>  such as  <e2> salbutamol </e2>  (the physician should provide the patient with such medication and instruct the patient in how it should be used).
false	In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin,  <e1> acetylsalicylic acid </e1> , piroxicam, and digoxin, nor the pharmacokinetics of  <e2> digoxin </e2>  at steady state.
effect	Concomitant administration of other  <e1> sympathomimetic agents </e1>  may potentiate the undesirable effects of  <e2> FORADIL </e2> .
false	 <e1> Ganciclovir </e1> : The pharmacokinetics of  <e2> foscarnet </e2>  and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.
false	Other Drugs:Drugs such as  <e1> quinidine </e1> , disopyramide,  <e2> procainamide </e2> , phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
false	Other Drugs:Drugs such as quinidine, disopyramide,  <e1> procainamide </e1> ,  <e2> phenothiazines </e2> , antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
advise	Because of foscarnets tendency to cause renal impairment, the use of  <e1> FOSCAVIR </e1>  should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides,  <e2> amphotericin B </e2>  and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
false	Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides,  <e1> amphotericin B </e1>  and intravenous  <e2> pentamidine </e2>  unless the potential benefits outweigh the risks to the patient.
false	Because of  <e1> foscarnet </e1> s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides,  <e2> amphotericin B </e2>  and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
false	Metoclopramide: When coadministered with  <e1> MONUROL </e1> , metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of  <e2> fosfomycin </e2> .
false	Cimetidine:  <e1> Cimetidine </e1>  does not affect the pharmacokinetics of fosfomycin when coadministered with  <e2> MONUROL </e2> .
false	Because of  <e1> foscarnet </e1> s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous  <e2> pentamidine </e2>  unless the potential benefits outweigh the risks to the patient.
false	In a study with concomitant administration of aspirin and  <e1> fosinopril sodium </e1> , the bioavailability of unbound  <e2> fosinoprilat </e2>  was not altered.
mechanism	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide,  <e1> magnesium hydroxide </e1> , and simethicone) with  <e2> fosinopril </e2>  reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with  <e1> fosinopril </e1>  administered alone, suggesting that  <e2> antacids </e2>  may impair absorption of fosinopril.
false	 <e1> Antacids </e1> : In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with  <e2> fosinopril </e2>  reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
false	In separate single or multiple dose pharmacokinetic interaction studies with  <e1> chlorthalidone </e1> ,  <e2> nifedipine </e2> , propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	Cimetidine: Cimetidine does not affect the pharmacokinetics of  <e1> fosfomycin </e1>  when coadministered with  <e2> MONUROL </e2> .
false	In separate single or multiple dose pharmacokinetic interaction studies with  <e1> chlorthalidone </e1> , nifedipine, propanolol,  <e2> hydrochlorothiazide </e2> , cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide,  <e1> propantheline </e1> , digoxin, and  <e2> warfarin </e2> , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	Antacids: In a clinical pharmacology study, coadministration of an  <e1> antacid </e1>  (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that  <e2> antacids </e2>  may impair absorption of fosinopril.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and  <e1> simethicone </e1> ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of  <e2> fosinopril </e2> .
false	 <e1> Diuretics </e1> : Patients on  <e2> diuretics </e2> , especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.
false	Antacids: In a clinical pharmacology study, coadministration of an  <e1> antacid </e1>  (aluminum hydroxide, magnesium hydroxide, and  <e2> simethicone </e2> ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
false	Antacids: In a clinical pharmacology study, coadministration of an  <e1> antacid </e1>  (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of  <e2> fosinoprilat </e2>  as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of  <e1> fosinoprilat </e1>  as compared with fosinopril administered alone, suggesting that antacids may impair absorption of  <e2> fosinopril </e2> .
false	Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum  <e1> digoxin </e1>  levels with the Digi- Tab  RIA Kit for  <e2> Digoxin </e2> .
false	Antacids: In a clinical pharmacology study, coadministration of an  <e1> antacid </e1>  (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with  <e2> fosinopril </e2>  administered alone, suggesting that antacids may impair absorption of fosinopril.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with  <e1> fosinopril </e1>  reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of  <e2> fosinopril </e2> .
false	Lithium: Increased serum  <e1> lithium </e1>  levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with  <e2> lithium </e2> .
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine,  <e1> propanolol </e1> , hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of  <e2> fosinoprilat </e2>  was not altered by coadministration of fosinopril with any one of these drugs.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide,  <e1> cimetidine </e1> , metoclopramide,  <e2> propantheline </e2> , digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with  <e1> fosinopril </e1>  reduced serum levels and urinary excretion of fosinoprilat as compared with  <e2> fosinopril </e2>  administered alone, suggesting that antacids may impair absorption of fosinopril.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine,  <e1> propanolol </e1> , hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of  <e2> fosinopril </e2>  with any one of these drugs.
false	Cimetidine:  <e1> Cimetidine </e1>  does not affect the pharmacokinetics of  <e2> fosfomycin </e2>  when coadministered with MONUROL.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine,  <e1> propanolol </e1> , hydrochlorothiazide, cimetidine,  <e2> metoclopramide </e2> , propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	Potassium Supplements and  <e1> Potassium-Sparing Diuretics </e1> :  <e2> Fosinopril sodium </e2>  can attenuate potassium loss caused by thiazide diuretics.
false	 <e1> Antacids </e1> : In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of  <e2> fosinopril </e2> .
false	In separate single or multiple dose pharmacokinetic interaction studies with  <e1> chlorthalidone </e1> , nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and  <e2> warfarin </e2> , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
effect	Potassium Supplements and Potassium-Sparing Diuretics:  <e1> Fosinopril sodium </e1>  can attenuate potassium loss caused by  <e2> thiazide diuretics </e2> .
effect	- Drugs whose efficacy is impaired by  <e1> phenytoin </e1>  include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin,  <e2> quinidine </e2> , theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide,  <e1> fluoxetine </e1> , H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines,  <e2> phenylbutazone </e2> , salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include:  <e1> anticoagulants </e1> , corticosteroids,  <e2> coumarin </e2> , digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	The pharmacokinetics and protein binding of  <e1> fosphenytoin </e1> , phenytoin, and  <e2> diazepam </e2>  were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and  <e1> warfarin </e1> , the bioavailability of fosinoprilat was not altered by coadministration of  <e2> fosinopril </e2>  with any one of these drugs.
effect	- Drugs whose efficacy is impaired by  <e1> phenytoin </e1>  include:  <e2> anticoagulants </e2> , corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
effect	- Drugs whose efficacy is impaired by  <e1> phenytoin </e1>  include: anticoagulants, corticosteroids, coumarin,  <e2> digitoxin </e2> , doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides,  <e1> sulfonamides </e1> ,  <e2> tolbutamide </e2> , trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam,  <e2> dicumarol </e2> , disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e1> succinimides </e1> ,  <e2> sulfonamides </e2> , tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides,  <e2> sulfonamides </e2> , tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e1> chlordiazepoxide </e1> , cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides,  <e2> tolbutamide </e2> , trazodone
false	Antacids: In a clinical pharmacology study, coadministration of an antacid ( <e1> aluminum hydroxide </e1> , magnesium hydroxide, and  <e2> simethicone </e2> ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline,  <e1> estrogens </e1> , furosemide, oral contraceptives, rifampin, quinidine, theophylline,  <e2> vitamin D </e2> .
false	Drug/Laboratory Test Interaction  <e1> Fosinopril </e1>  may cause a false low measurement of serum  <e2> digoxin </e2>  levels with the Digi- Tab  RIA Kit for Digoxin.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam,  <e1> dicumarol </e1> , disulfiram,  <e2> estrogens </e2> , ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e1> chlordiazepoxide </e1> , cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids,  <e1> coumarin </e1> , digitoxin, doxycycline, estrogens, furosemide, oral contraceptives,  <e2> rifampin </e2> , quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine,  <e1> diazepam </e1> , dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides,  <e2> sulfonamides </e2> , tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants,  <e1> corticosteroids </e1> , coumarin, digitoxin, doxycycline, estrogens, furosemide, oral  <e2> contraceptives </e2> , rifampin, quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e1> chlordiazepoxide </e1> , cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone,  <e2> salicylates </e2> , succinimides, sulfonamides, tolbutamide, trazodone
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol,  <e2> disulfiram </e2> , estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol,  <e2> disulfiram </e2> , estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol,  <e1> disulfiram </e1> , estrogens,  <e2> ethosuximide </e2> , fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e1> ethosuximide </e1> , fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides,  <e2> tolbutamide </e2> , trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram,  <e1> estrogens </e1> , ethosuximide, fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists,  <e1> halothane </e1> , isoniazid, methylphenidate, phenothiazines,  <e2> phenylbutazone </e2> , salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline,  <e1> estrogens </e1> , furosemide, oral  <e2> contraceptives </e2> , rifampin, quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol,  <e2> chlordiazepoxide </e2> , cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e1> ethosuximide </e1> , fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate,  <e2> phenothiazines </e2> , phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e1> ethosuximide </e1> , fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides,  <e2> sulfonamides </e2> , tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids,  <e1> coumarin </e1> , digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin,  <e2> quinidine </e2> , theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e2> ethosuximide </e2> , fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	 <e1> Potassium-sparing diuretics </e1>  (spironolactone, amiloride, <e2> triamterene </e2> , and others) or potassium supplements can increase the risk of hyperkalemia.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e1> methylphenidate </e1> , phenothiazines, phenylbutazone,  <e2> salicylates </e2> , succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane,  <e1> isoniazid </e1> , methylphenidate, phenothiazines, phenylbutazone,  <e2> salicylates </e2> , succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide,  <e1> cimetidine </e1> , diazepam, dicumarol,  <e2> disulfiram </e2> , estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine,  <e1> diazepam </e1> , dicumarol, disulfiram, estrogens, ethosuximide,  <e2> fluoxetine </e2> , H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine,  <e1> propanolol </e1> , hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and  <e2> warfarin </e2> , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e2> succinimides </e2> , sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e1> chlordiazepoxide </e1> , cimetidine, diazepam,  <e2> dicumarol </e2> , disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	Lithium: Increased serum  <e1> lithium </e1>  levels and symptoms of  <e2> lithium </e2>  toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin,  <e1> digitoxin </e1> , doxycycline, estrogens,  <e2> furosemide </e2> , oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide,  <e1> fluoxetine </e1> , H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists,  <e2> halothane </e2> , isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e1> methylphenidate </e1> , phenothiazines, phenylbutazone, salicylates, succinimides,  <e2> sulfonamides </e2> , tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram,  <e2> estrogens </e2> , ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine,  <e1> diazepam </e1> , dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol,  <e1> disulfiram </e1> , estrogens, ethosuximide,  <e2> fluoxetine </e2> , H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane,  <e1> isoniazid </e1> , methylphenidate, phenothiazines,  <e2> phenylbutazone </e2> , salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants,  <e1> corticosteroids </e1> , coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine,  <e2> theophylline </e2> , vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine,  <e1> diazepam </e1> , dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone,  <e2> salicylates </e2> , succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e1> chlordiazepoxide </e1> , cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e2> succinimides </e2> , sulfonamides, tolbutamide, trazodone
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants,  <e1> corticosteroids </e1> , coumarin, digitoxin, doxycycline,  <e2> estrogens </e2> , furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	The pharmacokinetics and protein binding of  <e1> fosphenytoin </e1> , phenytoin, and diazepam were not altered when  <e2> diazepam </e2>  and Cerebyx were concurrently administered in single submaximal doses.
false	- Drugs that may either increase or decrease plasma phenytoin concentrations include:  <e1> phenobarbital </e1> , vaiproic acid, and  <e2> sodium valproate </e2> .
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline,  <e1> digoxin </e1> , and  <e2> warfarin </e2> , the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram,  <e2> estrogens </e2> , ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute  <e1> alcohol </e1>  intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and  <e1> diazepam </e1>  were not altered when diazepam and  <e2> Cerebyx </e2>  were concurrently administered in single submaximal doses.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam,  <e1> dicumarol </e1> , disulfiram, estrogens, ethosuximide,  <e2> fluoxetine </e2> , H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide,  <e1> fluoxetine </e1> , H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides,  <e2> tolbutamide </e2> , trazodone
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide,  <e1> fluoxetine </e1> , H2-antagonists,  <e2> halothane </e2> , isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine,  <e1> diazepam </e1> , dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e2> succinimides </e2> , sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide,  <e1> fluoxetine </e1> , H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e2> succinimides </e2> , sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane,  <e1> isoniazid </e1> , methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e2> succinimides </e2> , sulfonamides, tolbutamide, trazodone
mechanism	Antacids: In a clinical pharmacology study, coadministration of an antacid ( <e1> aluminum hydroxide </e1> , magnesium hydroxide, and simethicone) with  <e2> fosinopril </e2>  reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants,  <e1> corticosteroids </e1> , coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives,  <e2> rifampin </e2> , quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine,  <e1> diazepam </e1> , dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin,  <e1> digitoxin </e1> , doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline,  <e2> vitamin D </e2> .
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e2> chlordiazepoxide </e2> , cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e1> chlordiazepoxide </e1> , cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid,  <e2> methylphenidate </e2> , phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram,  <e2> estrogens </e2> , ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines,  <e1> phenylbutazone </e1> , salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin,  <e1> doxycycline </e1> , estrogens, furosemide, oral contraceptives, rifampin,  <e2> quinidine </e2> , theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens,  <e1> ethosuximide </e1> , fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
false	Due to a theoretical risk of a pharmacodynamic interaction, use of  <e1> ergotamine </e1> -containing or ergot-type medications (like dihydroergotamine or  <e2> methysergide </e2> ) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
false	- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral  <e1> contraceptives </e1> , rifampin, quinidine,  <e2> theophylline </e2> , vitamin D.
effect	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine,  <e1> sertraline </e1> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  <e2> 5-HT1 agonists </e2> .
false	Potassium-sparing diuretics (spironolactone,  <e1> amiloride </e1> ,triamterene, and others) or  <e2> potassium </e2>  supplements can increase the risk of hyperkalemia.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine,  <e1> H2-antagonists </e1> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates,  <e2> succinimides </e2> , sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam,  <e1> dicumarol </e1> , disulfiram, estrogens, ethosuximide, fluoxetine,  <e2> H2-antagonists </e2> , halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g., fluoxetine, fluvoxamine, paroxetine,  <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	The pharmacokinetics and protein binding of  <e1> fosphenytoin </e1> , phenytoin, and diazepam were not altered when diazepam and  <e2> Cerebyx </e2>  were concurrently administered in single submaximal doses.
false	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like  <e1> dihydroergotamine </e1>  or  <e2> methysergide </e2> ) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
false	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine,  <e1> paroxetine </e1> ,  <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
effect	- Drugs whose efficacy is impaired by  <e1> phenytoin </e1>  include: anticoagulants, corticosteroids,  <e2> coumarin </e2> , digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol,  <e1> chlordiazepoxide </e1> , cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide,  <e2> trazodone </e2> 
advise	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or  <e1> methysergide </e1> ) and  <e2> FROVA </e2>  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
false	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone,  <e1> nifedipine </e1> , propanolol, hydrochlorothiazide,  <e2> cimetidine </e2> , metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
mechanism	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma  <e1> phenytoin </e1>  concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam,  <e2> dicumarol </e2> , disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide,  <e1> cimetidine </e1> , diazepam,  <e2> dicumarol </e2> , disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	 <e1> Selective serotonin reuptake inhibitors </e1>  (SSRIs) (e.g., fluoxetine, fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e1> fluoxetine </e1> , fluvoxamine,  <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
false	- Drugs whose efficacy is impaired by phenytoin include:  <e1> anticoagulants </e1> , corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine,  <e2> theophylline </e2> , vitamin D.
false	The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake,  <e1> amiodarone </e1> , chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate,  <e2> phenothiazines </e2> , phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
false	Patients receiving high doses of  <e1> salicylates </e1>  concomitantly with furosemide, as in rheumatic disease, may experience  <e2> salicylate </e2>  toxicity at lower doses because of competitive renal excretory sites.
effect	 <e1> Furosemide </e1>  may add to or potentiate the therapeutic effect of other  <e2> antihypertensive drugs </e2> .
advise	Patients receiving both  <e1> indomethacin </e1>  and  <e2> furosemide </e2>  should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
false	Tablets Simultaneous administration of  <e1> sucralfate </e1>  and furosemide tablets may reduce the natriuretic and antihypertensive effects of  <e2> furosemide </e2> .
false	Patients receiving both  <e1> indomethacin </e1>  and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of  <e2> furosemide </e2>  is achieved.
effect	Patients receiving high doses of  <e1> salicylates </e1>  concomitantly with  <e2> furosemide </e2> , as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
false	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months,  <e1> gabapentin </e1>  had no effect on the steady-state trough plasma concentrations of phenytoin and  <e2> phenytoin </e2>  had no effect on gabapentin pharmacokinetics.
false	Carbamazepine: Steady-state trough plasma  <e1> carbamazepine </e1>  and  <e2> carbamazepine 10, 11 epoxide </e2>  concentrations were not affected by concomitant gabapentin (400 mg TID;
false	Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when  <e1> gabapentin </e1>  was added to other  <e2> antiepileptic drugs </e2> , the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein
false	Oral  <e1> Contraceptive </e1> : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of  <e2> norethindrone acetate </e2>  and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;
mechanism	The Cmax of  <e1> norethindrone </e1>  was 13% higher when it was coadministered with  <e2> gabapentin </e2> ;
false	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on  <e1> phenytoin </e1>  monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on  <e2> gabapentin </e2>  pharmacokinetics.
false	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and  <e1> ethinyl estradiol </e1>  following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of  <e2> ethinyl estradiol </e2>  were similar with and without coadministration of gabapentin (400 mg TID;
mechanism	This decrease in bioavailability was about 5% when  <e1> gabapentin </e1>  was administered 2 hours after  <e2> Maalox </e2> .
false	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  <e1> norethindrone </e1>  and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of  <e2> gabapentin </e2>  (400 mg TID;
false	Oral  <e1> Contraceptive </e1> : Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and  <e2> ethinyl estradiol </e2>  following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;
false	Morphine: A literature article reported that when a 60-mg controlled-release  <e1> morphine </e1>  capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to  <e2> gabapentin </e2>  administered without morphine.
false	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of  <e1> norethindrone acetate </e1>  and 50 mcg of  <e2> ethinyl estradiol </e2>  were similar with and without coadministration of gabapentin (400 mg TID;
false	Morphine: A literature article reported that when a 60-mg controlled-release  <e1> morphine </e1>  capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean  <e2> gabapentin </e2>  AUC increased by 44% compared to gabapentin administered without morphine.
false	Antacid ( <e1> Maalox </e1>  ): Maalox reduced the bioavailability of  <e2> gabapentin </e2>  (N=16) by about 20%.
false	 <e1> Morphine </e1>  pharmacokinetic parameter values were not affected by administration of  <e2> Neurontin </e2>   2 hours after morphine.
false	Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of  <e1> phenytoin </e1>  and  <e2> phenytoin </e2>  had no effect on gabapentin pharmacokinetics.
false	Carbamazepine: Steady-state trough plasma  <e1> carbamazepine </e1>  and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant  <e2> gabapentin </e2>  (400 mg TID;
false	 <e1> Phenytoin </e1> : In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months,  <e2> gabapentin </e2>  had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.
false	 <e1> Gabapentin </e1>  pharmacokinetic parameters without and with  <e2> probenecid </e2>  were comparable.
false	 <e1> Morphine </e1> : A literature article reported that when a 60-mg controlled-release  <e2> morphine </e2>  capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.
false	Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of  <e1> norethindrone </e1>  and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of  <e2> ethinyl estradiol </e2>  were similar with and without coadministration of gabapentin (400 mg TID;
false	 <e1> Naproxen </e1> : Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of  <e2> gabapentin </e2>  absorbed by 12% to 15%.
false	Morphine: A literature article reported that when a 60-mg controlled-release  <e1> morphine </e1>  capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without  <e2> morphine </e2> .
false	Antacid ( <e1> Maalox </e1>  ):  <e2> Maalox </e2>  reduced the bioavailability of gabapentin (N=16) by about 20%.
false	Valproic Acid: The mean steady-state trough serum  <e1> valproic acid </e1>  concentrations prior to and during concomitant  <e2> gabapentin </e2>  administration (400 mg TID;
false	Phase II clinical trial data, where  <e1> IRESSA </e1>  and  <e2> vinorelbine </e2>  have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.
mechanism	Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as  <e1> ranitidine </e1>  or cimetidine) may reduce plasma concentrations of  <e2> IRESSA </e2>  and therefore potentially may reduce efficacy.
false	Phase II clinical trial data, where IRESSA and  <e1> vinorelbine </e1>  have been used concomitantly, indicate that  <e2> IRESSA </e2>  may exacerbate the neutropenic effect of vinorelbine.
false	Phase II clinical trial data, where IRESSA and  <e1> vinorelbine </e1>  have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of  <e2> vinorelbine </e2> .
false	Magnesium- and/or aluminum-containing  <e1> antacids </e1> , products containing ferrous sulfate ( <e2> iron </e2> ), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
mechanism	Concomitant administration of  <e1> FACTIVE </e1>  and calcium carbonate,  <e2> cimetidine </e2> , omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Concomitant administration of FACTIVE and  <e1> calcium carbonate </e1> , cimetidine, omeprazole, or an estrogen/ <e2> progesterone </e2>  oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
mechanism	Concomitant administration of  <e1> FACTIVE </e1>  with  <e2> probenecid </e2>  resulted in a 45% increase in systemic exposure to gemifloxacin.
false	Concomitant administration of FACTIVE and calcium carbonate, cimetidine,  <e1> omeprazole </e1> , or an estrogen/progesterone oral  <e2> contraceptive </e2>  produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or  <e1> Videx </e1>  ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an  <e1> estrogen </e1> /progesterone oral contraceptive produced minor changes in the pharmacokinetics of  <e2> gemifloxacin </e2> , which were considered to be without clinical significance.
advise	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron),  <e1> multivitamin preparations </e1>  containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after  <e2> FACTIVE </e2> .
false	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate ( <e1> iron </e1> ), multivitamin preparations containing zinc or other metal cations, or  <e2> Videx </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Magnesium- and/or aluminum-containing  <e1> antacids </e1> , products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after  <e2> FACTIVE </e2> .
false	Magnesium- and/or aluminum-containing antacids, products containing  <e1> ferrous sulfate </e1>  (iron), multivitamin preparations containing zinc or other metal cations, or  <e2> Videx </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of  <e1> theophylline </e1> , digoxin or an  <e2> ethinylestradiol </e2> /levonorgestrol oral contraceptive product in healthy subjects.
false	Magnesium- and/or  <e1> aluminum </e1> -containing antacids, products containing  <e2> ferrous sulfate </e2>  (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	 <e1> Magnesium </e1> - and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or  <e2> Videx </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Administration of repeat doses of  <e1> FACTIVE </e1>  had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral  <e2> contraceptive product </e2>  in healthy subjects.
false	However, because some quinolones have been reported to enhance the anticoagulant effects of  <e1> warfarin </e1>  or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a  <e2> quinolone antimicrobial </e2>  is administered concomitantly with warfarin or its derivatives.
false	However, because some  <e1> quinolones </e1>  have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with  <e2> warfarin </e2>  or its derivatives.
advise	 <e1> Magnesium </e1> - and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after  <e2> FACTIVE </e2> .
false	 <e1> Magnesium </e1> - and/or aluminum-containing antacids, products containing ferrous sulfate (iron),  <e2> multivitamin preparations </e2>  containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Magnesium- and/or aluminum-containing  <e1> antacids </e1> , products containing ferrous sulfate (iron),  <e2> multivitamin preparations </e2>  containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron),  <e1> multivitamin preparations </e1>  containing  <e2> zinc </e2>  or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	Concomitant administration of FACTIVE and calcium carbonate,  <e1> cimetidine </e1> , omeprazole, or an estrogen/ <e2> progesterone </e2>  oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of  <e1> theophylline </e1> , digoxin or an ethinylestradiol/levonorgestrol oral  <e2> contraceptive product </e2>  in healthy subjects.
false	However, 10 patients who switched from therapy with  <e1> Interferon beta </e1>  to  <e2> COPAXONE </e2>   did not report any serious and unexpected adverse reactions thought to be related to treatment.
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound,  <e1> salicylates </e1> , sulfonamides, chloramphenicol,  <e2> probenecid </e2> , coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
effect	The hypoglycemic action of  <e1> sulfonylureas </e1>  may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol,  <e2> probenecid </e2> , coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin,  <e2> nicotinic acid </e2> , sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides,  <e1> chloramphenicol </e1> , probenecid, coumarins, monoamine oxidase inhibitors, and  <e2> beta adrenergic blocking agents </e2> .
false	These drugs include the  <e1> thiazides </e1>  and other diuretics,  <e2> corticosteroids </e2> , phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the  <e1> thiazides </e1>  and other  <e2> diuretics </e2> , corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phe-nothiazines, thyroid products, estrogens, oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products,  <e1> estrogens </e1> , oral contraceptives, phenytoin,  <e2> nicotinic acid </e2> , sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol,  <e1> probenecid </e1> ,  <e2> coumarins </e2> , monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
false	A possible interaction between  <e1> glyburide </e1>  and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of  <e2> glyburide </e2> .
false	Concomitant administration of FACTIVE and calcium carbonate, cimetidine,  <e1> omeprazole </e1> , or an  <e2> estrogen </e2> /progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
false	A possible interaction between  <e1> glyburide </e1>  and ciprofloxacin, a  <e2> fluoroquinolone antibiotic </e2> , has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates,  <e2> sulfonamides </e2> , chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives,  <e1> phenytoin </e1> ,  <e2> nicotinic acid </e2> , sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound, salicylates, sulfonamides,  <e2> chloramphenicol </e2> , probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
effect	The hypoglycemic action of  <e1> sulfonylureas </e1>  may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates,  <e2> sulfonamides </e2> , chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins,  <e1> monoamine oxidase inhibitors </e1> , and  <e2> beta adrenergic blocking agents </e2> .
false	- a phenothiazine such as chlorpromazine (Thorazine),  <e1> fluphenazine </e1>  (Prolixin,  <e2> Permitil </e2> ), prochlorperazine (Compazine), promethazine (Phenergan), and others;
false	- a phenothiazine such as chlorpromazine ( <e1> Thorazine </e1> ), fluphenazine (Prolixin,  <e2> Permitil </e2> ), prochlorperazine (Compazine), promethazine (Phenergan), and others;
false	- a nonsteroidal anti-inflammatory drug ( <e1> NSAID </e1> ) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren,  <e2> Cataflam </e2> ), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate ( <e1> Disalcid </e1> , others), choline salicylate (Arthropan), magnesium salicylate ( <e2> Magan </e2> ), or bismuth subsalicylate (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn,  <e2> Aleve </e2> );
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate ( <e1> Disalcid </e1> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate ( <e2> Pepto-Bismol </e2> );
advise	Before taking  <e1> glimepiride </e1> , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate ( <e2> Pepto-Bismol </e2> );
false	- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone ( <e1> Prelone </e1> ,  <e2> Pediapred </e2> , others), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as  <e1> ibuprofen </e1>  (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren,  <e1> Cataflam </e1> ), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin),  <e1> nabumetone </e1>  (Relafen), oxaprozin ( <e2> Daypro </e2> ), and naproxen (Anaprox, Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate ( <e1> Disalcid </e1> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or  <e2> bismuth subsalicylate </e2>  (Pepto-Bismol);
false	- a diuretic (water pill) such as hydrochlorothiazide ( <e1> HCTZ </e1> ,  <e2> Hydrodiuril </e2> ), chlorothiazide (Diuril), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine),  <e1> indomethacin </e1>  (Indocin),  <e2> nabumetone </e2>  (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate),  <e1> salsalate </e1>  (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate ( <e2> Pepto-Bismol </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail),  <e1> diclofenac </e1>  (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e1> Indocin </e1> ), nabumetone (Relafen), oxaprozin (Daypro), and  <e2> naproxen </e2>  (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen ( <e1> Orudis </e1> , Orudis KT, Oruvail), diclofenac (Voltaren,  <e2> Cataflam </e2> ), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> phenothiazine </e1>  such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil),  <e2> prochlorperazine </e2>  (Compazine), promethazine (Phenergan), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e2> etodolac </e2>  (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products,  <e1> estrogens </e1> , oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
false	- a diuretic (water pill) such as  <e1> hydrochlorothiazide </e1>  (HCTZ, Hydrodiuril), chlorothiazide ( <e2> Diuril </e2> ), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen ( <e1> Orudis </e1> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin,  <e1> Advil </e1> , Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as  <e1> chlorpromazine </e1>  ( <e2> Thorazine </e2> ), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;
false	- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine ( <e1> Parnate </e1> ), or  <e2> phenelzine </e2>  (Nardil);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as  <e1> ibuprofen </e1>  (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e2> etodolac </e2>  (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and  <e1> naproxen </e1>  (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	- a phenothiazine such as chlorpromazine ( <e1> Thorazine </e1> ), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine ( <e2> Phenergan </e2> ), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin,  <e1> Advil </e1> , Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail),  <e2> diclofenac </e2>  (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen ( <e1> Orudis </e1> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e2> oxaprozin </e2>  (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug ( <e1> NSAID </e1> ) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen ( <e2> Orudis </e2> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin,  <e1> Advil </e1> , Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and  <e1> naproxen </e1>  ( <e2> Anaprox </e2> , Naprosyn, Aleve);
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e1> oxaprozin </e1>  (Daypro), and  <e2> naproxen </e2>  (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> ,  <e2> Advil </e2> , Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine),  <e1> indomethacin </e1>  (Indocin), nabumetone (Relafen), oxaprozin ( <e2> Daypro </e2> ), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e2> oxaprozin </e2>  (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin,  <e1> Advil </e1> , Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac ( <e2> Lodine </e2> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac ( <e1> Lodine </e1> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and  <e2> naproxen </e2>  (Anaprox, Naprosyn, Aleve);
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra),  <e1> sulfisoxazole </e1>  (Gantrisin), or sulfasalazine ( <e2> Azulfidine </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin ( <e1> Daypro </e1> ), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e1> oxaprozin </e1>  (Daypro), and naproxen ( <e2> Anaprox </e2> , Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis,  <e1> Orudis KT </e1> ,  <e2> Oruvail </e2> ), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil,  <e2> Nuprin </e2> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate ( <e1> Arthropan </e1> ), magnesium salicylate ( <e2> Magan </e2> ), or bismuth subsalicylate (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e1> etodolac </e1>  (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen ( <e2> Anaprox </e2> , Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as  <e1> ibuprofen </e1>  (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac ( <e2> Lodine </e2> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin),  <e1> acebutolol </e1>  (Sectral), metoprolol ( <e2> Lopressor </e2> ), and others;
false	- a monoamine oxidase inhibitor (MAOI) such as  <e1> isocarboxazid </e1>  (Marplan), tranylcypromine ( <e2> Parnate </e2> ), or phenelzine (Nardil);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another  <e1> salicylate </e1>  such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others),  <e2> choline salicylate </e2>  (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( <e1> Marplan </e1> ), tranylcypromine (Parnate), or phenelzine ( <e2> Nardil </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren,  <e1> Cataflam </e1> ), etodolac (Lodine),  <e2> indomethacin </e2>  (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen ( <e1> Orudis </e1> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and  <e2> naproxen </e2>  (Anaprox, Naprosyn, Aleve);
false	The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1>  and other drugs that are highly protein bound,  <e2> salicylates </e2> , sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	Coadministration of gly-buride and  <e1> metformin </e1>  did not result in any changes in either  <e2> metformin </e2>  pharmacokinetics or pharmaco-dynamics.
false	- a phenothiazine such as  <e1> chlorpromazine </e1>  (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine ( <e2> Phenergan </e2> ), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others),  <e2> ketoprofen </e2>  (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e1> ketoprofen </e1>  (Orudis, Orudis KT, Oruvail),  <e2> diclofenac </e2>  (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a steroid medicine such as prednisone (Deltasone,  <e1> Orasone </e1> , others), methylprednisolone (Medrol, others), prednisolone ( <e2> Prelone </e2> , Pediapred, others), and others;
false	- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan),  <e1> tranylcypromine </e1>  (Parnate), or phenelzine ( <e2> Nardil </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen ( <e2> Anaprox </e2> , Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate ( <e1> Trilisate </e1> ), salsalate ( <e2> Disalcid </e2> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra),  <e1> sulfisoxazole </e1>  (Gantrisin), or  <e2> sulfasalazine </e2>  (Azulfidine);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis,  <e1> Orudis KT </e1> , Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e2> Indocin </e2> ), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> monoamine oxidase inhibitor </e1>  (MAOI) such as isocarboxazid ( <e2> Marplan </e2> ), tranylcypromine (Parnate), or phenelzine (Nardil);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin,  <e1> Advil </e1> , Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn,  <e2> Aleve </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin,  <e1> Advil </e1> , Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin),  <e2> nabumetone </e2>  (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another  <e1> salicylate </e1>  such as magnesium/choline salicylate ( <e2> Trilisate </e2> ), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e1> ketoprofen </e1>  (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e2> oxaprozin </e2>  (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail),  <e1> diclofenac </e1>  (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e2> oxaprozin </e2>  (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e1> Indocin </e1> ), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a  <e1> steroid medicine </e1>  such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others),  <e2> prednisolone </e2>  (Prelone, Pediapred, others), and others;
false	- a steroid medicine such as prednisone (Deltasone,  <e1> Orasone </e1> , others), methylprednisolone (Medrol, others),  <e2> prednisolone </e2>  (Prelone, Pediapred, others), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac ( <e1> Lodine </e1> ),  <e2> indomethacin </e2>  (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another  <e1> salicylate </e1>  such as magnesium/choline salicylate (Trilisate), salsalate ( <e2> Disalcid </e2> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e1> ketoprofen </e1>  (Orudis, Orudis KT, Oruvail), diclofenac ( <e2> Voltaren </e2> , Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim ( <e1> Bactrim </e1> , Septra),  <e2> sulfisoxazole </e2>  (Gantrisin), or sulfasalazine (Azulfidine);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as  <e1> ibuprofen </e1>  (Motrin, Advil, Nuprin, others), ketoprofen ( <e2> Orudis </e2> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as  <e1> ibuprofen </e1>  (Motrin, Advil,  <e2> Nuprin </e2> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac ( <e1> Voltaren </e1> , Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen ( <e2> Anaprox </e2> , Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT,  <e1> Oruvail </e1> ), diclofenac (Voltaren,  <e2> Cataflam </e2> ), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
advise	Before taking  <e1> glimepiride </e1> , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate ( <e2> Arthropan </e2> ), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another  <e1> salicylate </e1>  such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate ( <e2> Pepto-Bismol </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen ( <e1> Orudis </e1> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin),  <e2> nabumetone </e2>  (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as  <e1> chlorpromazine </e1>  (Thorazine),  <e2> fluphenazine </e2>  (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen ( <e1> Orudis </e1> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine),  <e2> indomethacin </e2>  (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as chlorpromazine ( <e1> Thorazine </e1> ), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine),  <e2> promethazine </e2>  (Phenergan), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e1> ketoprofen </e1>  (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren,  <e2> Cataflam </e2> ), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren,  <e1> Cataflam </e1> ), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and  <e2> naproxen </e2>  (Anaprox, Naprosyn, Aleve);
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or  <e1> sulfasalazine </e1>  ( <e2> Azulfidine </e2> );
false	- a diuretic (water pill) such as hydrochlorothiazide ( <e1> HCTZ </e1> , Hydrodiuril),  <e2> chlorothiazide </e2>  (Diuril), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as  <e1> ibuprofen </e1>  (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin ( <e2> Daypro </e2> ), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a beta-blocker such as propranolol ( <e1> Inderal </e1> ), atenolol ( <e2> Tenormin </e2> ), acebutolol (Sectral), metoprolol (Lopressor), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail),  <e1> diclofenac </e1>  (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn,  <e2> Aleve </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis,  <e1> Orudis KT </e1> , Oruvail), diclofenac ( <e2> Voltaren </e2> , Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug ( <e1> NSAID </e1> ) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e2> ketoprofen </e2>  (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis,  <e1> Orudis KT </e1> , Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and  <e2> naproxen </e2>  (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as chlorpromazine ( <e1> Thorazine </e1> ), fluphenazine (Prolixin, Permitil), prochlorperazine ( <e2> Compazine </e2> ), promethazine (Phenergan), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: -  <e1> aspirin </e1>  or another salicylate such as magnesium/choline salicylate ( <e2> Trilisate </e2> ), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug ( <e1> NSAID </e1> ) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac ( <e2> Lodine </e2> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e1> etodolac </e1>  ( <e2> Lodine </e2> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT,  <e1> Oruvail </e1> ), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e2> oxaprozin </e2>  (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a beta-blocker such as  <e1> propranolol </e1>  (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol ( <e2> Lopressor </e2> ), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen),  <e1> oxaprozin </e1>  (Daypro), and naproxen (Anaprox, Naprosyn,  <e2> Aleve </e2> );
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as  <e1> ibuprofen </e1>  (Motrin, Advil, Nuprin, others), ketoprofen (Orudis,  <e2> Orudis KT </e2> , Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate ( <e1> iron </e1> ), multivitamin preparations containing  <e2> zinc </e2>  or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
false	- a beta-blocker such as propranolol ( <e1> Inderal </e1> ), atenolol (Tenormin), acebutolol ( <e2> Sectral </e2> ), metoprolol (Lopressor), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis,  <e1> Orudis KT </e1> , Oruvail), diclofenac (Voltaren, Cataflam), etodolac ( <e2> Lodine </e2> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac ( <e1> Voltaren </e1> , Cataflam), etodolac (Lodine),  <e2> indomethacin </e2>  (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac ( <e2> Lodine </e2> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e1> Indocin </e1> ), nabumetone (Relafen), oxaprozin ( <e2> Daypro </e2> ), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a beta-blocker such as  <e1> propranolol </e1>  (Inderal),  <e2> atenolol </e2>  (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;
false	- a sulfa-based drug such as sulfamethoxazole-trimethoprim ( <e1> Bactrim </e1> ,  <e2> Septra </e2> ), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
false	These drugs include the thiazides and other diuretics, corticosteroids,  <e1> phenothiazines </e1> , thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	- a  <e1> diuretic </e1>  (water pill) such as hydrochlorothiazide ( <e2> HCTZ </e2> , Hydrodiuril), chlorothiazide (Diuril), and others;
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1> , some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid,  <e2> coumarins </e2> , monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other  <e1> diuretics </e1> , corticosteroids, phenothiazines,  <e2> thyroid products </e2> , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids,  <e1> phenothiazines </e1> , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel blocking drugs, and isoniazid.
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1> , some  <e2> azoles </e2>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e2> estrogens </e2> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides,  <e1> chloramphenicol </e1> , probenecid,  <e2> coumarins </e2> , monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine),  <e2> indomethacin </e2>  (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as chlorpromazine ( <e1> Thorazine </e1> ), fluphenazine (Prolixin, Permitil),  <e2> prochlorperazine </e2>  (Compazine), promethazine (Phenergan), and others;
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1> , some azoles and other drugs that are highly protein bound, salicylates, sulfonamides,  <e2> chloramphenicol </e2> , probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	These drugs include the thiazides and other diuretics, corticosteroids,  <e1> phenothiazines </e1> , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e1> estrogens </e1> , oral contraceptives, phenytoin,  <e2> nicotinic acid </e2> , sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e1> ketoprofen </e1>  (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone ( <e2> Relafen </e2> ), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine),  <e2> indomethacin </e2>  (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin ( <e1> Indocin </e1> ), nabumetone (Relafen),  <e2> oxaprozin </e2>  (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e2> etodolac </e2>  (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a phenothiazine such as  <e1> chlorpromazine </e1>  (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine),  <e2> promethazine </e2>  (Phenergan), and others;
effect	Immediate and Extended Release Tablets The hypoglycemic action of  <e1> sulfonylureas </e1>  may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates,  <e2> sulfonamides </e2> , chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e1> ketoprofen </e1>  (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac ( <e2> Lodine </e2> ), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
effect	Immediate and Extended Release Tablets The hypoglycemic action of  <e1> sulfonylureas </e1>  may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and  <e2> beta adrenergic blocking agents </e2> .
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: -  <e1> aspirin </e1>  or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate ( <e2> Disalcid </e2> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a phenothiazine such as chlorpromazine (Thorazine),  <e1> fluphenazine </e1>  (Prolixin, Permitil),  <e2> prochlorperazine </e2>  (Compazine), promethazine (Phenergan), and others;
false	- a  <e1> steroid medicine </e1>  such as  <e2> prednisone </e2>  (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates,  <e1> sulfonamides </e1> ,  <e2> chloramphenicol </e2> , probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil,  <e1> Nuprin </e1> , others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and  <e2> naproxen </e2>  (Anaprox, Naprosyn, Aleve);
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral  <e1> contraceptives </e1> ,  <e2> phenytoin </e2> , nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others),  <e2> ketoprofen </e2>  (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	These drugs include the  <e1> thiazides </e1>  and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid,  <e2> sympathomimetics </e2> , calcium channel blocking drugs, and isoniazid.
false	- a  <e1> nonsteroidal anti-inflammatory drug </e1>  (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen ( <e2> Orudis </e2> , Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a steroid medicine such as prednisone (Deltasone, Orasone, others),  <e1> methylprednisolone </e1>  (Medrol, others),  <e2> prednisolone </e2>  (Prelone, Pediapred, others), and others;
false	These drugs include the thiazides and other diuretics,  <e1> corticosteroids </e1> , phe-nothiazines, thyroid products, estrogens, oral contraceptives,  <e2> phenytoin </e2> , nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis,  <e2> Orudis KT </e2> , Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
advise	Before taking  <e1> glimepiride </e1> , tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate ( <e2> Disalcid </e2> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	In vitro binding studies with human serum proteins indicate that glipizide binds differently than  <e1> tolbutamide </e1>  and does not interact with  <e2> salicylate </e2>  or dicumarol.
false	In vitro binding studies with human serum proteins indicate that  <e1> glipizide </e1>  binds differently than tolbutamide and does not interact with  <e2> salicylate </e2>  or dicumarol.
false	- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine ( <e1> Compazine </e1> ),  <e2> promethazine </e2>  (Phenergan), and others;
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam),  <e1> etodolac </e1>  (Lodine), indomethacin (Indocin),  <e2> nabumetone </e2>  (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	These drugs include the thiazides and other diuretics, corticosteroids,  <e1> phenothiazines </e1> , thyroid products, estrogens, oral  <e2> contraceptives </e2> , phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products,  <e1> estrogens </e1> , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics,  <e2> calcium channel blocking drugs </e2> , and isoniazid.
false	- a  <e1> monoamine oxidase inhibitor </e1>  (MAOI) such as isocarboxazid (Marplan), tranylcypromine ( <e2> Parnate </e2> ), or phenelzine (Nardil);
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as  <e1> magnesium/choline salicylate </e1>  (Trilisate), salsalate ( <e2> Disalcid </e2> , others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis,  <e1> Orudis KT </e1> , Oruvail),  <e2> diclofenac </e2>  (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen ( <e1> Motrin </e1> , Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	- a  <e1> diuretic </e1>  (water pill) such as  <e2> hydrochlorothiazide </e2>  (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: -  <e1> aspirin </e1>  or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan),  <e2> magnesium salicylate </e2>  (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including  <e1> nonsteroidal anti-inflammatory agents </e1> , some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and  <e2> beta adrenergic blocking agents </e2> .
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives,  <e1> phenytoin </e1> ,  <e2> nicotinic acid </e2> , sympathomimetics, calcium channel blocking drugs, and isoniazid.
false	These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin,  <e1> nicotinic acid </e1> , sympathomimetics, calcium channel blocking drugs, and  <e2> isoniazid </e2> .
false	Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as  <e1> magnesium/choline salicylate </e1>  ( <e2> Trilisate </e2> ), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid,  <e1> coumarins </e1> ,  <e2> monoamine oxidase inhibitors </e2> , and beta adrenergic blocking agents.
false	The concurrent use of Robinul Injection with other  <e1> anticholinergics </e1>  or medications with anticholinergic activity, such as phenothiazines,  <e2> antiparkinson drugs </e2> , or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
effect	The hypoglycemic action of  <e1> sulfonylureas </e1>  may be potentiated by certain drugs including  <e2> nonsteroidal anti-inflammatory agents </e2>  and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as  <e1> phenothiazines </e1> ,  <e2> antiparkinson drugs </e2> , or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
false	- a steroid medicine such as  <e1> prednisone </e1>  ( <e2> Deltasone </e2> , Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
false	These would include a variety of preparations which contain  <e1> androgens </e1> , estrogens,  <e2> progestins </e2> , or glucocorticoids.
false	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some  <e1> azoles </e1>  and other drugs that are highly protein bound, salicylates,  <e2> sulfonamides </e2> , chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
false	The gonadotropin levels may be transiently elevated by  <e1> spironolactone </e1> , minimally elevated by  <e2> levodopa </e2> , and suppressed by oral contraceptives and digoxin.
effect	The response to  <e1> Factrel </e1>  may be blunted by  <e2> phenothiazines </e2>  and dopamine antagonists which cause a rise in prolactin.
false	- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac ( <e1> Voltaren </e1> , Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox,  <e2> Naprosyn </e2> , Aleve);
false	The gonadotropin levels may be transiently elevated by  <e1> spironolactone </e1> , minimally elevated by levodopa, and suppressed by oral  <e2> contraceptives </e2>  and digoxin.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or  <e2> calcium </e2> , with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
mechanism	Caffeine Theobromine Grepafloxacin, like other  <e1> quinolones </e1> , may inhibit the metabolism of caffeine and  <e2> theobromine </e2> .
false	Administration of quinolones with  <e1> antacids </e1>  containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as  <e2> iron </e2> , or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or  <e2> zinc </e2> , or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
effect	Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a  <e1> nonsteroidal anti inflammatory drug </e1>  with a  <e2> quinolone </e2>  may increase the risks of CNS stimulation and convulsions.
mechanism	Administration of  <e1> quinolones </e1>  with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with  <e2> multivitamins </e2>  containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or  <e1> zinc </e1> , or with formulations containing divalent and trivalent cations such as  <e2> VIDEX </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of  <e1> grepafloxacin </e1>  on  <e2> theophylline </e2>  indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.
false	 <e1> Nonsteroidal Anti-inflammatory Drugs </e1>  (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a  <e2> quinolone </e2>  may increase the risks of CNS stimulation and convulsions.
false	Administration of quinolones with antacids containing  <e1> aluminum </e1> , magnesium, or calcium, with  <e2> sucralfate </e2> , with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with  <e1> sucralfate </e1> , with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Warfarin: In subjects receiving  <e1> warfarin </e1> , no significant change in clotting time was observed when  <e2> grepafloxacin </e2>  was coadministered.
false	Nonsteroidal Anti-inflammatory Drugs ( <e1> NSAIDs </e1> ): The concomitant administration of a  <e2> nonsteroidal anti inflammatory drug </e2>  with a quinolone may increase the risks of CNS stimulation and convulsions.
false	Administration of quinolones with antacids containing  <e1> aluminum </e1> , magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
mechanism	Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that  <e1> grepafloxacin </e1>  inhibits  <e2> theophylline </e2>  metabolism, which is mediated by CYP1A2.
false	include terfenadine, astemizole, cisapride,  <e1> midazolam </e1> , and  <e2> triazolam </e2> .
false	Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of  <e1> grepafloxacin </e1>  on theophylline indicates that grepafloxacin inhibits  <e2> theophylline </e2>  metabolism, which is mediated by CYP1A2.
false	Administration of quinolones with antacids containing aluminum, magnesium, or  <e1> calcium </e1> , with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as  <e2> VIDEX </e2>  (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
mechanism	In addition, other  <e1> quinolones </e1>  have been reported to decrease the CYP3A4-mediated metabolism of  <e2> cyclosporine </e2> .
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing  <e2> iron </e2>  or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	 <e1> Caffeine </e1>   <e2> Theobromine </e2>  Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
false	Administration of  <e1> quinolones </e1>  with  <e2> antacids </e2>  containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with sucralfate, with metal cations such as iron, or with  <e2> multivitamins </e2>  containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	include terfenadine,  <e1> astemizole </e1> , cisapride, midazolam, and  <e2> triazolam </e2> .
false	include terfenadine,  <e1> astemizole </e1> ,  <e2> cisapride </e2> , midazolam, and triazolam.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with  <e2> sucralfate </e2> , with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as  <e1> iron </e1> , or with multivitamins containing  <e2> iron </e2>  or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with  <e1> multivitamins </e1>  containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of  <e2> quinolones </e2> , resulting in systemic concentrations considerably lower than desired.
false	When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of  <e1> grepafloxacin </e1>  and monitoring of serum  <e2> theophylline </e2>  concentrations should be initiated as a guide to further dosage adjustments.
false	Administration of quinolones with antacids containing  <e1> aluminum </e1> ,  <e2> magnesium </e2> , or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing  <e1> iron </e1>  or zinc, or with formulations containing divalent and trivalent cations such as VIDEX ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	include terfenadine,  <e1> astemizole </e1> , cisapride,  <e2> midazolam </e2> , and triazolam.
false	Administration of quinolones with antacids containing  <e1> aluminum </e1> , magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing  <e2> iron </e2>  or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
mechanism	Administration of  <e1> quinolones </e1>  with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX ( <e2> didanosine </e2> ) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum,  <e1> magnesium </e1> , or calcium, with sucralfate, with metal cations such as  <e2> iron </e2> , or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
false	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as  <e1> iron </e1> , or with multivitamins containing iron or  <e2> zinc </e2> , or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
effect	The use of  <e1> dextromethorphan hydrobromide </e1>  may result in additive CNS depressant effects when coadministered with alcohol,  <e2> antihistamines </e2> , psychotropics or other drugs that produce CNS depression.
false	The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol,  <e1> antihistamines </e1> ,  <e2> psychotropics </e2>  or other drugs that produce CNS depression.
false	The use of codeine may result in additive CNS depressant effects when coadministered with alcohol,  <e1> antihistamines </e1> ,  <e2> psychotropics </e2>  or other drugs that produce CNS depression.
effect	Concomitant use of  <e1> barbiturates </e1>  usually depresses  <e2> griseofulvin </e2>  activity and may necessitate raising the dosage.
false	When initiating a multi-day course of  <e1> grepafloxacin </e1>  in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of  <e2> grepafloxacin </e2>  and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral  <e1> contraceptives </e1>  (18),  <e2> bronchodilators </e2>  (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were:  <e1> cardiac glycosides </e1>  (115),  <e2> sedatives </e2>  and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
effect	The potential for increased sedation when  <e1> guanfacine </e1>  is given with other  <e2> CNS-depressant drug </e2>  should be appreciated.
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103),  <e1> coronary vasodilators </e1>  (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13),  <e2> insulin </e2>  (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral  <e1> contraceptives </e1>  (18), bronchodilators (13), insulin (10), and  <e2> beta blockers </e2>  (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29),  <e1> antigout drugs </e1>  (24), oral contraceptives (18), bronchodilators (13), insulin (10), and  <e2> beta blockers </e2>  (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45),  <e1> NSAIDs </e1>  (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13),  <e2> insulin </e2>  (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38),  <e1> antihyperlipidemics </e1>  (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and  <e2> beta blockers </e2>  (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103),  <e1> coronary vasodilators </e1>  (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and  <e2> beta blockers </e2>  (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115),  <e1> sedatives </e1>  and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38),  <e2> antihyperlipidemics </e2>  (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115),  <e1> sedatives </e1>  and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18),  <e2> bronchodilators </e2>  (13), insulin (10), and beta blockers (10).
false	 <e1> Anticoagulants </e1> : Ten patients who were stabilized on oral  <e2> anticoagulants </e2>  were given guanfacine, 1-2 mg/day, for 4 weeks.
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and  <e1> hypnotics </e1>  (103), coronary vasodilators (52), oral  <e2> hypoglycemics </e2>  (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were:  <e1> cardiac glycosides </e1>  (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and  <e2> beta blockers </e2>  (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115),  <e1> sedatives </e1>  and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45),  <e2> NSAIDs </e2>  (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115),  <e1> sedatives </e1>  and hypnotics (103), coronary vasodilators (52), oral  <e2> hypoglycemics </e2>  (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as  <e1> anesthetics </e1> , opiates, and  <e2> alcohol </e2> .
false	A causal relationship between these events and the concomitant administration of  <e1> lithium </e1>  and  <e2> HALDOL </e2>  has not been established;
false	As with other  <e1> antipsychotic agents </e1> , it should be noted that  <e2> HALDOL </e2>  may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
effect	As with other  <e1> antipsychotic agents </e1> , it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics,  <e2> opiates </e2> , and alcohol.
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and  <e1> hypnotics </e1>  (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29),  <e2> antigout drugs </e2>  (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
effect	As with other  <e1> antipsychotic agents </e1> , it should be noted that HALDOL may be capable of potentiating CNS depressants such as  <e2> anesthetics </e2> , opiates, and alcohol.
false	The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103),  <e1> coronary vasodilators </e1>  (52), oral hypoglycemics (45), cough and cold preparations (45),  <e2> NSAIDs </e2>  (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
false	As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as  <e1> anesthetics </e1> ,  <e2> opiates </e2> , and alcohol.
mechanism	The administration of  <e1> guanfacine </e1>  concomitantly with known microsomal enzyme inducer (phenobarbital or  <e2> phenytoin </e2> ) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
false	In 5 other schizophrenic patients treated with oral  <e1> haloperidol </e1>  and  <e2> rifampin </e2> , discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.
false	Caution should also be applied for other  <e1> sympathomimetics </e1> , and for  <e2> aminophylline </e2>  and theophylline and tricyclic antidepressants, which may also precipitate arrhythmias.
false	Caution should also be applied for other sympathomimetics, and for  <e1> aminophylline </e1>  and  <e2> theophylline </e2>  and tricyclic antidepressants, which may also precipitate arrhythmias.
effect	As with other antipsychotic agents, it should be noted that  <e1> HALDOL </e1>  may be capable of potentiating  <e2> CNS depressants </e2>  such as anesthetics, opiates, and alcohol.
false	 <e1> Heparin Sodium </e1>  Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with  <e2> heparin </e2>  and a precipitate may form.
false	Platelet inhibitors: Drugs such as  <e1> acetylsalicylic acid </e1> , dextran, phenylbutazone, ibuprofen,  <e2> indomethacin </e2> , dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
false	Therefore, when heparin sodium is given with  <e1> dicumarol </e1>  or  <e2> warfarin sodium </e2> , a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
false	Platelet inhibitors: Drugs such as  <e1> acetylsalicylic acid </e1> , dextran, phenylbutazone,  <e2> ibuprofen </e2> , indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
false	Heparin Sodium Injection should not be mixed with doxorubicin, droperidol,  <e1> ciprofloxacin </e1> , or  <e2> mitoxantrone </e2> , since it has been reported that these drugs are incompatible with heparin and a precipitate may form.
effect	Drugs Decreasing Heparin Effect: Digitalis, tetracyclines,  <e1> nicotine </e1> , or antihistamines may partially counteract the anticoagulant action of  <e2> heparin sodium </e2> .
false	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone,  <e1> ibuprofen </e1> , indomethacin,  <e2> dipyridamole </e2> , hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
false	Drugs Decreasing  <e1> Heparin </e1>  Effect: Digitalis,  <e2> tetracyclines </e2> , nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
advise	Therefore, when  <e1> heparin sodium </e1>  is given with  <e2> dicumarol </e2>  or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
effect	Platelet inhibitors: Drugs such as acetylsalicylic acid,  <e1> dextran </e1> , phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving  <e2> heparin sodium </e2> .
false	Drug Interactions: a. Drugs Enhancing  <e1> Heparin </e1>  Effect: Oral  <e2> anticoagulants </e2> : Heparin sodium may prolong the one-stage prothrombin time.
false	Drugs Decreasing  <e1> Heparin </e1>  Effect: Digitalis, tetracyclines,  <e2> nicotine </e2> , or antihistamines may partially counteract the anticoagulant action of heparin sodium.
false	Heparin Sodium Injection should not be mixed with  <e1> doxorubicin </e1> , droperidol, ciprofloxacin, or  <e2> mitoxantrone </e2> , since it has been reported that these drugs are incompatible with heparin and a precipitate may form.
false	 <e1> Platelet inhibitors </e1> : Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving  <e2> heparin sodium </e2> .
false	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen,  <e1> indomethacin </e1> , dipyridamole,  <e2> hydroxychloroquine </e2>  and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
effect	Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole,  <e1> hydroxychloroquine </e1>  and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving  <e2> heparin sodium </e2> .
false	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as  <e1> diazepam </e1>  (Valium), and, to a rising degree,  <e2> methadone </e2> .
false	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol,  <e1> benzodiazepines </e1>  such as diazepam (Valium), and, to a rising degree,  <e2> methadone </e2> .
false	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including  <e1> alcohol </e1> , benzodiazepines such as  <e2> diazepam </e2>  (Valium), and, to a rising degree, methadone.
false	Toxicology studies of heroin-related deaths reveal frequent involvement of other  <e1> central nervous system depressants </e1> , including alcohol,  <e2> benzodiazepines </e2>  such as diazepam (Valium), and, to a rising degree, methadone.
false	Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol,  <e1> benzodiazepines </e1>  such as  <e2> diazepam </e2>  (Valium), and, to a rising degree, methadone.
effect	Drugs Decreasing Heparin Effect: Digitalis,  <e1> tetracyclines </e1> , nicotine, or antihistamines may partially counteract the anticoagulant action of  <e2> heparin sodium </e2> .
false	Toxicology studies of heroin-related deaths reveal frequent involvement of other  <e1> central nervous system depressants </e1> , including alcohol, benzodiazepines such as diazepam ( <e2> Valium </e2> ), and, to a rising degree, methadone.
effect	Toxicology studies of  <e1> heroin </e1> -related deaths reveal frequent involvement of other central nervous system depressants, including alcohol,  <e2> benzodiazepines </e2>  such as diazepam (Valium), and, to a rising degree, methadone.
false	 <e1> Platelet inhibitors </e1> : Drugs such as acetylsalicylic acid,  <e2> dextran </e2> , phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain  <e1> antibiotics </e1> , quinidine, theophylline, corticosteroids,  <e2> anticoagulants </e2> , and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics,  <e1> quinidine </e1> , theophylline, corticosteroids, anticoagulants, and  <e2> beta blockers </e2> .
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics,  <e1> quinidine </e1> ,  <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine,  <e1> theophylline </e1> ,  <e2> corticosteroids </e2> , anticoagulants, and beta blockers.
effect	 <e1> Barbiturates </e1>  may decrease the effectiveness of oral contraceptives, certain antibiotics,  <e2> quinidine </e2> , theophylline, corticosteroids, anticoagulants, and beta blockers.
effect	 <e1> Barbiturates </e1>  may decrease the effectiveness of oral  <e2> contraceptives </e2> , certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
false	Beta-blockers ( <e1> metoprolol </e1> ,  <e2> propranolol </e2> ) serum concentrations and pharmacologic effects may be increased.
false	 <e1> Beta-blockers </e1>  (metoprolol,  <e2> propranolol </e2> ) serum concentrations and pharmacologic effects may be increased.
effect	 <e1> NSAIDs </e1>  may decrease the hemodynamic effects of  <e2> hydralazine </e2> ;
false	Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide  <e1> d <e2> iuretics </e1>  </e2> .
false	 <e1> Skeletal muscle relaxants </e1> , nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the  <e2> muscle relaxant </e2> .
false	Alcohol,  <e1> barbiturates </e1> , or  <e2> narcotics </e2> : potentiation of orthostatic hypotension may occur.
false	 <e1> Alcohol </e1> ,  <e2> barbiturates </e2> , or narcotics: potentiation of orthostatic hypotension may occur.
false	 <e1> Skeletal muscle relaxants </e1> , nondepolarizing (e.g.,  <e2> tubocurarine </e2> ): possible increased responsiveness to the muscle relaxant.
false	Single doses of either cholestyramine or colestipol  <e1> resins </e1>  bind the  <e2> hydrochlorothiazide </e2>  and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
effect	 <e1> Diuretic agents </e1>  reduce the renal clearance of lithium and add a high risk of  <e2> lithium </e2>  toxicity.
advise	Refer to the package insert for  <e1> lithium </e1>  preparations before use of such preparations with  <e2> Hydrochlorothiazide </e2> .
false	Cholestyramine and colestipol  <e1> resins </e1> : Absorption of  <e2> hydrochlorothiazide </e2>  is impaired in the presence of anionic exchange resins.
mechanism	Single doses of either  <e1> cholestyramine </e1>  or colestipol resins bind the  <e2> hydrochlorothiazide </e2>  and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
false	Diuretic agents reduce the renal clearance of  <e1> lithium </e1>  and add a high risk of  <e2> lithium </e2>  toxicity.
effect	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other  <e1> CNS depressants </e1>  (including alcohol) concomitantly with  <e2> hydrocodone </e2>  and acetaminophen tablets may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesics </e1> , antipsychotics, antianxiety agents, or other CNS depressants (including  <e2> alcohol </e2> ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
effect	The concurrent use of  <e1> anticholinergics </e1>  with  <e2> hydrocodone </e2>  may produce paralytic ileus.
false	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other  <e1> CNS depressants </e1>  (including  <e2> alcohol </e2> ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics,  <e1> antipsychotics </e1> , antianxiety agents, or other CNS depressants (including  <e2> alcohol </e2> ) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
false	Cholestyramine and colestipol  <e1> resins </e1> : Absorption of hydrochlorothiazide is impaired in the presence of  <e2> anionic exchange resins </e2> .
false	The use of MAO inhibitors or tricyclic antidepressants with  <e1> hydrocodone </e1>  preparations may increase the effect of either the antidepressant or  <e2> hydrocodone </e2> .
false	Patients receiving other narcotic analgesics, antipsychotics,  <e1> antianxiety agents </e1> , or other  <e2> CNS depressants </e2>  (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
false	Amphotericin B or Corticosteroids or  <e1> Corticotropin </e1>  ( <e2> ACTH </e2> )
effect	( <e1> Thiazides </e1>  may decrease arterial responsiveness to  <e2> norepinephrine </e2> .
false	(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide  <e1> d <e2> iuretics </e1>  </e2> .
false	 <e1> Antihypertensive medications </e1> , other, especially diazoxide, or pre <e2> anesthetic </e2>  and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery
false	 <e1> Amphotericin B </e1>  or Corticosteroids or  <e2> Corticotropin </e2>  (ACTH)
effect	Patients receiving other narcotic analgesics, general anesthetics,  <e1> phenothiazines </e1> , tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with  <e2> DILAUDID </e2>  may exhibit an additive CNS depression.
effect	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers,  <e1> sedative-hypnotics </e1> , tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with  <e2> DILAUDID </e2>  may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers,  <e1> sedative-hypnotics </e1> ,  <e2> tricyclic antidepressants </e2>  or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other  <e1> CNS depressants </e1>  (including  <e2> alcohol </e2> ) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general anesthetics,  <e1> phenothiazines </e1> , tranquilizers,  <e2> sedative-hypnotics </e2> , tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general  <e1> anesthetics </e1> , phenothiazines,  <e2> tranquilizers </e2> , sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesic </e1> s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other  <e2> CNS depressants </e2>  (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other narcotic analgesics, general anesthetics,  <e1> phenothiazines </e1> , tranquilizers, sedative-hypnotics, tricyclic antidepressants or other  <e2> CNS depressants </e2>  (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	Patients receiving other  <e1> narcotic analgesic </e1> s, general anesthetics, phenothiazines, tranquilizers,  <e2> sedative-hypnotics </e2> , tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
false	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS,  <e1> NON-NARCOTIC ANALGESICS </e1>  AND  <e2> BARBITURATES </e2> .
false	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS  <e1> NARCOTICS </e1> , NON-NARCOTIC ANALGESICS AND  <e2> BARBITURATES </e2> .
effect	THE POTENTIATING ACTION OF  <e1> HYDROXYZINE </e1>  MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH  <e2> CENTRAL NERVOUS SYSTEM DEPRESSANTS </e2>  SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other  <e1> antimuscarinics </e1> , amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors,  <e2> tricyclic antidepressants </e2>  or some antihistamines.
effect	Additive adverse effects resulting from cholinergic blockade may occur when  <e1> LEVSIN </e1>  is administered concomitantly with other antimuscarinics, amantadine, haloperidol,  <e2> phenothiazines </e2> , monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine,  <e1> haloperidol </e1> ,  <e2> phenothiazines </e2> , monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other  <e1> antimuscarinics </e1> ,  <e2> amantadine </e2> , haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
effect	Additive adverse effects resulting from cholinergic blockade may occur when  <e1> LEVSIN </e1>  is administered concomitantly with other antimuscarinics,  <e2> amantadine </e2> , haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics,  <e1> amantadine </e1> , haloperidol, phenothiazines,  <e2> monoamine oxidase (MAO) inhibitors </e2> , tricyclic antidepressants or some antihistamines.
false	Similarly, in the 1-year monthly comparison study,  <e1> aspirin </e1>  and  <e2> nonsteroidal anti-inflammatory drugs </e2>  were taken by 39% of the 1602 patients.
false	 <e1> Aspirin </e1> / <e2> Nonsteroidal Antiinflammatory Drug </e2> s (NSAIDs)
false	However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  <e1> aspirin </e1>  or  <e2> NSAIDs </e2>  with Ibandronate.
advise	However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  <e1> aspirin </e1>  or NSAIDs with  <e2> Ibandronate </e2> .
false	However, since  <e1> aspirin </e1> , NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  <e2> aspirin </e2>  or NSAIDs with Ibandronate.
false	However, since aspirin,  <e1> NSAIDs </e1> , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with  <e2> Ibandronate </e2> .
mechanism	Products containing  <e1> calcium </e1>  and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of  <e2> Ibandronate </e2> .
false	However, since aspirin,  <e1> NSAIDs </e1> , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or  <e2> NSAIDs </e2>  with Ibandronate.
false	Of over 3500 patients enrolled in the  <e1> Ibandronate </e1>  osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and  <e2> PPIs </e2> ).
false	Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines,  <e1> monoamine oxidase (MAO) inhibitors </e1> ,  <e2> tricyclic antidepressants </e2>  or some antihistamines.
false	Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including  <e1> antacids </e1> , supplements or  <e2> vitamins </e2> ).
false	Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily  <e1> H2 blockers </e1>  and  <e2> PPIs </e2> ).
false	However, since  <e1> aspirin </e1> ,  <e2> NSAIDs </e2> , and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
false	However, because bleeding has been reported when  <e1> ibuprofen </e1>  and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering  <e2> ibuprofen </e2>  to patients on anticoagulants.
false	 <e1> Furosemide </e1> : Clinical studies, as well as random observations, have shown that  <e2> ibuprofen </e2>  can reduce the natriuretic effect of furosemide and thiazides in some patients.
advise	However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering  <e1> ibuprofen </e1>  to patients on  <e2> anticoagulants </e2> .
false	 <e1> Furosemide </e1> : Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of  <e2> furosemide </e2>  and thiazides in some patients.
effect	Furosemide: Clinical studies, as well as random observations, have shown that  <e1> ibuprofen </e1>  can reduce the natriuretic effect of furosemide and  <e2> thiazides </e2>  in some patients.
false	H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or  <e1> ranitidine </e1>  with ibuprofen had no substantive effect on  <e2> ibuprofen </e2>  serum concentrations.
false	 <e1> Furosemide </e1> : Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and  <e2> thiazides </e2>  in some patients.
false	 <e1> Lithium </e1> : Ibuprofen produced an elevation of plasma  <e2> lithium </e2>  levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
false	Lithium: Ibuprofen produced an elevation of plasma  <e1> lithium </e1>  levels and a reduction in renal  <e2> lithium </e2>  clearance in a study of eleven normal volunteers.
mechanism	Methotrexate:  <e1> Ibuprofen </e1> , as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of  <e2> methotrexate </e2>  based on in vitro studies in rabbit kidney slices.
false	 <e1> Lithium </e1> : Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal  <e2> lithium </e2>  clearance in a study of eleven normal volunteers.
false	 <e1> Aspirin </e1> : Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including  <e2> ibuprofen </e2> , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
false	Coadministration of  <e1> digoxin </e1>  did not have effects on either the safety or efficacy of  <e2> ibutilide </e2>  in the clinical trials.
false	Single dose bioavailability studies in normal volunteers have failed to wshow an effect of  <e1> aspirin </e1>  on  <e2> ibuprofen </e2>  blood levels.
false	Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on  <e1> insulin </e1>  absorption from the peritoneal cavity or on insulins ability to control blood glucose when  <e2> insulin </e2>  was administered intraperitoneally with EXTRANEAL.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of  <e1> vancomycin </e1> , cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and  <e2> amphotericin </e2>  demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
false	 <e1> Insulin </e1> : A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when  <e2> insulin </e2>  was administered intraperitoneally with EXTRANEAL.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin,  <e1> ampicillin </e1> , ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these  <e2> antibiotics </e2>  with EXTRANEAL.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin,  <e1> cefazolin </e1> , ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and  <e2> amphotericin </e2>  demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin,  <e1> ampicillin </e1> , ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with  <e2> EXTRANEAL </e2> .
false	In patients using  <e1> cardiac glycosides </e1>  ( <e2> digoxin </e2>  and others), plasma levels of calcium, potassium and magnesium must be carefully monitored.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin,  <e1> ceftazidime </e1> ,  <e2> gentamicin </e2> , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
false	 <e1> Insulin </e1> : A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on  <e2> insulin </e2> s ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin,  <e1> cefazolin </e1> ,  <e2> ampicillin </e2> , ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin,  <e1> ampicillin </e1> , ampicillin/flucoxacillin, ceftazidime,  <e2> gentamicin </e2> , and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
false	In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin,  <e1> ampicillin </e1> /flucoxacillin, ceftazidime, gentamicin, and  <e2> amphotericin </e2>  demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
false	 <e1> Insulin </e1> : A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with  <e2> EXTRANEAL </e2> .
int	Interactions may occur between  <e1> EPA </e1>  supplements and  <e2> aspirin </e2>  and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
false	Interactions may occur between EPA supplements and  <e1> aspirin </e1>  and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo ( <e2> Ginkgo biloba </e2> ).
false	Interactions may occur between EPA supplements and  <e1> aspirin </e1>  and other  <e2> non-steroidal anti-inflammatory drugs </e2>  and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
false	Interactions may occur between EPA supplements and aspirin and other  <e1> non-steroidal anti-inflammatory drugs </e1>  and herbs such as garlic (Allium sativum) and ginkgo ( <e2> Ginkgo biloba </e2> ).
false	In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either  <e1> nifedipine </e1> , diltiazem, or  <e2> captopril </e2> .
false	During clinical trials, iloprost was used concurrently with anticoagulants,  <e1> diuretics </e1> , cardiac glycosides, calcium channel blockers, analgesics, antipyretics,  <e2> nonsteroidal antiinflammatories </e2> , corticosteroids, and other medications.
false	During clinical trials,  <e1> iloprost </e1>  was used concurrently with anticoagulants,  <e2> diuretics </e2> , cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
effect	Since  <e1> iloprost </e1>  inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on  <e2> anticoagulants </e2> .
false	During clinical trials, iloprost was used concurrently with  <e1> anticoagulants </e1> , diuretics,  <e2> cardiac glycosides </e2> , calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
false	During clinical trials, iloprost was used concurrently with anticoagulants, diuretics,  <e1> cardiac glycosides </e1> ,  <e2> calcium channel blockers </e2> , analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
false	During clinical trials,  <e1> iloprost </e1>  was used concurrently with anticoagulants, diuretics,  <e2> cardiac glycosides </e2> , calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
false	Intravenous infusion of  <e1> iloprost </e1>  had no effect on the pharmacokinetics of  <e2> digoxin </e2> .
false	During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics,  <e1> antipyretics </e1> , nonsteroidal antiinflammatories,  <e2> corticosteroids </e2> , and other medications.
false	 <e1> Acetylsalicylic acid </e1>  did not alter the clearance (pharmacokinetics) of  <e2> iloprost </e2> .
false	Co-medications that induce CYP3A4 (e.g., dexamethasone,  <e1> phenytoin </e1> , carbamazepine,  <e2> rifampin </e2> , phenobarbital or St.
false	Drugs that may alter imatinib plasma concentrations Drugs that may increase  <e1> imatinib </e1>  plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g.,  <e2> ketoconazole </e2> , itraconazole, erythromycin, clarithromycin).
false	Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of  <e1> Gleevec </e1> , increased  <e2> Gleevec </e2>  oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
false	Co-medications that induce CYP3A4 (e.g.,  <e1> dexamethasone </e1> , phenytoin,  <e2> carbamazepine </e2> , rifampin, phenobarbital or St.
false	Drugs that may have their plasma concentration altered by  <e1> Gleevec </e1>   <e2> Gleevec </e2>  increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.
false	Drugs that may alter imatinib plasma concentrations Drugs that may increase  <e1> imatinib </e1>  plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole,  <e2> itraconazole </e2> , erythromycin, clarithromycin).
false	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole,  <e1> itraconazole </e1> ,  <e2> erythromycin </e2> , clarithromycin).
false	There is a significant increase in exposure to  <e1> imatinib </e1>  when Gleevec is coadministered with  <e2> ketoconazole </e2>  (CYP3A4 inhibitor).
false	Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole,  <e1> itraconazole </e1> , erythromycin,  <e2> clarithromycin </e2> ).
mechanism	There is a significant increase in exposure to imatinib when  <e1> Gleevec </e1>  is coadministered with  <e2> ketoconazole </e2>  (CYP3A4 inhibitor).
advise	Particular caution is recommended when administering  <e1> Gleevec </e1>  with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or  <e2> pimozide </e2> ).
false	Co-medications that induce CYP3A4 (e.g., dexamethasone,  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , rifampin, phenobarbital or St.
false	Avoid the use of preparations such as decongestants and local  <e1> anesthetics </e1>  which contain any  <e2> sympathomimetic amine </e2>  (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous  <e1> iloprost </e1>  and either  <e2> nifedipine </e2> , diltiazem, or captopril.
false	It is desirable to monitor  <e1> TCA </e1>  plasma levels whenever a  <e2> TCA </e2>  is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
false	The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates,  <e1> phenytoin </e1> ), and adjustment of the dosage of  <e2> imipramine </e2>  may therefore be necessary.
false	 <e1> cimetidine </e1> ) and many that are substrates for P450 2D6 (many other antidepressants,  <e2> phenothiazines </e2> , and the Type 1C antiarrhythmics propafenone and flecainide).
false	Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g.,  <e1> epinephrine </e1> ,  <e2> norepinephrine </e2> ), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	 <e1> cimetidine </e1> ) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the  <e2> Type 1C antiarrhythmics </e2>  propafenone and flecainide).
false	The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine,  <e1> fluoxetine </e1> ) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of  <e2> imipramine </e2>  may therefore be necessary.
mechanism	The plasma concentration of  <e1> imipramine </e1>  may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g.,  <e2> barbiturates </e2> , phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
false	cimetidine) and many that are substrates for P450 2D6 (many other  <e1> antidepressants </e1> ,  <e2> phenothiazines </e2> , and the Type 1C antiarrhythmics propafenone and flecainide).
advise	Avoid the use of preparations such as decongestants and local anesthetics which contain any  <e1> sympathomimetic amine </e1>  (e.g., epinephrine, norepinephrine), since it has been reported that  <e2> tricyclic antidepressants </e2>  can potentiate the effects of catecholamines.
false	Avoid the use of preparations such as decongestants and local anesthetics which contain any  <e1> sympathomimetic amine </e1>  (e.g., epinephrine,  <e2> norepinephrine </e2> ), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
false	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics  <e1> propafenone </e1>  and  <e2> flecainide </e2> ).
false	The plasma concentration of  <e1> imipramine </e1>  may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of  <e2> imipramine </e2>  may therefore be necessary.
false	The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g.,  <e1> cimetidine </e1> , fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g.,  <e2> barbiturates </e2> , phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
false	Co-medications that induce CYP3A4 (e.g.,  <e1> dexamethasone </e1> , phenytoin, carbamazepine,  <e2> rifampin </e2> , phenobarbital or St.
false	 <e1> indinavir </e1>  concentration    <e2> rifabutin </e2>  concentration
false	Ergot derivatives:  <e1> dihydroergotamine </e1> , ergonovine, ergotamine,  <e2> methylergonovine </e2> 
false	 <e1> clarithromycin </e1>  concentration    <e2> indinavir </e2>  concentration
false	 <e1> Anticonvulsants </e1> : carbamazepine, phenobarbital,  <e2> phenytoin </e2> 
false	 <e1> Antiarrhythmics </e1> : bepridil, lidocaine (systemic) and  <e2> quinidine </e2> 
false	Anticonvulsants:  <e1> carbamazepine </e1> ,  <e2> phenobarbital </e2> , phenytoin
false	 <e1> Protease inhibitor </e1> :  <e2> atazanavir </e2> 
false	Antiarrhythmics:  <e1> bepridil </e1> , lidocaine (systemic) and  <e2> quinidine </e2> 
false	Coadministration of  <e1> CRIXIVAN </e1>  and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of  <e2> indinavir </e2> .
false	HMG-CoA Reductase inhibitors:  <e1> lovastatin </e1> ,  <e2> simvastatin </e2> 
advise	Dose reduction of  <e1> CRIXIVAN </e1>  to 600 mg every 8 hours is recommended when administering  <e2> itraconazole </e2>  concurrently.
false	Dose reduction of rifabutin to half the standard dose and a dose increase of  <e1> CRIXIVAN </e1>  to 1000 mg (three 333-mg capsules) every 8 hours are recommended when  <e2> rifabutin </e2>  and CRIXIVAN are coadministered.
false	Coadministration of  <e1> CRIXIVAN </e1>  and other drugs that inhibit CYP3A4 may decrease the clearance of  <e2> indinavir </e2>  and may result in increased plasma concentrations of indinavir.
false	 <e1> Neuroleptic </e1> :  <e2> pimozide </e2> 
false	Anticonvulsants:  <e1> carbamazepine </e1> , phenobarbital,  <e2> phenytoin </e2> 
advise	 <e1> Indinavir </e1>  and  <e2> didanosine </e2>  formulations containing buffer should be administered at least one hour apart on an empty stomach.
false	Increasing the  <e1> indinavir </e1>  dose to 1000 mg every 8 hours does not compensate for the increased  <e2> indinavir </e2>  metabolism due to efavirenz.
false	 <e1> Calcium Channel Blockers </e1> , Dihydropyridine: e.g.,  <e2> felodipine </e2> , nifedipine, nicardipine
false	Antiarrhythmics: bepridil,  <e1> lidocaine </e1>  (systemic) and  <e2> quinidine </e2> 
false	Therefore, when INDOCIN and  <e1> digoxin </e1>  are used concomitantly, serum  <e2> digoxin </e2>  levels should be closely monitored.
effect	In post-marketing experience, bleeding has been reported in patients on concomitant treatment with  <e1> anticoagulants </e1>  and  <e2> INDOCIN </e2> .
effect	In some patients, the administration of  <e1> INDOCIN </e1>  can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide  <e2> diuretics </e2> .
false	In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and  <e1> thiazide d <e2> iuretics </e1>  </e2> .
mechanism	 <e1> INDOCIN </e1>  has been reported to decrease the tubular secretion of  <e2> methotrexate </e2>  and to potentiate its toxicity.
effect	Administration of  <e1> non-steroidal anti-inflammatory drugs </e1>  concomitantly with  <e2> cyclosporine </e2>  has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
false	 <e1> Antiarrhythmics </e1> : bepridil,  <e2> lidocaine </e2>  (systemic) and quinidine
advise	Use lowest possible dose of  <e1> atorvastatin </e1>  with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with  <e2> CRIXIVAN </e2> .
false	When  <e1> INDOCIN </e1>  is given to patients receiving probenecid, the plasma levels of  <e2> indomethacin </e2>  are likely to be increased.
false	Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or  <e1> rosuvastatin </e1>  in combination with  <e2> CRIXIVAN </e2> .
false	 <e1> INDOCIN </e1>  and  <e2> potassium-sparing diuretics </e2>  each may be associated with increased serum potassium levels.
false	Use lowest possible dose of  <e1> atorvastatin </e1>  with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or  <e2> rosuvastatin </e2>  in combination with CRIXIVAN.
advise	However, when any additional drug, including  <e1> INDOCIN </e1> , is added to the treatment of patients on  <e2> anticoagulant </e2>  therapy, the patients should be observed for alterations of the prothrombin time.
false	As a consequence, when  <e1> INDOCIN </e1>  and lithium are given concomitantly, the patient should be carefully observed for signs of  <e2> lithium </e2>  toxicity.
false	Ergot derivatives:  <e1> dihydroergotamine </e1> , ergonovine,  <e2> ergotamine </e2> , methylergonovine
false	Concomitant Crohn s disease medications were antibiotics,  <e1> antivirals </e1> , corticosteroids, 6-MP/ <e2> AZA </e2>  and aminosalicylates.
false	 <e1> INDOCIN </e1>  given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of  <e2> digoxin </e2> .
false	In normal volunteers receiving  <e1> indomethacin </e1> , the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of  <e2> indomethacin </e2> .
false	In psoriatic arthritis clinical trials, concomitant medications included  <e1> MTX </e1>  in approximately half of the patients as well as  <e2> nonsteroidal anti-inflammatory agents </e2> , folic acid and corticosteroids.
false	In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as  <e1> nonsteroidal anti-inflammatory agents </e1> , folic acid and  <e2> corticosteroids </e2> .
false	In rheumatoid arthritis, concomitant medications besides  <e1> MTX </e1>  were  <e2> nonsteroidal anti-inflammatory agents </e2> , folic acid, corticosteroids and/or narcotics.
false	Concomitant Crohn s disease medications were  <e1> antibiotics </e1> , antivirals, corticosteroids,  <e2> 6-MP </e2> /AZA and aminosalicylates.
false	Immunosuppressants: cyclosporine,  <e1> tacrolimus </e1> ,  <e2> sirolimus </e2> 
false	Concomitant Crohn s disease medications were  <e1> antibiotics </e1> , antivirals,  <e2> corticosteroids </e2> , 6-MP/AZA and aminosalicylates.
effect	 <e1> CRIXIVAN </e1>  may not be effective due to decreased  <e2> indinavir </e2>  concentrations in patients taking these agents concomitantly.
false	In psoriatic arthritis clinical trials, concomitant medications included  <e1> MTX </e1>  in approximately half of the patients as well as nonsteroidal anti-inflammatory agents,  <e2> folic acid </e2>  and corticosteroids.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens,  <e2> progestogens </e2>  (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids, danazol, diuretics, sympathomimetic agents (e.g.,  <e2> epinephrine </e2> , albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> , danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens,  <e2> progestogens </e2>  (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol,  <e1> terbutaline </e1> ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid,  <e1> phenothiazine derivatives </e1> ,  <e2> somatropin </e2> , thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates,  <e1> fluoxetine </e1> ,  <e2> MAO inhibitors </e2> , propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates,  <e2> somatostatin analog </e2>  (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline),  <e1> isoniazid </e1> , phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	 <e1> Beta-blockers </e1> , clonidine,  <e2> lithium </e2>  salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates,  <e1> somatostatin analog </e1>  (e.g.,  <e2> octreotide </e2> ), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates,  <e1> somatostatin analog </e1>  (e.g., octreotide),  <e2> sulfonamide antibiotics </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol,  <e1> terbutaline </e1> ), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine,  <e1> MAO inhibitors </e1> ,  <e2> propoxyphene </e2> , salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics,  <e1> sympathomimetic agents </e1>  (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics,  <e1> sympathomimetic agents </e1>  (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids,  <e2> danazol </e2> , diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	In addition, under the influence of sympatholytic medicinal products such as beta-blockers,  <e1> clonidine </e1> ,  <e2> guanethidine </e2> , and reserpine, the signs of hypoglycemia may be reduced or absent.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine,  <e1> albuterol </e1> , terbutaline),  <e2> isoniazid </e2> , phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline),  <e1> isoniazid </e1> , phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline),  <e1> isoniazid </e1> , phenothiazine derivatives, somatropin, thyroid hormones, estrogens,  <e2> progestogens </e2>  (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids,  <e1> danazol </e1> , diuretics, sympathomimetic agents (e.g., epinephrine, albuterol,  <e2> terbutaline </e2> ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin,  <e2> thyroid hormones </e2> , estrogens, progestogens (e.g., in oral contraceptives).
false	Beta-blockers,  <e1> clonidine </e1> , lithium salts, and  <e2> alcohol </e2>  may either potentiate or weaken the blood-glucose-lowering effect of insulin.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates,  <e1> fluoxetine </e1> , MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g.,  <e2> octreotide </e2> ), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids,  <e1> danazol </e1> , diuretics, sympathomimetic agents (e.g., epinephrine,  <e2> albuterol </e2> , terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e1> estrogens </e1> ,  <e2> progestogens </e2>  (e.g., in oral contraceptives).
false	Concomitant Crohn s disease medications were antibiotics, antivirals, corticosteroids,  <e1> 6-MP </e1> / <e2> AZA </e2>  and aminosalicylates.
effect	 <e1> Beta-blockers </e1> , clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of  <e2> insulin </e2> .
false	In addition, under the influence of sympatholytic medicinal products such as  <e1> beta-blockers </e1> , clonidine,  <e2> guanethidine </e2> , and reserpine, the signs of hypoglycemia may be reduced or absent.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids,  <e1> danazol </e1> ,  <e2> diuretics </e2> , sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> , danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives,  <e2> somatropin </e2> , thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	 <e1> Beta-blockers </e1> , clonidine, lithium salts, and  <e2> alcohol </e2>  may either potentiate or weaken the blood-glucose-lowering effect of insulin.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids,  <e1> danazol </e1> , diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates,  <e1> fluoxetine </e1> , MAO inhibitors, propoxyphene, salicylates,  <e2> somatostatin analog </e2>  (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline),  <e1> isoniazid </e1> , phenothiazine derivatives, somatropin,  <e2> thyroid hormones </e2> , estrogens, progestogens (e.g., in oral contraceptives).
false	If  <e1> NovoLog </e1>  is mixed with  <e2> NPH human insulin </e2> , NovoLog should be drawn into the syringe first.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates,  <e2> fluoxetine </e2> , MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors,  <e1> disopyramide </e1> , fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates,  <e2> somatostatin analog </e2>  (e.g., octreotide), sulfonamide antibiotics.
false	Beta-blockers,  <e1> clonidine </e1> , lithium salts, and  <e2> alcohol </e2>  may either potentiate or weaken the blood-glucose-lowering effect of insulin.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide),  <e2> sulfonamide antibiotics </e2> .
effect	Beta-blockers, clonidine, lithium salts, and  <e1> alcohol </e1>  may either potentiate or weaken the blood-glucose-lowering effect of  <e2> insulin </e2> .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline),  <e1> isoniazid </e1> , phenothiazine derivatives, somatropin, thyroid hormones, estrogens,  <e2> progestogens </e2>  (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect:  <e1> corticosteroids </e1> , niacin, danazol, diuretics, sympathomimetic agents (e.g.,  <e2> epinephrine </e2> , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids,  <e1> niacin </e1> , danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates,  <e1> fluoxetine </e1> , monoamine oxidase (MAO) inhibitors,  <e2> propoxyphene </e2> , salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors,  <e1> disopyramide </e1> ,  <e2> fibrates </e2> , fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin,  <e1> danazol </e1> , diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide,  <e1> fibrates </e1> , fluoxetine,  <e2> monoamine oxidase (MAO) inhibitors </e2> , propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine,  <e1> salbutamol </e1> , terbutaline),  <e2> isoniazid </e2> , phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with  <e1> NPH human insulin </e1>  immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of  <e2> NovoLog </e2>  were not significantly affected.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates,  <e1> fluoxetine </e1> , monoamine oxidase (MAO) inhibitors, propoxyphene,  <e2> salicylates </e2> , somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine,  <e1> salbutamol </e1> , terbutaline), isoniazid, phenothiazine derivatives, somatropin,  <e2> thyroid hormones </e2> , estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates,  <e2> fluoxetine </e2> , monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	Because there are no data on the compatibility of  <e1> NovoLog </e1>  and crystalline zinc insulin preparations,  <e2> NovoLog </e2>  should not be mixed with these preparations.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates,  <e2> somatostatin analog </e2>  (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid,  <e1> phenothiazine derivatives </e1> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g.,  <e1> epinephrine </e1> , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid,  <e1> phenothiazine derivatives </e1> , somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids, danazol,  <e2> diuretics </e2> , sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> , danazol, diuretics, sympathomimetic agents (e.g.,  <e2> epinephrine </e2> , albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> , danazol, diuretics,  <e2> sympathomimetic agents </e2>  (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide,  <e1> fibrates </e1> , fluoxetine, monoamine oxidase (MAO) inhibitors,  <e2> propoxyphene </e2> , salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin:  <e1> corticosteroids </e1> , danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline),  <e2> isoniazid </e2> , phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol,  <e1> terbutaline </e1> ), isoniazid, phenothiazine derivatives,  <e2> somatropin </e2> , thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	In addition, under the influence of sympatholytic medicinal products such as  <e1> beta-blockers </e1> , clonidine, guanethidine, and  <e2> reserpine </e2> , the signs of hypoglycemia may be reduced or absent.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g.,  <e1> epinephrine </e1> , salbutamol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide),  <e2> sulfonamide antibiotics </e2> .
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral  <e1> antidiabetic products </e1> ,  <e2> ACE inhibitors </e2> , disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin,  <e1> danazol </e1> , diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens,  <e2> progestogens </e2>  (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral  <e1> antidiabetic products </e1> , ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g.,  <e2> octreotide </e2> ), sulfonamide antibiotics.
false	In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents,  <e1> folic acid </e1> , corticosteroids and/or  <e2> narcotics </e2> .
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates,  <e1> fluoxetine </e1> , monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates,  <e2> somatostatin analog </e2>  (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives,  <e1> somatropin </e1> ,  <e2> thyroid hormones </e2> , estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide,  <e1> fibrates </e1> ,  <e2> fluoxetine </e2> , monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors,  <e1> disopyramide </e1> , fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g.,  <e2> octreotide </e2> ), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline),  <e1> isoniazid </e1> , phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine,  <e1> salbutamol </e1> , terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin,  <e1> danazol </e1> , diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral  <e2> contraceptives </e2> ).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral  <e1> antidiabetic products </e1> , ACE inhibitors, disopyramide,  <e2> fibrates </e2> , fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of  <e1> insulin </e1> : corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid,  <e2> phenothiazine derivatives </e2> , somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide,  <e1> fibrates </e1> , fluoxetine,  <e2> MAO inhibitors </e2> , propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products,  <e1> ACE inhibitors </e1> , disopyramide, fibrates, fluoxetine, MAO inhibitors,  <e2> propoxyphene </e2> , salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol,  <e1> diuretics </e1> , sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives,  <e2> somatropin </e2> , thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids,  <e1> niacin </e1> , danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens,  <e2> progestogens </e2>  (e.g., in oral contraceptives).
false	Because there are no data on the compatibility of  <e1> NovoLog </e1>  and crystalline  <e2> zinc insulin </e2>  preparations, NovoLog should not be mixed with these preparations.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids,  <e1> danazol </e1> , diuretics,  <e2> sympathomimetic agents </e2>  (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide,  <e1> fibrates </e1> , fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene,  <e2> salicylates </e2> , somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
false	The following are examples of substances that may reduce the blood-glucose-lowering effect:  <e1> corticosteroids </e1> , niacin,  <e2> danazol </e2> , diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
false	Also, the potential for hepatic injury should be considered when  <e1> Rebif </e1>   is used in combination with other products associated with hepatic injury, or when new agents are added to the regimen of patients already on  <e2> Rebif </e2>  .
false	The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g.,  <e1> epinephrine </e1> , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones,  <e2> estrogens </e2> , progestogens (e.g., in oral contraceptives).
false	 <e1> ATROVENT </e1>  Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators,  <e2> methylxanthines </e2> , and steroids, commonly used in the treatment of chronic obstructive pulmonary disease.
false	 <e1> ATROVENT </e1>  Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, and  <e2> steroids </e2> , commonly used in the treatment of chronic obstructive pulmonary disease.
false	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin,  <e1> irbesartan </e1>  administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of  <e2> digoxin </e2> .
false	In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors  <e1> sulphenazole </e1> ,  <e2> tolbutamide </e2>  and nifedipine.
false	In separate studies of patients receiving maintenance doses of warfarin,  <e1> hydrochlorothiazide </e1> , or  <e2> digoxin </e2> , irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.
false	In separate studies of patients receiving maintenance doses of warfarin,  <e1> hydrochlorothiazide </e1> , or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of  <e2> warfarin </e2>  (prothrombin time) or pharmacokinetics of digoxin.
false	However, in clinical studies the consequences of concomitant  <e1> irbesartan </e1>  on the pharmacodynamics of  <e2> warfarin </e2>  were negligible.
false	No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin,  <e1> warfarin </e1> , and  <e2> nifedipine </e2> .
false	In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by  <e1> CAMPTOSAR </e1> , the physician may wish to withhold diuretics during dosing with  <e2> CAMPTOSAR </e2>  and, certainly, during periods of active vomiting or diarrhea.
false	In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or  <e1> digoxin </e1> , irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of  <e2> digoxin </e2> .
effect	Lymphocytopenia has been reported in patients receiving  <e1> CAMPTOSAR </e1> , and it is possible that the administration of  <e2> dexamethasone </e2>  as antiemetic prophylaxis may have enhanced the likelihood of this effect.
advise	Concomitant use of  <e1> Isocarboxazid </e1>  and other  <e2> psychotropic agents </e2>  is generally not recommended because of possible potentiating effects.
false	The monoamine oxidase inhibitory effects of  <e1> Isocarboxazid </e1>  may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following  <e2> Isocarboxazid </e2> .
false	May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide,  <e1> quinidine </e1> , phenothiazines, and  <e2> procainamide </e2>  (these medicines may increase the risk of heart problems).
false	May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide,  <e1> quinidine </e1> ,  <e2> phenothiazines </e2> , and procainamide (these medicines may increase the risk of heart problems).
false	May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the  <e1> adrenergic bronchodilators </e1>  from working properly) and  <e2> disopyramide </e2> , quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).
false	May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and  <e1> disopyramide </e1> , quinidine,  <e2> phenothiazines </e2> , and procainamide (these medicines may increase the risk of heart problems).
false	 <e1> Carbamazepine </e1> : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of  <e2> carbamazepine </e2>  toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
false	Plasma  <e1> valproate </e1>  concentration should be monitored when isoniazid and  <e2> valproate </e2>  are co administered, and appropriate dosage adjustments of valproate should be made.
effect	 <e1> Isoflurane </e1>  potentiates the muscle relaxant effect of all muscle relaxants, most notably  <e2> nondepolarizing muscle relaxants </e2> , and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
false	 <e1> Ketoconazole </e1> : Potential interaction of  <e2> Ketoconazole </e2>  and Isoniazid may exist.
false	Carbamazepine: Isoniazid is known to slow the metabolism of  <e1> carbamazepine </e1>  and increase its serum levels  <e2> Carbamazepine </e2>  levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
false	 <e1> Valproate </e1> : A recent case study has shown a possible increase in the plasma level of valproate when co administered with  <e2> isoniazid </e2> .
false	Isoflurane potentiates the muscle relaxant effect of all  <e1> muscle relaxants </e1> , most notably  <e2> nondepolarizing muscle relaxants </e2> , and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
mechanism	Phenytoin:  <e1> Isoniazid </e1>  may increase serum levels of  <e2> phenytoin </e2> .
false	Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with  <e1> isoniazid </e1> , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the  <e2> anticonvulsant </e2>  should be made.
false	Carbamazepine:  <e1> Isoniazid </e1>  is known to slow the metabolism of carbamazepine and increase its serum levels  <e2> Carbamazepine </e2>  levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
false	 <e1> Carbamazepine </e1> : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with  <e2> isoniazid </e2> , signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
false	Carbamazepine:  <e1> Isoniazid </e1>  is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of  <e2> carbamazepine </e2>  toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
false	ISUPREL should be used with caution, if at all, when potent inhalational  <e1> anesthetics </e1>  such as  <e2> halothane </e2>  are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
advise	 <e1> Isoproterenol hydrochloride </e1>  injection and  <e2> epinephrine </e2>  should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.
false	Vitamin A: Because of the relationship of Accutane to  <e1> vitamin A </e1> , patients should be advised against taking vitamin supplements containing  <e2> vitamin A </e2>  to avoid additive toxic effects
false	 <e1> Phenytoin </e1> :  <e2> Accutane </e2>  has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.
false	Tetracyclines: Concomitant treatment with Accutane and  <e1> tetracyclines </e1>  should be avoided because  <e2> Accutane </e2>  use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
false	Micro-dosed Progesterone Preparations: Micro-dosed  <e1> progesterone </e1>  preparations (minipills that do not contain an  <e2> estrogen </e2> ) may be an inadequate method of contraception during Accutane therapy.
effect	Micro-dosed Progesterone Preparations: Micro-dosed  <e1> progesterone </e1>  preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during  <e2> Accutane </e2>  therapy.
false	 <e1> Vitamin A </e1> : Because of the relationship of  <e2> Accutane </e2>  to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects
false	Micro-dosed  <e1> Progesterone </e1>  Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during  <e2> Accutane </e2>  therapy.
mechanism	Rifampicin: In a study in healthy volunteers, a six-day course of  <e1> rifampicin </e1>  at 600 mg/day followed by a single 5 mg dose of  <e2> isradipine </e2>  resulted in a reduction in isradipine levels to below detectable limits.
false	 <e1> Hydrochlorothiazide </e1> : A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (isradipine) and  <e2> hydrochlorothiazide </e2>  does not result in altered pharmacoktnetics of either drug.
false	Propranolol: In a single dose study in normal volunteers, coadministration of  <e1> propranolol </e1>  had a small effect on the rate but no effect on the extent of  <e2> isradipine </e2>  bioavailability.
false	Tetracyclines: Concomitant treatment with  <e1> Accutane </e1>  and tetracyclines should be avoided because  <e2> Accutane </e2>  use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
false	Nitroglycerin:  <e1> DynaCirc </e1>   (isradipine) has been safely coadministered with  <e2> nitroglycerin </e2> .
false	 <e1> Nitroglycerin </e1> : DynaCirc  (isradipine) has been safely coadministered with  <e2> nitroglycerin </e2> .
false	 <e1> Digoxin </e1> : The concomitant administration of DynaCirc  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of  <e2> digoxin </e2> .
false	Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between  <e1> isradipine </e1>  and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d.  <e2> isradipine </e2> .
effect	Fentanyl Anesthesia: Severe hypotension has been reported during  <e1> fentanyl </e1>  anesthesia with concomitant use of a beta blocker and a  <e2> calcium channel blocker </e2> .
false	propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between  <e1> isradipine </e1>  given singly and in combination with propranolol, and between propranolol given singly and in combination with  <e2> isradipine </e2> .
false	 <e1> Rifampicin </e1> : In a study in healthy volunteers, a six-day course of  <e2> rifampicin </e2>  at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.
false	 <e1> Rifampicin </e1> : In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in  <e2> isradipine </e2>  levels to below detectable limits.
false	Neither racemic  <e1> warfarin </e1>  nor  <e2> isradipine </e2>  binding to plasma proteins in vitro was altered by the addition of the other drug.
false	 <e1> Warfarin </e1> : In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of  <e2> warfarin </e2>  (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.
false	 <e1> Fentanyl </e1>  Anesthesia: Severe hypotension has been reported during  <e2> fentanyl </e2>  anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
false	Vitamin A: Because of the relationship of  <e1> Accutane </e1>  to vitamin A, patients should be advised against taking vitamin supplements containing  <e2> vitamin A </e2>  to avoid additive toxic effects
false	 <e1> Hydrochlorothiazide </e1> : A study in normal healthy volunteers has shown that concomitant administration of  <e2> DynaCirc </e2>   (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.
mechanism	Human pharmacokinetics data indicate that oral  <e1> ketoconazole </e1>  potently inhibits the metabolism of  <e2> cisapride </e2>  resulting in an eight-fold increase in the mean AUC of cisapride.
false	Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of  <e1> cisapride </e1>  resulting in an eight-fold increase in the mean AUC of  <e2> cisapride </e2> .
false	Based on the chemical resemblance of itraconazole and  <e1> ketoconazole </e1> , coadministration of  <e2> astemizole </e2>  with itraconazole is contraindicated.
false	Another oral  <e1> azole antifungal </e1> , ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite  <e2> desmethylastermizole </e2>  which may prolong QT intervals.
false	Although no studies have been conducted, concomitant administration of  <e1> Itraconazole </e1>  and phenytoin may alter the metabolism of  <e2> phenytoin </e2> ;
false	Another oral  <e1> azole antifungal </e1> , ketoconazole, inhibits the metabolism of  <e2> astemizole </e2> , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.
advise	therefore, plasma concentrations of  <e1> phenytoin </e1>  should also be monitored when it is given concurrently with  <e2> Itraconazole </e2> .
false	In vitro data suggest that itraconazole, when compared to  <e1> ketoconazole </e1> , has a less pronounced effect on the biotransformation system responsible for the metabolism of  <e2> astemizole </e2> .
mechanism	Coadministration of  <e1> Itraconazole </e1>  and cyclosporine,  <e2> tacrolimus </e2>  or digoxin has led to increased plasma concentrations of the latter three drugs.
advise	therefore concomitant administration of  <e1> Itraconazole </e1>  with  <e2> cisapride </e2>  is contraindicated.
false	 <e1> Nitroglycerin </e1> :  <e2> DynaCirc </e2>   (isradipine) has been safely coadministered with nitroglycerin.
false	Based on the chemical resemblance of  <e1> itraconazole </e1>  and ketoconazole, coadministration of astemizole with  <e2> itraconazole </e2>  is contraindicated.
effect	Tinnitus and decreased hearing have been reported in patients concomitantly receiving  <e1> Itraconazole </e1>  and  <e2> quinidine </e2> .
false	Another oral azole antifungal,  <e1> ketoconazole </e1> , inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite  <e2> desmethylastermizole </e2>  which may prolong QT intervals.
mechanism	In vitro data suggest that  <e1> itraconazole </e1> , when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of  <e2> astemizole </e2> .
false	 <e1> Cimetidine </e1> : In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of  <e2> isradipine </e2>  on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
false	The results from a study in which eight HIV-infected individuals were treated with  <e1> zidovudine </e1> , 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of  <e2> Itraconazole </e2> , 100 mg b.i.d.
false	When Itraconazole was coadministered with phenytoin,  <e1> rifampin </e1> , or H2antagonists, reduced plasma concentrations of  <e2> itraconazole </e2>  were reported.
false	In vitro mixing of an aminoglycoside with beta-lactamtype  <e1> antibiotics </e1>  (penicillins or  <e2> cephalosporins </e2> ) may result in a significant mutual inactivation.
effect	Edema has been reported in patients concomitantly receiving  <e1> Itraconazole </e1>  and  <e2> dihydropyridine calcium channel blockers </e2> .
mechanism	Even when an  <e1> aminoglycoside </e1>  and a  <e2> penicillin </e2> -type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.
effect	Prolonged recovery time may occur if  <e1> barbiturates </e1>  and/or narcotics are used concurrently with  <e2> ketamine </e2> .
false	Prolonged recovery time may occur if  <e1> barbiturates </e1>  and/or  <e2> narcotics </e2>  are used concurrently with ketamine.
advise	Therefore concomitant administration of  <e1> ketoconazole </e1>  tablets with  <e2> cisapride </e2>  is contraindicated.
effect	Data suggest that coadministration of oral  <e1> ketoconazole </e1>  and  <e2> cisapride </e2>  can result in prolongation of the QT interval on the ECG.
false	Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of  <e1> cisapride </e1>  resulting in a mean eight-fold increase in AUC of  <e2> cisapride </e2> .
false	Dosage adjustment may be required if cyclosporine,  <e1> tacrolimus </e1> , or  <e2> methylprednisolone </e2>  are given concomitantly with NIZORAL  Tablets.
false	Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of  <e1> astemizole </e1> , resulting in elevated plasma levels of  <e2> astemizole </e2>  and its active metabolite desmethylastemizole which may prolong QT intervals.
mechanism	Concomitant administration of  <e1> ketoconazole </e1>  tablets with  <e2> phenytoin </e2>  may alter the metabolism of one or both of the drugs.
false	Also, there were no clinically significant differences in adverse events when  <e1> loratadine </e1>  was administered with or without  <e2> ketoconazole </e2> .
false	Because severe hypoglycemia has been reported in patients concomitantly receiving oral  <e1> miconazole </e1>  (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with  <e2> ketoconazole </e2>  tablets (an imidazole) can not be ruled out.
false	Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral  <e1> hypoglycemic agents </e1> , such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an  <e2> imidazole </e2> ) can not be ruled out.
false	The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system:  <e1> Ketoconazole </e1>  tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of  <e2> terfenadine </e2>  and a delay in the elimination of its acid metabolite.
mechanism	 <e1> Ketoconazole </e1>  tablets may alter the metabolism of  <e2> cyclosporine </e2> , tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
false	Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and  <e1> digoxin </e1>  were concomitantly administered, ketoprofen did not alter the serum levels of  <e2> digoxin </e2> .
false	After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of  <e1> loratadine </e1>  to 11 subjects, the AUC and Cmax of  <e2> loratadine </e2>  averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.
advise	It is recommended that plasma lithium levels be monitored when  <e1> ketoprofen </e1>  is coadministered with  <e2> lithium </e2> .
false	It is recommended that plasma  <e1> lithium </e1>  levels be monitored when ketoprofen is coadministered with  <e2> lithium </e2> .
false	however, in a study of 12 normal subjects, concurrent administration of aspirin decreased  <e1> ketoprofen </e1>  protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without  <e2> aspirin </e2>  to 0.11 L/kg/h with aspirin.
mechanism	Methotrexate:  <e1> Ketoprofen </e1> , like other NSAIDs, may cause changes in the elimination of  <e2> methotrexate </e2>  leading to elevated serum levels of the drug and increased toxicity.
false	 <e1> Methotrexate </e1> : Ketoprofen, like other NSAIDs, may cause changes in the elimination of  <e2> methotrexate </e2>  leading to elevated serum levels of the drug and increased toxicity.
false	however, in a study of 12 normal subjects, concurrent administration of aspirin decreased  <e1> ketoprofen </e1>  protein binding and increased  <e2> ketoprofen </e2>  plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.
false	 <e1> Digoxin </e1> : In a study in 12 patients with congestive heart failure where  <e2> ketoprofen </e2>  and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.
false	 <e1> Warfarin </e1> : In a short-term controlled study in 14 normal volunteers,  <e2> ketoprofen </e2>  did not significantly interfere with the effect of warfarin on prothrombin time.
false	Antacids: Concomitant administration of  <e1> magnesium hydroxide </e1>  and  <e2> aluminum hydroxide </e2>  does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.
false	Coadministration of NIZORAL  Tablets with  <e1> midazolam </e1>  or  <e2> triazolam </e2>  has resulted in elevated plasma concentrations of the latter two drugs.
false	 <e1> Digoxin </e1> : In a study in 12 patients with congestive heart failure where ketoprofen and  <e2> digoxin </e2>  were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.
false	Aspirin:  <e1> Ketoprofen </e1>  does not alter  <e2> aspirin </e2>  absorption;
false	however, in a study of 12 normal subjects, concurrent administration of  <e1> aspirin </e1>  decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with  <e2> aspirin </e2> .
mechanism	Probenecid:  <e1> Probenecid </e1>  increases both free and bound  <e2> ketoprofen </e2>  by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.
false	Therapeutic concentrations of digoxin, warfarin,  <e1> ibuprofen </e1> , naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter  <e2> ketorolac tromethamine </e2>  protein binding.
false	Although these results do not indicate a significant interaction between TORADOL and  <e1> warfarin </e1>  or  <e2> heparin </e2> , the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
false	Methotrexate: Concomitant administration of  <e1> methotrexate </e1>  and some NSAIDs has been reported to reduce the clearance of  <e2> methotrexate </e2> , enhancing the toxicity of methotrexate.
false	 <e1> Ketorolac </e1>  does not alter  <e2> digoxin </e2>  protein binding.
false	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen,  <e1> phenytoin </e1>  andtolbutamide did not alter  <e2> ketorolac tromethamine </e2>  protein binding.
false	Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam,  <e1> acetaminophen </e1> , phenytoin andtolbutamide did not alter  <e2> ketorolac tromethamine </e2>  protein binding.
false	Probenecid: Concomitant administration of TORADOL ORAL and  <e1> probenecid </e1>  resulted in decreased clearance of ketorolac and significant increases in  <e2> ketorolac </e2>  plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.
false	The following drug interactions have been identified involving  <e1> NIZORAL </e1>  Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of  <e2> terfenadine </e2> , resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.
advise	Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of  <e1> TORADOL </e1>  to patients taking  <e2> anticoagulants </e2>  should be done extremely cautiously, and patients should be closely monitored.
false	 <e1> Warfarin </e1> , Digoxin,  <e2> Salicylate </e2> , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
false	 <e1> Antiepileptic Drugs </e1> : Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin,  <e2> carbamazepine </e2> ).
false	 <e1> Warfarin </e1> , Digoxin, Salicylate, and Heparin The in vitro binding of  <e2> warfarin </e2>  to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
false	 <e1> Psychoactive Drugs </e1> : Hallucinations have been reported when  <e2> TORADOL </e2>  was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
false	The effect of TORADOL on plasma  <e1> lithium </e1>  has not been studied, but cases of increased  <e2> lithium </e2>  plasma levels during TORADOL therapy have been reported.
effect	Diuretic:  <e1> Hydrochlorothiazide </e1> , given concomitantly with  <e2> ketoprofen </e2> , produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
false	Warfarin, Digoxin,  <e1> Salicylate </e1> , and Heparin The in vitro binding of  <e2> warfarin </e2>  to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
false	 <e1> Morphine </e1> : TORADOLIV/IM has been administered concurrently with  <e2> morphine </e2>  in several clinical trials of postoperative pain without evidence of adverse interactions.
false	 <e1> Antiepileptic Drugs </e1> : Sporadic cases of seizures have been reported during concomitant use of TORADOL and  <e2> antiepileptic drugs </e2>  (phenytoin, carbamazepine).
false	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking  <e1> psychoactive drugs </e1>  (fluoxetine,  <e2> thiothixene </e2> , alprazolam).
false	 <e1> Antiepileptic Drugs </e1> : Sporadic cases of seizures have been reported during concomitant use of  <e2> TORADOL </e2>  and antiepileptic drugs (phenytoin, carbamazepine).
false	Warfarin,  <e1> Digoxin </e1> ,  <e2> Salicylate </e2> , and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
false	The effect of TORADOL on plasma  <e1> lithium </e1>  has not been studied, but cases of increased lithium plasma levels during  <e2> TORADOL </e2>  therapy have been reported.
false	Furosemide:  <e1> TORADOL </e1>  IV/IM reduced the  <e2> diuretic </e2>  response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
false	Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and  <e1> digoxin </e1>  were concomitantly administered,  <e2> ketoprofen </e2>  did not alter the serum levels of digoxin.
false	Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of  <e1> warfarin </e1>  to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when  <e2> ketorolac </e2>  plasma concentrations reach 5 to10 m g/mL.
false	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs ( <e1> fluoxetine </e1> ,  <e2> thiothixene </e2> , alprazolam).
mechanism	Probenecid: Concomitant administration of  <e1> TORADOL </e1>  ORAL and  <e2> probenecid </e2>  resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.
effect	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of  <e1> TORADOL </e1>  and  <e2> antiepileptic drugs </e2>  (phenytoin, carbamazepine).
false	Diuretic:  <e1> Hydrochlorothiazide </e1> , given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to  <e2> hydrochlorothiazide </e2>  alone.
false	The effect of  <e1> TORADOL </e1>  on  <e2> methotrexate </e2>  clearance has not been studied.
effect	Psychoactive Drugs: Hallucinations have been reported when  <e1> TORADOL </e1>  was used in patients taking psychoactive drugs ( <e2> fluoxetine </e2> , thiothixene, alprazolam).
false	Warfarin,  <e1> Digoxin </e1> , Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by  <e2> ketorolac tromethamine </e2>  (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
false	 <e1> Furosemide </e1> : TORADOL IV/IM reduced the  <e2> diuretic </e2>  response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
false	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking  <e1> psychoactive drugs </e1>  (fluoxetine, thiothixene,  <e2> alprazolam </e2> ).
false	The effect of  <e1> TORADOL </e1>  on plasma lithium has not been studied, but cases of increased lithium plasma levels during  <e2> TORADOL </e2>  therapy have been reported.
false	Therapeutic concentrations of digoxin, warfarin, ibuprofen,  <e1> naproxen </e1> , piroxicam, acetaminophen,  <e2> phenytoin </e2>  andtolbutamide did not alter ketorolac tromethamine protein binding.
false	Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine,  <e1> thiothixene </e1> ,  <e2> alprazolam </e2> ).
mechanism	Coadministration of  <e1> NIZORAL </e1>   Tablets with midazolam or  <e2> triazolam </e2>  has resulted in elevated plasma concentrations of the latter two drugs.
false	Furosemide: TORADOL IV/IM reduced the  <e1> diuretic </e1>  response to  <e2> furosemide </e2>  in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
false	Although these results do not indicate a significant interaction between TORADOL and  <e1> warfarin </e1>  or heparin, the administration of  <e2> TORADOL </e2>  to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
false	Paclitaxel - In one report,  <e1> L-glutamine </e1>  at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of  <e2> paclitaxel </e2> .
false	 <e1> Indomethacin </e1>  - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by  <e2> indomethacin </e2> .
false	 <e1> Paclitaxel </e1>  - In one report,  <e2> L-glutamine </e2>  at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
effect	In another report, nine patients with breast cancer were reported to have decreased symptoms of  <e1> methotrexate </e1> -related toxicity when given supplemental  <e2> L-glutamine </e2>  at a dose of 0.5 gram/kilogram/day.
false	H1 and  <e1> H2 Blockers </e1>  - Although not reported,  <e2> L-histidine </e2> , via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
false	 <e1> Paclitaxel </e1>  - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving  <e2> paclitaxel </e2> , appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
false	 <e1> Human growth hormone </e1>  - Concomitant use of  <e2> L-glutamine </e2>  and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.
effect	Medroxyprogesterone Acetate -  <e1> L-histidine </e1>  was observed to enhance (in tissue culture) the effect of  <e2> medroxyprogesterone acetate </e2>  in reducing the number of human breast cancer cells that were in the S phase.
false	H1 and H2  <e1> Blockers </e1>  - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2  <e2> blockers </e2> .
false	 <e1> Gentamicin </e1>  -  <e2> Methionine </e2>  may protect against the ototoxic effects of gentamicin.
effect	Acetaminophen and methotrexate -  <e1> L-methionine </e1>  may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking  <e2> methotrexate </e2> .
false	 <e1> Gentamicin </e1>  - Methionine may protect against the ototoxic effects of  <e2> gentamicin </e2> .
false	 <e1> Non-selective monoamine oxidase (MAO) inhibitors </e1>  - including phenelzine sulfate, tranylcypromine sulfate and  <e2> pargyline </e2>  HC1.
false	 <e1> Neuroleptic Drugs </e1>  - L-phenylalanine may potentiate the tardive dyskinesia side reactions of  <e2> neuroleptic drugs </e2>  if used concomitantly with them.
effect	 <e1> Neuroleptic Drugs </e1>  -  <e2> L-phenylalanine </e2>  may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.
false	Non-selective monoamine oxidase (MAO) inhibitors - including  <e1> phenelzine sulfate </e1> , tranylcypromine sulfate and  <e2> pargyline </e2>  HC1.
false	Monoamine oxidase (MAO) inhibitors such as  <e1> isocarboxazid </e1>  (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g.,  <e2> Eldepryl </e2> ), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	 <e1> Monoamine oxidase (MAO) inhibitors </e1>  such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane),  <e2> selegiline </e2>  (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as  <e1> isocarboxazid </e1>  (e.g.,  <e2> Marplan </e2> ), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g.,  <e1> Marplan </e1> ), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g.,  <e2> Eldepryl </e2> ), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan),  <e1> phenelzine </e1>  (e.g.,  <e2> Nardil </e2> ), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane),  <e1> selegiline </e1>  (e.g., Eldepryl), and  <e2> tranylcypromine </e2>  (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil),  <e1> procarbazine </e1>  (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with  <e2> L-tryptophan </e2>  may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as  <e1> isocarboxazid </e1>  (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g.,  <e2> Matulane </e2> ), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g.,  <e1> Eldepryl </e1> ), and tranylcypromine (e.g., Parnate): Using these medicines with  <e2> L-tryptophan </e2>  may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil),  <e1> procarbazine </e1>  (e.g., Matulane),  <e2> selegiline </e2>  (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g.,  <e1> Marplan </e1> ),  <e2> phenelzine </e2>  (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g.,  <e1> Marplan </e1> ), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with  <e2> L-tryptophan </e2>  may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil),  <e1> procarbazine </e1>  (e.g., Matulane), selegiline (e.g.,  <e2> Eldepryl </e2> ), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g.,  <e1> Marplan </e1> ), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g.,  <e2> Parnate </e2> ): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as  <e1> isocarboxazid </e1>  (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane),  <e2> selegiline </e2>  (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane),  <e1> selegiline </e1>  (e.g., Eldepryl), and tranylcypromine (e.g.,  <e2> Parnate </e2> ): Using these medicines with L-tryptophan may increase the chance of side effects.
false	Monoamine oxidase (MAO) inhibitors such as  <e1> isocarboxazid </e1>  (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and  <e2> tranylcypromine </e2>  (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
false	 <e1> Non-selective MAO inhibitors </e1>  including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of  <e2> L-tyrosine </e2>  and non-selective MAO inhibitors may cause hypertension.
false	Non-selective MAO inhibitors including  <e1> tranylcypromine sulfate </e1> , phenelzine sulfate, and  <e2> pargyline </e2>  HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.
false	 <e1> Non-selective MAO inhibitors </e1>  including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective  <e2> MAO inhibitors </e2>  may cause hypertension.
false	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g.,  <e1> Matulane </e1> ), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with  <e2> L-tryptophan </e2>  may increase the chance of side effects.
false	In one survey, 2.3% of patients taking  <e1> labetalol HCl </e1>  in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with  <e2> labetalol HCl </e2>  alone.
false	In one survey, 2.3% of patients taking labetalol HCl in combination with  <e1> tricyclic antidepressants </e1>  experienced tremor, as compared to 0.7% reported to occur with  <e2> labetalol HCl </e2>  alone.
effect	 <e1> Labetalol HCl </e1>  blunts the reflex tachycardia produced by  <e2> nitroglycerin </e2>  without preventing its hypotensive effect.
false	Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with  <e1> lactulose </e1>  may inhibit the desired  <e2> lactulose </e2> -induced drop in colonic pH.
false	There is no information regarding the effect on  <e1> lamivudine </e1>  pharmacokinetics of higher doses of TMP/ <e2> SMX </e2>  such as those used to treat Pneumocystis carinii pneumonia.
false	therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g.  <e1> ketoconazole </e1> ,  <e2> ampicillin </e2>  esters, iron salts, digoxin).
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol,  <e1> prednisone </e1> , diazepam, clarithromycin, or  <e2> terfenadine </e2>  in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin,  <e1> antipyrine </e1> , indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or  <e2> terfenadine </e2>  in healthy subjects.
false	 <e1> Lansoprazole </e1>  has also been shown to have no clinically significant interaction with  <e2> amoxicillin </e2> .
false	therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole,  <e1> ampicillin </e1>  esters, iron salts,  <e2> digoxin </e2> ).
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine,  <e1> indomethacin </e1> , ibuprofen, phenytoin, propranolol, prednisone, diazepam,  <e2> clarithromycin </e2> , or terfenadine in healthy subjects.
false	Studies have shown that  <e1> lansoprazole </e1>  does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin,  <e2> propranolol </e2> , prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone,  <e1> diazepam </e1> , clarithromycin, or  <e2> terfenadine </e2>  in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as  <e1> warfarin </e1> , antipyrine, indomethacin, ibuprofen, phenytoin, propranolol,  <e2> prednisone </e2> , diazepam, clarithromycin, or terfenadine in healthy subjects.
false	Studies have shown that  <e1> lansoprazole </e1>  does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam,  <e2> clarithromycin </e2> , or terfenadine in healthy subjects.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin,  <e1> antipyrine </e1> , indomethacin,  <e2> ibuprofen </e2> , phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
false	In a single-dose crossover study examining  <e1> lansoprazole </e1>  30 mg and omeprazole 20 mg each administered alone and concomitantly with  <e2> sucralfate </e2>  1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as  <e1> warfarin </e1> , antipyrine,  <e2> indomethacin </e2> , ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
mechanism	In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the  <e1> proton pump inhibitors </e1>  was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with  <e2> sucralfate </e2> .
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin,  <e1> antipyrine </e1> , indomethacin, ibuprofen, phenytoin, propranolol, prednisone,  <e2> diazepam </e2> , clarithromycin, or terfenadine in healthy subjects.
false	In a single-dose crossover study examining  <e1> lansoprazole </e1>  30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with  <e2> sucralfate </e2> .
false	 <e1> Carbamazepine </e1> : In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to  <e2> lapatinib </e2>  was decreased approximately 72%.
false	Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes  <e1> Lapatinib </e1>  undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter  <e2> lapatinib </e2>  concentrations significantly.
mechanism	Carbamazepine: In healthy subjects receiving the CYP3A4 inducer,  <e1> carbamazepine </e1> , at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to  <e2> lapatinib </e2>  was decreased approximately 72%.
false	 <e1> Ketoconazole </e1> : In healthy subjects receiving  <e2> ketoconazole </e2> , a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
false	therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters,  <e1> iron </e1>  salts,  <e2> digoxin </e2> ).
false	Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin,  <e1> propranolol </e1> , prednisone,  <e2> diazepam </e2> , clarithromycin, or terfenadine in healthy subjects.
false	Effects of  <e1> Lapatinib </e1>  on Drug Metabolizing Enzymes and Drug Transport Systems  <e2> Lapatinib </e2>  inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.
false	Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of  <e1> rifampin </e1> , M1 peak levels were increased (~40%) over those seen when  <e2> ARAVA </e2>  was given alone.
false	 <e1> Cholestyramine </e1>  and Charcoal Administration of cholestyramine or  <e2> activated charcoal </e2>  in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
mechanism	Rifampin: Following concomitant administration of a single dose of  <e1> ARAVA </e1>  to subjects receiving multiple doses of  <e2> rifampin </e2> , M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.
false	Cholestyramine and  <e1> Charcoal </e1>  Administration of  <e2> cholestyramine </e2>  or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
false	In vitro studies have shown that precipitation occurs when eye drops containing  <e1> thimerosal </e1>  are mixed with  <e2> latanoprost </e2> .
false	Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and  <e1> S- w <e2> arfarin </e1>  </e2> .
false	Rifampin: Following concomitant administration of a single dose of  <e1> ARAVA </e1>  to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when  <e2> ARAVA </e2>  was given alone.
false	Expected changes in laboratory assessments of PT and INR were observed after  <e1> warfarin </e1>  administration, but these changes were not affected by concomitant  <e2> lenalidomide </e2>  administration.
false	Concomitant treatment with thrombolytics (eg, rt-PA or  <e1> streptokinase </e1> ) may: - increase the risk of bleeding complications - considerably enhance the effect of  <e2> REFLUDAN </e2>  on aPTT prolongation
false	(See CLINICAL PHARMACOLOGY) Coadministration of Femara and  <e1> tamoxifen </e1>  20 mg daily resulted in a reduction of  <e2> letrozole </e2>  plasma levels by 38% on average.
false	Concomitant treatment with  <e1> thrombolytics </e1>  (eg, rt-PA or  <e2> streptokinase </e2> ) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation
effect	 <e1> Folic acid </e1>  in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and  <e2> primidone </e2> , and increase the frequency of seizures in susceptible pediatric patients.
false	 <e1> ERGAMISOL </e1>   ( <e2> levamisole hydrochloride </e2> ) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.
effect	 <e1> Leucovorin </e1>  may enhance the toxicity of  <e2> 5-fluorouracil </e2> .
false	 <e1> Warfarin </e1>   <e2> Keppra </e2>   (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital,  <e1> phenytoin </e1> , primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these  <e2> AEDs </e2>  during placebo-controlled clinical studies.
false	Dose adjustment is not recommended. <e1> Levetiracetam </e1>  had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or  <e2> lamotrigine </e2> .
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and  <e1> valproate </e1> ) were also assessed by evaluating the serum concentrations of levetiracetam and these  <e2> AEDs </e2>  during placebo-controlled clinical studies.
false	 <e1> Digoxin </e1>  Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of  <e2> digoxin </e2>  given as a 0.25 mg dose every day.
false	Potential drug interactions between Keppra  and other AEDs ( <e1> carbamazepine </e1> , gabapentin,  <e2> lamotrigine </e2> , phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	These data indicate that levetiracetam does not influence the plasma concentration of other  <e1> AEDs </e1>  and that these AEDs do not influence the pharmacokinetics of  <e2> levetiracetam </e2> .
false	In addition,  <e1> levetiracetam </e1>  does not affect the in vitro glucuronidation of  <e2> valproic acid </e2> .
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin,  <e1> lamotrigine </e1> , phenobarbital, phenytoin,  <e2> primidone </e2>  and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Dose adjustment is not recommended. <e1> Levetiracetam </e1>  had no effect on plasma concentrations of carbamazepine, valproate,  <e2> topiramate </e2> , or lamotrigine.
false	 <e1> Valproate </e1>  Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of  <e2> valproate </e2>  in healthy volunteers.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of  <e1> levetiracetam </e1>  and these  <e2> AEDs </e2>  during placebo-controlled clinical studies.
false	Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs ( <e1> AEDs </e1> ) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of  <e2> phenytoin </e2>  in patients with refractory epilepsy.
false	Drug-Drug Interactions Between  <e1> Keppra </e1>   And Other Antiepileptic Drugs (AEDs) Phenytoin  <e2> Keppra </e2>   (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin,  <e1> primidone </e1>  and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these  <e2> AEDs </e2>  during placebo-controlled clinical studies.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin,  <e1> valproate </e1> , oral  <e2> contraceptive </e2> , digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Warfarin  <e1> Keppra </e1>   (1000 mg twice daily) did not influence the pharmacokinetics of R and S  <e2> warfarin </e2> .
false	 <e1> Valproate </e1>   <e2> Keppra </e2>   (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.
false	Drug-Drug Interactions Between Keppra  And Other  <e1> Antiepileptic Drugs </e1>  (AEDs) Phenytoin  <e2> Keppra </e2>   (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin,  <e1> lamotrigine </e1> , phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these  <e2> AEDs </e2>  during placebo-controlled clinical studies.
false	 <e1> Warfarin </e1>  Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R and  <e2> S warfarin </e2> .
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral  <e1> contraceptive </e1> , digoxin,  <e2> warfarin </e2> , probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine,  <e1> valproate </e1> ,  <e2> topiramate </e2> , or lamotrigine.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin,  <e1> warfarin </e1> ,  <e2> probenecid </e2> ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( <e1> phenytoin </e1> , valproate, oral contraceptive, digoxin, warfarin,  <e2> probenecid </e2> ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Folic acid in large amounts may counteract the antiepileptic effect of  <e1> phenobarbital </e1> , phenytoin and  <e2> primidone </e2> , and increase the frequency of seizures in susceptible pediatric patients.
false	Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin  <e1> Keppra </e1>   (3000 mg daily) had no effect on the pharmacokinetic disposition of  <e2> phenytoin </e2>  in patients with refractory epilepsy.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive,  <e1> digoxin </e1> , warfarin,  <e2> probenecid </e2> ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine,  <e1> gabapentin </e1> , lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of  <e2> levetiracetam </e2>  and these AEDs during placebo-controlled clinical studies.
false	Although  <e1> BETAGAN </e1>  used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and  <e2> epinephrine </e2>  may occur.
effect	The concomitant use of  <e1> beta-adrenergic blocking agents </e1>  with digitalis and  <e2> calcium antagonist </e2> s may have additive effects on prolonging atrioventricular conduction time.
false	Other Drug Interactions Oral Contraceptives  <e1> Keppra </e1>   (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg  <e2> ethinyl estradiol </e2>  and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.
false	The concomitant use of beta-adrenergic blocking agents with  <e1> digitalis </e1>  and  <e2> calcium antagonist </e2> s may have additive effects on prolonging atrioventricular conduction time.
false	Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral  <e1> contraceptive </e1> , digoxin, warfarin,  <e2> probenecid </e2> ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
false	and calcium channel antagonists e.g.,  <e1> verapamil </e1> ), CYP1A2 inducers ( <e2> omeprazole </e2> ) and CYP1A2 inhibitors (furafylline and clarithromycin).
false	Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin,  <e1> phenobarbital </e1> , rifampin), CYP3A4 inhibitors (azole antimycotics e.g.,  <e2> ketoconazole </e2> ;
mechanism	Although no clinical studies have been conducted, it is likely that the metabolism of  <e1> levobupivacaine </e1>  may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g.,  <e2> ketoconazole </e2> ;
false	Potential drug interactions between Keppra  and other AEDs (carbamazepine,  <e1> gabapentin </e1> , lamotrigine,  <e2> phenobarbital </e2> , phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
false	Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin,  <e1> phenobarbital </e1> ,  <e2> rifampin </e2> ), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
false	and calcium channel antagonists e.g.,  <e1> verapamil </e1> ), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors ( <e2> furafylline </e2>  and clarithromycin).
false	Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as  <e1> phenytoin </e1> ,  <e2> phenobarbital </e2> , rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
mechanism	However, the systemic administration of some  <e1> quinolones </e1>  has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of  <e2> caffeine </e2> , and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
false	Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as  <e1> phenytoin </e1> , phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g.,  <e2> ketoconazole </e2> ;
false	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral  <e1> anticoagulant </e1>  warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic  <e2> cyclosporine </e2>  concomitantly.
false	and  <e1> calcium channel antagonists </e1>  e.g., verapamil), CYP1A2 inducers ( <e2> omeprazole </e2> ) and CYP1A2 inhibitors (furafylline and clarithromycin).
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg,  <e1> alcohol </e1> , sedatives, hypnotics, other  <e2> opioids </e2> , general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of  <e1> theophylline </e1> , interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant  <e2> warfarin </e2>  and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
effect	Interactions with Other CNS Agents: Concurrent use of  <e1> Levo-Dromoran </e1>  with all central nervous system depressants (eg,  <e2> alcohol </e2> , sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates,  <e1> tricyclic antidepressants </e1> ,  <e2> phenothiazines </e2> , tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
advise	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg,  <e1> pentazocine </e1> , nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as  <e2> Levo-Dromoran </e2> .
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol,  <e1> sedatives </e1> ,  <e2> hypnotics </e2> , other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine,  <e1> nalbuphine </e1> ,  <e2> butorphanol </e2> , dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
advise	Interactions with Mixed Agonist/Antagonist Opioid Analgesics:  <e1> Agonist/antagonist analgesics </e1>  (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as  <e2> Levo-Dromoran </e2> .
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives,  <e1> hypnotics </e1> , other opioids, general  <e2> anesthetics </e2> , barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics:  <e1> Agonist/antagonist analgesics </e1>  (eg,  <e2> pentazocine </e2> , nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates,  <e1> tricyclic antidepressants </e1> , phenothiazines, tranquilizers, skeletal muscle relaxants and  <e2> antihistamines </e2> ) may result in additive central nervous system depressant effects.
false	Interactions with  <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol,  <e2> dezocine </e2>  and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all  <e1> central nervous system depressants </e1>  (eg,  <e2> alcohol </e2> , sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives,  <e1> hypnotics </e1> , other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and  <e2> antihistamines </e2> ) may result in additive central nervous system depressant effects.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg,  <e1> pentazocine </e1> , nalbuphine, butorphanol,  <e2> dezocine </e2>  and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg,  <e1> alcohol </e1> , sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers,  <e2> skeletal muscle relaxants </e2>  and antihistamines) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of  <e1> Levo-Dromoran </e1>  with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics,  <e2> barbiturates </e2> , tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with  <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> :  <e2> Agonist/antagonist analgesics </e2>  (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates,  <e1> tricyclic antidepressants </e1> , phenothiazines, tranquilizers,  <e2> skeletal muscle relaxants </e2>  and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics:  <e1> Agonist/antagonist analgesics </e1>  (eg, pentazocine, nalbuphine, butorphanol,  <e2> dezocine </e2>  and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants,  <e1> phenothiazines </e1> , tranquilizers,  <e2> skeletal muscle relaxants </e2>  and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg,  <e1> alcohol </e1> ,  <e2> sedatives </e2> , hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all  <e1> central nervous system depressants </e1>  (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics,  <e2> barbiturates </e2> , tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
effect	Interactions with Other CNS Agents: Concurrent use of  <e1> Levo-Dromoran </e1>  with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates,  <e2> tricyclic antidepressants </e2> , phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg,  <e1> pentazocine </e1> , nalbuphine, butorphanol, dezocine and  <e2> buprenorphine </e2> ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with  <e1> captopril </e1> , beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or  <e2> itraconazole </e2> .
false	Interactions with  <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (eg, pentazocine, nalbuphine,  <e2> butorphanol </e2> , dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin,  <e1> isosorbide mononitrate </e1> ,  <e2> carvedilol </e2> , ethanol or itraconazole.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with  <e1> captopril </e1> , beta-blockers, felodipine, digoxin, warfarin,  <e2> isosorbide mononitrate </e2> , carvedilol, ethanol or itraconazole.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin,  <e1> warfarin </e1> , isosorbide mononitrate, carvedilol,  <e2> ethanol </e2>  or itraconazole.
false	No Important Interactions To Date  <e1> Levosimendan </e1>  does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol,  <e2> ethanol </e2>  or itraconazole.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other  <e1> opioids </e1> , general anesthetics, barbiturates,  <e2> tricyclic antidepressants </e2> , phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants,  <e1> phenothiazines </e1> ,  <e2> tranquilizers </e2> , skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with  <e1> captopril </e1> , beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate,  <e2> carvedilol </e2> , ethanol or itraconazole.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril,  <e1> beta-blockers </e1> , felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or  <e2> itraconazole </e2> .
false	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics,  <e1> barbiturates </e1> ,  <e2> tricyclic antidepressants </e2> , phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate,  <e1> carvedilol </e1> ,  <e2> ethanol </e2>  or itraconazole.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril,  <e1> beta-blockers </e1> , felodipine, digoxin,  <e2> warfarin </e2> , isosorbide mononitrate, carvedilol, ethanol or itraconazole.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane,  <e2> nitroprusside </e2> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones,  <e1> asparaginase </e1> , clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid,  <e2> mefenamic acid </e2> , methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e1> lithium </e1> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam,  <e1> dopamine </e1>  and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e2> dopamine agonists </e2> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide,  <e2> glucocorticoids </e2> , meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e1> diazepam </e1> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e1> metoclopramide </e1> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	 <e1> Somatrem </e1> /Somatropin: Excessive concurrent use of  <e2> thyroid hormone </e2>  may accelerate epiphyseal closure.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase,  <e1> clofibrate </e1> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids,  <e2> meclofenamic acid </e2> , mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related  <e1> anabolic hormones </e1> , asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone,  <e2> perphenazine </e2> , phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e1> carbamazepine </e1> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e2> dopamine agonists </e2> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	 <e1> Antidiabetic Agents </e1>  (Insulin,  <e2> Sulfonylureas </e2> ): Requirements for insulin or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
mechanism	Binding to Serum Proteins: The following agents may either inhibit  <e1> levothyroxine sodium </e1>  binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase,  <e2> clofibrate </e2> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid,  <e2> mefenamic acid </e2> , methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e1> 6-mercaptopurine </e1> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e2> diazepam </e2> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e1> glucocorticoids </e1> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e2> iodine-containing compounds </e2> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e1> lovastatin </e1> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Cytokines ( <e1> interferon </e1> , interleukin):  <e2> Cytokines </e2>  have been reported to induce both hyperthyroidism and hypothyroidism.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e1> levodopa </e1> , lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam,  <e2> dopamine </e2>  and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e2> resorcinol </e2> , rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e1> phenobarbital </e1> , phenytoin, resorcinol,  <e2> rifampin </e2> , somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related  <e1> anabolic hormones </e1> , asparaginase, clofibrate, estrogens and estrogen-containing compounds,  <e2> 5-fluorouracil </e2> , furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e1> lovastatin </e1> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e2> resorcinol </e2> , rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate,  <e1> estrogens </e1>  and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin,  <e2> salicylates </e2> , tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam,  <e1> dopamine </e1>  and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e2> perchlorate </e2> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
mechanism	Binding to Serum Proteins: The following agents may either inhibit  <e1> levothyroxine sodium </e1>  binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone,  <e2> phenytoin </e2> , salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e2> glucocorticoids </e2> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate,  <e1> estrogens </e1>  and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates,  <e2> tamoxifen </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e2> rifampin </e2> , somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e1> diazepam </e1> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e1> levodopa </e1> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e2> rifampin </e2> , somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e2> carbamazepine </e2> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e1> carbamazepine </e1> , chloral hydrate, diazepam, dopamine and dopamine agonists,  <e2> ethionamide </e2> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> ,  <e2> pertechnetate </e2> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e1> levodopa </e1> , lovastatin, lithium, 6-mercaptopurine, metoclopramide,  <e2> mitotane </e2> , nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam,  <e1> dopamine </e1>  and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e2> rifampin </e2> , somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related  <e1> anabolic hormones </e1> , asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide,  <e2> glucocorticoids </e2> , meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e1> dopamine agonists </e1> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related  <e1> anabolic hormones </e1> , asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine,  <e2> phenylbutazone </e2> , phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane,  <e2> nitroprusside </e2> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e1> rifampin </e1> , somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
mechanism	Binding to Serum Proteins: The following agents may either inhibit  <e1> levothyroxine sodium </e1>  binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates,  <e2> tamoxifen </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e2> rifampin </e2> , somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane,  <e2> nitroprusside </e2> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e2> diazepam </e2> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e2> heparin </e2> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril,  <e1> beta-blockers </e1> , felodipine, digoxin, warfarin,  <e2> isosorbide mononitrate </e2> , carvedilol, ethanol or itraconazole.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions ( <e2> thiocyanate </e2> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e1> methadone </e1> , perphenazine, phenylbutazone, phenytoin,  <e2> salicylates </e2> , tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide,  <e1> glucocorticoids </e1> , meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin,  <e2> salicylates </e2> , tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> ,  <e2> p-aminosalicylic acid </e2> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e1> dopamine agonists </e1> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane,  <e2> nitroprusside </e2> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e1> levodopa </e1> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate,  <e2> perchlorate </e2> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase,  <e1> clofibrate </e1> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone,  <e2> perphenazine </e2> , phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone,  <e1> perphenazine </e1> , phenylbutazone, phenytoin, salicylates,  <e2> tamoxifen </e2> .
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones,  <e1> asparaginase </e1> , clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine,  <e2> phenylbutazone </e2> , phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone,  <e2> androgens </e2>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e2> dopamine agonists </e2> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase,  <e1> clofibrate </e1> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide,  <e2> glucocorticoids </e2> , meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate,  <e1> estrogens </e1>  and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid,  <e2> mefenamic acid </e2> , methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e1> iodine-containing compounds </e1> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related  <e1> anabolic hormones </e1> , asparaginase, clofibrate,  <e2> estrogens </e2>  and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e1> 6-mercaptopurine </e1> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e2> sulfonamides </e2> , sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide,  <e1> glucocorticoids </e1> , meclofenamic acid, mefenamic acid, methadone,  <e2> perphenazine </e2> , phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> ,  <e2> carbamazepine </e2> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide,  <e2> mitotane </e2> , nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and  <e1> estrogen-containing compounds </e1> , 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone,  <e2> phenytoin </e2> , salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and  <e1> estrogen-containing compounds </e1> , 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid,  <e2> mefenamic acid </e2> , methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate,  <e1> estrogens </e1>  and estrogen-containing compounds, 5-fluorouracil,  <e2> furosemide </e2> , glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e2> rifampin </e2> , somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
mechanism	Binding to Serum Proteins: The following agents may either inhibit  <e1> levothyroxine sodium </e1>  binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide,  <e2> glucocorticoids </e2> , meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Antidiabetic Agents (Insulin,  <e1> Sulfonylureas </e1> ): Requirements for  <e2> insulin </e2>  or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e1> metoclopramide </e1> , mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds,  <e1> 5-fluorouracil </e1> , furosemide,  <e2> glucocorticoids </e2> , meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related  <e1> anabolic hormones </e1> , asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil,  <e2> furosemide </e2> , glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones,  <e1> asparaginase </e1> , clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates,  <e2> tamoxifen </e2> .
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds,  <e1> 5-fluorouracil </e1> ,  <e2> furosemide </e2> , glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e2> iodine-containing compounds </e2> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e1> glucocorticoids </e1> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane,  <e2> nitroprusside </e2> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and  <e1> estrogen-containing compounds </e1> , 5-fluorouracil,  <e2> furosemide </e2> , glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	 <e1> Theophylline </e1> :  <e2> Theophylline </e2>  clearance may decrease in hypothyroid patients and return toward normal when a euthyroid state is achieved.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones,  <e1> asparaginase </e1> , clofibrate, estrogens and estrogen-containing compounds,  <e2> 5-fluorouracil </e2> , furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e1> diazepam </e1> , dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e2> heparin </e2> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase,  <e1> clofibrate </e1> , estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine,  <e2> phenylbutazone </e2> , phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e1> dopamine agonists </e1> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
mechanism	Binding to Serum Proteins: The following agents may either inhibit  <e1> levothyroxine sodium </e1>  binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e2> methadone </e2> , perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane,  <e2> nitroprusside </e2> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate,  <e1> estrogens </e1>  and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone,  <e2> perphenazine </e2> , phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> , diazepam, dopamine and dopamine agonists,  <e2> ethionamide </e2> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs,  <e1> sulfonamides </e1> , sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e1> phenytoin </e1> , resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e2> resorcinol </e2> , rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e1> carbamazepine </e1> ,  <e2> chloral hydrate </e2> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e1> lovastatin </e1> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e2> rifampin </e2> , somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	 <e1> Antidiabetic Agents </e1>  ( <e2> Insulin </e2> , Sulfonylureas): Requirements for insulin or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam,  <e1> dopamine </e1>  and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide,  <e2> mitotane </e2> , nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane,  <e2> nitroprusside </e2> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e1> phenytoin </e1> ,  <e2> resorcinol </e2> , rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds,  <e1> 5-fluorouracil </e1> , furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin,  <e2> salicylates </e2> , tamoxifen.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase,  <e1> clofibrate </e1> ,  <e2> estrogens </e2>  and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e2> dopamine agonists </e2> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> ,  <e2> androgens </e2>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin,  <e1> resorcinol </e1> , rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e1> insulin </e1> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds,  <e1> 5-fluorouracil </e1> , furosemide, glucocorticoids, meclofenamic acid, mefenamic acid,  <e2> methadone </e2> , perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e2> glucocorticoids </e2> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e1> lovastatin </e1> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e1> somatostatin analogs </e1> , sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	 <e1> Levothyroxine Sodium </e1>  Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride,  <e2> ferrous sulfate </e2> , sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e1> glucocorticoids </e1> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e2> glucocorticoids </e2> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e1> rifampin </e1> ,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e1> ethionamide </e1> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e1> ethionamide </e1> , glucocorticoids,  <e2> heparin </e2> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e2> heparin </e2> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide,  <e1> glucocorticoids </e1> , heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane,  <e2> nitroprusside </e2> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Although no interaction between  <e1> MAO inhibitors </e1>  and  <e2> Levo-Dromoran </e2>  has been observed, it is not recommended for use with MAO inhibitors.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	 <e1> b-Adrenergic Blocking Agents </e1> : Actions of some of  <e2> beta-blocking agents </e2>  may be impaired when hypothyroid patients become euthyroid.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e2> dopamine agonists </e2> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam,  <e2> dopamine </e2>  and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e2> diazepam </e2> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e1> lithium </e1> , 6-mercaptopurine, metoclopramide, mitotane,  <e2> nitroprusside </e2> , phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> ,  <e2> b-adrenergic blocking agents </e2> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide,  <e1> p-aminosalicylic acid </e1> , amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide,  <e2> mitotane </e2> , nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
mechanism	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of  <e1> levothyroxine sodium </e1>  from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride,  <e2> ferrous sulfate </e2> , sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e2> b-adrenergic blocking agents </e2> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e1> lovastatin </e1> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents,  <e1> carbamazepine </e1> , chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e1> ethionamide </e1> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and  <e1> dopamine agonists </e1> , ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e2> rifampin </e2> , somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds,  <e2> levodopa </e2> , lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs,  <e1> b-adrenergic blocking agents </e1> , carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e2> iodine-containing compounds </e2> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	 <e1> Antidiabetic Agents </e1>  (Insulin, Sulfonylureas): Requirements for insulin or oral  <e2> antidiabetic agents </e2>  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
effect	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or norepinephrine to patients receiving  <e2> monoamine oxidase inhibitors </e2>  or tricyclic antidepressants may produce severe, prolonged hypertension.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids,  <e1> meclofenamic acid </e1> , mefenamic acid,  <e2> methadone </e2> , perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e2> antithyroid drugs </e2> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e2> ethionamide </e2> , glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	 <e1> Levothyroxine Sodium </e1>  Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide,  <e2> cholestyramine </e2>  resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine,  <e1> chloral hydrate </e1> , diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital,  <e2> phenytoin </e2> , resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid,  <e1> amiodarone </e1> , androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e2> pertechnetate </e2> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone,  <e1> phenytoin </e1> , salicylates,  <e2> tamoxifen </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol,  <e1> rifampin </e1> , somatostatin analogs, sulfonamides, sulfonylureas,  <e2> thiazide diuretics </e2> .
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> ,  <e2> perchlorate </e2> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists,  <e1> ethionamide </e1> , glucocorticoids, heparin, hepatic enzyme inducers,  <e2> insulin </e2> , iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	The administration of local  <e1> anesthetic solutions </e1>  containing epinephrine or  <e2> norepinephrine </e2>  to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone,  <e1> perphenazine </e1> , phenylbutazone, phenytoin,  <e2> salicylates </e2> , tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate,  <e1> perchlorate </e1> , pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine,  <e2> metoclopramide </e2> , mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin,  <e2> somatostatin analogs </e2> , sulfonamides, sulfonylureas, thiazide diuretics.
false	Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract:  <e1> aluminum hydoxide </e1> ,  <e2> cholestyramine </e2>  resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions ( <e1> thiocyanate </e1> , perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents,  <e2> iodine-containing compounds </e2> , levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate,  <e1> pertechnetate </e1> ), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides,  <e2> sulfonylureas </e2> , thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  <e1> aminoglutethimide </e1> , p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium,  <e2> 6-mercaptopurine </e2> , metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	The administration of local anesthetic solutions containing  <e1> epinephrine </e1>  or  <e2> norepinephrine </e2>  to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
effect	Antagonism between  <e1> lincomycin </e1>  and  <e2> erythromycin </e2>  in vitro has been demonstrated.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate),  <e1> antithyroid drugs </e1> , b-adrenergic blocking agents, carbamazepine, chloral hydrate,  <e2> diazepam </e2> , dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins:  <e1> androgens </e1>  and related anabolic hormones, asparaginase, clofibrate, estrogens and  <e2> estrogen-containing compounds </e2> , 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone,  <e1> androgens </e1>  and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin,  <e2> lithium </e2> , 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e1> lovastatin </e1> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside,  <e2> phenobarbital </e2> , phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids,  <e1> heparin </e1> , hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa,  <e2> lovastatin </e2> , lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
false	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including  <e1> antidepressants </e1>  such as selective serotonin reuptake inhibitors ( <e2> SSRIs </e2> ), have been reported.
false	Commonly used drugs such as  <e1> phenylpropanolamine </e1>  and  <e2> pseudoephedrine </e2>  have been specifically studied.
false	Initial doses of  <e1> adrenergic agents </e1> , such as  <e2> dopamine </e2>  or epinephrine, should be reduced and titrated to achieve the desired response.
effect	Adrenergic Agents:Some individuals receiving  <e1> ZYVOX </e1>  may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or  <e2> dopaminergic agents </e2> .
false	Therefore, linezolid has the potential for interaction with  <e1> adrenergic </e1>  and  <e2> serotonergic agents </e2> .
effect	Adrenergic Agents:Some individuals receiving  <e1> ZYVOX </e1>  may experience a reversible enhancement of the pressor response to indirect-acting  <e2> sympathomimetic agents </e2> , vasopressor or dopaminergic agents.
false	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and  <e1> serotonergic agents </e1> , including  <e2> antidepressants </e2>  such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing  <e1> estrogens </e1> , iodine-containing preparations and the numerous preparations containing  <e2> salicylates </e2> .
false	 <e1> Vasopressor </e1> s: Thyroxine increases the adrenergic effect of catecholamines such as  <e2> epinephrine </e2>  and norepinephrine.
false	 <e1> Tricyclic Antidepressants </e1> : Use of thyroid products with imipramine and other  <e2> tricyclic antidepressants </e2>  may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy:  <e1> androgens </e1> , corticosteroids, estrogens, oral contraceptives containing  <e2> estrogens </e2> , iodine-containing preparations and the numerous preparations containing salicylates.
mechanism	Cholestyramine:  <e1> Cholestyramine </e1>  binds both  <e2> T4 </e2>  and T3 in the intestine, thus impairing absorption of these thyroid hormones.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on  <e1> thyroid hormone </e1>  therapy: androgens, corticosteroids, estrogens, oral contraceptives containing  <e2> estrogens </e2> , iodine-containing preparations and the numerous preparations containing salicylates.
false	 <e1> Vasopressor </e1> s:  <e2> Thyroxine </e2>  increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.
false	Cholestyramine:  <e1> Cholestyramine </e1>  binds both T4 and T3 in the intestine, thus impairing absorption of these  <e2> thyroid hormones </e2> .
advise	Therefore, 4 to 5 hours should elapse between administration of  <e1> cholestyramine </e1>  and  <e2> thyroid hormones </e2> .
false	Cholestyramine: Cholestyramine binds both  <e1> T4 </e1>  and T3 in the intestine, thus impairing absorption of these  <e2> thyroid hormones </e2> .
false	Pregnancy  <e1> estrogens </e1>  and estrogen-containing oral  <e2> contraceptives </e2>  increase TBg concentrations.
false	Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting  <e1> sympathomimetic agents </e1> ,  <e2> vasopressor </e2>  or dopaminergic agents.
false	Tricyclic Antidepressants: Use of thyroid products with  <e1> imipramine </e1>  and other  <e2> tricyclic antidepressants </e2>  may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
false	Insulin or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in  <e1> insulin </e1>  or oral  <e2> hypoglycemic </e2>  requirements.
false	Cholestyramine: Cholestyramine binds both T4 and  <e1> T3 </e1>  in the intestine, thus impairing absorption of these  <e2> thyroid hormones </e2> .
false	 <e1> Tricyclic Antidepressants </e1> : Use of  <e2> thyroid products </e2>  with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
false	 <e1> Insulin </e1>  or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in  <e2> insulin </e2>  or oral hypoglycemic requirements.
effect	Digitalis:  <e1> Thyroid preparations </e1>  may potentiate the toxic effects of  <e2> digitalis </e2> .
false	Chlorpromazine:  <e1> Chlorpromazine </e1>  blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat  <e2> amphetamine </e2>  poisoning.
false	 <e1> Norepinephrine </e1> : Amphetamines enhance the adrenergic effect of  <e2> norepinephrine </e2> .
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on  <e1> thyroid hormone </e1>  therapy: androgens, corticosteroids,  <e2> estrogens </e2> , oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
false	Urinary acidifying agents These agents ( <e1> ammonium chloride </e1> ,  <e2> sodium acid phosphate </e2> , etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
effect	Meperidine:  <e1> Amphetamines </e1>  potentiate the analgesic effect of  <e2> meperidine </e2> .
false	 <e1> Meperidine </e1> :  <e2> Amphetamines </e2>  potentiate the analgesic effect of meperidine.
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens,  <e1> corticosteroids </e1> , estrogens, oral contraceptives containing  <e2> estrogens </e2> , iodine-containing preparations and the numerous preparations containing salicylates.
false	 <e1> Meperidine </e1> : Amphetamines potentiate the analgesic effect of  <e2> meperidine </e2> .
false	 <e1> Methenamine </e1>  therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in  <e2> methenamine </e2>  therapy.
false	 <e1> Norepinephrine </e1> :  <e2> Amphetamines </e2>  enhance the adrenergic effect of norepinephrine.
false	 <e1> Haloperidol </e1> : Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of  <e2> amphetamines </e2> .
false	 <e1> Antihistamines </e1> :  <e2> Amphetamines </e2>  may counteract the sedative effect of antihistamines.
mechanism	 <e1> d-amphetamine </e1>  with desipramine or  <e2> protriptyline </e2>  and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
effect	Lithium carbonate: The anorectic and stimulatory effects of  <e1> amphetamines </e1>  may be inhibited by  <e2> lithium carbonate </e2> .
false	 <e1> Lithium carbonate </e1> : The anorectic and stimulatory effects of amphetamines may be inhibited by  <e2> lithium carbonate </e2> .
false	Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens,  <e1> corticosteroids </e1> ,  <e2> estrogens </e2> , oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
effect	Tricyclic Antidepressants: Use of  <e1> thyroid products </e1>  with imipramine and other  <e2> tricyclic antidepressants </e2>  may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
mechanism	Phenobarbital:  <e1> Amphetamines </e1>  may delay intestinal absorption of  <e2> phenobarbital </e2> ;
false	Other Agents: PRINIVIL has been used concomitantly with  <e1> nitrates </e1>  and/or  <e2> digoxin </e2>  without evidence of clinically significant adverse interactions.
false	Studies with ACE inhibitors in combination with  <e1> diuretics </e1>  indicate that the dose of the  <e2> ACE inhibitor </e2>  can be reduced when it is given with a diuretic.
effect	Use of  <e1> PRINIVIL </e1>  with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride),  <e2> potassium </e2>  supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	Other Agents:  <e1> PRINIVIL </e1>  has been used concomitantly with  <e2> nitrates </e2>  and/or digoxin without evidence of clinically significant adverse interactions.
false	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of  <e1> PRINIVIL </e1>  alone were compared to PRINIVIL given concomitantly with  <e2> indomethacin </e2> , the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.
false	Studies with  <e1> ACE inhibitors </e1>  in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a  <e2> diuretic </e2> .
effect	The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the  <e1> diuretic </e1>  or increasing the salt intake prior to initiation of treatment with  <e2> PRINIVIL </e2> .
false	 <e1> Adrenergic blockers </e1>   <e2> Adrenergic blockers </e2>  are inhibited by amphetamines.
false	 <e1> Antidepressants </e1> , tricyclic Amphetamines may enhance the activity of  <e2> tricyclic antidepressants </e2>  or sympathomimetic agents;
false	The possibility of hypotensive effects with  <e1> PRINIVIL </e1>  can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with  <e2> PRINIVIL </e2> .
effect	Use of  <e1> PRINIVIL </e1>  with  <e2> potassium-sparing diuretics </e2>  (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
advise	It is recommended that serum lithium levels be monitored frequently if  <e1> PRINIVIL </e1>  is administered concomitantly with  <e2> lithium </e2> .
false	Use of PRINIVIL with potassium-sparing diuretics (e.g.,  <e1> spironolactone </e1> , triamterene, or  <e2> amiloride </e2> ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	 <e1> Non-steroidal Anti-inflammatory Agents </e1> : In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of  <e2> lisinopril </e2>  may result in a further deterioration of renal function.
false	Lithium:  <e1> Lithium </e1>  toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including  <e2> ACE inhibitors </e2> .
effect	Use of  <e1> PRINIVIL </e1>  with potassium-sparing diuretics (e.g., spironolactone, triamterene, or  <e2> amiloride </e2> ), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
false	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of  <e1> PRINIVIL </e1>  alone were compared to  <e2> PRINIVIL </e2>  given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.
false	Lithium:  <e1> Lithium </e1>  toxicity has been reported in patients receiving  <e2> lithium </e2>  concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
false	The possibility of hypotensive effects with  <e1> PRINIVIL </e1>  can be minimized by either discontinuing the  <e2> diuretic </e2>  or increasing the salt intake prior to initiation of treatment with PRINIVIL.
effect	-  <e1> Lofexidine </e1>  may enhance the effects of  <e2> anti-hypertensive drug </e2>  therapy
false	Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended  <e1> phenytoin sodium </e1>  capsules (100 mg tid) were coadministered with  <e2> lomefloxacin </e2>  (400 mg qd) for five days in 15 healthy males.
false	Theophylline: In three pharmacokinetic studies including 46 normal, healthy subjects,  <e1> theophylline </e1>  clearance and concentration were not significantly altered by the addition of  <e2> lomefloxacin </e2> .
false	Antacids and sucralfate:  <e1> Sucralfate </e1>  and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  ( <e2> didanosine </e2> ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
false	Phenytoin: No significant differences were observed in mean  <e1> phenytoin </e1>  AUC, C max , C min or T max (although C max increased by 11%) when extended  <e2> phenytoin sodium </e2>  capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.
false	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as  <e1> Videx </e1>   ( <e2> didanosine </e2> ), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
effect	Warfarin:  <e1> Quinolones </e1>  may enhance the effects of the oral anticoagulant,  <e2> warfarin </e2> , or its derivatives.
false	In clinical studies where patients were on chronic  <e1> theophylline </e1>  therapy, lomefloxacin had no measurable effect on the mean distribution of  <e2> theophylline </e2>  concentrations or the mean estimates of theophylline clearance.
false	 <e1> Phenytoin </e1> : No significant differences were observed in mean  <e2> phenytoin </e2>  AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.
false	Antacids and  <e1> sucralfate </e1> : Sucralfate and antacids containing  <e2> magnesium </e2>  or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
false	 <e1> Terfenadine </e1> : No clinically significant changes occurred in heart rate or corrected QT intervals, or in  <e2> terfenadine </e2>  metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.
false	In clinical studies where patients were on chronic theophylline therapy,  <e1> lomefloxacin </e1>  had no measurable effect on the mean distribution of  <e2> theophylline </e2>  concentrations or the mean estimates of theophylline clearance.
mechanism	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as  <e1> Videx </e1>   (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with  <e2> lomefloxacin </e2>  and interfere with its bioavailability.
mechanism	Magnesium- and  <e1> aluminum </e1> -containing antacids, administered concomitantly with  <e2> lomefloxacin </e2> , significantly decreased the bioavailability (48%) of lomefloxacin.
false	Interaction between  <e1> lomefloxacin </e1>  and  <e2> cyclosporine </e2>  has not been studied.
mechanism	Separating the doses of  <e1> antacid </e1>  and  <e2> lomefloxacin </e2>  minimizes this decrease in bioavailability;
false	 <e1> Cimetidine </e1> :  <e2> Cimetidine </e2>  has been demonstrated to interfere with the elimination of other quinolones.
false	 <e1> Terfenadine </e1> : No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and  <e2> terfenadine </e2>  at steady-state in 28 healthy males.
false	Antacids and sucralfate: Sucralfate and antacids containing magnesium or  <e1> aluminum </e1> , as well as formulations containing divalent and trivalent cations such as  <e2> Videx </e2>   (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
false	Antacids and sucralfate: Sucralfate and  <e1> antacids </e1>  containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as  <e2> Videx </e2>   (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
false	Warfarin: Quinolones may enhance the effects of the oral  <e1> anticoagulant </e1> ,  <e2> warfarin </e2> , or its derivatives.
false	- Lofexidine may enhance the CNS depressive effects of  <e1> alcohol </e1> , barbiturates and other  <e2> sedatives </e2> 
false	Antacids and sucralfate: Sucralfate and antacids containing  <e1> magnesium </e1>  or  <e2> aluminum </e2> , as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
false	 <e1> Warfarin </e1> : Quinolones may enhance the effects of the oral anticoagulant,  <e2> warfarin </e2> , or its derivatives.
false	 <e1> Magnesium </e1> - and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of  <e2> lomefloxacin </e2> .
false	In clinical studies where patients were on chronic theophylline therapy,  <e1> lomefloxacin </e1>  had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of  <e2> theophylline </e2>  clearance.
false	Antacids and  <e1> sucralfate </e1> :  <e2> Sucralfate </e2>  and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
false	 <e1> Warfarin </e1> :  <e2> Quinolones </e2>  may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
mechanism	Magnesium- and aluminum-containing  <e1> antacids </e1> , administered concomitantly with  <e2> lomefloxacin </e2> , significantly decreased the bioavailability (48%) of lomefloxacin.
false	Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by  <e1> probenecid </e1>  and resulted in an approximate 80% increase in the AUC for  <e2> loracarbef </e2> .
false	 <e1> Probenecid </e1> : As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for  <e2> loracarbef </e2> .
false	There does not appear to be an increase in adverse events in subjects who received oral  <e1> contraceptives </e1>  and  <e2> loratadine </e2> .
false	TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and  <e1> Descarboethoxyloratadine </e1>  After 10 Days of Coadministration ( <e2> Loratadine </e2>  10 mg) in Normal Volunteers
false	TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of  <e1> Loratadine </e1>  and  <e2> Descarboethoxyloratadine </e2>  After 10 Days of Coadministration (Loratadine 10 mg) in Normal Volunteers
false	Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or  <e1> descarboethoxyloratadine </e1>  were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of  <e2> loratadine </e2> , as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.
false	Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of  <e1> loratadine </e1>  with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of  <e2> loratadine </e2> , as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.
false	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines,  <e1> barbiturates </e1> , MAO inhibitors, and other antidepressants.When  <e2> scopolamine </e2>  is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Although increased plasma concentrations (AUC 0-24 hrs) of  <e1> loratadine </e1>  and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of  <e2> loratadine </e2> , as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.
effect	Tablets: The  <e1> benzodiazepines </e1> , including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or  <e2> alcohol </e2> .
false	Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as  <e1> barbiturates </e1>  or  <e2> alcohol </e2> .
false	Injection:  <e1> Lorazepam </e1>  injection, like other injectable  <e2> benzodiazepines </e2> , produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
effect	Injection:  <e1> Lorazepam </e1>  injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines,  <e2> barbiturates </e2> , MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates,  <e1> MAO inhibitors </e1> , and other  <e2> antidepressants </e2> .When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Tablets: The  <e1> benzodiazepines </e1> , including  <e2> lorazepam </e2> , produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
effect	Injection:  <e1> Lorazepam </e1>  injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates,  <e2> MAO inhibitors </e2> , and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Injection:  <e1> Lorazepam </e1>  injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When  <e2> scopolamine </e2>  is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol,  <e1> phenothiazines </e1> , barbiturates,  <e2> MAO inhibitors </e2> , and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol,  <e1> phenothiazines </e1> , barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable  <e2> lorazepam </e2> , an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	As with other drugs that block angiotensin II or its effects, concomitant use of  <e1> potassium-sparing diuretics </e1>  (e.g., spironolactone, triamterene, amiloride),  <e2> potassium </e2>  supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
false	As with other drugs that block angiotensin II or its effects, concomitant use of  <e1> potassium-sparing diuretics </e1>  (e.g., spironolactone, triamterene,  <e2> amiloride </e2> ), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
false	As with other drugs that block angiotensin II or its effects, concomitant use of  <e1> potassium-sparing diuretics </e1>  (e.g., spironolactone,  <e2> triamterene </e2> , amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
false	As with other  <e1> antihypertensive agents </e1> , the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug  <e2> indomethacin </e2> 
effect	Injection:  <e1> Lorazepam </e1>  injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol,  <e2> phenothiazines </e2> , barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
false	Coumarin Anticoagulants: In a small clinical trial in which  <e1> lovastatin </e1>  was administered to  <e2> warfarin </e2>  treated patients, no effect on prothrombin time was detected.
false	 <e1> Coumarin Anticoagulant </e1> s: In a small clinical trial in which lovastatin was administered to  <e2> warfarin </e2>  treated patients, no effect on prothrombin time was detected.
false	Itraconazole  <e1> Ketoconazole </e1>  Erythromycin Clarithromycin Telithromycin  <e2> HIV protease inhibitors </e2>  Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
false	 <e1> Itraconazole </e1>   <e2> Ketoconazole </e2>  Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
false	 <e1> Itraconazole </e1>  Ketoconazole Erythromycin Clarithromycin Telithromycin  <e2> HIV protease inhibitors </e2>  Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
false	As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene,  <e1> amiloride </e1> ),  <e2> potassium </e2>  supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
false	 <e1> Digoxin </e1> : In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on  <e2> digoxin </e2>  plasma concentrations.
false	 <e1> Amiodarone </e1>  or  <e2> Verapamil </e2> : The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
false	Itraconazole Ketoconazole  <e1> Erythromycin </e1>   <e2> Clarithromycin </e2>  Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
false	Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin  <e1> HIV protease inhibitors </e1>  Nefazodone  <e2> Cyclosporine </e2>  Large quantities of grapefruit juice ( 1 quart daily)
false	 <e1> Danazol </e1> : The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of  <e2> lovastatin </e2>  (see WARNINGS, Myopathy/Rhabdomyolysis).
false	 <e1> Itraconazole </e1>  Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors  <e2> Nefazodone </e2>  Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
effect	Also, bleeding and/or increased prothrombin time have been reported in a few patients taking  <e1> coumarin anticoagulant </e1> s concomitantly with  <e2> lovastatin </e2> .
false	Itraconazole Ketoconazole Erythromycin Clarithromycin  <e1> Telithromycin </e1>  HIV protease inhibitors  <e2> Nefazodone </e2>  Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
false	Oral  <e1> Hypoglycemic Agents </e1> : In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with  <e2> glipizide </e2>  or with chlorpropamide
false	Itraconazole Ketoconazole Erythromycin  <e1> Clarithromycin </e1>  Telithromycin HIV protease inhibitors Nefazodone  <e2> Cyclosporine </e2>  Large quantities of grapefruit juice ( 1 quart daily)
false	 <e1> Itraconazole </e1>  Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone  <e2> Cyclosporine </e2>  Large quantities of grapefruit juice ( 1 quart daily)
false	 <e1> Gemfibrozil </e1>  Other fibrates  <e2> Niacin </e2>  (nicotinic acid) (=1 g/day)
false	The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies,  <e1> iron </e1>  or  <e2> zinc </e2>  supplements.
false	 <e1> Aspirin </e1> : Concurrent administration of aspirin may lower  <e2> meclofenamate sodium </e2>  plasma levels, possibly by competing for protein-binding sites.
false	Antacids: Concomitant administration of aluminum and  <e1> magnesium h <e2> ydroxide </e1>  </e2> s does not interfere with absorption of meclofenamate sodium.
false	Antacids: Concomitant administration of aluminum and magnesium  <e1> hydroxide </e1> s does not interfere with absorption of  <e2> meclofenamate sodium </e2> .
false	 <e1> Antacids </e1> : Concomitant administration of aluminum and  <e2> magnesium hydroxide </e2> s does not interfere with absorption of meclofenamate sodium.
false	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of  <e1> magnesium hydroxide </e1>  with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including  <e2> fluconazole </e2> , lovastatin and trimethoprim.
false	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of  <e1> mefenamic acid </e1>  increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including  <e2> fluconazole </e2> , lovastatin and trimethoprim.
effect	ACE inhibitors: Reports suggest that  <e1> NSAIDs </e1>  may diminish the antihypertensive effect of  <e2> ACE inhibitors </e2> .
false	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of  <e1> mefenamic acid </e1>  by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including  <e2> fluconazole </e2> , lovastatin and trimethoprim.
false	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of  <e1> mefenamic acid </e1>  by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and  <e2> trimethoprim </e2> .
false	 <e1> Antacids </e1> : In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including  <e2> fluconazole </e2> , lovastatin and trimethoprim.
false	 <e1> Furosemide </e1> : Clinical studies, as well as post-marketing observations, have shown that  <e2> NSAIDs </e2>  can reduce the natriuretic effect of furosemide and thiazides in some patients.
false	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of  <e1> mefenamic acid </e1>  increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole,  <e2> lovastatin </e2>  and trimethoprim.
advise	Aspirin: As with other NSAIDs, concomitant administration of  <e1> Ponstel </e1>  and  <e2> aspirin </e2>  is not generally recommended because of the potential of increased adverse effects.
false	 <e1> Aspirin </e1> : As with other NSAIDs, concomitant administration of  <e2> Ponstel </e2>  and aspirin is not generally recommended because of the potential of increased adverse effects.
mechanism	Lithium:  <e1> NSAIDs </e1>  have produced an elevation of plasma  <e2> lithium </e2>  levels and a reduction in renal lithium clearance.
false	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including  <e1> fluconazole </e1> , lovastatin and  <e2> trimethoprim </e2> .
false	Lithium: NSAIDs have produced an elevation of plasma  <e1> lithium </e1>  levels and a reduction in renal  <e2> lithium </e2>  clearance.
false	Concomitant administration of Mefloquine and other related compounds (eg,  <e1> quinine </e1> ,  <e2> quinidine </e2>  and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
false	In patients taking an anticonvulsant (eg,  <e1> valproic acid </e1> , carbamazepine, phenobarbital or  <e2> phenytoin </e2> ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
effect	Concomitant administration of  <e1> Mefloquine </e1>  and other related compounds (eg, quinine,  <e2> quinidine </e2>  and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
false	Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including  <e1> fluconazole </e1> ,  <e2> lovastatin </e2>  and trimethoprim.
effect	In patients taking an anticonvulsant (eg, valproic acid,  <e1> carbamazepine </e1> , phenobarbital or phenytoin), the concomitant use of  <e2> Mefloquine </e2>  may reduce seizure control by lowering the plasma levels of the anticonvulsant.
advise	Because of the danger of a potentially fatal prolongation of the QTc interval,  <e1> halofantrine </e1>  must not be given simultaneously with or subsequent to  <e2> Mefloquine </e2> .
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or  <e1> H1-blocking agents </e1> , tricyclic antidepressants and  <e2> phenothiazines </e2> ) might also contribute to a prolongation of the QTc interval.
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers,  <e1> antihistamines </e1>  or  <e2> H1-blocking agents </e2> , tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
false	Concomitant administration of Mefloquine and other related compounds (eg,  <e1> quinine </e1> , quinidine and  <e2> chloroquine </e2> ) may produce electrocardiographic abnormalities and increase the risk of convulsions.
false	 <e1> Antacids </e1> : Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of  <e2> meclofenamate sodium </e2> .
false	In patients taking an  <e1> anticonvulsant </e1>  (eg, valproic acid, carbamazepine, phenobarbital or  <e2> phenytoin </e2> ), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or  <e1> beta-adrenergic blocking agents </e1> , calcium channel blockers, antihistamines or H1-blocking agents,  <e2> tricyclic antidepressants </e2>  and phenothiazines) might also contribute to a prolongation of the QTc interval.
false	 <e1> ACE inhibitors </e1> : Reports suggest that  <e2> NSAIDs </e2>  may diminish the antihypertensive effect of ACE inhibitors.
effect	In patients taking an  <e1> anticonvulsant </e1>  (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of  <e2> Mefloquine </e2>  may reduce seizure control by lowering the plasma levels of the anticonvulsant.
false	 <e1> Cholestyramine </e1> -Concomitant intake of cholestyramine and  <e2> vitamin K </e2>  may reduce the absorption of vitamin K.
mechanism	Cholestyramine-Concomitant intake of  <e1> cholestyramine </e1>  and  <e2> vitamin K </e2>  may reduce the absorption of vitamin K.
false	Cholestyramine-Concomitant intake of cholestyramine and  <e1> vitamin K </e1>  may reduce the absorption of  <e2> vitamin K </e2> .
false	 <e1> Colestipol </e1> -Concomitant intake of colestipol and  <e2> vitamin K </e2>  may reduce the absorption of vitamin K.
false	 <e1> Warfarin </e1> -Vitamin K can antagonize the effect of  <e2> warfarin </e2> 
false	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( <e1> cefmenoxime </e1> , cefoperazone,  <e2> cefotetan </e2> , cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
false	 <e1> Cholestyramine </e1> -Concomitant intake of cholestyramine and vitamin K may reduce the absorption of  <e2> vitamin K </e2> .
false	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime,  <e1> cefoperazone </e1> , cefotetan, cefamandole,  <e2> latamoxef </e2> ) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
false	 <e1> Mineral Oil </e1> -Concomitant intake of  <e2> mineral oil </e2>  and vitamin K may reduce the absorption of vitamin K.
effect	When  <e1> Mefloquine </e1>  is taken concurrently with oral  <e2> live typhoid vaccines </e2> , attenuation of immunization cannot be excluded.
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or  <e1> beta-adrenergic blocking agents </e1> , calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and  <e2> phenothiazines </e2> ) might also contribute to a prolongation of the QTc interval.
false	Concomitant administration of Mefloquine and other related compounds (eg, quinine,  <e1> quinidine </e1>  and  <e2> chloroquine </e2> ) may produce electrocardiographic abnormalities and increase the risk of convulsions.
false	 <e1> Mineral Oil </e1> -Concomitant intake of mineral oil and  <e2> vitamin K </e2>  may reduce the absorption of vitamin K.
false	Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime,  <e1> cefoperazone </e1> , cefotetan, cefamandole, latamoxef) or methylthiadiazole ( <e2> cefazolin </e2> ) can cause vitamin K deficiency and hypoprothrombinemia.
false	 <e1> Orlistat </e1> -Orlistat may decrease the absorption of  <e2> vitamin K </e2> .
false	 <e1> Broad-Spectrum Antibiotics </e1> -Broad-spectrum antibiotics may sterilize the bowel and decrease the  <e2> vitamin K </e2>  contribution to the body by the intestinal microflora.
advise	 <e1> Nabilone </e1>  should be administered with caution to patients who are taking other  <e2> psychoactive drugs </e2>  or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
false	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or  <e1> CNS depressants </e1> , including  <e2> alcohol </e2> , barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
false	Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including  <e1> alcohol </e1> , barbiturates and  <e2> narcotic analgesics </e2> , or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
false	In patients taking an  <e1> anticonvulsant </e1>  (eg, valproic acid, carbamazepine,  <e2> phenobarbital </e2>  or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
false	Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium,  <e1> alcohol </e1>  or  <e2> codeine </e2> .
effect	 <e1> Nabilone </e1>  has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium,  <e2> alcohol </e2>  or codeine.
false	This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg,  <e1> anti-arrhythmic </e1>  or beta-adrenergic blocking agents, calcium channel blockers,  <e2> antihistamines </e2>  or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
false	Caution should be exercised when administering  <e1> nabumetone </e1>  with warfarin since interactions have been seen with other  <e2> NSAIDs </e2> .
false	When administered concurrently, the following drugs may interact with  <e1> beta-adrenergic receptor blocking agents </e1> : Anesthetics, general: exaggeration of the hypotension induced by general  <e2> anesthetics </e2> .
false	Therefore,  <e1> cyclosporine </e1>  serum levels should be monitored and appropriate  <e2> cyclosporine </e2>  dosage adjustments made when these drugs are used concomitantly.
false	Elevated serum levels of  <e1> cyclosporine </e1>  have been reported with the concomitant use of some quinolones and  <e2> cyclosporine </e2> .
effect	 <e1> Nitrofurantoin </e1>  interferes with the therapeutic action of  <e2> nalidixic acid </e2> .
false	Therefore, monitoring of  <e1> theophylline </e1>  plasma levels should be considered and dosage of  <e2> theophylline </e2>  adjusted, as required.
false	Elevated serum levels of  <e1> cyclosporine </e1>  have been reported with the concomitant use of some  <e2> quinolones </e2>  and cyclosporine.
mechanism	and Videx , ( <e1> Didanosine </e1> ), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of  <e2> quinolones </e2> , resulting in systemic levels considerably lower than desired.
false	Patients taking REVIA may not benefit from  <e1> opioid </e1>  containing medicines, such as cough and cold preparations, antidiarrheal preparations, and  <e2> opioid analgesics </e2> .
effect	The safety and efficacy of concomitant use of  <e1> REVIA </e1>  and  <e2> disulfiram </e2>  is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.
false	Naproxen and other NSAIDs can reduce the antihypertensive effect of  <e1> propranolol </e1>  and other  <e2> beta-blockers </e2> .
false	 <e1> Naproxen </e1> ,  <e2> naproxen sodium </e2>  and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
false	Similarly, patients receiving the drug and a  <e1> hydantoin </e1> ,  <e2> sulfonamide </e2>  or sulfonylurea should be observed for signs of toxicity to these drugs.
effect	Naproxen and other  <e1> NSAIDs </e1>  can reduce the antihypertensive effect of propranolol and other  <e2> beta-blockers </e2> .
false	Naproxen, naproxen sodium and other  <e1> NSAIDs </e1>  have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of  <e2> methotrexate </e2> .
advise	Concomitant administration of  <e1> naproxen </e1>  and  <e2> aspirin </e2>  is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
mechanism	 <e1> Probenecid </e1>  given concurrently increases  <e2> naproxen </e2>  anion plasma levels and extends its plasma half-life significantly.
advise	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or  <e1> methysergide </e1> ) and  <e2> naratriptan </e2>  within 24 hours is contraindicated.
false	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine,  <e1> fluvoxamine </e1> , paroxetine,  <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
false	Because there is a theoretical basis that these effects may be additive, use of  <e1> ergotamine </e1> -containing or ergot-type medications (like dihydroergotamine or  <e2> methysergide </e2> ) and naratriptan within 24 hours is contraindicated.
false	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine,  <e1> fluvoxamine </e1> ,  <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
false	Because there is a theoretical basis that these effects may be additive, use of  <e1> ergotamine </e1> -containing or  <e2> ergot-type medications </e2>  (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
false	Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e1> fluoxetine </e1> ,  <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
false	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant  <e1> interferon beta-1a </e1>  (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the  <e2> beta-interferon </e2>  or glatiramer acetate.
false	 <e1> Selective serotonin reuptake inhibitors </e1>  (SSRIs) (e.g., fluoxetine,  <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
false	The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered  <e1> AVONEX </e1>  ) and Study 2 (with co-administered  <e2> AVONEX </e2>  ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).
false	Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a ( <e1> AVONEX </e1>   30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or  <e2> glatiramer acetate </e2> .
false	Results of studies in multiple sclerosis patients taking  <e1> TYSABRI </e1>   and concomitant interferon beta-1a ( <e2> AVONEX </e2>   30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.
false	Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin,  <e1> phenytoin </e1> ,  <e2> acetylsalicylic acid </e2> , and tolbutamide in vitro .
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine,  <e1> pravastatin </e1> , glyburide, warfarin, phenytoin,  <e2> acetylsalicylic acid </e2> , tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril,  <e1> nicardipine </e1> , pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid,  <e2> tolbutamide </e2> , and metformin showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide,  <e1> propranolol </e1> , captopril, nicardipine,  <e2> pravastatin </e2> , glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	Metformin: When  <e1> Starlix </e1>  120 mg three times daily before meals was administered in combination with  <e2> metformin </e2>  500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide,  <e1> propranolol </e1> , captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid,  <e2> tolbutamide </e2> , and metformin showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine,  <e1> pravastatin </e1> , glyburide, warfarin,  <e2> phenytoin </e2> , acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as  <e1> furosemide </e1> , propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of  <e2> nateglinide </e2>  protein binding.
false	Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide,  <e1> nicardipine </e1> , warfarin,  <e2> phenytoin </e2> , acetylsalicylic acid, and tolbutamide in vitro .
false	Similarly, nateglinide had no influence on the serum protein binding of  <e1> propranolol </e1> , glyburide, nicardipine, warfarin,  <e2> phenytoin </e2> , acetylsalicylic acid, and tolbutamide in vitro .
false	Similarly,  <e1> nateglinide </e1>  had no influence on the serum protein binding of propranolol, glyburide, nicardipine,  <e2> warfarin </e2> , phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
effect	Certain drugs, including nonsteroidal anti-inflammatory agents ( <e1> NSAIDs </e1> ), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral  <e2> antidiabetic drugs </e2> .
effect	Certain drugs, including  <e1> nonsteroidal anti-inflammatory agents </e1>  (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral  <e2> antidiabetic drugs </e2> .
effect	Certain drugs including thiazides, corticosteroids, thyroid products, and  <e1> sympathomimetics </e1>  may reduce the hypoglycemic action of Starlix and other oral  <e2> antidiabetic drugs </e2> .
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin,  <e1> glyburide </e1> , warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and  <e2> metformin </e2>  showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol,  <e1> captopril </e1> , nicardipine, pravastatin, glyburide, warfarin,  <e2> phenytoin </e2> , acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine,  <e1> pravastatin </e1> , glyburide, warfarin, phenytoin, acetylsalicylic acid,  <e2> tolbutamide </e2> , and metformin showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and  <e1> metformin </e1>  showed no influence on the extent of  <e2> nateglinide </e2>  protein binding.
false	 <e1> Warfarin </e1> : When healthy subjects were administered  <e2> Starlix </e2>  120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.
false	In vitro displacement studies with highly protein-bound drugs such as  <e1> furosemide </e1> , propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid,  <e2> tolbutamide </e2> , and metformin showed no influence on the extent of nateglinide protein binding.
false	Certain drugs including  <e1> thiazides </e1> , corticosteroids, thyroid products, and  <e2> sympathomimetics </e2>  may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin,  <e1> acetylsalicylic acid </e1> , tolbutamide, and metformin showed no influence on the extent of  <e2> nateglinide </e2>  protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol,  <e1> captopril </e1> , nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of  <e2> nateglinide </e2>  protein binding.
false	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates,  <e1> monoamine oxidase inhibitors </e1> , and  <e2> non-selective beta-adrenergic-blocking agents </e2>  may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	 <e1> Digoxin </e1> : When  <e2> Starlix </e2>  120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.
effect	Certain drugs including  <e1> thiazides </e1> , corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of  <e2> Starlix </e2>  and other oral antidiabetic drugs.
false	Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide,  <e1> nicardipine </e1> ,  <e2> warfarin </e2> , phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide,  <e1> warfarin </e1> , phenytoin, acetylsalicylic acid, tolbutamide, and  <e2> metformin </e2>  showed no influence on the extent of nateglinide protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide,  <e1> propranolol </e1> , captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of  <e2> nateglinide </e2>  protein binding.
false	In vitro displacement studies with highly protein-bound drugs such as  <e1> furosemide </e1> , propranolol, captopril, nicardipine,  <e2> pravastatin </e2> , glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	Certain drugs including  <e1> thiazides </e1> , corticosteroids,  <e2> thyroid products </e2> , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	Certain drugs, including nonsteroidal anti-inflammatory agents ( <e1> NSAIDs </e1> ), salicylates, monoamine oxidase inhibitors, and  <e2> non-selective beta-adrenergic-blocking agents </e2>  may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
effect	Certain drugs including thiazides, corticosteroids,  <e1> thyroid products </e1> , and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral  <e2> antidiabetic drugs </e2> .
false	In vitro displacement studies with highly protein-bound drugs such as furosemide,  <e1> propranolol </e1> , captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin,  <e2> acetylsalicylic acid </e2> , tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
false	In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral  <e1> bronchodilators </e1> , and inhaled  <e2> corticosteroids </e2> , with no evidence of increased frequency of adverse events or laboratory abnormalities.
false	In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine,  <e1> pravastatin </e1> , glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and  <e2> metformin </e2>  showed no influence on the extent of nateglinide protein binding.
false	Diclofenac: Administration of morning and lunch doses of  <e1> Starlix </e1>  120 mg in combination with a single 75-mg dose of  <e2> diclofenac </e2>  in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.
false	In clinical studies,  <e1> Tilade </e1>  has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators, and inhaled  <e2> corticosteroids </e2> , with no evidence of increased frequency of adverse events or laboratory abnormalities.
false	Coadministration of  <e1> VIRACEPT </e1>  and drugs that induce CYP3A may decrease  <e2> nelfinavir </e2>  plasma concentrations and reduce its therapeutic effect.
false	* This table is not all inclusive **  <e1> VIRACEPT </e1>  may not be effective due to decreased  <e2> nelfinavir </e2>  plasma concentrations in patients taking these agents concomitantly
false	Saquinavir: Coadministration of  <e1> saquinavir </e1>  (using an experimental soft-gelatin capsule formulation of  <e2> saquinavir </e2>  1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.
false	Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in  <e1> nelfinavir </e1>  plasma AUC and a 51% increase in  <e2> indinavir </e2>  plasma A.C.
false	Based on known metabolic profiles, clinically significant drug interactions are not expected between  <e1> VIRACEPT </e1>  and dapsone, trimethoprim/sulfamethoxazole, clarithromycin,  <e2> erythromycin </e2> , itraconazole or fluconazole.
false	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/ <e1> sulfamethoxazole </e1> , clarithromycin, erythromycin, itraconazole or  <e2> fluconazole </e2> .
false	Little or no change in the pharmacokinetics of either drug was observed when  <e1> VIRACEPT </e1>  was coadministered with lamivudine or  <e2> stavudine </e2> .
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone,  <e1> quinidine </e1>  Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin  <e2> Benzodiazepines </e2>  midazolam, triazolam GI motility agents: cisapride
false	Ethinyl Estradiol and  <e1> Norethindrone </e1> : Coadministration of  <e2> VIRACEPT </e2>  with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.
false	Rifabutin: Coadministration of  <e1> rifabutin </e1>  and VIRACEPT resulted in a 32% decrease in  <e2> nelfinavir </e2>  plasma AUC and a 207% increase in rifabutin plasma A.C.
mechanism	Rifampin: Coadministration of  <e1> rifampin </e1>  and  <e2> VIRACEPT </e2>  resulted in an 82% decrease in nelfinavir plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT  <e1> Antiarrhythmics </e1> :  <e2> amiodarone </e2> , quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives  <e1> Antimycobacterial agents </e1> : rifampin Benzodiazepines midazolam, triazolam GI motility agents:  <e2> cisapride </e2> 
false	 <e1> Rifampin </e1> : Coadministration of  <e2> rifampin </e2>  and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine:  <e1> ergot derivatives </e1>  Antimycobacterial agents: rifampin  <e2> Benzodiazepines </e2>  midazolam, triazolam GI motility agents: cisapride
false	 <e1> Ketoconazole </e1> : Coadministration of ketoconazole with  <e2> VIRACEPT </e2>  resulted in a 35% increase in nelfinavir plasma A.C.
advise	Drugs That Should Not Be Coadministered With  <e1> VIRACEPT </e1>  Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin  <e2> Benzodiazepines </e2>  midazolam, triazolam GI motility agents: cisapride
false	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone,  <e1> trimethoprim </e1> /sulfamethoxazole, clarithromycin, erythromycin,  <e2> itraconazole </e2>  or fluconazole.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines:  <e1> astemizole </e1> , terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines  <e2> midazolam </e2> , triazolam GI motility agents: cisapride
advise	Drugs That Should Not Be Coadministered With  <e1> VIRACEPT </e1>  Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents:  <e2> cisapride </e2> 
false	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/ <e1> sulfamethoxazole </e1> , clarithromycin,  <e2> erythromycin </e2> , itraconazole or fluconazole.
false	 <e1> Saquinavir </e1> : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with  <e2> VIRACEPT </e2>  resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.
false	Saquinavir: Coadministration of  <e1> saquinavir </e1>  (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in  <e2> nelfinavir </e2>  plasma AUC and a 4-fold increase in saquinavir plasma A.C.
false	 <e1> Ethinyl Estradiol </e1>  and Norethindrone: Coadministration of VIRACEPT with  <e2> OVCON-35 </e2>  resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents:  <e1> rifampin </e1>  Benzodiazepines midazolam, triazolam GI motility agents:  <e2> cisapride </e2> 
false	Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in  <e1> ethinyl estradiol </e1>  and an 18% decrease in  <e2> norethindrone </e2>  plasma concentrations.
false	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/ <e1> sulfamethoxazole </e1> ,  <e2> clarithromycin </e2> , erythromycin, itraconazole or fluconazole.
false	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone,  <e1> trimethoprim </e1> /sulfamethoxazole, clarithromycin, erythromycin, itraconazole or  <e2> fluconazole </e2> .
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics:  <e1> amiodarone </e1> , quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents:  <e2> rifampin </e2>  Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Coadministration of  <e1> VIRACEPT </e1>  and drugs that inhibit CYP3A may increase  <e2> nelfinavir </e2>  plasma concentrations.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole,  <e1> terfenadine </e1>  Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents:  <e2> cisapride </e2> 
false	Rifabutin: Coadministration of  <e1> rifabutin </e1>  and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in  <e2> rifabutin </e2>  plasma A.C.
false	Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in  <e1> nelfinavir </e1>  plasma AUC and very little change in  <e2> ritonavir </e2>  plasma A.C.
false	Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin,  <e1> erythromycin </e1> ,  <e2> itraconazole </e2>  or fluconazole.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine  <e1> Antihistamines </e1> : astemizole,  <e2> terfenadine </e2>  Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Ketoconazole: Coadministration of  <e1> ketoconazole </e1>  with VIRACEPT resulted in a 35% increase in  <e2> nelfinavir </e2>  plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole,  <e1> terfenadine </e1>  Antimigraine: ergot derivatives  <e2> Antimycobacterial agents </e2> : rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Based on known metabolic profiles, clinically significant drug interactions are not expected between  <e1> VIRACEPT </e1>  and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin,  <e2> itraconazole </e2>  or fluconazole.
advise	Drugs That Should Not Be Coadministered With  <e1> VIRACEPT </e1>  Antiarrhythmics: amiodarone,  <e2> quinidine </e2>  Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives  <e1> Antimycobacterial agents </e1> : rifampin Benzodiazepines midazolam,  <e2> triazolam </e2>  GI motility agents: cisapride
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines  <e1> midazolam </e1> ,  <e2> triazolam </e2>  GI motility agents: cisapride
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines:  <e1> astemizole </e1> , terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents:  <e2> cisapride </e2> 
advise	Drugs That Should Not Be Coadministered With  <e1> VIRACEPT </e1>  Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam,  <e2> triazolam </e2>  GI motility agents: cisapride
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole,  <e1> terfenadine </e1>  Antimigraine:  <e2> ergot derivatives </e2>  Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Drugs That Should Not Be Coadministered With VIRACEPT  <e1> Antiarrhythmics </e1> : amiodarone, quinidine Antihistamines: astemizole,  <e2> terfenadine </e2>  Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	 <e1> Ritonavir </e1> : Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in  <e2> nelfinavir </e2>  plasma AUC and very little change in ritonavir plasma A.C.
false	Caution should also be taken in concurrent or serial use of other aminoglycosides and  <e1> polymyxins </e1>  because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate  <e2> neomycin sulfate </e2>  neuromuscular blocking effects.
false	 <e1> Rifabutin </e1> : Coadministration of  <e2> rifabutin </e2>  and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.
mechanism	Oral  <e1> neomycin </e1>  inhibits the gastrointestinal absorption of  <e2> penicillin V </e2> , oral vitamin B-12, methotrexate and 5-fluorouracil.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines:  <e1> astemizole </e1> ,  <e2> terfenadine </e2>  Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral  <e1> vitamin B-12 </e1> , methotrexate and  <e2> 5-fluorouracil </e2> .
false	Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with  <e1> lamivudine </e1>  or  <e2> stavudine </e2> .
false	Ritonavir: Coadministration of  <e1> ritonavir </e1>  with VIRACEPT resulted in a 152% increase in  <e2> nelfinavir </e2>  plasma AUC and very little change in ritonavir plasma A.C.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone,  <e1> quinidine </e1>  Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives  <e2> Antimycobacterial agents </e2> : rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
advise	A dose adjustment is not needed when  <e1> zidovudine </e1>  is administered with  <e2> VIRACEPT </e2> .
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics:  <e1> amiodarone </e1> , quinidine Antihistamines: astemizole,  <e2> terfenadine </e2>  Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
false	 <e1> Rifabutin </e1> : Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in  <e2> rifabutin </e2>  plasma A.C.
false	 <e1> Saquinavir </e1> : Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in  <e2> nelfinavir </e2>  plasma AUC and a 4-fold increase in saquinavir plasma A.C.
false	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs),  <e1> salicylates </e1> , monoamine oxidase inhibitors, and  <e2> non-selective beta-adrenergic-blocking agents </e2>  may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
false	The co-administration of  <e1> Natrecor </e1>  with IV vasodilators such as nitroglycerin, nitroprusside,  <e2> milrinone </e2> , or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
false	The co-administration of Natrecor with IV  <e1> vasodilators </e1>  such as nitroglycerin, nitroprusside,  <e2> milrinone </e2> , or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
false	The co-administration of Natrecor with IV vasodilators such as nitroglycerin,  <e1> nitroprusside </e1> , milrinone, or IV  <e2> ACE inhibitors </e2>  has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
false	The co-administration of Natrecor with IV  <e1> vasodilators </e1>  such as nitroglycerin,  <e2> nitroprusside </e2> , milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
false	The co-administration of Natrecor with IV vasodilators such as  <e1> nitroglycerin </e1> , nitroprusside, milrinone, or IV  <e2> ACE inhibitors </e2>  has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
false	The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside,  <e1> milrinone </e1> , or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with  <e2> Natrecor </e2>  in clinical trials).
advise	 <e1> Netilmicin </e1>  should not be administered concomitantly with potent loop diuretics such as furosemide and  <e2> ethacrynic acid </e2>  as the potential for ototoxicity is enhanced by the combination.
false	Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines  <e1> midazolam </e1> , triazolam GI motility agents:  <e2> cisapride </e2> 
false	 <e1> Amiodarone </e1> ,  <e2> disopyramide </e2> , lidocaine
false	 <e1> Nevirapine </e1>  and ketoconazole should not beadministered concomitantly becausedecreases in  <e2> ketoconazole </e2>  plasmaconcentrations may reduce the efficacy of the drug.
false	 <e1> Methadone </e1>  levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning  <e2> nevirapine </e2>  therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
false	aBased on reports of narcotic withdrawal syndrome in patients treated with  <e1> nevirapine </e1>  and methadone concurrently, and evidence of decreased plasma concentrations of  <e2> methadone </e2> .
false	 <e1> Ethinyl estradiol </e1>   <e2> Norethindrone </e2> 
advise	 <e1> Nevirapine </e1>  and  <e2> rifampin </e2>  should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.
false	 <e1> Methadone </e1>  levels may be decreased; increased dosages may be required to prevent symptoms of  <e2> opiate </e2>  withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
false	The appropriate dose for  <e1> nelfinavir </e1>  incombination with  <e2> nevirapine </e2> , with respectto safety and efficacy, has not been established.
false	Interactions for Vitamin B3 ( <e1> Niacin </e1> ): Antihypertensive Therapy:  <e2> Nicotinic acid </e2>  may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.
false	Interactions for Vitamin B3 ( <e1> Niacin </e1> ): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of  <e2> ganglionic blocking agents </e2>  and vasoactive drugs resulting in postural hypotension.
false	 <e1> Amiodarone </e1> , disopyramide,  <e2> lidocaine </e2> 
false	Diltiazem,  <e1> nifedipine </e1> ,  <e2> verapamil </e2> 
false	 <e1> Cimetidine </e1> :  <e2> Cimetidine </e2>  increases nicardipine HCl plasma levels.
false	When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin,  <e1> quinidine </e1> , or naproxen were added to human plasma (in vitro), the plasma protein binding of  <e2> nicardipine HCl </e2>  was not altered.
false	 <e1> Nicardipine HCl </e1>  usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with  <e2> nicardipine HCl </e2>  is initiated.
advise	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal.  <e1> Methadone </e1>  maintained patients beginning  <e2> nevirapine </e2>  therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
false	When therapeutic concentrations of furosemide,  <e1> propranolol </e1> , dipyridamole, warfarin,  <e2> quinidine </e2> , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
false	When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin,  <e1> quinidine </e1> , or  <e2> naproxen </e2>  were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
false	 <e1> Digoxin </e1> : Some  <e2> calcium blockers </e2>  may increase the concentration of digitalis preparations in the blood.
false	When therapeutic concentrations of  <e1> furosemide </e1> ,  <e2> propranolol </e2> , dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
false	 <e1> Beta-Blockers </e1> : In controlled clinical studies,  <e2> adrenergic beta-receptor blockers </e2>  have been frequently administered concomitantly with nicardipine HCl.
false	Maalox * Coadministration of  <e1> Maalox TC </e1>  had no effect on  <e2> nicardipine HCl </e2>  absorption.
false	When therapeutic concentrations of furosemide, propranolol, dipyridamole,  <e1> warfarin </e1> ,  <e2> quinidine </e2> , or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
false	When therapeutic concentrations of furosemide,  <e1> propranolol </e1> , dipyridamole, warfarin, quinidine, or  <e2> naproxen </e2>  were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
false	 <e1> Digitalis </e1> : Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that  <e2> digoxin </e2>  levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
false	Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak  <e1> nifedipine </e1>  plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of  <e2> cimetidine </e2>  at 1000 mg per day and nifedipine at 40 mg per day.
false	Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between  <e1> quinidine </e1>  and nifedipine (with a decreased plasma level of  <e2> quinidine </e2> ).
false	Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and  <e1> nifedipine </e1> , it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing  <e2> nifedipine </e2>  to avoid possible over- or under-digitalization.
advise	Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that  <e1> digoxin </e1>  levels be monitored when initiating, adjusting, and discontinuing  <e2> nifedipine </e2>  to avoid possible over- or under-digitalization.
mechanism	Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between  <e1> quinidine </e1>  and  <e2> nifedipine </e2>  (with a decreased plasma level of quinidine).
false	Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between  <e1> digoxin </e1>  and nifedipine, it is recommended that  <e2> digoxin </e2>  levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
false	Long Acting  <e1> Nitrates </e1> : Nifedipine may be safely co-administered with  <e2> nitrates </e2> , but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
false	Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and  <e1> nifedipine </e1>  (with a decreased plasma level of  <e2> quinidine </e2> ).
false	Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated  <e1> digoxin </e1>  levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that  <e2> digoxin </e2>  levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
false	Consequently, drugs with a low therapeutic margin, such as  <e1> vitamin K antagonists </e1> ,  <e2> phenytoin </e2> , and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level.
false	Consequently, drugs with a low therapeutic margin, such as  <e1> vitamin K antagonists </e1> , phenytoin, and  <e2> theophylline </e2> , could have a delayed elimination and increases in their serum half-life leading to a toxic level.
false	Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists,  <e1> phenytoin </e1> , and  <e2> theophylline </e2> , could have a delayed elimination and increases in their serum half-life leading to a toxic level.
effect	 <e1> Propranolol </e1>  attenuated the heart rate increase following administration of immediate release  <e2> nisoldipine </e2> .
false	No significant interactions were found between nisoldipine and  <e1> warfarin </e1>  or  <e2> digoxin </e2> .
false	Pharmacokinetic interactions between nisoldipine and beta-blockers ( <e1> atenolol </e1> ,  <e2> propranolol </e2> ) were variable and not significant.
false	Pharmacokinetic interactions between  <e1> nisoldipine </e1>  and  <e2> beta-blockers </e2>  (atenolol, propranolol) were variable and not significant.
mechanism	 <e1> Quinidine </e1>  at 648 mg bid decreased the bioavailability (AUC) of  <e2> nisoldipine </e2>  by 26%, but not the peak concentration.
false	Pharmacokinetic interactions between nisoldipine and  <e1> beta-blockers </e1>  (atenolol,  <e2> propranolol </e2> ) were variable and not significant.
false	Although there are no study data to evaluate the possibility,  <e1> nitric oxide donor compounds </e1> , including  <e2> sodium nitroprusside </e2>  and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
false	 <e1> INOmax </e1>  has been administered with tolazoline, dopamine, dobutamine,  <e2> steroids </e2> , surfactant, and high-frequency ventilation.
false	INOmax has been administered with tolazoline,  <e1> dopamine </e1> , dobutamine,  <e2> steroids </e2> , surfactant, and high-frequency ventilation.
effect	Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including  <e1> sodium nitroprusside </e1>  and nitroglycerin, may have an additive effect with  <e2> INOmax </e2>  on the risk of developing methemoglobinemia.
false	INOmax has been administered with tolazoline,  <e1> dopamine </e1> ,  <e2> dobutamine </e2> , steroids, surfactant, and high-frequency ventilation.
false	INOmax has been administered with tolazoline,  <e1> dopamine </e1> , dobutamine, steroids,  <e2> surfactant </e2> , and high-frequency ventilation.
false	 <e1> Uricosuric drugs </e1> , such as  <e2> probenecid </e2>  and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
mechanism	Uricosuric drugs, such as probenecid and  <e1> sulfinpyrazone </e1> , can inhibit renal tubular secretion of  <e2> nitrofurantoin </e2> .
false	The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including  <e1> ganglionic blocking agents </e1> , negative inotropic agents, and inhaled  <e2> anesthetics </e2> .
effect	The hypotensive effect of  <e1> sodium nitroprusside </e1>  is augmented by that of most other hypotensive drugs, including  <e2> ganglionic blocking agents </e2> , negative inotropic agents, and inhaled anesthetics.
false	No interactions have been observed between nizatidine and theophylline, chlordiazepoxide,  <e1> lorazepam </e1> ,  <e2> lidocaine </e2> , phenytoin, and warfarin.
false	No interactions have been observed between  <e1> nizatidine </e1>  and theophylline, chlordiazepoxide,  <e2> lorazepam </e2> , lidocaine, phenytoin, and warfarin.
false	No interactions have been observed between  <e1> nizatidine </e1>  and theophylline,  <e2> chlordiazepoxide </e2> , lorazepam, lidocaine, phenytoin, and warfarin.
false	In patients given very high doses (3900 mg) of  <e1> aspirin </e1>  daily, increases in serum  <e2> salicylate </e2>  levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
false	No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine,  <e1> phenytoin </e1> , and  <e2> warfarin </e2> .
false	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the  <e1> anticonvulsants </e1>  phenytoin, carbamazepine, and  <e2> barbiturates </e2> , and the antituberculosis drug rifampin.
false	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin,  <e1> carbamazepine </e1> , and barbiturates, and the antituberculosis drug  <e2> rifampin </e2> .
false	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and  <e1> barbiturates </e1> , and the  <e2> antituberculosis drug </e2>  rifampin.
effect	The effectiveness of  <e1> progestin </e1> -only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  <e2> phenytoin </e2> , carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
false	No interactions have been observed between nizatidine and theophylline, chlordiazepoxide,  <e1> lorazepam </e1> , lidocaine, phenytoin, and  <e2> warfarin </e2> .
false	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the  <e1> anticonvulsants </e1>  phenytoin, carbamazepine, and barbiturates, and the  <e2> antituberculosis drug </e2>  rifampin.
false	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the  <e1> anticonvulsants </e1>   <e2> phenytoin </e2> , carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
mechanism	Some  <e1> quinolones </e1>  have also been shown to interfere with the metabolism of  <e2> caffeine </e2> .
false	Videx ( <e1> Didanosine </e1> ) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of  <e2> norfloxacin </e2> .
false	Therefore, monitoring of  <e1> theophylline </e1>  plasma levels should be considered and dosage of  <e2> theophylline </e2>  adjusted as required.
false	Multivitamins, or other products containing iron or  <e1> zinc </e1> ,  <e2> antacids </e2>  or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
effect	Quinolones, including  <e1> norfloxacin </e1> , may enhance the effects of oral anticoagulants, including  <e2> warfarin </e2>  or its derivatives or similar agents.
false	The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , and barbiturates, and the antituberculosis drug rifampin.
false	Therefore,  <e1> cyclosporine </e1>  serum levels should be monitored and appropriate  <e2> cyclosporine </e2>  dosage adjustments made when these drugs are used concomitantly.
advise	Videx ( <e1> Didanosine </e1> ) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of  <e2> norfloxacin </e2> , because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
effect	There have been reports of theophylline-related side effects in patients on concomitant therapy with  <e1> norfloxacin </e1>  and  <e2> theophylline </e2> .
false	 <e1> Multivitamins </e1> , or other products containing iron or zinc, antacids or  <e2> sucralfate </e2>  should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
false	Diminished urinary excretion of  <e1> norfloxacin </e1>  has been reported during the concomitant administration of probenecid and  <e2> norfloxacin </e2> .
false	A similar association, though less marked, has been suggested with barbiturates,  <e1> phenylbutazone </e1> , phenytoin sodium, carbamazepine, griseofulvin,  <e2> topiramate </e2> , and possibly with ampicillin and tetracyclines 72.
false	A similar association, though less marked, has been suggested with barbiturates, phenylbutazone,  <e1> phenytoin sodium </e1> , carbamazepine, griseofulvin, topiramate, and possibly with  <e2> ampicillin </e2>  and tetracyclines 72.
false	A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with  <e1> ampicillin </e1>  and  <e2> tetracyclines </e2>  72.
false	Multivitamins, or other products containing iron or  <e1> zinc </e1> , antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of  <e2> norfloxacin </e2> .
false	There have been reports of  <e1> theophylline </e1> -related side effects in patients on concomitant therapy with  <e2> norfloxacin </e2>  and theophylline.
false	A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium,  <e1> carbamazepine </e1> , griseofulvin, topiramate, and possibly with ampicillin and  <e2> tetracyclines </e2>  72.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants,  <e1> phenothiazines </e1> , carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and  <e2> encainide </e2> ), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other  <e1> antidepressants </e1> , phenothiazines, carbamazepine, and  <e2> Type 1C antiarrhythmics </e2>  (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	Concomitant use of  <e1> tricyclic antidepressants </e1>  with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the  <e2> tricyclic antidepressant </e2>  or the other drug.
effect	The therapeutic efficacy of  <e1> tricyclic antidepressants </e1>  may be compromised in these patients when  <e2> cimetidine </e2>  is discontinued.
advise	Therefore, co-administration of  <e1> tricyclic antidepressants </e1>  with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg,  <e2> quinidine </e2> ), should be approached with caution.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg,  <e1> propafenone </e1> , flecainide, and encainide), or that inhibit this enzyme (eg,  <e2> quinidine </e2> ), should be approached with caution.
false	Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other  <e1> anticholinergic drugs </e1>  or  <e2> sympathomimetic drugs </e2> .
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and  <e1> Type 1C antiarrhythmics </e1>  (eg, propafenone,  <e2> flecainide </e2> , and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
advise	Therefore, co-administration of  <e1> tricyclic antidepressants </e1>  with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and  <e2> encainide </e2> ), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium,  <e1> carbamazepine </e1> , griseofulvin,  <e2> topiramate </e2> , and possibly with ampicillin and tetracyclines 72.
false	Multivitamins, or other products containing  <e1> iron </e1>  or zinc,  <e2> antacids </e2>  or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg,  <e1> propafenone </e1> ,  <e2> flecainide </e2> , and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
mechanism	In well-controlled patients undergoing concurrent therapy with  <e1> cimetidine </e1> , a decrease in the steady-state serum concentrations of  <e2> tricyclic antidepressants </e2>  may occur when cime-tidine therapy is discontinued.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and  <e1> Type 1C antiarrhythmics </e1>  (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg,  <e2> quinidine </e2> ), should be approached with caution.
false	Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine,  <e1> phenytoin </e1>  and phenobarbital) have been shown to decrease the plasma levels of  <e2> MHD </e2>  (29-40%).
false	Hormonal contraceptives Co-administration of  <e1> Trileptal </e1>  with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and  <e2> levonorgestrel </e2>  (LNG).
false	Other drug interactions Cimetidine, erythromycin and  <e1> dextropropoxyphene </e1>  had no effect on the pharmacokinetics of  <e2> MHD </e2> .
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone,  <e1> flecainide </e1> , and  <e2> encainide </e2> ), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
false	Other drug interactions  <e1> Cimetidine </e1> ,  <e2> erythromycin </e2>  and dextropropoxyphene had no effect on the pharmacokinetics of MHD.
false	Strong inducers of cytochrome P450 enzymes (i.e.  <e1> carbamazepine </e1> , phenytoin and  <e2> phenobarbital </e2> ) have been shown to decrease the plasma levels of MHD (29-40%).
false	Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine,  <e1> phenytoin </e1>  and  <e2> phenobarbital </e2> ) have been shown to decrease the plasma levels of MHD (29-40%).
mechanism	Hormonal contraceptives Co-administration of  <e1> Trileptal </e1>  with an oral  <e2> contraceptive </e2>  has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).
false	Other drug interactions  <e1> Cimetidine </e1> , erythromycin and  <e2> dextropropoxyphene </e2>  had no effect on the pharmacokinetics of MHD.
false	In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of  <e1> dihydropyridine calcium antagonists </e1>  and oral  <e2> contraceptives </e2> , resulting in a lower plasma concentration of these drugs.
false	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other  <e1> antidepressants </e1> , phenothiazines,  <e2> carbamazepine </e2> , and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
advise	Therefore, when using doses of  <e1> Trileptal </e1>  greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of  <e2> phenytoin </e2>  may be required.
false	Although inhibition of CYP 3A4/5 by  <e1> OXC </e1>  and  <e2> MHD </e2>  did occur at high concentrations, it is not likely to be of clinical significance.
false	Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir,  <e1> indinavir </e1> , and  <e2> nelfinavir </e2> ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
false	Pharmacokinetic data from these patients demonstrated a decrease in  <e1> paclitaxel </e1>  clearance of approximately 33% when  <e2> TAXOL </e2>  was administered following cisplatin.
false	Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg,  <e1> cyclosporin </e1>  for injection concentrate and  <e2> teniposide </e2>  for injection concentrate) should not be treated with TAXOL.
false	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and  <e1> cisplatin </e1>  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before  <e2> cisplatin </e2> ).
false	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and  <e1> cisplatin </e1>  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie,  <e2> TAXOL </e2>  before cisplatin).
false	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  <e1> TAXOL </e1>  should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and  <e2> H2 antagonists </e2>  (such as cimetidine or ranitidine).
false	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and  <e1> cisplatin </e1>  (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after  <e2> cisplatin </e2>  than with the alternate sequence (ie, TAXOL before cisplatin).
false	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie,  <e1> TAXOL </e1>  before  <e2> cisplatin </e2> ).
false	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with  <e1> TAXOL </e1>  should be premedicated with  <e2> corticosteroids </e2>  (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).
mechanism	The increase of  <e1> phenobarbital </e1>  level, however, is small (15%) when given with  <e2> Trileptal </e2> .
false	Potential interactions between  <e1> TAXOL </e1> , a substrate of CYP3A4, and protease inhibitors (ritonavir,  <e2> saquinavir </e2> , indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
false	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with  <e1> corticosteroids </e1>  (such as  <e2> dexamethasone </e2> ), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).
false	Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir,  <e1> saquinavir </e1> , indinavir, and  <e2> nelfinavir </e2> ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
false	Potential interactions between TAXOL, a substrate of CYP3A4, and  <e1> protease inhibitors </e1>  (ritonavir, saquinavir,  <e2> indinavir </e2> , and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
effect	In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when  <e1> TAXOL </e1>  was given after  <e2> cisplatin </e2>  than with the alternate sequence (ie, TAXOL before cisplatin).
false	In addition,  <e1> oxcarbazepine </e1>  and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral  <e2> contraceptives </e2> , resulting in a lower plasma concentration of these drugs.
advise	Nucleoside Analogues Didanosine Co-administration of  <e1> COPEGUS </e1>  and  <e2> didanosine </e2>  is not recommended.
false	In patients with chronic hepatitis C treated with PEGASYS in combination with  <e1> COPEGUS </e1> ,  <e2> PEGASYS </e2>  treatment did not affect ribavirin distribution or clearance.
false	In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and  <e1> H2 antagonists </e1>  (such as  <e2> cimetidine </e2>  or ranitidine).
false	Use With  <e1> Ribavirin </e1>   <e2> Ribavirin </e2>  is genotoxic and mutagenic.
false	 <e1> Theophylline </e1>  serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and  <e2> PEGASYS </e2> .
false	Stavudine and  <e1> Zidovudine </e1>   <e2> Ribavirin </e2>  can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
false	Clinical studies of  <e1> PEGASYS </e1>  alone or in combination with  <e2> COPEGUS </e2>  did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.
false	Pregnancy: Category X: Use With  <e1> Ribavirin </e1>  (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to  <e2> ribavirin </e2> .
false	 <e1> Vecuronium </e1> : When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of  <e2> vecuronium </e2> .
false	 <e1> Aminoglycosides </e1> : The mixing of  <e2> piperacillin </e2>  with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.
false	Aminoglycosides: The mixing of  <e1> piperacillin </e1>  with an aminoglycoside in vitro can result in substantial inactivation of the  <e2> aminoglycoside </e2> .
false	Potential interactions between  <e1> TAXOL </e1> , a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and  <e2> nelfinavir </e2> ), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
effect	Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the  <e1> non-depolarizing muscle relaxants </e1>  could be prolonged in the presence of  <e2> piperacillin </e2> .
false	Probenecid: The oral combination of  <e1> probenecid </e1>  before intramuscular injection of PIPRACIL produces an increase in  <e2> piperacillin </e2>  peak serum level of about 30%.
false	Drug/Laboratory Test Interactions As with other  <e1> penicillins </e1> , the administration of  <e2> PIPRACIL </e2>  may result in a false-positive reaction for glucose in the urine using a copper-reduction method.
effect	Pyrantel (e.g., Antiminth) - Taking  <e1> piperazine </e1>  and  <e2> pyrantel </e2>  together may decrease the effects of piperazine.
false	 <e1> Probenecid </e1> : The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in  <e2> piperacillin </e2>  peak serum level of about 30%.
false	 <e1> Pyrantel </e1>  (e.g., Antiminth) - Taking piperazine and  <e2> pyrantel </e2>  together may decrease the effects of piperazine.
false	 <e1> Pyrantel </e1>  (e.g.,  <e2> Antiminth </e2> ) - Taking piperazine and pyrantel together may decrease the effects of piperazine.
false	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of  <e1> furosemide </e1>  and  <e2> thiazides </e2>  in some patients.
false	 <e1> Prednisone </e1> /prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of  <e2> prednisolone </e2>  or prednisone.
false	 <e1> Warfarin </e1> : Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving  <e2> warfarin </e2>  or similar agents, since these patients are at an increased risk of bleeding complications.
false	 <e1> Furosemide </e1> : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and  <e2> thiazides </e2>  in some patients.
false	At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of  <e1> rofecoxib </e1>  (88%) had  <e2> methotrexate </e2>  plasma concentrations below the measurable limit (5 ng/mL).
effect	In single and multiple dose studies in healthy subjects receiving both  <e1> warfarin </e1>  and  <e2> rofecoxib </e2> , prothrombin time (measured as INR) was increased by approximately 8% to 11%.
false	Oral Contraceptives  <e1> Rofecoxib </e1>  did not have any clinically important effect on the pharmacokinetics of  <e2> ethinyl estradiol </e2>  and norethindrone.
false	Standard monitoring of  <e1> methotrexate </e1> -related toxicity should be continued if  <e2> VIOXX </e2>  and methotrexate are administered concomitantly.
false	In patients with mild to moderate hypertension, administration of 25 mg daily of  <e1> VIOXX </e1>  with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to  <e2> ACE inhibitor </e2>  alone.
false	 <e1> Prednisone </e1> /prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or  <e2> prednisone </e2> .
mechanism	Cimetidine: Co-administration with high doses of  <e1> cimetidine </e1>  [800 mg twice daily] increased the Cmax of  <e2> rofecoxib </e2>  by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
false	Thus, when VIOXX and  <e1> lithium </e1>  are administered concurrently, subjects should be observed carefully for signs of  <e2> lithium </e2>  toxicity.
false	 <e1> Lithium </e1> :  <e2> NSAIDs </e2>  have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
advise	Adequate monitoring of theophylline plasma concentrations should be considered when therapy with  <e1> VIOXX </e1>  is initiated or changed in patients receiving  <e2> theophylline </e2> .
false	In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the  <e1> ACE inhibitor </e1>  benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to  <e2> ACE inhibitor </e2>  alone.
false	Lithium: NSAIDs have produced an elevation of plasma  <e1> lithium </e1>  levels and a reduction in renal  <e2> lithium </e2>  clearance.
false	Prednisone/ <e1> prednisolone </e1> :  <e2> Rofecoxib </e2>  did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.
false	Methotrexate  <e1> VIOXX </e1>  12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly  <e2> methotrexate </e2>  doses of 7.5 to 20 mg for rheumatoid arthritis.
false	At 24 hours postdose, a similar proportion of patients treated with  <e1> methotrexate </e1>  alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had  <e2> methotrexate </e2>  plasma concentrations below the measurable limit (5 ng/mL).
false	Patients taking low-dose  <e1> aspirin </e1>  plus  <e2> ibuprofen </e2>  were not studied.
false	In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the  <e1> ACE inhibitor </e1>   <e2> benazepril </e2> , 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers,  <e1> dapsone </e1> , disopyramide, quinine, amiodarone, quinidine,  <e2> warfarin </e2> , tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital,  <e1> phenytoin </e1> ,  <e2> dexamethasone </e2> , carbamazepine) may result in decreased plasma levels of saquinavir.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives,  <e1> pimozide </e1> , carbamazepine,  <e2> fentanyl </e2> , alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Ergot Derivatives </e1> :  <e2> Dihydroergotamine </e2> , ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone,  <e1> quinidine </e1> , warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine,  <e2> fentanyl </e2> , alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Antiarrhythmics: Amiodarone, bepridil,  <e1> flecainide </e1> , propafenone,  <e2> quinidine </e2>  CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
false	Prospective, long-term studies on concomitant administration of  <e1> VIOXX </e1>  and  <e2> aspirin </e2>  have not been conducted.
false	 <e1> Rifampin </e1> : Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in  <e2> rofecoxib </e2>  plasma concentrations.
false	Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with  <e1> saquinavir </e1>  in an antiretroviral regimen reduces the plasma concentrations of  <e2> saquinavir </e2> .
false	Ergot Derivatives: Dihydroergotamine,  <e1> ergonovine </e1> ,  <e2> ergotamine </e2> , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
false	Rifampin: Co-administration of VIOXX with  <e1> rifampin </e1>  600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in  <e2> rofecoxib </e2>  plasma concentrations.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide,  <e2> carbamazepine </e2> , fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Antimycobacterial Agents </e1> :  <e2> rifampin </e2>  CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl,  <e2> alfentanyl </e2> , alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
mechanism	Coadministration with compounds that are potent inducers of CYP3A4 (eg,  <e1> phenobarbital </e1> , phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of  <e2> saquinavir </e2> .
false	Coadministration with compounds that are potent inducers of CYP3A4 (eg,  <e1> phenobarbital </e1> ,  <e2> phenytoin </e2> , dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine,  <e1> warfarin </e1> ,  <e2> tacrolimus </e2> , cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Methotrexate </e1>  VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly  <e2> methotrexate </e2>  doses of 7.5 to 20 mg for rheumatoid arthritis.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine,  <e1> warfarin </e1> , tacrolimus,  <e2> cyclosporine </e2> , ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl,  <e1> alfentanyl </e1> ,  <e2> alprazolam </e2> , and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine,  <e1> amiodarone </e1> , quinidine, warfarin, tacrolimus,  <e2> cyclosporine </e2> , ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide,  <e1> quinine </e1> , amiodarone, quinidine,  <e2> warfarin </e2> , tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	No data are available for the coadministration of INVIRASE/ <e1> ritonavir </e1>  or FORTOVASE/ <e2> ritonavir </e2>  and garlic capsules.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers,  <e1> dapsone </e1> , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl,  <e2> alfentanyl </e2> , alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Antiarrhythmics: Amiodarone, bepridil, flecainide,  <e1> propafenone </e1> ,  <e2> quinidine </e2>  CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine,  <e1> amiodarone </e1> , quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl,  <e2> alfentanyl </e2> , alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide,  <e1> quinine </e1> , amiodarone, quinidine, warfarin, tacrolimus,  <e2> cyclosporine </e2> , ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine,  <e2> amiodarone </e2> , quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine,  <e1> ergot derivatives </e1> , pimozide, carbamazepine, fentanyl, alfentanyl,  <e2> alprazolam </e2> , and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
mechanism	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with  <e2> saquinavir </e2> ;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide,  <e1> quinine </e1> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives,  <e2> pimozide </e2> , carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Antimycobacterial Agents </e1> : rifampin CONTRAINDICATED since the coadministration of this product with  <e2> saquinavir </e2>  in an antiretroviral regimen reduces the plasma concentrations of saquinavir.
mechanism	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus,  <e1> cyclosporine </e1> , ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with  <e2> saquinavir </e2> ;
false	 <e1> Ergot Derivatives </e1> : Dihydroergotamine, ergonovine,  <e2> ergotamine </e2> , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
false	Garlic Capsules Garlic capsules should not be used while taking  <e1> saquinavir </e1>  (FORTOVASE) as the sole  <e2> protease inhibitor </e2>  due to the risk of decreased saquinavir plasma concentrations.
mechanism	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone,  <e1> quinidine </e1> , warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with  <e2> saquinavir </e2> ;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone,  <e1> quinidine </e1> , warfarin,  <e2> tacrolimus </e2> , cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine,  <e1> ergot derivatives </e1> , pimozide, carbamazepine, fentanyl,  <e2> alfentanyl </e2> , alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Several drug interaction studies have been completed with both  <e1> INVIRASE </e1>  and  <e2> FORTOVASE </e2> .
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine,  <e1> amiodarone </e1> ,  <e2> quinidine </e2> , warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin,  <e1> tacrolimus </e1> , cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and  <e2> triazolam </e2> ) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide,  <e1> quinine </e1> , amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and  <e2> triazolam </e2> ) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine,  <e1> amiodarone </e1> , quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives,  <e2> pimozide </e2> , carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	 <e1> Cimetidine </e1> : Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of  <e2> rofecoxib </e2>  by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
false	Since  <e1> INVIRASE </e1>  is coadministered with ritonavir, the  <e2> ritonavir </e2>  label should be reviewed for additional drugs that should not be coadministered.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide,  <e1> carbamazepine </e1> , fentanyl, alfentanyl,  <e2> alprazolam </e2> , and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Ergot Derivatives: Dihydroergotamine, ergonovine,  <e1> ergotamine </e1> , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  <e2> ergot </e2>  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide,  <e1> carbamazepine </e1> , fentanyl,  <e2> alfentanyl </e2> , alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone,  <e1> quinidine </e1> ,  <e2> warfarin </e2> , tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers,  <e1> dapsone </e1> , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide,  <e2> carbamazepine </e2> , fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone,  <e1> quinidine </e1> , warfarin, tacrolimus,  <e2> cyclosporine </e2> , ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	Antiarrhythmics:  <e1> Amiodarone </e1> , bepridil,  <e2> flecainide </e2> , propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
false	Additional drugs that are not recommended for coadministration with  <e1> INVIRASE </e1>  and  <e2> ritonavir </e2>  are included below.
mechanism	Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone,  <e1> carbamazepine </e1> ) may result in decreased plasma levels of  <e2> saquinavir </e2> .
false	 <e1> Lithium </e1> : NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal  <e2> lithium </e2>  clearance.
false	HMG-CoA Reductase Inhibitors:  <e1> lovastatin </e1> ,  <e2> simvastatin </e2>  WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  <e1> calcium channel blockers </e1> , dapsone, disopyramide, quinine, amiodarone, quinidine,  <e2> warfarin </e2> , tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
effect	- Methyldopa (e.g., Aldomet) Use of  <e1> methyldopa </e1>  with  <e2> sulfapyridine </e2>  may increase the chance of side effects affecting the liver and/or the blood
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e1> promethazine </e1>  [e.g.,  <e2> Phenergan </e2> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e1> promazine </e1>  [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Mercaptopurine </e1>  (e.g.,  <e2> Purinethol </e2> ) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e1> mesoridazine </e1>  [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e1> Stelazine </e1> ], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e2> perphenazine </e2>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Valproic acid </e1>  (e.g.,  <e2> Depakene </e2> ) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e2> Prolixin </e2> ], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Phenytoin </e1>  (e.g., Dilantin) Use of  <e2> phenytoin </e2>  with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin
false	- Vitamin K (e.g.,  <e1> AquaMEPHYTON </e1> ,  <e2> Synkayvite </e2> ) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood
false	-  <e1> Anabolic steroids </e1>  (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar],  <e2> oxymetholone </e2>  [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e1> Prolixin </e1> ],  <e2> mesoridazine </e2>  [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e1> promethazine </e1>  [e.g., Phenergan],  <e2> thioridazine </e2>  [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Anabolic steroids (nandrolone [e.g.,  <e1> Anabolin </e1> ], oxandrolone [e.g., Anavar],  <e2> oxymetholone </e2>  [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g.,  <e1> Compazine </e1> ], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine],  <e2> triflupromazine </e2>  [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e1> perphenazine </e1>  [e.g., Trilafon],  <e2> prochlorperazine </e2>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e1> mesoridazine </e1>  [e.g., Serentil], perphenazine [e.g., Trilafon],  <e2> prochlorperazine </e2>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e1> perphenazine </e1>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan],  <e2> thioridazine </e2>  [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenytoin (e.g.,  <e1> Dilantin </e1> ) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of  <e2> phenytoin </e2> 
false	- Methotrexate (e.g.,  <e1> Mexate </e1> ) Use of methotrexate with  <e2> sulfapyridine </e2>  may increase the chance of side effects affecting the liver and/or the side effects of methotrexate
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e1> trimeprazine </e1>  [e.g.,  <e2> Temaril </e2> ]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan],  <e1> thioridazine </e1>  [e.g.,  <e2> Mellaril </e2> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e1> Sparine </e1> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g.,  <e2> Temaril </e2> ]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e1> perphenazine </e1>  [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e2> promazine </e2>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal], chlorpromazine [e.g.,  <e2> Thorazine </e2> ], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine],  <e1> fluphenazine </e1>  [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e2> prochlorperazine </e2>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e1> promethazine </e1>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g.,  <e1> Tindal </e1> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e1> promazine </e1>  [e.g., Sparine], promethazine [e.g., Phenergan],  <e2> thioridazine </e2>  [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Valproic acid </e1>  (e.g., Depakene) Use of  <e2> sulfapyridine </e2>  with these medicines may increase the chance of side effects affecting the liver
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan],  <e1> thioridazine </e1>  [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Anabolic steroids (nandrolone [e.g.,  <e1> Anabolin </e1> ], oxandrolone [e.g.,  <e2> Anavar </e2> ], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
false	-  <e1> Naltrexone </e1>  (e.g.,  <e2> Trexan </e2> ) (with long-term, high-dose use) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenytoin (e.g.,  <e1> Dilantin </e1> ) Use of phenytoin with  <e2> sulfapyridine </e2>  may increase the chance of side effects affecting the liver and/or the side effects of phenytoin
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e1> promazine </e1>  [e.g., Sparine],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e1> Prolixin </e1> ], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine],  <e2> triflupromazine </e2>  [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Anabolic steroids ( <e1> nandrolone </e1>  [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g.,  <e2> Winstrol </e2> ]) or
false	- Phenothiazines (acetophenazine [e.g.,  <e1> Tindal </e1> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e2> Mellaril </e2> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Anabolic steroids (nandrolone [e.g., Anabolin],  <e1> oxandrolone </e1>  [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g.,  <e2> Winstrol </e2> ]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e1> promethazine </e1>  [e.g., Phenergan], thioridazine [e.g.,  <e2> Mellaril </e2> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine],  <e2> fluphenazine </e2>  [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e1> Prolixin </e1> ], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan],  <e2> thioridazine </e2>  [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g.,  <e1> Serentil </e1> ], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e2> promazine </e2>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan],  <e2> thioridazine </e2>  [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g.,  <e2> Tindal </e2> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril],  <e1> trifluoperazine </e1>  [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g.,  <e2> Temaril </e2> ]) or
false	- Phenothiazines (acetophenazine [e.g.,  <e1> Tindal </e1> ], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e2> prochlorperazine </e2>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine],  <e1> triflupromazine </e1>  [e.g., Vesprin], trimeprazine [e.g.,  <e2> Temaril </e2> ]) or
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e2> Prolixin </e2> ], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e1> Trilafon </e1> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine],  <e2> triflupromazine </e2>  [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e1> Prolixin </e1> ], mesoridazine [e.g.,  <e2> Serentil </e2> ], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g.,  <e1> Prolixin </e1> ], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e2> Phenergan </e2> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e1> Trilafon </e1> ], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g.,  <e1> Anavar </e1> ], oxymetholone [e.g., Anadrol],  <e2> stanozolol </e2>  [e.g., Winstrol]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g.,  <e1> Trilafon </e1> ], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e2> Phenergan </e2> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine],  <e1> fluphenazine </e1>  [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine],  <e2> triflupromazine </e2>  [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Methotrexate </e1>  (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of  <e2> methotrexate </e2> 
false	- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar],  <e1> oxymetholone </e1>  [e.g.,  <e2> Anadrol </e2> ], stanozolol [e.g., Winstrol]) or
false	- Methotrexate (e.g., Mexate) Use of methotrexate with  <e1> sulfapyridine </e1>  may increase the chance of side effects affecting the liver and/or the side effects of  <e2> methotrexate </e2> 
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e1> Sparine </e1> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril],  <e2> trifluoperazine </e2>  [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Carbamazepine </e1>  (e.g.,  <e2> Tegretol </e2> ) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril],  <e1> trifluoperazine </e1>  [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g.,  <e1> Serentil </e1> ], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g.,  <e2> Temaril </e2> ]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e2> Mellaril </e2> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e1> Sparine </e1> ],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g.,  <e1> Serentil </e1> ], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Anabolic steroids (nandrolone [e.g.,  <e1> Anabolin </e1> ],  <e2> oxandrolone </e2>  [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
false	Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers,  <e1> dapsone </e1> , disopyramide, quinine, amiodarone, quinidine, warfarin,  <e2> tacrolimus </e2> , cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g.,  <e1> Serentil </e1> ], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g.,  <e2> Mellaril </e2> ], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e1> perphenazine </e1>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g.,  <e1> Serentil </e1> ], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	- Anabolic steroids (nandrolone [e.g., Anabolin],  <e1> oxandrolone </e1>  [e.g.,  <e2> Anavar </e2> ], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e1> promazine </e1>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e2> Stelazine </e2> ], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e1> promazine </e1>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g.,  <e2> Temaril </e2> ]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin],  <e1> mesoridazine </e1>  [e.g.,  <e2> Serentil </e2> ], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil],  <e1> perphenazine </e1>  [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	 <e1> Phenobarbital </e1>  or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or  <e2> primidone </e2> .
false	 <e1> Phenobarbital </e1>  or  <e2> Primidone </e2>  : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.
false	-  <e1> Nitrofurantoin </e1>  (e.g.,  <e2> Furadantin </e2> ) or
false	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital ( <e1> primidone </e1> ) with or without other enzyme-inducing  <e2> AEDs </e2> .
false	- Phenothiazines ( <e1> acetophenazine </e1>  [e.g., Tindal],  <e2> chlorpromazine </e2>  [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Digoxin: Concomitant administration of  <e1> tiagabine </e1>  did not affect the steady-state pharmacokinetics of  <e2> digoxin </e2>  or the mean daily trough serum level of digoxin.
mechanism	Valproate:  <e1> Tiagabine </e1>  causes a slight decrease (about 10%) in steady-state  <e2> valproate </e2>  concentrations.
false	Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) :  <e1> Phenytoin </e1> : Tiagabine had no effect on the steady-state plasma concentrations of  <e2> phenytoin </e2>  in patients with epilepsy.
false	Effects of GABITRIL on other Antiepilepsy Drugs ( <e1> AEDs </e1> ) : Phenytoin:  <e2> Tiagabine </e2>  had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
false	In evaluating the potential for interactions among co-administered antiepilepsy drugs ( <e1> AEDs </e1> ), whether or not an  <e2> AED </e2>  induces or does not induce metabolic enzymes is an important consideration.
false	Phenobarbital or  <e1> Primidone </e1>  : No formal pharmacokinetic studies have been performed examining the addition of  <e2> tiagabine </e2>  to regimens containing phenobarbital or primidone.
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g.,  <e2> Sparine </e2> ], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of  <e1> cimetidine </e1>  (800 mg/day) to patients taking  <e2> tiagabine </e2>  chronically had no effect on tiagabine pharmacokinetics.
false	- Anabolic steroids ( <e1> nandrolone </e1>  [e.g.,  <e2> Anabolin </e2> ], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	Theophylline: A single 10 mg dose of  <e1> tiagabine </e1>  did not affect the pharmacokinetics of  <e2> theophylline </e2>  at steady state.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine],  <e2> promethazine </e2>  [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	 <e1> Digoxin </e1> : Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of  <e2> digoxin </e2> .
false	Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of  <e1> cimetidine </e1>  (800 mg/day) to patients taking tiagabine chronically had no effect on  <e2> tiagabine </e2>  pharmacokinetics.
false	 <e1> Digoxin </e1> : Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of  <e2> digoxin </e2>  or the mean daily trough serum level of digoxin.
false	- Anabolic steroids ( <e1> nandrolone </e1>  [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol],  <e2> stanozolol </e2>  [e.g., Winstrol]) or
false	 <e1> Phenytoin </e1> : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking  <e2> phenytoin </e2>  with or without other enzyme- inducing AEDs.
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal],  <e2> chlorpromazine </e2>  [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	 <e1> Valproate </e1> : The addition of tiagabine to patients taking  <e2> valproate </e2>  chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
false	Effects of other Antiepilepsy Drugs ( <e1> AEDs </e1> ) on  <e2> GABITRIL </e2>  : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
false	Warfarin: No significant differences were observed in the steady-state pharmacokinetics of  <e1> R-warfarin </e1>  or S-warfarin with the addition of  <e2> tiagabine </e2>  given as a single dose.
false	 <e1> Ethanol </e1>  or  <e2> Triazolam </e2> : No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.
false	Oral  <e1> Contraceptives </e1> : Multiple dose administration of  <e2> tiagabine </e2>  (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.
false	Valproate: The addition of tiagabine to patients taking  <e1> valproate </e1>  chronically had no effect on tiagabine pharmacokinetics, but  <e2> valproate </e2>  significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
false	- Methotrexate (e.g., Mexate) Use of  <e1> methotrexate </e1>  with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of  <e2> methotrexate </e2> 
false	Interaction of  <e1> GABITRIL </e1>  with Other Drugs :  <e2> Cimetidine </e2>  : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g.,  <e1> Serentil </e1> ], perphenazine [e.g., Trilafon], prochlorperazine [e.g.,  <e2> Compazine </e2> ], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Interaction of  <e1> GABITRIL </e1>  with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking  <e2> tiagabine </e2>  chronically had no effect on tiagabine pharmacokinetics.
false	Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) :  <e1> Phenytoin </e1> :  <e2> Tiagabine </e2>  had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine],  <e1> promazine </e1>  [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g.,  <e2> Vesprin </e2> ], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e1> prochlorperazine </e1>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	Antipyrine :  <e1> Antipyrine </e1>  pharmacokinetics were not significantly different before and after  <e2> tiagabine </e2>  multiple-dose regimens.
false	Because of the possible additive effects of drugs that may depress the nervous system,  <e1> ethanol </e1>  or  <e2> triazolam </e2>  should be used cautiously in combination with tiagabine.
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g.,  <e1> Stelazine </e1> ], triflupromazine [e.g., Vesprin],  <e2> trimeprazine </e2>  [e.g., Temaril]) or
false	Valproate: The addition of  <e1> tiagabine </e1>  to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but  <e2> valproate </e2>  significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
false	-  <e1> Phenothiazines </e1>  (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon],  <e2> prochlorperazine </e2>  [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g.,  <e1> Thorazine </e1> ], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g.,  <e2> Phenergan </e2> ], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
false	Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg  <e1> glyburide </e1>  BID) resulted in 21% increase in  <e2> glyburide </e2>  AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
false	 <e1> Digoxin </e1> : Concomitant administration of  <e2> tiagabine </e2>  did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.
false	 <e1> Anticoagulant </e1>  therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving  <e2> warfarin </e2>  or similar agents.
false	Coadministration of  <e1> valdecoxib </e1>  (40 mg BID (day 1) and 40 mg QD (days 2-7)) with  <e2> glyburide </e2>  (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.
advise	This interaction should be given consideration in patients taking  <e1> BEXTRA </e1>  concomitantly with  <e2> ACE-inhibitors </e2> .
false	 <e1> Tiagabine </e1>  has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or  <e2> alcohol </e2> .
false	Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with  <e1> glyburide </e1>  (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in  <e2> glyburide </e2>  Cmax leading to a 16% decrease in glucose AUC0-24.
mechanism	Plasma exposure of  <e1> diazepam </e1>  (10 mg BID) was increased by 28% following administration of  <e2> valdecoxib </e2>  (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
false	Because changes in glucose concentrations with  <e1> valdecoxib </e1>  coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for  <e2> glyburide </e2>  (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.
false	 <e1> Lithium </e1>  serum concentrations should be monitored closely when initiating or changing therapy with  <e2> BEXTRA </e2>  in patients receiving lithium.
false	Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg  <e1> glyburide </e1>  BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in  <e2> glyburide </e2>  Cmax leading to a 16% decrease in glucose AUC0-24.
false	 <e1> Lithium </e1> : Valdecoxib 40 mg BID for 7 days produced significant decreases in  <e2> lithium </e2>  serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
false	Oral  <e1> Contraceptives </e1> : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  <e2> norethindrone </e2> /ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).
false	 <e1> Fluconazole </e1>  and Ketoconazole:  <e2> Ketoconazole </e2>  and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.
false	 <e1> Diazepam </e1> :  <e2> Diazepam </e2>  (Valium) is a CYP 3A4 and CYP 2C19 substrate.
effect	Aspirin: Concomitant administration of  <e1> aspirin </e1>  with  <e2> valdecoxib </e2>  may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
false	In a parallel group drug interaction study comparing the intravenous prodrug form of  <e1> valdecoxib </e1>  at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro  <e2> aspirin </e2> -mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.
false	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of  <e1> furosemide </e1>  and  <e2> thiazides </e2>  in some patients.
false	Concomitant single dose administration of valdecoxib 20 mg with multiple doses of  <e1> ketoconazole </e1>  and fluconazole produced a significant increase in exposure of  <e2> valdecoxib </e2> .
false	Fluconazole and Ketoconazole:  <e1> Ketoconazole </e1>  and  <e2> fluconazole </e2>  are predominantly CYP 3A4 and 2C9 inhibitors, respectively.
false	Concomitant single dose administration of valdecoxib 20 mg with multiple doses of  <e1> ketoconazole </e1>  and  <e2> fluconazole </e2>  produced a significant increase in exposure of valdecoxib.
false	Interaction of  <e1> GABITRIL </e1>  with Highly Protein Bound Drugs: In vitro data showed that  <e2> tiagabine </e2>  is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.
mechanism	Coadministration of  <e1> valdecoxib </e1>  and  <e2> Ortho-Novum </e2>  1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.
false	Oral  <e1> Contraceptives </e1> : Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination,  <e2> Ortho-Novum </e2>  1/35 ).
false	These increased exposures of  <e1> norethindrone </e1>  and ethinyl estradiol should be taken into consideration when selecting an oral  <e2> contraceptive </e2>  for women taking valdecoxib.
false	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL :  <e1> Carbamazepine </e1> : Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking  <e2> carbamazepine </e2>  with or without other enzyme- inducing AEDs.
false	 <e1> Phenobarbital </e1>  (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital ( <e2> primidone </e2> ) with or without other enzyme-inducing AEDs.
false	 <e1> Lithium </e1> :  <e2> Valdecoxib </e2>  40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
false	Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of  <e1> valdecoxib </e1>  (40 mg BID) for 12 days, while plasma exposure of  <e2> valdecoxib </e2>  (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
false	This indicates that  <e1> tiagabine </e1>  does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of  <e2> antipyrine </e2> .
false	Coadministration of  <e1> valdecoxib </e1>  and Ortho-Novum 1/35  increased the exposure of norethindrone and  <e2> ethinyl estradiol </e2>  by 20% and 34%, respectively.
false	Coadministration of valdecoxib and  <e1> Ortho-Novum </e1>  1/35  increased the exposure of norethindrone and  <e2> ethinyl estradiol </e2>  by 20% and 34%, respectively.
mechanism	Lithium:  <e1> Valdecoxib </e1>  40 mg BID for 7 days produced significant decreases in  <e2> lithium </e2>  serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
false	Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of  <e1> norethindrone </e1>  and  <e2> ethinyl estradiol </e2>  by 20% and 34%, respectively.
false	 <e1> Omeprazole </e1> :  <e2> Omeprazole </e2>  is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor.
false	Because of its lack of anti-platelet effect  <e1> valdecoxib </e1>  is not a substitute for  <e2> aspirin </e2>  for cardiovascular prophylaxis.
false	 <e1> Nifedipine </e1> :  <e2> Vardenafil </e2>  20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.
false	 <e1> Ritonavir </e1>  and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of  <e2> ritonavir </e2>  were reduced by approximately 20%.
effect	In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with  <e1> Vardenafil </e1>  20 mg and  <e2> tamsulosin </e2>  0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
false	Ritonavir and indinavir: Upon concomitant administration of 5 mg of  <e1> Vardenafil </e1>  with 600 mg BID ritonavir, the Cmax and AUC of  <e2> ritonavir </e2>  were reduced by approximately 20%.
false	Other Drug Interactions: No pharmacokinetic interactions were observed between  <e1> vardenafil </e1>  and the following drugs: glyburide, warfarin,  <e2> digoxin </e2> , Maalox, and ranitidine.
false	 <e1> Alcohol </e1> :  <e2> Alcohol </e2>  (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.
false	Ritonavir (600 mg b.i.d.) co-administered with  <e1> Vardenafil </e1>  5 mg resulted in a 49-fold increase in  <e2> vardenafil </e2>  AUC and a 13-fold increase in vardenafil Cmax.
false	Aspirin: Concomitant administration of  <e1> aspirin </e1>  with valdecoxib may result in an increased risk of GI ulceration and complications compared to  <e2> valdecoxib </e2>  alone.
mechanism	The interaction is a consequence of blocking hepatic metabolism of  <e1> vardenafil </e1>  by  <e2> ritonavir </e2> , a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.
false	- Anabolic steroids (nandrolone [e.g.,  <e1> Anabolin </e1> ], oxandrolone [e.g., Anavar], oxymetholone [e.g.,  <e2> Anadrol </e2> ], stanozolol [e.g., Winstrol]) or
false	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide,  <e1> warfarin </e1> , digoxin,  <e2> Maalox </e2> , and ranitidine.
false	 <e1> Aspirin </e1> :  <e2> Vardenafil </e2>  (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).
false	 <e1> Nifedipine </e1>  did not alter the plasma levels of  <e2> Vardenafil </e2>  when taken in combination.
false	These increased exposures of norethindrone and  <e1> ethinyl estradiol </e1>  should be taken into consideration when selecting an oral  <e2> contraceptive </e2>  for women taking valdecoxib.
advise	Consequently, it is recommended not to exceed a single 2.5 mg  <e1> Vardenafil </e1>  dose in a 72-hour period when used in combination with  <e2> ritonavir </e2> .
false	In vivo studies:  <e1> Nitrates </e1> : The blood pressure lowering effects of sublingual  <e2> nitrates </e2>  (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
false	HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in  <e1> vardenafil </e1>  AUC, a 7-fold increase in  <e2> vardenafil </e2>  Cmax and a 2-fold increase in vardenafil half-life.
false	Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide,  <e1> warfarin </e1> ,  <e2> digoxin </e2> , Maalox, and ranitidine.
false	-  <e1> Carmustine </e1>  (e.g.,  <e2> BiCNU </e2> ) or
false	Nifedipine: Vardenafil 20 mg, when co-administered with slow-release  <e1> nifedipine </e1>  30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of  <e2> nifedipine </e2> , a drug that is metabolized via CYP3A4.
false	Ritonavir and  <e1> indinavir </e1> : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID  <e2> ritonavir </e2> , the Cmax and AUC of ritonavir were reduced by approximately 20%.
false	In vivo studies:  <e1> Nitrates </e1> : The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of  <e2> Vardenafil </e2>  in healthy middle-aged subjects.
false	Other interactions:  <e1> Vardenafil </e1>  had no effect on the pharmacodynamics of  <e2> glyburide </e2>  (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).
false	 <e1> Ritonavir </e1>  and indinavir: Upon concomitant administration of 5 mg of  <e2> Vardenafil </e2>  with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.
mechanism	Upon administration of 10 mg of  <e1> Vardenafil </e1>  with 800 mg TID  <e2> indinavir </e2> , the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.
false	HIV Protease Inhibitors:  <e1> Indinavir </e1>  (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in  <e2> vardenafil </e2>  Cmax and a 2-fold increase in vardenafil half-life.
false	Oral Contraceptives:  <e1> Valdecoxib </e1>  (40 mg BID) did not induce the metabolism of the combination oral  <e2> contraceptive </e2>  norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).
false	In a similar study with  <e1> tamsulosin </e1>  in healthy volunteers, 1 of 24 subjects dosed with  <e2> Vardenafil </e2>  20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
effect	Alpha-blockers: When  <e1> Vardenafil </e1>  10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of  <e2> terazosin </e2> , significant hypotension developed in a substantial number of subjects.
advise	A 5-mg  <e1> Vardenafil </e1>  dose should not be exceeded when used in combination with 200 mg once daily  <e2> ketoconazole </e2> .
false	When Vardenafil dosing was separated from  <e1> terazosin </e1>  10 mg by 6 hours, 7 of 28 subjects who received 20 mg of  <e2> Vardenafil </e2>  experienced a decrease in standing systolic blood pressure below 85 mm Hg.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin,  <e1> dapsone </e1> , disulfiram, ethionamide,  <e2> glutethimide </e2> , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Magnesium/Aluminum-containing  <e1> Antacid Products </e1> : Absorption of  <e2> zalcitabine </e2>  is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.
false	Probenecid or  <e1> Cimetidine </e1> : Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of  <e2> zalcitabine </e2> .
false	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other  <e1> HIVID </e1> -associated adverse events by interfering with the renal clearance of  <e2> zalcitabine </e2>  (thereby raising systemic exposure).
false	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as  <e1> amphotericin </e1> , foscarnet, and  <e2> aminoglycosides </e2>  may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	Magnesium/ <e1> Aluminum </e1> -containing Antacid Products: Absorption of  <e2> zalcitabine </e2>  is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues,  <e1> chloramphenicol </e1> , cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin,  <e2> ribavirin </e2> , and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues,  <e1> chloramphenicol </e1> ,  <e2> cisplatin </e2> , dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone,  <e1> disulfiram </e1> , ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole,  <e2> nitrofurantoin </e2> , phenytoin, ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol,  <e1> cisplatin </e1> , dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol,  <e2> isoniazid </e2> , metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
mechanism	In vivo studies: Nitrates: The blood pressure lowering effects of sublingual  <e1> nitrates </e1>  (0.4 mg) taken 1 and 4 hours after  <e2> vardenafil </e2>  and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
mechanism	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as  <e1> amphotericin </e1> , foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of  <e2> zalcitabine </e2>  (thereby raising systemic exposure).
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold,  <e1> hydralazine </e1> , iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and  <e2> vincristine </e2> .
false	Magnesium/Aluminum-containing Antacid Products: Absorption of  <e1> zalcitabine </e1>  is moderately reduced (approximately 25%) when coadministered with  <e2> magnesium </e2> /aluminum-containing antacid products.
false	 <e1> Metoclopramide </e1> : Bioavailability is mildly reduced (approximately 10%) when  <e2> zalcitabine </e2>  and metoclopramide are coadministered.
false	Ritonavir and  <e1> indinavir </e1> : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of  <e2> ritonavir </e2>  were reduced by approximately 20%.
advise	Concomitant use of  <e1> HIVID </e1>  with  <e2> didanosine </e2>  is not recommended.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin,  <e1> phenytoin </e1> ,  <e2> ribavirin </e2> , and vincristine.
false	 <e1> Magnesium </e1> /Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/ <e2> aluminum </e2> -containing antacid products.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide,  <e1> glutethimide </e1> , gold, hydralazine, iodoquinol, isoniazid, metronidazole,  <e2> nitrofurantoin </e2> , phenytoin, ribavirin, and vincristine.
effect	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as  <e1> amphotericin </e1> , foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other  <e2> HIVID </e2> -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	Drugs that have been associated with peripheral neuropathy include  <e1> antiretroviral nucleoside analogues </e1> , chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold,  <e2> hydralazine </e2> , iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues,  <e1> chloramphenicol </e1> , cisplatin,  <e2> dapsone </e2> , disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Amphotericin,  <e1> Foscarnet </e1> , and Aminoglycosides: Drugs such as amphotericin,  <e2> foscarnet </e2> , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin,  <e1> dapsone </e1> , disulfiram,  <e2> ethionamide </e2> , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone,  <e1> disulfiram </e1> , ethionamide,  <e2> glutethimide </e2> , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	 <e1> Amphotericin </e1> , Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of  <e2> zalcitabine </e2>  (thereby raising systemic exposure).
false	Magnesium/Aluminum-containing  <e1> Antacid Products </e1> : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/ <e2> aluminum </e2> -containing antacid products.
false	The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with  <e1> magnesium </e1> /aluminum-containing  <e2> antacids </e2> .
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol,  <e1> isoniazid </e1> , metronidazole, nitrofurantoin, phenytoin, ribavirin, and  <e2> vincristine </e2> .
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol,  <e1> cisplatin </e1> , dapsone, disulfiram, ethionamide, glutethimide,  <e2> gold </e2> , hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine,  <e1> iodoquinol </e1> ,  <e2> isoniazid </e2> , metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	 <e1> Magnesium </e1> /Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing  <e2> antacid products </e2> .
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide,  <e1> gold </e1> , hydralazine, iodoquinol, isoniazid, metronidazole,  <e2> nitrofurantoin </e2> , phenytoin, ribavirin, and vincristine.
false	Amphotericin,  <e1> Foscarnet </e1> , and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other  <e2> HIVID </e2> -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
advise	It is recommended not to exceed a single 5 mg dose of  <e1> Vardenafil </e1>  in a 24-hour period when used in combination with  <e2> erythromycin </e2> .
false	 <e1> Amphotericin </e1> , Foscarnet, and  <e2> Aminoglycosides </e2> : Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol,  <e1> cisplatin </e1> , dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin,  <e2> phenytoin </e2> , ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol,  <e1> cisplatin </e1> ,  <e2> dapsone </e2> , disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Amphotericin, Foscarnet, and  <e1> Aminoglycosides </e1> : Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other  <e2> HIVID </e2> -associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	Drugs that have been associated with peripheral neuropathy include  <e1> antiretroviral nucleoside analogues </e1> , chloramphenicol,  <e2> cisplatin </e2> , dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol,  <e1> cisplatin </e1> , dapsone, disulfiram, ethionamide, glutethimide, gold,  <e2> hydralazine </e2> , iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine,  <e1> iodoquinol </e1> , isoniazid, metronidazole, nitrofurantoin,  <e2> phenytoin </e2> , ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol,  <e1> cisplatin </e1> , dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and  <e2> vincristine </e2> .
false	Drugs that have been associated with peripheral neuropathy include  <e1> antiretroviral nucleoside analogues </e1> , chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide,  <e2> glutethimide </e2> , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	In the same study it was shown that  <e1> didanosine </e1>  and stavudine had no significant effect on the intracellular phosphorylation of  <e2> zalcitabine </e2>  in peripheral blood mononuclear cells.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues,  <e1> chloramphenicol </e1> , cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole,  <e2> nitrofurantoin </e2> , phenytoin, ribavirin, and vincristine.
false	 <e1> Saquinavir </e1> : The combination of  <e2> HIVID </e2> , saquinavir, and ZDV has been studied (as triple combination) in adults.
false	Amphotericin, Foscarnet, and  <e1> Aminoglycosides </e1> : Drugs such as amphotericin, foscarnet, and  <e2> aminoglycosides </e2>  may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol,  <e1> cisplatin </e1> , dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid,  <e2> metronidazole </e2> , nitrofurantoin, phenytoin, ribavirin, and vincristine.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin,  <e1> phenytoin </e1> , ribavirin, and  <e2> vincristine </e2> .
false	In the same study it was shown that  <e1> didanosine </e1>  and  <e2> stavudine </e2>  had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.
effect	Death due to fulminant pancreatitis possibly related to intravenous  <e1> pentamidine </e1>  and  <e2> HIVID </e2>  has been reported.
false	Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of  <e1> venlafaxine </e1>  ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either  <e2> zaleplon </e2>  or venlafaxine.
false	Drugs with a Narrow Therapeutic Index  <e1> Digoxin </e1> : Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of  <e2> digoxin </e2>  (0.375 mg q24h for 8 days).
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram,  <e1> ethionamide </e1> , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin,  <e2> phenytoin </e2> , ribavirin, and vincristine.
false	Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and  <e1> 5-oxo-desethylzaleplon glucuronide </e1> , account for only 9% of the urinary recovery of a  <e2> zaleplon </e2>  dose.
false	Amphotericin,  <e1> Foscarnet </e1> , and Aminoglycosides: Drugs such as  <e2> amphotericin </e2> , foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	 <e1> Warfarin </e1> : Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of  <e2> warfarin </e2> .
false	In the  <e1> warfarin </e1>  study,  <e2> vardenafil </e2>  had no effect on the prothrombin time or other pharmacodynamic parameters.
false	Venlafaxine: Coadministration of a single dose of  <e1> zaleplon </e1>  10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or  <e2> venlafaxine </e2> .
false	CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of  <e1> ethanol </e1>  0.75 g/kg on balance testing and reaction time for 1 hour after  <e2> ethanol </e2>  administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
false	CNS-Active Drugs  <e1> Ethanol </e1> :  <e2> Sonata </e2>  10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
false	Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive  <e1> norethindrone </e1> /ethinyl estradiol (1 mg /35 mcg combination,  <e2> Ortho-Novum </e2>  1/35 ).
false	There is no pharmacokinetic interaction between  <e1> zaleplon </e1>  and  <e2> diphenhydramine </e2>  following the administration of a single dose (10 mg and 50 mg, respectively) of each drug.
mechanism	Coadministration of single, oral doses of  <e1> zaleplon </e1>  with  <e2> erythromycin </e2>  (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram,  <e1> ethionamide </e1> , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin,  <e2> ribavirin </e2> , and vincristine.
false	An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as  <e1> rifampin </e1> ,  <e2> phenytoin </e2> , carbamazepine, and phenobarbital.
false	This was expected because  <e1> zaleplon </e1>  is primarily metabolized and renal excretion of unchanged  <e2> zaleplon </e2>  accounts for less than 1% of the administered dose.
false	Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either  <e1> zaleplon </e1>  or  <e2> venlafaxine </e2> .
false	An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin,  <e1> phenytoin </e1> , carbamazepine, and  <e2> phenobarbital </e2> .
false	Magnesium/Aluminum-containing Antacid Products: Absorption of  <e1> zalcitabine </e1>  is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing  <e2> antacid products </e2> .
false	 <e1> Venlafaxine </e1> : Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or  <e2> venlafaxine </e2> .
false	Magnesium/ <e1> Aluminum </e1> -containing  <e2> Antacid Products </e2> : Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.
false	 <e1> HIV Protease Inhibitors </e1> : Indinavir (800 mg t.i.d.) co-administered with  <e2> Vardenafil </e2>  10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide,  <e1> glutethimide </e1> , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and  <e2> vincristine </e2> .
effect	Thioridazine: Coadministration of single doses of  <e1> Sonata </e1>  20 mg and  <e2> thioridazine </e2>  50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
mechanism	Concomitant administration of  <e1> Sonata </e1>  (10 mg) and  <e2> cimetidine </e2>  (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
false	 <e1> Amphotericin </e1> , Foscarnet, and Aminoglycosides: Drugs such as amphotericin,  <e2> foscarnet </e2> , and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
false	 <e1> Venlafaxine </e1> : Coadministration of a single dose of zaleplon 10 mg and multiple doses of  <e2> venlafaxine </e2>  ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.
mechanism	 <e1> Ethanol </e1>  decreases the elimination of  <e2> abacavir </e2>  causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. 
false	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or  <e1> zidovudine </e1>  or the combination of  <e2> lamivudine </e2>  and zidovudine. 
false	 <e1> Ethanol </e1>  decreases the elimination of abacavir causing an increase in overall exposure . The addition of  <e2> methadone </e2>  has no clinically significant effect on the pharmacokinetic properties of abacavir. 
false	Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of  <e1> methadone </e1>  has no clinically significant effect on the pharmacokinetic properties of  <e2> abacavir </e2> . 
false	Effects of  <e1> GABITRIL </e1>  on other Antiepilepsy Drugs (AEDs) :  <e2> Phenytoin </e2> : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
false	Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid,  <e1> metronidazole </e1> , nitrofurantoin, phenytoin,  <e2> ribavirin </e2> , and vincristine.
false	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of  <e1> lamivudine </e1>  and  <e2> zidovudine </e2> . 
false	Drugs That Induce CYP3A4  <e1> Rifampin </e1> : CYP3A4 is ordinarily a minor metabolizing enzyme of  <e2> zaleplon </e2> .
false	In a study of 11 HIV-infected patients receiving  <e1> methadone </e1> -maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral  <e2> methadone </e2>  clearance increased 22% (90% CI 6% to 42%). 
false	In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of  <e1> ZIAGEN </e1>  twice daily (twice the currently recommended dose), oral  <e2> methadone </e2>  clearance increased 22% (90% CI 6% to 42%). 
false	When  <e1> ZETIA </e1>  is administered with an  <e2> HMG-CoA reductase inhibitor </e2>  in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. 
false	Fibrates: The safety and effectiveness of  <e1> ezetimibe </e1>  administered with  <e2> fibrates </e2>  have not been established. 
mechanism	Fenofibrate: In a pharmacokinetic study, concomitant  <e1> fenofibrate </e1>  administration increased total  <e2> ezetimibe </e2>  concentrations approximately 1.5-fold. 
false	Pharmacokinetic properties of abacavir were not altered by the addition of either  <e1> lamivudine </e1>  or zidovudine or the combination of lamivudine and  <e2> zidovudine </e2> . 
false	 <e1> Diphenhydramine </e1> :  <e2> Diphenhydramine </e2>  is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.
false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin,  <e1> pravastatin </e1> , lovastatin, or  <e2> fluvastatin </e2> . 
false	Ethanol decreases the elimination of  <e1> abacavir </e1>  causing an increase in overall exposure . The addition of  <e2> methadone </e2>  has no clinically significant effect on the pharmacokinetic properties of abacavir. 
false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with  <e1> atorvastatin </e1> ,  <e2> simvastatin </e2> , pravastatin, lovastatin, or fluvastatin. 
false	 <e1> HMG-CoA reductase inhibitors </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin,  <e2> simvastatin </e2> , pravastatin, lovastatin, or fluvastatin. 
false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin,  <e1> simvastatin </e1> , pravastatin,  <e2> lovastatin </e2> , or fluvastatin. 
false	 <e1> HMG-CoA reductase inhibitors </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with  <e2> atorvastatin </e2> , simvastatin, pravastatin, lovastatin, or fluvastatin. 
false	When ZETIA is administered with an  <e1> HMG-CoA reductase inhibitor </e1>  in a woman of childbearing potential, refer to the pregnancy category and package labeling for the  <e2> HMG-CoA reductase inhibitor </e2> . 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine,  <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus,  <e2> Short-acting benzodiazepines </e2> ,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral  <e1> contraceptives </e1>  produced an overall mean increase in  <e2> ethinyl estradiol </e2>  and levonorgestrel levels; 
false	These are described in greater detail below:  Oral hypoglycemics,  <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral  <e2> hypoglycemic agents </e2> ; 
false	In post-marketing experience, as with other  <e1> azole antifungals </e1> , bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with  <e2> warfarin </e2> . 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants,  <e1> Phenytoin </e1> , Cyclosporine, Rifampin,  <e2> Theophylline </e2> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin,  <e1> Theophylline </e1> ,  <e2> Terfenadine </e2> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	Careful monitoring of  <e1> phenytoin </e1>  concentrations in patients receiving  <e2> DIFLUCAN </e2>  and phenytoin is recommended. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole,  <e1> Rifabutin </e1> , Tacrolimus, Short-acting benzodiazepines,  Oral  <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	 <e1> Theophylline </e1> :  <e2> DIFLUCAN </e2>  increases the serum concentrations of theophylline. 
mechanism	 <e1> DIFLUCAN </e1>  reduces the metabolism of  <e2> tolbutamide </e2> , glyburide, and glipizide and increases the plasma concentration of these agents. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline,  <e1> Terfenadine </e1> ,  <e2> Cisapride </e2> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
mechanism	 <e1> DIFLUCAN </e1>  reduces the metabolism of tolbutamide, glyburide, and  <e2> glipizide </e2>  and increases the plasma concentration of these agents. 
false	These are described in greater detail below:  Oral hypoglycemics,  <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral  <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine,  <e1> Rifampin </e1> ,  <e2> Theophylline </e2> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	 <e1> Fluconazole </e1>  tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral  <e2> contraceptives </e2>  produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 
false	 <e1> Short-acting Benzodiazepines </e1> : Following oral administration of  <e2> midazolam </e2> , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine,  <e1> Rifampin </e1> , Theophylline,  <e2> Terfenadine </e2> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	A 104-week dietary carcinogenicity study with  <e1> ezetimibe </e1>  was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total  <e2> ezetimibe </e2> ). 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin,  <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus,  <e2> Short-acting benzodiazepines </e2> ,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	 <e1> Rifampin </e1> : Rifampin enhances the metabolism of concurrently administered  <e2> DIFLUCAN </e2> . 
false	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when  <e1> ezetimibe </e1>  was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or  <e2> fluvastatin </e2> . 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline,  <e1> Terfenadine </e1> , Cisapride, Astemizole, Rifabutin,  <e2> Tacrolimus </e2> , Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
advise	Patients receiving  <e1> rifabutin </e1>  and  <e2> fluconazole </e2>  concomitantly should be carefully monitored. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole,  <e1> Rifabutin </e1> , Tacrolimus,  <e2> Short-acting benzodiazepines </e2> ,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
advise	The combined use of  <e1> fluconazole </e1>  at doses of 400 mg or greater with  <e2> terfenadine </e2>  is contraindicated. 
effect	This effect on  <e1> midazolam </e1>  appears to be more pronounced following oral administration of  <e2> fluconazole </e2>  than with fluconazole administered intravenously. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral  <e1> hypoglycemics </e1> : Clinically significant hypoglycemia may be precipitated by the use of  <e2> DIFLUCAN </e2>  with oral hypoglycemic agents; 
false	The data presently available indicate that the decreases in some individual  <e1> ethinyl estradiol </e1>  and  <e2> levonorgestrel </e2>  AUC values with fluconazole treatment are likely the result of random variation. 
false	however, in some patients there were decreases up to 47% and 33% of  <e1> ethinyl estradiol </e1>  and  <e2> levonorgestrel </e2>  levels. 
mechanism	A controlled study found that concomitant  <e1> fluconazole </e1>  200 mg once daily and  <e2> cisapride </e2>  20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.
false	Fluconazole tablets coadministered with ethinyl estradiol- and  <e1> levonorgestrel </e1> -containing oral contraceptives produced an overall mean increase in  <e2> ethinyl estradiol </e2>  and levonorgestrel levels; 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride,  <e1> Astemizole </e1> , Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of  <e2> DIFLUCAN </e2>  with oral hypoglycemic agents; 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline,  <e1> Terfenadine </e1> , Cisapride, Astemizole,  <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
advise	The combined use of  <e1> fluconazole </e1>  with  <e2> cisapride </e2>  is contraindicated. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin,  <e1> Theophylline </e1> , Terfenadine, Cisapride, Astemizole,  <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	Multiple dose studies of  <e1> ezetimibe </e1>  given in combination with  <e2> HMG-CoA reductase inhibitors </e2>  (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin,  <e1> Cyclosporine </e1> , Rifampin,  <e2> Theophylline </e2> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	 <e1> Cisapride </e1> : There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and  <e2> cisapride </e2>  were coadministered. 
false	This effect on  <e1> midazolam </e1>  appears to be more pronounced following oral administration of fluconazole than with  <e2> fluconazole </e2>  administered intravenously. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine,  <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, Astemizole,  <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	DIFLUCAN reduces the metabolism of tolbutamide,  <e1> glyburide </e1> , and  <e2> glipizide </e2>  and increases the plasma concentration of these agents. 
false	Another study at a 400-mg and 800-mg daily dose of  <e1> fluconazole </e1>  demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of  <e2> terfenadine </e2>  when taken concomitantly. 
false	 <e1> Coumarin-type anticoagulants </e1> : Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and  <e2> coumarin-type anticoagulants </e2> . 
effect	Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant  <e1> DIFLUCAN </e1>  and  <e2> coumarin-type anticoagulants </e2> . 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin,  <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, Cisapride,  <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin,  <e1> Tacrolimus </e1> , Short-acting benzodiazepines,  Oral  <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
advise	You cannot take  <e1> mazindol </e1>  if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or  <e2> phenelzine </e2>  (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor),  <e1> imipramine </e1>  (Tofranil), clomipramine (Anafranil),  <e2> protriptyline </e2>  (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as  <e1> amitriptyline </e1>  ( <e2> Elavil </e2> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine,  <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of  <e2> DIFLUCAN </e2>  with oral hypoglycemic agents; 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as  <e1> amitriptyline </e1>  (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
mechanism	Rifampin:  <e1> Rifampin </e1>  enhances the metabolism of concurrently administered  <e2> DIFLUCAN </e2> . 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil),  <e1> amoxapine </e1>  (Asendin), doxepin ( <e2> Sinequan </e2> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e1> Anafranil </e1> ), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil),  <e1> amoxapine </e1>  (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin). 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin,  <e1> Cyclosporine </e1> ,  <e2> Rifampin </e2> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	While there is evidence that  <e1> fluconazole </e1>  can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of  <e2> ethinyl estradiol </e2>  or levonorgestrel metabolism. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), clomipramine (Anafranil),  <e2> protriptyline </e2>  (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a  <e1> tricyclic antidepressant </e1>  such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin),  <e1> doxepin </e1>  (Sinequan), nortriptyline (Pamelor),  <e2> imipramine </e2>  (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil),  <e1> clomipramine </e1>  (Anafranil), protriptyline (Vivactil), or  <e2> desipramine </e2>  (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as  <e1> amitriptyline </e1>  (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or  <e2> desipramine </e2>  (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin),  <e1> doxepin </e1>  (Sinequan),  <e2> nortriptyline </e2>  (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	DIFLUCAN reduces the metabolism of  <e1> tolbutamide </e1> ,  <e2> glyburide </e2> , and glipizide and increases the plasma concentration of these agents. 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine ( <e1> Parnate </e1> ), or  <e2> phenelzine </e2>  (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e1> Vivactil </e1> ), or  <e2> desipramine </e2>  (Norpramin). 
advise	Changes in  <e1> insulin </e1>  and other diabetes drug therapies may be necessary during treatment with  <e2> mazindol </e2> .
false	Fluconazole tablets coadministered with  <e1> ethinyl estradiol </e1> - and  <e2> levonorgestrel </e2> -containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine ( <e1> Parnate </e1> ), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or  <e1> desipramine </e1>  ( <e2> Norpramin </e2> ). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
false	Before taking this medication, tell your doctor if you are taking a  <e1> tricyclic antidepressant </e1>  such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or  <e2> desipramine </e2>  (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin). 
effect	Rifabutin: There have been reports of uveitis in patients to whom  <e1> fluconazole </e1>  and  <e2> rifabutin </e2>  were coadministered. 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan),  <e1> tranylcypromine </e1>  (Parnate), or  <e2> phenelzine </e2>  (Nardil) in the last 14 days. 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan),  <e1> tranylcypromine </e1>  (Parnate), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days. 
false	 <e1> Terfenadine </e1> : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving  <e2> azole antifungals </e2>  in conjunction with terfenadine, interaction studies have been performed. 
false	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin,  <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine,  <e2> Cisapride </e2> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin),  <e1> doxepin </e1>  (Sinequan), nortriptyline ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan),  <e1> nortriptyline </e1>  (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Another study at a 400-mg and 800-mg daily dose of  <e1> fluconazole </e1>  demonstrated that  <e2> DIFLUCAN </e2>  taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e1> Vivactil </e1> ), or desipramine ( <e2> Norpramin </e2> ). 
false	These are described in greater detail below:  Oral hypoglycemics,  <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine,  <e2> Rifampin </e2> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or  <e1> phenelzine </e1>  ( <e2> Nardil </e2> ) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	You cannot take mazindol if you have taken a  <e1> monoamine oxidase inhibitor </e1>  (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor),  <e1> imipramine </e1>  (Tofranil),  <e2> clomipramine </e2>  (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 
false	You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as isocarboxazid (Marplan),  <e2> tranylcypromine </e2>  (Parnate), or phenelzine (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or  <e2> desipramine </e2>  (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a  <e1> tricyclic antidepressant </e1>  such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil),  <e2> protriptyline </e2>  (Vivactil), or desipramine (Norpramin). 
false	You cannot take mazindol if you have taken a  <e1> monoamine oxidase inhibitor </e1>  (MAOI) such as  <e2> isocarboxazid </e2>  (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil),  <e1> clomipramine </e1>  (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
advise	Patients receiving  <e1> antibiotics </e1>  and sulfonamides generally should not be treated with  <e2> ganglion blockers </e2> .  
false	Patients receiving  <e1> antibiotics </e1>  and  <e2> sulfonamides </e2>  generally should not be treated with ganglion blockers.  
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil),  <e1> protriptyline </e1>  (Vivactil), or desipramine ( <e2> Norpramin </e2> ). 
false	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), clomipramine (Anafranil),  <e2> protriptyline </e2>  (Vivactil), or desipramine (Norpramin). 
false	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or  <e1> rifabutin </e1>  to warrant dosage adjustment when  <e2> megestrol acetate </e2>  is administered with these drugs. 
false	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of  <e1> zidovudine </e1>  or rifabutin to warrant dosage adjustment when  <e2> megestrol acetate </e2>  is administered with these drugs. 
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  <e2> corticosteroids </e2>  (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs:  <e1> aspirin </e1>  and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women),  <e2> benzodiazepenes </e2>  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral  <e1> melatonin </e1>  is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and  <e2> corticosteroids </e2>  may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered),  <e2> progestin </e2>  (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and  <e1> corticosteroids </e1>  may interfere with the efficacy of the  <e2> corticosteroids </e2> ).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease  <e1> melatonin </e1>  levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  <e2> corticosteroids </e2>  (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration),  <e1> beta blockers </e1>  (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and  <e2> corticosteroids </e2>  may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels),  <e1> fluvoxamine </e1>  (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  <e2> corticosteroids </e2>  (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	 <e1> Melatonin </e1>  may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of  <e2> melatonin </e2>  and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral  <e1> melatonin </e1>  is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the  <e2> corticosteroids </e2> ).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral  <e1> melatonin </e1>  is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered),  <e2> progestin </e2>  (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower  <e1> melatonin </e1>  levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with  <e2> progestin </e2>  can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	 <e1> Melatonin </e1>  may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and  <e2> corticosteroids </e2>  may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs:  <e1> aspirin </e1>  and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels),  <e2> fluoxetine </e2>  (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels),  <e1> fluvoxamine </e1>  (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women),  <e2> benzodiazepenes </e2>  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral  <e1> melatonin </e1>  is increased with coadministration), beta blockers (may decrease melatonin levels),  <e2> fluoxetine </e2>  (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels),  <e1> fluvoxamine </e1>  (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of  <e2> melatonin </e2>  and corticosteroids may interfere with the efficacy of the corticosteroids).
int	 <e1> Melatonin </e1>  may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration),  <e2> beta blockers </e2>  (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered),  <e1> progestin </e1>  (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and  <e2> corticosteroids </e2>  may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and  <e2> corticosteroids </e2>  may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs:  <e1> aspirin </e1>  and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease  <e2> melatonin </e2>  levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease  <e1> melatonin </e1>  levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with  <e2> progestin </e2>  can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	The effects of  <e1> indinavir </e1> , zidovudine or  <e2> rifabutin </e2>  on the pharmacokinetics of megestrol acetate were not studied.
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower  <e1> melatonin </e1>  levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  <e2> corticosteroids </e2>  (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of  <e1> melatonin </e1>  with progestin can inhibit ovarian function in women),  <e2> benzodiazepenes </e2>  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
int	 <e1> Melatonin </e1>  may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels),  <e2> fluvoxamine </e2>  (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs:  <e1> aspirin </e1>  and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of  <e2> melatonin </e2>  with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels),  <e1> fluvoxamine </e1>  (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with  <e2> progestin </e2>  can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	 <e1> Furosemide </e1> : Clinical studies, as well as post-marketing observations, have shown that  <e2> NSAIDs </e2>  can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. 
false	 <e1> Cholestyramine </e1> : Pretreatment for four days with cholestyramine significantly increased the clearance of  <e2> meloxicam </e2>  by 50%. 
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels),  <e1> fluoxetine </e1>  (reports of psychotic episodes when coadministered), progestin (coadministration of  <e2> melatonin </e2>  with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration),  <e1> beta blockers </e1>  (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  <e2> corticosteroids </e2>  (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of  <e1> furosemide </e1>  and  <e2> thiazide diuretics </e2>  in some patients. 
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower  <e1> melatonin </e1>  levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women),  <e2> benzodiazepenes </e2>  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
advise	This interaction should be given consideration in patients taking  <e1> NSAIDs </e1>  concomitantly with  <e2> ACE inhibitors </e2> . 
false	 <e1> Melatonin </e1>  may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with  <e2> progestin </e2>  can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels),  <e1> fluvoxamine </e1>  (bioavailability of oral melatonin is increased with coadministration),  <e2> beta blockers </e2>  (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
effect	Concomitant administration of low-dose  <e1> aspirin </e1>  with  <e2> MOBIC </e2>  may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. 
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower melatonin levels), fluvoxamine (bioavailability of oral  <e2> melatonin </e2>  is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	 <e1> Cimetidine </e1> : Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg  <e2> meloxicam </e2> . 
mechanism	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving  <e1> lithium </e1>  doses ranging from 804 to 1072 mg BID with  <e2> meloxicam </e2>  15 mg QD as compared to subjects receiving lithium alone. 
false	In vitro,  <e1> methotrexate </e1>  did not displace  <e2> meloxicam </e2>  from its human serum binding sites. 
false	 <e1> Warfarin </e1> : Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing  <e2> MOBIC </e2>  therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. 
false	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women),  <e1> benzodiazepenes </e1>  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the  <e2> corticosteroids </e2> ).
false	In a study conducted in healthy subjects, mean pre-dose  <e1> lithium </e1>  concentration and AUC were increased by 21% in subjects receiving  <e2> lithium </e2>  doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. 
false	 <e1> Furosemide </e1> : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and  <e2> thiazide diuretics </e2>  in some patients. 
effect	Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous  <e1> melphalan </e1>  and who subsequently received  <e2> cyclosporin </e2>  to prevent graft-versus-host disease
false	 <e1> Digoxin </e1> : Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of  <e2> digoxin </e2>  after b-acetyldigoxin administration for 7 days at clinical doses. 
false	DRUG INTERACTIONS  There are no known drug/drug interactions with oral  <e1> ALKERAN </e1>   Vaccinations with  <e2> live organism vaccines </e2>  are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  
false	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with  <e1> live organism vaccines </e1>  are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous  <e2> melphalan </e2>  has caused deaths in children due to haemorrhagic enterocolitis.  
false	Melatonin may interact with the following drugs: aspirin and other  <e1> NSAIDs </e1>  (may lower  <e2> melatonin </e2>  levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g.,  <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and  <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
effect	 <e1> Anticholinergics </e1>  antagonize the effects of  <e2> antiglaucoma agents </e2> . 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors,  <e1> narcotic analgesics </e1>  (e.g., meperidine), nitrates and nitrites,  <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity. 
effect	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and  <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines,  <e1> MAO inhibitors </e1> , narcotic analgesics (e.g., meperidine),  <e2> nitrates </e2>  and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines,  <e1> MAO inhibitors </e1> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents,  <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines,  <e1> antipsychotic agents </e1>  (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and  <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors,  <e1> narcotic analgesics </e1>  (e.g., meperidine),  <e2> nitrates </e2>  and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine),  <e1> nitrates </e1>  and nitrites, sympathomimetic agents,  <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs:  <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines),  <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
effect	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g.,  <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs:  <e1> amantadine </e1> ,  <e2> antiarrhythmic agents of class I </e2>  (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors,  <e1> narcotic analgesics </e1>  (e.g., meperidine), nitrates and nitrites, sympathomimetic agents,  <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines,  <e1> antipsychotic agents </e1>  (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g.,  <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines,  <e1> MAO inhibitors </e1> , narcotic analgesics (e.g.,  <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g.,  <e1> meperidine </e1> ), nitrates and  <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine,  <e1> antiarrhythmic agents of class I </e1>  (e.g., quinidine), antihistamines, antipsychotic agents (e.g.,  <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine),  <e1> nitrates </e1>  and  <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g.,  <e1> meperidine </e1> ),  <e2> nitrates </e2>  and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines),  <e1> benzodiazepines </e1> ,  <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g.,  <e1> quinidine </e1> ), antihistamines,  <e2> antipsychotic agents </e2>  (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g.,  <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g.,  <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING  <e2> ALCOHOL </e2> ). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES),  <e2> TRICYCLIC ANTIDEPRESSANTS </e2>  AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS,  <e1> PHENOTHIAZINES </e1> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER  <e2> CNS DEPRESSANTS </e2>  (INCLUDING ALCOHOL). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS,  <e1> PHENOTHIAZINES </e1> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING  <e2> BARBITURATES </e2> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	The following agents may increase certain actions or side effects of anticholinergic drugs:  <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g.,  <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL  <e1> ANESTHETICS </e1> ,  <e2> PHENOTHIAZINES </e2> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL  <e1> ANESTHETICS </e1> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES),  <e2> TRICYCLIC ANTIDEPRESSANTS </e2>  AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER  <e1> TRANQUILIZERS </e1> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING  <e2> ALCOHOL </e2> ). 
effect	The following agents may increase certain actions or side effects of  <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors,  <e2> narcotic analgesics </e2>  (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER  <e1> TRANQUILIZERS </e1> ,  <e2> SEDATIVE-HYPNOTICS </e2>  (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS,  <e1> PHENOTHIAZINES </e1> , OTHER  <e2> TRANQUILIZERS </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Interaction with Other  <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS,  <e2> PHENOTHIAZINES </e2> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
advise	Interaction with Other Central Nervous System Depressants:  <e1> MEPERIDINE </e1>  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER  <e2> TRANQUILIZERS </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines),  <e1> benzodiazepines </e1> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites,  <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL  <e1> ANESTHETICS </e1> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING  <e2> ALCOHOL </e2> ). 
advise	Interaction with Other Central Nervous System Depressants:  <e1> MEPERIDINE </e1>  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL  <e2> ANESTHETICS </e2> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 
false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines,  <e1> furosemide </e1>  and  <e2> theophylline </e2>  Please note that Mephenytoin may interact with other drugs that are not listed here.
false	Those anticonvulsants include  <e1> divalproex sodium </e1> ,  <e2> valproic acid </e2> , and phenobarbital. 
false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills,  <e1> anti-infective medicines </e1> , furosemide and theophylline Please note that  <e2> Mephenytoin </e2>  may interact with other drugs that are not listed here.
false	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine,  <e1> antiarrhythmic agents of class I </e1>  (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine),  <e2> nitrates </e2>  and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 
false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines,  <e1> furosemide </e1>  and theophylline Please note that  <e2> Mephenytoin </e2>  may interact with other drugs that are not listed here.
effect	 <e1> Mephenytoin </e1>  may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and  <e2> theophylline </e2>  Please note that Mephenytoin may interact with other drugs that are not listed here.
false	Mephenytoin may also affect the effects of other drugs, which include some  <e1> steroid medications </e1> , warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that  <e2> Mephenytoin </e2>  may interact with other drugs that are not listed here.
false	Those anticonvulsants include  <e1> divalproex sodium </e1> , valproic acid, and  <e2> phenobarbital </e2> . 
int	 <e1> Mequitazine </e1>  can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and  <e2> alcohol </e2> .
false	Mequitazine can interact with CNS depressant,  <e1> antichlolinergic </e1> , TCA, MAOIs, and  <e2> alcohol </e2> .
false	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and  <e1> theophylline </e1>  Please note that  <e2> Mephenytoin </e2>  may interact with other drugs that are not listed here.
false	Mequitazine can interact with CNS depressant, antichlolinergic,  <e1> TCA </e1> ,  <e2> MAOIs </e2> , and alcohol.
false	There is evidence that meropenem may reduce serum levels of  <e1> valproic acid </e1>  to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total  <e2> valproate </e2> ).
false	Mephenytoin may also affect the effects of other drugs, which include some  <e1> steroid medications </e1> ,  <e2> warfarin </e2> , certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
false	 <e1> ARAMINE </e1>  should be used with caution in digitalized patients, since the combination of digitalis and  <e2> sympathomimetic amines </e2>  may cause ectopic arrhythmias. 
effect	Monoamine oxidase inhibitors or  <e1> tricyclic antidepressants </e1>  may potentiate the action of  <e2> sympathomimetic amines </e2> . 
false	SKELAXIN may enhance the effects of  <e1> alcohol </e1> , barbiturates and other  <e2> CNS depressants </e2> .
effect	 <e1> SKELAXIN </e1>  may enhance the effects of alcohol, barbiturates and other  <e2> CNS depressants </e2> .
false	Caution is advised for patients receiving high-dose aspirin and  <e1> methazolamide </e1>  concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and  <e2> carbonic anhydrase inhibitors </e2> .
false	 <e1> Digitalis glycosides </e1> : Serum digitalis levels may be increased when hyperthyroid patients on a stable  <e2> digitalis glycoside </e2>  regimen become euthyroid; 
advise	Exert particular caution in combining  <e1> levomepromazine </e1>  with other anticholinergic drugs ( <e2> tricyclic antidepressants </e2>  and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. 
effect	Caffeine and/or stimulantes of the ephedrine/ <e1> amphetamine </e1>  type may counteract the specific actions of  <e2> levomepromazine </e2> . 
false	 <e1> Caffeine </e1>  and/or stimulantes of the ephedrine/ <e2> amphetamine </e2>  type may counteract the specific actions of levomepromazine. 
false	Dosages of concomitantly administered  <e1> opioids </e1>  should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of  <e2> opioids </e2> . 
false	Since  <e1> Celontin </e1>  (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of  <e2> phenytoin </e2>  and phenobarbital).
false	Since  <e1> Celontin </e1>  (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and  <e2> phenobarbital </e2> ).
false	Since  <e1> Celontin </e1>  ( <e2> methsuximide </e2> ) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
effect	 <e1> Thiazides </e1>  may add to or potentiate the action of other  <e2> antihypertensive drugs </e2> . 
false	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of  <e1> phenytoin </e1>  and  <e2> phenobarbital </e2> ).
false	Methyldopa does not interfere with measurement of  <e1> VMA </e1>  (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert  <e2> VMA </e2>  to vanillin. 
advise	Patients may require reduced doses of  <e1> anesthetics </e1>  when on  <e2> methyldopa </e2> . 
false	 <e1> Methyldopa </e1>  does not interfere with measurement of VMA ( <e2> vanillylmandelic acid </e2> ), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 
mechanism	Several studies demonstrate a decrease in the bioavailability of  <e1> methyldopa </e1>  when it is ingested with  <e2> ferrous sulfate </e2>  or ferrous gluconate. 
false	Methyldopa does not interfere with measurement of  <e1> VMA </e1>  ( <e2> vanillylmandelic acid </e2> ), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 
false	Examples of some of the more potent CYP 3A4 inhibitors include  <e1> macrolide antibiotics </e1>  (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
advise	Caution should be exercised when  <e1> Methergine </e1>     (methylergonovine maleate) is used concurrently with other  <e2> vasoconstrictors </e2>  or ergot alkaloids.
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g.,  <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g.,  <e2> ketoconazole </e2> , itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir,  <e1> indinavir </e1> ,  <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g.,  <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole,  <e2> itraconazole </e2> , voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin,  <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase  <e2> inhibitors </e2>  (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin,  <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice,  <e1> fluoxetine </e1> , fluvoxamine, zileuton, and  <e2> clotrimazole </e2> . 
false	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and  <e1> Protease Inhibitors </e1> ) There have been rare reports of serious adverse events in connection with the coadministration of certain  <e2> ergot alkaloid drugs </e2>  (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin,  <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or  <e2> azole antifungals </e2>  (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir,  <e1> indinavir </e1> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase  <e1> inhibitors </e1>  (e.g., ritonavir,  <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or  <e1> reverse transcriptase inhibitors </e1>  (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole,  <e2> itraconazole </e2> , voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir,  <e1> delavirdine </e1> ) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
false	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain  <e1> ergot alkaloid drugs </e1>  (e.g.  <e2> dihydroergotamine </e2>  and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or  <e1> reverse transcriptase i <e2> nhibitors </e1>  </e2>  (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or  <e1> azole antifungals </e1>  (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
false	Examples of some of the more potent CYP 3A4 inhibitors include  <e1> macrolide antibiotics </e1>  (e.g.,  <e2> erythromycin </e2> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine,  <e1> fluvoxamine </e1> , zileuton, and  <e2> clotrimazole </e2> . 
false	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and  <e1> Protease Inhibitors </e1> ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and  <e2> ergotamine </e2> ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 
false	CYP 3A4 Inhibitors (e.g.  <e1> Macrolide Antibiotics </e1>  and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g.  <e2> dihydroergotamine </e2>  and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 
false	Examples of some of the more potent CYP 3A4 inhibitors include  <e1> macrolide antibiotics </e1>  (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir,  <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Less potent inhibitors include  <e1> saquinavir </e1> ,  <e2> nefazodone </e2> , fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin,  <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g.,  <e2> ritonavir </e2> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include  <e1> macrolide antibiotics </e1>  (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g.,  <e2> ketoconazole </e2> , itraconazole, voriconazole). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase  <e1> inhibitors </e1>  (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g.,  <e2> ketoconazole </e2> , itraconazole, voriconazole). 
false	Less potent inhibitors include saquinavir, nefazodone,  <e1> fluconazole </e1> , grapefruit juice, fluoxetine, fluvoxamine, zileuton, and  <e2> clotrimazole </e2> . 
mechanism	Human pharmacologic studies have shown that  <e1> Ritalin </e1>  may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital,  <e2> diphenylhydantoin </e2> , primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase  <e1> inhibitors </e1>  (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole,  <e2> voriconazole </e2> ). 
mechanism	Human pharmacologic studies have shown that  <e1> Ritalin </e1>  may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine,  <e2> desipramine </e2> ). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and  <e1> tricyclic drugs </e1>  (imipramine,  <e2> clomipramine </e2> , desipramine). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital,  <e1> diphenylhydantoin </e1> , primidone), phenylbutazone, and tricyclic drugs (imipramine,  <e2> clomipramine </e2> , desipramine). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and  <e1> tricyclic drugs </e1>  (imipramine, clomipramine,  <e2> desipramine </e2> ). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin, primidone),  <e2> phenylbutazone </e2> , and tricyclic drugs (imipramine, clomipramine, desipramine). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine,  <e2> desipramine </e2> ). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin,  <e2> primidone </e2> ), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs ( <e1> imipramine </e1> ,  <e2> clomipramine </e2> , desipramine). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital,  <e1> diphenylhydantoin </e1> , primidone), phenylbutazone, and  <e2> tricyclic drugs </e2>  (imipramine, clomipramine, desipramine). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital,  <e1> diphenylhydantoin </e1> , primidone), phenylbutazone, and tricyclic drugs ( <e2> imipramine </e2> , clomipramine, desipramine). 
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin,  <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir,  <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone),  <e1> phenylbutazone </e1> , and tricyclic drugs ( <e2> imipramine </e2> , clomipramine, desipramine). 
false	Methyldopa does not interfere with measurement of VMA ( <e1> vanillylmandelic acid </e1> ), a test for pheochromocytoma, by those methods which convert  <e2> VMA </e2>  to vanillin. 
false	The safety of using  <e1> methylphenidate </e1>  in combination with clonidine or other centrally acting  <e2> alpha-2 agonists </e2>  has not been systemically evaluated.    
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine,  <e1> clomipramine </e1> ,  <e2> desipramine </e2> ). 
false	The safety of using  <e1> methylphenidate </e1>  in combination with  <e2> clonidine </e2>  or other centrally acting alpha-2 agonists has not been systemically evaluated.    
effect	This could lead to decreased salicylate serum levels or increase the risk of  <e1> salicylate </e1>  toxicity when  <e2> methylprednisolone </e2>  is withdrawn. 
false	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice,  <e1> fluoxetine </e1> ,  <e2> fluvoxamine </e2> , zileuton, and clotrimazole. 
mechanism	Drugs such as troleandomycin and  <e1> ketoconazole </e1>  may inhibit the metabolism of  <e2> methylprednisolone </e2>  and thus decrease its clearance. 
mechanism	Drugs that induce hepatic enzymes such as  <e1> phenobarbital </e1> , phenytoin, and rifampin may increase the clearance of  <e2> methylprednisolone </e2>  and may require increased in methylprednisolone dose to achieve the desired response. 
false	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin,  <e1> primidone </e1> ), phenylbutazone, and tricyclic drugs (imipramine,  <e2> clomipramine </e2> , desipramine). 
false	The effect of  <e1> methylprednisolone </e1>  on oral  <e2> anticoagulants </e2>  is variable. 
advise	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and  <e1> rifampin </e1>  may increase the clearance of methylprednisolone and may require increased in  <e2> methylprednisolone </e2>  dose to achieve the desired response. 
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
int	 <e1> Methscopolamine </e1>  may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e1> selegiline </e1> ,  <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
int	 <e1> Methscopolamine </e1>  may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e1> selegiline </e1> , furazolidone),  <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid,  <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with  <e1> antidepressants </e1>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine,  <e2> promethazine </e2> ).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine,  <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
int	 <e1> Methscopolamine </e1>  may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline,  <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e1> selegiline </e1> , furazolidone), quinidine, amantadine,  <e2> antihistamines </e2>  (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine,  <e2> antihistamines </e2>  (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine,  <e1> antihistamines </e1>  (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline,  <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g.,  <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> ,  <e2> tranylcypromine </e2> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline,  <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g.,  <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e1> amantadine </e1> , antihistamines (e.g.,  <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other  <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid,  <e2> tranylcypromine </e2> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements,  <e1> antacids </e1> , absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with  <e1> antidepressants </e1>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1>  type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type),  <e1> MAO inhibitors </e1>  (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid,  <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g.,  <e1> kaolin </e1> -pectin), phenothiazines (e.g., chlorpromazine,  <e2> promethazine </e2> ).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine,  <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g.,  <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other  <e1> anticholinergics </e1> , potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e1> potassium chloride </e1>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g.,  <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine,  <e1> isocarboxazid </e1> , selegiline,  <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g.,  <e1> chlorpromazine </e1> ,  <e2> promethazine </e2> ).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid,  <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine,  <e2> promethazine </e2> ).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine,  <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1>  type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine,  <e1> antihistamines </e1>  (e.g., diphenhydramine), other  <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
int	 <e1> Methscopolamine </e1>  may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or  <e1> reverse transcriptase inhibitors </e1>  (e.g., ritonavir,  <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid,  <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e1> potassium chloride </e1>  supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline,  <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g.,  <e2> chlorpromazine </e2> , promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine,  <e1> antihistamines </e1>  (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine,  <e2> promethazine </e2> ).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements,  <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics,  <e1> potassium chloride </e1>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g.,  <e2> chlorpromazine </e2> , promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e1> pectin </e1> ), phenothiazines (e.g., chlorpromazine,  <e2> promethazine </e2> ).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone),  <e1> quinidine </e1> ,  <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine,  <e2> antihistamines </e2>  (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
int	 <e1> Methscopolamine </e1>  may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
false	Concurrent use of  <e1> alcohol </e1>  and other  <e2> CNS depression-producing drugs </e2>  may increase the CNS depressant effects of methyprylon or these other medications.
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other  <e1> anticholinergics </e1> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin),  <e2> phenothiazines </e2>  (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g.,  <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g.,  <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,  <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics,  <e2> potassium chloride </e2>  supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with  <e1> antidepressants </e1>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline,  <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine,  <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g.,  <e2> chlorpromazine </e2> , promethazine).
false	Methscopolamine may interact with  <e1> antidepressants </e1>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine,  <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid,  <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type),  <e1> MAO inhibitors </e1>  (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,  <e2> absorbent-type anti-diarrhea medicines </e2>  (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine,  <e1> antihistamines </e1>  (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g.,  <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid,  <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other  <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	Concurrent use with  <e1> vasoconstrictor agents </e1>  including ergot alkaloids, sumatriptan, and  <e2> nicotine </e2>  (e.g. smoking) may result in enhanced vasoconstriction.
false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen,  <e1> tetracycline </e1> , levodopa,  <e2> ethanol </e2> , cyclosporine). 
false	Additive sedative effects can occur when metoclopramide is given with  <e1> alcohol </e1> , sedatives, hypnotics,  <e2> narcotics </e2> , or tranquilizers. 
effect	 <e1> Methysergide </e1>  may reverse the analgesic activity of  <e2> narcotic analgesics </e2> . 
false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen,  <e1> tetracycline </e1> , levodopa, ethanol,  <e2> cyclosporine </e2> ). 
false	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics,  <e1> narcotics </e1> , or  <e2> tranquilizers </e2> . 
false	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  <e1> acetaminophen </e1> ,  <e2> tetracycline </e2> , levodopa, ethanol, cyclosporine). 
false	Absorption of drugs from the stomach may be diminished (e.g.,  <e1> digoxin </e1> ) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  <e2> acetaminophen </e2> , tetracycline, levodopa, ethanol, cyclosporine). 
effect	Additive sedative effects can occur when  <e1> metoclopramide </e1>  is given with alcohol, sedatives, hypnotics,  <e2> narcotics </e2> , or tranquilizers. 
false	Absorption of drugs from the stomach may be diminished (e.g.,  <e1> digoxin </e1> ) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen,  <e2> tetracycline </e2> , levodopa, ethanol, cyclosporine). 
effect	Anticoagulants:  <e1> Metolazone </e1> , as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to  <e2> anticoagulants </e2> ; 
false	Other  <e1> Antihypertensives </e1> : When  <e2> MYKROX </e2>  Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. 
false	 <e1> Sympathomimetics </e1> :  <e2> Metolazone </e2>  may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. 
false	Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of  <e1> curariform drugs </e1>  (such as  <e2> tubocurarine </e2> ) the most serious effect would be respiratory depression which could proceed to apnea. 
false	Alcohol,  <e1> Barbiturates </e1> , and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with  <e2> metolazone </e2>  therapy. 
effect	Curariform Drugs:  <e1> Diuretic </e1> -induced hypokalemia may enhance neuromuscular blocking effects of  <e2> curariform drugs </e2>  (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. 
false	 <e1> Methscopolamine </e1>  may interact with  <e2> antidepressants </e2>  (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
false	 <e1> Diuretics </e1> : Furosemide and probably other loop diuretics given concomitantly with  <e2> metolazone </e2>  can cause unusually large or prolonged losses of fluid and electrolytes. 
false	Absorption of drugs from the stomach may be diminished (e.g.,  <e1> digoxin </e1> ) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa,  <e2> ethanol </e2> , cyclosporine). 
false	 <e1> Curariform Drugs </e1> : Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of  <e2> curariform drugs </e2>  (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. 
effect	Catecholamine-depleting drugs (e.g.,  <e1> reserpine </e1> ) may have an additive effect when given with  <e2> beta-blocking agents </e2> . 
false	Oral metronidazole has been reported to potentiate the anticoagulant effect of  <e1> coumarin </e1>  and  <e2> warfarin </e2> , resulting in a prolongation of prothrombin time. 
effect	Concurrent use of  <e1> DEMSER </e1>  with  <e2> alcohol </e2>  or other CNS depressants can increase their sedative effects.
false	Concurrent use of DEMSER with  <e1> alcohol </e1>  or other  <e2> CNS depressants </e2>  can increase their sedative effects.
false	Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to  <e1> Mexitil </e1>    , has been reported to lower serum  <e2> digoxin </e2>  levels. 
false	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and  <e1> digoxin </e1> ,  <e2> diuretics </e2> , or propranolol. 
false	Concurrent use of  <e1> Mexitil </e1>     and theophylline may lead to increased plasma  <e2> theophylline </e2>  levels. 
false	 <e1> Mexitil </e1>     does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to  <e2> Mexitil </e2>    , has been reported to lower serum digoxin levels. 
false	Concurrent administration of cimetidine and  <e1> Mexitil </e1>     has been reported to increase, decrease, or leave unchanged  <e2> Mexitil </e2>     plasma levels; 
mechanism	Concurrent use of  <e1> Mexitil </e1>     and  <e2> theophylline </e2>  may lead to increased plasma theophylline levels. 
false	Addition of  <e1> mexiletine </e1>  to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than  <e2> propafenone </e2>  alone. 
false	Addition of  <e1> mexiletine </e1>  to  <e2> propafenone </e2>  did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. 
false	ECG intervals (PR, QRS, and QT) were not affected by concurrent  <e1> Mexitil </e1>     and digoxin,  <e2> diuretics </e2> , or propranolol. 
false	In a formal study,  <e1> benzodiazepines </e1>  were shown not to affect  <e2> Mexitil </e2>     plasma concentrations. 
false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre- <e1> Mexitil </e1>     values within 48 hours after discontinuing  <e2> Mexitil </e2>    . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 
false	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and  <e1> theophylline </e1>  are to be used concurrently,  <e2> theophylline </e2>  blood levels should be monitored, particularly when the Mexitil    dose is changed. 
false	When  <e1> phenytoin </e1>  or other hepatic enzyme inducers such as  <e2> rifampin </e2>  and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 
mechanism	Additionally, in one controlled study in five normal subjects and seven patients, the clearance of  <e1> caffeine </e1>  was decreased 50% following the administration of  <e2> Mexitil </e2>    .
false	Concurrent use of Mexitil    and  <e1> theophylline </e1>  may lead to increased plasma  <e2> theophylline </e2>  levels. 
false	In this crossover steady state study, the pharmacokinetics of  <e1> propafenone </e1>  were unaffected in either phenotype by the coadministration of  <e2> mexiletine </e2> . 
mechanism	 <e1> Posicor </e1>  inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride,  <e2> cyclosporine </e2> , and tricyclic antidepressants. 
false	This increase was observed at the first test point which was the second day after starting Mexitil   .  <e1> Theophylline </e1>  plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If  <e2> Mexitil </e2>  and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 
false	This increase was observed at the first test point which was the second day after starting  <e1> Mexitil </e1>    .  <e2> Theophylline </e2>  plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 
false	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin,  <e1> diuretics </e1> , or  <e2> propranolol </e2> . 
false	Mexitil    does not alter serum  <e1> digoxin </e1>  levels but  <e2> magnesium-aluminum hydroxide </e2> , when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 
false	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil,  <e1> cyclosporine </e1> ,  <e2> tacrolimus </e2> , prednisolone, and fluconazole pharmacokinetics. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine,  <e1> tacrolimus </e1> , prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and  <e2> rifampin </e2> . 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  <e1> MYCAMINE </e1>  and mycophenolate mofetil,  <e2> cyclosporine </e2> , tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus,  <e1> prednisolone </e1> , sirolimus, nifedipine, fluconazole, ritonavir, and  <e2> rifampin </e2> . 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone,  <e1> sirolimus </e1> , nifedipine,  <e2> fluconazole </e2> , ritonavir, and rifampin. 
false	 <e1> Nifedipine </e1>  AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with  <e2> nifedipine </e2>  alone. 
false	There was no effect of a single dose or multiple doses of MYCAMINE on  <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, prednisolone, and  <e2> fluconazole </e2>  pharmacokinetics. 
mechanism	 <e1> Posicor </e1>  inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and  <e2> tricyclic antidepressants </e2> . 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  <e1> MYCAMINE </e1>  and mycophenolate mofetil, cyclosporine,  <e2> tacrolimus </e2> , prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
false	There was no effect of a single dose or multiple doses of MYCAMINE on  <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus,  <e2> prednisolone </e2> , and fluconazole pharmacokinetics. 
false	There was no effect of a single dose or multiple doses of  <e1> MYCAMINE </e1>  on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and  <e2> fluconazole </e2>  pharmacokinetics. 
false	Patients receiving sirolimus or nifedipine in combination with  <e1> MYCAMINE </e1>  should be monitored for sirolimus or nifedipine toxicity and sirolimus or  <e2> nifedipine </e2>  dosage should be reduced if necessary. 
false	There was no effect of a single dose or multiple doses of  <e1> MYCAMINE </e1>  on mycophenolate mofetil, cyclosporine, tacrolimus,  <e2> prednisolone </e2> , and fluconazole pharmacokinetics. 
false	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil,  <e1> cyclosporine </e1> , tacrolimus, prednisolone, and  <e2> fluconazole </e2>  pharmacokinetics. 
false	Patients receiving sirolimus or  <e1> nifedipine </e1>  in combination with MYCAMINE should be monitored for  <e2> sirolimus </e2>  or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine,  <e1> tacrolimus </e1> , prednisolone, sirolimus,  <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  <e1> MYCAMINE </e1>  and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole,  <e2> ritonavir </e2> , and rifampin. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and  <e1> mycophenolate mofetil </e1> ,  <e2> cyclosporine </e2> , tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone,  <e1> sirolimus </e1> , nifedipine, fluconazole, ritonavir, and  <e2> rifampin </e2> . 
false	Drugs such as  <e1> erythromycin </e1> ,  <e2> diltiazem </e2> , verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 
false	Drugs such as erythromycin,  <e1> diltiazem </e1> ,  <e2> verapamil </e2> , ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and  <e1> fentanyl </e1> ), propofol, ketamine, nitrous oxide, secobarbital and  <e2> droperidol </e2> . 
false	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate,  <e1> diazepam </e1> , hydroxyzine, and other muscle relaxants) or local  <e2> anesthetics </e2>  have been observed.
effect	The sedative effect of  <e1> VERSED Syrup </e1>  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide,  <e2> secobarbital </e2>  and droperidol. 
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus,  <e1> nifedipine </e1> ,  <e2> fluconazole </e2> , ritonavir, and rifampin. 
false	No significant adverse interactions with common premedications (such as atropine,  <e1> scopolamine </e1> , glycopyrrolate,  <e2> diazepam </e2> , hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
false	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as  <e1> rifampin </e1> ,  <e2> carbamazepine </e2> , and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl),  <e1> propofol </e1> , ketamine,  <e2> nitrous oxide </e2> , secobarbital and droperidol. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and  <e1> fentanyl </e1> ), propofol, ketamine, nitrous oxide,  <e2> secobarbital </e2>  and droperidol. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine,  <e1> meperidine </e1>  and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and  <e2> droperidol </e2> . 
mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin,  <e1> carbamazepine </e1> , and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral  <e2> midazolam </e2>  in adult studies. 
false	No significant adverse interactions with common premedications (such as  <e1> atropine </e1> , scopolamine,  <e2> glycopyrrolate </e2> , diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
false	Although not studied, the potent cytochrome P450 3A4 inhibitors  <e1> ritonavir </e1>  and  <e2> nelfinavir </e2>  may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. 
advise	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  <e1> midazolam </e1>  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  <e2> azole antimycotics </e2> , protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 
false	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other  <e1> muscle relaxants </e1> ) or local  <e2> anesthetics </e2>  have been observed.
false	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and  <e1> mycophenolate mofetil </e1> , cyclosporine,  <e2> tacrolimus </e2> , prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 
false	No significant adverse interactions with common premedications (such as  <e1> atropine </e1> , scopolamine, glycopyrrolate, diazepam,  <e2> hydroxyzine </e2> , and other muscle relaxants) or local anesthetics have been observed.
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine,  <e1> meperidine </e1>  and  <e2> fentanyl </e2> ), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 
effect	The sedative effect of  <e1> VERSED Syrup </e1>  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol,  <e2> ketamine </e2> , nitrous oxide, secobarbital and droperidol. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and  <e1> fentanyl </e1> ), propofol,  <e2> ketamine </e2> , nitrous oxide, secobarbital and droperidol. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl),  <e1> propofol </e1> ,  <e2> ketamine </e2> , nitrous oxide, secobarbital and droperidol. 
mechanism	Drugs such as erythromycin,  <e1> diltiazem </e1> , verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered  <e2> midazolam </e2> . 
false	There was no effect of a single dose or multiple doses of  <e1> MYCAMINE </e1>  on mycophenolate mofetil, cyclosporine,  <e2> tacrolimus </e2> , prednisolone, and fluconazole pharmacokinetics. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  <e1> metformin </e1> , cimetidine,  <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine. 
effect	ProAmatine.  <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of  <e2> ProAmatine </e2> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin,  <e1> terazosin </e1> , and  <e2> doxazosin </e2> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as  <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin,  <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine,  <e1> ephedrine </e1> ,  <e2> phenylpropanolamine </e2>  or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as  <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine,  <e2> procainamide </e2> , triamterene, flecainide, and quinidine. 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine,  <e1> pseudoephedrine </e1> ,  <e2> ephedrine </e2> , phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as  <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine,  <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  <e1> metformin </e1> , cimetidine, ranitidine,  <e2> procainamide </e2> , triamterene, flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of  <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	Drugs such as  <e1> erythromycin </e1> , diltiazem, verapamil, ketoconazole, fluconazole and  <e2> itraconazole </e2>  were shown to significantly increase the C max and AUC of orally administered midazolam. 
mechanism	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  <e1> desglymidodrine </e1>  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene,  <e2> flecainide </e2> , and quinidine. 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  <e1> phenylephrine </e1> , pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when  <e2> ProAmatine </e2>     is administered concomitantly with agents that cause vasoconstriction. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine,  <e1> ranitidine </e1> , procainamide, triamterene,  <e2> flecainide </e2> , and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and  <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin,  <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	 <e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene,  <e2> flecainide </e2> , and quinidine. 
false	ProAmatine.  <e1> Alpha-adrenergic blocking agents </e1> , such as  <e2> prazosin </e2> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene,  <e1> flecainide </e1> , and  <e2> quinidine </e2> . 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin,  <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  <e1> phenylephrine </e1> , pseudoephedrine,  <e2> ephedrine </e2> , phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  <e1> phenylephrine </e1> , pseudoephedrine, ephedrine, phenylpropanolamine or  <e2> dihydroergotamine </e2> ) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine,  <e1> ephedrine </e1> , phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when  <e2> ProAmatine </e2>     is administered concomitantly with agents that cause vasoconstriction. 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of  <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene,  <e2> flecainide </e2> , and quinidine. 
mechanism	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and  <e1> phenytoin </e1> , induce metabolism and caused a markedly decreased C max and AUC of oral  <e2> midazolam </e2>  in adult studies. 
effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine,  <e1> pseudoephedrine </e1> , ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of  <e2> ProAmatine </e2>    . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
false	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg,  <e1> morphine </e1> , meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and  <e2> droperidol </e2> . 
false	ProAmatine.  <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide,  <e2> triamterene </e2> , flecainide, and quinidine. 
effect	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine,  <e1> phenylpropanolamine </e1>  or dihydroergotamine) may enhance or potentiate the pressor effects of  <e2> ProAmatine </e2>    . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
false	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  <e1> ketoconazole </e1> ,  <e2> itraconazole </e2> , erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine,  <e1> ranitidine </e1> , procainamide,  <e2> triamterene </e2> , flecainide, and quinidine. 
mechanism	John   s Wort, and certain  <e1> anticonvulsants </e1>  (phenytoin, phenobarbital, carbamazepine) may induce  <e2> mifepristone </e2>  metabolism (lowering serum levels of mifepristone). 
false	John   s Wort, and certain  <e1> anticonvulsants </e1>  (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of  <e2> mifepristone </e2> ). 
false	Although specific drug or food interactions with  <e1> mifepristone </e1>  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  <e2> ketoconazole </e2> , itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and  <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and  <e2> quinidine </e2> . 
mechanism	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole,  <e1> itraconazole </e1> , erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of  <e2> mifepristone </e2> ). 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine,  <e1> phenylpropanolamine </e1>  or  <e2> dihydroergotamine </e2> ) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 
false	 <e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  <e2> desglymidodrine </e2>  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 
false	John   s Wort, and certain anticonvulsants ( <e1> phenytoin </e1> , phenobarbital,  <e2> carbamazepine </e2> ) may induce mifepristone metabolism (lowering serum levels of mifepristone). 
false	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin,  <e1> cimetidine </e1> , ranitidine, procainamide, triamterene,  <e2> flecainide </e2> , and quinidine. 
false	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine,  <e1> pseudoephedrine </e1> , ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when  <e2> ProAmatine </e2>     is administered concomitantly with agents that cause vasoconstriction. 
mechanism	While co-administration of  <e1> ZAVESCA </e1>     appeared to increase the clearance of  <e2> Cerezyme </e2>  by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. 
false	Combination therapy with  <e1> Cerezyme </e1>     ( <e2> imiglucerase </e2> ) and ZAVESCA    is not indicated.
false	Absorption of tetracyclines is impaired by  <e1> antacids </e1>  containing aluminum, calcium or  <e2> magnesium </e2> , and iron-containing preparations. 
false	Concurrent use of  <e1> tetracyclines </e1>  with oral contraceptives may render oral  <e2> contraceptives </e2>  less effective.
advise	Combination therapy with Cerezyme    ( <e1> imiglucerase </e1> ) and  <e2> ZAVESCA </e2>     is not indicated.
mechanism	Absorption of  <e1> tetracyclines </e1>  is impaired by antacids containing aluminum,  <e2> calcium </e2>  or magnesium, and iron-containing preparations. 
false	Absorption of tetracyclines is impaired by antacids containing aluminum,  <e1> calcium </e1>  or  <e2> magnesium </e2> , and iron-containing preparations. 
false	Since bacteriostatic drugs may interfere with the bactericidal action of  <e1> penicillin </e1> , it is advisable to avoid giving  <e2> tetracycline class drugs </e2>  in conjunction with penicillin. 
false	Interaction with  <e1> Guanethidine </e1> : Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving  <e2> guanethidine </e2>  can result in profound orthostatic effects. 
false	Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of  <e1> REMERON SolTab </e1>     ( <e2> mirtazapine </e2> ) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes. 
false	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab.  <e1> Diazepam </e1> : Concomitant administration of  <e2> diazepam </e2>  (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 
false	While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that  <e1> mirtazapine </e1>  is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of  <e2> REMERON SolTab </e2>  with most other drugs metabolized by these enzymes has not been formally studied. 
effect	However, the impairment of motor skills produced by  <e1> REMERON </e1>  has been shown to be additive with those caused by  <e2> diazepam </e2> . 
false	Therefore, physicians should closely monitor patients for a change in  <e1> anticoagulant </e1>  dosage requirements when administering Mitotane to patients on  <e2> coumarin-type anticoagulants </e2> . 
false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives,  <e1> glucocorticoids </e1> , or certain  <e2> monoamine oxidase inhibitors </e2> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain  <e1> antibiotics </e1>  given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local  <e2> anesthetics </e2>  such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection -  <e1> cisplatin </e1>  - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general  <e2> anesthetics </e2>  - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine -  <e1> polymyxin B </e1>  or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other  <e2> muscle relaxants </e2> 
false	Isoflurane and  <e1> enflurane </e1>  (administered with  <e2> nitrous oxide </e2> /oxygen to achieve 1.25 M.C. 
false	The use of MIVACRON before  <e1> succinylcholine </e1>  to attenuate some of the side effects of  <e2> succinylcholine </e2>  has not been studied. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e1> lincomycin </e1> ,  <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or  <e1> carbamazepine </e1>  - certain antibiotics given by injection - cisplatin -  <e2> edrophonium </e2>  - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or  <e1> bacitracin </e1>  - local  <e2> anesthetics </e2>  such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or  <e1> bacitracin </e1>  - local anesthetics such as  <e2> procaine </e2>  - general anesthetics - succinylcholine or other muscle relaxants
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> . 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain  <e1> antibiotics </e1>  (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine. 
false	Some drug interactions are:  - birth control pills -  <e1> corticosteroids </e1>  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine -  <e2> polymyxin B </e2>  or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin,  <e1> polymyxins </e1> ,  <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> ,  <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  <e1> phenytoin </e1>  or  <e2> carbamazepine </e2>  - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium -  <e1> neostigmine </e1>  -  <e2> polymyxin B </e2>  or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine -  <e1> polymyxin B </e1>  or bacitracin - local anesthetics such as procaine - general anesthetics -  <e2> succinylcholine </e2>  or other muscle relaxants
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> MIVACRON </e1>  include certain antibiotics (e.g., aminoglycosides,  <e2> tetracyclines </e2> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine. 
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> MIVACRON </e1>  include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e1> sodium colistimethate </e1> ), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> . 
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> MIVACRON </e1>  include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection -  <e1> cisplatin </e1>  - edrophonium - neostigmine - polymyxin B or bacitracin - local  <e2> anesthetics </e2>  such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or  <e1> carbamazepine </e1>  - certain antibiotics given by injection - cisplatin - edrophonium -  <e2> neostigmine </e2>  - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection -  <e1> cisplatin </e1>  - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as  <e2> procaine </e2>  - general anesthetics - succinylcholine or other muscle relaxants
false	Although  <e1> MIVACRON </e1>  (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and  <e2> succinylcholine </e2>  has not been systematically studied. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin -  <e1> edrophonium </e1>  - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other  <e2> muscle relaxants </e2> 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain  <e1> antibiotics </e1>  (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins,  <e1> lincomycin </e1> , clindamycin, colistin, and  <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or  <e1> bacitracin </e1>  - local anesthetics such as procaine - general anesthetics - succinylcholine or other  <e2> muscle relaxants </e2> 
false	Some drug interactions are:  - birth control pills -  <e1> corticosteroids </e1>  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium -  <e2> neostigmine </e2>  - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Some drug interactions are:  - birth control pills -  <e1> corticosteroids </e1>  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection -  <e2> cisplatin </e2>  - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines,  <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics,  <e2> procainamide </e2> , and quinidine. 
int	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin,  <e1> clindamycin </e1> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> . 
effect	The neuromuscular blocking effect of  <e1> MIVACRON </e1>  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  <e2> contraceptives </e2> , glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 
effect	While the effects of chronic  <e1> phenytoin </e1>  or carbamazepine therapy on the action of  <e2> MIVACRON </e2>  are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and  <e2> quinidine </e2> . 
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> MIVACRON </e1>  include certain antibiotics (e.g.,  <e2> aminoglycosides </e2> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general  <e1> anesthetics </e1>  -  <e2> succinylcholine </e2>  or other muscle relaxants
int	Other drugs which may enhance the neuromuscular blocking action of  <e1> nondepolarizing agents </e1>  such as MIVACRON include certain antibiotics (e.g., aminoglycosides,  <e2> tetracyclines </e2> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine -  <e1> polymyxin B </e1>  or bacitracin - local anesthetics such as procaine - general  <e2> anesthetics </e2>  - succinylcholine or other muscle relaxants
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and  <e1> sodium colistimethate </e1> ), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain  <e1> antibiotics </e1>  (e.g.,  <e2> aminoglycosides </e2> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  <e1> phenytoin </e1>  or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine -  <e2> polymyxin B </e2>  or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e1> colistin </e1> , and sodium colistimethate), magnesium salts,  <e2> lithium </e2> , local anesthetics, procainamide, and quinidine. 
false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  <e1> contraceptives </e1> , glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered  <e2> phenytoin </e2>  or carbamazepine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain  <e1> antibiotics </e1>  given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other  <e2> muscle relaxants </e2> 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin -  <e1> edrophonium </e1>  -  <e2> neostigmine </e2>  - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , triamterene, amiloride) or  <e2> potassium </e2>  supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 
false	UNIVASC    has been used in clinical trials concomitantly with  <e1> calcium-channel-blocking agents </e1> , diuretics, H2 blockers, digoxin, oral  <e2> hypoglycemic agents </e2> , and cholesterol-lowering agents. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection -  <e1> cisplatin </e1>  -  <e2> edrophonium </e2>  - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Use of  <e1> potassium-sparing diuretics </e1>  (spironolactone, triamterene,  <e2> amiloride </e2> ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin,  <e1> colistin </e1> , and sodium colistimethate), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin -  <e1> edrophonium </e1>  - neostigmine - polymyxin B or bacitracin - local  <e2> anesthetics </e2>  such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Lithium: Increased serum lithium levels and symptoms of  <e1> lithium </e1>  toxicity have been reported in patients receiving  <e2> ACE inhibitors </e2>  during therapy with lithium. 
false	Oral  <e1> Anticoagulants </e1> : Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the  <e2> anticoagulant </e2>  or on its anticoagulant effect. 
false	 <e1> Lithium </e1> : Increased serum  <e2> lithium </e2>  levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 
false	 <e1> UNIVASC </e1>     has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral  <e2> hypoglycemic agents </e2> , and cholesterol-lowering agents. 
effect	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving  <e1> ACE inhibitors </e1>  during therapy with  <e2> lithium </e2> . 
false	The use of  <e1> MIVACRON </e1>  before succinylcholine to attenuate some of the side effects of  <e2> succinylcholine </e2>  has not been studied. 
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides,  <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local  <e2> anesthetics </e2> , procainamide, and quinidine. 
false	Lithium: Increased serum  <e1> lithium </e1>  levels and symptoms of  <e2> lithium </e2>  toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 
false	UNIVASC    has been used in clinical trials concomitantly with  <e1> calcium-channel-blocking agents </e1> ,  <e2> diuretics </e2> , H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 
effect	Use of potassium-sparing diuretics (spironolactone,  <e1> triamterene </e1> , amiloride) or potassium supplements concomitantly with  <e2> ACE inhibitors </e2>  can increase the risk of hyperkalemia. 
false	The neuromuscular blocking effect of  <e1> MIVACRON </e1>  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  <e2> neuromuscular blocking agents </e2>  has been demonstrated in patients chronically administered phenytoin or carbamazepine. 
false	Use of  <e1> potassium-sparing diuretics </e1>  ( <e2> spironolactone </e2> , triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as  <e1> procaine </e1>  - general anesthetics -  <e2> succinylcholine </e2>  or other muscle relaxants
false	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers,  <e1> digoxin </e1> , oral  <e2> hypoglycemic agents </e2> , and cholesterol-lowering agents. 
int	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as  <e1> MIVACRON </e1>  include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate),  <e2> magnesium </e2>  salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection -  <e1> cisplatin </e1>  - edrophonium - neostigmine - polymyxin B or  <e2> bacitracin </e2>  - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
false	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g.,  <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin,  <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 
false	Use of potassium-sparing diuretics (spironolactone,  <e1> triamterene </e1> ,  <e2> amiloride </e2> ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 
false	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives,  <e1> glucocorticoids </e1> , or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered  <e2> phenytoin </e2>  or carbamazepine. 
false	Accordingly, patients should be advised to avoid  <e1> alcohol </e1>  while taking REMERON SolTab.  <e2> Diazepam </e2> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 
false	These medications included  <e1> thyroid hormones </e1> , sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and  <e2> decongestants </e2> . 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline,  <e1> prednisone </e1> , prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and  <e2> warfarin </e2> . 
advise	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as  <e1> phenobarbital </e1>  or rifampin, are co-administered with  <e2> montelukast </e2> .
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs:  <e1> theophylline </e1> , prednisone, prednisolone, oral  <e2> contraceptives </e2>  (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives ( <e1> norethindrone </e1>  1 mg/ <e2> ethinyl estradiol </e2>  35 mcg), terfenadine, digoxin, and warfarin. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral  <e1> contraceptives </e1>  (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine,  <e2> digoxin </e2> , and warfarin. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine,  <e1> digoxin </e1> , and  <e2> warfarin </e2> . 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ <e1> ethinyl estradiol </e1>  35 mcg),  <e2> terfenadine </e2> , digoxin, and warfarin. 
false	 <e1> Phenobarbital </e1> , which induces hepatic metabolism, decreased the AUC of  <e2> montelukast </e2>  approximately 40% following a single 10-mg dose of montelukast. 
false	In drug-interaction studies, the recommended clinical dose of  <e1> montelukast </e1>  did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives ( <e2> norethindrone </e2>  1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 
false	- did not cause any clinically significant change in plasma profiles of  <e1> prednisone </e1>  or prednisolone following administration of either oral  <e2> prednisone </e2>  or intravenous prednisolone.  
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ <e1> ethinyl estradiol </e1>  35 mcg), terfenadine, digoxin, and  <e2> warfarin </e2> . 
false	These medications included thyroid hormones,  <e1> sedative hypnotics </e1> , non-steroidal anti-inflammatory agents,  <e2> benzodiazepines </e2> , and decongestants. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives ( <e1> norethindrone </e1>  1 mg/ethinyl estradiol 35 mcg), terfenadine,  <e2> digoxin </e2> , and warfarin. 
false	These medications included  <e1> thyroid hormones </e1> ,  <e2> sedative hypnotics </e2> , non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 
false	These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents,  <e1> benzodiazepines </e1> , and  <e2> decongestants </e2> . 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs:  <e1> theophylline </e1> , prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ <e2> ethinyl estradiol </e2>  35 mcg), terfenadine, digoxin, and warfarin. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral  <e1> contraceptives </e1>  ( <e2> norethindrone </e2>  1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 
false	- did not change the plasma concentration profile of  <e1> terfenadine </e1>  (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with  <e2> terfenadine </e2>  60 mg twice daily. 
false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e.,  <e1> pentazocine </e1> , nalbuphine, butorphanol, or  <e2> buprenorphine </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 
advise	Interaction with Mixed Agonist/Antagonist Opioid Analgesics:  <e1> Agonist/antagonist analgesics </e1>  (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  <e2> opioid agonist analgesic </e2> . 
false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine,  <e1> butorphanol </e1> , or  <e2> buprenorphine </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 
false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics:  <e1> Agonist/antagonist analgesics </e1>  (i.e., pentazocine, nalbuphine, butorphanol, or  <e2> buprenorphine </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 
false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as  <e1> alcohol </e1> ,  <e2> sedatives </e2> , antihistaminics, or psychotropic drugs. 
false	Interaction with  <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (i.e., pentazocine,  <e2> nalbuphine </e2> , butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 
effect	Use with Other Central Nervous System Depressants: The depressant effects of  <e1> morphine </e1>  are potentiated by the presence of other CNS depressants such as  <e2> alcohol </e2> , sedatives, antihistaminics, or psychotropic drugs. 
false	In drug-interaction studies, the recommended clinical dose of  <e1> montelukast </e1>  did not have clinically important effects on the pharmacokinetics of the following drugs:  <e2> theophylline </e2> , prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 
false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other  <e1> CNS depressants </e1>  such as  <e2> alcohol </e2> , sedatives, antihistaminics, or psychotropic drugs. 
false	 <e1> Phenobarbital </e1> , which induces hepatic metabolism, decreased the AUC of  <e2> montelukast </e2>  approximately 40% following a single 10-mg dose of montelukast. 
false	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral  <e1> contraceptives </e1>  (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and  <e2> warfarin </e2> . 
false	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e.,  <e1> pentazocine </e1> , nalbuphine,  <e2> butorphanol </e2> , or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 
false	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking  <e1> magnesium </e1> -aluminum containing  <e2> antacids </e2>  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 
false	Oral Contraceptives: Given the different metabolism of  <e1> Myfortic </e1>  and oral  <e2> contraceptives </e2> , no drug interaction between these two classes of drug is expected. 
false	Therefore, do not administer  <e1> Myfortic </e1>  with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of  <e2> Myfortic </e2> . 
false	 <e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that  <e2> azathioprine </e2>  and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 
false	In drug-interaction studies, the recommended clinical dose of  <e1> montelukast </e1>  did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone,  <e2> prednisolone </e2> , oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 
mechanism	Antacids: Absorption of a single dose of  <e1> Myfortic </e1>  was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e2> aluminum </e2>  containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 
false	 <e1> Azathioprine </e1> / <e2> Mycophenolate Mofetil </e2> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 
false	Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce  <e1> MPA </e1>  exposure when coadministered with  <e2> mycophenolate mofetil </e2> . 
false	Cyclosporine: When studied in stable renal transplant patients,  <e1> cyclosporine </e1> , USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of  <e2> Myfortic </e2> . 
false	 <e1> Acyclovir </e1> /Ganciclovir: may be taken with  <e2> Myfortic </e2> ; 
false	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other  <e1> CNS depressants </e1>  such as alcohol, sedatives,  <e2> antihistaminics </e2> , or psychotropic drugs. 
advise	Live Vaccines: During treatment with  <e1> Myfortic </e1> , the use of  <e2> live attenuated vaccines </e2>  should be avoided and patients should be advised that vaccinations may be less effective. 
false	 <e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that azathioprine and  <e2> mycophenolate mofetil </e2>  inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 
false	Azathioprine/Mycophenolate Mofetil: Given that  <e1> azathioprine </e1>  and mycophenolate mofetil inhibit purine metabolism, it is recommended that  <e2> Myfortic </e2>  not be administered concomitantly with azathioprine or mycophenolate mofetil. 
advise	Therefore, it is recommended that oral  <e1> contraceptives </e1>  are co- administered with  <e2> Myfortic </e2>  with caution and additional birth control methods be considered. 
false	 <e1> Phenytoin </e1> , Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of  <e2> ondansetron </e2>  was significantly increased and ondansetron blood concentrations were decreased. 
false	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and  <e1> mycophenolate mofetil </e1>  inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with  <e2> azathioprine </e2>  or mycophenolate mofetil. 
false	In humans,  <e1> carmustine </e1> ,  <e2> etoposide </e2> , and cisplatin do not affect the pharmacokinetics of ondansetron.  
false	Phenytoin, Carbamazepine, and  <e1> Rifampicin </e1> : In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and  <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and  <e1> tramadol </e1>  has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  <e2> ondansetron </e2> . 
mechanism	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e.,  <e1> phenytoin </e1> , carbamazepine, and rifampicin), the clearance of  <e2> ondansetron </e2>  was significantly increased and ondansetron blood concentrations were decreased. 
false	In humans, carmustine,  <e1> etoposide </e1> , and  <e2> cisplatin </e2>  do not affect the pharmacokinetics of ondansetron.  
false	Phenytoin,  <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e.,  <e2> phenytoin </e2> , carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	Phenytoin, Carbamazepine, and  <e1> Rifampicin </e1> : In patients treated with potent inducers of CYP3A4 (i.e.,  <e2> phenytoin </e2> , carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	Phenytoin, Carbamazepine, and  <e1> Rifampicin </e1> : In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of  <e2> ondansetron </e2>  was significantly increased and ondansetron blood concentrations were decreased. 
false	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin,  <e1> carbamazepine </e1> , and  <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	Phenytoin, Carbamazepine, and  <e1> Rifampicin </e1> : In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and  <e2> ondansetron </e2>  blood concentrations were decreased. 
false	 <e1> Cholestyramine </e1>  and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with  <e2> mycophenolate mofetil </e2> . 
false	Beta adrenergic agonists should be administered with caution to patients being treated with  <e1> monoamine oxidase inhibitors </e1>  or  <e2> tricyclic antidepressants </e2> , since the action of beta adrenergic agonists on the vascular system may be potentiated.
advise	 <e1> Beta adrenergic agonists </e1>  should be administered with caution to patients being treated with  <e2> monoamine oxidase inhibitors </e2>  or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
false	However, on the basis of available data, no dosage adjustment for  <e1> ondansetron </e1>  is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and  <e2> tramadol </e2>  has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 
false	 <e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with  <e2> azathioprine </e2>  or mycophenolate mofetil. 
false	Phenytoin,  <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of  <e2> ondansetron </e2>  was significantly increased and ondansetron blood concentrations were decreased. 
false	Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days,  <e1> XENICAL </e1>  did not alter the bioavailability of  <e2> nifedipine </e2>  (extended-release tablets). 
false	 <e1> Warfarin </e1> : In 12 normal-weight subjects, administration of  <e2> XENICAL </e2>  120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). 
false	Cyclosporine: Preliminary data from a XENICAL and  <e1> cyclosporine </e1>  drug interaction study indicate a reduction in  <e2> cyclosporine </e2>  plasma levels when XENICAL was coadministered with cyclosporine. 
false	Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days,  <e1> XENICAL </e1>  did not affect the pharmacokinetics of  <e2> pravastatin </e2> . 
false	 <e1> Nifedipine </e1>  (extended-release tablets): In 17 normal-weight subjects receiving  <e2> XENICAL </e2>  120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). 
mechanism	Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when  <e1> XENICAL </e1>  was coadministered with  <e2> cyclosporine </e2> . 
false	 <e1> Glyburide </e1> : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of  <e2> glyburide </e2> . 
false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of  <e1> XENICAL </e1>  and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to  <e2> orlistat </e2> . 
false	Digoxin: In 12 normal-weight subjects receiving  <e1> XENICAL </e1>  120 mg three times a day for 6 days,  <e2> XENICAL </e2>  did not alter the pharmacokinetics of a single dose of digoxin. 
false	 <e1> Alcohol </e1> : In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics,  <e2> orlistat </e2>  pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 
false	 <e1> Pravastatin </e1> : In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days,  <e2> XENICAL </e2>  did not affect the pharmacokinetics of pravastatin. 
false	The effect of orlistat on the absorption of supplemental  <e1> vitamin D </e1> ,  <e2> vitamin A </e2> , and nutritionally-derived vitamin K is not known at this time. 
false	Therefore, as vitamin K absorption may be decreased with  <e1> XENICAL </e1> , patients on chronic stable doses of warfarin who are prescribed  <e2> XENICAL </e2>  should be monitored closely for changes in coagulation parameters.
false	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e.,  <e1> phenytoin </e1> , carbamazepine, and  <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	Glyburide: In 12 normal-weight subjects receiving  <e1> orlistat </e1>  80 mg three times a day for 5 days,  <e2> orlistat </e2>  did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. 
false	Cyclosporine: Preliminary data from a XENICAL and  <e1> cyclosporine </e1>  drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with  <e2> cyclosporine </e2> . 
false	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of  <e1> alcohol </e1>  pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to  <e2> orlistat </e2> . 
false	The effect of orlistat on the absorption of supplemental  <e1> vitamin D </e1> , vitamin A, and nutritionally-derived  <e2> vitamin K </e2>  is not known at this time. 
false	Phenytoin,  <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and  <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 
false	Cyclosporine: Preliminary data from a  <e1> XENICAL </e1>  and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when  <e2> XENICAL </e2>  was coadministered with cyclosporine. 
false	Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days,  <e1> XENICAL </e1>  did not alter the pharmacokinetics of a single dose of  <e2> digoxin </e2> . 
false	 <e1> Warfarin </e1> : In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either  <e2> warfarin </e2>  pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). 
false	 <e1> Adrenal steroids </e1>  or  <e2> ACTH </e2>  In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. 
false	Adrenal steroids or ACTH In patients with edema, concomitant administration with  <e1> adrenal cortical steroids </e1>  or  <e2> ACTH </e2>  may increase the edema. 
false	Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in  <e1> S-warfarin </e1>  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  <e2> R-warfarin </e2>  half-life and AUC were also detected. 
false	Oral  <e1> hypoglycemic agents </e1>   <e2> Oxandrolone </e2>  may inhibit the metabolism of oral hypoglycemic agents. 
false	When  <e1> oxandrolone </e1>  therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of  <e2> warfarin </e2>  adjusted as necessary until a stable target INR or PT has been achieved. 
false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and  <e1> miconazole </e1> ) or  <e2> macrolide antibiotics </e2>  (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  <e1> antimycotic agents </e1>  (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter  <e2> oxybutynin </e2>  mean pharmacokinetic parameters (i.e., Cmax and AUC). 
false	Warfarin: A multidose study of  <e1> oxandrolone </e1> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in  <e2> S-warfarin </e2>  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 
false	Concurrent ingestion of antacid (20 mL of antacid containing  <e1> aluminum hydroxide </e1> , magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or  <e2> desethyloxybutynin </e2> .    
mechanism	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g.,  <e1> itraconazole </e1>  and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter  <e2> oxybutynin </e2>  mean pharmacokinetic parameters (i.e., Cmax and AUC). 
false	Concurrent ingestion of  <e1> antacid </e1>  (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of  <e2> oxybutynin </e2>  or desethyloxybutynin.    
false	Concurrent ingestion of antacid (20 mL of  <e1> antacid </e1>  containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of  <e2> oxybutynin </e2>  or desethyloxybutynin.    
false	Concurrent ingestion of  <e1> antacid </e1>  (20 mL of  <e2> antacid </e2>  containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    
false	Concurrent ingestion of antacid (20 mL of  <e1> antacid </e1>  containing  <e2> aluminum hydroxide </e2> , magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    
false	Concurrent ingestion of antacid (20 mL of antacid containing  <e1> aluminum hydroxide </e1> , magnesium hydroxide, and  <e2> simethicone </e2> ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    
false	 <e1> Warfarin </e1> : A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  <e2> warfarin </e2> , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 
false	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or  <e1> macrolide antibiotics </e1>  (e.g.,  <e2> erythromycin </e2>  and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 
false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general  <e1> anesthetics </e1> , phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and  <e2> alcohol </e2>  may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including sedatives, hypnotics,  <e1> tranquilizers </e1> , general anesthetics, phenothiazines, other opioids, tricyclic antidepressants,  <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other  <e1> opioids </e1> ,  <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
effect	In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of  <e1> cimetidine </e1>  with  <e2> opioid analgesics </e2> ; 
false	The concomitant use of other CNS depressants including sedatives, hypnotics,  <e1> tranquilizers </e1> , general anesthetics, phenothiazines, other opioids,  <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other  <e1> CNS depressants </e1>  including sedatives, hypnotics, tranquilizers, general anesthetics,  <e2> phenothiazines </e2> , other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including  <e1> sedatives </e1> , hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and  <e2> alcohol </e2>  may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including  <e1> sedatives </e1> , hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids,  <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other CNS depressants including  <e1> sedatives </e1> , hypnotics,  <e2> tranquilizers </e2> , general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
false	The concomitant use of other  <e1> CNS depressants </e1>  including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants,  <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects. 
false	Given the primary CNS effects of  <e1> paliperidone </e1> ,  <e2> INVEGA </e2>     should be used with caution in combination with other centrally acting drugs and alcohol. 
advise	Given the primary CNS effects of paliperidone,  <e1> INVEGA </e1>     should be used with caution in combination with other  <e2> centrally acting drugs </e2>  and alcohol. 
false	The concomitant use of other  <e1> CNS depressants </e1>  including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other  <e2> opioids </e2> , tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 
false	Paliperidone may antagonize the effect of  <e1> levodopa </e1>  and other  <e2> dopamine agonists </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam,  <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride,  <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol ( <e1> THC </e1> ) in patients receiving most proton pump inhibitors, including  <e2> pantoprazole </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine,  <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e2> diclofenac </e2> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride,  <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral  <e2> contraceptive </e2>  (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen,  <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of  <e1> pantoprazole </e1>  with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine,  <e2> caffeine </e2> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of  <e1> pantoprazole </e1>  with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e1> warfarin </e1> ,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine,  <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or  <e2> amoxicillin </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e1> contraceptive </e1>  (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam,  <e2> clarithromycin </e2> , metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e1> contraceptive </e1>  (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	There have been postmarketing reports of increased INR and prothrombin time in patients receiving  <e1> proton pump inhibitors </e1> , including  <e2> pantoprazole </e2> , and warfarin concomitantly. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine,  <e1> diazepam </e1>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride,  <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of  <e1> pantoprazole </e1>  with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam,  <e2> clarithromycin </e2> , metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine,  <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol,  <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e1> metoprolol </e1> , nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following:  <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine,  <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
mechanism	Because of profound and long lasting inhibition of gastric acid secretion,  <e1> pantoprazole </e1>  may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole,  <e2> ampicillin </e2>  esters, and iron salts). 
effect	There have been postmarketing reports of increased INR and prothrombin time in patients receiving  <e1> proton pump inhibitors </e1> , including pantoprazole, and  <e2> warfarin </e2>  concomitantly. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following:  <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen,  <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine,  <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following:  <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e1> midazolam </e1> , clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin,  <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e1> contraceptive </e1>  (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e1> metoprolol </e1> , nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine,  <e1> diazepam </e1>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin,  <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride,  <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin,  <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride,  <e1> antipyrine </e1> , caffeine, carbamazepine,  <e2> diazepam </e2>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride,  <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol,  <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol,  <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin,  <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e1> contraceptive </e1>  ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e1> metoprolol </e1> , nifedipine, phenytoin, warfarin, midazolam,  <e2> clarithromycin </e2> , metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following:  <e1> theophylline </e1> , cisapride, antipyrine,  <e2> caffeine </e2> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e1> metoprolol </e1> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e1> metoprolol </e1> ,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin,  <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e2> contraceptive </e2>  (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride,  <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam,  <e2> clarithromycin </e2> , metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine,  <e2> diazepam </e2>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine,  <e1> diazepam </e1>  (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol,  <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e1> metoprolol </e1> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or  <e2> amoxicillin </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine,  <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen,  <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or  <e2> amoxicillin </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e1> warfarin </e1> , midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,  <e1> ritonavir </e1> ,  <e2> saquinavir </e2> , telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin,  <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e1> contraceptive </e1>  (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir,  <e1> itraconazole </e1> ,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and  <e2> ketoconazole </e2>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  <e1> paricalcitol </e1>  with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including  <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2>  or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac,  <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine,  <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
advise	Given the primary CNS effects of  <e1> paliperidone </e1> , INVEGA    should be used with caution in combination with other  <e2> centrally acting drugs </e2>  and alcohol. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine,  <e1> diazepam </e1>  (and its active metabolite, desmethyldiazepam), diclofenac,  <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled  <e1> paricalcitol </e1>  AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e1> ketoconazole </e1>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or  <e2> voriconazole </e2> . 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin,  <e1> indinavir </e1> , itraconazole, nefazodone, nelfinavir,  <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e1> ketoconazole </e1>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin,  <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine,  <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin,  <e2> metronidazole </e2> , or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam,  <e2> clarithromycin </e2> , metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite,  <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with  <e2> ketoconazole </e2>  and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir,  <e1> clarithromycin </e1> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or  <e2> voriconazole </e2> . 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir,  <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with  <e1> ketoconazole </e1>  and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir,  <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen,  <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol),  <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral  <e1> contraceptive </e1>  (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled  <e1> paricalcitol </e1>  AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2>  or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir,  <e1> itraconazole </e1> , nefazodone, nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with  <e1> ketoconazole </e1>  and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or  <e2> voriconazole </e2> . 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam),  <e1> diclofenac </e1> , naproxen, piroxicam, digoxin,  <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole,  <e1> nefazodone </e1> , nelfinavir, ritonavir, saquinavir, telithromycin or  <e2> voriconazole </e2> . 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with  <e1> ketoconazole </e1>  and other strong P450 3A inhibitors including  <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including  <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or  <e2> voriconazole </e2> . 
mechanism	Drugs that impair intestinal absorption of  <e1> fat-soluble vitamins </e1> , such as  <e2> cholestyramine </e2> , may interfere with the absorption of Zemplar Capsules.
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline,  <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including  <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with  <e1> ketoconazole </e1>  and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,  <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole. 
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  <e1> paricalcitol </e1>  with ketoconazole and other strong P450 3A inhibitors including  <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e1> ketoconazole </e1>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled  <e1> paricalcitol </e1>  AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir,  <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam,  <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin,  <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled  <e1> paricalcitol </e1>  AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or  <e2> voriconazole </e2> . 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including  <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled  <e1> paricalcitol </e1>  AUC0-   . Since paricalcitol is partially metabolized by CYP3A and  <e2> ketoconazole </e2>  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that  <e1> ketoconazole </e1>  approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  <e2> paricalcitol </e2>  with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
advise	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  <e1> paricalcitol </e1>  with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2>  or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin,  <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since  <e1> paricalcitol </e1>  is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 
false	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with  <e1> PEG-Intron </e1>  once weekly for 4 weeks was associated with a mean increase of 16% in  <e2> methadone </e2>  AUC; 
false	Acromegalic patients with diabetes mellitus being treated with  <e1> insulin </e1>  and/or oral  <e2> hypoglycemic </e2>  agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. 
false	Although  <e1> ibuprofen </e1>  (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with  <e2> ALIMTA </e2>  to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). 
false	Although  <e1> ibuprofen </e1>  (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering  <e2> ibuprofen </e2>  concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). 
advise	Acromegalic patients with diabetes mellitus being treated with  <e1> insulin </e1>  and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with  <e2> SOMAVERT </e2> . 
false	In the absence of data regarding potential interaction between ALIMTA and  <e1> NSAIDs </e1>  with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following  <e2> ALIMTA </e2>  administration. 
effect	Concurrent administration of  <e1> bacteriostatic antibiotics </e1>  (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of  <e2> penicillins </e2>  by slowing the rate of bacterial growth. 
false	Concurrent administration of  <e1> bacteriostatic antibiotics </e1>  (e.g., erythromycin,  <e2> tetracycline </e2> ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. 
false	 <e1> Penicillin </e1>  blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of  <e2> penicillins </e2> . 
false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis,  <e1> diuretics </e1> ,  <e2> antidiabetic agents </e2> , and antiarrhythmics, without observed problems. 
false	 <e1> TRENTAL </e1>  has been used concurrently with antihypertensive drugs, beta blockers, digitalis,  <e2> diuretics </e2> , antidiabetic agents, and antiarrhythmics, without observed problems. 
false	TRENTAL has been used concurrently with  <e1> antihypertensive drugs </e1> , beta blockers, digitalis, diuretics, antidiabetic agents, and  <e2> antiarrhythmics </e2> , without observed problems. 
false	TRENTAL has been used concurrently with  <e1> antihypertensive drugs </e1> ,  <e2> beta blockers </e2> , digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 
false	Concomitant administration of TRENTAL and  <e1> theophylline </e1> -containing drugs leads to increased  <e2> theophylline </e2>  levels and theophylline toxicity in some individuals. 
false	Dopamine antagonists, such as the neuroleptics (phenothiazines,  <e1> butyrophenones </e1> , thioxanthines ) or  <e2> metoclopramide </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
false	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones,  <e1> thioxanthines </e1>  ) or  <e2> metoclopramide </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers,  <e1> digitalis </e1> , diuretics, antidiabetic agents, and  <e2> antiarrhythmics </e2> , without observed problems. 
false	Because  <e1> pergolide mesylate </e1>  is approximately 90% bound to plasma proteins, caution should be exercised if  <e2> pergolide mesylate </e2>  is coadministered with other drugs known to affect protein binding.
false	Dopamine antagonists, such as the neuroleptics (phenothiazines,  <e1> butyrophenones </e1> ,  <e2> thioxanthines </e2>  ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 
false	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers,  <e1> digitalis </e1> , diuretics,  <e2> antidiabetic agents </e2> , and antiarrhythmics, without observed problems. 
advise	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones,  <e1> thioxanthines </e1>  ) or metoclopramide, ordinarily should not be administered concurrently with  <e2> Permax </e2>  (a dopamine agonist); 
false	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin,  <e1> heparin </e1> ,  <e2> cyclosporine </e2>  and others) can increase the risk of hyperkalemia. 
false	 <e1> Potassium </e1>  Supplements and Potassium-Sparing Diuretics:  <e2> ACEON </e2>     Tablets may increase serum potassium because of its potential to decrease aldosterone production. 
false	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others),  <e1> potassium </e1>  supplements or other drugs capable of increasing serum potassium (indomethacin, heparin,  <e2> cyclosporine </e2>  and others) can increase the risk of hyperkalemia. 
false	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others),  <e1> potassium </e1>  supplements or other drugs capable of increasing serum potassium ( <e2> indomethacin </e2> , heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
false	Use of  <e1> potassium-sparing diuretics </e1>  ( <e2> spironolactone </e2> , amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
false	 <e1> Gentamicin </e1> : Animal data have suggested the possibility of interaction between perindopril and  <e2> gentamicin </e2> . 
false	Use of  <e1> potassium-sparing diuretics </e1>  (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin,  <e2> cyclosporine </e2>  and others) can increase the risk of hyperkalemia. 
false	 <e1> Diuretics </e1> : Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of  <e2> ACEON </e2>     Tablets therapy. 
false	 <e1> Gentamicin </e1> : Animal data have suggested the possibility of interaction between  <e2> perindopril </e2>  and gentamicin. 
false	Concomitant administration of TRENTAL and  <e1> theophylline </e1> -containing drugs leads to increased theophylline levels and  <e2> theophylline </e2>  toxicity in some individuals. 
false	Use of potassium-sparing diuretics ( <e1> spironolactone </e1> ,  <e2> amiloride </e2> , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
false	Lithium: Increased serum lithium and symptoms of  <e1> lithium </e1>  toxicity have been reported in patients receiving concomitant  <e2> lithium </e2>  and ACE inhibitor therapy. 
false	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with  <e1> ACEON </e1>     Tablets, but an effect of  <e2> digoxin </e2>  on the plasma concentration of perindopril/perindoprilat has not been excluded. 
false	Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride,  <e2> triamterene </e2>  and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
false	Use of  <e1> potassium-sparing diuretics </e1>  (spironolactone, amiloride, triamterene and others),  <e2> potassium </e2>  supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
false	Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e2> indomethacin </e2> , heparin, cyclosporine and others) can increase the risk of hyperkalemia. 
effect	MAO Inhibitors: The pressor effect of  <e1> sympathomimetic pressor amines </e1>  is markedly potentiated in patients receiving  <e2> monoamine oxidase inhibitors </e2>  (MAOI). 
false	MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving  <e1> monoamine oxidase inhibitors </e1>  ( <e2> MAOI </e2> ). 
false	 <e1> MAO Inhibitors </e1>  - The pressor effect of  <e2> sympathomimetic pressor amines </e2>  is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 
effect	MAO Inhibitors - The pressor effect of  <e1> sympathomimetic pressor amines </e1>  is markedly potentiated in patients receiving monoamine oxidase inhibitors ( <e2> MAOI </e2> ). 
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium,  <e1> medroxyprogesterone acetate </e1> , methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and  <e2> prednisone </e2> .
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole,  <e2> paracetamol </e2> , and prednisone.
false	These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g.,  <e1> atropine </e1> , inhaled  <e2> ipratropium </e2> ). 
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears,  <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate,  <e2> ibuprofen </e2> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens,  <e2> hydroxychloroquine sulfate </e2> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate,  <e2> ibuprofen </e2> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen,  <e1> levothyroxine sodium </e1> , medroxyprogesterone acetate, methotrexate, multivitamins, naproxen,  <e2> omeprazole </e2> , paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears,  <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen,  <e2> omeprazole </e2> , paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium,  <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole,  <e2> paracetamol </e2> , and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium,  <e1> medroxyprogesterone acetate </e1> , methotrexate, multivitamins, naproxen,  <e2> omeprazole </e2> , paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens,  <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium,  <e2> medroxyprogesterone acetate </e2> , methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate,  <e1> multivitamins </e1> , naproxen,  <e2> omeprazole </e2> , paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium,  <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate,  <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate,  <e1> multivitamins </e1> ,  <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate,  <e1> ibuprofen </e1> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate,  <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens,  <e1> hydroxychloroquine sulfate </e1> , ibuprofen,  <e2> levothyroxine sodium </e2> , medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
false	Pindolol has been used with a variety of antihypertensive agents, including  <e1> hydrochlorothiazide </e1> ,  <e2> hydralazine </e2> , and guanethidine without unexpected adverse interactions. 
false	Pindolol has been used with a variety of  <e1> antihypertensive agents </e1> , including hydrochlorothiazide,  <e2> hydralazine </e2> , and guanethidine without unexpected adverse interactions. 
false	Pindolol has been used with a variety of antihypertensive agents, including  <e1> hydrochlorothiazide </e1> , hydralazine, and  <e2> guanethidine </e2>  without unexpected adverse interactions. 
false	 <e1> Pindolol </e1>  has been used with a variety of antihypertensive agents, including hydrochlorothiazide,  <e2> hydralazine </e2> , and guanethidine without unexpected adverse interactions. 
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate,  <e1> ibuprofen </e1> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins,  <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.
false	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins,  <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.
mechanism	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including  <e1> FELDENE </e1> , have been reported to increase steady state plasma  <e2> lithium </e2>  levels. 
false	Plasma levels of  <e1> piroxicam </e1>  are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of  <e2> antacids </e2>  has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 
false	Plasma levels of  <e1> piroxicam </e1>  are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including  <e2> FELDENE </e2> , have been reported to increase steady state plasma lithium levels. 
false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on  <e1> piroxicam </e1>  plasma levels .  <e2> Nonsteroidal anti-inflammatory agents </e2> , including FELDENE, have been reported to increase steady state plasma lithium levels. 
false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on  <e1> piroxicam </e1>  plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma  <e2> lithium </e2>  levels. 
false	Although this has not occurred in in vitro studies with  <e1> coumarin-type anticoagulants </e1> , interactions with coumarin-type anticoagulants have been reported with  <e2> FELDENE </e2>  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 
false	Although this has not occurred in in vitro studies with  <e1> coumarin-type anticoagulants </e1> , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  <e2> FELDENE </e2>  to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 
false	Although this has not occurred in in vitro studies with  <e1> coumarin-type anticoagulants </e1> , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on  <e2> coumarin-type anticoagulants </e2>  and other highly protein-bound drugs. 
false	morphine,  <e1> theophylline </e1> , aminophylline, succinylcholine, reserpine, and  <e2> phenothiazine-type tranquilizers </e2>  should be avoided in patients with organophosphate poisoning.
false	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when  <e1> FELDENE </e1>  is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of  <e2> antacids </e2>  has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 
false	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with  <e1> FELDENE </e1>  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  <e2> FELDENE </e2>  to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 
false	morphine, theophylline, aminophylline,  <e1> succinylcholine </e1> , reserpine, and  <e2> phenothiazine-type tranquilizers </e2>  should be avoided in patients with organophosphate poisoning.
false	When  <e1> atropine </e1>  and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when  <e2> atropine </e2>  is used alone. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and  <e1> quinine </e1> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins,  <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of  <e2> pramipexole </e2>  by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil,  <e1> quinidine </e1> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin,  <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Carbidopa/ <e1> Levodopa </e1> : Carbidopa/ <e2> Levodopa </e2>  does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 
false	Dopamine antagonists: Since  <e1> pramipexole </e1>  is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines,  <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g.,  <e1> cephalosporins </e1> , penicillins,  <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins,  <e1> penicillins </e1> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of  <e2> pramipexole </e2> . 
false	Dopamine antagonists: Since  <e1> pramipexole </e1>  is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of  <e2> MIRAPEX </e2> . 
false	 <e1> Dopamine antagonists </e1> : Since  <e2> pramipexole </e2>  is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Dopamine antagonists: Since  <e1> pramipexole </e1>  is a  <e2> dopamine agonist </e2> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins,  <e1> penicillins </e1> , indomethacin, hydrochlorothiazide, and  <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g.,  <e1> cephalosporins </e1> ,  <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem,  <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and  <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole. 
false	morphine, theophylline,  <e1> aminophylline </e1> , succinylcholine,  <e2> reserpine </e2> , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones,  <e1> thioxanthenes </e1> ) or  <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and  <e1> quinine </e1> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of  <e2> pramipexole </e2> . 
effect	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines,  <e1> butyrophenones </e1> , thioxanthenes) or metoclopramide, may diminish the effectiveness of  <e2> MIRAPEX </e2> . 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin,  <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	 <e1> Amantadine </e1> : Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of  <e2> pramipexole </e2>  (N= 54). 
false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that  <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or  <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX. 
false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that  <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines,  <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, thioxanthenes) or  <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX. 
false	Dopamine antagonists: Since pramipexole is a  <e1> dopamine agonist </e1> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones,  <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of  <e1> pramipexole </e1>  by about 20%, while those secreted by the anionic transport system (e.g.,  <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine,  <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin,  <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem,  <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of  <e2> pramipexole </e2> . 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine,  <e1> ranitidine </e1> ,  <e2> diltiazem </e2> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Carbidopa/Levodopa: Carbidopa/ <e1> Levodopa </e1>  does not influence the pharmacokinetics of  <e2> pramipexole </e2>  in healthy volunteers (N= 10). 
mechanism	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and  <e1> quinine </e1> ) decreases the oral clearance of  <e2> pramipexole </e2>  by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine,  <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g.,  <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Probenecid:  <e1> Probenecid </e1> , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence  <e2> pramipexole </e2>  pharmacokinetics (N= 12). 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem,  <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin,  <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin,  <e1> hydrochlorothiazide </e1> , and  <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole. 
advise	When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as  <e1> analgesics </e1> ), the agent should be administered at least 1 hour prior to or 2 hours after  <e2> SYMLIN </e2>  injection. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil,  <e1> quinidine </e1> , and  <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	In clinical trials, the concomitant use of  <e1> sulfonylureas </e1>  or  <e2> biguanides </e2>  did not alter the adverse event profile of SYMLIN. 
false	Selegiline: In healthy volunteers (N= 11),  <e1> selegiline </e1>  did not influence the pharmacokinetics of  <e2> pramipexole </e2> . 
mechanism	Mixing SYMLIN and Insulin The pharmacokinetic parameters of  <e1> SYMLIN </e1>  were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant  <e2> human insulin </e2>  immediately prior to injection. 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil,  <e1> quinidine </e1> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g.,  <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	In clinical trials, the concomitant use of sulfonylureas or  <e1> biguanides </e1>  did not alter the adverse event profile of  <e2> SYMLIN </e2> . 
false	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of  <e1> pralidoxime </e1> : since barbiturates are potentiated by the  <e2> anticholinesterases </e2> , they should be used cautiously in the treatment of convulsions; 
false	Thus,  <e1> SYMLIN </e1>  and  <e2> insulin </e2>  should not be mixed and must be administered separately.
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine,  <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and  <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	Drugs that induce hepatic enzymes such as  <e1> phenobarbital </e1> , phenytoin and  <e2> rifampin </e2>  may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 
false	 <e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines,  <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 
mechanism	Drugs such as  <e1> troleandomycin </e1>  and ketoconazole may inhibit the metabolism of  <e2> corticosteroids </e2>  and thus decrease their clearance. 
mechanism	Drugs that induce hepatic enzymes such as phenobarbital,  <e1> phenytoin </e1>  and rifampin may increase the clearance of corticosteroids and may require increases in  <e2> corticosteroid </e2>  dose to achieve the desired response. 
false	Mixing  <e1> SYMLIN </e1>  and  <e2> Insulin </e2>  The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. 
effect	There are reports of enhanced as well as diminished effects of  <e1> anticoagulants </e1>  when given concurrently with  <e2> corticosteroids </e2> . 
false	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene,  <e1> verapamil </e1> ,  <e2> quinidine </e2> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 
false	 <e1> Acetazolamide </e1> : Concurrent use of  <e2> acetazolamide </e2>  and procaine hydrochloride may extend the plasma half-life of procaine.
effect	The effect of  <e1> corticosteroids </e1>  on oral  <e2> anticoagulants </e2>  is variable. 
mechanism	Acetazolamide: Concurrent use of  <e1> acetazolamide </e1>  and  <e2> procaine hydrochloride </e2>  may extend the plasma half-life of procaine.
false	Acetazolamide: Concurrent use of  <e1> acetazolamide </e1>  and procaine hydrochloride may extend the plasma half-life of  <e2> procaine </e2> .
false	Anticholinesterases: Concurrent use of procaine hydrochloride and  <e1> anticholinesterase agents </e1>  may result in increased systemic toxicity since  <e2> anticholinesterases </e2>  inhibit the breakdown of procaine hydrochloride. 
false	 <e1> Hyaluronidase </e1> : Hyaluronidase may increase the diffusion rate of  <e2> procaine hydrochloride </e2> , resulting in a decreased time of onset, but an increase in systemic toxicity. 
false	 <e1> Sulfonamides </e1> : Concurrent use of  <e2> procaine hydrochloride </e2>  and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. 
false	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of  <e1> corticosteroids </e1>  and may require increases in  <e2> corticosteroid </e2>  dose to achieve the desired response. 
false	Because Matulane exhibits some monoamine oxidase inhibitory activity,  <e1> sympathomimetic drugs </e1> , tricyclic antidepressant drugs (e.g.,  <e2> amitriptyline HCl </e2> , imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 
false	Anticholinesterases: Concurrent use of procaine hydrochloride and  <e1> anticholinesterase agents </e1>  may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of  <e2> procaine hydrochloride </e2> . 
false	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs,  <e1> tricyclic antidepressant </e1>  drugs (e.g., amitriptyline HCl,  <e2> imipramine HCl </e2> ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 
false	Sulfonamides: Concurrent use of  <e1> procaine hydrochloride </e1>  and sulfonamides may result in a reduction of the antibacterial action of the  <e2> sulfonamide </e2> . 
advise	Because  <e1> Matulane </e1>  exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs,  <e2> tricyclic antidepressant </e2>  drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 
false	 <e1> Sulfonamides </e1> : Concurrent use of procaine hydrochloride and  <e2> sulfonamides </e2>  may result in a reduction of the antibacterial action of the sulfonamide. 
advise	During maintenance of anesthesia or sedation, the rate of  <e1> DIPRIVAN </e1>  Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental  <e2> analgesic agents </e2>  (eg, nitrous oxide or opioids). 
false	The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and  <e1> halothane </e1> ) during maintenance with  <e2> DIPRIVAN </e2>  Injectable Emulsion has not been extensively evaluated. 
false	and combinations of  <e1> opioids </e1>  and sedatives (eg,  <e2> benzodiazepines </e2> , barbiturates, chloral hydrate, droperidol, etc.). 
false	 <e1> DIPRIVAN </e1>  Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg,  <e2> succinylcholine </e2>  and nondepolarizing muscle relaxants). 
effect	The induction dose requirements of  <e1> DIPRIVAN </e1>  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg,  <e2> morphine </e2> , meperidine, and fentanyl, etc.) 
false	and combinations of opioids and sedatives (eg, benzodiazepines,  <e1> barbiturates </e1> , chloral hydrate,  <e2> droperidol </e2> , etc.). 
false	and combinations of  <e1> opioids </e1>  and sedatives (eg, benzodiazepines, barbiturates,  <e2> chloral hydrate </e2> , droperidol, etc.). 
false	 <e1> DIPRIVAN </e1>  Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used  <e2> neuromuscular blocking agents </e2>  (eg, succinylcholine and nondepolarizing muscle relaxants). 
false	and combinations of opioids and  <e1> sedatives </e1>  (eg, benzodiazepines,  <e2> barbiturates </e2> , chloral hydrate, droperidol, etc.). 
false	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of  <e1> muscle relaxants </e1> , inhalational agents, analgesic agents, and local  <e2> anesthetic agents </e2> ) have been observed.
false	and combinations of  <e1> opioids </e1>  and  <e2> sedatives </e2>  (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 
false	The concurrent administration of potent inhalational agents (eg,  <e1> isoflurane </e1> , enflurane, and halothane) during maintenance with  <e2> DIPRIVAN </e2>  Injectable Emulsion has not been extensively evaluated. 
effect	 <e1> Thiazide diuretics </e1>  may accentuate the orthostatic hypotension that may occur with  <e2> phenothiazines </e2> . 
false	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg,  <e1> succinylcholine </e1>  and  <e2> nondepolarizing muscle relaxants </e2> ). 
effect	 <e1> Sympathomimetics </e1>  may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and  <e2> veratrum alkaloids </e2> .
false	Sympathomimetics may reduce the antihypertensive effects of  <e1> methyldopa </e1> ,  <e2> mecamylamine </e2> , reserpine and veratrum alkaloids.
false	Sympathomimetics may reduce the antihypertensive effects of  <e1> methyldopa </e1> , mecamylamine,  <e2> reserpine </e2>  and veratrum alkaloids.
false	 <e1> Pyrimethamine </e1>  may be used with sulfonamides, quinine and other antimalarials, and with other  <e2> antibiotics </e2> . 
false	Pyrimethamine may be used with sulfonamides, quinine and other  <e1> antimalarials </e1> , and with other  <e2> antibiotics </e2> . 
false	Pyrimethamine may be used with  <e1> sulfonamides </e1> ,  <e2> quinine </e2>  and other antimalarials, and with other antibiotics. 
false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as  <e1> clofibrate </e1> , indomethacin, naproxen,  <e2> ibuprofen </e2> , diazepam, and diazoxide. 
false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen,  <e1> ibuprofen </e1> , diazepam, and  <e2> diazoxide </e2> . 
false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as  <e1> clofibrate </e1> ,  <e2> indomethacin </e2> , naproxen, ibuprofen, diazepam, and diazoxide. 
false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen,  <e1> diazepam </e1> , and  <e2> diazoxide </e2> . 
false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate,  <e1> indomethacin </e1> , naproxen,  <e2> ibuprofen </e2> , diazepam, and diazoxide. 
false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin,  <e1> naproxen </e1> , ibuprofen, diazepam, and  <e2> diazoxide </e2> . 
advise	Caution should be used when  <e1> EVISTA </e1>  is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen,  <e2> diazepam </e2> , and diazoxide. 
advise	Caution should be used when  <e1> EVISTA </e1>  is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and  <e2> diazoxide </e2> . 
mechanism	Coadministration with a high dose of  <e1> antacid </e1>  (170 mEq) results in a 28% decrease in plasma concentrations of  <e2> ranitidine </e2>  and may decrease plasma concentrations of bismuth from TRITEC. 
false	Coadministration of  <e1> TRITEC </e1>  with clarithromycin resulted in increased plasma  <e2> ranitidine </e2>  concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). 
false	Coadministration with  <e1> aspirin </e1>  results in a slight decrease in the rate of  <e2> salicylate </e2>  absorption that is clinically unimportant. 
false	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen,  <e1> ibuprofen </e1> ,  <e2> diazepam </e2> , and diazoxide. 
false	In vitro, raloxifene did not affect the binding of warfarin,  <e1> phenytoin </e1> , or  <e2> tamoxifen </e2> . 
false	Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for  <e1> retapamulin </e1>  are unnecessary when co-administered with CYP3A4 inhibitors, such as  <e2> ketoconazole </e2> . 
effect	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and  <e1> abciximab </e1> ) may increase the risk of bleeding if administered prior to or after  <e2> Retavase </e2>     therapy.
false	In addition to bleeding associated with heparin and  <e1> vitamin K antagonists </e1> , drugs that alter platelet function (such as aspirin,  <e2> dipyridamole </e2> , and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
false	In addition to bleeding associated with heparin and  <e1> vitamin K antagonists </e1> , drugs that alter platelet function (such as aspirin, dipyridamole, and  <e2> abciximab </e2> ) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
false	Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of  <e1> ALTABAX </e1> ,  <e2> retapamulin </e2>  is unlikely to affect the metabolism of other P450 substrates. 
false	Interactions for  <e1> Vitamin B2 </e1>  (Riboflavin):   <e2> Alcohol </e2>  - impairs the intestinal absorption of riboflavin
false	 <e1> Aspirin </e1> :  <e2> Rimantadine HCl </e2> , 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. 
false	 <e1> Cimetidine </e1> : The effects of chronic  <e2> cimetidine </e2>  use on the metabolism of rimantadine are not known. 
false	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of  <e1> Cimetidine </e1>  (300 mg four times a day), the apparent total  <e2> rimantadine </e2>  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 
mechanism	When a single 100 mg dose of  <e1> rimantadine HCl </e1>  was administered one hour after the initiation of  <e2> Cimetidine </e2>  (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 
false	Effect of Other Drugs on the Metabolism of  <e1> Exelon </e1> : Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of  <e2> rivastigmine </e2> . 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as  <e1> antacids </e1>  (n=77),  <e2> antihypertensives </e2>  (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72),  <e1> calcium channel blockers </e1>  (n=75),  <e2> antidiabetics </e2>  (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as  <e1> antacids </e1>  (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and  <e2> antihistamines </e2>  (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  <e1> rivastigmine </e1>  were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21),  <e2> nonsteroidal anti-inflammatory drugs </e2>  (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	No pharmacokinetic interaction was observed between  <e1> rivastigmine </e1>  and digoxin, warfarin, diazepam, or  <e2> fluoxetine </e2>  in studies in healthy volunteers. 
false	Use with Cholinomimetics and Other  <e1> Cholinesterase Inhibitors </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar  <e2> neuromuscular blocking agents </e2>  or cholinergic agonists such as bethanechol.
false	Single dose pharmacokinetic studies demonstrated that the metabolism of  <e1> rivastigmine </e1>  is not significantly affected by concurrent administration of digoxin,  <e2> warfarin </e2> , diazepam, or fluoxetine. 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77),  <e1> antihypertensives </e1>  (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79),  <e2> estrogens </e2>  (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21),  <e1> nonsteroidal anti-inflammatory drugs </e1>  (n=79), estrogens (n=70), salicylate analgesics (n=177),  <e2> antianginals </e2>  (n=35), and antihistamines (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  <e1> rivastigmine </e1>  were not influenced by commonly prescribed medications such as antacids (n=77),  <e2> antihypertensives </e2>  (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	No pharmacokinetic interaction was observed between rivastigmine and  <e1> digoxin </e1> ,  <e2> warfarin </e2> , diazepam, or fluoxetine in studies in healthy volunteers. 
false	Use with Cholinomimetics and Other  <e1> Cholinesterase Inhibitors </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as  <e2> bethanechol </e2> .
false	Use with  <e1> Cholinomimetics </e1>  and Other Cholinesterase Inhibitors: A synergistic effect may be expected when  <e2> cholinesterase inhibitors </e2>  are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
false	Use with Cholinomimetics and Other  <e1> Cholinesterase Inhibitors </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or  <e2> cholinergic agonists </e2>  such as bethanechol.
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as  <e1> antacids </e1>  (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21),  <e2> nonsteroidal anti-inflammatory drugs </e2>  (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70),  <e1> salicylate analgesics </e1>  (n=177), antianginals (n=35), and  <e2> antihistamines </e2>  (n=15). 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77),  <e1> antihypertensives </e1>  (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70),  <e2> salicylate analgesics </e2>  (n=177), antianginals (n=35), and antihistamines (n=15). 
effect	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when  <e1> cholinesterase inhibitors </e1>  are given concurrently with succinylcholine, similar neuromuscular blocking agents or  <e2> cholinergic agonists </e2>  such as bethanechol.
false	No pharmacokinetic interaction was observed between rivastigmine and digoxin,  <e1> warfarin </e1> , diazepam, or  <e2> fluoxetine </e2>  in studies in healthy volunteers. 
false	There are no controlled studies documenting the use of  <e1> ZEMURON </e1>     before or after other  <e2> nondepolarizing muscle relaxants </e2> . 
false	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with  <e1> succinylcholine </e1> , similar  <e2> neuromuscular blocking agents </e2>  or cholinergic agonists such as bethanechol.
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72),  <e1> calcium channel blockers </e1>  (n=75), antidiabetics (n=21),  <e2> nonsteroidal anti-inflammatory drugs </e2>  (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	No pharmacokinetic interaction was observed between rivastigmine and  <e1> digoxin </e1> , warfarin,  <e2> diazepam </e2> , or fluoxetine in studies in healthy volunteers. 
false	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as  <e1> antacids </e1>  (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79),  <e2> estrogens </e2>  (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 
false	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of  <e1> Ropivacaine </e1> , can interact with  <e2> Ropivacaine </e2>  leading to increased ropivacaine plasma levels. 
false	Coadministration of a selective and potent inhibitor of CYP3A4,  <e1> ketoconazole </e1>  (100 mg bid for 2 days with  <e2> ropivacaine </e2>  infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.
false	Thus strong inhibitors of cytochrome P4501A2, such as  <e1> fluvoxamine </e1> , given concomitantly during administration of Ropivacaine, can interact with  <e2> Ropivacaine </e2>  leading to increased ropivacaine plasma levels. 
false	Thus strong inhibitors of cytochrome P4501A2, such as  <e1> fluvoxamine </e1> , given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased  <e2> ropivacaine </e2>  plasma levels. 
mechanism	In vivo, the plasma clearance of  <e1> ropivacaine </e1>  was reduced by 70% during coadministration of  <e2> fluvoxamine </e2>  (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. 
false	An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of  <e1> rosiglitazone </e1>  and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of  <e2> rosiglitazone </e2> . 
false	Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as  <e1> theophylline </e1>  and  <e2> imipramine </e2>  may also occur. 
false	Concomitant administrations not recommended:  - Terfenadine and  <e1> astemizole </e1> : Certain macrolides interact with  <e2> terfenadine </e2>  and astemizole leading to increased serum concentrations of the latter. 
false	Although such a risk is not verified for  <e1> roxithromycin </e1> , combination of  <e2> roxithromycin </e2>  with such drugs is not recommended.
false	Concomitant administrations not recommended:  -  <e1> Terfenadine </e1>  and astemizole: Certain  <e2> macrolides </e2>  interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 
false	- Cisapride,  <e1> pimozide </e1> : Other drugs such as cisapride or  <e2> pimozide </e2> , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 
false	Concomitant administrations not recommended:  -  <e1> Terfenadine </e1>  and astemizole: Certain macrolides interact with terfenadine and  <e2> astemizole </e2>  leading to increased serum concentrations of the latter. 
mechanism	 <e1> Salicylate </e1>  competes with a number of drugs for protein binding sites, notably penicillin, thiopental,  <e2> thyroxine </e2> , triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 
false	ASPIRIN AND OTHER  <e1> SALICYLATE DRUGS </e1>  WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF  <e2> SALICYLIC ACID </e2>  TO TOXIC LEVELS. 
false	Salicylate competes with a number of drugs for protein binding sites, notably  <e1> penicillin </e1> , thiopental, thyroxine, triiodothyronine,  <e2> phenytoin </e2> , sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone,  <e1> naproxen </e1> ,  <e2> warfarin </e2> , methotrexate, and possibly corticosteroids. 
mechanism	 <e1> Salicylate </e1>  competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin,  <e2> methotrexate </e2> , and possibly corticosteroids. 
false	 <e1> ASPIRIN </e1>  AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF  <e2> SALICYLIC ACID </e2>  TO TOXIC LEVELS. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin,  <e1> thiopental </e1> , thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly  <e2> corticosteroids </e2> . 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin,  <e1> sulfinpyrazone </e1> ,  <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids. 
effect	ASPIRIN AND OTHER  <e1> SALICYLATE DRUGS </e1>  WILL BE ADDITIVE TO  <e2> DISALCID </e2>  AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin,  <e1> thiopental </e1> , thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin,  <e2> methotrexate </e2> , and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably  <e1> penicillin </e1> , thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone,  <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin,  <e1> thiopental </e1> , thyroxine, triiodothyronine, phenytoin, sulfinpyrazone,  <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental,  <e1> thyroxine </e1> , triiodothyronine, phenytoin, sulfinpyrazone,  <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids. 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen,  <e1> warfarin </e1> , methotrexate, and possibly  <e2> corticosteroids </e2> . 
false	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine,  <e1> phenytoin </e1> , sulfinpyrazone,  <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids. 
effect	Drugs which may potentiate the myeloproliferative effects of  <e1> Leukine </e1> , such as  <e2> lithium </e2>  and corticosteroids, should be used with caution.
advise	 <e1> Scopolamine </e1>  should be used with care in patients taking other drugs that are capable of causing CNS effects such as  <e2> sedatives </e2> , tranquilizers, or alcohol. 
false	e.g., other  <e1> belladonna alkaloids </e1> , antihistamines (including meclizine),  <e2> tricyclic antidepressants </e2> , and muscle relaxants. 
false	e.g., other  <e1> belladonna alkaloids </e1> ,  <e2> antihistamines </e2>  (including meclizine), tricyclic antidepressants, and muscle relaxants. 
false	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as  <e1> sedatives </e1> ,  <e2> tranquilizers </e2> , or alcohol. 
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine,  <e1> theophylline </e1> , corticosteroids, anticoagulants, and  <e2> beta blockers </e2> .
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain  <e1> antibiotics </e1> , quinidine, theophylline, corticosteroids,  <e2> anticoagulants </e2> , and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics,  <e1> quinidine </e1> ,  <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.
false	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics,  <e1> quinidine </e1> , theophylline, corticosteroids,  <e2> anticoagulants </e2> , and beta blockers.
int	 <e1> Barbiturates </e1>  may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline,  <e2> corticosteroids </e2> , anticoagulants, and beta blockers.
false	e.g., other  <e1> belladonna alkaloids </e1> , antihistamines (including  <e2> meclizine </e2> ), tricyclic antidepressants, and muscle relaxants. 
false	One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a  <e1> sympathomimetic medication </e1>  ( <e2> ephedrine </e2> ).
effect	One case of hypertensive crisis has been reported in a patient taking the recommended doses of  <e1> selegiline </e1>  and a  <e2> sympathomimetic medication </e2>  (ephedrine).
false	Severe toxicity has also been reported in patients receiving the combination of  <e1> tricyclic antidepressants </e1>  and ELDEPRYL and  <e2> selective serotonin reuptake inhibitors </e2>  and ELDEPRYL. 
int	This is typical of the interaction of  <e1> meperidine </e1>  and  <e2> MAOIs </e2> . 
false	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and  <e1> ELDEPRYL </e1>  and  <e2> selective serotonin reuptake inhibitors </e2>  and ELDEPRYL. 
false	 <e1> norepinephrine </e1>  and  <e2> dobutamine </e2>  are incompatible with sodium bicarbonate solution. 
false	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with  <e1> solifenacin </e1>  10 mg than with 30 mg (three times the maximum recommended dose), and the effect of  <e2> solifenacin </e2>  30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. 
false	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  <e1> corticosteroids </e1> ,  <e2> sex steroids </e2> , anticonvulsants, cyclosporin). 
mechanism	Limited published data indicate that  <e1> GH </e1>  treatment increases cytochrome P450 (CP450) mediated  <e2> antipyrine </e2>  clearance in man. 
false	If  <e1> glucocorticoid </e1>  replacement is required, the  <e2> glucocorticoid </e2>  dose should be carefully adjusted. 
effect	 <e1> Zidovudine </e1>  competitively inhibits the intracellular phosphorylation of  <e2> stavudine </e2> . 
false	Use of  <e1> Anticoagulants </e1>  and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with  <e2> antiplatelet agents </e2>  and anticoagulants, may cause bleeding complications. 
false	Use of Anticoagulants and  <e1> Antiplatelet Agents </e1>  --  <e2> Streptase </e2> , Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 
effect	Use of Anticoagulants and Antiplatelet Agents --  <e1> Streptase </e1> , Streptokinase, alone or in combination with antiplatelet agents and  <e2> anticoagulants </e2> , may cause bleeding complications. 
false	Use of Anticoagulants and  <e1> Antiplatelet Agents </e1>  -- Streptase,  <e2> Streptokinase </e2> , alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 
false	The concurrent use of  <e1> streptozocin </e1>  and phenytoin has been reported in one case to result in reduced  <e2> streptozocin </e2>  cytotoxicity.    
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of  <e1> methotrexate </e1> ), phenytoin (decreased hepatic clearance of  <e2> phenytoin </e2> ).
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect),  <e1> methotrexate </e1>  (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of  <e2> phenytoin </e2> ).
false	It may also interact with  <e1> thiazides </e1>  (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect),  <e2> methotrexate </e2>  (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response),  <e1> warfarin </e1>  (increased anticoagulant effect), methotrexate (decreased renal excretion of  <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).
false	It may also interact with thiazides (increased thrombocytopenia),  <e1> cyclosporine </e1>  (increased nephrotoxicity),  <e2> sulfonylurea agents </e2>  (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
effect	 <e1> Sulfamethizole </e1>  may increase the effects of barbiturates, tolbutamide, and  <e2> uricosurics </e2> . 
false	It may also interact with thiazides (increased thrombocytopenia),  <e1> cyclosporine </e1>  (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of  <e2> phenytoin </e2> ).
false	It has been reported that  <e1> sulfamethoxazole </e1>  may prolong the prothrombin time in patients who are receiving the  <e2> anticoagulant </e2>  warfarin. 
mechanism	At a 1.6-g dose,  <e1> sulfamethoxazole </e1>  produced a slight but significant increase in the half-life of  <e2> phenytoin </e2>  but did not produce a corresponding decrease in the metabolic clearance rate. 
false	Anticoagulation and  <e1> Antiplatelets </e1>  After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of  <e2> aspirin </e2>  has been shown to reduce the incidence of reinfarction and stroke. 
false	Sulfamethizole may increase the effects of  <e1> barbiturates </e1> , tolbutamide, and  <e2> uricosurics </e2> . 
false	It may also interact with  <e1> thiazides </e1>  (increased thrombocytopenia), cyclosporine (increased nephrotoxicity),  <e2> sulfonylurea agents </e2>  (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
false	It may also interact with  <e1> thiazides </e1>  (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of  <e2> phenytoin </e2> ).
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of  <e1> methotrexate </e1> ),  <e2> phenytoin </e2>  (decreased hepatic clearance of phenytoin).
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect),  <e1> methotrexate </e1>  (decreased renal excretion of methotrexate),  <e2> phenytoin </e2>  (decreased hepatic clearance of phenytoin).
false	It may also interact with  <e1> thiazides </e1>  (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate),  <e2> phenytoin </e2>  (decreased hepatic clearance of phenytoin).
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity),  <e1> sulfonylurea agents </e1>  (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate),  <e2> phenytoin </e2>  (decreased hepatic clearance of phenytoin).
effect	 <e1> Sulfoxone </e1>  may increase the effects of  <e2> barbiturates </e2> , tolbutamide, and uricosurics. 
false	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity),  <e1> sulfonylurea agents </e1>  (increased hypoglycemic response), warfarin (increased anticoagulant effect),  <e2> methotrexate </e2>  (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
advise	Because there is a theoretical basis that these effects may be additive, use of  <e1> ergotamine </e1> -containing or ergot-type medications (like dihydroergotamine or methysergide) and  <e2> sumatriptan </e2>  within 24 hours of each other should be avoided. 
false	It may also interact with  <e1> thiazides </e1>  (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect),  <e2> methotrexate </e2>  (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated .  <e1> Selective serotonin reuptake inhibitors </e1>  (SSRIs) (e.g.,  <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g.,  <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
effect	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine,  <e1> sertraline </e1> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  <e2> sumatriptan </e2> . 
false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e1> fluoxetine </e1> , fluvoxamine, paroxetine,  <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Therefore, the use of sumatriptan succinate tablets in patients receiving  <e1> MAO-A inhibitors </e1>  is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine,  <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Therefore, the use of sumatriptan succinate tablets in patients receiving  <e1> MAO-A inhibitors </e1>  is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g.,  <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	It may also interact with  <e1> thiazides </e1>  (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of  <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,  <e1> telithromycin </e1> , voriconizole) may increases  <e2> sunitinib </e2>  concentrations. 
false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin,  <e1> rifabutin </e1> , rifapentin,  <e2> phenobarbital </e2> , St. Johns Wort) may decrease sunitinib concentrations. 
false	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine,  <e1> paroxetine </e1> ,  <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone,  <e1> phenytoin </e1> , carbamazepine, rifampin,  <e2> rifabutin </e2> , rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 
false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin,  <e1> rifapentin </e1> , phenobarbital, St. Johns Wort) may decrease  <e2> sunitinib </e2>  concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir,  <e1> indinavir </e1> , nefazodone, nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g.,  <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,  <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine,  <e1> rifampin </e1> ,  <e2> rifabutin </e2> , rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone,  <e1> nelfinavir </e1> , ritonavir,  <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin,  <e1> atazanavir </e1> , indinavir,  <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g.,  <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,  <e2> voriconizole </e2> ) may increases sunitinib concentrations. 
mechanism	Co-administration of  <e1> SUTENT </e1>  with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations. 
mechanism	Co-administration of  <e1> SUTENT </e1>  with strong inhibitors of the CYP3A4 family (e.g.,  <e2> ketoconazole </e2> , itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole,  <e1> clarithromycin </e1> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,  <e2> voriconizole </e2> ) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir,  <e1> nefazodone </e1> ,  <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone,  <e1> nelfinavir </e1> , ritonavir, saquinavir, telithromycin, voriconizole) may increases  <e2> sunitinib </e2>  concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin,  <e1> atazanavir </e1> , indinavir, nefazodone, nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine,  <e1> rifampin </e1> , rifabutin,  <e2> rifapentin </e2> , phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 
mechanism	Co-administration of  <e1> SUTENT </e1>  with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,  <e2> voriconizole </e2> ) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin,  <e1> atazanavir </e1> , indinavir, nefazodone, nelfinavir,  <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,  <e1> voriconizole </e1> ) may increases  <e2> sunitinib </e2>  concentrations. 
false	Therefore, the use of  <e1> sumatriptan succinate </e1>  tablets in patients receiving MAO-A inhibitors is contraindicated .  <e2> Selective serotonin reuptake inhibitors </e2>  (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole,  <e1> clarithromycin </e1> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir,  <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole,  <e1> itraconazole </e1> , clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir,  <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
mechanism	Co-administration of  <e1> SUTENT </e1>  with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin,  <e2> phenobarbital </e2> , St. Johns Wort) may decrease sunitinib concentrations. 
false	Other eye drops or medications such as acetylcholine chloride (Miochol) and  <e1> carbachol </e1>  (Carboptic,  <e2> Isopto Carbachol </e2> ) may decrease the effects of suprofen ophthalmic.
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir,  <e1> saquinavir </e1> , telithromycin, voriconizole) may increases  <e2> sunitinib </e2>  concentrations. 
mechanism	Co-administration of  <e1> SUTENT </e1>  with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir,  <e2> indinavir </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol ( <e1> Carboptic </e1> ,  <e2> Isopto Carbachol </e2> ) may decrease the effects of suprofen ophthalmic.
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole,  <e1> itraconazole </e1> , clarithromycin, atazanavir,  <e2> indinavir </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
false	Because there is a theoretical basis that these effects may be additive, use of  <e1> ergotamine </e1> -containing or ergot-type medications (like  <e2> dihydroergotamine </e2>  or methysergide) and sumatriptan within 24 hours of each other should be avoided. 
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole,  <e1> itraconazole </e1> , clarithromycin, atazanavir, indinavir, nefazodone,  <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 
effect	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol ( <e1> Carboptic </e1> , Isopto Carbachol) may decrease the effects of  <e2> suprofen </e2>  ophthalmic.
advise	Therefore,  <e1> FLOMAX </e1>  capsules should be used with caution in combination with  <e2> cimetidine </e2> , particularly at doses higher than 0.4 mg. 
false	Other eye drops or medications such as acetylcholine chloride ( <e1> Miochol </e1> ) and carbachol (Carboptic,  <e2> Isopto Carbachol </e2> ) may decrease the effects of suprofen ophthalmic.
false	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone,  <e1> nelfinavir </e1> , ritonavir, saquinavir,  <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations. 
false	 <e1> Anticoagulants </e1>  (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as  <e2> acetylsalicylic acid </e2> , dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 
false	 <e1> Anticoagulants </e1>  (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid,  <e2> dipyridamole </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 
effect	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as  <e1> acetylsalicylic acid </e1> , dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  <e2> TNKase </e2>  therapy. 
false	The pharmacokinetic interaction between  <e1> cimetidine </e1>  and  <e2> FLOMAX </e2>  capsules was investigated. 
mechanism	An increase in intracellular levels of  <e1> methotrexate </e1>  was observed in vitro in the presence of  <e2> teniposide </e2> .
false	Anticoagulants (such as heparin and  <e1> vitamin K antagonists </e1> ) and drugs that alter platelet function (such as acetylsalicylic acid,  <e2> dipyridamole </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 
false	 <e1> Anticoagulants </e1>  (such as  <e2> heparin </e2>  and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 
false	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that  <e1> terbinafine </e1>  does not affect the clearance of  <e2> antipyrine </e2>  or digoxin. 
false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies,  <e1> hypoglycemics </e1> , theophyllines, phenytoins, thiazide diuretics,  <e2> beta blockers </e2> , and calcium channel blockers.
false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  <e1> contraceptives </e1> , hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics,  <e2> beta blockers </e2> , and calcium channel blockers.
mechanism	 <e1> Terbinafine </e1>  clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by  <e2> cimetidine </e2> , a CyP450 enzyme inhibitor. 
false	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol,  <e1> ethoxycoumarin </e1> , and  <e2> cyclosporine </e2> . 
false	 <e1> Terbinafine </e1>  clearance is unaffected by  <e2> cyclosporine </e2> . 
false	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide,  <e1> ethinylestradiol </e1> , ethoxycoumarin, and  <e2> cyclosporine </e2> . 
false	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and  <e1> warfarin </e1> , however, a causal relationship between  <e2> LAMISIL </e2>     Tablets and these changes has not been established. 
false	In vitro studies with human liver microsomes showed that  <e1> terbinafine </e1>  does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and  <e2> cyclosporine </e2> . 
false	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide,  <e1> sodium salicylate </e1>  and  <e2> sulfamethizole </e2>  displaced protein-bound teniposide in fresh human serum to a small but significant extent. 
false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to  <e1> ketoconazole </e1> , and  <e2> itraconazole </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
false	Concomitant administration of terfenadine with clarithromycin,  <e1> erythromycin </e1> , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including  <e2> azithromycin </e2> , is not recommended. 
false	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers,  <e1> selective serotonin reuptake inhibitors </e1>  (SSRIs), and  <e2> monoamine oxidase inhibitors (MAO-Is) Type B </e2> , if they have a narrow therapeutic window. 
false	Due to the chemical similarity of other  <e1> azole-type antifungal agents </e1>  (including fluconazole, metronidazole, and  <e2> miconazole </e2> ) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole,  <e1> metronidazole </e1> , and  <e2> miconazole </e2> ) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins,  <e1> thiazide diuretics </e1> ,  <e2> beta blockers </e2> , and calcium channel blockers.
false	Due to the chemical similarity of other azole-type antifungal agents (including  <e1> fluconazole </e1> ,  <e2> metronidazole </e2> , and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
advise	Concomitant administration of  <e1> terfenadine </e1>  with  <e2> clarithromycin </e2> , erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 
false	Concomitant administration of  <e1> terfenadine </e1>  with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other  <e2> macrolide antibiotics </e2> , including azithromycin, is not recommended. 
false	Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on  <e1> terfenadine </e1>  metabolism by a mechanism which may be similar to that of  <e2> ketoconazole </e2> , but to a lesser extent. 
false	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and  <e1> miconazole </e1> ) to  <e2> ketoconazole </e2> , and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 
mechanism	 <e1> Terbinafine </e1>  clearance is increased 100% by  <e2> rifampin </e2> , a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. 
advise	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of  <e1> terfenadine </e1>  with other macrolide antibiotics, including  <e2> azithromycin </e2> , is not recommended. 
false	 <e1> Ketoconazole </e1> : Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of  <e2> terfenadine </e2>  demonstrate QT interval prolongation and rare serious cardiac events, e.g. 
false	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  <e1> contraceptives </e1> , hormone replacement therapies,  <e2> hypoglycemics </e2> , theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.
false	 <e1> Macrolides </e1> : Clinical drug interaction studies indicate that erythromycin and  <e2> clarithromycin </e2>  can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 
false	Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of  <e1> terfenadine </e1> , resulting in elevated plasma  <e2> terfenadine </e2>  levels. 
false	Concomitant administration of terfenadine with  <e1> clarithromycin </e1> , erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including  <e2> azithromycin </e2> , is not recommended. 
false	Itraconazole: Torsades de pointes and elevated parent  <e1> terfenadine </e1>  levels have been reported during concomitant use of  <e2> terfenadine </e2>  and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 
false	Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol,  <e1> chlorpromazine </e1> , and  <e2> reserpine </e2> . 
false	Important Non- <e1> Thalidomide </e1>  Drug Interactions Drugs That Interfere with  <e2> Hormonal Contraceptives </e2> : Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non- <e1> Thalidomide </e1>  Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin,  <e2> rifabutin </e2> , phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins,  <e1> rifampin </e1> , rifabutin,  <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St. 
false	Important Non- <e1> Thalidomide </e1>  Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of  <e2> HIV-protease inhibitors </e2> , griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with  <e1> Hormonal Contraceptives </e1> : Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins,  <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors,  <e1> griseofulvin </e1> , modafinil, penicillins,  <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of  <e1> HIV-protease inhibitors </e1> , griseofulvin, modafinil, penicillins,  <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Thalidomide has been reported to enhance the sedative activity of  <e1> barbiturates </e1> ,  <e2> alcohol </e2> , chlorpromazine, and reserpine. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin,  <e1> modafinil </e1> , penicillins, rifampin,  <e2> rifabutin </e2> , phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of  <e1> norethindrone </e1>  and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of  <e2> ethinyl estradiol </e2>  were studied. 
false	Important Non- <e1> Thalidomide </e1>  Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil,  <e2> penicillins </e2> , rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
false	Thalidomide has been reported to enhance the sedative activity of  <e1> barbiturates </e1> , alcohol,  <e2> chlorpromazine </e2> , and reserpine. 
false	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and  <e1> ethinyl estradiol </e1>  following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of  <e2> ethinyl estradiol </e2>  were studied. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin,  <e1> phenytoin </e1> ,  <e2> carbamazepine </e2> , or certain herbal supplements such as St. 
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with  <e1> Hormonal Contraceptives </e1> : Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin,  <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St. 
int	Interactions for  <e1> Vitamin B1 </e1>  (Thiamine):  Loop Diuretics, Oral Contraceptives,  <e2> Stavudine </e2> , Tricyclic Antidepressants
int	Interactions for  <e1> Vitamin B1 </e1>  (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine,  <e2> Tricyclic Antidepressants </e2> 
false	Interactions for  <e1> Vitamin B1 </e1>  ( <e2> Thiamine </e2> ):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
false	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of  <e1> HIV-protease inhibitors </e1> ,  <e2> griseofulvin </e2> , modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 
effect	 <e1> Phenothiazines </e1>  are capable of potentiating CNS depressants (e.g.,  <e2> barbiturates </e2> , anesthetics, opiates, alcohol, etc.) 
false	Phenothiazines are capable of potentiating  <e1> CNS depressants </e1>  (e.g., barbiturates,  <e2> anesthetics </e2> , opiates, alcohol, etc.) 
false	Phenothiazines are capable of potentiating  <e1> CNS depressants </e1>  (e.g., barbiturates, anesthetics,  <e2> opiates </e2> , alcohol, etc.) 
false	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates,  <e1> anesthetics </e1> , opiates,  <e2> alcohol </e2> , etc.) 
false	As there is in vitro evidence that aminosalicylate derivatives (e.g.,  <e1> olsalazine </e1> , mesalazine, or  <e2> sulphasalazine </e2> ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    
effect	There is usually complete cross-resistance between PURINETHOL ( <e1> mercaptopurine </e1> ) and TABLOID brand  <e2> Thioguanine </e2> . 
false	As there is in vitro evidence that  <e1> aminosalicylate derivatives </e1>  (e.g., olsalazine, mesalazine, or  <e2> sulphasalazine </e2> ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    
mechanism	As there is in vitro evidence that aminosalicylate derivatives (e.g.,  <e1> olsalazine </e1> , mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  <e2> thioguanine </e2>  therapy.    
false	Concurrent use of antibacterial drugs with oral  <e1> contraceptives </e1>  may render oral  <e2> contraceptives </e2>  less effective.  
false	The bioavailability of SKELID is decreased 80% by  <e1> calcium </e1> , when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before  <e2> SKELID </e2> . 
mechanism	The bioavailability of  <e1> SKELID </e1>  is decreased 80% by  <e2> calcium </e2> , when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 
false	The bioavailability of SKELID is decreased 80% by  <e1> calcium </e1> , when calcium and  <e2> SKELID </e2>  are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 
false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and  <e1> SKELID </e1>  are administered at the same time, and 60% by some aluminum- or magnesium-containing  <e2> antacids </e2> , when administered 1 hour before SKELID. 
false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing  <e1> antacids </e1> , when administered 1 hour before  <e2> SKELID </e2> . 
false	The bioavailability of SKELID is decreased 80% by calcium, when calcium and  <e1> SKELID </e1>  are administered at the same time, and 60% by some  <e2> aluminum </e2> - or magnesium-containing antacids, when administered 1 hour before SKELID. 
false	The bioavailability of  <e1> SKELID </e1>  is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing  <e2> antacids </e2> , when administered 1 hour before SKELID. 
false	The bioavailability of SKELID is decreased 80% by  <e1> calcium </e1> , when calcium and SKELID are administered at the same time, and 60% by some  <e2> aluminum </e2> - or magnesium-containing antacids, when administered 1 hour before SKELID. 
false	The bioavailability of  <e1> SKELID </e1>  is decreased 80% by calcium, when calcium and  <e2> SKELID </e2>  are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 
false	The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to  <e1> heparin </e1>  and  <e2> aspirin </e2>  alone (see
false	The use of AGGRASTAT, in combination with  <e1> heparin </e1>  and aspirin, has been associated with an increase in bleeding compared to heparin and  <e2> aspirin </e2>  alone (see
false	The use of AGGRASTAT, in combination with heparin and  <e1> aspirin </e1> , has been associated with an increase in bleeding compared to heparin and  <e2> aspirin </e2>  alone (see
advise	 <e1> TOBI </e1>  should not be administered concomitantly with ethacrynic acid, furosemide, urea, or  <e2> mannitol </e2> .
false	In clinical studies of  <e1> TOBI </e1> , patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other  <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
false	However, the co   administration of SPIRIVA with other  <e1> anticholinergic </e1>    containing drugs (e.g.,  <e2> ipratropium </e2> ) has not been studied and is therefore not recommended.
false	In clinical studies of  <e1> TOBI </e1> , patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled  <e2> corticosteroids </e2> , other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
false	In clinical studies of TOBI, patients taking TOBI concomitantly with  <e1> dornase alfa </e1>  ( <e2> PULMOZYME </e2>    , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
false	In clinical studies of TOBI, patients taking TOBI concomitantly with  <e1> dornase alfa </e1>  (PULMOZYME   , Genentech), (beta)-agonists, inhaled  <e2> corticosteroids </e2> , other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
effect	In clinical studies of TOBI, patients taking  <e1> TOBI </e1>  concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other  <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
effect	Some  <e1> diuretics </e1>  can enhance  <e2> aminoglycoside </e2>  toxicity by altering antibiotic concentrations in serum and tissue. 
false	In clinical studies of  <e1> TOBI </e1> , patients taking  <e2> TOBI </e2>  concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
advise	Therefore, caution should be exercised when administering  <e1> TOLECTIN </e1>  to patients on  <e2> anticoagulants </e2> . 
false	 <e1> TOLECTIN </e1>  and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of  <e2> methotrexate </e2> . 
false	The in vitro binding of  <e1> warfarin </e1>  to human plasma proteins is unaffected by  <e2> tolmetin </e2> , and tolmetin does not alter the prothrombin time of normal volunteers. 
false	The in vitro binding of  <e1> warfarin </e1>  to human plasma proteins is unaffected by tolmetin, and  <e2> tolmetin </e2>  does not alter the prothrombin time of normal volunteers. 
false	In clinical studies of TOBI, patients taking TOBI concomitantly with  <e1> dornase alfa </e1>  (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other  <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other  <e1> azole antifungals </e1>  (eg, itraconazole, miconazole) or macrolide antibiotics (eg,  <e2> erythromycin </e2> , clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or  <e1> cyclosporine </e1>  or vinblastine, the recommended dose of  <e2> DETROL LA </e2>  is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin,  <e1> clarithromycin </e1> ) or  <e2> cyclosporine </e2>  or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
false	For patients receiving  <e1> ketoconazole </e1>  or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or  <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily. 
false	 <e1> TOLECTIN </e1>  and other  <e2> nonsteroidal anti-inflammatory drugs </e2>  have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. 
advise	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole,  <e1> miconazole </e1> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of  <e2> DETROL LA </e2>  is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg,  <e1> itraconazole </e1> ,  <e2> miconazole </e2> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other  <e1> azole antifungals </e1>  (eg,  <e2> itraconazole </e2> , miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or  <e1> macrolide antibiotics </e1>  (eg, erythromycin, clarithromycin) or cyclosporine or  <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily. 
false	For patients receiving  <e1> ketoconazole </e1>  or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or  <e2> macrolide antibiotics </e2>  (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
false	Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in  <e1> HERCEPTIN </e1>  clearance in a non-human primate study and in a 1.5-fold increase in  <e2> HERCEPTIN </e2>  serum levels in clinical studies.
false	Administration of paclitaxel in combination with  <e1> HERCEPTIN </e1>  resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in  <e2> HERCEPTIN </e2>  serum levels in clinical studies.
false	For patients receiving  <e1> ketoconazole </e1>  or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole,  <e2> miconazole </e2> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 
false	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or  <e1> cyclosporine </e1>  or  <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily. 
mechanism	 <e1> Trimethoprim </e1> , given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the  <e2> phenytoin </e2>  metabolic clearance rate by 30%. 
mechanism	Based on an in vitro rat liver model, nitrogen substituted  <e1> imidazole drugs </e1>  (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of  <e2> trimetrexate </e2>  metabolism. 
false	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs ( <e1> clotrimazole </e1> , ketoconazole,  <e2> miconazole </e2> ) were potent, non-competitive inhibitors of trimetrexate metabolism. 
false	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include  <e1> erythromycin </e1> ,  <e2> rifampin </e2> , rifabutin, ketoconazole, and fluconazole. 
false	Based on an in vitro rat liver model, nitrogen substituted  <e1> imidazole drugs </e1>  (clotrimazole, ketoconazole,  <e2> miconazole </e2> ) were potent, non-competitive inhibitors of trimetrexate metabolism. 
false	In vitro perfusion of isolated rat liver has shown that  <e1> cimetidine </e1>  caused a significant reduction in trimetrexate metabolism and that  <e2> acetaminophen </e2>  altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. 
effect	Agents that might be coadministered with  <e1> trimetrexate </e1>  in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin,  <e2> rifabutin </e2> , ketoconazole, and fluconazole. 
false	The effects of anticholinergic drugs, such as  <e1> atropine </e1>  and  <e2> tricyclic antidepressants </e2>  may be enhanced by the concomitant administration of triprolidine. 
effect	 <e1> Triprolidine </e1>  may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates,  <e2> hypnotics </e2> , narcotic analgesics, sedatives, and tranquillisers. 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including  <e1> alcohol </e1> , barbiturates, hypnotics, narcotic analgesics, sedatives, and  <e2> tranquillisers </e2> . 
false	Triprolidine may enhance the sedative effects of  <e1> central nervous system depressants </e1>  including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and  <e2> tranquillisers </e2> . 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol,  <e1> barbiturates </e1> , hypnotics,  <e2> narcotic analgesics </e2> , sedatives, and tranquillisers. 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics,  <e1> narcotic analgesics </e1> ,  <e2> sedatives </e2> , and tranquillisers. 
effect	The effects of  <e1> anticholinergic drugs </e1> , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of  <e2> triprolidine </e2> . 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including  <e1> alcohol </e1> ,  <e2> barbiturates </e2> , hypnotics, narcotic analgesics, sedatives, and tranquillisers. 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  <e1> digoxin </e1> , procainamide, pancuronium, morphine, vancomycin,  <e2> metformin </e2>  and tenofovir). 
effect	The concomitant use of  <e1> Sanctura </e1>  with other  <e2> anticholinergic agents </e2>  that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide,  <e1> pancuronium </e1> , morphine,  <e2> vancomycin </e2> , metformin and tenofovir). 
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted,  <e1> Sanctura </e1>  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine,  <e2> vancomycin </e2> , metformin and tenofovir). 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin,  <e1> procainamide </e1> , pancuronium, morphine, vancomycin,  <e2> metformin </e2>  and tenofovir). 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin,  <e1> metformin </e1>  and  <e2> tenofovir </e2> ). 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  <e1> Sanctura </e1>  have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  <e2> digoxin </e2> , procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  <e1> Sanctura </e1>  have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin,  <e2> metformin </e2>  and tenofovir). 
false	Triprolidine may enhance the sedative effects of central nervous system depressants including  <e1> alcohol </e1> , barbiturates,  <e2> hypnotics </e2> , narcotic analgesics, sedatives, and tranquillisers. 
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B,  <e1> colistin </e1> ,  <e2> viomycin </e2> , or cisplatin, when indicated, requires careful monitoring.
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B,  <e1> colistin </e1> , viomycin, or  <e2> cisplatin </e2> , when indicated, requires careful monitoring.
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides,  <e1> bacitracin </e1> , polymyxin B,  <e2> colistin </e2> , viomycin, or cisplatin, when indicated, requires careful monitoring.
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  <e1> amphotericin B </e1> , aminoglycosides, bacitracin, polymyxin B,  <e2> colistin </e2> , viomycin, or cisplatin, when indicated, requires careful monitoring.
false	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin,  <e1> polymyxin B </e1> , colistin,  <e2> viomycin </e2> , or cisplatin, when indicated, requires careful monitoring.
false	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium,  <e1> morphine </e1> ,  <e2> vancomycin </e2> , metformin and tenofovir). 
mechanism	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted,  <e1> Sanctura </e1>  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  <e2> digoxin </e2> , procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 
false	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering  <e1> vigabatrin </e1>  with phenytoin lowered the serum  <e2> phenytoin </e2>  concentration in patients with treatment-resistant epilepsy. 
false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  <e1> Phenytoin </e1> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm -  <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine
int	 <e1> Vindesine </e1>  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity -  <e2> Live virus vaccines </e2> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity -  <e1> Live virus vaccines </e1> : may potentiate the replication of the  <e2> vaccine </e2>  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity -  <e1> Live virus vaccines </e1> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the  <e2> vaccine </e2> 
false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  <e1> Phenytoin </e1> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the  <e2> vaccine </e2> 
false	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm -  <e1> Killed virus vaccines </e1> : may decrease patient's response to the  <e2> vaccine </e2> 
false	Other  <e1> HDAC Inhibitors </e1>  Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g.,  <e2> valproic acid </e2> ). 
effect	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of  <e1> ZOLINZA </e1>  and other  <e2> HDAC inhibitors </e2>  (e.g., valproic acid). 
